

EWS 1 Web Page for STN Seminar Schedule - N. America  
 NEWS 2 JAN 02 STN pricing information for 2008 now available  
 NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
 prophetic substances  
 NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
 custom IPC display formats  
 NEWS 5 JAN 28 MARPAT searching enhanced  
 NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
 of publication  
 NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
 NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements  
 NEWS 9 FEB 08 STN Express, Version 8.3, now available  
 NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
 NEWS 11 FEB 25 IFIREF reloaded with enhancements  
 NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
 NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
 U.S. National Patent Classification  
 NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
 IPC display formats  
 NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
 spectra  
 NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.  
 applications updated  
 NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
 NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
 NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
 NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
 predefined hit display formats  
 NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
 NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements  
 NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family  
 searching  
 NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
 sequence search option  
 NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts  
 NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents  
 NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character  
 patent numbers for U.S. applications  
 NEWS 28 JUN 19 CAS REGISTRY includes selected substances from  
 web-based collections  
  
 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
 AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	0.42

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2008 VOL 148 ISS 26  
FILE LAST UPDATED: 23 Jun 2008 (20080623/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> e us2004-785093/apps  
E1 1 US2004-785090/AP  
E2 1 US2004-785091/AP  
E3 1 --> US2004-785093/AP  
E4 0 US2004-785093/PRN  
E5 1 US2004-785099/AP  
E6 1 US2004-785099/PRN  
E7 1 US2004-785103/AP  
E8 1 US2004-785103/PRN  
E9 1 US2004-785105/AP  
E10 1 US2004-785106/AP  
E11 1 US2004-785106/PRN  
E12 2 US2004-785109/AP

=> s e3  
L1 1 US2004-785093/AP

=> sel rn l1  
E1 THROUGH E41 ASSIGNED

=> file reg  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
2.69	3.11

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2008 HIGHEST RN 1030103-54-8  
DICTIONARY FILE UPDATES: 23 JUN 2008 HIGHEST RN 1030103-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s el-e41

```
1 100-42-5/BI
  (100-42-5/RN)
1 103-23-1/BI
  (103-23-1/RN)
1 105-99-7/BI
  (105-99-7/RN)
1 105729-79-1/BI
  (105729-79-1/RN)
1 106107-54-4/BI
  (106107-54-4/RN)
1 108388-87-0/BI
  (108388-87-0/RN)
1 109-43-3/BI
  (109-43-3/RN)
1 110-15-6/BI
  (110-15-6/RN)
1 110-40-7/BI
  (110-40-7/RN)
1 110900-80-6/BI
  (110900-80-6/RN)
1 111-20-6/BI
  (111-20-6/RN)
1 117-81-7/BI
  (117-81-7/RN)
1 122-62-3/BI
  (122-62-3/RN)
1 123-25-1/BI
  (123-25-1/RN)
1 124-04-9/BI
  (124-04-9/RN)
1 131-11-3/BI
  (131-11-3/RN)
1 144-15-0/BI
  (144-15-0/RN)
1 144470-58-6/BI
  (144470-58-6/RN)
1 17140-33-9/BI
  (17140-33-9/RN)
1 24817-92-3/BI
  (24817-92-3/RN)
1 24980-41-4/BI
  (24980-41-4/RN)
```

1 25248-42-4/BI  
 (25248-42-4/RN)  
 1 27924-99-8/BI  
 (27924-99-8/RN)  
 1 2915-57-3/BI  
 (2915-57-3/RN)  
 1 31807-55-3/BI  
 (31807-55-3/RN)  
 1 39413-05-3/BI  
 (39413-05-3/RN)  
 1 58128-22-6/BI  
 (58128-22-6/RN)  
 1 60908-77-2/BI  
 (60908-77-2/RN)  
 1 6938-94-9/BI  
 (6938-94-9/RN)  
 1 7491-02-3/BI  
 (7491-02-3/RN)  
 1 77-89-4/BI  
 (77-89-4/RN)  
 1 77-90-7/BI  
 (77-90-7/RN)  
 1 77-94-1/BI  
 (77-94-1/RN)  
 1 82469-79-2/BI  
 (82469-79-2/RN)  
 1 84-66-2/BI  
 (84-66-2/RN)  
 1 84-74-2/BI  
 (84-74-2/RN)  
 1 85-68-7/BI  
 (85-68-7/RN)  
 1 88-99-3/BI  
 (88-99-3/RN)  
 1 9002-88-4/BI  
 (9002-88-4/RN)  
 1 9003-27-4/BI  
 (9003-27-4/RN)  
 1 90605-17-7/BI  
 (90605-17-7/RN)  
 L2 41 (100-42-5/BI OR 103-23-1/BI OR 105-99-7/BI OR 105729-79-1/BI OR  
 106107-54-4/BI OR 108388-87-0/BI OR 109-43-3/BI OR 110-15-6/BI  
 OR 110-40-7/BI OR 110900-80-6/BI OR 111-20-6/BI OR 117-81-7/BI  
 OR 122-62-3/BI OR 123-25-1/BI OR 124-04-9/BI OR 131-11-3/BI OR  
 144-15-0/BI OR 144470-58-6/BI OR 17140-33-9/BI OR 24817-92-3/BI  
 OR 24980-41-4/BI OR 25248-42-4/BI OR 27924-99-8/BI OR 2915-57-3/  
 BI OR 31807-55-3/BI OR 39413-05-3/BI OR 58128-22-6/BI OR 60908-7  
 7-2/BI OR 6938-94-9/BI OR 7491-02-3/BI OR 77-89-4/BI OR 77-90-7/  
 BI OR 77-94-1/BI OR 82469-79-2/BI OR 84-66-2/BI OR 84-74-2/BI  
 OR 85-68-7/BI OR 88-99-3/BI OR 9002-88-4/BI OR 9003-27-4/BI OR  
 90605-17-7/BI)

=> d scan 12

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Benzene, ethenyl-  
 MF C8 H8  
 CI COM

H<sub>2</sub>C=CH-Ph



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):43

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Butanedioic acid  
MF C4 H6 O4  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Decanedioic acid, 1,10-bis(2-ethylhexyl) ester  
MF C26 H50 O4  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-tris(2-ethylhexyl)  
ester  
MF C32 H58 O8  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Ethene, homopolymer  
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT  
MF (C2 H4)x  
CI PMS, COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 2-Oxepanone, homopolymer  
 MF (C6 H10 O2)x  
 CI PMS, COM

\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\*


CM 1



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1-methylethyl ester  
 MF C6 H8 O7 . x C3 H8 O

CM 1



CM 2




L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, isodecyl ester (9CI)  
 MF C10 H22 O . x C6 H8 O7

CM 1


(iso-C<sub>10</sub>H<sub>21</sub>) - OH

CM 2



L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN Benzene, ethenyl-, polymer with 1,3-butadiene and ethene, block  
MF (C8 H8 . C4 H6 . C2 H4)x  
CI PMS

CM 1




CM 2



CM 3



L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-tributyl ester  
MF C18 H32 O7  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,2-Benzenedicarboxylic acid  
 MF C8 H6 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Decanedioic acid, 1,10-dibutyl ester  
 MF C18 H34 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester  
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT  
 MF C24 H38 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2-Benzenedicarboxylic acid, 1,2-dimethyl ester  
 MF C10 H10 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Decanedioic acid, 1,10-bis(1-methylethyl) ester  
 MF C16 H30 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-trihexyl ester  
 MF C26 H46 O8



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Isododecane  
 MF C12 H26  
 CI IDS, COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN


IN 1,2,3-Propanetricarboxylic acid, 2-(1-oxobutoxy)-, 1,2,3-trihexyl ester  
 MF C28 H50 O8



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Benzene, ethenyl-, polymer with ethene and 1-propene, block  
 MF (C8 H8 . C3 H6 . C2 H4)x  
 CI PMS

CM 1



CM 2




CM 3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-tributyl ester  
 MF C20 H34 O8  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2-Benzenedicarboxylic acid, 1-butyl 2-(phenylmethyl) ester  
 MF C19 H20 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Hexanedioic acid, 1,6-dibutyl ester  
 MF C14 H26 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Decanedioic acid  
 MF C10 H18 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Hexanedioic acid  
 MF C6 H10 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Hexanedioic acid, 1,6-bis(1-methylethyl) ester  
 MF C12 H22 O4  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-  
 MF C8 H10 O8  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Octadecanoic acid, 12-hydroxy-, homopolymer  
 MF (C18 H36 O3)x  
 CI PMS, COM


\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\*

CM 1






L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Isohexadecane (7CI, 9CI)  
 MF C16 H34  
 CI IDS, COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Benzene, ethenyl-, polymer with 1,3-butadiene, block  
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT  
 MF (C8 H8 . C4 H6)x  
 CI PMS, COM

CM 1




CM 2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-triethyl ester  
 MF C14 H22 O8  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester  
 MF C16 H22 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Hexanedioic acid, 1,6-bis(2-ethylhexyl) ester  
 MF C22 H42 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Decanedioic acid, 1,10-diethyl ester  
 MF C14 H26 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Butanedioic acid, 1,4-diethyl ester  
 MF C8 H14 O4  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Butanedioic acid, 1,4-bis(2-ethylhexyl) ester  
 MF C20 H38 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1-Propene, 2-methyl-, homopolymer  
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT  
 MF (C4 H8)x  
 CI PMS, COM


CM 1



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Poly[oxy(1-oxo-1,6-hexanediyl)]  
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT  
 MF (C6 H10 O2)n  
 CI PMS, COM

\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\*



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Octadecanoic acid, 12-hydroxy-, homopolymer, octadecanoate  
 MF (C18 H36 O3)x . C18 H36 O2  
 CI COM

CM 1



CM 2

CM 3




L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Benzene, ethenyl-, polymer with 2-methyl-1,3-butadiene, block  
 MF (C8 H8 . C5 H8)x  
 CI PMS

CM 1



CM 2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Octadecanoic acid, 12-hydroxy-, homopolymer, ester with 1,2,3-propanetriol  
 homopolymer  
 MF (C18 H36 O3)x . x (C3 H8 O3)x


CM 1

CM 2




CM 3

CM 4



L2 41 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2-Benzenedicarboxylic acid, 1,2-diethyl ester  
 MF C12 H14 O4  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus biosis scisearch embase medline		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.22	6.33

FILE 'CAPLUS' ENTERED AT 22:03:05 ON 24 JUN 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 22:03:05 ON 24 JUN 2008  
 Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 22:03:05 ON 24 JUN 2008  
 Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 22:03:05 ON 24 JUN 2008  
 Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 22:03:05 ON 24 JUN 2008

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008  
 E US2004-785093/APPS

L1 1 S E3  
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008  
 41 S E1-E41

L2

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

```
=> s 12
L3      432048 L2

=> s 13 and ("acetic acid")
L4      13513 L3 AND ("ACETIC ACID")

=> s 14 and sucrose
L5      603 L4 AND SUCROSE

=> s 15 and ("acrylic copolymer")
L6      0 L5 AND ("ACRYLIC COPOLYMER")

=> s 15 and ("acrylic acid")
L7      39 L5 AND ("ACRYLIC ACID")

=> s 17 and acrylate
L8      10 L7 AND ACRYLATE

=> s 18 and polyethylene
L9      3 L8 AND POLYETHYLENE

=> d scan 19

L9      3 ANSWERS  CAPLUS  COPYRIGHT 2008 ACS on STN
IC      ICM  A61K031-74
ICS     A61K009-00; A01N025-00; A61K009-70; A61F013-00; A61L015-16;
        A61L015-00; A61F013-02; B65D073-00
INCL    424443000
CC      63-7 (Pharmaceuticals)
TI      Treating traumatic burns or blisters of the skin by a polymer-based
        hydrogel
ST      polymer hypertonic hydrogel dressing blister burn
IT      Textiles
        (backing support; hypertonic polymer-based hydrogel patch for treatment
        of traumatic burns or blisters)
IT      Plastics, biological studies
        RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (backing support; hypertonic polymer-based hydrogel patch for treatment
        of traumatic burns or blisters)
IT      Medical goods
        (bandages, cloth; hypertonic polymer-based hydrogel patch for treatment
        of traumatic burns or blisters)
IT      Medical goods
        (dressings; hypertonic polymer-based hydrogel patch for treatment of
        traumatic burns or blisters)
IT      Acrylic polymers, biological studies
        RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (emulsions; hypertonic polymer-based hydrogel patch for treatment of
        traumatic burns or blisters)
IT      Polyelectrolytes
        (gels; hypertonic polymer-based hydrogel patch for treatment of
        traumatic burns or blisters)
IT      Seaweed
        (gum; hypertonic polymer-based hydrogel patch for treatment of
        traumatic burns or blisters)
IT      Antimicrobial agents
        Blister
```

- Burn
- Gelation agents
- Gums and Mucilages
- Humectants
- Osmolytes
- Thickening agents
  - (hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Albumins, biological studies
- Biopolymers
- Carbohydrates, biological studies
- Fluoropolymers, biological studies
- Polymers, biological studies
- Polysiloxanes, biological studies
- Waxes
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Acids, biological studies
- Alcohols, biological studies
- Amino acids, biological studies
- Bases, biological studies
- Proteins
- Salts, biological studies
- RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (osmotic pressure increase by; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Hydrogels
  - (patches; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Alcohols, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (polyhydric; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Quaternary ammonium compounds, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (polymeric; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Vinyl compounds, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (polymers, emulsions; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Polymers, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (polysulfonates; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Adhesives
  - (pressure-sensitive; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Inflammation
- Pain
- Swelling, biological
  - (reduction of; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Hydration, physiological
  - (skin; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)
- IT Osmotic pressure
  - (solutes for increase of; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Skin  
(stratum corneum, hydrophilic bridge with; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT 9005-25-8, Starch, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(corn; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT 7647-14-5, Sodium Chloride, biological studies 10043-52-4, Calcium chloride, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT 56-81-5, Glycerin, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene Glycol, biological studies 60-54-8, Tetracycline 64-19-7, Acetic acid, biological studies 67-63-0, Isopropyl alcohol, biological studies 69-72-7, Salicylic acid, biological studies 70-30-4, Hexachlorophene 79-10-7D, Acrylic acid, esters, copolymer 94-36-0, Benzoyl peroxide, biological studies 107-21-1, Ethylene Glycol, biological studies 114-07-8, Erythromycin 129-16-8, Mercurochrome 302-79-4, Retinoic acid 4759-48-2, Isotretinoin 7722-84-1, Hydrogen peroxide, biological studies 7761-88-8, Silver nitrate, biological studies 9000-36-6, Karaya gum 9000-69-5, Pectin 9002-84-0, Polytetrafluoroethylene 9002-88-4, Polyethylene 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-05-8, Polyacrylamide 9003-20-7, Vinyl acetate resin 9004-32-4, Carboxymethyl cellulose 9050-36-6, Maltodextrin 18472-51-0, Chlorhexidine gluconate 22916-47-8, Miconazole 25549-84-2, Polysodium acrylate 25655-41-8, Povidone iodine 26061-64-3, Dioctyl maleate-vinyl acetate copolymer 59277-89-3, Acyclovir 66676-63-9, Carboxypropyl cellulose  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L9 3 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
IC ICM C11D017-06  
ICS C11D003-39

CC 46-5 (Surface Active Agents and Detergents)

TI Formulations comprising water-soluble granulates

ST formulation comprising water soluble granulate; aluminum phthalocyanine anionic dispersing agent sodium sulfate granulate prepn

IT Polyoxyalkylenes, uses  
RL: TEM (Technical or engineered material use); USES (Uses)  
(alkyl group-terminated, nonionic surfactants; formulations comprising water-soluble granulates)

IT Dispersing agents  
Surfactants  
(anionic; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(arenesulfonic, salts, alkyl, dispersing agents; formulations comprising water-soluble granulates)

IT Detergents  
(bars; formulations comprising water-soluble granulates)

IT Polyoxyalkylenes, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(block, dispersing agents; formulations comprising water-soluble granulates)



IT Fibers  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (cellulosic; formulations comprising water-soluble granulates)

IT Pastes  
 (detergent; formulations comprising water-soluble granulates)

IT Polyoxyalkylenes, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (dispersing agent; formulations comprising water-soluble granulates)

IT Acrylic polymers, uses  
 Gelatins, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (dispersing agents; formulations comprising water-soluble granulates)

IT Alcohols, uses  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (ethoxylated, nonionic surfactants; formulations comprising water-soluble granulates)

IT Granulating apparatus  
 (fluidized bed; formulations comprising water-soluble granulates)

IT Drying  
 (fluidized-bed; formulations comprising water-soluble granulates)

IT Bleaching agents  
 Dispersing agents  
 Dyes  
 Fillers  
 Fluorescent brighteners  
 Pigments, nonbiological  
 Textiles  
 Wetting agents  
 (formulations comprising water-soluble granulates)

IT A zeolites  
 Aluminosilicates, uses  
 Borates  
 Carbonates, uses  
 Carboxylic acids, uses  
 Diphosphates  
 Halides  
 Kaolin, uses  
 Peroxides, uses  
 Peroxysulfates  
 Phosphates, uses  
 Polysiloxanes, uses  
 Salts, uses  
 Silicates, uses  
 Sulfates, uses  
 Sulfites  
 Zeolites (synthetic), uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (formulations comprising water-soluble granulates)

IT Detergents  
 (granular; formulations comprising water-soluble granulates)

IT Fluidized beds  
 (granulating apparatus; formulations comprising water-soluble granulates)

IT Surfactants  
 (nonionic; formulations comprising water-soluble granulates)

IT Acids, uses  
 Peroxy acids  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (organic; formulations comprising water-soluble granulates)

IT Detergents  
 (paste; formulations comprising water-soluble granulates)

IT Group IIIA element compounds

RL: MOA (Modifier or additive use); USES (Uses)  
(perborates; formulations comprising water-soluble granulates)

IT Catalysts  
(photo; formulations comprising water-soluble granulates)

IT Carboxylic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(polycarboxylic acid esters, amino; formulations comprising water-soluble granulates)

IT Carboxylic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(polycarboxylic, dispersing agents; formulations comprising water-soluble granulates)

IT Carboxylic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(polycarboxylic, salts; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(polymers, dispersing agents; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(polymers, heterocyclic, dispersing agents; formulations comprising water-soluble granulates)

IT Detergents  
(powdered; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(sodium salts, polymers, dispersing agents; formulations comprising water-soluble granulates)

IT Polyphosphates  
RL: MOA (Modifier or additive use); USES (Uses)  
(sodium salts; formulations comprising water-soluble granulates)

IT Drying  
(spray; formulations comprising water-soluble granulates)

IT Detergents  
(stain removers; formulations comprising water-soluble granulates)

IT Polymers, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(sulfo-containing, heterocyclic, dispersing agents; formulations comprising water-soluble granulates)

IT Aromatic compounds  
RL: MOA (Modifier or additive use); USES (Uses)  
(sulfonates, alkyl, dispersing agents; formulations comprising water-soluble granulates)

IT Polymers, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(water-soluble, dispersing agents; formulations comprising water-soluble granulates)

IT 9017-33-8, Naphthalenesulfonic acid, polymer with formaldehyde  
RL: MOA (Modifier or additive use); USES (Uses)  
(anionic dispersing agent; formulations comprising water-soluble granulates)

IT 151-21-3, Sodium lauryl sulfate, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(anionic surfactant; formulations comprising water-soluble granulates)

IT 25155-30-0, Sodium laurylbenzenesulfonate  
RL: TEM (Technical or engineered material use); USES (Uses)  
(anionic surfactant; formulations comprising water-soluble granulates)

IT 25608-40-6, Polyaspartic acid  
RL: MOA (Modifier or additive use); USES (Uses)  
(dispersing agent, assumed monomers; formulations comprising water-soluble

- granulates)
- IT 57-50-1, Sucrose, uses 63-42-3, Lactose 79-10-7D, Acrylic acid, ester, polymers 88-12-0, uses 108-05-4, Vinyl acetate, uses 1321-69-3D, Naphthalenesulfonic acid sodium salt, alkyl derivs. 8061-51-6, Sodium lignosulfonate 9000-01-5, Arabic gum 9000-65-1, Tragacanth 9002-89-5, Polyvinyl alcohol 9003-05-8, Polyacrylamide 9003-11-6, Ethylene oxide-propylene oxide copolymer 9003-20-7, Polyvinyl acetate 9003-39-8, Polyvinyl pyrrolidone 9004-32-4, Carboxymethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9050-31-1, Hydroxypropyl methylcellulose phthalate 9050-36-6, Maltodextrin 25085-34-1, Acrylic acid-styrene copolymer 25086-89-9, Vinyl acetate-vinyl pyrrolidone copolymer 25155-19-5D, Naphthalenesulfonic acid, alkyl derivs., polymers, sodium salts 25322-68-3, Polyethylene glycol 26063-13-8, Polyaspartic acid 26101-52-0, Polyethylenesulfonic acid 30581-59-0, Dimethylaminoethyl methacrylate-vinyl pyrrolidone copolymer 37353-59-6, Hydroxymethyl cellulose 50851-57-5, Polystyrenesulfonic acid 52503-47-6, Ethylene oxide-propylene oxide copolymer ether with ethylenediamine 55989-05-4, Ethyl acrylate -methacrylic acid-methyl methacrylate copolymer ammonium salt 58226-28-1 64519-82-0, Isomalt 102972-64-5, Dimethylaminoethyl methacrylate-vinyl caprolactam-vinyl pyrrolidone copolymer 131954-48-8 156218-88-1, Dimethylaminopropyl methacrylate-vinyl pyrrolidone copolymer 478243-90-2, Dimethylaminopropylmethacrylamide-vinyl pyrrolidone copolymer
- RL: MOA (Modifier or additive use); USES (Uses)
- (dispersing agent; formulations comprising water-soluble granulates)
- IT 9004-34-6, Cellulose, uses
- RL: MOA (Modifier or additive use); USES (Uses)
- (fibrous; formulations comprising water-soluble granulates)
- IT 64-18-6, Formic acid, uses 64-19-7, Acetic acid, uses 65-85-0, Benzoic acid, uses 68-04-2, Sodium citrate 71-52-3, Hydrogen carbonate, uses 77-92-9, Citric acid, uses 79-09-4, Propionic acid, uses 79-10-7, Acrylic acid, uses 83-86-3 87-69-4, Tartaric acid, uses 88-99-3, Phthalic acid, uses 100-21-0, Terephthalic acid, uses 104-15-4, p-Toluenesulfonic acid, uses 110-15-6, Succinic acid, uses 110-16-7, Maleic acid, uses 144-62-7, Oxalic acid, uses 497-19-8, Sodium carbonate, uses 526-95-4, Gluconic acid 563-69-9, Carbonoperoxoic acid 1344-09-8, Sodium silicate 2809-21-4, Hydroxyethanediphosphonic acid 3313-92-6, Sodium percarbonate 7631-86-9, Silica, uses 7632-05-5, Sodium phosphate 7647-14-5, Sodium chloride, uses 7757-82-6, Sodiumsulfate, uses 7758-29-4, Sodium tripolyphosphate 8061-51-6D, Sodium lignosulfonate, oxy derivs. 9001-92-7, Protease 9003-01-4, Polyacrylic acid 9012-54-8, Cellulase 10332-33-9, Sodium perborate monohydrate 11138-47-9, Sodium perborate 13463-67-7, Titanioxide, uses 14807-96-6, Talc, uses 14987-04-3, Magnesium trisilicate 15477-76-6, Phosphate 41376-15-2D, Chloromethylbiphenyl, polymers with naphthalenesulfonic acid 102568-16-1D, salts
- RL: MOA (Modifier or additive use); USES (Uses)
- (formulations comprising water-soluble granulates)
- IT 672911-83-0, Neodol 23-6.5E
- RL: TEM (Technical or engineered material use); USES (Uses)
- (nonionic surfactant; formulations comprising water-soluble granulates)
- IT 14320-04-8, Zinc phthalocyanine 84370-49-0
- RL: CAT (Catalyst use); USES (Uses)
- (photoactivator; formulations comprising water-soluble granulates)
- IT 132-16-1, Ferrous phthalocyanine 574-93-6D, Phthalocyanine, complexes 1661-03-6, Magnesium phthalocyanine 7440-21-3D, Silicon, phthalocyanine complex 7440-31-5D, Tin, phthalocyanine complex 7440-32-6D, Titanium, phthalocyanine complex 7440-47-3D, Chromium, phthalocyanine complex 7440-55-3D, Gallium, phthalocyanine complex 7440-56-4D, Germanium,

phthalocyanine complex 7440-58-6D, Hafnium, phthalocyanine complex  
7440-67-7D, Zirconium, phthalocyanine complex 7440-74-6D, Indium,  
phthalocyanine complex 7723-14-0D, Phosphorus, phthalocyanine complex  
21328-73-4, Calcium phthalocyanine 25047-77-2 25476-27-1, Sodium  
phthalocyanine

RL: TEM (Technical or engineered material use); USES (Uses)  
(photoactivator; formulations comprising water-soluble granulates)

IT 25155-19-5D, Naphthalenesulfonic acid, polymers with  
polychloromethylbiphenyl

RL: MOA (Modifier or additive use); USES (Uses)  
(polymers; formulations comprising water-soluble granulates)

L9 3 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN

CC 63-6 (Pharmaceuticals)

TI Pharmaceutical formulations of cannabinoids for application to the skin  
and method of use

ST transdermal pharmaceutical formulation cannabinoid skin

IT G protein-coupled receptors

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); BIOL (Biological study)

(HM74A/GPR109A; pharmaceutical formulations of cannabinoids for  
application to skin and method of use)

IT Nervous system, disease

(Huntington's chorea; pharmaceutical formulations of cannabinoids for  
application to skin and method of use)

IT Drugs of abuse

(abuse of; pharmaceutical formulations of cannabinoids for application  
to skin and method of use)

IT Cannabinoid receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(agonist; pharmaceutical formulations of cannabinoids for application  
to skin and method of use)

IT Nicotinic receptors

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); BIOL (Biological study)  
(agonists; pharmaceutical formulations of cannabinoids for application  
to skin and method of use)

IT Essential oils

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); BIOL (Biological study)  
(bitter almond; pharmaceutical formulations of cannabinoids for  
application to skin and method of use)

IT Flavonoids

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); BIOL (Biological study)  
(cannabinoid; pharmaceutical formulations of cannabinoids for  
application to skin and method of use)

IT Shock (circulatory collapse)

(cardiogenic; pharmaceutical formulations of cannabinoids for  
application to skin and method of use)

IT Ischemia

(cerebral; pharmaceutical formulations of cannabinoids for application  
to skin and method of use)

IT Essential oils

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); BIOL (Biological study)  
(citrus; pharmaceutical formulations of cannabinoids for application to  
skin and method of use)

IT Mental and behavioral disorders

(depression; pharmaceutical formulations of cannabinoids for  
application to skin and method of use)

IT Intestine  
(disorders; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Beverages  
(dyes; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Cannabinoids  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(endocannabinoids; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(eucalyptus; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Seizures  
(febrile; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(grapefruit; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Digestive tract  
(irritants; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Brain, disease  
(ischemia; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Pigments, nonbiological  
(lakes; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(lemon; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(lime; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Membranes, nonbiological  
(microporous; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(nutmeg; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Resins  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(oleoresins; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
(orange, sour; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (peppermint; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Alcoholism  
 Alzheimer's disease  
 Amyotrophic lateral sclerosis  
 Analgesics  
 Animal tissue  
 Anxiolytics  
 Atherosclerosis  
 Buccal drug delivery systems  
 Cartagena ipecacuanha  
 Cirrhosis  
 Cognitive disorders  
 Coloring materials  
 Dissolution  
 Dopamine agonists  
 Drug withdrawal  
 Emetics  
 Encephalitis  
 Flavor  
 Glaucoma (disease)  
 Human  
 Hypertension  
 Inhalation drug delivery systems  
 Irritants  
 Laxatives  
 Memory disorders  
 Metabolism  
 Mucosal drug delivery systems  
 Mucous membrane  
 Multiple sclerosis  
 Myocardial infarction  
 Nasal drug delivery systems  
 Neoplasm  
 Neurotoxicity  
 Obesity  
 Opioid antagonists  
 Oral drug delivery systems  
 Parenteral drug delivery systems  
 Parkinson's disease  
 Permeation enhancers  
 Pimenta dioica  
 Psychotomimetics  
 Rectal drug delivery systems  
 Schizophrenia  
 Skin  
 Solubility  
 Stains, coloring materials  
 Stroke  
 Sublingual drug delivery systems  
 Transdermal drug delivery systems  
 Vasodilators  
 Vomiting  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Acrylic polymers, biological studies  
 Capsaicinoids  
 Terpenes, biological studies

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Polyesters, biological studies  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Polyolefins  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Polyurethanes, biological studies  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Vanilloids  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (phorboid; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Adhesives  
 (polymer; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Parturition disorders  
 (premature parturition; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Headache  
 (producing agents; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Nausea  
 (producing compds.; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Shock (circulatory collapse)  
 (septic; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (spearment; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Cannabinoid receptors  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (type CB2; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT 12794-10-4, Benzodiazepine  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (antagonists; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT 9040-75-9, Monoacylglycerol lipase  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (inhibitors; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT 50-78-2, Acetylsalicylic acid 53-84-9, Nadide 57-06-7, Allyl isothiocyanate 57-50-1D, Sucrose, derivs. 58-00-4,

Apomorphine 59-30-3, biological studies 59-67-6, Niacin, biological studies 62-67-9, Nalorphine 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 89-78-1, Menthol 91-21-4D, analogs 94-62-2, Piperine 98-92-0, Nicotinamide 103-85-5, (Phenylthiocarbamide) 107-92-6, Butyric acid, biological studies 109-52-4, Valeric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glu-taric acid 122-48-5, Zingerone 124-04-9, Adipic acid, biological studies 124-07-2, Octanoic acid, biological studies 126-14-7, Sucrose octaacetate 130-95-0, Quinine 141-82-2, Malonic acid, biological studies 142-62-1, Caproic acid, biological studies 144-62-7, Oxalic acid, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 152-02-3, Levallorphan 299-29-6, Ferrous gluconate 300-85-6,  $\beta$ -Hydroxybutyric acid 306-08-1 334-48-5, Capric acid 404-86-4, Capsaicin 404-86-4D, Capsaicin, analogs 465-65-6, Naloxone 483-17-0, Cephaeline 483-18-1, Emetine 505-60-2, Mustard 521-35-7, Cannabinol 523-01-3, O-Methylpsychotrine 532-27-4, Mace 583-08-4, Nicotinuric acid 1972-08-3, Dronabinol 1972-08-3D, Pr analogs 2086-86-4, p-Hydroxybenzyl isothiocyanate 2444-46-4, Nonanoyl vanillylamide 3194-25-0, Nalorphine dinicotinate 3572-80-3, Cyclazocine 3734-33-6, Denatonium benzoate 4163-15-9, Cyclophorphan 6793-51-7 7440-66-6, Zinc, biological studies 7447-40-7, Potassium chloride, biological studies 7487-88-9, Magnesium sulfate, biological studies 7633-29-6, Psychotrine 7720-78-7, Ferrous sulfate 7791-08-4, Antimony oxychloride 10025-91-9, Antimony trichloride 12125-02-9, Ammonium chloride, biological studies 12441-09-7D, Sorbitan, monoesters 13956-29-1, Cannabidiol 13956-29-1D, Cannabidiol, Pr analogs 16590-41-3, Naltrexone 19408-84-5, Dihydrocapsaicin 20594-83-6, Nalbuphine 20675-51-8, Cannabichromene 20675-51-8D, Cannabichromene, Pr analogs 25496-72-4, Glyceryl monooleate 25654-31-3, Cannabigerol 28371-16-6, Aloin 42281-59-4, Oxilorphan 47324-98-1 51022-71-0, Nabilone 53847-30-6 55096-26-9, Nalmefene 57444-62-9, Resiniferatoxin 58493-49-5, Olvanil 58821-95-7, Tinyatoxin 71160-24-2, Leukotriene B(4) 73179-98-3 73232-52-7, Methylnaltrexone 75473-05-1 78755-81-4, Flumazenil) 79732-51-7, CP55244 80286-75-5, Desacetyllevonantradol 83002-04-4, CP55940 94421-68-8, Anandamide 106392-12-5, Poloxamer 112830-95-2, HU210 131543-22-1, WIN55212-2 142521-04-8 156053-89-3, Alvimopan 157182-49-5 158681-13-1, Sr 141716a 164178-33-0, AM630 168273-06-1, SR141716 175796-50-6 179469-40-0 183232-66-8, Am251 192703-06-3, SR144528 202463-68-1, Am281 256934-39-1, HU 308 494844-07-4 494844-07-4D, analogs 565460-15-3, URB602 611207-11-5 1007306-14-0D, derivs. 1007376-35-3 1007376-36-4

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)

(pharmaceutical formulations of cannabinoids for application to skin and method of use)

- IT 9002-88-4, Polyethylene 9003-07-0, Polypropylene 9003-20-7, Polyvinyl acetate 9003-21-8, Polymethyl acrylate 9003-32-1, Polyethyl acrylate 9003-53-6, Polystyrene 9010-77-9, Ethylene-acrylic acid copolymer 9010-86-0, Ethylene-ethylacrylate copolymer 9065-92-3, Polyoctene 24937-78-8, Ethylene-vinyl acetate copolymer 25103-74-6, Ethylenemethyl acrylate copolymer 70800-37-2, Ethyleneoctene copolymer

RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulations of cannabinoids for application to skin and method of use)



ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

L3 432048 S L2  
L4 13513 S L3 AND ("ACETIC ACID")  
L5 603 S L4 AND SUCROSE  
L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
L7 39 S L5 AND ("ACRYLIC ACID")  
L8 10 S L7 AND ACRYLATE  
L9 3 S L8 AND POLYETHYLENE

=> d l7 1-39 hitstr ibib all

L7 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2008 ACS ON STN

IT 24980-41-4, Polycaprolactone 25248-42-4,

Polycaprolactone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(abuse deterrent oral pharmaceutical of opioid agonists)

RN 24980-41-4 CAPLUS

CN 2-Oxepanone, homopolymer (CA INDEX NAME)

CM 1


CRN 502-44-3

CMF C6 H10 O2



RN 25248-42-4 CAPLUS

CN Poly[oxy(1-oxo-1,6-hexanediyl)] (CA INDEX NAME)



IT 110-15-6, Succinic acid, biological studies 124-04-9,

Adipic acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transient receptor potential vanilloid 1 agonist; abuse deterrent oral pharmaceutical of opioid agonists)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2008:285717 CAPLUS

DOCUMENT NUMBER: 148:315339

TITLE: Abuse deterrent oral pharmaceutical formulations of opioid agonists

INVENTOR(S): Babul, Najib

PATENT ASSIGNEE(S): Theraquest Biosciences, LLC, USA

SOURCE: PCT Int. Appl., 21pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008027442	A2	20080306	WO 2007-US19015	20070830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

US 2006-840970P P 20060830

US 2006-848994P P 20061004

AN 2008:285717 CAPLUS

DN 148:315339

ED Entered STN: 07 Mar 2008

TI Abuse deterrent oral pharmaceutical formulations of opioid agonists

IN Babul, Najib

PA Theraquest Biosciences, LLC, USA

SO PCT Int. Appl., 21pp.

CODEN: PIXXD2

DT Patent

LA English

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 4

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2008027442 A2 20080306 WO 2007-US19015 20070830

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2006-840970P P 20060830  
US 2006-848994P P 20061004

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2008027442 IPCI A61K0009-52 [I,A]  
IPCR A61K0009-52 [I,C]; A61K0009-52 [I,A]

AB The present invention is directed to pharmaceutical compns. of opioid agonists and the use thereof for preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alc. from either intentional or unintentional tampering. The present invention is also directed at methods of preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alc. from either intentional or unintentional tampering. A composition was prepared comprising an aversive agent loading on sphere containing rimonabant-HCl, a sphere overcoating, a sequestration overcoating and a final overcoating.

ST abuse deterrent oral pharmaceutical opioid agonist

IT Natural products, pharmaceutical  
(Senna; abuse deterrent oral pharmaceutical of opioid agonists)

IT Transient receptor potential cation channels  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TRPV1, agonists; abuse deterrent oral pharmaceutical of opioid agonists)

IT Chloride channel openers  
Dopamine agonists  
Drugs of abuse  
Laxatives  
Nicotinic agonists  
Opium  
Rhamnus purshiana  
(abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils  
Opioids  
Polyanhydrides  
Polyesters, biological studies  
Polyoxyalkylenes, biological studies  
Polyphosphazenes  
Polysaccharides, biological studies  
Proteins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bitter almond; abuse deterrent oral pharmaceutical of opioid agonists)

IT Cartagena ipecacuanha  
(emetic; abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (eucalyptus; abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (grapefruit; abuse deterrent oral pharmaceutical of opioid agonists)

IT Amides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (iso-Bu, guaiacyl, transient receptor potential vanilloid 1 agonist;  
 abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lemon; abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lime; abuse deterrent oral pharmaceutical of opioid agonists)

IT Resins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oleoresins; abuse deterrent oral pharmaceutical of opioid agonists)

IT Alkaloids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (opium, hydrochlorides; abuse deterrent oral pharmaceutical of opioid  
 agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (orange, sweet; abuse deterrent oral pharmaceutical of opioid agonists)

IT Polyethers, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (ortho ester group-containing; abuse deterrent oral pharmaceutical of  
 opioid agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (peppermint; abuse deterrent oral pharmaceutical of opioid agonists)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (spearmint; abuse deterrent oral pharmaceutical of opioid agonists)

IT Capsaicinoids

Dialdehydes

Vanilloids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (transient receptor potential vanilloid 1 agonist; abuse deterrent oral  
 pharmaceutical of opioid agonists)

IT Cannabinoid receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type CB1; abuse deterrent oral pharmaceutical of opioid agonists)

IT Cannabinoid receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type CB2; abuse deterrent oral pharmaceutical of opioid agonists)

IT Capsaicin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type VR1, agonists; abuse deterrent oral pharmaceutical of opioid  
 agonists)

IT 192703-06-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (SR 144528, cannabinoid antagonist; abuse deterrent oral pharmaceutical  
 of opioid agonists)

IT 57-50-1D, Sucrose, derivs. 103-85-5, Phenylthiourea  
 126-14-7, Sucrose octaacetate 130-95-0, Quinine 3734-33-6,  
 Denatonium benzoate 40984-18-7D, derivs. 47324-98-1 90823-38-4,  
 Denatonium saccharide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (T2R or TAS2R agonists; abuse deterrent oral pharmaceutical of opioid

agonists)

IT 57-27-2, Morphine, biological studies 57-42-1, Meperidine 64-39-1, Promedol 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-58-4, Ethylmorphine 76-99-3, Methadone 77-07-6 77-14-5, Propheptazine 77-15-6, Ethoheptazine 77-20-3, Alphaprodine 107-92-6D, Butyric acid, dioxaheptyl esters 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 127-35-5, Phenazocine 131-28-2, Narceine 143-52-2, Metopon 144-14-9, Anileridine 302-41-0, Piritramide 357-56-2, Dextromoramide 359-83-1, Pentazocine 427-00-9, Desomorphine 428-37-5, Profadol 437-38-7, Fentanyl 441-61-2, Ethylmethylthiambutene 466-40-0, Isomethadone 466-97-7, Normorphine 466-99-9, Hydromorphone 467-18-5, Myrophine 467-83-4, Dipipanone 467-84-5, Phenadoxone 467-85-6, Normethadone 468-07-5, Phenomorphan 468-56-4, Hydroxypethidine 469-62-5, Propoxyphene 469-79-4, Ketobemidone 509-60-4, Dihydromorphone 509-67-1, Pholcodine 509-78-4, Dimenoxadol 524-84-5, Dimethylthiambutene 545-90-4, Dimepheptanol 552-25-0, Diampromide 561-27-3, Heroin 561-48-8, Norpipanone 561-76-2, Propiridine 562-26-5, Phenoperidine 639-48-5, Nicomorphine 911-65-9, Etonitazene 1531-12-0, Norlevorphanol 3734-52-9, Metazocine 3861-76-5, Clonitazene 4163-15-9, Cyclophorphan 4406-22-8, Cyprenorphine 10061-32-2, Levophenacylmorphane 13495-09-5, Piminodine 14297-87-1, Benzylmorphine 15301-48-1, Bezitramide 15686-91-6, Propiram 20290-10-2, Morphine 6-glucuronide 20594-83-6, Nalbuphine 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone 25384-17-2, Allylprodine 27203-92-5, Tramadol 33434-24-1, Eudragit rs30d 42408-82-2, Butorphanol 51931-66-9, Tilidine 52485-79-7, Buprenorphine 53648-55-8, Dezocine 54340-58-8, Meptazinol 56030-54-7, Sufentanil 59708-52-0, Carfentanil 61380-40-3, Lofentanil 71195-58-9, Alfentanil 72522-13-5, Eptazocine 78995-14-9, Ohmefentanyl 101345-71-5, Brifentanil 117523-47-4, Mirfentanil 120656-74-8, Trefentanil 132875-61-7, Remifentanil 170713-75-4, Nociceptin 175591-23-8, Tapentadol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(abuse deterrent oral pharmaceutical of opioid agonists)

IT 94-20-2, Chlorpropamide 9028-86-8 37174-63-3 97240-79-4, Topiramate

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(alc. deterrent; abuse deterrent oral pharmaceutical of opioid agonists)

IT 97-77-8, Disulfiram 97-77-8D, Disulfiram, metabolites 156-62-7, Calcium carbimide 443-48-1, Metronidazole 77337-76-9, Acamprosate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alc. deterrent; abuse deterrent oral pharmaceutical of opioid agonists)

IT 158681-13-1, Rimobabant hydrochloride 168273-06-1, Rimobabant

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(cannabinoid antagonist; abuse deterrent oral pharmaceutical of opioid agonists)

IT 13956-29-1, Cannabidiol 112830-95-2, Hu-210 164178-33-0, Am630 183232-66-8, Am251 202463-68-1, Am281 256934-39-1, Hu-308 494844-07-4 494844-07-4D, analogs 611207-11-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cannabinoid antagonist; abuse deterrent oral pharmaceutical of opioid agonists)

IT 1007306-14-0D, tricyclic derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cannabinoid antagonists; abuse deterrent oral pharmaceutical of opioid agonists)

IT 69-65-8, D-Mannitol 77-09-8, Phenolphthalein 81-27-6, Sennoside a 125-13-3, Oxyphenisatine 128-57-4, Sennoside b 1309-42-8, Magnesium

hydroxide 1309-48-4, Magnesium oxide, biological studies 7632-05-5,  
Sodium phosphate 7779-25-1, Magnesium citrate 10040-45-6, Sodium  
picosulfate 25322-68-3, Peg 136790-76-6, Lubiprostone  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chloride channel activator; abuse deterrent oral pharmaceutical of  
opioid agonists)

IT 64-17-5, Ethanol, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(deterrents; abuse deterrent oral pharmaceutical of opioid agonists)

IT 58-00-4, Apomorphine 59-30-3, Folic acid, biological studies 59-30-3D,  
Folic acid, derivs. 98-92-0, Nicotinamide 299-29-6, Ferrous gluconate  
483-17-0, Cephaline 483-18-1, Emetine 523-01-3 6793-51-7  
7440-66-6, Zinc, biological studies 7447-40-7, Potassium chloride,  
biological studies 7487-88-9, Magnesium sulfate, biological studies  
7633-29-6, Psychotrine 7720-78-7, Ferrous sulfate 7791-08-4  
8015-61-0, Aloin 10025-91-9, Antimony trichloride 12125-02-9, Ammonium  
chloride, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(emetic; abuse deterrent oral pharmaceutical of opioid agonists)

IT 84-65-1, Anthraquinone 84-65-1D, Anthraquinone, analogs 117-10-2,  
Dantrol 128-49-4, Docusate calcium 577-11-7, Docusate sodium  
603-50-9, Bisacodyl 7491-09-0, Docusate potassium 8024-48-4,  
Casanthranol 17692-24-9 18321-66-9 71036-28-7, Hydroxyanthracene  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(laxative; abuse deterrent oral pharmaceutical of opioid agonists)

IT 53-84-9, Nadide 152-02-3, Levallorphan 465-65-6, Naloxone 3572-80-3,  
Cyclazocine 16590-41-3, Naltrexone 42281-59-4, Oxilorphan  
55096-26-9, Nalmefene 73232-52-7, Methyl naltrexone 83387-25-1,  
N-Methyl naltrexone 156053-89-3, Alvimopan 342639-47-8 342639-49-0  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(opioid antagonist; abuse deterrent oral pharmaceutical of opioid  
agonists)

IT 79-10-7D, Acrylic acid, copolymers 79-41-4D,  
Methacrylic acid, copolymers 80-62-6D, Methyl methacrylate, copolymers  
106-91-2D, Glycidyl methacrylate, copolymers 2370-63-0D, Ethoxyethyl  
methacrylate, polymers 4513-53-5D, Cyanoethyl methacrylate, polymers  
9003-01-4, Polyacrylic acid 9003-05-8, Polyacrylamide 9004-35-7  
9004-35-7D, dimethylamino derivs. 9004-36-8, Cellulose acetate butyrate  
9004-38-0, Cellulose acetate phthalate 9004-39-1, Cellulose acetate  
propionate 9004-48-2, Cellulose propionate 9004-57-3, Ethyl cellulose  
9011-14-7, Pmma 9012-09-3 25087-26-7, Poly(methacrylic acid)  
25300-99-6, Poly(methacrylic anhydride) 26009-03-0, Polyglycolide  
26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26202-08-4,  
Polyglycolide 26680-10-4, Polylactide 29223-92-5 31621-87-1,  
Polydioxanone 34346-01-5, Glycolic acid-lactic acid polymer  
52352-27-9, Poly(hydroxybutyric acid) 75734-93-9, Polyglyconate  
97089-04-8, Cellulose acetate ethylcarbamate 97089-05-9, Cellulose  
acetate methylcarbamate 112143-11-0  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sequestant; abuse deterrent oral pharmaceutical of opioid agonists)

IT 50-78-2, Acetylsalicylic acid 57-06-7, Allyl isothiocyanate 64-18-6,  
Formic acid, biological studies 64-19-7, Acetic acid  
, biological studies 77-92-9, Citric acid, biological studies 79-09-4,  
Propanoic acid, biological studies 91-21-4D, thiourea analogs 94-62-2,  
Piperine 107-92-6, Butyric acid, biological studies 109-52-4, Valeric  
acid, biological studies 110-15-6, Succinic acid, biological  
studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric  
acid, biological studies 110-94-1, Glutaric acid 122-48-5, Zingerone  
124-04-9, Adipic acid, biological studies 124-07-2, Caprylic  
acid, biological studies 141-82-2, Malonic acid, biological studies  
142-62-1, Caproic acid, biological studies 144-62-7, Oxalic acid,

biological studies 151-21-3, Sodium lauryl sulfate, biological studies  
 334-48-5, Capric acid 404-86-4, Capsaicin 404-86-4D, Capsaicin,  
 analogs 505-60-2, Mustard 1701-57-1D, derivs. 2086-86-4,  
 p-Hydroxybenzyl isothiocyanate 12441-09-7D, Sorbitan, monoesters  
 19072-58-3, Vanillylamide 19408-84-5, Dihydrocapsaicin 25496-72-4,  
 Glyceryl monooleate 54845-95-3, 15-(S)-Hydroxyeicosatetraenoic acid  
 57444-62-9, Resiniferatoxin 58418-78-3 58493-49-5, Olvanil  
 58821-95-7, Tinyatoxin 70608-72-9D, 5-(S)-Hydroxyeicosatetraenoic acid,  
 derivs. 70981-96-3D, derivs. 71160-24-2, Leukotriene b4 71774-10-2D,  
 derivs. 94421-68-8, Anandamide 106392-12-5, Poloxamer 142521-04-8  
 179469-40-0 500294-39-3 1007355-45-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (transient receptor potential vanilloid 1 agonist; abuse deterrent oral  
 pharmaceutical of opioid agonists)

IT 300-85-6,  $\beta$ -Hydroxybutyric acid 583-08-4, Nicotinuric acid  
 603-41-8  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vasodilator; abuse deterrent oral pharmaceutical of opioid agonists)

L7 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, biological studies 124-04-9,  
 Adipic acid, biological studies  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
 activity); BIOL (Biological study)  
 (pharmaceutical formulations of cannabinoids for application to skin  
 and method of use)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-(\text{CH}_2)_4-\text{CO}_2\text{H}$

IT 9002-88-4, Polyethylene  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin  
 and method of use)

RN 9002-88-4 CAPLUS

CN Ethene, homopolymer (CA INDEX NAME)

CM 1

CRN 74-85-1

CMF C2 H4

$\text{H}_2\text{C}=\text{CH}_2$

ACCESSION NUMBER: 2008:252463 CAPLUS

DOCUMENT NUMBER: 148:269465

TITLE: Pharmaceutical formulations of cannabinoids for  
 application to the skin and method of use

INVENTOR(S): Babul, Najib  
 PATENT ASSIGNEE(S): Theraquest Biosciences, Inc., USA  
 SOURCE: PCT Int. Appl., 181pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008024408	A2	20080228	WO 2007-US18585	20070822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2006-839115P	P 20060822
			US 2006-839117P	P 20060822
			US 2006-840969P	P 20060830
			US 2006-840971P	P 20060830

AN 2008:252463 CAPLUS  
 DN 148:269465  
 ED Entered STN: 29 Feb 2008  
 TI Pharmaceutical formulations of cannabinoids for application to the skin and method of use  
 IN Babul, Najib  
 PA Theraquest Biosciences, Inc., USA  
 SO PCT Int. Appl., 181pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008024408	A2	20080228	WO 2007-US18585	20070822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-839115P	P	20060822		
US 2006-839117P	P	20060822		
US 2006-840969P	P	20060830		
US 2006-840971P	P	20060830		

CLASS



PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2008024408	IPCI	A61K0009-70 [I,A]
	IPCR	A61K0009-70 [I,C]; A61K0009-70 [I,A]
AB	<p>The present invention is directed to pharmaceutical compns. of cannabinoid agonists for application to the skin and the use thereof for preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. The present invention is also directed at a method of preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. Monolithic transdermal cannabinoid agonist reservoirs were prepared containing 3 mg/cm<sup>2</sup> of cannabinoid agonist base. Apolacrylate adhesive (National Starch 87-2287, 200 g) was solubilized in a solvent (Et acetate, 250 mL). Cannabinoid agonist base was added to the polacrylate adhesive solution in amts. sufficient to generate a mixture containing approx. 4% of cannabinoid agonist</p>	
in	<p>the adhesive solution and stirred to dissolve. The solution was cast on to a peelable protective liner such as a siliconized polyester film, and the solvent was evaporated to provide a 0.05 mm (2 mil) thick reservoir layer. Similarly, monolithic transdermal cannabinoid agonist reservoirs were prepared using the polacrylate adhesive (National Starch 87-4287, 200 g), as described above.</p>	
ST	transdermal pharmaceutical formulation cannabinoid skin	
IT	G protein-coupled receptors	
	<p>RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)</p> <p>(HM/4A/GPR109A; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Nervous system, disease	
	<p>(Huntington's chorea; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Drugs of abuse	
	<p>(abuse of; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Cannabinoid receptors	
	<p>RL: BSU (Biological study, unclassified); BIOL (Biological study)</p> <p>(agonist; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Nicotinic receptors	
	<p>RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)</p> <p>(agonists; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Essential oils	
	<p>RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)</p> <p>(bitter almond; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Flavonoids	
	<p>RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)</p> <p>(cannabinoid; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Shock (circulatory collapse)	
	<p>(cardiogenic; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Ischemia	
	<p>(cerebral; pharmaceutical formulations of cannabinoids for application to skin and method of use)</p>	
IT	Essential oils	

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (citrus; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Mental and behavioral disorders  
 (depression; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Intestine  
 (disorders; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Beverages  
 (dyes; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Cannabinoids  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (endocannabinoids; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (eucalyptus; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Seizures  
 (febrile; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (grapefruit; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Digestive tract  
 (irritants; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Brain, disease  
 (ischemia; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Pigments, nonbiological  
 (lakes; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (lemon; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (lime; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Membranes, nonbiological  
 (microporous; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (nutmeg; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Resins  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)

(oleoresins; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (orange, sour; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Essential oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (peppermint; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Alcoholism  
 Alzheimer's disease  
 Amyotrophic lateral sclerosis  
 Analgesics  
 Animal tissue  
 Anxiolytics  
 Atherosclerosis  
 Buccal drug delivery systems  
 Cartagena ipecacuanha  
 Cirrhosis  
 Cognitive disorders  
 Coloring materials  
 Dissolution  
 Dopamine agonists  
 Drug withdrawal  
 Emetics  
 Encephalitis  
 Flavor  
 Glaucoma (disease)  
 Human  
 Hypertension  
 Inhalation drug delivery systems  
 Irritants  
 Laxatives  
 Memory disorders  
 Metabolism  
 Mucosal drug delivery systems  
 Mucous membrane  
 Multiple sclerosis  
 Myocardial infarction  
 Nasal drug delivery systems  
 Neoplasm  
 Neurotoxicity  
 Obesity  
 Opioid antagonists  
 Oral drug delivery systems  
 Parenteral drug delivery systems  
 Parkinson's disease  
 Permeation enhancers  
 Pimenta dioica  
 Psychotomimetics  
 Rectal drug delivery systems  
 Schizophrenia  
 Skin  
 Solubility  
 Stains, coloring materials  
 Stroke  
 Sublingual drug delivery systems  
 Transdermal drug delivery systems

Vasodilators  
 Vomiting  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Acrylic polymers, biological studies  
 Capsaicinoids  
 Terpenes, biological studies  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Polyesters, biological studies  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Polyolefins  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Polyurethanes, biological studies  
 RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Vanilloids  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (phorboid; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Adhesives  
 (polymer; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Parturition disorders  
 (premature parturition; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Headache  
 (producing agents; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Nausea  
 (producing compds.; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Shock (circulatory collapse)  
 (septic; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Oils  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (spearmint; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT Cannabinoid receptors  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (type CB2; pharmaceutical formulations of cannabinoids for application to skin and method of use)

IT 12794-10-4, Benzodiazepine  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (antagonists; pharmaceutical formulations of cannabinoids for application to skin and method of use)

- IT 9040-75-9, Monoacylglycerol lipase  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (inhibitors; pharmaceutical formulations of cannabinoids for application to skin and method of use)
- IT 50-78-2, Acetylsalicylic acid 53-84-9, Nadide 57-06-7, Allyl isothiocyanate 57-50-1D, Sucrose, derivs. 58-00-4, Apomorphine 59-30-3, biological studies 59-67-6, Niacin, biological studies 62-67-9, Nalorphine 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 89-78-1, Menthyl 91-21-4D, analogs 94-62-2, Piperine 98-92-0, Nicotinamide 103-85-5, (Phenylthiocarbamide) 107-92-6, Butyric acid, biological studies 109-52-4, Valeric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glu-taric acid 122-48-5, Zingerone 124-04-9, Adipic acid, biological studies 124-07-2, Octanoic acid, biological studies 126-14-7, Sucrose octaacetate 130-95-0, Quinine 141-82-2, Malonic acid, biological studies 142-62-1, Caproic acid, biological studies 144-62-7, Oxalic acid, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 152-02-3, Levallorphan 299-29-6, Ferrous gluconate 300-85-6,  $\beta$ -Hydroxybutyric acid 306-08-1 334-48-5, Capric acid 404-86-4, Capsaicin 404-86-4D, Capsaicin, analogs 465-65-6, Naloxone 483-17-0, Cephaeline 483-18-1, Emetine 505-60-2, Mustard 521-35-7, Cannabinol 523-01-3, O-Methylpsychotrine 532-27-4, Mace 583-08-4, Nicotinuric acid 1972-08-3, Dronabinol 1972-08-3D, Pr analogs 2086-86-4, p-Hydroxybenzyl isothiocyanate 2444-46-4, Nonanoyl vanillylamide 3194-25-0, Nalorphine dinicotinate 3572-80-3, Cyclozocine 3734-33-6, Denatonium benzoate 4163-15-9, Cyclophorphan 6793-51-7 7440-66-6, Zinc, biological studies 7447-40-7, Potassium chloride, biological studies 7487-88-9, Magnesium sulfate, biological studies 7633-29-6, Psychotrine 7720-78-7, Ferrous sulfate 7791-08-4, Antimony oxychloride 10025-91-9, Antimony trichloride 12125-02-9, Ammonium chloride, biological studies 12441-09-7D, Sorbitan, monoesters 13956-29-1, Cannabidiol 13956-29-1D, Cannabidiol, Pr analogs 16590-41-3, Naltrexone 19408-84-5, Dihydrocapsaicin 20594-83-6, Nalbuphine 20675-51-8, Cannabichromene 20675-51-8D, Cannabichromene, Pr analogs 25496-72-4, Glycerol monooleate 25654-31-3, Cannabigerol 28371-16-6, Aloin 42281-59-4, Oxilorphan 47324-98-1 51022-71-0, Nabilone 53847-30-6 55096-26-9, Nalmefene 57444-62-9, Resiniferatoxin 58493-49-5, Olvanil 58821-95-7, Tinyatoxin 71160-24-2, Leukotriene B(4) 73179-98-3 73232-52-7, Methylnaltrexone 75473-05-1 78755-81-4, Flumazenil 79732-51-7, CP55244 80286-75-5, Desacetyllevonantradol 83002-04-4, CP55940 94421-68-8, Anandamide 106392-12-5, Poloxamer 112830-95-2, HU210 131543-22-1, WIN55212-2 142521-04-8 156053-89-3, Alvimopan 157182-49-5 158681-13-1, Sr 141716a 164178-33-0, AM630 168273-06-1, SR141716 175796-50-6 179469-40-0 183232-66-8, Am251 192703-06-3, SR144528 202463-68-1, Am281 256934-39-1, HU 308 494844-07-4 494844-07-4D, analogs 565460-15-3, URB602 611207-11-5 1007306-14-0D, derivs. 1007376-35-3 1007376-36-4  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)  
 (pharmaceutical formulations of cannabinoids for application to skin and method of use)
- IT 9002-88-4, Polyethylene 9003-07-0, Polypropylene 9003-20-7, Polyvinyl acetate 9003-21-8, Polymethyl acrylate 9003-32-1, Polyethyl acrylate 9003-53-6, Polystyrene 9010-77-9, Ethylene-acrylic acid copolymer 9010-86-0, Ethylene-ethylacrylate copolymer 9065-92-3, Polyoctene 24937-78-8, Ethylene-vinyl acetate copolymer

25103-74-6, Ethylenemethyl acrylate copolymer 70800-37-2, Ethyleneoctene copolymer

RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulations of cannabinoids for application to skin and method of use)

L7 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN


IT 109-43-3, Dibutyl sebacate 110-15-6, Succinic acid, biological studies 124-04-9, Adipic acid, biological studies 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of oral comps. of cannabinoids for decreasing potential abuse and toxicity)

RN 109-43-3 CAPLUS

CN Decanedioic acid, 1,10-dibutyl ester (CA INDEX NAME)




RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)



RN 24980-41-4 CAPLUS

CN 2-Oxepanone, homopolymer (CA INDEX NAME)

CM 1


CRN 502-44-3

CMF C6 H10 O2



RN 25248-42-4 CAPLUS

CN Poly[oxy(1-oxo-1,6-hexanediyl)] (CA INDEX NAME)



ACCESSION NUMBER: 2008:221461 CAPLUS  
 DOCUMENT NUMBER: 148:292088  
 TITLE: Pharmaceutical oral formulations of cannabinoids for decreasing potential abuse and toxicity  
 INVENTOR(S): Babul, Najib  
 PATENT ASSIGNEE(S): Theraquest Biosciences, LLC, USA  
 SOURCE: PCT Int. Appl., 190pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021394	A2	20080221	WO 2007-US18062	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2006-837606P	P 20060815
			US 2006-837607P	P 20060815
			US 2006-842359P	P 20060906
			US 2006-849006P	P 20061004

AN 2008:221461 CAPLUS  
 DN 148:292088  
 ED Entered STN: 21 Feb 2008  
 TI Pharmaceutical oral formulations of cannabinoids for decreasing potential abuse and toxicity  
 IN Babul, Najib  
 PA Theraquest Biosciences, LLC, USA  
 SO PCT Int. Appl., 190pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 4

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008021394	A2	20080221	WO 2007-US18062	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2006-837606P P 20060815  
 US 2006-837607P P 20060815  
 US 2006-842359P P 20060906  
 US 2006-849006P P 20061004

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2008021394	IPCI	A61K0008-37 [I,A]; A61K0008-30 [I,C*] IPCR A61K0008-30 [I,C]; A61K0008-37 [I,A]
---------------	------	--

AB The present invention is directed to pharmaceutical compns. of cannabinoid agonists and the use thereof for preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. The present invention is also directed at a method of preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. Thus, a mixture containing 700 g rimonabant HCl (aversive agent), 5 g Methocel E5P, 200 g ethanol and 200 g water was coated onto 700 g of sugar spheres in fluidized-bed and the cores obtained were then coated with a sequestering overcoating composition containing 140 g Eudragit RS30D, 14 g tri-Et citrate and 1260 g ethanol up to a 20% to 60% weight gain. A tablet formulation comprising an immediate release cannabinoid agonist A9-tetrahydrocannabinol (THC) with a suitable amount of substantially non-releasable aversive agent was prepared by granulation of a mixture containing THC 25 mg, polyvinylpyrrolidone 7.5 mg, lactose 30 mg, Alc. SD3A-2 proof 3 mL stearic acid 5 mg, talc 705 mg, corn starch 20 mg, and rimonabant HCl spheres suitable amount and compression.

ST cannabinoid receptor agonist aversive agent oral abuse toxicity

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (GPR109A (HM74A), agonists; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Nervous system, disease  
 (Huntington's chorea; preparation and therapeutic uses of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Natural products, pharmaceutical  
 (Senna; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Transient receptor potential cation channels  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (TRPV1, agonists; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Drugs of abuse  
 (abuse of; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Cannabinoid receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (agonists and antagonists; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Nicotinic receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (agonists; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (allspice; preparation of oral compns. of cannabinoids for decreasing



potential abuse and toxicity)

IT Benzodiazepine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antagonists; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Dyes  
 (beverage and tissue; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bitter almond; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Taste receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (bitter, T2R, agonists; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Taste receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (bitter, TAS2R, agonists; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (caprolactone-based; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Shock (circulatory collapse)  
 (cardiogenic; preparation and therapeutic uses of oral compns. of  
 cannabinoids for decreasing potential abuse and toxicity)

IT Ischemia  
 (cerebral; preparation and therapeutic uses of oral compns. of cannabinoids  
 for decreasing potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (citrus; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Mental and behavioral disorders  
 (depression; preparation and therapeutic uses of oral compns. of  
 cannabinoids for decreasing potential abuse and toxicity)

IT Feces

Urine  
 (discolorants; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Drug withdrawal  
 (drugs for precipitation of; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Cannabinoids  
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (endocannabinoids; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (eucalyptus; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Seizures  
 (febrile; preparation and therapeutic uses of oral compns. of cannabinoids  
 for decreasing potential abuse and toxicity)

IT Aromatic compounds  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (flavoring; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Coating process

- (fluidized-bed; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Essences
  - (fruit; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Polyesters, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (glycolide-based; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Essential oils
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (grapefruit; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Polyesters, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (hydroxycarboxylic acid-based; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Digestive tract
  - Respiratory system
    - (irritants; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Brain, disease
  - (ischemia; preparation and therapeutic uses of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Polyesters, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (lactide; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Pigments, nonbiological
  - (lakes; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Essential oils
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (lemon; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Essential oils
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (lime; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Odor and Odorous substances
  - (malodorous agents; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Mouth
  - Nose
    - (mucosa, irritants; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Fats and Glyceridic oils, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (nutmeg butter; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Essential oils
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (nutmeg; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Resins
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (oleoresins; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)
- IT Essential oils
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (orange, sour; preparation of oral compns. of cannabinoids for decreasing

potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (orange, sweet; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Polyethers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (ortho ester group-containing; preparation of oral compns. of cannabinoids  
 for decreasing potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (peppermint; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Vanilloids  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phorboid; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phosphorus-containing; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Polyoxalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyester-; preparation of oral compns. of cannabinoids for decreasing  
 potential abuse and toxicity)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyoxalkylene-; preparation of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Parturition disorders  
 (premature parturition; preparation and therapeutic uses of oral compns. of  
 cannabinoids for decreasing potential abuse and toxicity)

IT Alcoholism  
 Alzheimer's disease  
 Amyotrophic lateral sclerosis  
 Atherosclerosis  
 Cirrhosis  
 Cognitive disorders  
 Encephalitis  
 Glaucoma (disease)  
 Hypertension  
 Intestine, disease  
 Memory disorders  
 Multiple sclerosis  
 Myocardial infarction  
 Neoplasm  
 Neurotoxicity  
 Obesity  
 Pain  
 Parkinson's disease  
 Schizophrenia  
 Stroke  
 Vomiting  
 (preparation and therapeutic uses of oral compns. of cannabinoids for  
 decreasing potential abuse and toxicity)

IT Cartagena ipecacuanha  
 Chloride channel openers  
 Coating materials  
 Coloring materials  
 Controlled-release drug delivery systems

Dopamine agonists  
 Drug toxicity  
 Emetics  
 Laxatives  
 Opioid antagonists  
 Oral drug delivery systems  
 Pharmaceutical beads  
 Pharmaceutical capsules  
 Pharmaceutical tablets  
 Rhamnus  
 Rhamnus purshiana  
 Sequestering agents  
 Vasodilators  
 (preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Cannabinoids  
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Capsaicinoids  
 Carnauba wax  
 Essential oils  
 Polyanhydrides  
 Polyethers, biological studies  
 Polyoxymethylenes, biological studies  
 Polyphosphazenes  
 Polysaccharides, biological studies  
 Proteins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Bitterness  
 Headache  
 Nausea  
 (producing agents; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Capsaicinoids  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (resiniferanoids; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Shock (circulatory collapse)  
 (septic; preparation and therapeutic uses of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Essential oils  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (spearmint; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Aldehydes, biological studies  
 Terpenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (terpene aldehydes, 1,4-unsatd. dialdehydes; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Cannabinoid receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type CB2, agonists; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Capsaicin receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (type VR1, agonists; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Opioid antagonists  
( $\delta$ -opioid; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT Opioid antagonists  
( $\mu$ -opioid; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 33434-24-1, Eudragit RS 100  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Eudragit RS PO, Eudragit RS30D; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 168273-06-1, Rimobabant  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(SR 141716; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 7631-86-9, Cabosil, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(colloidal; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 64-17-5, Ethanol, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(deterrents; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 9028-86-8, Aldehyde dehydrogenase 153301-19-0, Anandamide amidase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 9004-34-6, Cellulose, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microcryst.; preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 120-72-9D, Indole, aminoalkyl compds. 1972-08-3, A9-Tetrahydrocannabinol 53847-30-6 79732-51-7, CP 55244 80286-75-5, Desacetylvonnantradol 83002-04-4, CP 55940 94421-68-8, Anandamide 112830-95-2, HU 210 131543-22-1, WIN 55212-2  
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

IT 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 53-84-9, Nadide 57-06-7, Allyl isothiocyanate 57-11-4, Stearic acid, biological studies 57-29-4, Nalorphine hydrochloride 57-50-1D, Sucrose, chloro, derivs. 57-50-1D, Sucrose, derivs. 58-00-4, Apomorphine 59-30-3, Folic acid, biological studies 59-67-6, Niacin, biological studies 62-67-9, Nalorphine 63-42-3, Lactose 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 69-65-8, Mannitol 77-09-8, Phenolphthalein 77-92-9, Citric acid, biological studies 77-93-0, Triethyl citrate 79-09-4, Propionic acid, biological studies 79-10-7D, Acrylic acid, copolymers 79-41-4D, Methacrylic acid, derivs., copolymers 80-62-6D, Methyl methacrylate, copolymers 81-27-6, Sennoside A 84-65-1, Anthraquinone 84-65-1D, Anthraquinone, analogs and derivs. 89-78-1, Menthol 94-20-2, Chloropropamide 94-62-2, Piperine 97-77-8, Disulfiram 98-92-0, Nicotinamide 102-76-1, Triacetin 103-85-5, Phenylthiourea 106-91-2D, Glycidyl methacrylate, copolymers 107-92-6, Butyric acid, biological studies 109-43-3, Dibutyl sebacate 109-52-4, Valeric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 112-92-5, Stearyl alcohol 117-10-2, Dantron 122-48-5, Zingerone 124-04-9, Adipic acid, biological studies 124-07-2, Caprylic acid, biological studies 125-13-3, Oxyphenisatine

126-14-7, Sucrose octaacetate 128-37-0, Butylated  
 hydroxytoluene, biological studies 128-49-4, Docusate calcium  
 128-57-4, Sennoside B 130-95-0, Quinine 134-03-2, Sodium ascorbate  
 141-82-2, Malonic acid, biological studies 142-62-1, Caproic acid,  
 biological studies 144-62-7, Oxalic acid, biological studies 151-21-3,  
 Sodium lauryl sulfate, biological studies 152-02-3, Levallorphan  
 156-62-7, Calcium carbimide 299-29-6, Ferrous gluconate 300-85-6  
 334-48-5, Capric acid 357-08-4, Naloxone hydrochloride 404-86-4,  
 Capsaicin 404-86-4D, Capsaicin, analogs 443-48-1, Metronidazole  
 465-65-6, Naloxone 483-17-0, Cephaeline 483-18-1, Emetine 505-60-2,  
 Mustard 521-35-7, Cannabinol 523-01-3, O-Methylpsychotrine 557-04-0,  
 Magnesium stearate 563-83-7D, derivs. 577-11-7, Docusate sodium  
 583-08-4, Nicotinuric acid 603-41-8 603-50-9, Bisacodyl 1309-42-8,  
 Magnesium hydroxide 1309-48-4, Magnesium oxide, biological studies  
 1972-08-3D, A9-Tetrahydrocannabinol, Pr analog 2086-86-4,  
 p-Hydroxybenzyl isothiocyante 2370-63-0D, Ethoxyethyl methacrylate,  
 copolymers 2444-46-4, Nonanoylvanillylamide 3194-25-0, Nalorphine  
 dinicotinate 3572-80-3, Cyclazocine 3734-33-6, Denatonium benzoate  
 4163-15-9, Cyclophorphan 4513-53-5D, Cyanoethyl methacrylate, copolymers  
 6793-51-7, N-Methylcephaeline 7440-66-6D, Zinc, salts 7447-40-7,  
 Potassium chloride, biological studies 7487-88-9, Magnesium sulfate,  
 biological studies 7491-09-0, Docusate potassium 7632-05-5, Sodium  
 phosphate 7633-29-6, Psychotrine 7720-78-7, Ferrous sulfate  
 7757-93-9, Dibasic calcium phosphate 7779-25-1, Magnesium citrate  
 7791-08-4, Antimony oxychloride 8015-61-0, Aloin 8024-48-4,  
 Casanthranol 9003-01-4, Poly(acrylic acid)  
 9003-05-8, Polyacrylamide 9003-39-8, Plasdone K29/32 9003-43-4,  
 Polyvinylpyrrolidone 9004-35-7 9004-35-7D, acetaldehyde di-Me derivs.  
 9004-36-8, Cellulose acetate butyrate 9004-38-0, Cellulose acetate  
 phthalate 9004-39-1, Cellulose acetate propionate 9004-48-2, Cellulose  
 propionate 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl  
 cellulose 9004-65-3, Methocel E 5P 9005-25-8, Starch, biological  
 studies 9010-88-2, Eudragit NE 30D 9011-14-7, Poly(methyl  
 methacrylate) 9012-09-3 10025-91-9, Antimony trichloride 10040-45-6,  
 Sodium picosulfate 12125-02-9, Ammonium chloride, biological studies  
 12441-09-7D, Sorbitan, monoesters 13956-29-1, Cannabidiol 14807-96-6,  
 Talc, biological studies 16590-41-3, Naltrexone 16676-29-2, Naltrexone  
 hydrochloride 17692-24-9, Bisoxatin 18321-66-9, Glucofrangulin  
 19408-84-5, Dihydrocapsaicin 20594-83-6, Nalbuphine 20675-51-8,  
 Cannabichromene 24980-41-4, Polycaprolactone 25087-26-7,  
 Poly(methacrylic acid) 25212-88-8, Eudragit L30D 25248-42-4,  
 Polycaprolactone 25322-68-3, Polyethylene glycol 25496-72-4, Glyceryl  
 monoolate 25654-31-3, Cannabigerol 26009-03-0, Polyglycolide  
 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediy)] 26063-00-3,  
 Poly(hydroxybutyrate) 26202-08-4, Polyglycolide 26680-10-4,  
 Poly lactide 26744-04-7 31566-31-1, Glyceryl monostearate 31621-87-1,  
 Polydioxanone 34346-01-5, Poly(lactic acid-glycolic acid) 37174-63-3  
 42281-59-4, Oxilorphan 47324-98-1 51022-71-0, Nabilone 51822-44-7,  
 Eudragit L 54845-95-3, 15-(S)-Hydroxyicosatetraenoic acid 55096-26-9,  
 Nalmefene 57444-62-9, Resiniferatoxin 58493-49-5, Olvanil  
 58821-95-7, Tinyatoxin 58895-64-0, Nalmefene hydrochloride 70608-72-9,  
 5-(S)-Hydroxyicosatetraenoic acid 70981-96-3 71036-28-7,  
 Hydroxyanthracene 71160-24-2, Leukotriene B4 71774-10-2 77337-76-9,  
 Acamprosate 77538-19-3, Glyceryl behenate 78755-81-4, Flumazenil  
 83387-25-1, N-Methylnaltrexone 90823-38-4 97089-04-8 97089-05-9  
 97240-79-4, Topiramate 106392-12-5, Poloxamer 110268-21-8, Opadry  
 Clear 118441-60-4 124423-64-9 136790-76-6, Lubiprostone  
 142521-04-8 156053-89-3, Alvimopan 158681-13-1, SR 141716A  
 164178-33-0, AM630 175796-50-6 179469-40-0 183232-66-8, AM 251  
 192703-06-3, SR 144528 202463-68-1, AM 281 216695-86-2, Ethylene  
 oxide-lactic acid copolymer 256934-39-1, HU-308 337526-33-7

342639-47-8 342639-49-0 611207-11-5, 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole 693784-16-6 1007347-23-0  
 1007572-25-9, Opadry White Y 5-7068 1007572-42-0, Opadry Pink Y-S 14518A  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

L7 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 110-15-6, Succinic acid, biological studies 124-04-9, Adipic acid, biological studies  
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (binder system for bonding calcium phosphate particles and patient-specific bone development medium)  
 RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-(\text{CH}_2)_4-\text{CO}_2\text{H}$

ACCESSION NUMBER: 2008:218760 CAPLUS  
 DOCUMENT NUMBER: 148:246603  
 TITLE: Binder system for bonding calcium phosphate particles, patient-specific bone development medium and a procedure for its production  
 INVENTOR(S): Duerr, Holger; Haenel, T.; Peters, Fabian  
 PATENT ASSIGNEE(S): Curasan AG, Germany  
 SOURCE: Ger. Offen., 18pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102006026000	A1	20080221	DE 2006-102006026000	20060601
PRIORITY APPLN. INFO.:			DE 2006-102006026000	20060601
AN 2008:218760 CAPLUS				
DN 148:246603				
ED Entered STN: 21 Feb 2008				
TI Binder system for bonding calcium phosphate particles, patient-specific bone development medium and a procedure for its production				
IN Duerr, Holger; Haenel, T.; Peters, Fabian				
PA Curasan AG, Germany				
SO Ger. Offen., 18pp.				
CODEN: GWXXBX				
DT Patent				
LA German				
CC 63-7 (Pharmaceuticals)				
FAN.CNT 1				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	DE 102006026000	A1	20080221	DE 2006-102006026000	20060601
PRAI	DE 2006-102006026000		20060601		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 102006026000	IPCI	A61L0027-00 [I,A]; A61L0027-12 [I,A]; A61L0027-20 [I,A]; A61L0027-56 [I,A]; A61L0027-54 [I,A]; C07C0059-245 [I,A]; C07C0059-00 [I,C*]; C07C0055-06 [I,A]; C07C0055-00 [I,C*]
	IPCR	A61L0027-00 [I,C]; A61L0027-00 [I,A]; A61L0027-12 [I,A]; A61L0027-20 [I,A]; A61L0027-54 [I,A]; A61L0027-56 [I,A]; C07C0055-00 [I,C]; C07C0055-06 [I,A]; C07C0059-00 [I,C]; C07C0059-245 [I,A]
AB	The invention concerns a binder system for bonding calcium phosphate particles for a patient-specific bone development medium and a procedure for the production of the bone development medium. The binder system for bonding calcium phosphate particles and/or glass ceramics particles, contains the inventive aqueous or alc. solution of organic acids from the class of	
	carboxylic acids. The bone development medium is produced according to the inventive calcium phosphate particles and/or glass ceramics particles using this binder system, which contains an aqueous or alc. solution of organic acids from the class of the carboxylic acids. Inventively, the production of the bone development medium consists of calcium phosphate particles and/or glass ceramic particles which takes place using an aqueous or alc. solution of organic acids from the class of binder systems containing carboxylic acids by means of layered three-dimensional pressing, followed by a thermal sinter process, whereby the binder system is removed and the calcium phosphate particles and/or glass ceramics particles sinter with one another.	
ST	bone formation binder system phosphate particle	
IT	Platelet (blood) (-rich plasma; binder system for bonding calcium phosphate particles and patient-specific bone development medium)	
IT	Bone (artificial; binder system for bonding calcium phosphate particles and patient-specific bone development medium)	
IT	Binders Bone formation Compression Glass ceramics Human Hydrogels Particle size distribution Pharmaceutical gels Pore size distribution Porous materials Precipitation (chemical) Presses Viscosity (binder system for bonding calcium phosphate particles and patient-specific bone development medium)	
IT	Carboxylic acids, biological studies Collagens, biological studies Gelatin, biological studies Polyoxyalkylenes, biological studies RL: PEP (Physical, engineering or chemical process); PRP (Properties); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (binder system for bonding calcium phosphate particles and patient-specific bone development medium)	



IT Bone morphogenetic protein 1  
 Bone morphogenetic protein 12  
 Bone morphogenetic protein 2  
 Bone morphogenetic protein 7  
 Bone morphogenetic proteins  
 Hepatocyte growth factor  
 Platelet-derived growth factors  
 Silicate glasses  
 Transforming growth factor  $\beta$   
 RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT Ceramics  
 (biocompatible; binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT Artificial tissue  
 (bone; binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT Biocompatible materials  
 (ceramics; binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT Blood plasma  
 (platelet-rich; binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 50-99-7, Glucose, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 69-79-4, Maltose 75-98-9, Pivalic acid 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-14-1, Hydroxyacetic acid, biological studies 79-31-2, Iso-Butyric acid 79-33-4, L Lactic acid, biological studies 87-69-4, Tartaric acid, biological studies 97-67-6, L Malic acid 107-92-6, Butyric acid, biological studies 109-52-4, Pentanoic acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 111-16-0, Pimelic acid 116-53-0, 2-Methylbutyric acid 124-04-9, Adipic acid, biological studies 141-82-2, Malonic acid, biological studies 144-62-7, Oxalic acid, biological studies 328-42-7, Oxaloacetic acid 473-90-5, Mesoxalic acid 499-12-7, Aconitic acid 503-66-2,  $\beta$  Hydroxypropionic acid 503-74-2, Isovaleric acid 542-05-2 617-31-2,  $\alpha$  Hydroxyvaleric acid 9003-39-8, Polyvinylpyrrolidone 9004-34-6D, Cellulose, derivs. 9004-54-0, Dextran, biological studies 9004-57-3, Ethylcellulose 9004-61-9D, Hyaluronic acid, salts 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropyl cellulose 9004-67-5, Methylcellulose 9005-18-9, Propylcellulose 9005-25-8D, Starch, derivs. 9005-32-7D, Alginate, salts 9042-14-2, Dextran sulfate 10103-46-5, Calcium phosphate 10237-77-1,  $\beta$  Hydroxyvaleric acid 10326-41-7, D Lactic acid, biological studies 13532-37-1,  $\gamma$  Hydroxyvaleric acid 25322-68-3, Polyethylene glycol 77323-58-1, Hydroxymethyl starch  
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT 1312-76-1, Potassium silicate 1343-88-0, Magnesium silicate 1344-95-2,

Calcium silicate 9002-64-6, Pth 61912-98-9, Igf 62031-54-3, Fgf 127464-60-2, Vegf  
 RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(binder system for bonding calcium phosphate particles and patient-specific bone development medium)

IT 1306-04-3, Chlorapatite 1306-05-4, Fluorapatite 1306-06-5, Hydroxylapatite 10086-45-0, Calcium pyrophosphate 11080-10-7, Chlorapatite 12525-40-5, Fluorapatite 13767-12-9, Tetracalcium phosphate 14096-86-7 14567-92-1, Brushite 21063-37-6, Monettite  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (binder system for bonding calcium phosphate particles and patient-specific bone development medium)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; WO 02083194 A1 CAPLUS
- (2) Anon; EP 0899247 A1 CAPLUS
- (3) Anon; DE 10018394 A1 CAPLUS
- (4) Anon; DE 102004012411 A1 CAPLUS
- (5) Anon; DE 10219765 A1 CAPLUS
- (6) Anon; DE 10236685 A1 CAPLUS
- (7) Anon; EP 1685860 A1 CAPLUS
- (8) Anon; DE 19938704 C1 CAPLUS
- (9) Anon; US 5518680 A CAPLUS
- (10) Anon; US 61174456 A

L7 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, uses

RL: CAT (Catalyst use); USES (Uses)

(preparation of chlorohydrins from crude glycerol)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2008:74157 CAPLUS

DOCUMENT NUMBER: 148:170782

TITLE: Preparation of chlorohydrins from crude glycerol  
 INVENTOR(S): Hook, Bruce D.; Briggs, John; Campbell, Robert M.; Kruper, William J.; Schreck, David J.; Varjian, Richard D.; Hippler, Jeffrey G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 25pp., Cont.-in-part of U.S. Ser. No. 628,269.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080015370	A1	20080117	US 2007-710010	20070222
WO 2006020234	A1	20060223	WO 2005-US25443	20050718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-589683P P 20040721  
 US 2005-628269 A2 20050718  
 WO 2005-US25443 W 20050718  
 US 2005-673210P P 20050419

OTHER SOURCE(S): CASREACT 148:170782  
 AN 2008:74157 CAPLUS  
 DN 148:170782  
 ED Entered SIN: 18 Jan 2008  
 TI Preparation of chlorohydrins from crude glycerol  
 IN Hook, Bruce D.; Briggs, John; Campbell, Robert M.; Kruper, William J.;  
 Schreck, David J.; Varjian, Richard D.; Hippler, Jeffrey G.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 25pp., Cont.-in-part of U.S. Ser. No. 628,269.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 INCL 549514000; 568841000  
 CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)  
 Section cross-reference(s): 67

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080015370	A1	20080117	US 2007-710010	20070222
WO 2006020234	A1	20060223	WO 2005-US25443	20050718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-589683P	P	20040721		
US 2005-628269	A2	20050718		
WO 2005-US25443	W	20050718		
US 2005-673210P	P	20050419		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20080015370	INCL	549514000; 568841000
	IPCI	C07D0301-27 [I,A]; C07D0301-00 [I,C*]; C07C0031-34 [I,A]; C07C0031-00 [I,C*]
	NCL	549/514.000; 568/841.000
WO 2006020234	IPCI	C07C0029-62 [I,A]; C07C0029-00 [I,C*]; C07D0303-08 [I,A]; C07D0303-00 [I,C*]
	IPCR	C07C0029-00 [I,C]; C07C0029-62 [I,A]; C07D0303-00 [I,C]; C07D0303-08 [I,A]
	ECLA	C07C029/62; C07D301/24

OS CASREACT 148:170782

AB A chlorohydrin, an ester of a chlorohydrin, or a mixture is prepared by contacting a crude glycerol, an ester of a crude glycerol, or a mixture thereof with a source of a superatmospheric partial pressure of hydrogen chloride, in the presence of a catalyst to produce a chlorohydrin, an ester of a chlorohydrin, or a mixture thereof, said contacting step carried out without substantial removal of water; wherein said crude glycerol, said ester of crude glycerol, or mixture thereof is derived from a renewable raw material. The invention also relates to a process for preparing an epoxide comprising the steps of: (a) contacting a crude glycerol, an ester of a crude glycerol, or a mixture thereof with hydrogen chloride source at superatmospheric pressure to produce a chlorohydrin, said contacting step carried out without substantial removal of water; and (b) contacting the chlorohydrin formed in step (a) above with a base to form an epoxide; wherein said crude glycerol, said ester of crude glycerol, or mixture thereof is derived from a renewable raw material.

ST glycerol chlorohydrin epoxide prepn

IT Acid halides

RL: CAT (Catalyst use); USES (Uses)

(acid chlorides; preparation of chlorohydrins from crude glycerol)

IT Fats and Glyceridic oils, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(animal, renewable raw material; preparation of chlorohydrins from crude glycerol)

IT Fats and Glyceridic oils, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(babassu, renewable raw material; preparation of chlorohydrins from crude glycerol)

IT Halohydrins

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(chlorohydrins; preparation of chlorohydrins from crude glycerol)

IT Biomass

(preparation of chlorohydrins from crude glycerol)

IT Amides, uses

Anhydrides

Carboxylic acids, uses

Esters, uses

Lactams

Lactones

Metals, uses

Polyamides, uses

Polyesters, uses

RL: CAT (Catalyst use); USES (Uses)

(preparation of chlorohydrins from crude glycerol)

IT Epoxides

RL: IMF (Industrial manufacture); PREP (Preparation)

(preparation of chlorohydrins from crude glycerol)

IT Canola oil

Carbohydrates, reactions

Castor oil

Coconut oil

Corn oil

Cottonseed oil

Linseed oil

Olive oil

Palm kernel oil

Palm oil

Peanut oil

Rape oil

Soybean oil

Sunflower oil

RL: RCT (Reactant); RACT (Reactant or reagent)

(renewable raw material; preparation of chlorohydrins from crude glycerol)

IT Fats and Glyceridic oils, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(vegetable, renewable raw material; preparation of chlorohydrins from crude glycerol)

IT 50-21-5, Lactic acid, uses 56-12-2, 4-Aminobutyric acid, uses 56-40-6,

Glycine, uses 57-11-4, Stearic acid, uses 64-19-7, Acetic

acid, uses 79-09-4, Propionic acid, uses 79-10-7D,

Acrylic acid, esters, polymers 79-14-1, Glycolic acid,

uses 96-48-0 99-96-7, 4-Hydroxybenzoic acid, uses 103-82-2,

Phenylacetic acid, uses 105-43-1, 3-Methylvaleric acid 105-60-2,

Caprolactam, uses 107-43-7, N,N,N-Trimethylglycine 107-92-6, Butyric

acid, uses 109-52-4, Valeric acid, uses 110-15-6, Succinic

acid, uses 111-14-8, Heptanoic acid 112-02-7, n-

Hexadecyltrimethylammonium chloride 118-92-3, 2-Aminobenzoic acid

119-68-6, 2-Methylaminobenzoic acid 142-62-1, Hexanoic acid, uses

150-13-0, 4-Aminobenzoic acid 156-38-7, 4-Hydroxyphenylacetic acid

407-64-7 502-44-3, Epsilon-Caprolactone 542-28-9,  $\delta$ -

Valerolactone 591-81-1, 4-Hydroxybutyric acid 595-37-9,

2,2-Dimethylbutyric acid 619-84-1, 4-Dimethylaminobenzoic acid

621-82-9, Cinnamic acid, uses 627-00-9, 4-Chlorobutyric acid 646-07-1,

4-Methylvaleric acid 693-11-8, 4-Dimethylaminobutyric acid 1070-83-3,

3,3-Dimethylbutyric acid 1118-68-9, N,N-Dimethylglycine 1119-46-6,

5-Chlorovaleric acid 1197-55-3, 4-Aminophenylacetic acid 1323-83-7,

Glycerin distearate 3068-88-0,  $\beta$ -Butyrolactone 4224-62-8,

6-Chlorohexanoic acid 6249-56-5 9002-29-3, Amberlite IRC 50

9003-01-4, Polyacrylic acid 13392-69-3, 5-Hydroxyvaleric acid

17078-28-3, 4-Dimethylaminophenylacetic acid 25395-31-7, Glycerin

diacetate 26446-35-5, Glycerin monoacetate 31712-69-3 80892-32-6,

Amberlite IRP 64 88641-55-8 98846-22-1, Acrylic acid

-ethylene graft copolymer 1001671-75-5 1001671-76-6

RL: CAT (Catalyst use); USES (Uses)

(preparation of chlorohydrins from crude glycerol)

IT 96-24-2P, 1-Chloro-2,3-propanediol 106-89-8P, Epichlorohydrin,

preparation 107-07-3P, Chloroethanol, preparation 127-00-4P,

1-Chloropropan-2-ol 542-58-5P 589-96-8P, 1-Acetoxy-2,3-Dichloropropane

623-60-9P, 1-Chloro-2-acetoxyp propane 627-68-9P, 2-Chloro-1-

acetoxyp propane 3674-10-0P, 2-Acetoxy-1,3-Dichloropropane 89416-37-5P

99143-13-2P 185805-20-3P, 2-Monochlorohydrin 1002104-92-8P

RL: IMF (Industrial manufacture); PREP (Preparation)

(preparation of chlorohydrins from crude glycerol)

IT 96-23-1P, 1,3-Dichloropropan-2-ol 616-23-9P, 2,3-Dichloropropan-1-ol

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of chlorohydrins from crude glycerol)

IT 56-81-5, Glycerol, reactions 56-81-5D, Glycerol, esters 57-55-6,

1,2-Propylene glycol, reactions 102-76-1, Triacetin 107-21-1, Ethylene

glycol, reactions 504-63-2, 1,3-Propanediol 7647-01-0, Hydrogen

chloride, reactions 25265-75-2, Butanediol

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of chlorohydrins from crude glycerol)

IT 57-50-1, Sucrose, reactions 9004-34-6, Cellulose, reactions

9005-25-8, Starch, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)


(renewable raw material; preparation of chlorohydrins from crude glycerol)

L7 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN


IT 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate

88-99-3, Phthalic acid, biological studies 100-42-5,

Styrene, biological studies 103-23-1, biological studies  
 117-81-7, Di(2-ethylhexyl)phthalate 122-62-3,  
 Di-(2-ethylhexyl)sebacate 131-11-3, Dimethyl phthalate  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)  
 (identification of structural requirements for mutagenicity, by  
 incorporating mol. flexibility and metabolic activation of chems. in  
 general Ames mutagenicity model (Erratum))  
 RN 84-66-2 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-diethyl ester (CA INDEX NAME)




RN 84-74-2 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester (CA INDEX NAME)




RN 88-99-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 100-42-5 CAPLUS  
 CN Benzene, ethenyl- (CA INDEX NAME)




RN 103-23-1 CAPLUS  
 CN Hexanedioic acid, 1,6-bis(2-ethylhexyl) ester (CA INDEX NAME)




RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)




RN 122-62-3 CAPLUS

CN Decanedioic acid, 1,10-bis(2-ethylhexyl) ester (CA INDEX NAME)



RN 131-11-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-dimethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 2007:825678 CAPLUS

DOCUMENT NUMBER: 147:228569

TITLE: Identification of the Structural Requirements for Mutagenicity, by Incorporating Molecular Flexibility and Metabolic Activation of Chemicals. II. General Ames Mutagenicity Model. [Erratum to document cited in CA146:516278]

AUTHOR(S): Serafimova, R.; Todorov, M.; Pavlov, T.; Kotov, S.; Jacob, E.; Aptula, A.; Mekenyan, O.

CORPORATE SOURCE: Laboratory of Mathematical Chemistry, University Prof. As. Zlatarov, Bourgas, 8000, Bulg.

SOURCE: Chemical Research in Toxicology (2007), 20(8), 1225  
CODEN: CRTOEC; ISSN: 0893-228X

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AN 2007:825678 CAPLUS

DN 147:228569  
ED Entered STN: 30 Jul 2007  
TI Identification of the Structural Requirements for Mutagenicity, by  
Incorporating Molecular Flexibility and Metabolic Activation of Chemicals.  
II. General Ames Mutagenicity Model. [Erratum to document cited in  
CA146:516278]  
AU Serafimova, R.; Todorov, M.; Pavlov, T.; Kotov, S.; Jacob, E.; Aptula, A.;  
Mekenyan, O.  
CS Laboratory of Mathematical Chemistry, University Prof. As. Zlatarov,  
Bourga, 8000, Bulg.  
SO Chemical Research in Toxicology (2007), 20(8), 1225  
CODEN: CRTOC; ISSN: 0893-228X  
PB American Chemical Society  
DT Journal  
LA English  
CC 4-6 (Toxicology)  
AB On page 673, in the conclusion section, the text, "As a comparative  
exercise, the alerts used in the present work were compared with three  
alert lists of Ashby, Kazius, and Benigni," should read: "As a comparative  
exercise, the alerts used in the present work were compared with alert  
lists of Ashby and Kazius, as well as the lists reported by Benigni in his  
review."  
ST erratum mutagenicity mol flexibility QSAR model mutagen  
IT Molecular topology  
Mutagenicity  
Mutagens  
Salmonella typhimurium  
Simulation and Modeling  
(identification of structural requirements for mutagenicity, by  
incorporating mol. flexibility and metabolic activation of chems. in  
general Ames mutagenicity model (Erratum))  
IT Polyoxalkylenes, biological studies  
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
(Biological study)  
(identification of structural requirements for mutagenicity, by  
incorporating mol. flexibility and metabolic activation of chems. in  
general Ames mutagenicity model (Erratum))  
IT Structure-activity relationship  
(mutagenic; identification of structural requirements for mutagenicity,  
by incorporating mol. flexibility and metabolic activation of chems. in  
general Ames mutagenicity model (Erratum))  
IT 50-00-0, Formaldehyde, biological studies 50-18-0, Cyclophosphamide  
50-29-3, 4,4'-DDT, biological studies 50-32-8, 3,4-Benzopyrene,  
biological studies 50-33-9, Phenylbutazone, biological studies  
50-34-0, Propantheline bromide 50-53-3, Chlorpromazine, biological  
studies 50-55-5, Reserpine 50-78-2, Acetylsalicylic acid 50-81-7,  
Vitamin C, biological studies 51-17-2, Benzimidazole 51-21-8,  
Fluorouracil 51-28-5, 2,4-Dinitrophenol, biological studies 51-30-9,  
Isoproterenol hydrochloride 51-41-2 51-43-4, Epinephrine 51-65-0,  
4-Fluoro-DL-phenylalanine 51-79-6, Urethane 52-24-4 52-28-8, Codeine  
phosphate 52-68-6, Trichlorfon 53-03-2, Prednisone 53-19-0  
53-70-3, Dibenz[a,h]anthracene 53-86-1, Indomethacin 53-94-1 53-95-2  
53-96-3, 2-Acetylaminofluorene 54-31-9, Furosemide 55-18-5,  
N-Nitrosodiethylamine 55-21-0, Benzamide 55-38-9, Fenthion 55-55-0  
55-86-7, Nitrogen mustard hydrochloride 55-98-1, Myleran 56-04-2,  
6-Methyl-2-thiouracil 56-18-8 56-23-5, Carbon tetrachloride,  
biological studies 56-38-2, Parathion 56-40-6, Glycine, biological  
studies 56-49-5, 3-Methylcholanthrene 56-53-1 56-54-2, Quinidine  
56-57-5, 4-Nitroquinoline-1-oxide 56-72-4, Coumaphos 56-81-5,  
Glycerol, biological studies 56-93-9 57-13-6, Urea, biological studies  
57-14-7, 1,1-Dimethylhydrazine 57-41-0, 5,5-Diphenylhydantoin 57-50-1,



Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 57-57-8,  $\beta$ -Propiolactone 57-63-6, Ethynylestradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-71-6, 57-74-9 57-83-0, Progesterone, biological studies 57-97-6, 7,12-Dimethylbenz[a]anthracene 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-33-3, Promethazine hydrochloride 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-89-9, Lindane 58-90-2, 2,3,4,6-Tetrachlorophenol 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-50-7, p-Chloro-m-cresol 59-87-0, Nitrofurazone 59-89-2, N-Nitrosomorpholine 60-09-3, Solvent yellow 1 60-33-3, Linoleic acid, biological studies 60-34-4, Methylhydrazine 60-35-5, Acetamide, biological studies 60-51-5, Dimethoate 60-57-1, Dieldrin 61-25-6, Papaverine hydrochloride 61-76-7, Phenylephrine hydrochloride 61-82-5, 1H-1,2,4-Triazol-3-amine 62-23-7, p-Nitrobenzoic acid 62-44-2, Phenacetin 62-50-0, Ethyl methanesulfonate 62-53-3, Aniline, biological studies 62-55-5, Thioacetamide 62-56-6, Thiourea, biological studies 62-73-7, Dichlorvos 62-75-9, N-Nitrosodimethylamine 63-56-9, Thonzylamine hydrochloride 63-74-1, Sulfanilamide 63-92-3, Phenoxybenzamine hydrochloride 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-67-5, Diethyl sulfate 64-75-5, Tetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 66-27-3, Methyl methanesulfonate 66-71-7, o-Phenanthroline 66-75-1, Uracil mustard 66-81-9, Cycloheximide 67-20-9 67-21-0, DL-Ethionine 67-48-1, Choline chloride 67-63-0, Isopropanol, biological studies 67-64-1, Acetone, biological studies 67-72-1, Hexachloroethane 67-97-0, Vitamin D3 68-12-2, N,N-Dimethylformamide, biological studies 69-05-6, Quinacrine dihydrochloride 69-65-8, D-Mannitol 69-74-9, Cytarabine hydrochloride 70-25-7 70-30-4, Hexachlorophene 70-34-8, 1-Fluoro-2,4-dinitrobenzene 71-58-9, Medroxyprogesterone acetate 72-14-0, Sulfathiazole 72-20-8, Endrin 72-43-5, Methoxychlor 72-54-8, DDD 72-55-9, DDE, biological studies 72-56-0 73-22-3, L-Tryptophan, biological studies 73-49-4, Quinethazone 74-11-3, p-Chlorobenzoic acid 74-31-7, N,N'Diphenyl-p-phenylenediamine 74-85-1, Ethylene, biological studies 74-89-5, Monomethylamine, biological studies 74-96-4, Ethyl bromide 75-00-3, Ethyl chloride 75-04-7, Ethylamine, biological studies 75-05-8, Acetonitrile, biological studies 75-07-0, Acetaldehyde, biological studies 75-12-7, Formamide, biological studies 75-25-2, Tribromomethane 75-26-3, 2-Bromopropane 75-27-4, Dichlorobromomethane 75-31-0, Isopropylamine, biological studies 75-34-3, 1,1-Dichloroethane 75-35-4, Vinylidene chloride, biological studies 75-36-5, Acetyl chloride 75-47-8, Triiodomethane 75-52-5, Nitromethane, biological studies 75-55-8, Propylenimine 75-64-9, tert-Butylamine, biological studies 75-65-0, tert-Butyl alcohol, biological studies 75-69-4, Trichlorofluoromethane 75-83-2, 2,2-Dimethylbutane 75-86-5, 2-Hydroxy-2-methylpropanenitrile 75-87-6, Anhydrous chloral 75-91-2, tert-Butyl hydroperoxide 76-01-7, Pentachloroethane 76-06-2, Chloropicrin 76-38-0, Methoxyflurane 76-44-8, Heptachlor 77-06-5, Gibberellic acid 77-47-4, Hexachlorocyclopentadiene 77-65-6, Bombdiethylacetylcarbamide 77-73-6, Dicyclopentadiene 77-79-2, 3-Sulfolene 78-11-5 78-34-2, Dioxathion 78-38-6, Diethyl ethylphosphonate 78-40-0, Triethyl phosphate 78-42-2, Tris(2-ethylhexyl) phosphate 78-44-4, Carisoprodol 78-51-3 78-59-1, Isophorone 78-79-5, Isoprene, biological studies 78-81-9, Isobutyl amine 78-83-1, Isobutyl alcohol, biological studies 78-84-2, Isobutyraldehyde 78-87-5, 1,2-Dichloropropane 78-88-6, 2,3-Dichloro-1-propene 78-90-0, Propylenediamine 78-93-3, Ethyl methyl ketone, biological studies 78-94-4, Methyl vinyl ketone, biological studies 79-00-5, 1,1,2-Trichloroethane 79-01-6, Trichloroethylene,

biological studies 79-08-3, Bromoacetic acid 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-11-8, Chloroacetic acid, biological studies 79-15-2, N-Bromoacetamide 79-20-9, Methyl acetate 79-21-0, Peroxyacetic acid 79-24-3, Nitroethane 79-29-8, 2,3-Dimethylbutane 79-36-7, Dichloroacetyl chloride 79-41-4, Methacrylic acid, biological studies 79-44-7, Dimethylcarbamyl chloride 79-46-9, 2-Nitropropane 79-94-7 80-05-7, biological studies 80-08-0 80-13-7, Halazone 80-15-9, Cumene hydroperoxide 80-30-8 80-39-7 80-43-3, Cumene peroxide 80-46-6, p-tert-Pentylphenol 80-62-6, Methyl methacrylate 81-07-2, Saccharin 81-11-8, 4,4'-Diamino-2,2'-stilbenedisulfonic acid 81-14-1, Musk ketone 81-49-2, 1-Amino-2,4-dibromoanthraquinone 81-54-9, 1,2,4-Trihydroxyanthraquinone 81-55-0, 1,8-Dihydroxy-4,5-dinitroanthraquinone 82-33-7, 1,4-Diamino-5-nitroanthraquinone 82-50-8 82-62-2 82-68-8, Pentachloronitrobenzene 82-75-7, Peri acid 83-26-1, 2-Pivalyl-1,3-indandione 83-32-9, Acenaphthene 83-38-5, 2,6-Dichlorobenzaldehyde 83-66-9, Musk ambrette 83-72-7, 2-Hydroxy-1,4-naphthalenedione 83-79-4, Rotenone 84-61-7, Dicyclohexyl phthalate 84-64-0, biological studies 84-65-1, 9,10-Anthraquinone 84-66-2, Diethyl phthalate 84-69-5, Diisobutyl phthalate 84-74-2, Dibutyl phthalate 84-75-3, Di-n-hexyl phthalate 85-01-8, Phenanthrene, biological studies 85-02-9, Benzo[f]quinoline 85-22-3, 2,3,4,5,6-Pentabromoethylbenzene 85-44-9, Phthalic anhydride 85-98-3, N,N'-Diethylcarbanilide 86-00-0, 2-Nitro-biphenyl 86-28-2, 9-Ethylcarbazole 86-30-6, N-Nitrosodiphenylamine  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model (Erratum))  
 IT 86-50-0, Gusathion 86-57-7, 1-Nitronaphthalene 87-25-2, Ethyl anthranilate 87-29-6, Cinnamyl anthranilate 87-59-2, 2,3-Xylidine 87-61-6, 1,2,3-Trichlorobenzene 87-65-0, 2,6-Dichlorophenol 87-68-3, Hexachloro-1,3-butadiene 87-82-1, Hexabromobenzene 87-83-2, Pentabromotoluene 87-86-5, Pentachlorophenol 88-06-2, 2,4,6-Trichlorophenol 88-16-4, o-Chlorobenzotrifluoride 88-21-1, o-Aminobenzenesulfonic acid 88-23-3, 6-Amino-4-chloro-1-phenol-2-sulfonic acid 88-72-2, o-Nitrotoluene 88-73-3, 1-Chloro-2-nitrobenzene 88-75-5, o-Nitrophenol 88-88-0, Picryl chloride 88-89-1, Picric acid 88-96-0, Phthalaldehyde 88-99-3, Phthalic acid, biological studies 89-25-8, 1-Phenyl-3-methyl-5-pyrazolone 89-40-7, 4-Nitrophthalimide 89-61-2, 1,4-Dichloro-2-nitrobenzene 89-63-4, 4-Chloro-2-nitroaniline 89-72-5, O-sec-Butylphenol 89-78-1, Menthol 89-98-5, 2-Chlorobenzaldehyde 90-00-6, O-Ethylphenol 90-04-0, o-Anisidine 90-13-1, 1-Chloronaphthalene 90-33-5,  $\beta$ -Methylumbelliferone 90-41-5, 2-Aminobiphenyl 90-45-9, 9-Aminoacridine 91-08-7, Toluene 2,6-diisocyanate 91-20-3, Naphthalene, biological studies 91-23-6, 2-Nitroanisole 91-44-1 91-58-7, 2-Chloronaphthalene 91-62-3, 6-Methylquinoline 91-66-7, N,N-Diethylaniline 91-68-9, 3-Diethylaminophenol 91-84-9, Pyrilamine 91-93-0 91-97-4 92-52-4, Biphenyl, biological studies 92-59-1, N-Ethyl-N-phenylbenzylamine 92-66-0, 4-Bromobiphenyl 92-67-1, 4-Aminobiphenyl 92-84-2, Phenothiazine 92-93-3, 4-Nitrobiphenyl 93-05-0, N,N-Diethyl-p-phenylenediamine 93-15-2, Methyl eugenol 93-46-9 93-58-3, Methyl benzoate 94-20-2, Chlorpropamide 94-25-7, Butyl p-aminobenzoate 94-36-0, Benzoyl peroxide, biological studies 94-52-0, 6-Nitrobenzimidazole 94-59-7, Saffrole 95-05-6 95-06-7, Sulfallate 95-14-7, 1,2,3-Benzotriazole 95-19-2 95-31-8 95-46-5, o-Bromotoluene 95-47-6, o-Xylene, biological studies 95-48-7, o-Cresol, biological studies 95-50-1, 1,2-Dichlorobenzene 95-51-2, o-Chloroaniline 95-54-5, o-Phenylenediamine, biological studies 95-55-6, 2-Aminophenol

95-57-8, o-Chlorophenol 95-64-7, 3,4-Xylidine 95-68-1,  
 2,4-Dimethylaniline 95-74-9, 4-Methyl-3-chloroaniline 95-76-1,  
 3,4-Dichloroaniline 95-77-2, 3,4-Dichlorophenol 95-78-3, 2,5-Xylidine  
 95-79-4, 5-Chloro-o-toluidine 95-80-7, 2,4-Diaminotoluene 95-82-9,  
 2,5-Dichloroaniline 95-83-0, 4-Chloro-o-phenylenediamine 95-84-1,  
 2-Amino-4-methylphenol 95-85-2, 2-Amino-4-chlorophenol 95-94-3,  
 1,2,4,5-Tetrachlorobenzene 95-95-4, 2,4,5-Trichlorophenol 96-09-3,  
 Styrene oxide 96-12-8, 1,2-Dibromo-3-chloropropane 96-13-9,  
 2,3-Dibromo-1-propanol 96-18-4, 1,2,3-Trichloropropane 96-23-1,  
 1,3-Dichloro-2-propanol 96-31-1, N,N'-Dimethylurea 96-33-3, Methyl  
 acrylate 96-37-7, Methyl cyclopentane 96-45-7, N,N'-Ethylene thiourea  
 96-67-3, 6-Amino-4-nitrophenol-2-sulfonic acid 96-69-5 96-91-3,  
 2-Amino-4,6-dinitrophenol 97-02-9, 2,4-Dinitroaniline 97-18-7  
 97-23-4 97-24-5 97-32-5, 4-Methoxy-3-nitro-N-phenylbenzamide  
 97-42-7, Carvyl acetate 97-53-0 97-54-1, Isoeugenol 97-56-3, Solvent  
 yellow 3 97-63-2, Ethyl methacrylate 97-77-8, Tetraethylthiuram  
 97-84-7 97-88-1, Butyl methacrylate 98-00-0, 2-Furanmethanol  
 98-01-1, Furfural, biological studies 98-07-7, Benzotrifluoride  
 98-08-8, Benzotrifluoride 98-11-3, Benzenesulfonic acid, biological  
 studies 98-15-7, m-Chlorobenzotrifluoride 98-16-8 98-30-6 98-37-3  
 98-46-4 98-51-1, p-tert-Butyltoluene 98-56-6 98-83-9,  
 α-Methylstyrene, biological studies 98-85-1, α-Methylbenzyl  
 alcohol 98-87-3, α,α-Dichlorotoluene 98-95-3,  
 Nitrobenzene, biological studies 98-96-4, Pyrazinamide 99-08-1,  
 m-Nitrotoluene 99-30-9, 2,6-Dichloro-4-nitroaniline 99-35-4,  
 1,3,5-Trinitrobenzene 99-48-9, Carveol 99-54-7, 3,4-  
 Dichloronitrobenzene 99-55-8, 5-Nitro-o-toluidine 99-56-9,  
 4-Nitro-o-phenylenediamine 99-57-0, 2-Amino-4-nitrophenol 99-59-2,  
 5-Nitro-o-anisidine 99-65-0, m-Dinitrobenzene 99-75-2, Methyl  
 p-toluate 99-82-1, p-Menthane 99-98-9, N,N-Dimethyl-p-phenylenediamine  
 100-00-5, 1-Chloro-4-nitrobenzene 100-01-6, p-Nitroaniline,  
 biological studies 100-02-7, p-Nitrophenol, biological studies  
 100-14-1, p-Nitrobenzyl chloride 100-17-4, 4-Nitroanisole 100-19-6,  
 p-Nitroacetophenone 100-21-0, Terephthalic acid, biological studies  
 100-22-1, N,N,N',N'-Tetramethyl-p-phenylenediamine 100-25-4,  
 p-Dinitrobenzene 100-27-6, p-Nitrophenethyl alcohol 100-37-8,  
 2-(Diethylamino)ethanol 100-39-0, α-Bromotoluene 100-40-3,  
 4-Vinylcyclohexene 100-41-4, Ethylbenzene, biological studies  
 100-42-5, Styrene, biological studies 100-44-7, Benzyl chloride,  
 biological studies 100-47-0, Benzonitrile, biological studies  
 100-51-6, Benzyl alcohol, biological studies 100-52-7, Benzaldehyde,  
 biological studies 100-61-8, N-Methylaniline, biological studies  
 100-65-2, N-Phenylhydroxylamine 100-74-3, N-Ethylmorpholine 100-75-4,  
 N-Nitrosopiperidine 100-97-0, biological studies 101-02-0, Triphenyl  
 phosphite 101-05-3, Anilazine 101-14-4, 4,4'-Methylenebis(2-  
 chloroaniline) 101-18-8, 3-Hydroxy-N-phenylaniline 101-20-2,  
 Triclocarban 101-25-7, N,N-Dinitrosopentamethylenetetramine 101-39-3,  
 α-Methylcinnamaldehyde 101-54-2, N-Phenyl-p-phenylenediamine  
 101-67-7, 4,4'-Diocetylphenylamine 101-68-8, 4,4'-Diphenylmethane  
 diisocyanate 101-70-2, 4,4'-Dimethoxydiphenylamine 101-72-4,  
 N-Isopropyl-N'-phenyl-1,4-phenylenediamine 101-73-5,  
 4-Isopropoxydiphenylamine 101-77-9, 4,4'-Methylenedianiline 101-80-4,  
 4,4'-Oxydianiline 101-83-7, Dicyclohexylamine 101-84-8, Diphenyl oxide  
 102-01-2, Acetoacetanilide 102-06-7, 1,3-Diphenylguanidine 102-28-3,  
 m-Aminoacetanilide 102-50-1, m-Cresidine 102-70-5, Triallylamine  
 102-71-6, Triethanolamine, biological studies 102-77-2 102-81-8  
 102-82-9, Tributylamine 102-96-5, β-Nitrostyrene 103-11-7  
 103-23-1, biological studies 103-30-0, trans-Stilbene  
 103-33-3, Azobenzene 103-50-4 103-69-5, N-Ethylaniline 103-70-8,  
 Formanilide 103-84-4, Acetanilide 103-85-5, 1-Phenyl-2-thiourea  
 103-89-9, N-Acetyl-p-toluidine 103-90-2, Acetaminophen 104-28-9,

Cinoxate 104-75-6, 2-Ethylhexylamine 104-85-8, p-Tolunitrile 104-88-1, 4-Chlorobenzaldehyde, biological studies 104-91-6 104-94-9, p-Anisidine 105-11-3, p-Benzoquinone dioxime 105-20-4, 1H-Pyrazole-3-ethanamine 105-55-5, N,N'-Diethylthiourea 105-58-8, Diethyl carbonate 105-59-9, N-Methyldiethanolamine 105-60-2, Caprolactam, biological studies 105-67-9, 2,4-Dimethylphenol 105-87-3, Geranyl acetate 106-20-7 106-38-7, p-Bromotoluene 106-40-1, p-Bromoaniline 106-42-3, p-Xylene, biological studies 106-43-4, p-Chlorotoluene 106-44-5, p-Cresol, biological studies 106-46-7, 1,4-Dichlorobenzene 106-47-8, p-Chloroaniline, biological studies 106-51-4, p-Quinone, biological studies 106-63-8, Isobutyl acrylate 106-65-0, Dimethyl succinate 106-87-6 106-93-4, 1,2-Dibromoethane 107-02-8, Acrolein, biological studies 107-06-2, 1,2-Dichloroethane, biological studies 107-07-3, 2-Chloroethanol, biological studies 107-11-9, Allylamine 107-12-0, Propionitrile

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model (Erratum))

IT 107-14-2, Chloroacetonitrile 107-15-3, Ethylenediamine, biological studies 107-21-1, Ethylene glycol, biological studies 107-31-3, Methyl formate 107-35-7, Taurine 107-68-6, N-Methyltaurine 107-70-0 108-01-0, 2-Dimethylaminoethanol 108-03-2, 1-Nitropropane 108-09-8, 1,3-Dimethylbutylamine 108-10-1, Methyl isobutyl ketone 108-18-9, Diisopropylamine 108-21-4, Isopropyl acetate 108-24-7, Acetic anhydride 108-30-5, Succinic anhydride, biological studies 108-31-6, Maleic anhydride, biological studies 108-38-3, m-Xylene, biological studies 108-39-4, m-Cresol, biological studies 108-42-9, m-Chloroaniline 108-43-0, m-Chlorophenol 108-45-2, m-Phenylenediamine, biological studies 108-46-3, Resorcinol, biological studies 108-60-1, Bis(2-chloro-1-methylethyl) ether 108-69-0, 3,5-Xylylene 108-70-3, 1,3,5-Trichlorobenzene 108-78-1, 1,3,5-Triazine-2,4,6-triamine, biological studies 108-80-5, Cyanuric acid 108-83-8, Diisobutyl ketone 108-88-3, Toluene, biological studies 108-90-7, Monochlorobenzene, biological studies 108-91-8, Cyclohexylamine, biological studies 108-93-0, Cyclohexanol, biological studies 108-94-1, Cyclohexanone, biological studies 108-95-2, Phenol, biological studies 108-99-6,  $\beta$ -Picoline 109-55-7, 3-(Dimethylamino)-1-propanamine 109-57-9, Allylthiourea 109-64-8, 1,3-Dibromopropane 109-69-3, n-Butyl chloride 109-73-9, n-Butylamine, biological studies 109-76-2, 1,3-Diaminopropane 109-77-3, Malonic acid dinitrile 109-78-4, 3-Hydroxypropanenitrile 109-83-1, N-Methylethanolamine 109-86-4, 2-Methoxyethanol 109-89-7, Diethylamine, biological studies 109-99-9, Tetrahydrofuran, biological studies 110-00-9, Furan 110-02-1, Thiophene 110-05-4, Di-tert-butyl peroxide 110-17-8, Fumaric acid, biological studies 110-18-9, N,N,N',N'-Tetramethylethylenediamine 110-21-4, Biurea 110-26-9 110-46-3, Isoamyl nitrite 110-49-6, 2-Methoxyethylacetate 110-52-1 110-58-7, N-Amylamine 110-61-2, Succinonitrile 110-63-4, 1,4-Butanediol, biological studies 110-82-7, Cyclohexane, biological studies 110-85-0, Piperazine, biological studies 110-86-1, Pyridine, biological studies 110-88-3, 1,3,5-Trioxane, biological studies 110-91-8, Morpholine, biological studies 110-96-3, Diisobutylamine 110-97-4, Diisopropanolamine 111-14-8, Heptanoic acid 111-30-8, Glutaraldehyde 111-40-0, Diethylenetriamine 111-41-1 111-42-2, Diethanolamine, biological studies 111-44-4, Bis(2-chloroethyl) ether 111-46-6, Diethylene glycol, biological studies 111-69-3, Adiponitrile 111-71-7, Heptanal 111-76-2, 2-Butoxyethanol 111-84-2, Nonane 111-92-2, Dibutylamine 111-96-6, Bis(2-methoxyethyl)ether 112-34-5, 2-(2-Butoxyethoxy)ethanol 112-52-7, Lauryl chloride 112-56-1, 2-(2-Butoxyethoxy)ethyl thiocyanate 112-57-2, Tetraethylenepentamine

112-62-9, Methyl oleate 112-80-1, Oleic acid, biological studies  
 112-95-8, Eicosane 113-92-8, Chlorpheniramine maleate 114-83-0,  
 1-Acetyl-2-phenylhydrazine 115-07-1, Propylene, biological studies  
 115-28-6, Chlorogenic acid 115-29-7, Endosulfan 115-32-2 115-86-6,  
 Triphenyl phosphate 115-96-8, Tris(2-chloroethyl) phosphate 116-06-3,  
 TEMIK 116-85-8, 1-Amino-4-hydroxyanthraquinone 117-05-5,  
 1-Benzamido-5-chloro-9,10-anthraquinone 117-08-8, Tetrachlorophthalic  
 acid anhydride 117-12-4, 1,5-Dihydroxyanthraquinone 117-18-0  
 117-39-5, Quercetin 117-79-3, 2-Aminoanthraquinone 117-81-7,  
 Di(2-ethylhexyl)phthalate 117-84-0, Di-n-octyl phthalate 118-52-5,  
 1,3-Dichloro-5,5-dimethylhydantoin 118-55-8, Phenyl salicylate  
 118-56-9, 3,3,5-Trimethylcyclohexyl salicylate 118-58-1, Benzyl  
 salicylate 118-71-8, Maltol 118-74-1, Hexachlorobenzene 118-79-6,  
 2,4,6-Tribromophenol 118-91-2, o-Chlorobenzoic acid 118-92-3,  
 o-Anthranilic acid 119-06-2, Ditridecyl phthalate 119-15-3,  
 4-(2,4-Dinitroanilino)phenol 119-34-6, 4-Amino-2-nitrophenol 119-36-8,  
 Methyl salicylate 119-39-1, Phthalazinone 119-53-9,  
 2-Hydroxy-1,2-diphenylethanone 119-61-9, Benzophenone, biological  
 studies 119-75-5, 2-Nitrodiphenylamine 119-84-6, 3,4-Dihydrocoumarin  
 119-90-4, 3,3'-Dimethoxybenzidine 119-93-7, 3,3'-Tolidine 120-12-7,  
 Anthracene, biological studies 120-14-9, Veratraldehyde 120-32-1,  
 o-Benzyl-p-chlorophenol 120-37-6, 3-Ethylamino-4-methylphenol  
 120-40-1, Lauroyl diethanolamine 120-57-0, Piperonal 120-61-6,  
 Dimethyl terephthalate 120-62-7, Piperonyl sulfoxide 120-66-1,  
 N-Acetyl-o-toluidine 120-71-8, p-Cresidine 120-78-5,  
 2,2'-Dithiobisbenzothiazole 120-80-9, 1,2-Dihydroxybenzene, biological  
 studies 120-82-1, 1,2,4-Trichlorobenzene 120-83-2, 2,4-Dichlorophenol  
 121-14-2, 2,4-Dinitrotoluene 121-17-5, 4-Chloro-3-nitro-1-  
 (trifluoromethyl)benzene 121-32-4, Ethyl vanillin 121-33-5, Vanillin  
 121-44-8, Triethylamine, biological studies 121-47-1,  
 m-Aminobenzenesulfonic acid 121-54-0, Benzethonium chloride 121-66-4,  
 2-Amino-5-nitrothiazole 121-69-7, N,N-Dimethylaniline, biological  
 studies 121-73-3, 3-Chloronitrobenzene 121-75-5 121-79-9, Propyl  
 gallate 121-88-0, 2-Amino-5-nitrophenol 121-90-4, m-Nitrobenzoyl  
 chloride 121-92-6, m-Nitrobenzoic acid 122-04-3, p-Nitrobenzoyl  
 chloride 122-19-0 122-20-3, Tri-isopropanolamine 122-39-4,  
 N-Phenylbenzenamine, biological studies 122-62-3,  
 Di-(2-ethylhexyl)sebacate 122-66-7, Hydrazobenzene 122-80-5,  
 p-Aminoacetanilide 123-05-7, 2-Ethylhexanal 123-30-8, p-Aminophenol  
 123-31-9, Hydroquinone, biological studies 123-33-1,  
 1,2-Dihydro-3,6-pyridazinedione 123-38-6, Propionaldehyde, biological  
 studies 123-72-8, Butyraldehyde 123-73-9, trans-Crotonaldehyde  
 123-77-3, Azodicarbonamide 123-86-4, Butyl acetate 123-91-1,  
 1,4-Dioxane, biological studies 123-92-2, Isoamyl acetate 124-02-7,  
 Diallylamine 124-07-2, Octanoic acid, biological studies 124-09-4,  
 1,6-Hexanediamine, biological studies 124-30-1, Octadecylamine  
 124-40-3, Dimethylamine, biological studies 124-48-1,  
 Dibromochloromethane 124-64-1 125-33-7, Primacelone 126-07-8,  
 Griseofulvin 126-27-2, Oxethazine 126-72-7, Tris 126-73-8, Tributyl  
 phosphate, biological studies 126-92-1, biological studies 126-98-7,  
 Methacrylonitrile 126-99-8, 2-Chloro-1,3-butadiene 127-00-4,  
 1-Chloro-2-propanol 127-18-4, Tetrachloroethylene, biological studies  
 127-19-5, Dimethylacetamide 127-69-5, Sulfisoxazole 128-37-0,  
 biological studies 128-66-5, Vat yellow 4 128-95-0, Disperse violet 1  
 129-00-0, Pyrene, biological studies 129-15-7, 2-Methyl-1-  
 nitroanthraquinone 129-17-9, Acid blue 1 130-26-7 131-11-3,  
 Dimethyl phthalate 131-14-6, 2,6-Diaminoanthraquinone 131-17-9,  
 Diallyl phthalate 131-53-3 131-57-7 132-20-7, Pheniramine maleate  
 132-27-4 132-98-9, Penicillin VK 133-06-2, Captan 133-18-6,  
 Phenethyl anthranilate 133-90-4, Chloramben 134-20-3, Methyl  
 anthranilate 134-29-2, o-Anisidine hydrochloride 134-31-6,

8-Hydroxyquinoline sulfate 134-32-7, 1-Naphthylamine 134-62-3  
 134-72-5, Ephedrine sulfate 135-20-6, Cupferron 135-23-9,  
 Methacrylamine hydrochloride 135-88-6 136-35-6, Diazoaminobenzene  
 136-40-3, Phenazopyridine hydrochloride 136-77-6, 4-Hexylresorcinol  
 136-79-8 137-09-7, 2,4-Diaminophenol hydrochloride 137-89-3,  
 biological studies 138-89-6, N,N-Dimethyl-4-nitrosobenzeneamine  
 139-65-1, 4,4'-Thiodianiline 139-94-6, Nithiazide 140-08-9,  
 Tris(2-chloroethyl)phosphite 140-11-4, Benzyl acetate 140-29-4,  
 Phenylacetoneitrile 140-49-8 140-56-7 140-67-0, Estragole 140-88-5,  
 Ethyl acrylate 140-95-4, N,N'-Bis(hydroxymethyl)urea 141-32-2  
 141-43-5, Monoethanolamine, biological studies  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)

(identification of structural requirements for mutagenicity, by  
 incorporating mol. flexibility and metabolic activation of chems. in  
 general Ames mutagenicity model (Erratum))

IT 141-75-3, Butyryl chloride 141-78-6, Ethyl acetate, biological studies  
 141-84-4, 2-Thioxo-4-thiazolidinone 141-91-3, 2,6-Dimethylmorpholine  
 142-04-1, Aniline hydrochloride 142-09-6, N-Hexyl methacrylate  
 142-46-1, 2,5-Dithiobiurea 142-47-2, Monosodium L-glutamate 142-78-9,  
 Lauryl ethanolamide 142-84-7, Dipropylamine 142-96-1, Dibutyl ether  
 143-07-7, Lauric acid, biological studies 143-16-8, Dihexylamine  
 143-27-1, Hexadecylamine 143-50-0, Chlordecone 144-62-7, Oxalic acid,  
 biological studies 144-82-1, Sulfamethizole 145-49-3,  
 1,5-Dihydroxy-4,8-diaminoanthraquinone 147-24-0, Diphenhydramine  
 hydrochloride 147-47-7 148-18-5, biological studies 148-24-3,  
 8-Hydroxyquinoline, biological studies 148-65-2, Chlorothene 148-79-8,  
 2-(4-Thiazolyl)benzimidazole 148-82-3, Melfalan 149-30-4,  
 2-Mercaptobenzothiazole 149-57-5, 2-Ethylhexanoic acid 149-91-7,  
 Gallic acid, biological studies 150-13-0, p-Aminobenzoic acid  
 150-38-9, Trisodium EDTA 150-68-5 150-69-6, Dulcine 150-76-5,  
 4-Methoxyphenol 150-78-7 151-41-7 151-67-7, Halothane 153-78-6,  
 2-Aminoofluorene 154-69-8, Tripeleannamine hydrochloride 156-10-5,  
 p-Nitrosodiphenylamine 156-43-4, p-Phenetidine 156-59-2,  
 cis-1,2-Dichloroethylene 156-62-7, Calcium cyanamide 192-97-2,  
 Benzo[e]pyrene 205-99-2, Benz[e]acephenanthrylene 207-08-9,  
 Benzo[k]fluoranthene 262-20-4, Dibenzothioxin 271-89-6, Benzofuran  
 298-00-0, Methyl parathion 298-59-9, Methylphenidate hydrochloride  
 301-04-2, Lead acetate 301-12-2, Metasystox-R 301-13-3, biological  
 studies 302-01-2, Hydrazine, biological studies 302-17-0, Chloral  
 hydrate 303-34-4, Lasiocarpine 303-47-9, Ochrotoxin A 305-03-3,  
 Chlorambucil 309-00-2, Aldrin 309-36-4, Sodium methohexital  
 314-13-6, Direct blue 53 316-42-7, Emetine hydrochloride 320-67-2,  
 5-Azacytidine 326-61-4, Piperonyl acetate 334-48-5, Decanoic acid  
 346-18-9, Polythiazide 357-57-3, Brucine 367-25-9, 2,4-Difluoroaniline  
 367-51-1, Sodium Thioglycolate 379-79-3, Ergotamine tartrate 384-22-5  
 393-52-2, 2-Fluorobenzoyl chloride 393-75-9 396-01-0, Triamterene  
 434-13-9, Lithocholic acid 439-14-5, Diazepam 443-48-1, Metronidazole  
 446-86-6, Azathioprine 458-37-7, Curcumin 463-04-7, N-Amyl nitrite  
 464-10-8, Bromopicrin 470-82-6, Cineole 476-66-4, Ellagic acid  
 480-19-3 480-81-9, Seneciophylline 481-72-1, 1,8-Dihydroxy-3-  
 hydroxymethylanthraquinone 485-47-2, Nihydrin 488-41-5 493-52-7,  
 Acid red 2 495-18-1, Benzohydroxamic acid 495-48-7, Azoxybenzene  
 496-72-0, 3,4-Diaminotoluene 498-21-5, Methylsuccinic acid 500-66-3,  
 Olivetol 503-09-3 503-30-0, 1,3-Propylene oxide 504-29-0,  
 2-Aminopyridine 504-88-1, 3-Nitropropionic acid 505-22-6, 1,3-Dioxane  
 509-14-8, Tetranitromethane 510-15-6, Chlorobenzilate 512-56-1,  
 Trimethylphosphate 513-37-1, Dimethylvinyl chloride 517-28-2,  
 Hematoxylin 518-47-8, Acid yellow 73 521-31-3 523-47-7,  
 β-Cadinene 523-87-5, Dimenhydrinate 527-85-5, 2-Methylbenzamide  
 528-74-5, Dichloromethotrexate 529-19-1, o-Tolunitrile 529-20-4,

o-Tolualdehyde 531-85-1, Benzidine dihydrochloride 532-27-4,  
 2-Chloroacetophenone 532-28-5,  $\alpha$ -Hydroxybenzeneacetoneitrile  
 532-82-1, Basic orange 2 534-22-5, 2-Methylfuran 535-80-8,  
 m-Chlorobenzoic acid 536-33-4, Ethionamide 536-90-3, m-Anisidine  
 537-92-8, N-Acetyl-m-toluidine 538-74-9, Benzyl sulfide 540-23-8,  
 p-Toluidine hydrochloride 540-51-2 540-59-0, 1,2-Dichloroethene  
 541-73-1, 1,3-Dichlorobenzene 542-56-3, Isobutyl nitrite 542-75-6,  
 1,3-Dichloropropene 544-63-8, Tetradecanoic acid, biological studies  
 545-06-2, Trichloroacetoneitrile 548-62-9, Basic violet 3 551-06-4,  
 $\alpha$ -Naphthyl isothiocyanate 552-16-9, o-Nitrobenzoic acid  
 552-30-7, Trimellitic anhydride 553-30-0, Proflavine sulfate 554-00-7,  
 2,4-Dichloroaniline 554-10-9, 3-Iodo-1,2-propanediol 554-84-7,  
 m-Nitrophenol 555-30-6 557-11-9, Allyl urea 562-10-7 563-04-2,  
 Tri-m-cresyl phosphate 563-47-3, 3-Chloro-2-methylpropene 564-00-1,  
 meso-1,2:3,4-Diepoxybutane 569-57-3, Chlorotrianisene 569-61-9, Basic  
 red 9 576-24-9, 2,3-Dichlorophenol 577-33-3, 1,2,10-Anthracenetriol  
 577-59-3, o-Nitroacetophenone 581-64-6, Thionine 583-39-1,  
 2-Mercaptobenzimidazole 583-78-8, 2,5-Dichlorophenol 584-84-9,  
 2,4-Toluene diisocyanate 590-17-0, Bromoacetoneitrile 591-17-3,  
 m-Bromotoluene 593-56-6, O-Methylhydroxylamine hydrochloride 594-71-8,  
 2-Chloro-2-nitropropane 594-72-9, 1,1-Dichloro-1-nitroethane 597-25-1,  
 Dimethyl morpholinophosphonate 598-55-0, Methyl carbamate 599-79-1,  
 Salicylazosulfapyridine 602-38-0, 1,8-Dinitronaphthalene 602-60-8,  
 9-Nitroanthracene 602-64-2, 1,2,3-Trihydroxyanthraquinone 602-87-9,  
 5-Nitroacenaphthene 603-34-9, Triphenylamine 603-35-0, Triphenyl  
 phosphine, biological studies 603-54-3, N,N-Diphenylurea 605-71-0,  
 1,5-Dinitronaphthalene 606-37-1, 1,3-Dinitronaphthalene 607-57-8,  
 2-Nitro-9H-fluorene 608-71-9, Pentabromophenol 608-93-5,  
 Pentachlorobenzene 609-19-8, 3,4,5-Trichlorophenol 609-20-1,  
 2,6-Dichloro-p-phenylenediamine 609-31-4, 2-Nitro-1-butanol 610-49-1,  
 1-Anthracenamine 611-06-3, 2,4-Dichloronitrobenzene 612-23-7,  
 o-Nitrobenzyl chloride 612-82-8, 3,3'-Dimethylbenzidine dihydrochloride  
 612-83-9, 3,3'-Dichlorobenzidine dihydrochloride 613-08-1,  
 2-Anthracenecarboxylic acid 613-13-8, 2-Aminoanthracene 613-47-8,  
 N-2-Naphthylhydroxylamine 613-93-4, N-Methylbenzamide 614-45-9,  
 tert-Butyl perbenzoate 615-66-7, 2-Chloro-p-phenylenediamine 616-23-9,  
 2,3-Dichloro-1-propanol 618-87-1, 3,5-Dinitroaniline 619-17-0,  
 4-Nitroanthranilic acid 619-23-8, m-Nitrobenzyl chloride 620-22-4,  
 m-Tolunitrile 621-31-8, 3-Ethylaminophenol 621-42-1,  
 N-Acetyl-m-aminophenol 621-77-2, Tri-N-amyamine 622-51-5, p-Tolylurea  
 623-15-4, Furfural acetone 623-17-6, Furfuryl acetate 623-30-3,  
 $\beta$ -2-Furyl acrolein 625-48-9, 2-Nitroethanol 625-86-5,  
 2,5-Dimethylfuran 627-05-4, 1-Nitrobutane 627-18-9, 3-Bromo-1-propanol  
 627-30-5, 3-Chloro-1-propanol 628-02-4, Hexanamide 628-94-4, Adipamide  
 630-20-6, 1,1,1,2-Tetrachloroethane 634-66-2, 1,2,3,4-Tetrachlorobenzene  
 634-90-2, 1,2,3,5-Tetrachlorobenzene 634-93-5, 2,4,6-Trichloroaniline  
 636-26-0, 5-Methyl-2-thiouracil 638-03-9, m-Toluidine hydrochloride  
 643-22-1, Erythromycin stearate 645-05-6, Hexamethylmelamine 645-49-8,  
 cis-Stilbene 645-62-5, 2-Ethyl-2-hexenal 646-14-0, 1-Nitrohexane  
 673-06-3, D-Phenylalanine 688-74-4, Tributyl borate 723-46-6,  
 Sulfamethoxazole 738-70-5, Trimethoprim 756-79-6, Dimethyl  
 methylphosphonate 759-94-4, Eptam 764-42-1, Fumaroneitrile 765-34-4,  
 Glycidaldehyde 768-52-5, N-Isopropylaniline 785-30-8,  
 4,4'-Diaminobenzaniline 793-24-8 828-00-2, Dimethoxane 834-28-6,  
 Phenformin hydrochloride 839-90-7 842-07-9, Solvent yellow 14  
 872-50-4, N-Methyl-2-pyrrolidinone, biological studies 874-42-0,  
 2,4-Dichlorobenzaldehyde 879-39-0 881-03-8, 1-Nitro-2-  
 methylnaphthalene 920-66-1 924-42-5, N-Methylolacrylamide  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)

(identification of structural requirements for mutagenicity, by

incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model (Erratum))

IT 931-97-5, Cyclohexanone cyanohydrin 933-75-5, 2,3,6-Trichlorophenol 933-78-8, 2,3,5-Trichlorophenol 934-32-7, 2-Aminobenzimidazole 935-95-5, 2,3,5,6-Tetrachlorophenol 952-21-6, 3-Methyl-4'-nitrobiphenyl 958-93-0, Thenyldiamine hydrochloride 968-81-0, Acetohexamide 982-57-0, biological studies 989-38-8, Basic red 1 992-59-6, Direct red 2 999-55-3, Allyl acrylate 999-81-5 1025-15-6, Triallyl isocyanurate 1034-41-9, Chlorodecane alcohol 1071-83-6, Glyphosate 1072-52-2, 1-Aziridineethanol 1116-40-1, Triisobutylamine 1116-54-7, N-Nitrosodiethanolamine 1122-54-9, 4-Acetylpyridine 1126-61-0 1143-38-0, 1,8-Dihydroxyanthrone 1163-19-5, Decabromodiphenyl ether 1187-42-4, Diaminomaleonitrile 1212-29-9, N,N'-Dicyclohexylthiourea 1229-35-2, Methdilazine hydrochloride 1241-94-7, biological studies 1325-37-7, Direct yellow 11 1326-03-0, Pigment violet 1 1397-89-3, Amphoterin B 1421-63-2 1455-77-2, 1H-1,2,4-Triazole-3,5-diamine 1465-25-4 1467-79-4, Dimethyl cyanamide 1484-12-4, 9-Methylcarbazole 1504-74-1, o-Methoxycinnamaldehyde 1522-92-5, 3-Bromo-2,2-bis(bromomethyl)propanol 1562-94-3, p-Azoxyanisole 1570-64-5, p-Chloro-o-cresol 1571-08-0, Methyl p-formylbenzoate 1576-35-8, p-Toluenesulfonyl hydrazide 1596-84-5, biological studies 1606-67-3, 1-Pyrenamine 1634-78-2 1635-61-6, 5-Chloro-2-nitroaniline 1646-75-9, Aldicarb oxime 1675-54-3 1694-09-3, Acid violet 49 1694-20-8, (E)-4-Nitrostilbene 1758-68-5, 1,2-Diaminoanthraquinone 1761-71-3 1777-84-0, 3-Nitro-p-acetophenetide 1806-54-8 1817-73-8, 2-Bromo-4,6-dinitroaniline 1825-21-4, Pentachloroanisole 1836-75-5, Nitrofen 1854-26-8, Dimethyloldihydroxyethyleneurea 1897-45-6 1912-24-9, Atrazine 1918-02-1, Picloram 1929-82-4 1934-21-0, Acid yellow 23 1936-15-8, Acid orange 10 1937-37-7, Direct black 38 1948-33-0, tert-Butylhydroquinone 1955-45-9, Pivalolactone 1972-08-3, trans-A9-Tetrahydrocannabinol 2016-88-8, Amiloride hydrochloride 2039-87-4, o-Chlorostyrene 2045-52-5, Phenbenzamine hydrochloride 2050-92-2, Di-N-amylamine 2052-07-5, 2-Bromobiphenyl 2107-76-8 2113-57-7, 3-Bromobiphenyl 2143-88-6, 4-Methyl-4'-nitrobiphenyl 2150-54-1, Direct blue 25 2150-60-9 2157-01-9, n-Octyl methacrylate 2164-17-2, Fluometuron 2179-59-1, Allyl propyl disulfide 2185-92-4, 2-Biphenylamine hydrochloride 2206-89-5, 2-Chloroethyl acrylate 2210-28-8, n-Propyl methacrylate 2213-63-0, 2,3-Dichloroquinoxaline 2243-61-0, 1,4-Naphthalenediamine 2243-62-1, 1,5-Naphthalenediamine 2244-16-8, D-Carvone 2244-21-5, Potassium dichloroacrylate 2385-85-5, Mirex 2425-85-6, C.I. Pigment red 3 2429-71-2, Direct blue 8 2429-73-4 2429-74-5, Direct blue 15 2429-80-3, C. I. Acid orange 45 2432-99-7, 11-Aminoundecanoic acid 2438-88-2 2439-35-2, biological studies 2461-15-6, 2-Ethylhexyl glycidyl ether 2465-27-2, Basic yellow 2 2475-45-8, 1,4,5,8-Tetraaminoanthraquinone 2493-84-7, p-Octyloxybenzoic acid 2508-20-5, 2-Nitrosofluorene 2528-36-1, Dibutyl phenyl phosphate 2602-46-2, Direct blue 6 2645-07-0, 4-Nitrohippuric acid 2646-17-5 2675-77-6, Chloroneb 2682-20-4, 2-Methyl-4-Isothiazolin-3-one 2698-41-1, o-Chlorobenzalmononitrile 2735-04-8, 2,4-Dimethoxyaniline 2782-57-2, Dichloroisocyanuric acid 2782-91-4, Tetramethylthiourea 2783-94-0, FD&C yellow 6 2784-94-3, HC blue 1 2810-69-7 2832-40-8, Disperse yellow 3 2835-95-2, 3-Amino-6-methylphenol 2871-01-4, HC Red 3 2873-97-4, Diacetone acrylamide 2893-78-9, Sodium dichloroacrylate 2941-64-2, S-Ethyl chlorothiocarbonate 2945-96-2, C. I. Direct black 17 3018-12-0, Dichloroacetoneitrile 3025-77-2 3066-70-4, biological studies 3068-88-0,  $\beta$ -Butyrolactone 3081-14-9 3129-91-7, Dicyclohexylamine nitrite 3160-37-0, Piperonylidene acetone 3165-93-3, 4-Chloro-o-toluidine hydrochloride 3179-47-3, n-Decyl methacrylate 3209-22-1, 2,3-Dichloronitrobenzene 3237-50-1, Alloxan monohydrate 3252-43-5, Dibromoacetoneitrile 3266-23-7, 2,3-Epoxybutane 3268-87-9,



Octachlorodibenzo-p-dioxin 3319-31-1 3322-93-8 3333-52-6,  
Tetramethylsuccinonitrile 3468-63-1, Pigment orange 5 3524-68-3,  
Pentaerythritol triacrylate 3544-23-8 3546-10-9, biological studies  
3567-69-9, Acid red 14 3626-28-6, Direct green 1 3648-20-2, Diundecyl  
phthalate 3658-77-3, 2,5-Dimethyl-4-hydroxy-3(2H)-furanone 3682-19-7  
3688-53-7 3689-24-5 3731-39-3 3761-53-3, Acid red 26 4067-16-7,  
Pentaethylenhexamine 4080-31-3 4098-71-9, Isophorone diisocyanate  
4170-30-3, Crotonaldehyde 4196-86-5 4196-87-6 4198-19-0 4309-66-4,  
trans-4-Aminostilbene 4337-65-9, Mono(2-ethylhexyl) adipate 4342-03-4,  
Dacarbazine 4345-03-3 4350-09-8, 5-Hydroxyl-tryptophan 4403-61-6,  
2-Methyl-2-butenenitrile 4418-26-2, Sodium dehydroacetate 4424-06-0,  
Pigment orange 43 4444-68-2 4460-86-0, 2,4,5-Trimethoxybenzaldehyde  
4465-94-5 4548-53-2, FD&C red 4 4553-62-2,  $\alpha$ -Methyl  
glutaronitrile 4568-28-9, Triethanolamine stearate 4635-87-4,  
3-Pentenitrile 4637-56-3 4655-34-9, Isopropyl methacrylate  
4719-04-4 4801-39-2, 2-Aminoacetanilide hydrochloride 4802-20-4,  
Limonene dimercaptan 4823-47-6, 2-Bromoethyl acrylate 4901-51-3,  
2,3,4,5-Tetrachlorophenol 5064-31-3, Nitrilotriacetic acid trisodium  
salt 5131-58-8, 4-Nitro-m-phenylenediamine 5131-60-2,  
4-Chloro-m-phenylenediamine 5160-02-1, D And C red 9 5216-25-1,  
4-Chlorobenzotrichloride 5307-14-2 5323-95-5, Sodium ricinoleate  
5397-31-9 5466-77-3 5466-84-2, 4-Nitrophthalic anhydride 5493-45-8  
5989-27-5, D-Limonene 6041-94-7, C.I. Pigment red 2 6088-51-3  
6109-97-3, 3-Amino-9-ethylcarbazole monohydrochloride 6112-76-1,  
6-Mercaptopurine monohydrate 6197-30-4 6201-87-2, 5-Amino-3-  
sulfosalicylic acid 6219-89-2 6285-57-0, 2-Amino-6-nitrobenzothiazole  
6287-38-3, 3,4-Dichlorobenzaldehyde 6317-18-6, biological studies  
6358-07-2, 2-Amino-4-chloro-5-nitrophenol 6358-23-2 6358-29-8, Direct  
red 39 6358-31-2, C.I. Pigment yellow 74 6358-53-8, Solvent red 80  
6358-85-6, Pigment yellow 12 6369-59-1 6373-74-6, Acid orange 3  
6428-94-0, Direct violet 32 6459-94-5, Acid red 114 6471-49-4, Pigment  
red 23 6483-86-9 6533-68-2, Scopalamine hydrobromide trihydrate  
6610-08-8, 2-Nitrosanaphthalene 6810-26-0 6959-47-3,  
2-(Chloromethyl)pyridine hydrochloride 6959-48-4, 3-  
(Chloromethyl)pyridine hydrochloride 7149-26-0, Linalyl anthranilate  
7166-19-0,  $\beta$ -Bromo- $\beta$ -nitrostyrene 7177-48-2, Ampicillin  
trihydrate 7195-43-9, Isophthalic acid diglycidyl ester 7206-76-0,  
2-Phenyl-2-ethylmalondiamide 7314-08-1 7493-63-2, Allyl anthranilate  
7756-96-9, Butyl anthranilate 7779-16-0, Cyclohexyl anthranilate  
7779-77-3, Isobutyl anthranilate 8003-22-3, Solvent yellow 33  
10043-35-3, Boric acid (H3BO3), biological studies 10125-76-5,  
4-Nitrosobiphenyl 10143-23-4, 2,3-Dimethyl-1-pentanol 10213-75-9  
10277-43-7, Lanthanum nitrate hexahydrate 10318-26-0, Dibromodulcitol  
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
(Biological study)

(identification of structural requirements for mutagenicity, by  
incorporating mol. flexibility and metabolic activation of chems. in  
general Ames mutagenicity model (Erratum))

IT 10605-21-7, Carbazepine 11097-69-1, PCB 1254 12224-98-5, Pigment red  
81 12225-21-7, Pigment yellow 100 12789-03-6, Chlordane 13014-18-1  
13014-24-9 13048-33-4, 1,6-Hexanediol diacrylate 13071-79-9,  
biological studies 13098-39-0 13114-72-2 13284-42-9,  
2-Pentenitrile 13360-63-9, Ethyl N-butylamine 13366-73-9,  
Photodioldrin 13552-21-1 13552-44-8, 4,4'-Methylenedianiline  
dihydrochloride 13674-84-5 13674-87-8 13684-63-4, Phenmedipham  
13889-92-4, Propyl chlorothioformate 13952-84-6, sec-Butylamine  
13961-86-9, biological studies 14371-10-9, trans-Cinnamaldehyde  
14882-18-9, Bismuth subsalicylate 14901-07-6 15110-74-4,  
2,5-Dinitrofluorene 15121-84-3, o-Nitrophenethylalcohol 15481-70-6  
15893-52-4 15950-66-0, 2,3,4-Trichlorophenol 16219-75-3, Ethylidene  
norbornene 16238-56-5 16452-01-0 16529-56-9, 2-Methyl-3-

butenenitrile 17026-81-2, 3-Amino-4-ethoxyacetanilide 17341-40-1  
 17359-54-5 17369-59-4, 3-Propylidenephthalide 17372-87-1, Eosin  
 17433-31-7 17804-35-2, Benomyl 17831-71-9, Tetraethylene glycol  
 diacrylate 17924-92-4, Zearalenone 18024-11-8, 1,4,9-  
 Trimethylcarbazole 18028-55-2, 1,4-Dimethylcarbazole 18028-56-3,  
 1,4,6-Trimethylcarbazole 18662-53-8, Nitrilotriacetic acid trisodium  
 salt monohydrate 19315-64-1 19660-16-3, 2,3-Dibromopropyl acrylate  
 19686-73-8, 1-Bromo-2-propanol 19780-11-1 20020-02-4,  
 1,2,3,4-Tetrachloronaphthalene 20265-97-8, p-Anisidine hydrochloride  
 20548-62-3, biological studies 20702-77-6, Neohesperidin dihydrochalcone  
 21285-46-1, trans-2,3-Dibromo-2-butene-1,4-diol 21739-91-3, Cytembena  
 21829-25-4, Nifedipine 22224-92-6, Phenamiphos 23255-93-8, Hycanthone  
 methanesulfonate 23564-05-8, Thiophanate methyl 24140-30-5  
 24169-02-6, Econazole nitrate 24325-70-0, trans-4-Methyl-4'-  
 nitrostilbene 24370-25-0, 2-Benzimidazolylurea 24382-04-5, Propanedial  
 sodium 24554-26-5, N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide  
 24815-24-5, Rescinnamine 25322-68-3, Peg 25637-99-4,  
 Hexabromocyclododecane 25843-45-2, Azoxymethane 25953-06-4  
 26446-35-5, Acetin 26471-62-5 26530-20-1, Kathon 893 26638-28-8,  
 Methyl pentachlorostearate 26761-40-0, Diisodecyl phthalate  
 28322-02-3, 4-Acetylaminofluorene 29385-43-1, Tolyltriazole  
 29743-15-5, 4-Butyloxybenzal-4'-ethyl-aniline 29761-21-5, Isodecyl  
 diphenyl phosphate 29964-84-9, Isodecyl methacrylate 31386-38-6  
 31551-45-8, 2,7-Dinitrofluoren-9-one 32588-76-4 33229-34-4, HC blue 2  
 34807-41-5, Mezerein 36355-01-8, Hexabromobiphenyl 37853-59-1  
 38848-76-9 39156-41-7, 2,4-Diaminoanisole sulfate 41122-70-7  
 42397-64-8, 1,6-Dinitropyrene 42397-65-9, 1,8-Dinitropyrene 52551-67-4  
 54810-82-1, 3,5-Dimethyl-4-aminobiphenyl 54827-17-7,  
 3,3',5,5'-Tetramethylbenzidine 56803-37-3, tert-Butylphenyl diphenyl  
 phosphate 62625-14-3, 2-Amino-6-chloro-4-nitrophenol hydrochloride  
 64532-97-4, biological studies 67219-70-9, 1-Butyl-2-aminonaphthalene  
 69314-47-2, 3-Methyl-4-nitrobiphenyl 69884-05-5 70634-28-5  
 72917-35-2, 1,4-Dimethyl-6-hydroxy-3-nitrocarbazole 74518-95-9  
 74518-99-3 76002-91-0 78491-02-8, Diazolidinylurea 92814-28-3,  
 4-Ethyl-3-nitrobiphenyl 108100-28-3, 2-Methyl-7-nitrofluorene  
 126335-31-7 126335-36-2 127502-68-5, 2-Isopropyl-4-phenylnitrobenzene  
 127502-69-6, 3-Isopropyl-4-aminobiphenyl 127750-13-4 128714-75-0,  
 1,6-Dinitrobenzo[a]pyrene 128714-76-1, 3,6-Dinitrobenzo[a]pyrene  
 129117-54-0, 1,4-Dimethyl-6-methoxy-3-aminocarbazole 188107-70-2,  
 9-Methyl-2-nitro-9H-carbazole 188107-72-4, 1,4,6-Trimethyl-3-nitro-9H-  
 carbazole 189084-64-8 275795-12-5 275795-16-9 275795-17-0  
 279242-09-0 279242-10-3 279242-11-4 279242-12-5 279242-14-7  
 279242-16-9 279242-17-0 314084-63-4, 3,5-Diethyl-4-aminobiphenyl  
 345667-01-8 345667-02-9 345667-57-4 345667-58-5 345667-59-6  
 345667-60-9 345667-61-0 345667-62-1 389104-53-4,  
 1-Ethyl-2-aminonaphthalene 389104-54-5 389104-55-6,  
 1-tert-Butyl-2-aminonaphthalene 389104-56-7, 1-Ethyl-2-aminofluorene  
 389104-57-8, 1-Isopropyl-2-aminofluorene 389104-58-9,  
 1-Butyl-2-aminofluorene 389104-59-0, 1-tert-Butyl-2-aminofluorene  
 389104-60-3, 3-Ethyl-4-aminobiphenyl 389104-61-4, 3-Butyl-4-  
 aminobiphenyl 389104-62-5, 3,5-Diisopropyl-4-aminobiphenyl  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)  
 (identification of structural requirements for mutagenicity, by  
 incorporating mol. flexibility and metabolic activation of chems. in  
 general Ames mutagenicity model (Erratum))

L7 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 88-99-3, Phthalic acid, biological studies 110-15-6,  
 Succinic acid, biological studies 124-04-9, Adipic acid,  
 biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compsn. comprising guaiacol component and mucoadhesive polymer for  
prevention and treatment of common cold and influenza-like symptoms)


RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2007:538047 CAPLUS

DOCUMENT NUMBER: 146:507689

TITLE: Compositions comprising guaiacol component useful for  
prevention and treatment of common cold and  
influenza-like symptoms

INVENTOR(S): Clymer, Jeffrey Warren; Ho, Begonia Y.; Jump, Mary  
Lynn; Small, Leonard Edwin; Walanski, Amy Ann; Rennie,  
Paul John; Zukowski, Claudine Killar

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S. Pat. Appl. Publ., 13pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070110676	A1	20070517	US 2005-282010	20051117
WO 2007057858	A2	20070524	WO 2006-IB54301	20061116
WO 2007057858	A3	20071011		
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p>				
<p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA</p>				

PRIORITY APPLN. INFO.:

US 2005-282010

A 20051117

AN 2007:538047 CAPLUS  
 DN 146:507689  
 ED Entered STN: 18 May 2007  
 TI Compositions comprising guaiacol component useful for prevention and treatment of common cold and influenza-like symptoms  
 IN Clymer, Jeffrey Warren; Ho, Begonia Y.; Jump, Mary Lynn; Small, Leonard Edwin; Walanski, Amy Ann; Rennie, Paul John; Zukowski, Claudine Killar  
 PA The Procter & Gamble Company, USA  
 SO U.S. Pat. Appl. Publ., 13pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 INCL 424045000; 424737000; 514699000; 514717000; 424641000; 514494000;  
 424756000; 514569000; 514570000; 514649000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070110676	A1	20070517	US 2005-282010	20051117
	WO 2007057858	A2	20070524	WO 2006-IB54301	20061116
	WO 2007057858	A3	20071011		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2005-282010 A 20051117

# CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20070110676	INCL	424045000; 424737000; 514699000; 514717000; 424641000; 514494000; 424756000; 514569000; 514570000; 514494000	
	IPCI	A61K0009-12 [I,A]; A61K0036-906 [I,A]; A61K0036-88 [I,C*]; A61K0036-28 [I,A]; A61K0036-185 [I,C*]; A61K0033-32 [I,A]; A61K0031-192 [I,A]; A61K0031-185 [I,C*]; A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; A61K0031-137 [I,A]	
	IPCR	A61K0009-12 [I,C]; A61K0009-12 [I,A]; A61K0031-137 [I,C]; A61K0031-137 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-4738 [I,C]; A61K0031-4745 [I,A]; A61K0033-32 [I,C]; A61K0033-32 [I,A]; A61K0036-185 [I,C]; A61K0036-28 [I,A]; A61K0036-88 [I,C]; A61K0036-906 [I,A]	
	NCL	424/045.000; 424/641.000; 424/737.000; 424/756.000; 514/250.000; 514/291.000; 514/424.000; 514/494.000; 514/569.000; 514/570.000; 514/649.000; 514/699.000; 514/717.000	
WO 2007057858	IPCI	A61K0031-045 [I,C]; A61K0031-05 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0031-00 [I,C]; A61P0031-16 [I,A]	
	IPCR	A61K0031-045 [I,C]; A61K0031-05 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0031-00 [I,C]; A61P0031-16 [I,A]	
	ECLA	A61K045/06; A61K009/00M14; A61K031/05; A61K031/137+M;	

A61K031/192+M; A61K031/4745+M; A61K036/00+M

- AB The present invention is directed to compns. that are useful in the prevention and treatment of common cold and influenza-like symptoms due to respiratory tract viral infections. These compns. comprise a guaiacol component about 0.0001-1%, and a mucoadhesive polymer wherein the pH of the composition is  $\leq 5.5$ . Thus, a composition comprised pyroglutamic acid 0.36, succinic acid 1.04, disodium succinate 0.47, sodium chloride 0.21, Polysorbate 80 0.08, Lutrol F127 16, sodium saccharin 0.03, benzalkonium chloride (50%) 0.3, Echinacea 0.3, a premix composition (containing ethanol 54.5, methanol 6.0, eucalyptol 2.5, Optabreeze A 14.7, and eugenol 22.3), and water to 100%, resp.
- ST guaiacol mucoadhesive polymer nasal spray common cold influenza
- IT Quaternary ammonium compounds, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkylbenzyltrimethyl, chlorides; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)
- IT Vinyl compounds, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(carboxy-containing, polymers; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)
- IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(clove; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)
- IT Aconitum napellus  
Allium cepa  
Astragalus menziesii  
Baptisia tinctoria  
Common cold  
Croton tiglium  
Dioscorea villosa  
Drug delivery systems  
Echinacea angustifolia  
Echinacea pallida  
Echinacea purpurea  
Gelsemium sempervirens  
Helianthus annuus  
Hydrastis canadensis  
Influenza  
Lobaria pulmonaria  
Onion  
Propellants (sprays and foams)  
Prophylaxis  
Pulsatilla  
Pulsatilla nuttalliana  
Sambucus canadensis  
Sambucus nigra  
Spigelia marilandica  
Stachys officinalis  
Thuja occidentalis  
Thymus serpyllum  
Viscosity  
Zingiber officinale  
pH  
(compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)
- IT Biopolymers

Chlorides, biological studies  
 Fluorides, biological studies  
 Iodides, biological studies  
 Nitrates, biological studies  
 Phosphates, biological studies  
 Polyoxyalkylenes, biological studies  
 Sulfates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT Health products  
 (homeopathic preps.; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT Respiratory system, disease  
 (infection, viral; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT Adhesion, biological  
 (mucoadhesion; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT Polymers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mucoadhesive; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT Nasal drug delivery systems  
 Pharmaceutical sprays  
 (nasal sprays; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT 106392-12-5, Poloxamer  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Lutrol F127; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT 79-10-7D, Acrylic acid, polymers  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (carboxypolymethylenes; compns. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)

IT 50-21-5, Lactic acid, biological studies 50-53-3, Chlorpromazine, biological studies 50-78-2, Aspirin 50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological studies 52-26-6, Morphine hydrochloride 55-48-1, Atropine sulfate 56-40-6, Glycine, biological studies 56-81-5, Glycerol, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 56-92-8, Histamine hydrochloride 57-55-6, Propylene glycol, biological studies 58-73-1, Diphenhydramine 59-42-7, Phenylephrine 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 68-04-2, Sodium citrate 69-72-7, Salicylic acid, biological studies 76-22-2, Camphor 77-92-9, Citric acid, biological studies 79-10-7D, Acrylic acid, copolymer with pentaerythritol or sucrose allyl ether or divinyl glycol 79-14-1, Glycolic acid, biological studies 86-22-6, Brompheniramine 87-69-4, Tartaric acid, biological studies 88-99-3, Phthalic acid, biological studies 89-78-1, Menthol 89-83-8, Thymol 90-05-1, Guaiacol 90-82-4, Pseudoephedrine 93-28-7, 4-Allyl-2-methoxyphenyl acetate 93-51-6, 4-Methyl guaiacol 94-86-0, 5-Propenylguaiethol 97-53-0, Eugenol 97-54-1, Isoeugenol 98-79-3,

Pyroglutamic acid 101-31-5, Hyoscyamine 101-40-6, Propylhexedrine 102-71-6, Triethanolamine, biological studies 103-90-2, Acetaminophen 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 111-90-0, Transcutol 114-49-8, Scopalamine hydrobromide 121-33-5, Vanillin 124-04-9, Adipic acid, biological studies 128-44-9, Sodium saccharin 130-89-2, Quinine hydrochloride 132-22-9, Chloropheniramine 141-82-2, Malonic acid, biological studies 144-55-8, Sodium bicarbonate, biological studies 147-93-3, Thiosalicylic acid 150-90-3, Disodium succinate 299-42-3, Ephedrine 306-03-6, Hyoscyamine hydrobromide 469-21-6, Doxylamine 470-82-6, Eucalyptol 471-34-1, Calcium carbonate, biological studies 486-12-4, Triprolidine 526-36-3, Xylometazoline 526-95-4, D-Gluconic acid 557-34-6, Zinc acetate 584-08-7, Potassium carbonate 835-31-4, Naphazoline 1310-73-2, Sodium hydroxide, biological studies 1314-13-2, Zinc oxide, biological studies 1336-21-6, Ammonium hydroxide 1406-18-4, Vitamin E 1491-59-4, Oxymetazoline 2086-83-1, Berberin 2785-87-7, Dihydroeugenol 2785-89-9, 4-Ethyl-2-methoxyphenol 3486-35-9, Zinc carbonate 4468-02-4, Zinc gluconate 5936-28-7, Hydrastine, hydrochloride 6228-53-1, Zinc succinate 6485-40-1, L-Carvone 6915-15-7, Malic acid 7429-90-5, Aluminum, biological studies 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-02-0, Nickel, biological studies 7440-22-4, Silver, biological studies 7440-31-5, Tin, biological studies 7440-48-4, Cobalt, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7447-40-7, Potassium chloride, biological studies 7601-54-9, Sodium phosphate 7646-85-7, Zinc chloride, biological studies 7647-14-5, Sodium chloride, biological studies 7681-11-0, Potassium iodide, biological studies 7699-45-8, Zinc bromide 7733-02-0, Zinc sulfate 7758-02-3, Potassium bromide, biological studies 7779-90-0, Zinc phosphate 7786-30-3, Magnesium chloride, biological studies 9004-32-4, Carboxymethyl cellulose sodium salt 9004-58-4, Ethyl hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-65-6, Polysorbate 80 9011-16-9, Maleic anhydride-methyl vinyl ether copolymer 10043-52-4, Calcium chloride, biological studies 12058-66-1, Sodium stannate 12125-02-9, Ammonium chloride, biological studies 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15454-75-8, 15686-51-8, Clemastine 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 25322-68-3, Polyethylene glycol 33817-09-3, (-)-Deoxyephedrine 60205-81-4, Ipratropium 82654-98-6, Vanillyl butyl ether 151728-40-4, Zinc ascorbate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comps. comprising guaiacol component and mucoadhesive polymer for prevention and treatment of common cold and influenza-like symptoms)


L7 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2008 ACS ON STN

IT 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate 88-99-3, Phthalic acid, biological studies 100-42-5, Styrene, biological studies 103-23-1 117-81-7, Di(2-ethylhexyl)phthalate 122-62-3, Di-(2-ethylhexyl)sebacate 131-11-3, Dimethyl phthalate

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)  
 (identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)


RN 84-66-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-diethyl ester (CA INDEX NAME)



RN 84-74-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester (CA INDEX NAME)




RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




RN 100-42-5 CAPLUS

CN Benzene, ethenyl- (CA INDEX NAME)



RN 103-23-1 CAPLUS


CN Hexanedioic acid, 1,6-bis(2-ethylhexyl) ester (CA INDEX NAME)




RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)






RN 122-62-3 CAPLUS  
 CN Decanedioic acid, 1,10-bis(2-ethylhexyl) ester (CA INDEX NAME)



RN 131-11-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-dimethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 2007:334667 CAPLUS  
 DOCUMENT NUMBER: 146:516278  
 TITLE: Identification of the Structural Requirements for Mutagenicity, by Incorporating Molecular Flexibility and Metabolic Activation of Chemicals. II. General Ames Mutagenicity Model  
 AUTHOR(S): Serafimova, R.; Todorov, M.; Pavlov, T.; Kotov, S.; Jacob, E.; Aptula, A.; Mekenyan, O.  
 CORPORATE SOURCE: Laboratory of Mathematical Chemistry, University Prof. As. Zlatarov, Bourgas, 8000, Bulg.  
 SOURCE: Chemical Research in Toxicology (2007), 20(4), 662-676  
 CODEN: CRTOEC; ISSN: 0893-228X  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AN 2007:334667 CAPLUS  
 DN 146:516278  
 ED Entered STN: 25 Mar 2007  
 TI Identification of the Structural Requirements for Mutagenicity, by Incorporating Molecular Flexibility and Metabolic Activation of Chemicals. II. General Ames Mutagenicity Model  
 AU Serafimova, R.; Todorov, M.; Pavlov, T.; Kotov, S.; Jacob, E.; Aptula, A.; Mekenyan, O.  
 CS Laboratory of Mathematical Chemistry, University Prof. As. Zlatarov, Bourgas, 8000, Bulg.  
 SO Chemical Research in Toxicology (2007), 20(4), 662-676  
 CODEN: CRTOEC; ISSN: 0893-228X  
 PB American Chemical Society

DT Journal  
 LA English  
 CC 4-6 (Toxicology)  
 AB The tissue metabolic simulator (TIMES) modeling approach is a hybrid expert system that couples a metabolic simulator together with structure toxicity rules, underpinned by structural alerts, to predict interaction of chems. or their metabolites with target macromols. Some of the structural alerts representing the reactivity pattern-causing effect could interact directly with the target whereas others necessitated a combination with two- or three-dimensional quant. structure-activity relationship models describing the firing of the alerts from the rest of the mols. Recently, TIMES has been used to model bacterial mutagenicity (O. Mekenyan, O., et al., 2004). The original model was derived for a single tester strain, *Salmonella typhimurium* (TA100), using the Ames test by the National Toxicol. Program (NTP). The model correctly identified 82% of the primary acting mutagens, 94% of the nonmutagens, and 77% of the metabolically activated chems. in a training set. The identified high correlation between activities across different strains changed the initial strategic direction to look at the other strains in the next modeling developments. In this respect, the focus of the present work was to build a general mutagenicity model predicting mutagenicity with respect to any of the Ames tester strains. The use of all reactivity alerts in the model was justified by their interaction mechanisms with DNA, found in the literature. The alerts identified for the current model were analyzed by comparison with other established alerts derived from human experts. In the new model, the original NTP training set with 1341 structures was expanded by 1626 proprietary chems. provided by BASF AG. Eventually, the training set consisted of 435 chems., which are mutagenic as parents, 397 chems. that are mutagenic after S9 metabolic activation, and 2012 nonmutagenic chems. The general mutagenicity model was found to have 82% sensitivity, 89% specificity, and 88% concordance for training set chems. The model applicability domain was introduced accounting for similarity (structural, mechanistic, etc.) between predicted chems. and training set chems. for which the model performs correctly.

ST mutagenicity mol flexibility QSAR model mutagen

IT Molecular topology  
 Mutagenicity  
 Mutagens  
*Salmonella typhimurium*  
 Simulation and Modeling  
 (identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

IT Polyoxoalkylenes, biological studies  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)  
 (identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

IT Structure-activity relationship  
 (mutagenic; identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

IT 50-00-0, Formaldehyde, biological studies 50-18-0, Cyclophosphamide  
 50-29-3, 4,4'-DDT, biological studies 50-32-8, 3,4-Benzopyrene, biological studies 50-33-9, Phenylbutazone, biological studies  
 50-34-0, Propantheline bromide 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-78-2, Acetylsalicylic acid 50-81-7, Vitamin C, biological studies 51-17-2, Benzimidazole 51-21-8, Fluorouracil 51-28-5, 2,4-Dinitrophenol, biological studies 51-30-9, Isoproterenol hydrochloride 51-41-2 51-43-4, Epinephrine 51-65-0,

4-Fluoro-DL-phenylalanine 51-79-6, Urethane 52-24-4 52-28-8, Codeine phosphate 52-68-6, Trichlorfon 53-03-2, Prednisone 53-19-0  
 53-70-3, Dibenz[a,h]anthracene 53-86-1, Indomethacin 53-94-1 53-95-2  
 53-96-3, 2-Acetylaminofluorene 54-31-9, Furosemide 55-18-5,  
 N-Nitrosodiethylamine 55-21-0, Benzamide 55-38-9, Fenthion 55-55-0  
 55-86-7, Nitrogen mustard hydrochloride 55-98-1, Myleran 56-04-2,  
 6-Methyl-2-thiouracil 56-18-8 56-23-5, Carbon tetrachloride,  
 biological studies 56-38-2, Parathion 56-40-6, Glycine, biological studies 56-49-5, 3-Methylcholanthrene 56-53-1 56-54-2, Quinidine 56-57-5, 4-Nitroquinoline-1-oxide 56-72-4, Coumaphos 56-81-5, Glycerol, biological studies 56-93-9 57-13-6, Urea, biological studies 57-14-7, 1,1-Dimethylhydrazine 57-41-0, 5,5-Diphenylhydantoin 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 57-57-8,  $\beta$ -Propiolactone 57-63-6, Ethynylestradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-71-6 57-74-9 57-83-0, Progesterone, biological studies 57-97-6, 7,12-Dimethylbenz[a]anthracene 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-33-3, Promethazine hydrochloride 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-89-9, Lindane 58-90-2, 2,3,4,6-Tetrachlorophenol 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-50-7, p-Chloro-m-cresol 59-87-0, Nitrofurazone 59-89-2, N-Nitrosomorpholine 60-09-3, Solvent yellow 1 60-33-3, Linoleic acid, biological studies 60-34-4, Methylhydrazine 60-35-5, Acetamide, biological studies 60-51-5, Dimethoate 60-57-1, Dieldrin 61-25-6, Papaverine hydrochloride 61-76-7, Phenylephrine hydrochloride 61-82-5, 1H-1,2,4-Triazol-3-amine 62-23-7, p-Nitrobenzoic acid 62-44-2, Phenacetin 62-50-0, Ethyl methanesulfonate 62-53-3, Aniline, biological studies 62-55-5, Thiocetamide 62-56-6, Thiourea, biological studies 62-73-7, Dichlorvos 62-75-9, N-Nitrosodimethylamine 63-56-9, Thonzylamine hydrochloride 63-74-1, Sulfanilamide 63-92-3, Phenoxylbenzamide hydrochloride 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-67-5, Diethyl sulfate 64-75-5, Tetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 66-27-3, Methyl methanesulfonate 66-71-7, o-Phenanthroline 66-75-1, Uracil mustard 66-81-9, Cycloheximide 67-20-9 67-21-0, DL-Ethionine 67-48-1, Choline chloride 67-63-0, Isopropanol, biological studies 67-64-1, Acetone, biological studies 67-72-1, Hexachloroethane 67-97-0, Vitamin D3 68-12-2, N,N-Dimethylformamide, biological studies 69-05-6, Quinacrine dihydrochloride 69-65-8, D-Mannitol 69-74-9, Cytarabine hydrochloride 70-25-7 70-30-4, Hexachlorophene 70-34-8, 1-Fluoro-2,4-dinitrobenzene 71-58-9, Medroxyprogesterone acetate 72-14-0, Sulfathiazole 72-20-8, Endrin 72-43-5, Methoxychlor 72-54-8, DDD 72-55-9, DDE, biological studies 72-56-0 73-22-3, L-Tryptophan, biological studies 73-49-4, Quinethazone 74-11-3, p-Chlorobenzoic acid 74-31-7, N,N'Diphenyl-p-phenylenediamine 74-85-1, Ethylene, biological studies 74-89-5, Monomethylamine, biological studies 74-96-4, Ethyl bromide 75-00-3, Ethyl chloride 75-04-7, Ethylamine, biological studies 75-05-8, Acetonitrile, biological studies 75-07-0, Acetaldehyde, biological studies 75-12-7, Formamide, biological studies 75-25-2, Tribromomethane 75-26-3, 2-Bromopropane 75-27-4, Dichlorobromomethane 75-31-0, Isopropylamine, biological studies 75-34-3, 1,1-Dichloroethane 75-35-4, Vinylidene chloride, biological studies 75-36-5, Acetyl chloride 75-47-8, Triiodomethane 75-52-5, Nitromethane, biological studies 75-55-8, Propylenimine 75-64-9, tert-Butylamine, biological studies 75-65-0, tert-Butyl alcohol, biological studies 75-69-4, Trichlorofluoromethane 75-83-2, 2,2-Dimethylbutane 75-86-5, 2-Hydroxy-2-methylpropanenitrile 75-87-6, Anhydrous chloral 75-91-2, tert-Butyl hydroperoxide 76-01-7, Pentachloroethane 76-06-2,

Chloropicrin 76-38-0, Methoxyflurane 76-44-8, Heptachlor 77-06-5, Gibberellic acid 77-47-4, Hexachlorocyclopentadiene 77-65-6, Bromodiethylacetylcarbamide 77-73-6, Dicyclopentadiene 77-79-2, 3-Sulfolene 78-11-5 78-34-2, Dioxathion 78-38-6, Diethyl ethylphosphonate 78-40-0, Triethyl phosphate 78-42-2, Tris(2-ethylhexyl) phosphate 78-44-4, Carisoprodol 78-51-3 78-59-1, Isophorone 78-79-5, Isoprene, biological studies 78-81-9, Isobutyl amine 78-83-1, Isobutyl alcohol, biological studies 78-84-2, Isobutyraldehyde 78-87-5, 1,2-Dichloropropane 78-88-6, 2,3-Dichloro-1-propene 78-90-0, Propylenediamine 78-93-3, Ethyl methyl ketone, biological studies 78-94-4, Methyl vinyl ketone, biological studies 79-00-5, 1,1,2-Trichloroethane 79-01-6, Trichloroethylene, biological studies 79-08-3, Bromoacetic acid 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-11-8, Chloroacetic acid, biological studies 79-15-2, N-Bromoacetamide 79-20-9, Methyl acetate 79-21-0, Peroxyacetic acid 79-24-3, Nitroethane 79-29-8, 2,3-Dimethylbutane 79-36-7, Dichloroacetyl chloride 79-41-4, Methacrylic acid, biological studies 79-44-7, Dimethylcarbamyl chloride 79-46-9, 2-Nitropropane 79-94-7 80-05-7, biological studies 80-08-0 80-13-7, Halazone 80-15-9, Cumene hydroperoxide 80-30-8 80-39-7 80-43-3, Cumene peroxide 80-46-6, p-tert-Pentylphenol 80-62-6, Methyl methacrylate 81-07-2, Saccharin 81-11-8, 4,4'-Diamino-2,2'-stilbenedisulfonic acid 81-14-1, Musk ketone 81-49-2, 1-Amino-2,4-dibromoanthraquinone 81-54-9, 1,2,4-Trihydroxyanthraquinone 81-55-0, 1,8-Dihydroxy-4,5-dinitroanthraquinone 82-33-7, 1,4-Diamino-5-nitroanthraquinone 82-50-8 82-62-2 82-68-8, Pentachloronitrobenzene 82-75-7, Peric acid 83-26-1, 2-Pivalyl-1,3-indandione 83-32-9, Acenaphthene 83-38-5, 2,6-Dichlorobenzaldehyde 83-66-9, Musk ambrette 83-72-7, 2-Hydroxy-1,4-naphthalenedione 83-79-4, Rotenone 84-61-7, Dicyclohexyl phthalate 84-64-0 84-65-1, 9,10-Anthraquinone 84-66-2, Diethyl phthalate 84-69-5, Diisobutyl phthalate 84-74-2, Dibutyl phthalate 84-75-3, Di-n-hexyl phthalate 85-01-8, Phenanthrene, biological studies 85-02-9, Benzo[f]quinoline 85-22-3, 2,3,4,5,6-Pentabromoethylbenzene 85-44-9, Phthalic anhydride 85-98-3, N,N'-Diethylcarbanilide 86-00-0, 2-Nitro-biphenyl 86-28-2, 9-Ethylcarbazole 86-30-6, N-Nitrosodiphenylamine

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

- IT 86-50-0, Gusathion 86-57-7, 1-Nitronaphthalene 87-25-2, Ethyl anthranilate 87-29-6, Cinnamyl anthranilate 87-59-2, 2,3-Xylidine 87-61-6, 1,2,3-Trichlorobenzene 87-65-0, 2,6-Dichlorophenol 87-68-3, Hexachloro-1,3-butadiene 87-82-1, Hexabromobenzene 87-83-2, Pentabromotoluene 87-86-5, Pentachlorophenol 88-06-2, 2,4,6-Trichlorophenol 88-16-4, o-Chlorobenzotrifluoride 88-21-1, o-Aminobenzenesulfonic acid 88-23-3, 6-Amino-4-chloro-1-phenol-2-sulfonic acid 88-72-2, o-Nitrotoluene 88-73-3, 1-Chloro-2-nitrobenzene 88-75-5, o-Nitrophenol 88-88-0, Picryl chloride 88-89-1, Picric acid 88-96-0, Phthalamide 88-99-3, Phthalic acid, biological studies 89-25-8, 1-Phenyl-3-methyl-5-pyrazolone 89-40-7, 4-Nitrophthalimide 89-61-2, 1,4-Dichloro-2-nitrobenzene 89-63-4, 4-Chloro-2-nitroaniline 89-72-5, O-sec-Butylphenol 89-78-1, Menthol 89-98-5, 2-Chlorobenzaldehyde 90-00-6, O-Ethylphenol 90-04-0, o-Anisidine 90-13-1, 1-Chloronaphthalene 90-33-5,  $\beta$ -Methylumbelliferone 90-41-5, 2-Aminobiphenyl 90-45-9, 9-Aminoacridine 91-08-7, Toluene 2,6-diisocyanate 91-20-3, Naphthalene, biological studies 91-23-6, 2-Nitroanisole 91-44-1 91-58-7, 2-Chloronaphthalene 91-62-3, 6-Methylquinoline 91-66-7, N,N-Diethylaniline 91-68-9,

3-Diethylaminophenol 91-84-9, Pyrilamine 91-93-0 91-97-4 92-52-4,  
 Biphenyl, biological studies 92-59-1, N-Ethyl-N-phenylbenzylamine  
 92-66-0, 4-Bromobiphenyl 92-67-1, 4-Aminobiphenyl 92-84-2,  
 Phenothiazine 92-93-3, 4-Nitrobiphenyl 93-05-0, N,N-Diethyl-p-  
 phenylenediamine 93-15-2, Methyl eugenol 93-46-9 93-58-3, Methyl  
 benzoate 94-20-2, Chlorpropamide 94-25-7, Butyl p-aminobenzoate  
 94-36-0, Benzoyl peroxide, biological studies 94-52-0,  
 6-Nitrobenzimidazole 94-59-7, Safrole 95-05-6 95-06-7, Sulfallate  
 95-14-7, 1,2,3-Benzotriazole 95-19-2 95-31-8 95-46-5, o-Bromotoluene  
 95-47-6, o-Xylene, biological studies 95-48-7, o-Cresol, biological  
 studies 95-50-1, 1,2-Dichlorobenzene 95-51-2, o-Chloroaniline  
 95-54-5, o-Phenylenediamine, biological studies 95-55-6, 2-Aminophenol  
 95-57-8, o-Chlorophenol 95-64-7, 3,4-Xylidine 95-68-1,  
 2,4-Dimethylaniline 95-74-9, 4-Methyl-3-chloroaniline 95-76-1,  
 3,4-Dichloroaniline 95-77-2, 3,4-Dichlorophenol 95-78-3, 2,5-Xylidine  
 95-79-4, 5-Chloro-o-toluidine 95-80-7, 2,4-Diaminotoluene 95-82-9,  
 2,5-Dichloroaniline 95-83-0, 4-Chloro-o-phenylenediamine 95-84-1,  
 2-Amino-4-methylphenol 95-85-2, 2-Amino-4-chlorophenol 95-94-3,  
 1,2,4,5-Tetrachlorobenzene 95-95-4, 2,4,5-Trichlorophenol 96-09-3,  
 Styrene oxide 96-12-8, 1,2-Dibromo-3-chloropropane 96-13-9,  
 2,3-Dibromo-1-propanol 96-18-4, 1,2,3-Trichloropropane 96-23-1,  
 1,3-Dichloro-2-propanol 96-31-1, N,N'-Dimethylurea 96-33-3, Methyl  
 acrylate 96-37-7, Methyl cyclopentane 96-45-7, N,N'-Ethylenethiourea  
 96-67-3, 6-Amino-4-nitrophenol-2-sulfonic acid 96-69-5 96-91-3,  
 2-Amino-4,6-dinitrophenol 97-02-9, 2,4-Dinitroaniline 97-18-7  
 97-23-4 97-24-5 97-32-5, 4-Methoxy-3-nitro-N-phenylbenzamide  
 97-42-7, Carvyl acetate 97-53-0 97-54-1, Isoeugenol 97-56-3, Solvent  
 yellow 3 97-63-2, Ethyl methacrylate 97-77-8, Tetraethylthiuram  
 97-84-7 97-88-1, Butyl methacrylate 98-00-0, 2-Furanmethanol  
 98-01-1, Furfural, biological studies 98-07-7, Benzotrichloride  
 98-08-8, Benzotrifluoride 98-11-3, Benzenesulfonic acid, biological  
 studies 98-15-7, m-Chlorobenzotrifluoride 98-16-8 98-30-6 98-37-3  
 98-46-4 98-51-1, p-tert-Butyltoluene 98-56-6 98-83-9,  
 α-Methylstyrene, biological studies 98-85-1, α-Methylbenzyl  
 alcohol 98-87-3, α,α-Dichlorotoluene 98-95-3,  
 Nitrobenzene, biological studies 98-96-4, Pyrazinamide 99-08-1,  
 m-Nitrotoluene 99-30-9, 2,6-Dichloro-4-nitroaniline 99-35-4,  
 1,3,5-Trinitrobenzene 99-48-9, Carveol 99-54-7, 3,4-  
 Dichloronitrobenzene 99-55-8, 5-Nitro-o-toluidine 99-56-9,  
 4-Nitro-o-phenylenediamine 99-57-0, 2-Amino-4-nitrophenol 99-59-2,  
 5-Nitro-o-anisidine 99-65-0, m-Dinitrobenzene 99-75-2, Methyl  
 p-toluate 99-82-1, p-Menthane 99-98-9, N,N-Dimethyl-p-phenylenediamine  
 100-00-5, 1-Chloro-4-nitrobenzene 100-01-6, p-Nitroaniline, biological  
 studies 100-02-7, p-Nitrophenol, biological studies 100-14-1,  
 p-Nitrobenzyl chloride 100-17-4, 4-Nitroanisole 100-19-6,  
 p-Nitroacetophenone 100-21-0, Terephthalic acid, biological studies  
 100-22-1, N,N,N',N'-Tetramethyl-p-phenylenediamine 100-25-4,  
 p-Dinitrobenzene 100-27-6, p-Nitrophenethyl alcohol 100-37-8,  
 2-(Diethylamino)ethanol 100-39-0, α-Bromotoluene 100-40-3,  
 4-Vinylcyclohexene 100-41-4, Ethylbenzene, biological studies  
 100-42-5, Styrene, biological studies 100-44-7, Benzyl chloride,  
 biological studies 100-47-0, Benzonitrile, biological studies  
 100-51-6, Benzyl alcohol, biological studies 100-52-7, Benzaldehyde,  
 biological studies 100-61-8, N-Methylaniline, biological studies  
 100-65-2, N-Phenylhydroxylamine 100-74-3, N-Ethylmorpholine 100-75-4,  
 N-Nitrosopiperidine 100-97-0, biological studies 101-02-0, Triphenyl  
 phosphite 101-05-3, Anilazine 101-14-4, 4,4'-Methylenbis(2-  
 chloroaniline) 101-18-8, 3-Hydroxy-N-phenylaniline 101-20-2,  
 Triclocarban 101-25-7, N,N-Dinitrosopentamethylenetetramine 101-39-3,  
 α-Methylcinnamaldehyde 101-54-2, N-Phenyl-p-phenylenediamine  
 101-67-7, 4,4'-Diocetylphenylamine 101-68-8, 4,4'-Diphenylmethane

diisocyanate 101-70-2, 4,4'-Dimethoxydiphenylamine 101-72-4,  
 N-Isopropyl-N'-phenyl-1,4-phenylenediamine 101-73-5,  
 4-Isopropoxydiphenylamine 101-77-9, 4,4'-Methylenedianiline 101-80-4,  
 4,4'-Oxydianiline 101-83-7, Dicyclohexylamine 101-84-8, Diphenyl oxide  
 102-01-2, Acetoacetanilide 102-06-7, 1,3-Diphenylguanidine 102-28-3,  
 m-Aminoacetanilide 102-50-1, m-Cresidine 102-70-5, Triallylamine  
 102-71-6, Triethanolamine, biological studies 102-77-2 102-81-8  
 102-82-9, Tributylamine 102-96-5,  $\beta$ -Nitrostyrene 103-11-7  
 103-23-1 103-30-0, trans-Stilbene 103-33-3, Azobenzene  
 103-50-4 103-69-5, N-Ethylaniline 103-70-8, Formanilide 103-84-4,  
 Acetanilide 103-85-5, 1-Phenyl-2-thiourea 103-89-9,  
 N-Acetyl-p-toluidine 103-90-2, Acetaminophen 104-28-9, Cinoxate  
 104-75-6, 2-Ethylhexylamine 104-85-8, p-Tolunitrile 104-88-1,  
 4-Chlorobenzaldehyde, biological studies 104-91-6 104-94-9,  
 p-Anisidine 105-11-3, p-Benzquinone dioxime 105-20-4,  
 1H-Pyrazole-3-ethanamine 105-55-5, N,N'-Diethylthiourea 105-58-8,  
 Diethyl carbonate 105-59-9, N-Methyldiethanolamine 105-60-2,  
 Caprolactam, biological studies 105-67-9, 2,4-Dimethylphenol 105-87-3,  
 Geranyl acetate 106-20-7 106-38-7, p-Bromotoluene 106-40-1,  
 p-Bromoaniline 106-42-3, p-Xylene, biological studies 106-43-4,  
 p-Chlorotoluene 106-44-5, p-Cresol, biological studies 106-46-7,  
 1,4-Dichlorobenzene 106-47-8, p-Chloroaniline, biological studies  
 106-51-4, p-Quinone, biological studies 106-63-8, Isobutyl acrylate  
 106-65-0, Dimethyl succinate 106-87-6 106-93-4, 1,2-Dibromethane  
 107-02-8, Acrolein, biological studies 107-06-2, 1,2-Dichloroethane,  
 biological studies 107-07-3, 2-Chloroethanol, biological studies  
 107-11-9, Allylamine 107-12-0, Propionitrile  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)

(identification of structural requirements for mutagenicity, by  
 incorporating mol. flexibility and metabolic activation of chems. in  
 general Ames mutagenicity model)

IT 107-14-2, Chloroacetonitrile 107-15-3, Ethylenediamine, biological  
 studies 107-21-1, Ethylene glycol, biological studies 107-31-3, Methyl  
 formate 107-35-7, Taurine 107-68-6, N-MethylTaurine 107-70-0  
 108-01-0, 2-Dimethylaminoethanol 108-03-2, 1-Nitropropane 108-09-8,  
 1,3-Dimethylbutylamine 108-10-1, Methyl isobutyl ketone 108-18-9,  
 Diisopropylamine 108-21-4, Isopropyl acetate 108-24-7, Acetic  
 anhydride 108-30-5, Succinic anhydride, biological studies 108-31-6,  
 Maleic anhydride, biological studies 108-38-3, m-Xylene, biological  
 studies 108-39-4, m-Cresol, biological studies 108-42-9,  
 m-Chloroaniline 108-43-0, m-Chlorophenol 108-45-2, m-Phenylenediamine,  
 biological studies 108-46-3, Resorcinol, biological studies 108-60-1,  
 Bis(2-chloro-1-methylethyl) ether 108-69-0, 3,5-Xylidine 108-70-3,  
 1,3,5-Trichlorobenzene 108-78-1, 1,3,5-Triazine 2,4,6-triamine,  
 biological studies 108-80-5, Cyanuric acid 108-83-8, Diisobutyl ketone  
 108-88-3, Toluene, biological studies 108-90-7, Monochlorobenzene,  
 biological studies 108-91-8, Cyclohexylamine, biological studies  
 108-93-0, Cyclohexanol, biological studies 108-94-1, Cyclohexanone,  
 biological studies 108-95-2, Phenol, biological studies 108-99-6,  
 $\beta$ -Picoline 109-55-7, 3-(Dimethylamino)-1-propanamine 109-57-9,  
 Allylthiourea 109-64-8, 1,3-Dibromopropane 109-69-3, n-Butyl chloride  
 109-73-9, n-Butylamine, biological studies 109-76-2, 1,3-Diaminopropane  
 109-77-3, Malonic acid dinitrile 109-78-4, 3-Hydroxypropanenitrile  
 109-83-1, N-Methylethanolamine 109-86-4, 2-Methoxyethanol 109-89-7,  
 Diethylamine, biological studies 109-99-9, Tetrahydrofuran, biological  
 studies 110-00-9, Furan 110-02-1, Thiophene 110-05-4, Di-tert-butyl  
 peroxide 110-17-8, Fumaric acid, biological studies 110-18-9,  
 N,N,N',N'-Tetramethylethylenediamine 110-21-4, Biurea 110-26-9  
 110-46-3, Isoamyl nitrite 110-49-6, 2-Methoxyethylacetate 110-52-1  
 110-58-7, N-Amylamine 110-61-2, Succinonitrile 110-63-4,

1,4-Butanediol, biological studies 110-82-7, Cyclohexane, biological studies 110-85-0, Piperazine, biological studies 110-86-1, Pyridine, biological studies 110-88-3, 1,3,5-Trioxane, biological studies 110-91-8, Morpholine, biological studies 110-96-3, Diisobutylamine 110-97-4, Diisopropanolamine 111-14-8, Heptanoic acid 111-30-8, Glutaraldehyde 111-40-0, Diethylenetriamine 111-41-1 111-42-2, Diethanolamine, biological studies 111-44-4, Bis(2-chloroethyl) ether 111-46-6, Diethylene glycol, biological studies 111-69-3, Adiponitrile 111-71-7, Heptanal 111-76-2, 2-Butoxyethanol 111-84-2, Nonane 111-92-2, Dibutylamine 111-96-6, Bis(2-methoxyethyl)ether 112-34-5, 2-(2-Butoxyethoxy)ethanol 112-52-7, Lauryl chloride 112-56-1, 2-(2-Ethoxyethoxy)ethyl thiocyanate 112-57-2, Tetraethylenepentamine 112-62-9, Methyl oleate 112-80-1, Oleic acid, biological studies 112-95-8, Eicosane 113-92-8, Chlorpheniramine maleate 114-83-0, 1-Acetyl-2-phenylhydrazine 115-07-1, Propylene, biological studies 115-28-6, Chloroendric acid 115-29-7, Endosulfan 115-32-2 115-86-6, Triphenyl phosphate 115-96-8, Tris(2-chloroethyl) phosphate 116-06-3, TEMIK 116-85-8, 1-Amino-4-hydroxyanthraquinone 117-05-5, 1-Benzamido-5-chloro-9,10-anthraquinone 117-08-8, Tetrachlorophthalic acid anhydride 117-12-4, 1,5-Dihydroxyanthraquinone 117-18-0 117-39-5, Quercetin 117-79-3, 2-Aminoanthraquinone 117-81-7, Di(2-ethylhexyl)phthalate 117-84-0, Di-n-octyl phthalate 118-52-5, 1,3-Dichloro-5,5-dimethylhydantoin 118-55-8, Phenyl salicylate 118-56-9, 3,3,5-Trimethylcyclohexyl salicylate 118-58-1, Benzyl salicylate 118-71-8, Maltol 118-74-1, Hexachlorobenzene 118-79-6, 2,4,6-Tribromophenol 118-91-2, o-Chlorobenzoic acid 118-92-3, o-Anthranilic acid 119-06-2, Ditridecyl phthalate 119-15-3, 4-(2,4-Dinitroanilino)phenol 119-34-6, 4-Amino-2-nitrophenol 119-36-8, Methyl salicylate 119-39-1, Phthalazinone 119-53-9, 2-Hydroxy-1,2-diphenylethanone 119-61-9, Benzophenone, biological studies 119-75-5, 2-Nitrodiphenylamine 119-84-6, 3,4-Dihydrocoumarin 119-90-4, 3,3'-Dimethoxybenzidine 119-93-7, 3,3'-Tolidine 120-12-7, Anthracene, biological studies 120-14-9, Veratraldehyde 120-32-1, o-Benzyl-p-chlorophenol 120-37-6, 3-Ethylamino-4-methylphenol 120-40-1, Lauroyl diethanolamine 120-57-0, Piperonal 120-61-6, Dimethyl terephthalate 120-62-7, Piperonyl sulfoxide 120-66-1, N-Acetyl-o-toluidine 120-71-8, p-Cresidine 120-78-5, 2,2'-Dithiobisbenzothiazole 120-80-9, 1,2-Dihydroxybenzene, biological studies 120-82-1, 1,2,4-Trichlorobenzene 120-83-2, 2,4-Dichlorophenol 121-14-2, 2,4-Dinitrotoluene 121-17-5, 4-Chloro-3-nitro-1-(trifluoromethyl)benzene 121-32-4, Ethyl vanillin 121-33-5, Vanillin 121-44-8, Triethylamine, biological studies 121-47-1, m-Aminobenzenesulfonic acid 121-54-0, Benzethonium chloride 121-66-4, 2-Amino-5-nitrothiazole 121-69-7, N,N-Dimethylaniline, biological studies 121-73-3, 3-Chloronitrobenzene 121-75-5 121-79-9, Propyl gallate 121-88-0, 2-Amino-5-nitrophenol 121-90-4, m-Nitrobenzoyl chloride 121-92-6, m-Nitrobenzoic acid 122-04-3, p-Nitrobenzoyl chloride 122-19-0 122-20-3, Tri-isopropanolamine 122-39-4, N-Phenylbenzamine, biological studies 122-62-3, Di-(2-ethylhexyl)sebacate 122-66-7, Hydrazobenzene 122-80-5, p-Aminoacetanilide 123-05-7, 2-Ethylhexanal 123-30-8, p-Aminophenol 123-31-9, Hydroquinone, biological studies 123-33-1, 1,2-Dihydroxy-3,6-pyridazinedione 123-38-6, Propionaldehyde, biological studies 123-72-8, Butyraldehyde 123-73-9, trans-Crotonaldehyde 123-77-3, Azodicarbonamide 123-86-4, Butyl acetate 123-91-1, 1,4-Dioxane, biological studies 123-92-2, Isoamyl acetate 124-02-7, Diallylamine 124-07-2, Octanoic acid, biological studies 124-09-4, 1,6-Hexanediamine, biological studies 124-30-1, Octadecylamine 124-40-3, Dimethylamine, biological studies 124-48-1, Dibromochloromethane 124-64-1 125-33-7, Primaclone 126-07-8, Griseofulvin 126-27-2, Oxethazaine 126-72-7, Tris 126-73-8, Tributyl

phosphate, biological studies 126-92-1 126-98-7, Methacrylonitrile 126-99-8, 2-Chloro-1,3-butadiene 127-00-4, 1-Chloro-2-propanol 127-18-4, Tetrachloroethylene, biological studies 127-19-5, Dimethylacetamide 127-69-5, Sulfisoxazole 128-37-0, biological studies 128-66-5, Vat yellow 4 128-95-0, Disperse violet 1 129-00-0, Pyrene, biological studies 129-15-7, 2-Methyl-1-nitroanthraquinone 129-17-9, Acid blue 1 130-26-7 131-11-3, Dimethyl phthalate 131-14-6, 2,6-Diaminoanthraquinone 131-17-9, Diallyl phthalate 131-53-3 131-57-7 132-20-7, Pheniramine maleate 132-27-4 132-98-9, Penicillin VK 133-06-2, Captan 133-18-6, Phenethyl anthranilate 133-90-4, Chloramben 134-20-3, Methyl anthranilate 134-29-2, o-Anisidine hydrochloride 134-31-6, 8-Hydroxyquinoline sulfate 134-32-7, 1-Naphthylamine 134-62-3 134-72-5, Ephedrine sulfate 135-20-6, Cupferron 135-23-9, Methapyrilene hydrochloride 135-88-6 136-35-6, Diazoaminobenzene 136-40-3, Phenazopyridine hydrochloride 136-77-6, 4-Hexylresorcinol 136-79-8 137-09-7, 2,4-Diaminophenol hydrochloride 137-89-3 138-89-6, N,N-Dimethyl-4-nitrosobenzeneamine 139-65-1, 4,4'-Thiodianiline 139-94-6, Nithiazide 140-08-9, Tris(2-chloroethyl)phosphite 140-11-4, Benzyl acetate 140-29-4, Phenylacetone nitrile 140-49-8 140-56-7 140-67-0, Estragole 140-88-5, Ethyl acrylate 140-95-4, N,N'-Bis(hydroxymethyl)urea 141-32-2 141-43-5, Monoethanolamine, biological studies  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

IT 141-75-3, Butyryl chloride 141-78-6, Ethyl acetate, biological studies 141-84-4, 2-Thioxo-4-thiazolidinone 141-91-3, 2,6-Dimethylmorpholine 142-04-1, Aniline hydrochloride 142-09-6, N-Hexyl methacrylate 142-46-1, 2,5-Dithiobiurea 142-47-2, Monosodium L-glutamate 142-78-9, Lauryl ethanolamide 142-84-7, Dipropylamine 142-96-1, Dibutyl ether 143-07-7, Lauric acid, biological studies 143-16-8, Dihexylamine 143-27-1, Hexadecylamine 143-50-0, Chlordecone 144-62-7, Oxalic acid, biological studies 144-82-1, Sulfamethizole 145-49-3, 1,5-Dihydroxy-4,8-diaminoanthraquinone 147-24-0, Diphenhydramine hydrochloride 147-47-7 148-18-5 148-24-3, 8-Hydroxyquinoline, biological studies 148-65-2, Chlorothen 148-79-8, 2-(4-Thiazolyl)benzimidazole 148-82-3, Melphalan 149-30-4, 2-Mercaptobenzothiazole 149-57-5, 2-Ethylhexanoic acid 149-91-7, Gallic acid, biological studies 150-13-0, p-Aminobenzoic acid 150-38-9, Trisodium EDTA 150-68-5 150-69-6, Dulcine 150-76-5, 4-Methoxyphenol 150-78-7 151-41-7 151-67-7, Halothane 153-78-6, 2-Aminofluorene 154-69-8, Tripelennamine hydrochloride 156-10-5, p-Nitrosodiphenylamine 156-43-4, p-Phenetidine 156-59-2, cis-1,2-Dichloroethylene 156-62-7, Calcium cyanamide 192-97-2, Benzo[e]pyrene 205-99-2, Benz[e]acephenanthrylene 207-08-9, Benzo[k]fluoranthene 262-20-4, Dibenzothioxin 271-89-6, Benzofuran 298-00-0, Methyl parathion 298-59-9, Methylphenidate hydrochloride 301-04-2, Lead acetate 301-12-2, Metasytox-R 301-13-3 302-01-2, Hydrazine, biological studies 302-17-0, Chloral hydrate 303-34-4, Lasiocarpine 303-47-9, Ochrotoxin A 305-03-3, Chlorambucil 309-00-2, Aldrin 309-36-4, Sodium methohexital 314-13-6, Direct blue 53 316-42-7, Emetine hydrochloride 320-67-2, 5-Azacytidine 326-61-4, Piperonyl acetate 334-48-5, Decanoic acid 346-18-9, Polythiazide 357-57-3, Brucine 367-25-9, 2,4-Difluoroaniline 367-51-1, Sodium Thioglycolate 379-79-3, Ergotamine tartrate 384-22-5 393-52-2, 2-Fluorobenzoyl chloride 393-75-9 396-01-0, Triamterene 434-13-9, Lithocholic acid 439-14-5, Diazepam 443-48-1, Metronidazole 446-86-6, Azathioprine 458-37-7, Curcumin 463-04-7, N-Amyl nitrite 464-10-8, Bromopicrin 470-82-6, Cineole 476-66-4, Ellagic acid



480-19-3 480-81-9, Seneciphylline 481-72-1, 1,8-Dihydroxy-3-hydroxymethylanthraquinone 485-47-2, Ninhydrin 488-41-5 493-52-7, Acid red 2 495-18-1, Benzohydroxamic acid 495-48-7, Azoxybenzene 496-72-0, 3,4-Diaminotoluene 498-21-5, Methylsuccinic acid 500-66-3, Olivetol 503-09-3 503-30-0, 1,3-Propylene oxide 504-29-0, 2-Aminopyridine 504-88-1, 3-Nitropropionic acid 505-22-6, 1,3-Dioxane 509-14-8, Tetranitromethane 510-15-6, Chlorobenzilate 512-56-1, Trimethylphosphate 513-37-1, Dimethylvinyl chloride 517-28-2, Hematoxilin 518-47-8, Acid yellow 73 521-31-3 523-47-7,  $\beta$ -Cadinene 523-87-5, Dimenhydrinate 527-85-5, 2-Methylbenzamide 528-74-5, Dichloromethotrexate 529-19-1, o-Tolunitrile 529-20-4, o-Tolualdehyde 531-85-1, Benzidine dihydrochloride 532-27-4, 2-Chloroacetophenone 532-28-5,  $\alpha$ -Hydroxybenzeneacetoneitrile 532-82-1, Basic orange 2 534-22-5, 2-Methylfuran 535-80-8, m-Chlorobenzoic acid 536-33-4, Ethionamide 536-90-3, m-Anisidine 537-92-8, N-Acetyl-m-toluidine 538-74-9, Benzyl sulfide 540-23-8, p-Toluidine hydrochloride 540-51-2 540-59-0, 1,2-Dichloroethene 541-73-1, 1,3-Dichlorobenzene 542-56-3, Isobutyl nitrite 542-75-6, 1,3-Dichloropropene 544-63-8, Tetradecanoic acid, biological studies 545-06-2, Trichloroacetoneitrile 548-62-9, Basic violet 3 551-06-4,  $\alpha$ -Naphthyl isothiocyanate 552-16-9, o-Nitrobenzoic acid 552-30-7, Trimellitic anhydride 553-30-0, Proflavine sulfate 554-00-7, 2,4-Dichloroaniline 554-10-9, 3-Iodo-1,2-propanediol 554-84-7, m-Nitrophenol 555-30-6 557-11-9, Allyl urea 562-10-7 563-04-2, Tri-m-cresyl phosphate 563-47-3, 3-Chloro-2-methylpropene 564-00-1, meso-1,2:3,4-Diepoxybutane 569-57-3, Chlorotrianiene 569-61-9, Basic red 9 576-24-9, 2,3-Dichlorophenol 577-33-3, 1,2,10-Anthracenetriol 577-59-3, o-Nitroacetophenone 581-64-6, Thionine 583-39-1, 2-Mercaptobenzimidazole 583-78-8, 2,5-Dichlorophenol 584-84-9, 2,4-Toluene diisocyanate 590-17-0, Bromoacetoneitrile 591-17-3, m-Bromotoluene 593-56-6, O-Methylhydroxylamine hydrochloride 594-71-8, 2-Chloro-2-nitropropane 594-72-9, 1,1-Dichloro-1-nitroethane 597-25-1, Dimethyl morpholinophosphonate 598-55-0, Methyl carbamate 599-79-1, Salicylazosulphapyridine 602-38-0, 1,8-Dinitronaphthalene 602-60-8, 9-Nitroanthracene 602-64-2, 1,2,3-Trihydroxyanthraquinone 602-87-9, 5-Nitroacenaphthene 603-34-9, Triphenylamine 603-35-0, Triphenyl phosphine, biological studies 603-54-3, N,N-Diphenylurea 605-71-0, 1,5-Dinitronaphthalene 606-37-1, 1,3-Dinitronaphthalene 607-57-8, 2-Nitro-9H-fluorene 608-71-9, Pentabromophenol 608-93-5, Pentachlorobenzene 609-19-8, 3,4,5-Trichlorophenol 609-20-1, 2,6-Dichloro-p-phenylenediamine 609-31-4, 2-Nitro-1-butanol 610-49-1, 1-Anthracenamine 611-06-3, 2,4-Dichloronitrobenzene 612-23-7, o-Nitrobenzyl chloride 612-82-8, 3,3'-Dimethylbenzidine dihydrochloride 612-83-9, 3,3'-Dichlorobenzidine dihydrochloride 613-08-1, 2-Anthracenecarboxylic acid 613-13-8, 2-Aminoanthracene 613-47-8, N-2-Naphthylhydroxylamine 613-93-4, N-Methylbenzamide 614-45-9, tert-Butyl perbenzoate 615-66-7, 2-Chloro-p-phenylenediamine 616-23-9, 2,3-Dichloro-1-propanol 618-87-1, 3,5-Dinitroaniline 619-17-0, 4-Nitroanthranilic acid 619-23-8, m-Nitrobenzyl chloride 620-22-4, m-Tolunitrile 621-31-8, 3-Ethylaminophenol 621-42-1, N-Acetyl-m-aminophenol 621-77-2, Tri-N-amyamine 622-51-5, p-Tolylurea 623-15-4, Furfural acetone 623-17-6, Furfuryl acetate 623-30-3,  $\beta$ -2-Furyl acrolein 625-48-9, 2-Nitroethanol 625-86-5, 2,5-Dimethylfuran 627-05-4, 1-Nitrobutane 627-18-9, 3-Bromo-1-propanol 627-30-5, 3-Chloro-1-propanol 628-02-4, Hexanamide 628-94-4, Adipamide 630-20-6, 1,1,1,2-Tetrachloroethane 634-66-2, 1,2,3,4-Tetrachlorobenzene 634-90-2, 1,2,3,5-Tetrachlorobenzene 634-93-5, 2,4,6-Trichloroaniline 636-26-0, 5-Methyl-2-thiouracil 638-03-9, m-Toluidine hydrochloride 643-22-1, Erythromycin stearate 645-05-6, Hexamethylmelamine 645-49-8, cis-Stilbene 645-62-5, 2-Ethyl-2-hexenal 646-14-0, 1-Nitrohexane 673-06-3, D-Phenylalanine 688-74-4, Tributyl borate 723-46-6,

Sulfamethoxazole 738-70-5, Trimethoprim 756-79-6, Dimethyl  
 methylphosphonate 759-94-4, Eptam 764-42-1, Fumaronitrile 765-34-4,  
 Glycidaldehyde 768-52-5, N-Isopropylaniline 785-30-8,  
 4,4'-Diaminobenzanilide 793-24-8 828-00-2, Dimethoxane 834-28-6,  
 Phenformin hydrochloride 839-90-7 842-07-9, Solvent yellow 14  
 872-50-4, N-Methyl-2-pyrrolidinone, biological studies 874-42-0,  
 2,4-Dichlorobenzaldehyde 879-39-0 881-03-8, 1-Nitro-2-  
 methylnaphthalene 920-66-1 924-42-5, N-Methylolacrylamide  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)

(identification of structural requirements for mutagenicity, by  
 incorporating mol. flexibility and metabolic activation of chems. in  
 general Ames mutagenicity model)

IT 931-97-5, Cyclohexanone cyanohydrin 933-75-5, 2,3,6-Trichlorophenol  
 933-78-8, 2,3,5-Trichlorophenol 934-32-7, 2-Aminobenzimidazole  
 935-95-5, 2,3,5,6-Tetrachlorophenol 952-21-6, 3-Methyl-4'-nitrobiphenyl  
 958-93-0, Thenyldiamine hydrochloride 968-81-0, Acetohexamide 982-57-0  
 989-38-8, Basic red 1 992-59-6, Direct red 2 999-55-3, Allyl acrylate  
 999-81-5 1025-15-6, Triallyl isocyanurate 1034-41-9, Chlordecone  
 alcohol 1071-83-6, Glyphosate 1072-52-2, 1-Aziridineethanol  
 1116-40-1, Triisobutylamine 1116-54-7, N-Nitrosodiethanolamine  
 1122-54-9, 4-Acetylpyridine 1126-61-0 1143-38-0, 1,8-Dihydroxyanthrone  
 1163-19-5, Decabromodiphenyl ether 1187-42-4, Diaminomaleonitrile  
 1212-29-9, N,N'-Dicyclohexylthiourea 1229-35-2, Methdilazine  
 hydrochloride 1241-94-7 1325-37-7, Direct yellow 11 1326-03-0,  
 Pigment violet 1 1397-89-3, Amphotericin B 1421-63-2 1455-77-2,  
 1H-1,2,4-Triazole-3,5-diamine 1465-25-4 1467-79-4, Dimethyl cyanamide  
 1484-12-4, 9-Methylcarbazole 1504-74-1, o-Methoxycinnamaldehyde  
 1522-92-5, 3-Bromo-2,2-bis(bromomethyl)propanol 1562-94-3,  
 p-Azoxyanisole 1570-64-5, p-Chloro-o-cresol 1571-08-0, Methyl  
 p-formylbenzoate 1576-35-8, p-Toluenesulfonyl hydrazide 1596-84-5  
 1606-67-3, 1-Pyrenamine 1634-78-2 1635-61-6, 5-Chloro-2-nitroaniline  
 1646-75-9, Aldicarb oxime 1675-54-3 1694-09-3, Acid violet 49  
 1694-20-6, (E)-4-Nitrostilbene 1758-68-5, 1,2-Diaminoanthraquinone  
 1761-71-3 1777-84-0, 3-Nitro-p-acetophenetide 1806-54-8 1817-73-8,  
 2-Bromo-4,6-dinitroaniline 1825-21-4, Pentachloroanisole 1836-75-5,  
 Nitrofen 1854-26-8, Dimethyloldihydroxyethyleneurea 1897-45-6  
 1912-24-9, Atrazine 1918-02-1, Picloram 1929-82-4 1934-21-0, Acid  
 yellow 23 1936-15-8, Acid orange 10 1937-37-7, Direct black 38  
 1948-33-0, tert-Butylhydroquinone 1955-45-9, Pivalolactone 1972-08-3,  
 trans-A9-Tetrahydrocannabinol 2016-88-8, Amiloride hydrochloride  
 2039-87-4, o-Chlorostyrene 2045-52-5, Phenbenzamine hydrochloride  
 2050-92-2, Di-N-amylamine 2052-07-5, 2-Bromobiphenyl 2107-76-8  
 2113-57-7, 3-Bromobiphenyl 2143-88-6, 4-Methyl-4'-nitrobiphenyl  
 2150-54-1, Direct blue 25 2150-60-9 2157-01-9, n-Octyl methacrylate  
 2164-17-2, Fluometuron 2179-59-1, Allyl propyl disulfide 2185-92-4,  
 2-Biphenylamine hydrochloride 2206-89-5, 2-Chloroethyl acrylate  
 2210-28-8, n-Propyl methacrylate 2213-63-0, 2,3-Dichloroquinoxaline  
 2243-61-0, 1,4-Naphthalenediamine 2243-62-1, 1,5-Naphthalenediamine  
 2244-16-8, D-Carvone 2244-21-5, Potassium dichlorocyanurate 2385-85-5,  
 Mirex 2425-85-6, C.I. Pigment red 3 2429-71-2, Direct blue 8  
 2429-73-4 2429-74-5, Direct blue 15 2429-80-3, C. I. Acid orange 45  
 2432-99-7, 11-Aminoundecanoic acid 2438-88-2 2439-35-2 2461-15-6,  
 2-Ethylhexyl glycidyl ether 2465-27-2, Basic yellow 2 2475-45-8,  
 1,4,5,8-Tetraaminoanthraquinone 2493-84-7, p-Octyloxybenzoic acid  
 2508-20-5, 2-Nitrosofluorene 2528-36-1, Dibutyl phenyl phosphate  
 2602-46-2, Direct blue 6 2645-07-0, 4-Nitrohippuric acid 2646-17-5  
 2675-77-6, Chloroneb 2682-20-4, 2-Methyl-4-Isothiazolin-3-one  
 2698-41-1, o-Chlorobenzalmononitrile 2735-04-8, 2,4-Dimethoxyaniline  
 2782-57-2, Dichloroisocyanuric acid 2782-91-4, Tetramethylthiourea  
 2783-94-0, FD&C yellow 6 2784-94-3, HC blue 1 2810-69-7 2832-40-8,

Disperse yellow 3 2835-95-2, 3-Amino-6-methylphenol 2871-01-4, HC Red 3 2873-97-4, Diacetone acrylamide 2893-78-9, Sodium dichlorocyanurate 2941-64-2, S-Ethyl chlorothiocarbonate 2945-96-2, C. I. Direct black 17 3018-12-0, Dichloroacetonitrile 3025-77-2 3066-70-4 3068-88-0,  $\beta$ -Butyrolactone 3081-14-9 3129-91-7, Dicyclohexylamine nitrite 3160-37-0, Piperonylidene acetone 3165-93-3, 4-Chloro-o-toluidine hydrochloride 3179-47-3, n-Decyl methacrylate 3209-22-1, 2,3-Dichloronitrobenzene 3237-50-1, Alloxan monohydrate 3252-43-5, Dibromoaetonitrile 3266-23-7, 2,3-Epoxybutane 3268-87-9, Octachlorodibenzo-p-dioxin 3319-31-1 3322-93-8 3333-52-6, Tetramethylsuccinonitrile 3468-63-1, Pigment orange 5 3524-68-3, Pentaerythritol triacrylate 3544-23-8 3546-10-9 3567-69-9, Acid red 14 3626-28-6, Direct green 1 3648-20-2, Diundecyl phthalate 3658-77-3, 2,5-Dimethyl-4-hydroxy-3(2H)-furanone 3682-19-7 3688-53-7 3689-24-5 3731-39-3 3761-53-3, Acid red 26 4067-16-7, Pentaethylenehexamine 4080-31-3 4098-71-9, Isophorone diisocyanate 4170-30-3, Crotonaldehyde 4196-86-5 4196-87-6 4198-19-0 4309-66-4, trans-4-Aminostilbene 4337-65-9, Mono(2-ethylhexyl) adipate 4342-03-4, Dacarbazine 4345-03-3 4350-09-8, 5-Hydroxyl-tryptophan 4403-61-6, 2-Methyl-2-butenenitrile 4418-26-2, Sodium dehydroacetate 4424-06-0, Pigment orange 43 4444-68-2 4460-86-0, 2,4,5-Trimethoxybenzaldehyde 4465-94-5 4548-53-2, FD&C red 4 4553-62-2,  $\alpha$ -Methyl glutaronitrile 4568-28-9, Triethanolamine stearate 4635-87-4, 3-Pentenitrile 4637-56-3 4655-34-9, Isopropyl methacrylate 4719-04-4 4801-39-2, 2-Aminoacetanilide hydrochloride 4802-20-4, Limonene dimercaptan 4823-47-6, 2-Bromoethyl acrylate 4901-51-3, 2,3,4,5-Tetrachlorophenol 5064-31-3, Nitrilotriacetic acid trisodium salt 5131-58-8, 4-Nitro-m-phenylenediamine 5131-60-2, 4-Chloro-m-phenylenediamine 5160-02-1, D And C red 9 5216-25-1, 4-Chlorobenzotrichloride 5307-14-2 5323-95-5, Sodium ricinoleate 5397-31-9 5466-77-3 5466-84-2, 4-Nitrophthalic anhydride 5493-45-8 5989-27-5, D-Limonene 6041-94-7, C.I. Pigment red 2 6088-51-3 6109-97-3, 3-Amino-9-ethylcarbazole monohydrochloride 6112-76-1, 6-Mercaptapurine monohydrate 6197-30-4 6201-87-2, 5-Amino-3-sulfosalicylic acid 6219-89-2 6285-57-0, 2-Amino-6-nitrobenzothiazole 6287-38-3, 3,4-Dichlorobenzaldehyde 6317-18-6 6358-07-2, 2-Amino-4-chloro-5-nitrophenol 6358-23-2 6358-29-8, Direct red 39 6358-31-2, C.I. Pigment yellow 74 6358-53-8, Solvent red 80 6358-85-6, Pigment yellow 12 6369-59-1 6373-74-6, Acid orange 3 6428-94-0, Direct violet 32 6459-94-5, Acid red 114 6471-49-4, Pigment red 23 6483-86-9 6533-68-2, Scopolamine hydrobromide trihydrate 6610-08-8, 2-Nitrosanaphthalene 6810-26-0 6959-47-3, 2-(Chloromethyl)pyridine hydrochloride 6959-48-4, 3-(Chloromethyl)pyridine hydrochloride 7149-26-0, Linalyl anthranilate 7166-19-0,  $\beta$ -Bromo- $\beta$ -nitrostyrene 7177-48-2, Ampicillin trihydrate 7195-43-9, Isophthalic acid diglycidyl ester 7206-76-0, 2-Phenyl-2-ethylmalondiamide 7314-08-1 7493-63-2, Allyl anthranilate 7756-96-9, Butyl anthranilate 7779-16-0, Cyclohexyl anthranilate 7779-77-3, Isobutyl anthranilate 8003-22-3, Solvent yellow 33 10043-35-3, Boric acid (H3BO3), biological studies 10125-76-5, 4-Nitrosobiphenyl 10143-23-4, 2,3-Dimethyl-1-pentanol 10213-75-9 10277-43-7, Lanthanum nitrate hexahydrate 10318-26-0, Dibromodulcitol

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

IT 10605-21-7, Carbazadim 11097-69-1, PCB 1254 12224-98-5, Pigment red 81 12225-21-7, Pigment yellow 100 12789-03-6, Chlordane 13014-18-1 13014-24-9 13048-33-4, 1,6-Hexanediol diacrylate 13071-79-9 13098-39-0 13114-72-2 13284-42-9, 2-Pentenitrile 13360-63-9, Ethyl

N-butylamine 13366-73-9, Photodieldrin 13552-21-1 13552-44-8,  
 4,4'-Methylenedianiline dihydrochloride 13674-84-5 13674-87-8  
 13684-63-4, Phenmedipham 13889-92-4, Propyl chlorothioformate  
 13952-84-6, sec-Butylamine 13961-86-9 14371-10-9, trans-Cinnamaldehyde  
 14882-18-9, Bismuth subsalicylate 14901-07-6 15110-74-4,  
 2,5-Dinitrofluorene 15121-84-3, o-Nitrophenethylalcohol 15481-70-6  
 15893-52-4 15950-66-0, 2,3,4-Trichlorophenol 16219-75-3, Ethylidene  
 norbornene 16238-56-5 16452-01-0 16529-56-9, 2-Methyl-3-  
 butenenitrile 17026-81-2, 3-Amino-4-ethoxyacetanilide 17341-40-1  
 17359-54-5 17369-59-4, 3-Propyldienephthalide 17372-87-1, Eosin  
 17433-31-7 17804-35-2, Benomyl 17831-71-9, Tetraethylene glycol  
 diacrylate 17924-92-4, Zearalenone 18024-11-8, 1,4,9-  
 Trimethylcarbazole 18028-55-2, 1,4-Dimethylcarbazole 18028-56-3,  
 1,4,6-Trimethylcarbazole 18662-53-8, Nitrilotriacetic acid trisodium  
 salt monohydrate 19315-64-1 19660-16-3, 2,3-Dibromopropyl acrylate  
 19686-73-8, 1-Bromo-2-propanol 19780-11-1 20020-02-4,  
 1,2,3,4-Tetrachloronaphthalene 20265-97-8, p-Anisidine hydrochloride  
 20548-62-3 20702-77-6, Neohesperidin dihydrochalcone 21285-46-1,  
 trans-2,3-Dibromo-2-butene-1,4-diol 21739-91-3, Cytembena 21829-25-4,  
 Nifedipine 22224-92-6, Phenamiphos 23255-93-8, Hycanthone  
 methanesulfonate 23564-05-8, Thiophanate methyl 24140-30-5  
 24169-02-6, Econazole nitrate 24325-70-0, trans-4-Methyl-4'-  
 nitrostilbene 24370-25-0, 2-Benzimidazolylurea 24382-04-5, Propanedial  
 sodium 24554-26-5, N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide  
 24815-24-5, Rescinnamine 25322-68-3, Peg 25637-99-4,  
 Hexabromocyclododecane 25843-45-2, Azoxymethane 25953-06-4  
 26446-35-5, Acetin 26471-62-5 26530-20-1, Kathon 893 26638-28-8,  
 Methyl pentachlorostearate 26761-40-0, Diisodecyl phthalate  
 28322-02-3, 4-Acetylamino fluorene 29385-43-1, Tolyltriazole  
 29743-15-5, 4-Butyloxybenzal-4'-ethylaniline 29761-21-5, Isodecyl  
 diphenyl phosphate 29964-84-9, Isodecyl methacrylate 31386-38-6  
 31551-45-8, 2,7-Dinitrofluoren-9-one 32588-76-4 33229-34-4, HC blue 2  
 34807-41-5, Mezerein 36355-01-8, Hexabromobiphenyl 37853-59-1  
 38848-76-9 39156-41-7, 2,4-Diaminoanisole sulfate 41122-70-7  
 42397-64-8, 1,6-Dinitropyrene 42397-65-9, 1,8-Dinitropyrene 52551-67-4  
 54810-82-1, 3,5-Dimethyl-4-aminobiphenyl 54827-17-7,  
 3,3',5,5'-Tetramethylbenzidine 56803-37-3, tert-Butylphenyl diphenyl  
 phosphate 62625-14-3, 2-Amino-6-chloro-4-nitrophenol hydrochloride  
 64532-97-4 67219-70-9, 1-Butyl-2-aminonaphthalene 69314-47-2,  
 3-Methyl-4-nitrophenyl 69884-05-5 70634-28-5 72917-35-2,  
 1,4-Dimethyl-6-hydroxy-3-nitrocarbazole 74518-95-9 74518-99-3  
 76002-91-0 78491-02-8, Diazolidinylurea 92814-28-3,  
 4-Ethyl-3-nitrophenyl 108100-28-3, 2-Methyl-7-nitrofluorene  
 126335-31-7 126335-36-2 127502-68-5, 2-Isopropyl-4-phenylnitrobenzene  
 127502-69-6, 3-Isopropyl-4-aminobiphenyl 127750-13-4 128714-75-0,  
 1,6-Dinitrobenzo[al]pyrene 128714-76-1, 3,6-Dinitrobenzo[al]pyrene  
 129117-54-0, 1,4-Dimethyl-6-methoxy-3-aminocarbazole 188107-70-2,  
 9-Methyl-2-nitro-9H-carbazole 188107-72-4, 1,4,6-Trimethyl-3-nitro-9H-  
 carbazole 189084-64-8 275795-12-5 275795-16-9 275795-17-0  
 279242-09-0 279242-10-3 279242-11-4 279242-12-5 279242-14-7  
 279242-16-9 279242-17-0 314084-63-4, 3,5-Diethyl-4-aminobiphenyl  
 345667-01-8 345667-02-9 345667-57-4 345667-58-5 345667-59-6  
 345667-60-9 345667-61-0 345667-62-1 389104-53-4,  
 1-Ethyl-2-aminonaphthalene 389104-54-5 389104-55-6,  
 1-tert-Butyl-2-aminonaphthalene 389104-56-7, 1-Ethyl-2-aminofluorene  
 389104-57-8, 1-Isopropyl-2-aminofluorene 389104-58-9,  
 1-Butyl-2-aminofluorene 389104-59-0, 1-tert-Butyl-2-aminofluorene  
 389104-60-3, 3-Ethyl-4-aminobiphenyl 389104-61-4, 3-Butyl-4-  
 aminobiphenyl 389104-62-5, 3,5-Diisopropyl-4-aminobiphenyl  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)


(identification of structural requirements for mutagenicity, by incorporating mol. flexibility and metabolic activation of chems. in general Ames mutagenicity model)

RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE


- (1) Anon; <http://linkage.garvan.unsw.edu.au/public/gerham/macros/public/thesis/NitreniumIons.html>
- (2) Anon; <http://monographs.iarc.fr/htdocs/monographs/vol60-11.htm>
- (3) Anon; <http://potency.berkeley.edu/chempages/beta-BUTYROLACTONE.html>
- (4) Anon; <http://www.biolab.co.uk/dna.html>
- (5) Anon; [http://www.inchem.org/documents/cicads/cicads/cicad\\_19.htm#PartNumber](http://www.inchem.org/documents/cicads/cicads/cicad_19.htm#PartNumber)
- (6) Anon; <http://www.oehha.ca.gov/prop65/pdf/BCMEEF.pdf>
- (7) Anon; [www.uic.edu/classes/pcol/pcol425/restricted/Tiruppathi/Carcinogenst.PDF](http://www.uic.edu/classes/pcol/pcol425/restricted/Tiruppathi/Carcinogenst.PDF)
- (8) Ariens, E; Drug Metab Rev 1984, V15(3), P425 CAPLUS
- (9) Ashby, J; Environ Mutagen 1985, V7, P919 CAPLUS
- (10) Ashby, J; Mutat Res 1988, V204(1), P17 CAPLUS
- (11) Ashby, J; Mutat Res-Rev Mutat Res 1991, V257(3), P229 CAPLUS
- (12) Bartsch, H; IARC Sci Publ 1981, V40, P13 CAPLUS
- (13) Benfenati, E; Toxicology 1997, V119, P213 CAPLUS
- (14) Benigni, R; Arch Toxicol Suppl 1992, V15, P228 CAPLUS
- (15) Benigni, R; Curr Comput-Aided Drug Des 2006, V2, P1
- (16) Benigni, R; Methods 1998, V14, P264 CAPLUS
- (17) Bradbury, S; Toxicol Sci 2000, V58, P253 CAPLUS
- (18) Connolly, M; J Appl Crystallogr 1983, V16, P548
- (19) Couch, D; Mutat Res 1978, V57(2), P217 CAPLUS
- (20) Cronin, M; Environ Health Perspect 2003, V111, P1391 CAPLUS
- (21) Deadren, J; ATLA, <http://altweb.jhsph.edu/publications/ECVAM/ecvam24.htm> 1997, P223
- (22) Dimitrov, S; J Chem Inf Model 2005, V45(4), P839 CAPLUS
- (23) Dimitrov, S; Poster presented at SETAC Europe 15th Annual Meeting 2005
- (24) Dimitrov, S; QSAR Comb Sci 2003, V22, P58 CAPLUS
- (25) Dimitrov, S; SAR QSAR Environ Res 2001, V13, P445
- (26) Enslein, K; Toxicity and Industrial Health 1988, 4, P479 CAPLUS
- (27) Enslein, K; Toxicol Ind Health 1987, V3, P267 CAPLUS
- (28) Glatt, H; Cancer Causes Control 2004, V15(3), P225
- (29) Greene, N; Adv Drug Delivery Rev 2002, V54, P417 CAPLUS
- (30) Guengerich, F; Drug Metab Dispos 1997, V25(11), P1234 CAPLUS
- (31) Hecht, S; Toxicology 2001, V166(1-2), P31 CAPLUS
- (32) Hemminki, K; Chem-Biol Interact 1981, V34(3), P323 CAPLUS
- (33) Iarc; Evaluation of the Carcinogenic Risk of Chemicals to Humans-Views and Expert Opinions of an IARC Working Group 1987
- (34) Jaworska, J; SAR QSAR Environ Res 2001, V13, P307
- (35) Johnson, D; Drug Discovery Today 2000, V5, P445
- (36) Kazius, J; J Med Chem 2005, V48(1), P312 CAPLUS
- (37) Kiese, M; Naunyn-Schmiedeberg's Arch Pathol Pharmacol 1966, V252(5), P480 CAPLUS
- (38) Klopman, G; Mutat Res 1990, V228, P1 CAPLUS
- (39) Klopman, G; Quant Struct-Act Relat 1992, V11(2), P176 CAPLUS
- (40) Kovacic, P; Curr Med Chem 2001, V8(7), P863 CAPLUS
- (41) Kroger-Koepeke, M; Proc Natl Acad Sci U S A 1981, V78(10), P6489
- (42) Lenk, W; Xenobiotica 1993, V23, P241 CAPLUS
- (43) Lewis, D; Mutat Res 1993, V291, P61 CAPLUS
- (44) Low, L; Textbook of Organic Medicinal and Pharmaceutical Chemistry 1998, P43
- (45) Lu, O; Drug Metab Dispos 1994, V22, P731
- (46) Lynn, R; Drug Metab Dispos 1983, V11, P109 CAPLUS
- (47) Mays, D; Drug Metab Dispos 1987, V15, P318 CAPLUS
- (48) McKay, S; Drug Metab Dispos 1987, V15, P682 CAPLUS
- (49) Mekenyan, O; Chem Inf Comput Sci 1999, V39, P997 CAPLUS
- (50) Mekenyan, O; Chem Res Toxicol 2004, V17(6), P753 CAPLUS

- (51) Mekenyan, O; Curr Pharm Des 2004, V10(11), P1273 CAPLUS  
 (52) Mekenyan, O; Environ Sci Technol 1997, V31, P3702 CAPLUS  
 (53) Mekenyan, O; Environ Sci Technol 1997, V31, P3702 CAPLUS  
 (54) Mekenyan, O; J Mol Struct (THEOCHEM) 2003, V622, P147 CAPLUS  
 (55) Mekenyan, O; QSAR Comb Sci 2004, V23(1), P5 CAPLUS  
 (56) Mekenyan, O; QSAR Comb Sci 2004, V23(1), P5 CAPLUS  
 (57) Mekenyan, O; Toxicol Sci 2000, V58, P270 CAPLUS  
 (58) Nakajama, M; Drug Metab Dispos 1998, V26(1), P36  
 (59) Noguchi, M; Exp Anim 1996, V45(2), P161 CAPLUS  
 (60) Oecd; Final Report of the Sixth Meeting of the Task Force on Endocrine Disrupters Testing and Assessment (EDTA 6) 2003, P4  
 (61) Pearl, G; Curr Top Med Chem 2001, V1, P247 CAPLUS  
 (62) Purdy, R; Environ Health Perspect 1996, V104, P1085 CAPLUS  
 (63) Richard, A; Mutat Res 1994, V305, P73 CAPLUS  
 (64) Ridings, J; Toxicology 1996, V106(1-3), P267 CAPLUS  
 (65) Rozenkranz, H; Mutat Res 1990, V228, P51  
 (66) Sabboni, G; Environ Health Perspect 1994, V102(6), P61  
 (67) Sanderson, D; Hum Exp Toxicol 1991, V10(4), P261 CAPLUS  
 (68) Sawatari, K; Ind Health 2001, V39(4), P341 CAPLUS  
 (69) Schultz, T; J Mol Struct (THEOCHEM) 2003, V622, P1 CAPLUS  
 (70) Schultz, T; J Mol Struct (THEOCHEM) 2003, V622, P23 CAPLUS  
 (71) Serafimova, R; SAR QSAR Environ Res In press 2006  
 (72) Singer, B; Annu Rev Biochem 1982, V51, P655 CAPLUS  
 (73) Stanton, D; Anal Chem 1990, V62(21), P2323 CAPLUS  
 (74) Steward, J; J Comput-Aided Mol Des 1990, V4, P1  
 (75) Steward, J; MOPAC 93 1993  
 (76) Tennant, R; Mutat Res-Rev Mutat Res 1991, V257(3), P209 CAPLUS  
 (77) Todorov, M; J Chem Inf Model In press  
 (78) Westwood, I; Biochem J 2005, V385(2), P605 CAPLUS  
 (79) Wiaderkiewicz, R; Acta Biochim Pol 1986, V33(2), P73 CAPLUS  
 (80) Williams, J; Cancer Res 2000, V60, P4667 CAPLUS  
 (81) Woo, Y; Toxicol Lett 1995, V79(1-3), P219 CAPLUS

L7 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2008 ACS ON STN  
 IT 77-89-4, Acetyl triethyl citrate 77-94-1, Tributyl  
 citrate 84-66-2, Diethyl phthalate 84-74-2, Dibutyl  
 phthalate 88-99-3D, Phthalic acid, alkyl esters 109-43-3  
 , Dibutyl sebacate 111-20-6D, Sebacic acid, alkyl esters  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (flavoring of drug-containing chewing gum)  
 RN 77-89-4 CAPLUS  
 CN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-triethyl ester (CA  
 INDEX NAME)




RN 77-94-1 CAPLUS  
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-tributyl ester (CA  
 INDEX NAME)




RN 84-66-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-diethyl ester (CA INDEX NAME)



RN 84-74-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester (CA INDEX NAME)




RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




RN 109-43-3 CAPLUS

CN Decanedioic acid, 1,10-dibutyl ester (CA INDEX NAME)



RN 111-20-6 CAPLUS

CN Decanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2006:1229073 CAPLUS  
 DOCUMENT NUMBER: 146:13167  
 TITLE: Flavoring of drug-containing chewing gums  
 INVENTOR(S): Koll, Gregory Edwin; Mody, Seema Kirtikumar  
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA  
 SOURCE: PCT Int. Appl., 27pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006124366	A2	20061123	WO 2006-US17715	20060509
WO 2006124366	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20060275344	A1	20061207	US 2005-131561	20050518
AU 2006247847	A1	20061123	AU 2006-247847	20060509
CA 2608531	A1	20061123	CA 2006-2608531	20060509
EP 1888042	A2	20080220	EP 2006-770085	20060509
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2007KN04401	A	20080606	IN 2007-KN4401	20071116
KR 2008037614	A	20080430	KR 2007-729653	20071218
PRIORITY APPLN. INFO.:			US 2005-131561	A 20050518
			WO 2006-US17715	W 20060509

AN 2006:1229073 CAPLUS  
 DN 146:13167  
 ED Entered STN: 24 Nov 2006  
 TI Flavoring of drug-containing chewing gums  
 IN Koll, Gregory Edwin; Mody, Seema Kirtikumar  
 PA Warner-Lambert Company LLC, USA  
 SO PCT Int. Appl., 27pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 62  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006124366	A2	20061123	WO 2006-US17715	20060509
WO 2006124366	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			



SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM  
US 20060275344 A1 20061207 US 2005-131561 20050518  
AU 2006247847 A1 20061123 AU 2006-247847 20060509  
CA 2608531 A1 20061123 CA 2006-2608531 20060509  
EP 1888042 A2 20080220 EP 2006-770085 20060509  
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR  
IN 2007KN04401 A 20080606 IN 2007-KN4401 20071116  
KR 2008037614 A 20080430 KR 2007-729653 20071218  
PRAI US 2005-131561 A 20050518  
WO 2006-US17715 W 20060509

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2006124366	ICM	A61K
	IPCI	A61K0009-30 [I,C]; A61K0009-36 [I,A]
	IPCR	A61K0009-30 [I,C]; A61K0009-36 [I,A]
	ECLA	A61K009/00M18B2
US 20060275344	IPCI	A61K0047-00 [I,A]
	IPCR	A61K0047-00 [I,C]; A61K0047-00 [I,A]
	NCL	424/439.000
	ECLA	A61K009/00M18B2
AU 2006247847	IPCI	A61K0009-30 [I,C]; A61K0009-36 [I,A]
	IPCR	A61K0009-30 [I,C]; A61K0009-36 [I,A]
	ECLA	A61K009/00M18B2
CA 2608531	IPCI	A61K0009-36 [I,A]; A61K0009-30 [I,C*]
	IPCR	A61K0009-30 [I,C]; A61K0009-36 [I,A]
EP 1888042	IPCI	A61K0009-36 [I,A]; A61K0009-30 [I,C*]
	IPCR	A61K0009-30 [I,C]; A61K0009-36 [I,A]
IN 2007KN04401	IPCI	A61K0009-36 [ICM,7]; A61K0009-30 [ICM,7,C*]
KR 2008037614	IPCI	A61K0009-68 [I,A]; A61K0009-48 [I,A]; A61K0009-62 [I,A]; A61K0009-52 [I,C*]
AB	A chewing gum comprises at least one active pharmaceutical ingredient (API) with a core onto which is applied at least one inner polymer film coating and thereafter onto which is applied at least one outer hard coating. A preferred API is nicotine. Flavoring agents may be incorporated in the core, in the at least one inner polymer film coating and/or in the at least one outer hard coating. The gums formed exhibit a long lasting effect of flavoring agent(s) and result in the domination of flavoring agents in the coating(s) over flavoring agent(s) in the core, thereby (a) avoiding problems of chemical or pharmaceutical incompatibility between an API in the core and flavoring agent(s) in the coating(s) and (b) achieving an increased control of the release of the API and of non-active excipients. A dextromethorphan-containing chewing gum, having a gum core comprising 10 mg the API dextromethorphan, may have an inner polymer film comprising Methocel K3, the surfactant Polysorbate-80, the sweetener Sucralose, and dextromethorphan and mint flavor.	
ST	flavoring drug chewing gum	
IT	Monoglycerides	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (acetates; flavoring of drug-containing chewing gum)	
IT	Quaternary ammonium compounds, biological studies	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzylidimethyl, chlorides; flavoring of drug-containing chewing gum)	
IT	Polyoxyalkylenes, biological studies	

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (block; flavoring of drug-containing chewing gum)

IT Tooth, disease  
 (calculus; flavoring of drug-containing chewing gum)

IT Vinyl compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (carboxy-containing, polymers; flavoring of drug-containing chewing gum)

IT Calculi  
 (dental; flavoring of drug-containing chewing gum)

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters; flavoring of drug-containing chewing gum)

IT Analgesics  
 Anti-inflammatory agents  
 Antibiotics  
 Antihistamines  
 Antimicrobial agents  
 Antioxidants  
 Antitussives  
 Coating materials  
 Dentifrices  
 Flavoring materials  
 Fungicides  
 Pharmaceutical chewing gum  
 Plasticizers  
 Sweetening agents  
 Thaumatooccus danielli  
 (flavoring of drug-containing chewing gum)

IT Diphosphates  
 Polyphosphates  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (flavoring of drug-containing chewing gum)

IT Alditols  
 Caseins, biological studies  
 Diglycerides  
 Diphosphonates  
 Disaccharides  
 Enzymes, biological studies  
 Gelatins, biological studies  
 Glutens  
 Glycerides, biological studies  
 Glycols, biological studies  
 Monosaccharides  
 Phosphates, biological studies  
 Polymers, biological studies  
 Polyoxyalkylenes, biological studies  
 Polysaccharides, biological studies  
 Polyurethanes, biological studies  
 Shellac  
 Waxes  
 Zeins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (flavoring of drug-containing chewing gum)

IT Castor oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; flavoring of drug-containing chewing gum)

IT Rosin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polymerized; flavoring of drug-containing chewing gum)

IT Proteins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (soybean; flavoring of drug-containing chewing gum)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; flavoring of drug-containing chewing gum)

IT Polymers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (water-soluble; flavoring of drug-containing chewing gum)

IT Proteins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (whey; flavoring of drug-containing chewing gum)

IT 9003-01-4D, crosslinked  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Carbomer; flavoring of drug-containing chewing gum)

IT 60-00-4, EDTA, biological studies 108-31-6D, Maleic anhydride, polymers  
 124-43-6 128-37-0, Butylated hydroxytoluene, biological studies  
 1305-79-9, Calcium peroxide 1313-60-6, Sodium peroxide 2809-21-4,  
 Etidronic acid 7440-66-6D, Zinc, salts 7632-05-5, Sodium phosphate  
 7664-38-2, Phosphoric acid, biological studies 7758-16-9 7758-19-2,  
 Sodium chlorite 7758-29-4, Sodium tripolyphosphate 7772-99-8, Stannous  
 chloride, biological studies 9011-16-9, Maleic anhydride-methyl vinyl  
 ether copolymer 10049-04-4, Chlorine dioxide 12773-27-2, Sodium tin  
 oxide 13478-98-3, Hexametaphosphate 14127-68-5, Tripolyphosphate  
 14314-27-3, Potassium chlorite 14380-61-1, Hypochlorite 14674-72-7,  
 Calcium chlorite 14674-74-9, Barium chlorite 15630-89-4, Sodium  
 percarbonate 17188-11-3, Magnesium chlorite 24991-23-9 25513-46-6,  
 Polyglutamic acid 25608-40-6, Polyaspartic acid 26063-13-8,  
 Polyaspartic acid 27119-07-9 27505-49-3, Lithium chlorite  
 178326-57-3, Zinc citrate trihydrate  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (flavoring of drug-containing chewing gum)

IT 50-23-7, Hydrocortisone 50-70-4, Sorbitol, biological studies 50-78-2,  
 Aspirin 54-11-5, Nicotine 55-56-1, Chlorhexidine 57-50-1,  
 Sucrose, biological studies 57-50-1D, Sucrose, esters  
 57-55-6, Propylene glycol, biological studies 59-42-7, Phenylephrine  
 59-67-6, Niacin, biological studies 60-54-8, Tetracycline 64-19-7D,  
 Acetic acid, derivs. 65-45-2, Salicylamide  
 77-89-4, Acetyl triethyl citrate 77-92-9, Citric acid,  
 biological studies 77-92-9D, Citric acid, alkyl esters 77-93-0,  
 Triethyl citrate 77-94-1, Tributyl citrate 80-62-6D, Methyl  
 methacrylate, polymers 81-07-2D, Saccharin, salts 84-66-2,  
 Diethyl phthalate 84-74-2, Dibutyl phthalate 88-99-3D,  
 Phthalic acid, alkyl esters 91-40-7D, Fenamic acid, derivs. 102-76-1,  
 Glyceryl triacetate 109-43-3, Dibutyl sebacate 111-20-6D  
 , Sebacic acid, alkyl esters 123-03-5, Cetylpyridinium chloride  
 125-71-3, Dextromethorphan 132-22-9, Chlorpheniramine 141-94-6,  
 Hexetidine 143-03-7, Lauric acid, biological studies 443-48-1,  
 Metronidazole 538-71-6, Domiphen bromide 564-25-0, Doxycycline  
 1398-61-4, Chitin 2447-54-3, Sanguinarine 2785-54-8,  
 Tetradecylpyridinium chloride 3380-34-5, 5-Chloro-2-(2,4-  
 dichlorophenoxy)-phenol 3572-43-8, Bromhexine 5104-49-4, Flurbiprofen  
 7440-66-6, Zinc, biological studies 8050-81-5, Simethicone 9000-01-5,  
 Acacia gum 9000-11-7, Carboxymethyl cellulose 9000-30-0, Guar gum  
 9000-65-1, Tragacanth gum 9000-69-5, Pectin 9002-86-2, Polyvinyl  
 chloride 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid  
 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose  
 sodium 9004-34-6D, Cellulose, derivs. 9004-53-9, Dextrin 9004-62-0,  
 Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3,  
 Hydroxypropyl methyl cellulose 9005-38-3, Sodium alginate 9005-65-6,

Polysorbate 80 9005-82-7, Amylose 9012-76-4, Chitosan 9057-02-7,  
 Pullulan 10118-90-8, Minocycline 12441-09-7D, Sorbitan, esters  
 15687-27-1, Ibuprofen 16984-48-8, Fluoride, biological studies  
 17692-38-5, Fluprofen 21256-18-8, Oxaprozin 22071-15-4, Ketoprofen  
 22204-53-1, Naproxen 22573-93-9, Alexidine 22832-87-7, Miconazole  
 nitrate 22839-47-0, Aspartame 25322-68-3, Polyethylene glycol  
 25496-72-4, Glycerol monooleate 25751-21-7D, Acrylic  
 acid-methacrylic acid copolymer, esters 26787-78-0, Amoxicillin  
 29679-58-1, Fenoprofen 31566-31-1, Glycerol monostearate 31793-07-4,  
 Pirprofen 31842-01-0, Indoprofen 32808-51-8, Bucloxic acid  
 33005-95-7, Tiaprofenic acid 35014-84-7, N-Tetradecyl-4-ethylpyridinium  
 chloride 36330-85-5, Fenbufen 39718-89-3, Alminoprofen 40198-53-6,  
 Tioxaprofen 40828-46-4, Suprofen 51234-28-7, Benoxaprofen  
 51317-27-2D, Biphenylcarboxylic acid, derivs. 52549-17-4, Pranoprofen  
 53179-11-6, Loperamide 53716-49-7, Carprofen 55843-86-2, Mioprofen  
 56038-13-2D, Sucralose, chlorinated derivs. 71125-38-7, Meloxicam  
 71138-71-1, Octapinol 71251-02-0, Octenidine 76824-35-6, Famotidine  
 79874-76-3, Delmopinol 83881-51-0, Cetirizine 106392-12-5, Poloxamer  
 162011-90-7, Rofecoxib 165450-17-9, Neotame 169590-42-5, Celecoxib  
 181695-72-7, Valdecocix 202409-33-4, Etoricocix  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (flavoring of drug-containing chewing gum)  
 IT 9005-82, Starch, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (high amylose; flavoring of drug-containing chewing gum)  
 L7 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 88-99-3D, Phthalic acid, esters 110-15-6, Succinic acid,  
 biological studies 124-04-9, Adipic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (gastroresistant pharmaceutical formulations containing rifaximin)  
 RN 88-99-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2006:944418 CAPLUS  
 DOCUMENT NUMBER: 145:321732  
 TITLE: Gastroresistant pharmaceutical formulations containing  
 rifaximin  
 INVENTOR(S): Viscomi, Giuseppe C.; Palazzini, Ernesto; Zamboni,  
 Villiam; Pantaleo, Maria Rosaria

PATENT ASSIGNEE(S): Alfa Wassermann S.p.A., Italy  
 SOURCE: PCT Int. Appl., 34pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006094737	A2	20060914	WO 2006-EP2022	20060306
WO 2006094737	A3	20070215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006222206	A1	20060914	AU 2006-222206	20060306
CA 2595033	A1	20060914	CA 2006-2595033	20060306
EP 1874273	A2	20080109	EP 2006-723226	20060306
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
MX 200710889	A	20071123	MX 2007-10889	20070906
CN 101137350	A	20080305	CN 2006-80007595	20070907
KR 2007117616	A	20071212	KR 2007-722318	20070928
NO 2007005046	A	20071205	NO 2007-5046	20071008
PRIORITY APPLN. INFO.:			IT 2005-B0123	A 20050307
			WO 2006-EP2022	W 20060306

AN 2006:944418 CAPLUS  
 DN 145:321732  
 ED Entered STN: 14 Sep 2006  
 TI Gastroresistant pharmaceutical formulations containing rifaximin  
 IN Viscomi, Giuseppe C.; Palazzini, Ernesto; Zamboni, Villiam; Pantaleo, Maria Rosaria  
 PA Alfa Wassermann S.p.A., Italy  
 SO PCT Int. Appl., 34pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006094737	A2	20060914	WO 2006-EP2022	20060306
WO 2006094737	A3	20070215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

AU 2006222206 A1 20060914 AU 2006-222206 20060306  
CA 2595033 A1 20060914 CA 2006-2595033 20060306  
EP 1874273 A2 20080109 EP 2006-723226 20060306

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
BA, HR, MK, YU

MX 200710889 A 20071123 MX 2007-10889 20070906  
CN 101137350 A 20080305 CN 2006-80007595 20070907  
KR 2007117616 A 20071212 KR 2007-722318 20070928  
NO 2007005046 A 20071205 NO 2007-5046 20071008

PRAI IT 2005-BO123 A 20050307  
WO 2006-EP2022 W 20060306

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2006094737	IPCI	A61K0009-16 [I,A]; A61K0031-44 [I,A]; A61K0031-395 [I,A]; A61K0009-16 [I,C]; A61K0031-395 [I,C]; A61K0031-44 [I,C]; A61K0009-16 [I,A]; A61K0031-395 [I,A]; A61K0031-44 [I,A]
	IPCR	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]
AU 2006222206	IPCI	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]
CA 2595033	IPCI	A61K0009-16 [I,A]; A61K0031-395 [I,A]; A61K0031-44 [I,A]
	IPCR	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]
EP 1874273	IPCI	A61K0009-16 [I,A]
MX 200710889	IPCI	A61K0009-16 [I,A]; A61K0031-395 [I,A]; A61K0031-44 [I,A]
CN 101137350	IPCI	A61K0009-16 [I,A]; A61K0031-44 [I,A]; A61K0031-395 [I,A]
KR 2007117616	IPCI	A61K0009-16 [I,A]; A61K0031-437 [I,A]; A61K0031-4353 [I,C*]
NO 2007005046	IPCI	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]
	IPCR	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]
AB	The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insol. polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preps. useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. Gastroresistant rifaximin microgranules 9.12 kg were prepared and mixed with sorbitol, aspartame, anhydrous citric acid, pectin, mannitol, and neohesperidin.	
ST	gastroresistant pharmaceutical rifaximin	
IT	Inflammation (Crohn's disease; gastroresistant pharmaceutical formulations containing rifaximin)	
IT	Intestine, disease	

(Crohn's; gastroresistant pharmaceutical formulations containing rifaximin)

IT Monoglycerides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (acetates; gastroresistant pharmaceutical formulations containing rifaximin)

IT Drug delivery systems  
 (capsules; gastroresistant pharmaceutical formulations containing rifaximin)

IT Dissolution  
 Flavoring materials  
 Gums and Mucilages  
 Human  
 Lubricants  
 Plasticizers  
 Polymorphism (crystal)  
 Stabilizing agents  
 Sweetening agents  
 (gastroresistant pharmaceutical formulations containing rifaximin)

IT Alcohols, biological studies  
 Alditols  
 Carbohydrates, biological studies  
 Carboxylic acids, biological studies  
 Gelatins, biological studies  
 Kaolin, biological studies  
 Polymers, biological studies  
 Polyoxymethylenes, biological studies  
 Silica gel, biological studies  
 Waxes  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (gastroresistant pharmaceutical formulations containing rifaximin)

IT Intestine, disease  
 (inflammatory; gastroresistant pharmaceutical formulations containing rifaximin)

IT Drug delivery systems  
 (microgranules; gastroresistant pharmaceutical formulations containing rifaximin)

IT Drug delivery systems  
 (tablets; gastroresistant pharmaceutical formulations containing rifaximin)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; gastroresistant pharmaceutical formulations containing rifaximin)

IT 9003-39-8D, crosslinked  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Crospovidone; gastroresistant pharmaceutical formulations containing rifaximin)

IT 80621-81-4, Rifaximin  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (gastroresistant pharmaceutical formulations containing rifaximin)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 56-81-5, Glycerin, biological studies 57-11-4, Stearic acid, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 60-00-4, EDTA, biological studies 63-42-3, Lactose 64-19-7, Acetic acid, biological studies 69-65-8, Mannitol 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, esters 79-10-7D, Acrylic acid, copolymers 79-41-4D, Methacrylic acid, copolymers 81-07-2, Saccharin 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 88-99-3D, Phthalic acid, esters 102-76-1, Triacetin 110-15-6, Succinic

acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 124-04-9, Adipic acid, biological studies 139-05-9, Sodium cyclamate 139-33-3 557-04-0, Magnesium stearate 585-86-4, Lactitol 585-88-6, Maltitol 1309-37-1, Red Iron Oxide, biological studies 1332-37-2, Iron oxide, biological studies 1592-23-0, Calcium stearate 6915-15-7, Malic acid 7631-86-9, Silica, biological studies 7647-14-5, Sodium chloride, biological studies 7757-93-9, Dicalcium phosphate 7778-18-9, Calcium sulphate 9000-11-7, Carboxymethyl cellulose 9000-69-5, Pectin 9002-18-0, Agar 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Sodium carboxymethyl cellulose 9004-38-0, Cellulose acetate phthalate 9004-53-9, Dextrin 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-38-3, Sodium alginate 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11138-66-2, Xanthan gum 13241-33-3, Neohesperidin 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 22839-47-0, Aspartame 25212-88-8, Kollicoat MAE 100P 25322-68-3, Polyethylene glycol 33665-90-6, Acesulfame 37353-59-6, Hydroxymethyl cellulose 53237-50-6 56038-13-2, SLENDA 74811-65-7, Croscarmellose sodium 188979-58-0, Hydroxypropyl cellulose acetate phthalate

IT 9004-34-6, Cellulose, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (gastroresistant pharmaceutical formulations containing rifaximin)

IT 9004-34-6, Cellulose, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; gastroresistant pharmaceutical formulations containing rifaximin)

L7 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aqueous comps. comprising organic acid buffer system for reducing vaginal pH)

pH and odor)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2006:768514 CAPLUS  
 DOCUMENT NUMBER: 145:195705  
 TITLE: Compositions comprising an acid buffer system for reducing vaginal pH  
 INVENTOR(S): Ahmad, Nawaz; Cui, Cheng-Ji; Fu, Ann; Lin, Shun Y.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 23pp., Cont.-in-part of U.S. Ser. No. 128,611.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
US 20060172007	A1	20060803	US 2005-224189	20050912
US 20030064103	A1	20030403	US 2002-109097	20020328
US 20030017207	A1	20030123	US 2002-128611	20020423
US 20060105008	A1	20060518	US 2005-224870	20050913



AU 2006208421 A1 20070329 AU 2006-208421 20060908  
 EP 1764100 A2 20070321 EP 2006-254711 20060911  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, YU  
 CA 2559510 A1 20070312 CA 2006-2559510 20060912  
 JP 2007077152 A 20070329 JP 2006-246959 20060912  
 BR 2006003783 A 20070612 BR 2006-3783 20060912  
 CN 101032513 A 20070912 CN 2006-10154075 20060912  
 PRIORITY APPLN. INFO.: US 2001-287942P P 20010501  
 US 2002-109097 B2 20020328  
 US 2002-128611 A2 20020423  
 US 2005-224189 A2 20050912  
 US 2005-224870 A 20050913

AN 2006:768514 CAPLUS  
 DN 145:195705  
 ED Entered SIN: 04 Aug 2006  
 TI Compositions comprising an acid buffer system for reducing vaginal pH  
 IN Ahmad, Nawaz; Cui, Cheng-Ji; Fu, Ann; Lin, Shun Y.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 23pp., Cont.-in-part of U.S. Ser. No. 128,611.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 INCL 424487000; 514557000  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060172007	A1	20060803	US 2005-224189	20050912
	US 20030064103	A1	20030403	US 2002-109097	20020328
	US 20030017207	A1	20030123	US 2002-128611	20020423
	US 20060105008	A1	20060518	US 2005-224870	20050913
	AU 2006208421	A1	20070329	AU 2006-208421	20060908
	EP 1764100	A2	20070321	EP 2006-254711	20060911
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CA 2559510	A1	20070312	CA 2006-2559510	20060912
	JP 2007077152	A	20070329	JP 2006-246959	20060912
	BR 2006003783	A	20070612	BR 2006-3783	20060912
PRAI	CN 101032513	A	20070912	CN 2006-10154075	20060912
	US 2001-287942P	P	20010501		
	US 2002-109097	B2	20020328		
	US 2002-128611	A2	20020423		
	US 2005-224189	A2	20050912		
	US 2005-224870	A	20050913		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20060172007	INCL	424487000; 514557000
	IPCI	A61K0031-19 [I,A]; A61K0031-185 [I,C*]; A61K0009-14 [I,A]
US 20030064103	NCL	424/487.000; 514/557.000
	ECLA	A61K009/00M8; A61K031/19
	IPCI	A61K0031-496 [ICM,7]; A61K0009-14 [ICS,7]
	IPCR	A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4174 [I,A]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0031-496 [I,C*];

		A61K0031-496 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]
	NCL	424/486.000; 514/254.070
	ECLA	A61K031/415; A61K031/4174; A61K031/4178; A61K031/4196; A61K031/426; A61K031/496; A61K031/506
US 20030017207	IPCI	A61K0031-496 [ICM,7]; A61K0009-14 [ICS,7]
	IPCR	A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4174 [I,A]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]
	NCL	424/486.000; 514/254.070
	ECLA	A61K031/415; A61K031/4174; A61K031/4178; A61K031/4196; A61K031/426; A61K031/496; A61K031/506
US 20060105008	IPCI	A61F0013-00 [I,A]
	IPCR	A61F0013-00 [I,A]; A61F0013-00 [I,C]
	NCL	424/405.000; 424/422.000
AU 2006208421	IPCI	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0031-185 [I,C]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0031-185 [I,C]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
EP 1764100	IPCI	A61K0031-4174 [I,A]; A61K0031-4164 [I,C*]; A61K0009-00 [I,A]; A61K0009-02 [I,A]; A61K0047-12 [I,A]; A61K0047-14 [I,A]; A61K0047-32 [I,A]; A61K0047-38 [I,A]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]
	IPCR	A61K0031-4164 [I,C]; A61K0031-4174 [I,A]; A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0009-02 [I,C]; A61K0047-12 [I,C]; A61K0047-12 [I,A]; A61K0047-14 [I,C]; A61K0047-14 [I,A]; A61K0047-32 [I,C]; A61K0047-32 [I,A]; A61K0047-38 [I,C]; A61K0047-38 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
CA 2559510	IPCI	A61K0009-02 [I,A]; A61K0031-19 [I,A]; A61K0031-185 [I,C*]; A61K0031-78 [I,A]; A61K0031-74 [I,C*]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-00 [I,C*]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0009-02 [I,C]; A61K0009-02 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]; A61P0031-00 [I,C]; A61P0031-04 [I,A]
JP 2007077152	IPCI	A61K0031-78 [I,A]; A61K0031-74 [I,C*]; A61K0031-19 [I,A]; A61K0031-192 [I,A]; A61K0031-734 [I,A]; A61K0031-20 [I,A]; A61K0031-201 [I,A]; A61K0031-366 [I,A]; A61K0031-194 [I,A]; A61K0031-375 [I,A]; A61K0047-10 [I,A]; A61K0047-34 [I,A]; A61K0047-44 [I,A]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]; A61K0031-198 [I,A]; A61K0031-191 [I,A]; A61K0031-185 [I,C*]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-198 [I,A]; A61K0031-20 [I,A]; A61K0031-201 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A]; A61K0031-375 [I,C]; A61K0031-375 [I,A]; A61K0031-734 [I,C]; A61K0031-734 [I,A]; A61K0047-10 [I,C]; A61K0047-10 [I,A]; A61K0047-34 [I,C]; A61K0047-34 [I,A]; A61K0047-44 [I,C]; A61K0047-44 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]

FTERM 4C076/AA01; 4C076/BB30; 4C076/CC17; 4C076/DD38G;  
 4C076/EE23G; 4C076/EE58G; 4C076/FF17; 4C076/FF61;  
 4C086/AA01; 4C086/AA02; 4C086/BA10; 4C086/BA18;  
 4C086/EA25; 4C086/FA02; 4C086/MA02; 4C086/MA03;  
 4C086/MA04; 4C086/MA05; 4C086/MA09; 4C086/MA31;  
 4C086/MA59; 4C086/NA14; 4C086/ZA81; 4C206/AA01;  
 4C206/AA02; 4C206/DA02; 4C206/DA03; 4C206/DA04;  
 4C206/DA17; 4C206/DA36; 4C206/DA39; 4C206/MA02;  
 4C206/MA03; 4C206/MA04; 4C206/MA05; 4C206/MA11;  
 4C206/MA29; 4C206/MA51; 4C206/NA14; 4C206/ZA81  
 BR 2006003783 IPCI A1K0031-74 [I,C]; A1K0031-765 [I,A]; A1K0031-185  
 [I,C]; A1K0031-185 [I,A]; A1K0031-78 [I,A];  
 A1P0015-00 [I,C]; A1P0015-02 [I,A]  
 CN 101032513 IPCI A1K0031-78 [I,A]; A1K0031-74 [I,C\*]; A1K0031-19  
 [I,A]; A1K0031-185 [I,C\*]; A1K0009-02 [I,A];  
 A1P0015-02 [I,A]; A1P0015-00 [I,C\*]  
 IPCR A1K0031-74 [I,C]; A1K0031-78 [I,A]  
 AB This invention relates to aqueous buffered compns. and methods for lowering  
 vaginal pH and reducing the level of self-perceived vaginal odor. Such  
 compns. may be applied to the vaginal area to lower vaginal pH and assist  
 in maintaining such pH over a period of time. Thus, a vaginal gel was  
 prepared containing Carbomer 971 2.00, Mineral Oil 4.20, Glycerin 12.90,  
 Carbomer 974 1.00, monoglycerides 1.00, Sorbic Acid 0.08, Miconazole  
 Nitrate 4.00 and water 74.82%, resp.  
 ST org acid buffer acidic polymer vaginal odor pH  
 IT Polyelectrolytes  
 (anionic; aqueous compns. comprising organic acid buffer system for reducing  
 vaginal pH and odor)  
 IT Antibacterial agents  
 Buffers  
 Human  
 Odor and Odorous substances  
 Vagina  
 pH  
 (aqueous compns. comprising organic acid buffer system for reducing vaginal  
 pH  
 and odor)  
 IT Hydrocarbon oils  
 Polyoxyalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aqueous compns. comprising organic acid buffer system for reducing vaginal  
 pH  
 and odor)  
 IT Drug delivery systems  
 (gels, vaginal; aqueous compns. comprising organic acid buffer system for  
 reducing vaginal pH and odor)  
 IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydroxy; aqueous compns. comprising organic acid buffer system for reducing  
 vaginal pH and odor)  
 IT Drug delivery systems  
 (ointments, creams, vaginal; aqueous compns. comprising organic acid buffer  
 system for reducing vaginal pH and odor)  
 IT Acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (organic; aqueous compns. comprising organic acid buffer system for reducing  
 vaginal pH and odor)  
 IT Diglycerides  
 Monoglycerides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (palm-oil monoglycerides and diglycerides, hydrogenated; aqueous compns.

comprising organic acid buffer system for reducing vaginal pH and odor)

IT Drug delivery systems  
(suppositories, vaginal; aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

IT Vagina, disease  
(treatment of; aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

IT Drug delivery systems  
(vaginal; aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated, Wecobee M; aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerin, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 59-02-9,  $\alpha$ -Tocopherol 60-00-4, Edetic acid, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 87-69-4, Tartaric acid, biological studies 90-80-2, Glucono- $\delta$ -lactone 110-15-6, Succinic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 110-44-1, Sorbic acid 112-80-1, Oleic acid, biological studies 112-92-5, Stearyl alcohol 443-48-1, Metronidazole 526-95-4, D-Gluconic acid 6915-15-7, Malic acid 9003-01-4D, Polyacrylic acid, crosslinked 9004-32-4, Sodium CM-cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-32-7, Alginate 9005-67-8, Polysorbate 60 19387-91-8, Tinidazole 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 25322-68-3, Polyethylene glycol 30049-31-1, Acrylic acid-allylpentaerythritol copolymer 36653-82-4, Cetyl alcohol 67915-31-5, Terconazole 86386-73-4, Fluconazole 90803-96-6, Wecobee FS 94290-13-8, Gantrez MS-955 151687-96-6, Carbopol 974P 330988-84-6, Carbopol 971 330988-85-7, Carbopol 974  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

IT 7631-86-9, Silica, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(colloidal; aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

IT 57-50-1D, Sucrose, allyl ethers  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(crosslinker; aqueous compns. comprising organic acid buffer system for reducing vaginal pH and odor)

L7 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(acid-containing aqueous buffered compns. for reducing vaginal pH)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2006:470297 CAPLUS  
 DOCUMENT NUMBER: 144:474964  
 TITLE: Acid-containing compositions and methods for reducing vaginal pH  
 INVENTOR(S): Ahmad, Nawaz; Cui, Cheng-Ji; Fu, Ann; Lin, Shun Y.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 224,189.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060105008	A1	20060518	US 2005-224870	20050913
US 20030064103	A1	20030403	US 2002-109097	20020328
US 20030017207	A1	20030123	US 2002-128611	20020423
US 20060172007	A1	20060803	US 2005-224189	20050912
AU 2006208421	A1	20070329	AU 2006-208421	20060908
EP 1764100	A2	20070321	EP 2006-254711	20060911
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CA 2559510	A1	20070312	CA 2006-2559510	20060912
JP 2007077152	A	20070329	JP 2006-246959	20060912
BR 2006003783	A	20070612	BR 2006-3783	20060912
CN 101032513	A	20070912	CN 2006-10154075	20060912

PRIORITY APPLN. INFO.:

US 2002-109097	B2	20020328
US 2002-128611	A2	20020423
US 2005-224189	A2	20050912
US 2001-287942P	P	20010501
US 2005-224870	A	20050913

AN 2006:470297 CAPLUS  
 DN 144:474964  
 ED Entered STN: 19 May 2006  
 TI Acid-containing compositions and methods for reducing vaginal pH  
 IN Ahmad, Nawaz; Cui, Cheng-Ji; Fu, Ann; Lin, Shun Y.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 224,189.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 INCL 424405000; 424422000  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060105008	A1	20060518	US 2005-224870	20050913
US 20030064103	A1	20030403	US 2002-109097	20020328
US 20030017207	A1	20030123	US 2002-128611	20020423
US 20060172007	A1	20060803	US 2005-224189	20050912
AU 2006208421	A1	20070329	AU 2006-208421	20060908
EP 1764100	A2	20070321	EP 2006-254711	20060911
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CA 2559510	A1	20070312	CA 2006-2559510	20060912
JP 2007077152	A	20070329	JP 2006-246959	20060912

BR 2006003783	A	20070612	BR 2006-3783	20060912
CN 101032513	A	20070912	CN 2006-10154075	20060912
PRAI US 2002-109097	B2	20020328		
US 2002-128611	A2	20020423		
US 2005-224189	A2	20050912		
US 2001-287942P	P	20010501		
US 2005-224870	A	20050913		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20060105008	INCL	424405000; 424422000
	IPCI	A61F0013-00 [I,A]
	IPCR	A61F0013-00 [I,A]; A61F0013-00 [I,C]
	NCL	424/405.000; 424/422.000
US 20030064103	IPCI	A61K0031-496 [ICM,7]; A61K0009-14 [ICS,7]
	IPCR	A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4174 [I,A]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]
	NCL	424/486.000; 514/254.070
	ECLA	A61K031/415; A61K031/4174; A61K031/4178; A61K031/4196; A61K031/426; A61K031/496; A61K031/506
US 20030017207	IPCI	A61K0031-496 [ICM,7]; A61K0009-14 [ICS,7]
	IPCR	A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4174 [I,A]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]
	NCL	424/486.000; 514/254.070
	ECLA	A61K031/415; A61K031/4174; A61K031/4178; A61K031/4196; A61K031/426; A61K031/496; A61K031/506
US 20060172007	IPCI	A61K0031-19 [I,A]; A61K0031-185 [I,C*]; A61K0009-14 [I,A]
	NCL	424/487.000; 514/557.000
	ECLA	A61K009/00M8; A61K031/19
AU 2006208421	IPCI	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0031-185 [I,C]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0031-185 [I,C]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
EP 1764100	IPCI	A61K0031-4174 [I,A]; A61K0031-4164 [I,C*]; A61K0009-00 [I,A]; A61K0009-02 [I,A]; A61K0047-12 [I,A]; A61K0047-14 [I,A]; A61K0047-32 [I,A]; A61K0047-38 [I,A]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]
	IPCR	A61K0031-4164 [I,C]; A61K0031-4174 [I,A]; A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0009-02 [I,C]; A61K0009-02 [I,A]; A61K0047-12 [I,C]; A61K0047-12 [I,A]; A61K0047-14 [I,C]; A61K0047-14 [I,A]; A61K0047-32 [I,C]; A61K0047-32 [I,A]; A61K0047-38 [I,C]; A61K0047-38 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
CA 2559510	IPCI	A61K0009-02 [I,A]; A61K0031-19 [I,A]; A61K0031-185 [I,C*]; A61K0031-78 [I,A]; A61K0031-74 [I,C*]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-00 [I,C*]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0009-02 [I,C]; A61K0009-02 [I,A]; A61K0031-185 [I,C];

JP 2007077152	IPCI	A61K0031-19 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]; A61P0031-00 [I,C]; A61P0031-04 [I,A] A61K0031-78 [I,A]; A61K0031-74 [I,C*]; A61K0031-19 [I,A]; A61K0031-192 [I,A]; A61K0031-734 [I,A]; A61K0031-20 [I,A]; A61K0031-201 [I,A]; A61K0031-366 [I,A]; A61K0031-194 [I,A]; A61K0031-375 [I,A]; A61K0047-10 [I,A]; A61K0047-34 [I,A]; A61K0047-44 [I,A]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]; A61K0031-198 [I,A]; A61K0031-191 [I,A]; A61K0031-185 [I,C*]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-198 [I,A]; A61K0031-20 [I,A]; A61K0031-201 [I,A]; A61K0031-366 [I,C]; A61K0031-366 [I,A]; A61K0031-375 [I,C]; A61K0031-375 [I,A]; A61K0031-734 [I,C]; A61K0031-734 [I,A]; A61K0047-10 [I,C]; A61K0047-10 [I,A]; A61K0047-34 [I,C]; A61K0047-34 [I,A]; A61K0047-44 [I,C]; A61K0047-44 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
	FTERM	4C076/AA01; 4C076/BB30; 4C076/CC17; 4C076/DD38G; 4C076/EE23G; 4C076/EE58G; 4C076/FF17; 4C076/FF61; 4C086/AA01; 4C086/AA02; 4C086/BA10; 4C086/BA18; 4C086/EA25; 4C086/FA02; 4C086/MA02; 4C086/MA03; 4C086/MA04; 4C086/MA05; 4C086/MA09; 4C086/MA31; 4C086/MA59; 4C086/NA14; 4C086/ZA81; 4C206/AA01; 4C206/AA02; 4C206/DA02; 4C206/DA03; 4C206/DA04; 4C206/DA17; 4C206/DA36; 4C206/DA39; 4C206/MA02; 4C206/MA03; 4C206/MA04; 4C206/MA05; 4C206/MA11; 4C206/MA29; 4C206/MA51; 4C206/NA14; 4C206/ZA81
BR 2006003783	IPCI	A61K0031-74 [I,C]; A61K0031-765 [I,A]; A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-78 [I,A]; A61P0015-00 [I,C]; A61P0015-02 [I,A]
CN 101032513	IPCI	A61K0031-78 [I,A]; A61K0031-74 [I,C*]; A61K0031-19 [I,A]; A61K0031-185 [I,C*]; A61K0009-02 [I,A]; A61P0015-02 [I,A]; A61P0015-00 [I,C*]
	IPCR	A61K0031-74 [I,C]; A61K0031-78 [I,A]
AB	This invention relates to (i) aqueous compns. containing acid buffer system comprising a water-soluble acidic polymer and an organic acid and (ii) methods for lowering vaginal pH and reducing the level of self-perceived vaginal odor. Such compns. may be applied to the vaginal area to lower vaginal pH and assist in maintaining such pH over a period of time. Thus, a vaginal composition was prepared containing CM-cellulose 2.00, benzoic acid 0.20, dl- $\alpha$ -tocopherol (Vitamin E) 0.10, propylene glycol 20.00, Carbopol 974P 4.00, lactic acid 3.00, and water to 100.00%, resp.	
ST	org acid polyelectrolyte buffer vaginal pH vaginosis	
IT	Antibacterial agents	
	Buffers	
	Fungicides	
	Human	
	Vagina	
	Vagina, disease	
	pH	
	(acid-containing aqueous buffered compns. for reducing vaginal pH)	
IT	Polyoxyalkylenes, biological studies	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(acid-containing aqueous buffered compns. for reducing vaginal pH)	
IT	Polyelectrolytes	
	(anionic; acid-containing aqueous buffered compns. for reducing vaginal pH)	
IT	Drug delivery systems	
	(gels, vaginal; acid-containing aqueous buffered compns. for reducing vaginal	

pH)

IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydroxy; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT Drug delivery systems  
 (ointments, creams, vaginal; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT Acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (organic; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT Diglycerides  
 Monoglycerides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (palm-oil monoglycerides and diglycerides, hydrogenated; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT Drug delivery systems  
 (suppositories, vaginal; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT Drug delivery systems  
 (vaginal; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT 330988-84-6, Carbopol 971  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Carbomer 971; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT 330988-85-7, Carbopol 974  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Carbomer 974; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT 9003-01-4D, crosslinked  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Carbomer; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 60-00-4, Edetic acid, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 79-10-7D, Acrylic acid, polymers, crosslinked 87-69-4, Tartaric acid, biological studies 90-80-2, D-Glucono-8-lactone 110-15-6, Succinic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-44-1, Sorbic acid 112-80-1, Oleic acid, biological studies 526-95-4, D-Gluconic acid 6915-15-7, Malic acid 9004-32-4, Sodium CMC 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-32-7, Alginate acid 10191-41-0, DL- $\alpha$ -Tocopherol 11138-66-2, Xanthan gum 22832-87-7, Miconazole nitrate 25322-68-3, Polyethylene glycol 90803-96-6, Wecobee FS 94290-13-8, Gantrez MS-955 136392-67-1, Stabileze 06 151687-96-6, Carbopol 974P  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (acid-containing aqueous buffered compns. for reducing vaginal pH)

IT 7631-86-9, Silica, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (colloidal; acid-containing aqueous buffered compns. for reducing vaginal pH)

IT 57-50-1D, Sucrose, allyl esters 115-77-5D, Pentaerythritol,



allyl esters

RL: RCT (Reactant); RACT (Reactant or reagent)

(crosslinking agent; acid-containing aqueous buffered comps. for reducing vaginal pH)

L7 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, 1,2-Benzenedicarboxylic acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Chinese formulations of breviscapine for treatment of cardiovascular disease)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



ACCESSION NUMBER: 2006:251540 CAPLUS

DOCUMENT NUMBER: 145:14545

TITLE: Chinese formulations of breviscapine for treatment of cardiovascular disease

INVENTOR(S): Wang, Hengxin

PATENT ASSIGNEE(S): Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1739544	A	20060301	CN 2005-10032117	20050906

PRIORITY APPLN. INFO.:

AN 2006:251540 CAPLUS

DN 145:14545

ED Entered STN: 20 Mar 2006

TI Chinese formulations of breviscapine for treatment of cardiovascular disease

IN Wang, Hengxin

PA Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1739544	A	20060301	CN 2005-10032117	20050906

PRAI CN 2005-10032117

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
CN 1739544	IPC1	A61K0031-7048 [A]; A61K0031-7042 [C*]; A61K0009-20 [A]; A61K0009-19 [A]; A61P0009-00 [A]; G01N0030-02 [A]; G01N0030-00 [C*]; G01N0033-15 [A]

IPCR A61K0031-7042 [I,C]; A61K0031-7048 [I,A]

- AB The breviscapine pill is prepared by mixing breviscapine with a suitable amount of accessories and forming pill in the presence of water and/or honey. The accessories for preparing pill is starch, sucrose, lactose, dextrin, microcryst. cellulose, hydroxymethyl cellulose, sodium carboxymethyl starch, aspartame, crosslinked povidone, povidone K30, Et cellulose, polyoxypropylene polysiloxane, waxes, polyethylene glycol, stearic acid, shellac, acrylic resin, polyvinyl alc., Me cellulose, hydroxypropyl cellulose, cellulose propionate, acrylic resin water dispersing agent, Et cellulose pseudo-latex, cellulose acetate-phthalate latex, polyvinyl acetate-phthalate water dispersing agent, propanediol, glycerin, glyceryl triacetate, acetyl monoglyceride, phthalate, polysorbate 80, sodium dodecyl sulfate, fructose and/or sucrose. The oral freeze-dried powder of breviscapine is prepared by dissolving breviscapine in water, adding a suitable amount of adjuvants, sterilization filtration subpackaging and freeze drying. The adjuvants for preparing oral freeze-dried powder is sodium citrate, citric acid, mannitol, albumin, lactose, sorbitol, xylitol, arabinitol, stevioside and/or saccharin sodium. The content of breviscapine in the formulation was determined by HPLC at 250-350 nm on an octadecyl silane column with methanol-water-acetic acid(20-40:50-80:0.5-2) as mobile phase.
- ST breviscapine prepn cardiovascular disease quality control HPLC
- IT Cardiovascular system, disease  
Cytoprotective agents  
Honey  
Quality control  
(Chinese formulations of breviscapine for treatment of cardiovascular disease)
- IT Albumins, biological studies  
Polyoxyalkylenes, biological studies  
Polysiloxanes, biological studies  
Shellac  
Waxes  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Chinese formulations of breviscapine for treatment of cardiovascular disease)
- IT Drug delivery systems  
(freeze-dried; Chinese formulations of breviscapine for treatment of cardiovascular disease)
- IT Drug delivery systems  
(tablets; Chinese formulations of breviscapine for treatment of cardiovascular disease)
- IT 116122-36-2, Breviscapine  
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Chinese formulations of breviscapine for treatment of cardiovascular disease)
- IT 50-70-4, Sorbitol, biological studies 56-81-5, Glycerin, biological studies 57-11-4, Stearic acid, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 68-04-2, Sodium citrate 69-65-8, Mannitol 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid , biological studies 87-99-0, Xylitol 88-99-3, 1,2-Benzenedicarboxylic acid, biological studies 102-76-1, Glyceryl triacetate 128-44-9, Saccharin sodium 151-21-3, Sodium dodecyl sulfate, biological studies 2152-56-9, Arabinitol 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinylpyrrolidone 9003-39-8D, Povidone, crosslinked 9004-38-0, Cellulose acetate phthalate 9004-48-2, Cellulose propionate 9004-53-9, Dextrin 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-65-6, Polysorbate 80

9063-38-1, Sodium carboxymethyl starch 22839-47-0, Aspartame  
 25322-68-3, Polyethylene glycol 25322-69-4 26264-14-2, Propanediol  
 26446-35-5, Acetyl monoglyceride 37353-59-6, Hydroxymethyl cellulose  
 53237-50-6 57817-89-7, Stevioside

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Chinese formulations of breviscapine for treatment of cardiovascular  
 disease)

IT 9004-34-6, Cellulose, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; Chinese formulations of breviscapine for treatment of  
 cardiovascular disease)

L7 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, biological studies 124-04-9,  
 Adipic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (particulate dosage forms)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-(\text{CH}_2)_4-\text{CO}_2\text{H}$

ACCESSION NUMBER: 2005:1220699 CAPLUS

DOCUMENT NUMBER: 143:466230

TITLE: Particulate dosage forms

INVENTOR(S): Bar-Shalom, Daniel; Slot, Lillian; Fischer, Gina;  
 Hemmingsen, Pernille Hoeyrup  
 PATENT ASSIGNEE(S): Egalet A/S, Den.

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005107713	A2	20051117	WO 2005-DK317	20050511
WO 2005107713	A3	20060518		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2566793	A1	20051117	CA 2005-2566793	20050511

EP 1758557 A2 20070307 EP 2005-739537 20050511  
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
HR, MK, YU

JP 2007537169 T 20071220 JP 2007-511867 20050511  
PRIORITY APPLN. INFO.: DK 2004-755 A 20040511  
WO 2005-DK317 W 20050511

AN 2005:1220699 CAPLUS  
DN 143:466230  
ED Entered STN: 18 Nov 2005  
TI Particulate dosage forms  
IN Bar-Shalom, Daniel; Slot, Lillian; Fischer, Gina; Hemmingsen, Pernille  
Hoeyrup  
PA Egalet A/S, Den.  
SO PCT Int. Appl., 105 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K009-16  
ICS A61J007-00; A61K031-167; A61K033-26; A61K031-4415; A61K031-192  
CC 63-6 (Pharmaceuticals)  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005107713	A2	20051117	WO 2005-DK317	20050511
WO 2005107713	A3	20060518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2566793	A1	20051117	CA 2005-2566793	20050511
EP 1758557	A2	20070307	EP 2005-739537	20050511
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2007537169	T	20071220	JP 2007-511867	20050511
PRAI DK 2004-755	A	20040511		
WO 2005-DK317	W	20050511		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005107713	ICM	A61K009-16
	ICS	A61J007-00; A61K031-167; A61K033-26; A61K031-4415; A61K031-192
	IPCI	A61J0007-00 [I,C]; A61K0009-16 [I,C]; A61K0031-167 [I,C]; A61K0031-185 [I,C]; A61K0031-4415 [I,C]; A61K0033-26 [I,C]; A61K0009-16 [I,A]; A61J0007-00 [I,A]; A61K0031-167 [I,A]; A61K0031-192 [I,A]; A61K0031-4415 [I,A]; A61K0033-26 [I,A]
	IPCR	A61J0007-00 [I,C*]; A61J0007-00 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A];

		A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-4415 [I,C*]; A61K0031-4415 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]
CA 2566793	ECLA	A61K009/16H6F; A61K009/00M18B; A61K009/20K2B; A61K031/167; A61K031/192; A61K031/4415; A61J007/00D
	IPCI	A61J0007-00 [I,A]; A61K0009-16 [I,A]; A61K0031-167 [I,A]; A61K0031-192 [I,A]; A61K0031-185 [I,C*]; A61K0031-4415 [I,A]; A61K0033-26 [I,A]
	IPCR	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61J0007-00 [I,C]; A61J0007-00 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0031-167 [I,C]; A61K0031-167 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-4415 [I,C]; A61K0031-4415 [I,A]; A61K0033-26 [I,C]; A61K0033-26 [I,A]
	ECLA	A61K009/16H6F; A61J007/00D; A61K009/00M18B; A61K009/20K2B; A61K031/167; A61K031/192; A61K031/4415
EP 1758557	IPCI	A61K0009-16 [I,A]; A61J0007-00 [I,A]; A61K0031-167 [I,A]; A61K0033-26 [I,A]; A61K0031-4415 [I,A]; A61K0031-192 [I,A]; A61K0031-185 [I,C*]
	IPCR	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61J0007-00 [I,C]; A61J0007-00 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0031-167 [I,C]; A61K0031-167 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-4415 [I,C]; A61K0031-4415 [I,A]; A61K0033-26 [I,C]; A61K0033-26 [I,A]
	ECLA	A61K009/16H6F; A61J007/00D; A61K009/00M18B; A61K009/20K2B; A61K031/167; A61K031/192; A61K031/4415
JP 2007537169	IPCI	A61K0047-36 [I,A]; A61K0047-38 [I,A]; A61K0047-42 [I,A]; A61K0009-06 [I,A]; A61K0047-32 [I,A]; A61K0047-34 [I,A]; A61K0047-02 [I,A]; A61K0047-12 [I,A]; A61K0047-16 [I,A]; A61K0047-26 [I,A]; A61K0047-10 [I,A]; A61K0047-18 [I,A]; A61K0047-22 [I,A]; A61K0009-14 [I,A]; A61K0009-50 [I,A]
	IPCR	A61K0047-36 [I,C]; A61K0047-36 [I,A]; A61J0007-00 [I,C*]; A61J0007-00 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-06 [I,C]; A61K0009-06 [I,A]; A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-50 [I,C]; A61K0009-50 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-4415 [I,C*]; A61K0031-4415 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0047-02 [I,C]; A61K0047-10 [I,C]; A61K0047-10 [I,A]; A61K0047-12 [I,C]; A61K0047-12 [I,A]; A61K0047-16 [I,C]; A61K0047-16 [I,A]; A61K0047-18 [I,A]; A61K0047-22 [I,C]; A61K0047-22 [I,A]; A61K0047-26 [I,C]; A61K0047-26 [I,A]; A61K0047-32 [I,C]; A61K0047-32 [I,A]; A61K0047-34 [I,C]; A61K0047-34 [I,A]; A61K0047-38 [I,C]; A61K0047-38 [I,A]; A61K0047-42 [I,C]; A61K0047-42 [I,A]
	FTERM	4C076/AA09; 4C076/AA29; 4C076/AA31; 4C076/AA51; 4C076/AA61; 4C076/AA90; 4C076/AA95; 4C076/BB01; 4C076/DD02; 4C076/DD04; 4C076/DD05; 4C076/DD09; 4C076/DD12; 4C076/DD22; 4C076/DD23; 4C076/DD24; 4C076/DD25; 4C076/DD26; 4C076/DD30; 4C076/DD38; 4C076/DD41; 4C076/DD42; 4C076/DD43; 4C076/DD50; 4C076/DD55; 4C076/DD57; 4C076/DD67; 4C076/EE06;

4C076/EE09; 4C076/EE11; 4C076/EE12; 4C076/EE16;  
4C076/EE23; 4C076/EE30; 4C076/EE32; 4C076/EE36;  
4C076/EE38; 4C076/EE42; 4C076/EE47; 4C076/EE57;  
4C076/FF35; 4C076/FF43; 4C076/FF68

- AB A dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetd. amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a  $\leq 5$  min swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cPs. In one embodiment of the invention, the particulate matter can be molded into a desired shape or pressed onto a dispensing unit such as a spoon. Thus, a formulation contained Kelcogel LT100 50, xylitol 47.5, and vanilla flavor 2.5% and a drug 25% was mixed with the above composition
- ST particulate dosage form sugar polymer
- IT Surfactants  
(amphiphilic; particulate dosage forms)
- IT Surfactants  
(amphoteric; particulate dosage forms)
- IT Surfactants  
(anionic; particulate dosage forms)
- IT Drug delivery systems  
(beads; particulate dosage forms)
- IT Surfactants  
(cationic; particulate dosage forms)
- IT Drug delivery systems  
(granules; particulate dosage forms)
- IT Crystal growth  
(inhibitors; particulate dosage forms)
- IT Bitterness  
(masking agents; particulate dosage forms)
- IT Surfactants  
(nonionic; particulate dosage forms)
- IT Antimicrobial agents  
Antioxidants  
Buffers  
Chelating agents  
Dispersing agents  
Dyes  
Electrolytes  
Emulsifying agents  
Eucheuma  
Flavoring materials  
Gelation agents  
Gums and Mucilages  
Hydrocolloids  
Nutrients  
Particle size distribution  
Plasticizers  
Pore size distribution  
Preservatives  
Seaweed  
Solubilizers  
Stabilizing agents  
Sunscreens  
Surfactants

Sweetening agents  
 Swelling, physical  
 Thickening agents  
 Viscosity  
 Wetting agents  
 (particulate dosage forms)

IT Acrylic polymers, biological studies  
 Bases, biological studies  
 Borates  
 Bromides, biological studies  
 Carbohydrates, biological studies  
 Carboxylic acids, biological studies  
 Chlorides, biological studies  
 Gelatins, biological studies  
 Polyoxaalkylenes, biological studies  
 Polysaccharides, biological studies  
 Salts, biological studies  
 Sulfates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (particulate dosage forms)

IT Drug delivery systems  
 (pellets; particulate dosage forms)

IT Vinyl compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polymers; particulate dosage forms)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts  
 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological  
 studies 56-81-5, 1,2,3-Propanetriol, biological studies 57-13-6, Urea,  
 biological studies 57-48-7, Fructose, biological studies 57-50-1,  
 Sucrose, biological studies 63-42-3, Lactose 64-19-7D,  
 Acetic acid, salts 65-85-0, Benzoic acid, biological  
 studies 68-04-2, Sodium citrate 69-65-8, Mannitol 77-92-9, Citric  
 acid, biological studies 77-92-9D, Citric acid, salts 87-69-4,  
 Tartaric acid, biological studies 87-89-8, Inositol 87-99-0, Xylitol  
 102-71-6, Triethanolamine, biological studies 110-15-6, Succinic  
 acid, biological studies 110-16-7, Maleic acid, biological studies  
 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid  
 124-04-9, Adipic acid, biological studies 127-09-3, Sodium  
 acetate 144-55-8, Sodium bicarbonate, biological studies 151-21-3,  
 biological studies 497-19-8, Sodium carbonate, biological studies  
 512-42-5 512-69-6, Raffinose 577-11-7, Dioctyl sodium sulfosuccinate  
 814-80-2, Calcium lactate 1303-96-4, Borax (B4Na2O7.10H2O) 1310-73-2,  
 Sodium hydroxide (Na(OH)), biological studies 1336-21-6, Ammonium  
 hydroxide 6915-15-7, Malic acid 7447-40-7, Potassium chloride,  
 biological studies 7447-41-8, Lithium chloride, biological studies  
 7487-88-9, Magnesium sulfate, biological studies 7558-79-4, Disodium  
 hydrogen phosphate 7558-80-7, Dihydrogen sodium phosphate 7647-01-0,  
 Hydrochloric acid, biological studies 7647-14-5, Sodium chloride,  
 biological studies 7681-49-4, Sodium fluoride, biological studies  
 7705-12-6, Ferrofumarate 7757-82-6, Sodium sulfate, biological studies  
 7757-83-7, Sodium sulfite 7758-02-3, Potassium bromide (KBr), biological  
 studies 7778-18-9, Calcium sulfate 7778-53-2, Tripotassium phosphate  
 7778-80-5, Potassium sulfate, biological studies 7786-30-3, Magnesium  
 chloride, biological studies 7789-23-3, Potassium fluoride (KF)  
 9000-01-5, Acacia gum 9000-07-1, Carrageenan 9000-11-7, Carboxymethyl  
 cellulose 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-40-2,  
 Locust bean gum 9000-65-1, Tragacanth gum 9000-69-5, Pectin  
 9002-18-0, Agar 9002-89-5, Poly(vinyl alcohol) 9003-01-4, Poly(  
 acrylic acid) 9003-39-8, Polyvinylpyrrolidone  
 9003-97-8, Polycarbophil 9004-32-4, Sodium carboxymethyl cellulose  
 9004-32-4D, Sodium carboxymethyl cellulose, derivs. 9004-34-6D,

Cellulose, derivs. 9004-42-6, Carboxyethyl cellulose 9004-59-5, Ethyl methyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-32-7, Alginic acid 9005-34-9, Ammonium alginate 9005-35-0, Calcium alginate 9005-36-1, Potassium alginate 9005-37-2, Propylene glycol alginate 9005-38-3, Sodium alginate 9005-80-5, Inulin 9063-38-1, Sodium starch glycolate 10043-52-4, Calcium chloride, biological studies 10377-48-7, Lithium sulfate 11138-66-2, Xanthan gum 12773-27-2, Sodium tin oxide 25087-26-7, Poly(methacrylic acid) 25249-16-5, Poly(2-hydroxyethyl methacrylate) 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 26008-54-8, Vinyl alcohol-vinylpyrrolidone copolymer 37220-17-0, Konjak mannan 39300-88-4, Tara gum 71010-52-1, Gellan gum 71010-52-1D, Gellan gum, derivs. 106392-12-5  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (particulate dosage forms)

L7 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 110-15-6, Succinic acid, biological studies 110-15-6D, Succinic acid, derivs. 124-04-9D, Adipic acid, derivs.  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (entrapping, inactivating, and removing viral infections by administration of respiratory tract comps.)  
 RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2005:1132616 CAPLUS  
 DOCUMENT NUMBER: 143:393081  
 TITLE: Entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions  
 INVENTOR(S): Rennie, Paul John; Khanolkar, Jayant Ekanth; Jessen, George William  
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
 SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 692,634.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 27  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------



US 20050232868	A1	20051020	US 2004-979498	20041102
AU 2005302032	A1	20060511	AU 2005-302032	20051101
CA 2586039	A1	20060511	CA 2005-2586039	20051101
WO 2006050489	A2	20060511	WO 2005-US39926	20051101
WO 2006050489	A3	20061116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1809304	A2	20070725	EP 2005-849251	20051101
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101052407	A	20071010	CN 2005-80037865	20051101
JP 2008519037	T	20080605	JP 2007-540059	20051101
IN 2007DN03147	A	20070831	IN 2007-DN3147	20070426
PRIORITY APPLN. INFO.:				
			US 1999-421131	B2 19991019
			US 2000-692634	A2 20001019
			US 2004-979498	A 20041102
			WO 2005-US39926	W 20051101
AN 2005:1132616 CAPLUS				
DN 143:393081				
ED Entered STN: 21 Oct 2005				
TI Entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions				
IN Rennie, Paul John; Khanolkar, Jayant Ekanth; Jessen, George William				
PA The Procter & Gamble Company, USA				
SO U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 692,634.				
CODEN: USXXCO				
DT Patent				
LA English				
IC ICM A61L009-04				
ICS A61K031-315; A61K035-78				
INCL 424045000; 424754000; 424755000; 424760000; 514494000				
CC 63-6 (Pharmaceuticals)				
FAN.CNT 27				
PATENT NO. KIND DATE APPLICATION NO. DATE				
PI US 20050232868 A1 20051020 US 2004-979498 20041102				
AU 2005302032 A1 20060511 AU 2005-302032 20051101				
CA 2586039 A1 20060511 CA 2005-2586039 20051101				
WO 2006050489 A2 20060511 WO 2005-US39926 20051101				
WO 2006050489 A3 20061116				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

	GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
EP 1809304	A2	20070725	EP 2005-849251 20051101
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
CN 101052407	A	20071010	CN 2005-80037865 20051101
JP 2008519037	T	20080605	JP 2007-540059 20051101
IN 2007/DN03147	A	20070831	IN 2007-DN3147 20070426
PRAI US 1999-421131	B2	19991019	
US 2000-692634	A2	20001019	
US 2004-979498	A	20041102	
WO 2005-US39926	W	20051101	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20050232868	ICM	A61L009-04
	ICS	A61K031-315; A61K035-78
	INCL	424045000; 424754000; 424755000; 424760000; 514494000
	IPCI	A61L0009-04 [ICM,7]; A61K0031-315 [ICS,7]; A61K0031-28 [ICS,7,C*]; A61K0035-78 [ICS,7]
	IPCR	A01N0043-34 [I,C*]; A01N0043-36 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-315 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0036-185 [I,C*]; A61K0036-31 [I,A]; A61K0036-81 [I,A]; A61K0036-88 [I,C*]; A61K0036-8962 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
	NCL	424/045.000; 424/754.000; 424/755.000; 424/760.000; 514/494.000
AU 2005302032	IPCI	A61K0031-74 [I,C]; A61K0031-765 [I,A]; A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61K0045-00 [I,C]; A61K0045-00 [I,A]
	IPCR	A61K0031-74 [I,C]; A61K0031-765 [I,A]; A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61K0045-00 [I,C]; A61K0045-00 [I,A]
CA 2586039	ECLA	A61K031/765+M; A61K033/30+M; A61K045/06
	IPCI	A61K0031-765 [I,A]; A61K0031-74 [I,C*]; A61K0033-30 [I,A]; A61K0045-00 [I,A]
	IPCR	A61K0031-74 [I,C]; A61K0031-765 [I,A]; A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61K0045-00 [I,C]; A61K0045-00 [I,A]
WO 2006050489	ECLA	A61K031/765+M; A61K033/30+M; A61K045/06
	IPCI	A61K0031-74 [I,C]; A61K0033-30 [I,C]; A61K0045-00 [I,C]; A61K0031-765 [I,A]; A61K0033-30 [I,A]; A61K0045-00 [I,A]
	IPCR	A61K0031-74 [I,C]; A61K0031-765 [I,A]; A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61K0045-00 [I,C]; A61K0045-00 [I,A]
EP 1809304	ECLA	A61K031/765+M; A61K033/30+M; A61K045/06
	IPCI	A61K0031-765 [I,A]; A61K0031-74 [I,C*]; A61K0033-30 [I,A]; A61K0045-00 [I,A]
CN 101052407	ECLA	A61K031/765+M; A61K033/30+M; A61K045/06
	IPCI	A61K0031-765 [I,A]; A61K0031-74 [I,C*]; A61K0045-00 [I,A]; A61K0033-30 [I,A]
	IPCR	A61K0031-74 [I,C]; A61K0031-765 [I,A]
	ECLA	A61K031/765+M; A61K033/30+M; A61K045/06

JP 2008519037 IPCI A61K0009-72 [I,A]; A61K0009-12 [I,A]; A61K0047-38 [I,A]; A61M0011-00 [N,A]  
 FTERM 4C076/AA24; 4C076/AA93; 4C076/BB25; 4C076/CC35; 4C076/EE31G; 4C076/FF17; 4C076/FF61; 4C076/FF68

IN 2007DN03147 IPCI A61K0045-00 [ICM,7]

AB The present invention is directed to methods of preventing and treating respiratory tract viral infections by administering compns. to areas of the respiratory tract such as the nasal cavity, wherein the compns. provide for the encapsulation, inactivation, and/or removal of viruses and/or viral strains associated with the common cold and influenza. The methods of encapsulation, inactivation, and removal of cold and influenza viruses have been shown to create and maintain environments that are hostile to the viruses to result in effective prevention and treatment of cold and influenza-like symptoms. A composition contained HPMC, Zn acetate, succinic acid nasal secretion agent, Polysorbate 80, Na saccharin, phenylethylanol, Sensate Mix A, di-Na succinate and deionized water.

ST virus infection removal compn respiratory tract

IT Animal virus  
 Antiviral agents  
 Chelating agents  
 Respiratory system  
 Surfactants  
 Thickening agents  
 (entrapping, inactivating, and removing viral infections by administration of respiratory tract compns.)

IT Chlorides, biological studies  
 Fluorides, biological studies  
 Iodides, biological studies  
 Nitrates, biological studies  
 Phosphates, biological studies  
 Polyoxyalkylenes, biological studies  
 Sulfates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (entrapping, inactivating, and removing viral infections by administration of respiratory tract compns.)

IT Drug delivery systems  
 (nasal; entrapping, inactivating, and removing viral infections by administration of respiratory tract compns.)

IT Polyphosphoric acids  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sodium salts; entrapping, inactivating, and removing viral infections by administration of respiratory tract compns.)

IT 50-21-5D, Lactic acid, derivs. 50-81-7D, Ascorbic acid, derivs.  
 56-40-6D, Glycine, derivs. 56-84-8D, Aspartic acid, derivs. 57-50-1D, Sucrose, allyl ether derivs., polyacrylic-crosslinked 60-00-4, Edta, biological studies 62-33-9, Calcium edta 64-02-8, Tetrasodium edta 64-19-7, Acetic acid, biological studies 64-19-7D, Acetic acid, derivs. 65-85-0D, Benzoic acid, derivs. 77-92-9D, Citric acid, derivs. 79-14-1D, Glycolic acid, derivs. 87-69-4D, Tartaric acid, derivs. 98-79-3, Pyroglutamic acid 107-18-6D, Allyl alcohol, polyol ether derivs., polyacrylic-crosslinked 110-15-6, Succinic acid, biological studies 110-15-6D, Succinic acid, derivs. 110-16-7D, Maleic acid, derivs. 110-17-8D, Fumaric acid, derivs. 110-94-1D, Glutaric acid, derivs. 124-04-9D, Adipic acid, derivs. 141-82-2D, Malonic acid, derivs. 147-93-3D, Thiosalicylic acid, derivs. 148-24-3, 8-Quinololinol, biological studies 150-25-4, Di(hydroxyethyl)glycine 150-90-3, Disodium succinate 404-86-4, Capsaicin 526-95-4D, D-Gluconic acid, derivs. 557-34-6, Zinc acetate 6915-15-7D, Malic acid, derivs. 7647-14-5, Sodium chloride, biological studies 9000-11-7, Carboxymethyl cellulose 9003-01-4, Carboxypolymethylene 9003-01-4D, Polyacrylic

acid, allyl ether crosslinked derivs. 9003-39-8, Pvp 9004-32-4, Sodium carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose 12519-36-7, Zinc edta 25322-68-3, PEG 26027-38-3, Nonoxynol 9 73038-24-1, Acrylic acid-divinyl glycol copolymer 106392-12-5, Lutrol F-127

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(entrapping, inactivating, and removing viral infections by administration of respiratory tract compns.)

L7 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl


citrate 77-94-1, Tributyl citrate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(preparation of mixed phase co-crystals with pharmaceuticals)


RN 77-89-4 CAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-tributyl ester (CA INDEX NAME)




RN 77-90-7 CAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-tributyl ester (CA INDEX NAME)



RN 77-94-1 CAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-tributyl ester (CA INDEX NAME)



IT 110-15-6, Succinic acid, biological studies 124-04-9, Adipic acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)  
 RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2005:540476 CAPLUS  
 DOCUMENT NUMBER: 143:65441  
 TITLE: Preparation of mixed phase co-crystals with  
 pharmaceuticals  
 INVENTOR(S): Goldman, David  
 PATENT ASSIGNEE(S): Medcrystalforms, LLC, USA  
 SOURCE: PCT Int. Appl., '78 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005055983	A2	20050623	WO 2004-US41500	20041209
WO 2005055983	A3	20070301		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2548281	A1	20050623	CA 2004-2548281	20041209
US 20050181041	A1	20050818	US 2004-8034	20041209
EP 1727520	A2	20061206	EP 2004-813765	20041209
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
JP 2007516259	T	20070621	JP 2006-544038	20041209
PRIORITY APPLN. INFO.:			US 2003-528232P	P 20031209
			US 2004-559862P	P 20040406
			WO 2004-US41500	W 20041209

AN 2005:540476 CAPLUS  
 DN 143:65441  
 ED Entered STN: 23 Jun 2005  
 TI Preparation of mixed phase co-crystals with pharmaceuticals  
 IN Goldman, David  
 PA Medcrystalforms, LLC, USA  
 SO PCT Int. Appl., '78 pp.

CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-00  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005055983	A2	20050623	WO 2004-US41500	20041209
	WO 2005055983	A3	20070301		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GR, ML, MR, NE, SN, TD, TG			
	CA 2548281	A1	20050623	CA 2004-2548281	20041209
	US 20050181041	A1	20050818	US 2004-8034	20041209
	EP 1727520	A2	20061206	EP 2004-813765	20041209
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007516259	T	20070621	JP 2006-544038	20041209
PRAI	US 2003-528232P	P	20031209		
	US 2004-559862P	P	20040406		
	WO 2004-US41500	W	20041209		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005055983	ICM	A61K009-00	
	IPCI	A61K0009-14 [I,C]; A61K0009-14 [I,A]	
	IPCR	A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-10 [N,C*]; A61K0009-10 [N,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]	
CA 2548281	ECLA	A61K009/14H4; A61K009/14H6; A61K009/14H8; K61K; K61K	
	IPCI	A61K0009-00 [I,A]	
US 20050181041	ECLA	A61K009/14H4; A61K009/14H6; A61K009/14H8	
	IPCI	A61K0031-56 [ICM,7]; A61K0038-00 [ICS,7]; A61K0009-64 [ICS,7]; A61K0009-52 [ICS,7,C*]	
	IPCR	A61K0009-52 [I,C*]; A61K0009-64 [I,A]; A61K0031-56 [I,A]; A61K0031-56 [I,C*]; A61K0038-00 [I,A]; A61K0038-00 [I,C*]	
EP 1727520	NCL	424/456.000; 514/002.000; 514/179.000; 514/221.000	
	IPCI	A61K0009-00 [I,A]	
	IPCR	A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0009-10 [N,C*]; A61K0009-10 [N,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]	
JP 2007516259	ECLA	A61K009/14H4; A61K009/14H6; A61K009/14H8	
	IPCI	A61K0047-38 [I,A]; A61K0047-26 [I,A]; A61K0047-06 [I,A]; A61K0047-36 [I,A]; A61K0047-32 [I,A]	
	IPCR	A61K0047-38 [I,C]; A61K0047-38 [I,A]; A61K0009-10 [N,C*]; A61K0009-10 [N,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]; A61K0047-06 [I,C]; A61K0047-06 [I,A]; A61K0047-26 [I,C]; A61K0047-26 [I,A]; A61K0047-32	

[I,C]; A61K0047-32 [I,A]; A61K0047-36 [I,C];  
A61K0047-36 [I,A]  
ECLA A61K009/14H4; A61K009/14H6; A61K009/14H8; K61K; K61K  
FTERM 4C076/AA54; 4C076/AA56; 4C076/BB01; 4C076/CC30;  
4C076/DD37; 4C076/DD60; 4C076/EE32A; 4C076/FF63;  
4C076/FF70; 4C076/GG50

- AB This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new phys./crystal form with unique properties useful for the delivery of the active agent, as well as compns. comprising the mixed phase co-crystals. Thus, a mixed phase co-crystal formulation contained itraconazole 5000, Steareth-20 2500, and Pluronic F 68 2500 mg, and soybean oil 100 mL.
- ST mixed phase cocrystal pharmaceutical
- IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(C16-18; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Glycerides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(C8-10, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Monoglycerides  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(acetates; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Glycerides, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(acetylated; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Sulfonic acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkanesulfonic; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Polyoxyalkylenes, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkyl group-terminated; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Phenols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkyl, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Glycosides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkyl; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Fats and Glyceridic oils, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(almond, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Solvents  
(antisolvents; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Drug delivery systems  
(capsules, soft; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Drug delivery systems  
(capsules; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Carbohydrates, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compressible; preparation of mixed phase co-crystals with pharmaceuticals)
- IT Fatty acids, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)  
 (esters; preparation of mixed phase co-crystals with pharmaceuticals)

IT Castor oil  
 Corn oil  
 Glycerides, biological studies  
 Olive oil  
 Palm kernel oil  
 Peanut oil  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty; preparation of mixed phase co-crystals with pharmaceuticals)

IT Castor oil  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (hydrogenated, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Encapsulation  
 (microencapsulation; preparation of mixed phase co-crystals with pharmaceuticals)

IT Antioxidants  
 Crystallinity  
 Molecular weight distribution  
 Solubility  
 Solvents  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Diglycerides  
 Fatty acids, biological studies  
 Polyoxyalkylenes, biological studies  
 Sterols  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Amino acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Bentonite, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Bile salts  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Coconut oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Corn oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Gelatins, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Kaolin, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Phospholipids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Soybean oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(preparation of mixed phase co-crystals with pharmaceuticals)

IT Tannins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of mixed phase co-crystals with pharmaceuticals)

IT Dissolution  
 (rate; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (salts; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (saturated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sesame; preparation of mixed phase co-crystals with pharmaceuticals)

IT Sterols  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (soya, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Carbohydrates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sugar esters; preparation of mixed phase co-crystals with pharmaceuticals)

IT Drug delivery systems  
 (tablets; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fatty acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (unsatd., esters; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (unsatd.; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (vegetable, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated, ethoxylated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (vegetable, transesterified; preparation of mixed phase co-crystals with pharmaceuticals)

IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (vegetable; preparation of mixed phase co-crystals with pharmaceuticals)

IT 9003-01-4D, crosslinked  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Carbomer; preparation of mixed phase co-crystals with pharmaceuticals)

IT 9004-34-6, Cellulose, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; preparation of mixed phase co-crystals with pharmaceuticals)

IT 94555-53-0, Pentaerythritol caprate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pentaerythritol caprate; preparation of mixed phase co-crystals with pharmaceuticals)

IT 50-21-5D, Lactic acid, conjugates with mono- and diglycerides 56-81-5, Glycerol, biological studies 56-87-1, L-Lysine, biological studies 57-55-6, Propylene glycol, biological studies 57-55-6D, Propylene glycol, esters 59-02-9 60-29-7, Ethyl ether, biological studies 64-17-5, Ethanol, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 67-63-0, Isopropanol, biological studies 67-64-1, 2-Propanone, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 71-23-8, 1-Propanol, biological studies 71-36-3, 1-Butanol, biological studies 71-41-0, 1-Pentanol, biological studies 74-79-3, L-Arginine, biological studies 75-75-2, Methanesulfonic acid 77-86-1 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-93-0, Triethyl citrate 77-94-1, Tributyl citrate 78-83-1, 2-Methyl-1-propanol, biological studies 78-92-2, 2-Butanol 78-93-3, Methyl ethyl ketone, biological studies 79-09-4, Propionic acid, biological studies 79-20-9, Methyl acetate 98-82-8, Cumene 100-51-6, Benzyl alcohol, biological studies 102-71-6, Biological studies 102-76-1, Triacetin 104-15-4, p-Toluenesulfonic acid, biological studies 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 106-32-1, Ethyl caprylate 108-10-1, Methyl isobutyl ketone 108-21-4, Isopropyl acetate 109-60-4, Propyl acetate 109-66-0, Pentane, biological studies 109-94-4, Ethyl formate 109-99-9, Tetrahydrofuran, biological studies 110-19-0, Isobutyl acetate 111-42-2, Biological studies 111-62-6, Ethyl oleate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 115-77-5, Pentaerythritol, biological studies 121-79-9, Propyl gallate 123-51-3, 3-Methyl-1-butanol 123-86-4, Butyl acetate 128-37-0, Butylated hydroxytoluene, biological studies 137-66-6 141-43-5, biological studies 141-78-6, Ethyl acetate, biological studies 142-82-5, Heptane, biological studies 143-07-7, Lauric acid, biological studies 144-55-8, Sodium bicarbonate, biological studies 298-14-6, Potassium bicarbonate 463-79-6, Carbonic acid, biological studies 497-19-8, Sodium carbonate, biological studies 584-08-7, Potassium carbonate 616-45-5, 2-Pyrrolidone 616-45-5D, Pyrrolidone, hydroxyalkyl derivs. 623-84-7, Propylene glycol diacetate 675-20-7, 2-Piperidone 1066-33-7, Ammonium bicarbonate 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1335-71-3, Propylene glycol oleate 1338-39-2, Sorbitan monolaurate 1338-43-8, Sorbitan monooleate 1634-04-4, tert-Butylmethyl ether 3416-24-8 5306-85-4, Dimethyl isosorbide 6915-15-7, Malic acid 7647-01-0, Hydrochloric acid, biological studies 7664-38-2, Phosphoric acid, biological studies 7664-41-7, Ammonia, biological studies 9004-74-4, Methoxy polyethylene glycol 9004-96-0, Polyethylene glycol oleate 9005-02-1, Polyethylene glycol dilaurate 9005-07-6, Polyethylene glycol dioleate 9005-08-7, Polyethylene glycol distearate 9005-63-4D, Polyoxyethylene sorbitan, esters with fatty acids 9007-48-1, Polyglyceryl oleate 12441-09-7D, Sorbitan, esters with fatty acids 25013-16-5, Butylated hydroxyanisole 25265-75-2, Butanediol 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 25322-69-4D, Polypropylene glycol, esters with fatty acids 25496-72-4, Glyceryl monooleate 25618-55-7D, Polyglycerol, esters with fatty acids 25637-84-7, Glyceryl dioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 27215-38-9, Glyceryl monolaurate 27638-00-2, Glyceryl dilaurate 31692-85-0, Glycofurol 35296-72-1, Butanol 36354-80-0, Glyceryl dicaprylate 37318-31-3, Crodesta F 160 37321-62-3, Propylene glycol laurate 53988-07-1, Glyceryl dicaprate 106392-12-5 146478-45-7, Polyglyceryl

dioleate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(preparation of mixed phase co-crystals with pharmaceuticals)

IT 50-21-5, Lactic acid, biological studies 50-70-4, Sorbitol, biological studies 50-70-4D, Sorbitol, esters 50-81-7, Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, biological studies 57-88-5, Cholesterol, biological studies 63-42-3, Lactose 65-85-0, Benzoic acid, biological studies 68-11-1, Thioglycolic acid, biological studies 69-65-8, D-Mannitol 69-72-7, Salicylic acid, biological studies 69-93-2, Uric acid, biological studies 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 88-46-0, Hydroquinonesulfonic acid 89-65-6, IsoAscorbic acid 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 115-77-5D, Pentaerythritol, esters 115-83-3, Pentaerythritol tetrastearate 124-04-9, Adipic acid, biological studies 138-36-3, p-Bromophenylsulfonic acid 142-91-6, Isopropyl palmitate 144-62-7, Oxalic acid, biological studies 526-95-4, D-Gluconic acid 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 546-93-0, Magnesium carbonate 585-88-6, Maltitol 1309-48-4, Magnesium oxide, biological studies 1327-43-1, Magnesium aluminum silicate 1338-41-6, Sorbitan monostearate 7631-86-9, Silica, biological studies 7778-18-9, Calcium sulfate 8007-43-0, Sorbitan sesquioleate 9002-96-4 9003-39-8, Povidone 9004-53-9, Dextrans 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9004-81-3, Polyethylene glycol laurate 9004-95-9, Polyethylene glycol cetyl ether 9004-98-2, Polyethylene glycol oleyl ether 9004-99-3, Polyethylene glycol stearate 9005-00-9, Polyethylene glycol stearyl ether 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9005-82-7, Amylose 9009-32-9, Polyglyceryl stearate 9011-21-6, Polyethylene glycol glyceryl stearate 9011-29-4, Polyethylene glycol sorbitan hexastearate 9036-19-5, Polyethylene glycol octylphenyl ether 9050-36-6, Maltodextrin 9062-73-1, Polyethylene glycol sorbitan laurate 9063-38-1, Sodium starch glycolate 10043-35-3, Boric acid, biological studies 10103-46-5, Calcium phosphate 12619-70-4, Cyclodextrin 12772-47-3, Pentaerythritol oleate 13081-97-5, Pentaerythritol distearate 14807-96-6, Talc, biological studies 18641-57-1, Compritol 888ATO 22882-95-7, Isopropyl linoleate 25168-73-4, Sucrose monostearate 25339-99-5, Sucrose monolaurate 25637-97-2, Sucrose dipalmitate 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate 27195-16-0, Sucrose distearate 27321-96-6, Polyethylene glycol cholesteryl ether 36928-92-4 37353-59-6, Hydroxymethyl cellulose 51938-44-4, Sorbitan sesquistearate 54392-26-6, Sorbitan monoisostearate 57307-93-4, Pentaerythritol caprylate 59070-56-3 61725-93-7, Polyglyceryl distearate 64044-51-5 67660-31-5 68958-64-5, Polyethylene glycol glyceryl trioleate 69070-98-0, Polyoxethylene sorbitan tetraoleate 74504-64-6, Polyglyceryl laurate 74811-65-7, Croscarmellose sodium 83138-62-9, Polyglyceryl isostearate 98913-68-9, Pentaerythritol isostearate 110540-43-7, Polyglyceryl pentaoleate 121548-04-7, Gelucire 44/14 354575-58-9, Polyethylene glycol sorbitan tetrastearate 403821-12-5, Polyglyceryl trioleate 691397-13-4, Pluronic 854602-44-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of mixed phase co-crystals with pharmaceuticals)


L7 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
IT 88-99-3, Phthalic acid, biological studies 110-15-6,  
Succinic acid, biological studies 110-15-6D, Succinic acid,  
salts 124-04-9, Adipic acid, biological studies  
124-04-9D, Adipic acid, salts  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treatment of SARS by using low-pH respiratory tract compns.)  
RN 88-99-3 CAPLUS  
CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)




RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2004:1019496 CAPLUS  
DOCUMENT NUMBER: 141:428038  
TITLE: Treatment of SARS by using low-pH respiratory tract  
compositions  
INVENTOR(S): Rennie, Paul John; De La Harpe, Shane Michael;  
Khanolkar, Jayant Ekanth; Mullet, Benoit Maurice  
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S.  
Ser. No. 692,634.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 27

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040234457	A1	20041125	US 2004-770138	20040202
CA 2554975	A1	20050818	CA 2005-2554975	20050201
WO 2005074990	A2	20050818	WO 2005-US3172	20050201
WO 2005074990	A3	20060713		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1711161	A2	20061018	EP 2005-722661	20050201
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
PRIORITY APPLN. INFO.:			US 1999-421131	B2 19991019
			US 2000-692634	A2 20001019
			US 2004-770138	A 20040202
			WO 2005-US3172	W 20050201
AN 2004:1019496	CAPLUS			
DN 141:428038				
ED Entered STN:	26 Nov 2004			
TI Treatment of SARS by using low-pH respiratory tract compositions				
IN Rennie, Paul John; De La Harpe, Shane Michael; Khanolkar, Jayant Ekanth; Mullet, Benoit Maurice				
PA The Procter & Gamble Company, USA				
SO U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 692,634.				
CODEN: USXXCO				
DT Patent				
LA English				
IC ICM A61K009-04				
ICS A61K009-14; A61K033-24				
INCL 424046000				
CC 63-6 (Pharmaceuticals)				
FAN.CNT 27				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040234457	A1	20041125	US 2004-770138	20040202
CA 2554975	A1	20050818	CA 2005-2554975	20050201
WO 2005074990	A2	20050818	WO 2005-US3172	20050201
WO 2005074990	A3	20060713		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1711161	A2	20061018	EP 2005-722661	20050201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
BA, HR, IS, YU

PRAI US 1999-421131 B2 19991019  
US 2000-692634 A2 20001019  
US 2004-770138 A 20040202  
WO 2005-US3172 W 20050201

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004023445/	ICM	A61L009-04
	ICS	A61K009-14; A61K033-24
	INCL	424046000
	IPCI	A61L0009-04 [ICM,7]; A61K0009-14 [ICS,7]; A61K0033-24 [ICS,7]
	IPCR	A01N0043-34 [I,C*]; A01N0043-36 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-315 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0036-185 [I,C*]; A61K0036-31 [I,A]; A61K0036-81 [I,A]; A61K0036-88 [I,C*]; A61K0036-8962 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
	NCL	424/046.000
	ECLA	A01N043/36; A01N043/36+M; A61K008/02C; A61K008/49C2; A61K031/19+M; A61K031/28+M; A61K031/315+M; A61K033/24+M; A61K033/30+M; A61K045/06; A61Q017/00; D21H021/36
CA 2554975	IPCI	A61K0009-00 [I,A]; A61K0031-19 [I,A]; A61K0031-185 [I,C*]; A61K0031-28 [I,A]; A61K0033-24 [I,A]; A61K0033-30 [I,A]; A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0031-14 [I,A]; A61P0031-00 [I,C*]
	IPCR	A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0031-28 [I,C]; A61K0031-28 [I,A]; A61K0033-24 [I,C]; A61K0033-24 [I,A]; A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0031-00 [I,C]; A61P0031-14 [I,A]
	ECLA	A61K009/00M14; A61K031/19+M; A61K031/28+M; A61K033/24+M; A61K033/24; A61K033/30+M; A61K033/30; A61K045/06
WO 2005074990	IPCI	A61K0009-00 [I,C]; A61K0031-185 [I,C]; A61K0031-28 [I,C]; A61K0033-24 [I,C]; A61K0033-30 [I,C]; A61K0045-00 [I,C]; A61P0031-00 [I,C]; A61K0009-00 [I,A]; A61K0031-19 [I,A]; A61K0031-28 [I,A]; A61K0033-24 [I,A]; A61K0033-30 [I,A]; A61K0045-06 [I,A]; A61P0031-14 [I,A]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	ECLA	A61K009/00M14; A61K031/19+M; A61K031/28+M; A61K033/24+M; A61K033/24; A61K033/30+M; A61K033/30; A61K045/06
EP 1711161	IPCI	A61K0009-00 [ICM,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61K0033-30 [ICS,7]; A61K0033-24 [ICS,7];

A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C\*];  
A61K0031-28 [ICS,7]; A61P0031-14 [ICS,7]; A61P0031-00  
[ICS,7,C\*]

IPCR A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0031-185  
[I,C]; A61K0031-19 [I,A]; A61K0031-28 [I,C];  
A61K0031-28 [I,A]; A61K0033-24 [I,C]; A61K0033-24  
[I,A]; A61K0033-30 [I,C]; A61K0033-30 [I,A];  
A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0031-00  
[I,C]; A61P0031-14 [I,A]

ECLA A61K009/00M14; A61K031/19+M; A61K031/28+M;  
A61K033/24+M; A61K033/24; A61K033/30+M; A61K033/30;  
A61K045/06

AB The present invention is directed to methods of preventing and treating  
severe acute respiratory syndrome (SARS) by the administration of  
respiratory tract compns. having low pH values. The respiratory tract  
compns. have a pH of 3.0-5.5, and are preferably administered to areas of  
the respiratory tract such as the nasal cavity to effectively prevent and  
treat respiratory tract viral infections, particularly SARS. The  
respiratory tract compns. comprise an organic acid in combination with a  
metal compound. Thus, a formulation contained pyroglutamic acid 0.35,  
succinic acid 1.00, zinc acetate dihydrate 0.12, zinc-EDTA 0.255,  
Polysorbate-80 0.05, hydroxypropyl Me cellulose 1.20, sucralose 0.025,  
phenylethyl alc. 0.37, sodium chloride 0.20, Sensate Mix A 0.067, disodium  
succinate 1.00, and water qs to 100%.

ST SARS respiratory tract metal salt; pH low SARS respiratory tract metal  
salt

IT Infection  
Respiratory system, disease  
(SARS (severe acute respiratory syndrome); treatment of SARS by using  
low-pH respiratory tract compns.)

IT Drug delivery systems  
(aerosols, inhalants; treatment of SARS by using low-pH respiratory  
tract compns.)

IT Vinyl compounds, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(carboxy-containing, polymers; treatment of SARS by using low-pH  
respiratory tract compns.)

IT Drug delivery systems  
(nasal sprays; treatment of SARS by using low-pH respiratory tract  
compns.)

IT Drug delivery systems  
(nasal; treatment of SARS by using low-pH respiratory tract compns.)

IT Drug delivery systems  
(powders, inhalants; treatment of SARS by using low-pH respiratory  
tract compns.)

IT Drug delivery systems  
(powders, nasal; treatment of SARS by using low-pH respiratory tract  
compns.)

IT pH  
(treatment of SARS by using low-pH respiratory tract compns.)

IT Carboxylic acids, biological studies  
Chlorides, biological studies  
Fluorides, biological studies  
Iodides, biological studies  
Metals, biological studies  
Nitrates, biological studies  
Phosphates, biological studies  
Polymers, biological studies  
Polyoxyalkylenes, biological studies  
Sulfates, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of SARS by using low-pH respiratory tract compns.)

IT Respiratory system  
(upper respiratory tract; treatment of SARS by using low-pH respiratory tract compns.)

IT 1310-73-2, Sodium hydroxide, processes 1336-21-6, Ammonium hydroxide  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)  
(treatment of SARS by using low-pH respiratory tract compns.)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts  
50-81-7, Ascorbic acid, biological studies 50-81-7D, Ascorbic acid, salts  
56-40-6D, Glycine, salts 56-81-5, Glycerol, biological studies  
56-84-8, Aspartic acid, biological studies 56-84-8D, Aspartic acid, salts  
56-86-0, Glutamic acid, biological studies 57-50-1D, Sucrose, allyl ether derivs., polymers with acrylic acid 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 64-19-7D, Acetic acid, salts  
65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, salts  
68-04-2, Sodium citrate 69-72-7, Salicylic acid, biological studies  
69-72-7D, Salicylic acid, salts 77-92-9, Citric acid, biological studies  
77-92-9D, Citric acid, salts 79-10-7D, Acrylic acid, polymers with pentaerythritol/sucrose allyl ethers 79-14-1, Glycolic acid, biological studies 79-14-1D, Glycolic acid, salts  
87-69-4, Tartaric acid, biological studies 87-69-4D, Tartaric acid, salts 88-99-3, Phthalic acid, biological studies 98-79-3, Pyroglutamic acid 98-79-3D, Pidolic acid, salts 102-71-6, Triethanolamine, biological studies 110-15-6, Succinic acid, biological studies 110-15-6D, Succinic acid, salts 110-16-7D, Maleic acid, salts 110-17-8, Fumaric acid, biological studies 110-17-8D, Fumaric acid, salts 110-94-1, Glutaric acid 110-94-1D, Glutaric acid, salts 111-90-0, Transcutol 115-77-5D, Pentaerythritol, allyl ether derivs., polymers with acrylic acid 124-04-9, Adipic acid, biological studies 124-04-9D, Adipic acid, salts 141-82-2, Malonic acid, biological studies 141-82-2D, Malonic acid, salts 144-55-8, Sodium bicarbonate, biological studies 147-93-3D, Thiosalicylic acid, salts 150-90-3, Disodium succinate 526-95-4, D-Gluconic acid 526-95-4D, D-Gluconic acid, salts 557-34-6, Zinc acetate 5970-45-6, Zinc acetate dihydrate 6915-15-7, Malic acid 6915-15-7D, Malic acid, salts 7632-05-5, Sodium phosphate 9000-11-7, Carboxymethyl cellulose 9000-11-7D, Carboxymethyl cellulose, salts 9003-01-4, Polyacrylic acid 9003-39-8, Polyvinylpyrrolidone 9004-34-6D, Cellulose, derivs. 9004-54-0, Dextran, biological studies 9004-58-4, Ethyl hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9011-16-9, Maleic anhydride-methyl vinyl ether copolymer 12773-27-2, Sodium tin oxide 25322-68-3, Polyethylene glycol 73038-24-1, Acrylic acid-divinyl glycol copolymer 106392-12-5, Poloxamer 138757-67-2, Carbopol 980  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treatment of SARS by using low-pH respiratory tract compns.)

L7 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, processes 124-04-9, Adipic acid, processes  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)  
(morphine controlled release system)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)



HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2004:817682 CAPLUS  
DOCUMENT NUMBER: 141:307480  
TITLE: Morphine controlled release system  
INVENTOR(S): Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Jensen, Christine  
PATENT ASSIGNEE(S): Egalet A/S, Den.  
SOURCE: PCT Int. Appl., 100 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004084868	A1	20041007	WO 2004-DK215	20040326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1610767	A1	20060104	EP 2004-723522	20040326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
US 20070003617	A1	20070104	US 2005-550453	20050926
PRIORITY APPLN. INFO.:			DK 2003-463	A 20030326
			WO 2004-DK215	W 20040326

AN 2004:817682 CAPLUS  
DN 141:307480  
ED Entered STN: 07 Oct 2004  
TI Morphine controlled release system  
IN Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Jensen, Christine  
PA Egalet A/S, Den.  
SO PCT Int. Appl., 100 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K009-22  
CC 1-2 (Pharmacology)  
Section cross-reference(s): 63, 64  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004084868	A1	20041007	WO 2004-DK215	20040326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,			

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

EP 1610767 A1 20060104 EP 2004-723522 20040326  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
 US 20070003617 A1 20070104 US 2005-550453 20050926  
 PRAI DK 2003-463 A 20030326  
 WO 2004-DK215 W 20040326

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004084868	ICM	A61K009-22
	IPCI	A61K0009-22 [ICM,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]
	ECLA	A61K009/00Z4; A61K031/485
EP 1610767	IPCI	A61K0009-22 [ICM,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]
	ECLA	A61K009/00Z4; A61K031/485
US 20070003617	IPCI	A61K0009-22 [I,A]; A61K0031-485 [I,A]
	NCL	424/468.000; 514/282.000
	ECLA	A61K009/00Z4; A61K031/485

AB A composition for controlled release of an opioid from a pharmaceutical composition,  
 the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising a matrix composition comprising (a) polymer or a mixture of  
 polymers, (b) an opioid and, optionally, (c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissoln. of the opioid-when tested in a Dissoln. Test as described herein with or without application of sinkers-results in a zero order release of at least 80% of the opioid contained in the composition Such compns. are especially suitable  
 for controlled release of an opioid to obtain a delayed peak concentration and  
 a prolonged therapeutically effective plasma concentration upon oral administration. Once or twice daily administration is possible. The matrix typically comprises PEO and the active substance is typically an opioid such as morphine or a glucuronide thereof.  
 ST morphine controlled release system opioid  
 IT Drug delivery systems  
 (controlled-release; morphine controlled release system)  
 IT Acacia  
 Analgesics  
 Blood analysis  
 Dizziness  
 Drug bioavailability

Extracellular matrix  
 Gums and Mucilages  
 Human  
 Molasses  
 Moss  
 Nausea  
 Pain  
 Sedation  
 Urine  
 Vomiting  
 (morphine controlled release system)

IT Alkali metal salts  
 Alkaline earth metals  
 Clays, processes  
 Fatty acids, processes  
 Gelatins, processes  
 Polyoxyalkylenes, processes  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)  
 (morphine controlled release system)

IT Opioids  
 RL: PKT (Pharmacokinetics); BIOL (Biological study)  
 (morphine controlled release system)

IT Alkaloids, biological studies  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (opium, hydrochlorides; morphine controlled release system)

IT Natural products, pharmaceutical  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (opium; morphine controlled release system)

IT Drug delivery systems  
 (oral; morphine controlled release system)

IT Drug delivery systems  
 (powders; morphine controlled release system)

IT Fats and Glyceridic oils, processes  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)  
 (vegetable, hydrogenated; morphine controlled release system)

IT Fats and Glyceridic oils, processes  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)  
 (vegetable; morphine controlled release system)

IT 57-27-2, Morphine, biological studies 57-42-1, Meperidine 62-67-9, Nalorphine 64-39-1, Promedol 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-58-4, Ethylmorphine 76-99-3, Methadone 77-07-6, Levorphanol 77-14-5, Propheptazine 77-15-6, Ethoheptazine 77-20-3, Alphaprodine 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 127-35-5, Phenazocine 131-28-2, Narceine 143-52-2, Metopon 144-14-9, Anileridine 152-02-3, Levallorphan 302-41-0, Piritramide 357-56-2, Dextromoramide 359-83-1, Pentazocine 427-00-9, Desomorphine 437-38-7, Fentanyl 441-61-2, Ethylmethylthiambutene 466-40-0, Isomethadone 466-97-7, Normorphine 466-99-9, Hydromorphone 467-18-5, Myrophine 467-83-4, Dipipanone 467-84-5, Phenadoxone 467-85-6, Normethadone 467-86-7, Dioxaphetyl butyrate 468-07-5, Phenomorphan 468-56-4, Hydroxypethidine 469-62-5, Dextropropoxyphene 469-79-4, Ketobemidone 509-60-4, Dihydromorphine 509-78-4, Dimenoxadol 524-84-5, Dimethylthiambutene 545-90-4 561-27-3, Heroin 561-48-8, Norpipanone 561-76-2, Properidine 562-26-5, Phenoperidine 639-48-5, Nicomorphine 911-65-9, Etonitazene 1531-12-0, Norlevorphanol 3572-80-3, Cyclazocine 3734-52-9, Metazocine 3861-76-5, Clonitazene

10061-32-2, Levophenacylmorphan 13495-09-5, Piminodine 14297-87-1, Benzylmorphine 15301-48-1, Bezitramide 15686-91-6, Propiram 20290-09-9, Morphine 3-glucuronide 20290-10-2, Morphine 6-glucuronide 20594-83-6, Nalbuphine 25384-17-2, Allylprodine 27203-92-5, Tramadol 42408-82-2, Butorphanol 51931-66-9, Tilidine 52485-79-7, Buprenorphine 53648-55-8, Dexocine 54340-58-8, Meptazinol 56030-54-7 61380-40-3, Lofentanil 71195-58-9, Alfentanil 72522-13-5, Eptazocine

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(morphine controlled release system)

- IT 50-21-5, Lactic acid, processes 50-70-4, Sorbitol, processes 50-81-7, Ascorbic acid, processes 50-99-7, Dextrose, processes 56-81-5, Glycerin, processes 56-84-8, L-Aspartic acid, processes 56-86-0, L-Glutamic acid, processes 57-03-4, Glycerophosphoric acid 57-11-4, Stearic acid, processes 57-48-7, D-Fructose, processes 57-50-1, Sucrose, processes 58-86-6, D-Xylose, processes 59-23-4, D-Galactose, processes 62-54-4, Calcium acetate 63-42-3, Lactose 64-18-6, Formic acid, processes 64-19-7, Acetic acid , processes 65-42-9, Lyxose 65-85-0, Benzoic acid, processes 68-04-2, Sodium citrate 69-65-8, Mannitol 75-15-0, Carbon disulfide, processes 75-21-8, Ethylene oxide, processes 75-56-9, Propylene oxide, processes 77-86-1, Tris(hydroxymethyl)aminomethane 77-92-9, Citric acid, processes 79-10-7, Acrylic acid, processes 79-14-1, Glycolic acid, processes 87-69-4, Tartaric acid, processes 90-64-2, Mandelic acid 98-10-2, Benzenesulfonamide 98-95-3, Nitrobenzene, processes 100-02-7, p-Nitrophenol, processes 109-97-7, Pyrrole 110-15-6, Succinic acid, processes 110-16-7, Maleic acid, processes 110-17-8, Fumaric acid, processes 110-94-1, Glutaric acid 111-16-0, Pimelic acid 111-42-2, Diethanolamine, processes 123-56-8, Succinimide 123-76-2, Levulinic acid 124-04-9, Adipic acid, processes 127-08-2, Potassium acetate 127-09-3, Sodium acetate 127-17-3, Pyruvic acid, processes 140-99-8, Calcium succinate 141-82-2, Malonic acid, processes 144-55-8, Sodium hydrogen carbonate, processes 144-62-7, Oxalic acid, processes 147-81-9, Arabinose 149-91-7, Gallic acid, processes 150-90-3, Sodium succinate 288-32-4, Imidazole, processes 298-12-4, Glyoxylic acid 298-14-6 302-01-2, Hydrazine, processes 463-77-4, Carbamic acid, processes 471-34-1, Calcium carbonate, processes 471-47-6, Oxamic acid 473-81-4, Glyceric acid 490-79-9, Gentisic acid 497-19-8, Sodium carbonate, processes 506-87-6, Ammonium carbonate 546-93-0, Magnesium carbonate 557-04-0, Magnesium stearate 565-63-9, Angelic acid 584-08-7, Potassium carbonate 593-67-9, Ethylenamine 597-44-4, Citramalic acid 613-78-5,  $\beta$ -Naphthyl salicylate 621-82-9, Cinnamic acid, processes 866-83-1, Potassium citrate 921-53-9, Potassium tartrate 1310-58-3, Potassium hydroxide, processes 1310-73-2, Sodium hydroxide, processes 1336-21-6, Ammonium hydroxide 1344-28-1, Aluminum oxide, processes 1592-23-0, Calcium stearate 1724-02-3, Glutaconic acid 2152-76-3, Idoe 2466-09-3, Pyrophosphoric acid 3164-34-9, Calcium tartrate 3458-28-4, D-Mannose 5987-68-8, Altrose 6038-51-3, Allose 6915-15-7, Malic acid 6917-35-7, Inositol 7429-90-5, Aluminum, processes 7447-40-7, Potassium chloride, processes 7558-80-7, Sodium dihydrogen phosphate 7601-54-9, Sodium phosphate 7647-01-0, Hydrochloric acid, processes 7647-14-5, Sodium chloride, processes 7664-38-2, Phosphoric acid, processes 7664-93-9, Sulfuric acid, processes 7693-13-2, Calcium citrate 7757-82-6, Sodium sulfate, processes 7757-93-9 7778-18-9, Calcium sulfate 7778-53-2, Potassium phosphate 7778-77-0, Potassium dihydrogen phosphate 7778-80-5, Potassium sulfate, processes 7786-30-3, Magnesium chloride, processes 7803-49-8, Hydroxylamine, processes 9000-69-5, Pectin 9002-18-0, Agar 9003-11-6 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, processes 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-48-2,

Cellulose propionate 9004-53-9, Dextrin 9004-54-0, Dextran, processes 9004-57-3, Ethyl cellulose 9004-58-4, Ethylhydroxyethyl cellulose 9004-59-5, Ethylmethylcellulose 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropylmethyl cellulose 9004-67-5, Methyl cellulose 9004-70-0, Cellulose nitrate 9004-99-3, Polyethylene glycol 400 monostearate 9005-25-8, Starch, processes 9005-32-7, Alginic acid 9005-35-0, Calcium alginate 9005-38-3, Sodium alginate 9005-82-7, Amylose 9014-63-5, Xylan 9032-42-2, Hydroxyethylmethyl cellulose 9037-22-3, Amylopectin 10043-35-3, Boric acid, processes 10043-52-4, Calcium chloride, processes 10316-66-2, 2-Hydroxy-2-cyclohexenone 12408-02-5, Hydrogen ion, processes 13463-67-7, Titanium dioxide, processes 14475-11-7, Sodium tartrate 14807-96-6, Talc, processes 19163-87-2, Glucose 21645-51-2, Aluminum oxide trihydrate, processes 22445-04-1 25322-68-3, Polyethylene glycol 30077-17-9, Talose 37353-59-6, Hydroxymethylcellulose 62212-91-3, Sodium starch 69670-80-0, Hydroxymethylpropyl cellulose 199915-32-7 443360-37-0  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)

(morphine controlled release system)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Bar-Shalom, D; WO 03024426 A 2003 CAPLUS
- (2) Bar-Shalom, D; WO 03024429 A 2003 CAPLUS
- (3) Bar-Shalom, D; WO 03024430 A 2003 CAPLUS
- (4) Bar Shalom, D; WO 9522962 A 1995 CAPLUS
- (5) Bukh Meditec; EP 0746310 A 1996 CAPLUS
- (6) Hoffmann La Roche; WO 0174357 A 2001 CAPLUS

L7 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 100-42-5, Styrene, biological studies 117-81-7,  
 Ethylhexyl phthalate  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (characterization of skin penetration processes of organic mols. using mol. similarity and QSAR anal.)


RN 100-42-5 CAPLUS

CN Benzene, ethenyl- (CA INDEX NAME)

$H_2C=CH-Ph$

RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



ACCESSION NUMBER:

2004:795415 CAPLUS

DOCUMENT NUMBER:

141:420033

TITLE:

Characterization of Skin Penetration Processes of Organic Molecules Using Molecular Similarity and QSAR

Analysis

AUTHOR(S): Santos-Filho, Osvaldo A.; Hopfinger, A. J.; Zheng, Tao

CORPORATE SOURCE: Laboratory of Molecular Modeling and Design, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL, 60612-7231, USA

SOURCE: Molecular Pharmaceutics (2004), 1(6), 466-476  
CODEN: MPOHBP; ISSN: 1543-8384

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AN 2004:795415 CAPLUS

DN 141:420033

ED Entered STN: 30 Sep 2004

TI Characterization of Skin Penetration Processes of Organic Molecules Using Molecular Similarity and QSAR Analysis

AU Santos-Filho, Osvaldo A.; Hopfinger, A. J.; Zheng, Tao

CS Laboratory of Molecular Modeling and Design, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL, 60612-7231, USA

SO Molecular Pharmaceutics (2004), 1(6), 466-476  
CODEN: MPOHBP; ISSN: 1543-8384

PB American Chemical Society

DT Journal

LA English

CC 1-3 (Pharmacology)

Section cross-reference(s): 2

AB Mol. similarity and QSAR analyses have been used to develop compact, robust, and definitive models for skin penetration by organic compds. The QSAR models have been sought to provide an interpretation and characterization of plausible mol. mechanisms of skin penetration. A training set of 40 structurally diverse compds. were selected to be representative of a parent set of 152 compds. in terms of both structural diversity and range in measured skin penetration. The subset of 40 compds. was used in a series of QSAR analyses in the search for the most significant, compact, and straightforward skin penetration QSAR models. Mol. dynamics simulations were employed to determine a set of MI (membrane-interaction) descriptors for each test compound (solute) interacting with a model DMPC monolayer membrane model. The MI-QSAR models may capture features of cellular membrane lateral transverse transport involved in the overall skin penetration process by organic compds. An addnl. set of intramol. solute descriptors, the non-MI-QSAR descriptors, were computed and added to the trial pool of descriptors for building QSAR models. All QSAR models were constructed using multidimensional linear regression fitting and a genetic algorithm optimization function. QSAR models were constructed using only non-MI-QSAR descriptors and using a combination of both these descriptor sets. It was found that a combination of non-MI-QSAR and MI-QSAR descriptors yielded the optimum models, not only with respect to the statistical measures of fit but also regarding model predictivity.

ST skin penetration QSAR

IT QSAR (quantitative structure-activity relationship)

Simulation and Modeling

Skin

(characterization of skin penetration processes of organic mols. using mol. similarity and QSAR anal.)

IT Biological transport

(permeation; characterization of skin penetration processes of organic mols. using mol. similarity and QSAR anal.)

IT Structure-activity relationship

(transport-affecting; characterization of skin penetration processes of organic mols. using mol. similarity and QSAR anal.)

IT 50-00-0, Formaldehyde, biological studies 50-02-2, Dexamethasone

50-06-6, Phenobarbital, biological studies 50-22-6, Corticosterone  
 50-23-7, Hydrocortisone 50-27-1, Estriol 50-28-2, Estradiol,  
 biological studies 51-34-3, Scopolamine 51-55-8, Atropine, biological  
 studies 52-39-1, Aldosterone 53-06-5, Cortisone 53-16-7, Estrone,  
 biological studies 53-86-1, Indometacin 54-11-5, Nicotine 55-63-0,  
 Nitroglycerine 57-27-2, Morphine, biological studies 57-42-1,  
 Meperidine 57-43-2, Amobarbital 57-44-3, Barbitol 57-50-1,  
 Sucrose, biological studies 57-83-0, Progesterone, biological  
 studies 58-08-2, Caffeine, biological studies 58-22-0, Testosterone  
 60-12-8, 2-Phenylethanol 60-29-7, Diethyl ether, biological studies  
 60-34-4, Monomethylhydrazine 62-53-3, Aniline, biological studies  
 64-17-5, Ethanol, biological studies 64-19-7, Acetic  
 acid, biological studies 64-85-7, Cortexone 67-56-1, Methanol,  
 biological studies 67-68-5, Dimethyl sulfoxide, biological studies  
 67-72-1, Hexachloroethane 68-12-2, Dimethylformamide, biological studies  
 68-96-2, 17-Hydroxyprogesterone 69-72-7, Salicylic acid, biological  
 studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol,  
 biological studies 71-41-0, n-Pentanol, biological studies 71-43-2,  
 Benzene, biological studies 71-55-6, 1,1,1-Trichloroethane 71-63-6,  
 Digitoxin 75-09-2, Methylene chloride, biological studies 75-31-0,  
 Isopropylamine, biological studies 75-56-9, Propylene oxide, biological  
 studies 76-57-3, Codeine 77-28-1, Butobarbital 78-83-1, Isobutanol,  
 biological studies 78-93-3, Butanone, biological studies 79-09-4,  
 Propionic acid, biological studies 79-10-7, Acrylic  
 acid, biological studies 79-41-4, Methylacrylic acid, biological  
 studies 88-04-0, 4-Chloro-3,5-xylene 88-06-2, 2,4,6-Trichlorophenol  
 89-83-8, Thymol 90-89-1, Diethylcarbamazine 95-48-7, 2-Cresol,  
 biological studies 95-53-4, biological studies 95-57-8, 2-Chlorophenol  
 95-65-8, 3,4-Xylene 96-33-3, Methyl acrylate 96-48-0,  
 gamma-Butyrolactone 99-76-3, Methyl 4-Hydroxybenzoate 100-02-7,  
 4-Nitrophenol, biological studies 100-41-4, Ethylbenzene, biological  
 studies 100-42-5, Styrene, biological studies 100-51-6, Benzyl  
 alcohol, biological studies 100-52-7, Benzaldehyde, biological studies  
 100-66-3, Anisole, biological studies 106-41-2, 4-Bromophenol  
 106-44-5, 4-Cresol, biological studies 106-48-9, 4-Chlorophenol  
 106-89-8, Epichlorohydrin, biological studies 107-06-2, Ethylene  
 dichloride, biological studies 107-13-1, Acrylonitrile, biological  
 studies 107-18-6, Allyl alcohol, biological studies 107-21-1, Ethylene  
 glycol, biological studies 107-87-9, 2-Pentanone 107-92-6, Butyric  
 acid, biological studies 108-05-4, Vinyl acetate, biological studies  
 108-11-2, 4-Methyl-2-pentanol 108-32-7, Propylene carbonate 108-38-3,  
 biological studies 108-39-4, biological studies 108-46-3, Resorcinol,  
 biological studies 108-88-3, Toluene, biological studies 108-94-1,  
 Cyclohexanone, biological studies 108-95-2, Phenol, biological studies  
 109-52-4, Pentanoic acid, biological studies 109-86-4, Methyl Cellulosolve  
 109-89-7, Diethylamine, biological studies 109-94-4, Ethyl formate  
 110-43-0, 2-Heptanone 110-80-5, 2-Ethoxyethanol 110-91-8, Morpholine,  
 biological studies 111-14-8, Heptanoic acid 111-27-3, n-Hexanol,  
 biological studies 111-70-6, n-Heptanol 111-76-2, 2-Butoxyethanol  
 111-87-5, n-Octanol, biological studies 112-30-1, 1-Decanol 113-92-8  
 117-81-7, Ethylhexyl phthalate 119-65-3, Isoquinoline  
 120-80-9, Catechol, biological studies 120-83-2, 2,4-Dichlorophenol  
 121-44-8, Triethylamine, biological studies 121-69-7,  
 N,N-Dimethylaniline, biological studies 122-60-1, Phenyl glycidyl ether  
 123-07-9, 4-Ethylphenol 123-51-3, Isoamyl alcohol 124-07-2, Octanoic  
 acid, biological studies 126-33-0, Sulfolane 127-19-5,  
 Dimethylacetamide 135-19-3, 2-Naphthol, biological studies 137-58-6,  
 Lidocaine 140-88-5, Ethyl acrylate 141-32-2, Butyl acrylate  
 142-62-1, Hexanoic acid, biological studies 143-08-8, 1-Nonanol  
 145-13-1, Pregnenolone 152-58-9, Cortexolone 299-42-3, Ephedrine  
 356-12-7, Fluocinonide 437-38-7, Fentanyl 466-99-9, Hydromorphone

513-85-9, 2,3-Butanediol 542-75-6, 1,3-Dichloropropene 554-84-7,  
 3-Nitrophenol 591-78-6, 2-Hexanone 630-60-4, Ouabain 872-50-4,  
 n-Methyl-2-pyrrolidone, biological studies 1570-64-5, 4-Chloro-o-cresol  
 2203-97-6, Hydrocortisone 21-hemisuccinate 3593-96-2, Hydrocortisone  
 21-hexanoate 6677-98-1, Hydrocortisone 21-propionate 6678-14-4,  
 Hydrocortisone 21-octanoate 7732-18-5, Water, biological studies  
 12041-98-4, Hydroxypregnenolone 14521-96-1, Etophine 15307-86-5,  
 Diclofenac 22204-53-1, Naproxen 56030-54-7 74253-50-2 107085-84-7,  
 Hydrocortisone 21-hemipemlate 114593-85-0 114593-86-1 114593-87-2  
 114593-88-3 114611-36-8

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (characterization of skin penetration processes of organic mols. using  
 mol. similarity and QSAR anal.)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Barratt, M; Toxicol in Vitro 1995, V9, P27 CAPLUS
- (2) Berendsen, H; J Chem Phys 1984, V81, P3684 CAPLUS
- (3) Chem21; 4D-MS [Molecular Similarity] Users Manual 2002
- (4) Degim, T; J Pharm Sci 2003, V92, P656 CAPLUS
- (5) Doherty, D; Molsim Version 3.0 User's Guide 1994
- (6) Fitzpatrick, D; Chemosphere 2004, V55, P1309 CAPLUS
- (7) Flynn, G; Principles of Route-to-Route Extrapolation for Risk Assessment  
 1990, P93
- (8) Friedman, J; Multivariate Adaptive Regression Splines 1988
- (9) Geinoz, S; Pharm Res 2004, V21, P83 CAPLUS
- (10) Hauser, H; Biochim Biophys Acta 1981, V650, P21 CAPLUS
- (11) HyperChem; HyperChem Release 4.5 for MS Windows 1998
- (12) Iyer, M; Pharm Res 2002, V19, P1611 CAPLUS
- (13) Johnson, M; J Pharm Sci 1997, V86, P1162 CAPLUS
- (14) Kasting, G; Pharmacology and the Skin, Skin Pharmacokinetics 1987, V1,  
 P138
- (15) Kirchner, L; ATLA 1997, V25, P359
- (16) Kulkarni, A; J Chem Inf Comput Sci 2002, V42, P331 CAPLUS
- (17) Kulkarni, A; Pharm Res 1999, V16, P1244
- (18) Kulkarni, A; Toxicol Sci 2001, V59, P335 CAPLUS
- (19) Mopac; Mopac 6.0 Release Notes 1990
- (20) Msi; Cerius2 Molecular Simulations Users Guide Ver 3.0 1997
- (21) Patel, H; Chemosphere 2002, V48, P603 CAPLUS
- (22) Pearlstein, R; CHEMLAB-II Users Guide 1988
- (23) Potts, R; Pharm Res 1992, V9, P663 CAPLUS
- (24) Rogers, D; J Chem Inf Comput Sci 1994, V34, P854 CAPLUS
- (25) Rogers, D; WOLF 6.2 GFA Program 1994
- (26) Ursin, C; Am Ind Hyg Assoc J 1995, V56, P651 CAPLUS
- (27) Wilschut, A; Chemosphere 1995, V30, P1275 CAPLUS

L7 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, Phthalic acid, biological studies 110-15-6,  
 Succinic acid, biological studies 110-15-6D, Succinic acid,  
 salts 124-04-9, Adipic acid, biological studies  
 124-04-9D, Adipic acid, salts

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compsns. comprising mucoadhesive polymers for prevention and treatment  
 of cold and influenza-like symptoms)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)






RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)




RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2004:633550 CAPLUS

DOCUMENT NUMBER: 141:162405

TITLE: Compositions comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers  
INVENTOR(S): Khanolkar, Jayant Ekanth; De La Harpe, Shane Michael; Mullet, Benoit Maurice; Rennie, Paul John; Williams, Philip David

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064867	A1	20040805	WO 2003-US41106	20031223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

CA 2509775 A1 20040805 CA 2003-2509775 20031223  
 AU 2003302332 A1 20040813 AU 2003-302332 20031223  
 EP 1583559 A1 20051012 EP 2003-810888 20031223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1735434 A 20060215 CN 2003-80108601 20031223  
 JP 2006514077 T 20060427 JP 2004-566948 20031223  
 MX 2005PA07491 A 20050921 MX 2005-PA7491 20050712

PRIORITY APPLN. INFO.: US 2003-341156 A 20030113  
 WO 2003-US41106 W 20031223

AN 2004:633550 CAPLUS  
 DN 141:162405  
 ED Entered STN: 06 Aug 2004  
 TI Compositions comprising mucoadhesive polymers for prevention and treatment  
 of cold and influenza-like symptoms comprising select mucoadhesive  
 polymers  
 IN Khanolkar, Jayant Ekanth; De La Harpe, Shane Michael; Mullet, Benoit  
 Maurice; Rennie, Paul John; Williams, Philip David  
 PA The Procter & Gamble Company, USA  
 SO PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K045-06  
 ICS A61K031-28; A61P011-00  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004064867	A1	20040805	WO 2003-US41106	20031223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2509775	A1	20040805	CA 2003-2509775	20031223
AU 2003302332	A1	20040813	AU 2003-302332	20031223
EP 1583559	A1	20051012	EP 2003-810888	20031223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1735434	A	20060215	CN 2003-80108601	20031223
JP 2006514077	T	20060427	JP 2004-566948	20031223
MX 2005PA07491	A	20050921	MX 2005-PA7491	20050712
PRAI US 2003-341156	A	20030113		
WO 2003-US41106	W	20031223		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004064867	ICM	A61K045-06
	ICS	A61K031-28; A61P011-00
	IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61K0031-28 [ICS,7]; A61P0011-00 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0045-00 [I,C*];

		A61K0045-06 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
CA 2509775	ECLA	A61K009/00M20B3; A61K009/00M14; A61K009/00M20; A61K009/00M20B6; A61K031/28+M; A61K045/06; A61K047/32
	IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61P0011-00 [ICS,7]; A61K0031-28 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
	ECLA	A61K009/00M14; A61K009/00M20; A61K009/00M20B; A61K031/28+M; A61K045/06; A61K047/32
AU 2003302332	IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61K0031-28 [ICS,7]; A61P0011-00 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
EP 1583559	IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61K0031-28 [ICS,7]; A61P0011-00 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
	ECLA	A61K009/00M14; A61K009/00M20; A61K009/00M20B; A61K031/28+M; A61K045/06; A61K047/32
CN 1735434	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61K0031-28 [I,A]; A61P0011-00 [I,A]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
	ECLA	A61K009/00M14; A61K009/00M20; A61K009/00M20B; A61K031/28+M; A61K045/06; A61K047/32
JP 2006514077	IPCI	A61K0033-00 [I,A]; A61K0047-22 [I,A]; A61K0047-12 [I,A]; A61K0047-18 [I,A]; A61K0047-16 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,A]; A61K0047-38 [I,A]; A61K0047-34 [I,A]; A61K0047-04 [I,A]; A61K0047-02 [I,C*]; A61K0009-08 [I,A]; A61K0009-72 [I,A]; A61K0009-14 [I,A]; A61P0011-00 [I,A]; A61P0031-16 [I,A]; A61P0031-00 [I,C*]; A61K0047-10 [I,A]; A61P0029-00 [I,A]; A61P0025-06 [I,A]; A61P0025-00 [I,C*]
	IPCR	A61K0033-00 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-08 [I,C]; A61K0009-08 [I,A]; A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-72 [I,C]; A61K0009-72 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0033-00 [I,C]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-02 [I,C]; A61K0047-04 [I,A]; A61K0047-10 [I,C]; A61K0047-10 [I,A]; A61K0047-12 [I,C]; A61K0047-12 [I,A]; A61K0047-16 [I,C]; A61K0047-18 [I,A]; A61K0047-22 [I,C]; A61K0047-22 [I,A]; A61K0047-32 [I,C]; A61K0047-34 [I,C]; A61K0047-34 [I,A]; A61K0047-36 [I,C]; A61K0047-36 [I,A]; A61K0047-38 [I,C]; A61K0047-38 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0025-00 [I,C]; A61P0025-06 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C]; A61P0031-16 [I,A]
	FTERM	4C076/AA12; 4C076/AA30; 4C076/AA93; 4C076/BB25; 4C076/CC15; 4C076/CC35; 4C076/CC45; 4C076/CC46;

4C076/DD23; 4C076/DD25Z; 4C076/DD26A; 4C076/DD26Z;  
 4C076/DD30Z; 4C076/DD31Z; 4C076/DD37A; 4C076/DD37T;  
 4C076/DD38A; 4C076/DD41A; 4C076/DD42A; 4C076/DD42Z;  
 4C076/DD43A; 4C076/DD50Z; 4C076/DD51A; 4C076/DD59A;  
 4C076/DD60A; 4C076/DD61T; 4C076/DD67T; 4C076/EE06A;  
 4C076/EE09A; 4C076/EE15A; 4C076/EE16A; 4C076/EE23A;  
 4C076/EE30A; 4C076/EE31A; 4C076/EE32A; 4C076/EE48A;  
 4C076/EE53T; 4C076/EE58T; 4C076/FF11; 4C076/FF12;  
 4C076/FF17; 4C076/FF57; 4C076/FF61; 4C076/FF68;  
 4C086/AA01; 4C086/AA02; 4C086/GA13; 4C086/HA03;  
 4C086/HA28; 4C086/MA03; 4C086/MA05; 4C086/MA07;  
 4C086/MA08; 4C086/MA09; 4C086/MA10; 4C086/MA13;  
 4C086/MA17; 4C086/MA43; 4C086/MA59; 4C086/NA10;  
 4C086/NA11; 4C086/NA14; 4C086/ZA07; 4C086/ZA08;  
 4C086/ZA59; 4C086/ZB33

MX 2005PA07491 IPCI A61K0031-28 [ICM,7]; A61K0045-06 [ICS,7]; A61K0045-00  
 [ICS,7,C\*]; A61P0011-00 [ICS,7]

- AB The present invention is directed to respiratory tract compns. that are highly effective in the prevention and treatment of cold and influenza-like symptoms due to respiratory tract viral infections. These compns. preferably comprise a metal compound such as zinc acetate, an organic acid, and a select mucoadhesive polymer, wherein the select mucoadhesive polymer provides for adherence of the compns. to mucosal tissues and fluids to result in improved prevention and treatment of cold and influenza-like symptoms. Thus, a composition contained pyrogultamic acid 0.35, succinic acid 1.00, zinc acetate dihydrate 0.12, Polysorbate-80 0.05, HPMC 1.20, sucralose 0.025, phenylethyl alc. 0.37, NaCl 0.20, a sensate mix consisting of essential components 0.067, disodium succinate 1.00, and water qs to 100%.
- ST mucoadhesive polymer cold influenza
- IT Drug delivery systems  
 (aerosols; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)
- IT Vinyl compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (carboxy-containing, polymers; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)
- IT Common cold  
 Influenza  
 Propellants (sprays and foams)  
 Respiratory system  
 Respiratory system, disease  
 (compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)
- IT Carboxylic acids, biological studies  
 Chlorides, biological studies  
 Fluorides, biological studies  
 Iodides, biological studies  
 Metals, biological studies  
 Nitrates, biological studies  
 Phosphates, biological studies  
 Polymers, biological studies  
 Polyoxalkylenes, biological studies  
 Sulfates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)
- IT Drug delivery systems  
 (drops, nasal; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)
- IT Drug delivery systems

(inhalants; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)

IT Drug delivery systems  
(liqs., nasal; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)

IT Drug delivery systems  
(nasal sprays; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)

IT Drug delivery systems  
(nasal; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)

IT Drug delivery systems  
(powders, nasal; compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts 50-81-7D, Ascorbic acid, salts 56-40-6D, Glycine, salts 56-84-8, Aspartic acid, biological studies 56-84-8D, Aspartic acid, salts 56-86-0, Glutamic acid, biological studies 57-50-1D, Sucrose, allyl ethers, polymers with acrylic acid 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 64-19-7D, Acetic acid, salts 65-85-0D, Benzoic acid, biological studies 65-85-0D, Benzoic acid, salts 68-04-2, Sodium citrate 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, salts 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, salts 79-10-7D, Acrylic acid, polymers with allylsucrose 79-14-1, Glycolic acid, biological studies 79-14-1D, Glycolic acid, salts 87-69-4, Tartaric acid, biological studies 87-69-4D, Tartaric acid, salts 88-99-3, Phthalic acid, biological studies 98-79-3, Pyrogutamic acid 98-79-3D, Pidolic acid, salts 102-71-6, Triethanolamine, biological studies 110-15-6, Succinic acid, biological studies 110-15-6D, Succinic acid, salts 110-16-7D, Maleic acid, salts 110-17-8, Fumaric acid, biological studies 110-17-8D, Fumaric acid, salts 110-94-1, Glutaric acid 110-94-1D, Glutaric acid, salts 111-90-0, Transcutol 124-04-9, Adipic acid, biological studies 124-04-9D, Adipic acid, salts 141-82-2, Malonic acid, biological studies 141-82-2D, Malonic acid, salts 144-55-8, Carbonic acid monosodium salt, biological studies 147-93-3D, Thiosalicylic acid, salts 150-90-3, Disodium succinate 526-95-4, D-Gluconic acid 526-95-4D, D-Gluconic acid, salts 557-34-6, Zinc acetate 1310-73-2, Sodium hydroxide, biological studies 1336-21-6, Ammonium hydroxide 4468-02-4, Zinc gluconate 5970-45-6, Zinc acetate dihydrate 6228-53-1, Zinc succinate 6915-15-7, Malic acid 6915-15-7D, Malic acid, salts 7632-05-5, Sodium phosphate 7646-85-7, Zinc chloride (ZnCl<sub>2</sub>), biological studies 7733-02-0, Zinc sulfate 9000-11-7, CMC 9003-01-4 9003-39-8, Polyvinylpyrrolidone 9004-32-4, CMC 9004-34-6D, Cellulose, derivs. 9004-54-0, Dextran, biological studies 9004-58-4, Ethyl hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9011-16-9, Maleic anhydride-methyl vinyl ether copolymer 12058-66-1, Sodium stannate 15454-75-8 25322-68-3, Polyethylene glycol 73038-24-1, Acrylic acid-divinyl glycol copolymer 106392-12-5, Poloxamer 138757-67-2, Carbopol 980 151728-40-4, Zinc ascorbate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compns. comprising mucoadhesive polymers for prevention and treatment of cold and influenza-like symptoms)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Nayak, S; US 5989535 A 1999 CAPLUS
- (2) Procter & Gamble; WO 0128556 A 2001 CAPLUS

L7 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 88-99-3, Phthalic acid, uses 110-15-6, Succinic acid,  
 uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (formulations comprising water-soluble granulates)  
 RN 88-99-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2004:220420 CAPLUS  
 DOCUMENT NUMBER: 140:272716  
 TITLE: Formulations comprising water-soluble granulates  
 INVENTOR(S): Dreyer, Pierre; Haiss, Elke; Iltis, Laure; Kvita,  
 Petr; Menge, Ullrich  
 PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.  
 SOURCE: PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022693	A1	20040318	WO 2003-EP9409	20030826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003267010	A1	20040329	AU 2003-267010	20030826
EP 1534814	A1	20050601	EP 2003-747927	20030826
EP 1534814	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014340	A	20050705	BR 2003-14340	20030826
CN 1678728	A	20051005	CN 2003-820763	20030826
JP 2005537370	T	20051208	JP 2004-533402	20030826
AT 327313	T	20060615	AT 2003-747927	20030826
ES 2263996	T3	20061216	ES 2003-747927	20030826
IN 2004CN03172	A	20060303	IN 2004-CN3172	20041213
MX 2005PA01651	A	20050419	MX 2005-PA1651	20050211

US 20050227891 A1 20051013 US 2005-526093 20050223  
 PRIORITY APPLN. INFO.: EP 2002-405766 A 20020904  
 WO 2003-EP9409 W 20030826

OTHER SOURCE(S): MARPAT 140:272716

AN 2004:220420 CAPLUS

DN 140:272716

ED Entered STN: 19 Mar 2004

TI Formulations comprising water-soluble granulates

IN Dreyer, Pierre; Haiss, Elke; Iltis, Laure; Kvita, Petr; Menge, Ullrich

PA Ciba Specialty Chemicals Holding Inc., Switz.

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C11D017-06

ICS C11D003-39

CC 46-5 (Surface Active Agents and Detergents)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022693	A1	20040318	WO 2003-EP9409	20030826
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003267010	A1	20040329	AU 2003-267010	20030826
	EP 1534814	A1	20050601	EP 2003-747927	20030826
	EP 1534814	B1	20060524		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003014340	A	20050705	BR 2003-14340	20030826
	CN 1678728	A	20051005	CN 2003-820763	20030826
	JP 2005537370	T	20051208	JP 2004-533402	20030826
	AT 327313	T	20060615	AT 2003-747927	20030826
	ES 2263996	T3	20061216	ES 2003-747927	20030826
	IN 2004CN03172	A	20060303	IN 2004-CN3172	20041213
	MX 2005PA01651	A	20050419	MX 2005-PA1651	20050211
	US 20050227891	A1	20051013	US 2005-526093	20050223
PRAI	EP 2002-405766	A	20020904		
	WO 2003-EP9409	W	20030826		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004022693	ICM	C11D017-06
	ICS	C11D003-39
	IPCI	C11D0017-06 [ICM,7]; C11D0003-39 [ICS,7]
	IPCR	C11D0001-02 [I,C*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,C*]; C11D0001-72 [I,A]; C11D0003-04 [I,C*]; C11D0003-04 [I,A]; C11D0003-06 [I,C*]; C11D0003-06 [I,A]; C11D0003-08 [I,C*]; C11D0003-08 [I,A]; C11D0003-10 [I,C*]; C11D0003-10 [I,A]; C11D0003-16 [I,C*]; C11D0003-16 [I,A]; C11D0003-37 [I,C*]; C11D0003-37 [I,A]; C11D0003-39 [I,C*]; C11D0003-39 [I,A]; C11D0003-39S [I,C*]; C11D0003-39S [I,A]; C11D0003-40 [I,C*]; C11D0003-40

AU 2003267010	ECLA	[I,A]; C11D0017-06 [I,C*]; C11D0017-06 [I,A]
	IPCI	C11D003/16K; C11D003/39B2F; C11D017/06
	IPCR	C11D0017-06 [I,C,M,7]; C11D0003-39 [ICS,7]
EP 1534814	IPCI	C11D0001-02 [I,C*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,C*]; C11D0001-72 [I,A]; C11D0003-04 [I,C*]; C11D0003-04 [I,A]; C11D0003-06 [I,C*]; C11D0003-06 [I,A]; C11D0003-08 [I,C*]; C11D0003-08 [I,A]; C11D0003-10 [I,C*]; C11D0003-10 [I,A]; C11D0003-16 [I,C*]; C11D0003-16 [I,A]; C11D0003-37 [I,C*]; C11D0003-37 [I,A]; C11D0003-39 [I,C*]; C11D0003-39 [I,A]; C11D0003-395 [I,C*]; C11D0003-395 [I,A]; C11D0003-40 [I,C*]; C11D0003-40 [I,A]; C11D0017-06 [I,C*]; C11D0017-06 [I,A]
	IPCR	C11D0003-39 [I,C]; C11D0017-06 [I,C]; C11D0017-06 [I,A]; C11D0003-39 [I,A]
	IPCR	C11D0017-06 [I,A]; C11D0003-39 [I,C]; C11D0003-39 [I,A]; C11D0017-06 [I,C]
BR 2003014340	IPCI	C11D0017-06 [I,C,M,7]; C11D0003-39 [ICS,7]
	IPCR	C11D0001-02 [I,C*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,C*]; C11D0001-72 [I,A]; C11D0003-04 [I,C*]; C11D0003-04 [I,A]; C11D0003-06 [I,C*]; C11D0003-06 [I,A]; C11D0003-08 [I,C*]; C11D0003-08 [I,A]; C11D0003-10 [I,C*]; C11D0003-10 [I,A]; C11D0003-16 [I,C*]; C11D0003-16 [I,A]; C11D0003-37 [I,C*]; C11D0003-37 [I,A]; C11D0003-39 [I,C*]; C11D0003-39 [I,A]; C11D0003-395 [I,C*]; C11D0003-395 [I,A]; C11D0003-40 [I,C*]; C11D0003-40 [I,A]; C11D0017-06 [I,C*]; C11D0017-06 [I,A]
	IPCR	C11D003/16K; C11D003/39B2F; C11D017/06
CN 1678728	ECLA	C11D0017-06 [I,C,M,7]; C11D0003-39 [ICS,7]
	IPCI	C11D0001-02 [I,C*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,C*]; C11D0001-72 [I,A]; C11D0003-04 [I,C*]; C11D0003-04 [I,A]; C11D0003-06 [I,C*]; C11D0003-06 [I,A]; C11D0003-10 [I,C*]; C11D0003-10 [I,A]; C11D0003-16 [I,C*]; C11D0003-16 [I,A]; C11D0003-37 [I,C*]; C11D0003-37 [I,A]; C11D0003-39 [I,C*]; C11D0003-39 [I,A]; C11D0003-395 [I,C*]; C11D0003-395 [I,A]; C11D0003-40 [I,C*]; C11D0003-40 [I,A]; C11D0017-06 [I,C*]; C11D0017-06 [I,A]
	IPCR	C11D003/16K; C11D003/39B2F; C11D017/06
JP 2005537370	ECLA	C11D003/16K; C11D003/39B2F; C11D017/06
	IPCI	C11D0017-06 [I,C,M,7]; C11D0001-10 [ICS,7]; C11D0001-22 [ICS,7]; C11D0001-02 [ICS,7,C*]; C11D0001-72 [ICS,7]; C11D0003-04 [ICS,7]; C11D0003-06 [ICS,7]; C11D0003-08 [ICS,7]; C11D0003-10 [ICS,7]; C11D0003-37 [ICS,7]; C11D0003-39 [ICS,7]; C11D0003-395 [ICS,7]; C11D0003-40 [ICS,7]
	FTERM	4H003/AB03; 4H003/AB19; 4H003/AB31; 4H003/AC08; 4H003/BA10; 4H003/DA01; 4H003/EA08; 4H003/EA12; 4H003/EA15; 4H003/EA16; 4H003/EA18; 4H003/EA25; 4H003/EA26; 4H003/EA28; 4H003/EB07; 4H003/EB08; 4H003/EB12; 4H003/EB22; 4H003/EB24; 4H003/EB26; 4H003/EB30; 4H003/EB42; 4H003/EC01; 4H003/EC02; 4H003/EC03; 4H003/EE05; 4H003/EE06; 4H003/FA12
AT 327313	IPCI	C11D0017-06 [ICS,7]; C11D0003-39 [ICS,7]
	IPCR	C11D0001-02 [I,C*]; C11D0001-72 [I,C*]; C11D0003-04 [I,C*]; C11D0003-06 [I,C*]; C11D0003-08 [I,C*]; C11D0003-10 [I,C*]; C11D0003-16 [I,C*]; C11D0003-37 [I,C*]; C11D0003-39 [I,C*]; C11D0003-395 [I,C*]; C11D0003-40 [I,C*]; C11D0017-06 [I,C*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,A];



C11D0003-04 [I,A]; C11D0003-06 [I,A]; C11D0003-08 [I,A]; C11D0003-10 [I,A]; C11D0003-16 [I,A]; C11D0003-37 [I,A]; C11D0003-39 [I,A]; C11D0003-395 [I,A]; C11D0003-40 [I,A]; C11D0017-06 [I,A]  
 ES 2263996 ECLA C11D003/16K; C11D003/39B2F; C11D017/06  
 IPCI C11D0017-06 [I,C]; C11D0003-39 [I,C]; C11D0017-06 [I,A]; C11D0003-39 [I,A]  
 IPCR C11D0017-06 [I,C]; C11D0017-06 [I,A]; C11D0001-02 [I,C\*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,C\*]; C11D0001-72 [I,A]; C11D0003-04 [I,C\*]; C11D0003-04 [I,A]; C11D0003-06 [I,C\*]; C11D0003-06 [I,A]; C11D0003-08 [I,C\*]; C11D0003-08 [I,A]; C11D0003-10 [I,C\*]; C11D0003-10 [I,A]; C11D0003-16 [I,C\*]; C11D0003-16 [I,A]; C11D0003-37 [I,C\*]; C11D0003-37 [I,A]; C11D0003-39 [I,C]; C11D0003-39 [I,A]; C11D0003-395 [I,C\*]; C11D0003-395 [I,A]; C11D0003-40 [I,C\*]; C11D0003-40 [I,A]  
 IN 2004CN03172 ECLA C11D003/16K; C11D003/39B2F; C11D017/06  
 MX 2005PA01651 IPCI C11D0017-06 [ICM,7]  
 US 20050227891 IPCI C11D0017-06 [ICM,7]; C11D0003-39 [ICS,7]  
 IPCI C11D0003-00 [ICM]  
 IPCR C11D0001-02 [I,C\*]; C11D0001-10 [I,A]; C11D0001-22 [I,A]; C11D0001-72 [I,C\*]; C11D0001-72 [I,A]; C11D0003-04 [I,C\*]; C11D0003-04 [I,A]; C11D0003-06 [I,C\*]; C11D0003-06 [I,A]; C11D0003-08 [I,C\*]; C11D0003-08 [I,A]; C11D0003-10 [I,C\*]; C11D0003-10 [I,A]; C11D0003-16 [I,C\*]; C11D0003-16 [I,A]; C11D0003-37 [I,C\*]; C11D0003-37 [I,A]; C11D0003-39 [I,C\*]; C11D0003-39 [I,A]; C11D0003-395 [I,C\*]; C11D0003-395 [I,A]; C11D0003-40 [I,C\*]; C11D0003-40 [I,A]; C11D0017-06 [I,C\*]; C11D0017-06 [I,A]  
 510/301.000  
 NCL C11D003/16K; C11D003/39B2F; C11D017/06  
 ECLA  
 OS MARPAT 140:272716  
 AB The present invention relates to (i) formulations comprising water-soluble granulates of phthalocyanine compds., (ii) a process for the preparation thereof, and (iii) the use thereof in washing agent and washing agent additive formulations. Thus, a composition comprising 564 g 19.5% aqueous aluminum phthalocyanine solution 564 and 1857 g an aqueous solution containing 541 g anionic dispersing agent and 270 g sodium sulfate was stirred at 25° for 1 h and dried in a spray-dryer with inlet air temperature 190° and exhaust air temperature 105° to give a granulate with average particle d. 70 µm, bulk d. 520 g/L, and residual water content 6%, 0.03% of which was mixed with sodium laurylbenzenesulfonate 10, sodium laurylsulfate 3, Neodol 23-6.5E 4, zeolite A 25, sodium percarbonate 20, perfume 0.1, cellulose 1.5, CM-cellulose 2, sodium sulfate 15, sodium carbonate 10, and tetraacetyl ethylenediamine 3% to give a washing agent.  
 ST formulation comprising water soluble granulate; aluminum phthalocyanine anionic dispersing agent sodium sulfate granulate prep  
 IT Polyoxalkylenes, uses  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (alkyl group-terminated, nonionic surfactants; formulations comprising water-soluble granulates)  
 IT Dispersing agents  
 Surfactants  
 (anionic; formulations comprising water-soluble granulates)  
 IT Sulfonic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (arenesulfonic, salts, alkyl, dispersing agents; formulations

comprising water-soluble granulates)

IT Detergents  
(bars; formulations comprising water-soluble granulates)

IT Polyoxyalkylenes, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(block, dispersing agents; formulations comprising water-soluble granulates)

IT Fibers  
RL: MOA (Modifier or additive use); USES (Uses)  
(cellulosic; formulations comprising water-soluble granulates)

IT Pastes  
(detergent; formulations comprising water-soluble granulates)

IT Polyoxyalkylenes, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(dispersing agent; formulations comprising water-soluble granulates)

IT Acrylic polymers, uses  
Gelatins, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(dispersing agents; formulations comprising water-soluble granulates)

IT Alcohols, uses  
RL: TEM (Technical or engineered material use); USES (Uses)  
(ethoxylated, nonionic surfactants; formulations comprising water-soluble granulates)

IT Granulating apparatus  
(fluidized bed; formulations comprising water-soluble granulates)

IT Drying  
(fluidized-bed; formulations comprising water-soluble granulates)

IT Bleaching agents  
Dispersing agents  
Dyes  
Fillers  
Fluorescent brighteners  
Pigments, nonbiological  
Textiles  
Wetting agents  
(formulations comprising water-soluble granulates)

IT A zeolites  
Aluminosilicates, uses  
Borates  
Carbonates, uses  
Carboxylic acids, uses  
Diphosphates  
Halides  
Kaolin, uses  
Peroxides, uses  
Peroxyulfates  
Phosphates, uses  
Polysiloxanes, uses  
Salts, uses  
Silicates, uses  
Sulfates, uses  
Sulfites  
Zeolites (synthetic), uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(formulations comprising water-soluble granulates)

IT Detergents  
(granular; formulations comprising water-soluble granulates)

IT Fluidized beds  
(granulating apparatus; formulations comprising water-soluble granulates)

IT Surfactants  
(nonionic; formulations comprising water-soluble granulates)

IT Acids, uses  
 Peroxy acids  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (organic; formulations comprising water-soluble granulates)

IT Detergents  
 (paste; formulations comprising water-soluble granulates)

IT Group IIIA element compounds  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (perborates; formulations comprising water-soluble granulates)

IT Catalysts  
 (photo; formulations comprising water-soluble granulates)

IT Carboxylic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (polycarboxylic acid esters, amino; formulations comprising water-soluble granulates)

IT Carboxylic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (polycarboxylic, dispersing agents; formulations comprising water-soluble granulates)

IT Carboxylic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (polycarboxylic, salts; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (polymers, dispersing agents; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (polymers, heterocyclic, dispersing agents; formulations comprising water-soluble granulates)

IT Detergents  
 (powdered; formulations comprising water-soluble granulates)

IT Sulfonic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (sodium salts, polymers, dispersing agents; formulations comprising water-soluble granulates)

IT Polyphosphates  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (sodium salts; formulations comprising water-soluble granulates)

IT Drying  
 (spray; formulations comprising water-soluble granulates)

IT Detergents  
 (stain removers; formulations comprising water-soluble granulates)

IT Polymers, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (sulfo-containing, heterocyclic, dispersing agents; formulations comprising water-soluble granulates)

IT Aromatic compounds  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (sulfonates, alkyl, dispersing agents; formulations comprising water-soluble granulates)

IT Polymers, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (water-soluble, dispersing agents; formulations comprising water-soluble granulates)

IT 9017-33-8, Naphthalenesulfonic acid, polymer with formaldehyde  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (anionic dispersing agent; formulations comprising water-soluble granulates)

IT 151-21-3, Sodium lauryl sulfate, uses  
 RL: MOA (Modifier or additive use); USES (Uses)

(anionic surfactant; formulations comprising water-soluble granulates)

IT 25155-30-0, Sodium laurylbenzenesulfonate  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (anionic surfactant; formulations comprising water-soluble granulates)

IT 25608-40-6, Polyaspartic acid  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (dispersing agent, assumed monomers; formulations comprising water-soluble granulates)

IT 57-50-1, Sucrose, uses 63-42-3, Lactose 79-10-7D,  
 Acrylic acid, ester, polymers 88-12-0, uses  
 108-05-4, Vinyl acetate, uses 1321-69-3D, Naphthalenesulfonic acid  
 sodium salt, alkyl derivs. 8061-51-6, Sodium lignosulfonate 9000-01-5,  
 Arabic gum 9000-65-1, Tragacanth 9002-89-5, Polyvinyl alcohol  
 9003-05-8, Polyacrylamide 9003-11-6, Ethylene oxide-propylene oxide  
 copolymer 9003-20-7, Polyvinyl acetate 9003-39-8, Polyvinyl  
 pyrrolidone 9004-32-4, Carboxymethyl cellulose 9004-64-2,  
 Hydroxypropyl cellulose 9050-31-1, Hydroxypropyl methylcellulose  
 phthalate 9050-36-6, Maltodextrin 25085-34-1, Acrylic  
 acid-styrene copolymer 25086-89-9, Vinyl acetate-vinyl  
 pyrrolidone copolymer 25155-19-5D, Naphthalenesulfonic acid, alkyl  
 derivs., polymers, sodium salts 25322-68-3, Polyethylene glycol  
 26063-13-8, Polyaspartic acid 26101-52-0, Polyethylenesulfonic acid  
 30581-59-0, Dimethylaminoethyl methacrylate-vinyl pyrrolidone copolymer  
 37353-59-6, Hydroxymethyl cellulose 50851-57-5, Polystyrenesulfonic acid  
 52503-47-6, Ethylene oxide-propylene oxide copolymer ether with  
 ethylenediamine 55989-05-4, Ethyl acrylate-methacrylic acid-methyl  
 methacrylate copolymer ammonium salt 58226-28-1 64519-82-0, Isomalt  
 102972-64-5, Dimethylaminoethyl methacrylate-vinyl caprolactam-vinyl  
 pyrrolidone copolymer 131954-48-8 156218-88-1, Dimethylaminopropyl  
 methacrylate-vinyl pyrrolidone copolymer 478243-90-2,  
 Dimethylaminopropylmethacrylamide-vinyl pyrrolidone copolymer  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (dispersing agent; formulations comprising water-soluble granulates)

IT 9004-34-6, Cellulose, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (fibrous; formulations comprising water-soluble granulates)

IT 64-18-6, Formic acid, uses 64-19-7, Acetic acid,  
 uses 65-85-0, Benzoic acid, uses 68-04-2, Sodium citrate 71-52-3,  
 Hydrogen carbonate, uses 77-92-9, Citric acid, uses 79-09-4, Propionic  
 acid, uses 79-10-7, Acrylic acid, uses 83-86-3  
 87-69-4, Tartaric acid, uses 88-99-3, Phthalic acid, uses  
 100-21-0, Terephthalic acid, uses 104-15-4, p-Toluenesulfonic acid, uses  
 110-15-6, Succinic acid, uses 110-16-7, Maleic acid, uses  
 144-62-7, Oxalic acid, uses 497-19-8, Sodium carbonate, uses 526-95-4,  
 Gluconic acid 563-69-9, Carbonoperoxoic acid 1344-09-8, Sodium  
 silicate 2809-21-4, Hydroxyethanediophosphonic acid 3313-92-6, Sodium  
 percarbonate 7631-86-9, Silica, uses 7632-05-5, Sodium phosphate  
 7647-14-5, Sodium chloride, uses 7757-82-6, Sodiumsulfate, uses  
 7758-29-4, Sodium tripolyphosphate 8061-51-6D, Sodium lignosulfonate,  
 oxy derivs. 9001-92-7, Protease 9003-01-4, Polyacrylic acid  
 9012-54-8, Cellulase 10332-33-9, Sodium perborate monohydrate  
 1138-47-9, Sodium perborate 13463-67-7, Titaniumoxide, uses  
 14807-96-6, Talc, uses 14987-04-3, Magnesium trisilicate 15477-76-6,  
 Phosphate 41376-15-2D, Chloromethylbiphenyl, polymers with  
 naphthalenesulfonic acid 102568-16-1D, salts  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (formulations comprising water-soluble granulates)

IT 672911-83-0, Neodol 23-6.5E  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (nonionic surfactant; formulations comprising water-soluble granulates)

IT 14320-04-8, Zinc phthalocyanine 84370-49-0

RL: CAT (Catalyst use); USES (Uses)  
 (photoactivator; formulations comprising water-soluble granulates)

IT 132-16-1, Ferrous phthalocyanine 574-93-6D, Phthalocyanine, complexes  
 1661-03-6, Magnesium phthalocyanine 7440-21-3D, Silicon, phthalocyanine  
 complex 7440-31-5D, Tin, phthalocyanine complex 7440-32-6D, Titanium,  
 phthalocyanine complex 7440-47-3D, Chromium, phthalocyanine complex  
 7440-55-3D, Gallium, phthalocyanine complex 7440-56-4D, Germanium,  
 phthalocyanine complex 7440-58-6D, Hafnium, phthalocyanine complex  
 7440-67-7D, Zirconium, phthalocyanine complex 7440-74-6D, Indium,  
 phthalocyanine complex 7723-14-0D, Phosphorus, phthalocyanine complex  
 21328-73-4, Calcium phthalocyanine 25047-77-2 25476-27-1, Sodium  
 phthalocyanine

RL: TEM (Technical or engineered material use); USES (Uses)  
 (photoactivator; formulations comprising water-soluble granulates)

IT 25155-19-5D, Naphthalenesulfonic acid, polymers with  
 polychloromethylbiphenyl

RL: MOA (Modifier or additive use); USES (Uses)  
 (polymers; formulations comprising water-soluble granulates)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ciba Geigy Ag; EP 0124478 A 1984 CAPLUS
- (2) Ciba Geigy Ag; DE 3430773 A 1985 CAPLUS
- (3) Ciba Geigy Ag; CH 659082 A 1986 CAPLUS
- (4) Ciba Geigy Ag; EP 0899325 A 1999 CAPLUS
- (5) Ciba Sc Holding Ag; EP 0959123 A 1999 CAPLUS
- (6) David, W; US 5916481 A 1999 CAPLUS
- (7) Hoelzle, G; US 4394125 A 1983 CAPLUS
- (8) Jeffreys, B; US 6407049 B1 2002 CAPLUS
- (9) Richard, R; US 4097418 A 1978
- (10) Thomas, B; US 6339055 B1 2002 CAPLUS

L7 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, Phthalic acid, biological studies 110-15-6,  
 Succinic acid, biological studies 124-04-9, Adipic acid,  
 biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comps. for prevention and treatment of cold and influenza-like  
 symptoms comprising chelated zinc)


RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2004:142609 CAPLUS  
 DOCUMENT NUMBER: 140:187391  
 TITLE: Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc  
 INVENTOR(S): Rennie, Paul John; De La Harpe, Shane Michael; Khanolkar, Jayant Ekanth; McDonald, Michael Ray; Sutton, Richard Matthew Charles  
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 692,634.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 27  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040033260	A1	20040219	US 2003-456465	20030606
AU 2004247082	A1	20041223	AU 2004-247082	20040601
AU 2004247082	B2	20080424		
CA 2527365	A1	20041223	CA 2004-2527365	20040601
WO 2004110463	A1	20041223	WO 2004-US17390	20040601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633376	A1	20060315	EP 2004-754081	20040601
EP 1633376	B1	20080416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004011050	A	20060711	BR 2004-11050	20040601
CN 1802162	A	20060712	CN 2004-80015703	20040601
JP 2006526026	T	20061116	JP 2006-515104	20040601
AT 392208	T	20080515	AT 2004-754081	20040601
IN 2005DN05403	A	20070713	IN 2005-DN5403	20051124
MX 2005PA13214	A	20060317	MX 2005-PA13214	20051206
PRIORITY APPLN. INFO.:				
			US 1999-421131	B2 19991019
			US 2000-692634	A2 20001019
			US 2003-456465	A 20030606
			WO 2004-US17390	W 20040601

AN 2004:142609 CAPLUS  
 DN 140:187391  
 ED Entered STN: 22 Feb 2004  
 TI Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc  
 IN Rennie, Paul John; De La Harpe, Shane Michael; Khanolkar, Jayant Ekanth; McDonald, Michael Ray; Sutton, Richard Matthew Charles  
 PA The Procter & Gamble Company, USA  
 SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 692,634.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K009-20

INCL 424465000  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1  
 FAN.CNT 27

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040033260	A1	20040219	US 2003-456465	20030606
	AU 2004247082	A1	20041223	AU 2004-247082	20040601
	AU 2004247082	B2	20080424		
	CA 2527365	A1	20041223	CA 2004-2527365	20040601
	WO 2004110463	A1	20041223	WO 2004-US17390	20040601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1633376	A1	20060315	EP 2004-754081	20040601
	EP 1633376	B1	20080416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004011050	A	20060711	BR 2004-11050	20040601
	CN 1802162	A	20060712	CN 2004-80015703	20040601
	JP 2006526026	T	20061116	JP 2006-515104	20040601
	AT 392208	T	20080515	AT 2004-754081	20040601
	IN 2005DN05403	A	20070713	IN 2005-DN5403	20051124
	MX 2005PA13214	A	20060317	MX 2005-PA13214	20051206
PRAI	US 1999-421131	B2	19991019		
	US 2000-692634	A2	20001019		
	US 2003-456465	A	20030606		
	WO 2004-US17390	W	20040601		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20040033260	ICM	A61K009-20
	INCL	424465000
	IPCI	A61K0009-20 [ICM,7]
	IPCR	A01N0043-34 [I,C*]; A01N0043-36 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-315 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0036-185 [I,C*]; A61K0036-31 [I,A]; A61K0036-81 [I,A]; A61K0036-88 [I,C*]; A61K0036-8962 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
	NCL	424/465.000
	ECLA	A01N043/36; A01N043/36+M; A61K008/02C; A61K008/49C2; A61K031/19+M; A61K031/28+M; A61K031/315+M; A61K033/24+M; A61K033/30+M; A61K045/06; A61Q017/00; D21H021/36
AU 2004247082	IPCI	A61K0033-30 [I,C]; A61P0011-00 [I,C]; A61K0033-30 [I,A]; A61P0011-00 [I,A]; A61K0031-185 [I,C*];

		A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-315 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
	IPCR	A61K0033-30 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-315 [I,A]; A61K0033-30 [I,C]; A61P0011-00 [I,C]; A61P0011-00 [I,A]
CA 2527365	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
	IPCI	A61K0033-30 [I,A]; A61P0011-00 [I,A]
	IPCR	A61K0033-30 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-315 [I,A]; A61K0033-30 [I,C]; A61P0011-00 [I,C]; A61P0011-00 [I,A]
WO 2004110463	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
	IPCI	A61K0033-30 [ICM,7]; A61P0011-00 [ICS,7]
	IPCR	A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-315 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
EP 1633376	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
	IPCI	A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]
	IPCR	A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-315 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]
BR 2004011050	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
	IPCI	A61K0033-30 [ICS,7]; A61P0011-00 [ICS,7]
	IPCR	A61K0031-185 [I,C*]; A61K0031-28 [I,C*]; A61K0033-30 [I,C*]; A61P0011-00 [I,C*]; A61K0031-19 [I,A]; A61K0031-315 [I,A]; A61K0033-30 [I,A]; A61P0011-00 [I,A]
CN 1802162	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
	IPCI	A61K0033-30 [I,A]; A61P0011-00 [I,A]
JP 2006526026	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
	IPCI	A61K0033-30 [I,A]; A61P0011-00 [I,A]; A61P0031-16 [I,A]; A61P0031-00 [I,C*]; A61K0031-19 [I,A]; A61K0031-185 [I,A]; A61K0031-191 [I,A]; A61K0031-375 [I,A]; A61K0047-10 [I,A]; A61K0047-12 [I,A]; A61K0047-30 [I,A]; A61K0009-08 [I,A]
	FTERM	4C076/AA11; 4C076/AA25; 4C076/AA93; 4C076/BB25; 4C076/BB27; 4C076/CC03; 4C076/CC10; 4C076/DD37E; 4C076/DD38E; 4C076/DD41A; 4C076/DD42A; 4C076/DD43A; 4C076/DD51A; 4C076/EE01A; 4C076/EE23E; 4C076/FF12; 4C076/FF15; 4C076/FF34; 4C086/AA01; 4C086/AA02; 4C086/BA18; 4C086/HA03; 4C086/MA01; 4C086/MA02; 4C086/MA03; 4C086/MA04; 4C086/MA05; 4C086/MA17; 4C086/MA43; 4C086/MA59; 4C086/NA10; 4C086/NA14; 4C086/ZA59; 4C086/ZB31; 4C086/ZB33; 4C206/AA01; 4C206/AA02; 4C206/DA02; 4C206/DA07; 4C206/DA35; 4C206/FA44; 4C206/MA01; 4C206/MA02; 4C206/MA03; 4C206/MA04; 4C206/MA05; 4C206/MA37; 4C206/MA63; 4C206/MA79; 4C206/NA10; 4C206/NA14; 4C206/ZA59; 4C206/ZB31; 4C206/ZB33
AT 392208	IPCI	A61K0033-30 [I,C]; A61K0033-30 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]
	IPCR	A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-28 [I,C*]; A61K0031-315 [I,A]
IN 2005DN05403	ECLA	A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M
MX 2005PA13214	IPCI	A61K0033-30 [ICM,7]
	IPCR	A61K0033-30 [ICM,7]; A61P0011-00 [ICS,7]
AB	The present invention is directed to respiratory tract compns.,	ECLA A61K031/19+M; A61K031/315+M; A61K033/30; A61K033/30+M



particularly nasal compns., that are highly effective in the prevention and treatment of cold and influenza-like symptoms due to respiratory tract viral infections. These compns. comprise chelated and unchelated zinc ions, wherein the quantity of chelated zinc ions is at least about 50.1%. The formulation of a composition containing 0.12% zinc acetate dihydrate is disclosed.


- ST cold influenza pharmaceutical chelate zinc
- IT Drug delivery systems
  - (aerosols, inhalants; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Vinyl compounds, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (carboxy-containing, polymers; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Common cold
  - Propellants (sprays and foams)
    - (compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Acrylic polymers, biological studies
  - Carboxylic acids, biological studies
  - Polymers, biological studies
  - Polyoxyalkylenes, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Drug delivery systems
  - (inhalants; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Drug delivery systems
  - (nasal sprays; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Drug delivery systems
  - (nasal; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Drug delivery systems
  - (powders, nasal; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT Drug delivery systems
  - (solns., nasal; compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT 546-46-3, Zinc citrate 551-64-4 557-34-6, Zinc acetate 2847-05-4, Zinc malate 4468-02-4, Zinc gluconate 6228-53-1, Zinc succinate 7440-66-6D, Zinc, chelates 7646-85-7, Zinc chloride, biological studies 7733-02-0, Zinc sulfate 12519-36-7, Zinc-EDTA 16039-53-5, Zinc lactate 151728-40-4, Zinc ascorbate
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (compns. for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc)
- IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerol, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-50-1D, Sucrose, allyl ethers, polymers with acrylic acid 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 69-72-7, Salicylic acid, biological studies 77-92-9, Citric acid, biological studies 79-10-7D, Acrylic acid, polymers with pentaerythritol allyl ethers and/or sucrose allyl ethers 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid,

biological studies 88-99-3, Phthalic acid, biological studies  
 98-79-3, Pyroglutamic acid 102-71-6, Triethanolamine, biological studies  
 110-15-6, Succinic acid, biological studies 110-16-7, Maleic  
 acid, biological studies 110-17-8, Fumaric acid, biological studies  
 110-94-1, Glutaric acid 111-90-0, Transcutol 115-77-5D,  
 Pentaerythritol, allyl ethers, polymers with acrylic  
 acid 124-04-9, Adipic acid, biological studies  
 141-82-2, Malonic acid, biological studies 144-55-8, Sodium bicarbonate,  
 biological studies 150-90-3, Disodium succinate 526-95-4, Gluconic  
 acid 994-36-5, Sodium citrate 1310-73-2, Sodium hydroxide, biological  
 studies 1336-21-6, Ammonium hydroxide 5970-45-6, Zinc acetate  
 dihydrate 6915-15-7, Malic acid 7632-05-5, Sodium phosphate  
 9003-39-8, Polyvinyl pyrrolidone 9004-34-6D, Cellulose, derivs.  
 9004-54-0, Dextran, biological studies 9004-65-3, Hydroxypropyl methyl  
 cellulose 25322-68-3, Polyethylene glycol 27100-68-1, Vinyl  
 ether-Maleic anhydride copolymer 73038-24-1, Acrylic  
 acid-divinyl glycol copolymer 138757-67-2, Carbol 980  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comps. for prevention and treatment of cold and influenza-like  
 symptoms comprising chelated zinc)


L7 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 88-99-3, Phthalic acid, processes  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical  
 process); PROC (Process)  
 (liquid comps. for slow-release soft capsules)  
 RN 88-99-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




IT 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate  
 109-43-3, Dibutyl sebacate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (liquid comps. for slow-release soft capsules)  
 RN 84-66-2 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-diethyl ester (CA INDEX NAME)



RN 84-74-2 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester (CA INDEX NAME)



RN 109-43-3 CAPLUS  
CN Decanedioic acid, 1,10-dibutyl ester (CA INDEX NAME)



ACCESSION NUMBER: 2003:820197 CAPLUS  
DOCUMENT NUMBER: 139:312468  
TITLE: Liquid compositions for slow-release soft capsules  
INVENTOR(S): Paris, Laurence  
PATENT ASSIGNEE(S): Fr.  
SOURCE: Fr. Demande, 38 pp.  
CODEN: FRXXBL  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2838349	A1	20031017	FR 2002-4697	20020415
FR 2838349	B1	20040625		
WO 2003086368	A1	20031023	WO 2003-FR1195	20030415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003262129	A1	20031027	AU 2003-262129	20030415
EP 1499304	A1	20050126	EP 2003-740610	20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531531	T	20051020	JP 2003-583389	20030415
US 20050244489	A1	20051103	US 2005-511260	20050620
PRIORITY APPLN. INFO.:			FR 2002-4697	A 20020415
			WO 2003-FR1195	W 20030415

AN 2003:820197 CAPLUS  
DN 139:312468  
ED Entered STN: 19 Oct 2003  
TI Liquid compositions for slow-release soft capsules  
IN Paris, Laurence  
PA Fr.  
SO Fr. Demande, 38 pp.

CODEN: FRXXBL  
 DT Patent  
 LA French  
 IC ICM A61K009-48  
 ICS A61K009-56  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 17, 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2838349	A1	20031017	FR 2002-4697	20020415
	FR 2838349	B1	20040625		
	WO 2003086368	A1	20031023	WO 2003-FR1195	20030415
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
	AU 2003262129	A1	20031027	AU 2003-262129	20030415
	EP 1499304	A1	20050126	EP 2003-740610	20030415
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005531531	T	20051020	JP 2005-583389	20030415
	US 20050244489	A1	20051103	US 2005-511260	20050620
PRAI	FR 2002-4697	A	20020415		
	WO 2003-FR1195	W	20030415		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2838349	ICM	A61K009-48
	ICS	A61K009-56
	IPCI	A61K0009-48 [ICM,7]; A61K0009-56 [ICS,7]; A61K0009-52 [ICS,7,C*]
	IPCR	A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-56 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-26 [I,C*]; A61K0047-26 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]
	ECLA	A61K009/48
WO 2003086368	IPCI	A61K0009-48 [ICM,7]
	IPCR	A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-56 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-26 [I,C*]; A61K0047-26 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]

		[I,A]; A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]
AU 2003262129	ECLA	A61K009/48
	IPCI	A61K0009-48 [ICM,7]
	IPCR	A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-56 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-26 [I,C*]; A61K0047-26 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]
EP 1499304	IPCI	A61K0009-48 [ICM,7]
	IPCR	A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-56 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-26 [I,C*]; A61K0047-26 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]
	IPCI	A61K0009-48 [ICM,7]; A61K0009-08 [ICS,7]; A61K0031-167 [ICS,7]; A61K0031-192 [ICS,7]; A61K0031-196 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-26 [ICS,7]; A61K0047-32 [ICS,7]; A61K0047-36 [ICS,7]; A61K0047-38 [ICS,7]; A61K0047-42 [ICS,7]; A61P0029-00 [ICS,7]
JP 2005531531	IPCI	A61K0009-48 [ICM,7]; A61K0009-08 [ICS,7]; A61K0031-167 [ICS,7]; A61K0031-192 [ICS,7]; A61K0031-196 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-26 [ICS,7]; A61K0047-32 [ICS,7]; A61K0047-36 [ICS,7]; A61K0047-38 [ICS,7]; A61K0047-42 [ICS,7]; A61P0029-00 [ICS,7]
	IPCR	A61K0009-48 [I,A]; A61K0009-48 [I,C*]
	FTERM	4C076/AA11; 4C076/AA56; 4C076/BB01; 4C076/CC05; 4C076/DD07; 4C076/DD17; 4C076/DD22; 4C076/DD23; 4C076/DD26; 4C076/DD38; 4C076/DD43; 4C076/EE05; 4C076/EE06; 4C076/EE09; 4C076/EE11; 4C076/EE16; 4C076/EE24; 4C076/EE26; 4C076/EE30; 4C076/EE31; 4C076/EE38; 4C076/FF11; 4C076/FF31; 4C206/AA01; 4C206/AA02; 4C206/DA24; 4C206/FA31; 4C206/MA03; 4C206/MA05; 4C206/MA36; 4C206/MA57; 4C206/NA12; 4C206/ZB11
US 20050244489	IPCI	A61K0009-48 [ICM,7]
	IPCR	A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-56 [I,A]; A61K0031-167 [I,C*]; A61K0031-167 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-26 [I,C*]; A61K0047-26 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]
	NCL	424/451.000

ECLA A61K009/48

- AB The invention relates to liquid compns. intended for formation od prolonged-release capsules. The prolonged release of the drug is achieved by in situ formation of a matrix, which being compact and biodegradable, is obtained by instantaneous phys. modification of the contents of the capsule in contact with the gastric juices. Thus, slow-release soft capsules contained dimenhydrinate 50.0000g, Transcutol P 425.0000, Sepiegel-305 400.0000 and sucrose acetate isobutyrate 25.0000 g.
- ST liq slow release soft capsule
- IT Surfactants  
(amphoteric; liquid compns. for slow-release soft capsules)
- IT Drug delivery systems  
(capsules, sustained-release; liquid compns. for slow-release soft capsules)
- IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(esters; liquid compns. for slow-release soft capsules)
- IT Polyesters, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydroxycarboxylic acid-based; liquid compns. for slow-release soft capsules)
- IT Surfactants  
(ionic; liquid compns. for slow-release soft capsules)
- IT Polyesters, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lactic acid-based; liquid compns. for slow-release soft capsules)
- IT Buffers  
Dissolution  
Particle size distribution  
Plasticizers  
Surfactants  
Viscosity  
(liquid compns. for slow-release soft capsules)
- IT Carbonates, biological studies  
Gelatin, biological studies  
Paraffin oils  
Phosphates, biological studies  
Polyamides, biological studies  
Polyesters, biological studies  
Polymers, biological studies  
Polyoxyalkylenes, biological studies  
Polysaccharides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(liquid compns. for slow-release soft capsules)
- IT Surfactants  
(nonionic; liquid compns. for slow-release soft capsules)
- IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyhydric; liquid compns. for slow-release soft capsules)
- IT Fats and Glycidic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable; liquid compns. for slow-release soft capsules)
- IT 50-21-5, Lactic acid, processes 64-19-7, Acetic acid  
, processes 77-92-9, Citric acid, processes 79-09-4, Propionic acid,  
processes 88-99-3, Phthalic acid, processes 1305-62-0, Calcium  
hydroxide, processes 1310-58-3, Potassium hydroxide, processes  
1310-73-2, Sodium hydroxide, processes 7647-01-0, Hydrochloric acid,  
processes 7664-38-2, Phosphoric acid, processes  
RL: PEP (Physical, engineering or chemical process); PYP (Physical  
process); PROC (Process)  
(liquid compns. for slow-release soft capsules)

IT 50-70-4, Sorbitol, biological studies 57-50-1D, Saccharose, derivs.  
 63-42-3, Lactose 69-65-8, Mannitol 79-06-1D, Acrylamide, polymers  
 79-10-7D, Acrylic acid, polymers 79-41-4D,  
 Methacrylic acid, polymers 84-66-2, Diethyl phthalate  
 84-74-2, Dibutyl phthalate 87-99-0, Xylitol 88-12-0D, polymers  
 102-76-1, Triacetin 109-43-3, Dibutyl sebacate 111-90-0,  
 Transcutol P 126-13-6, Sucrose acetate isobutyrate 585-88-6,  
 Maltitol 1338-39-2, Montane 20 3812-32-6, Carbonate, biological  
 studies 7558-79-4, Disodium phosphate 7558-80-7, Monosodium phosphate  
 7778-77-0, Monobasic potassium phosphate 9000-01-5, Arabic gum  
 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-65-1, Tragacanth gum  
 9000-69-5, Pectin 9002-89-5, Poly(vinyl alcohol) 9003-39-8,  
 Polyvinylpyrrolidone 9004-34-6D, Cellulose, derivs. 9004-36-8,  
 Cellulose acetate butyrate 9004-38-0, Cellulose acetate phthalate  
 9004-39-1, Cellulose acetate propionate 9004-57-3, Ethyl cellulose  
 9004-58-4, Ethyl hydroxyethyl cellulose 9004-64-2, Hydroxypropyl  
 cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Starch,  
 biological studies 9005-25-8D, Starch, derivs. 9005-32-7, Alginic acid  
 9012-76-4, Chitosan 9049-76-7, Hydroxypropyl starch 9050-31-1,  
 Hydroxypropyl methyl cellulose phthalate 9050-36-6, Maltodextrin  
 1138-66-2, Xanthan gum 25014-41-9, Polyacrylonitrile 25322-68-3,  
 Polyethylene glycol 25496-72-4, Glycerin monooleate 26009-03-0,  
 Polyglycolic acid 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)]  
 26100-51-6, Polylactic acid 26124-68-5, Polyglycolic acid 37348-65-5,  
 Glycerin linoleate 71010-52-1, Gellan gum 78474-45-0, Plastoid B  
 148093-12-3, Sepigel 305  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (liquid comps. for slow-release soft capsules)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Anon; PATENT ABSTRACTS OF JAPAN 1989, V013(049), PC-565
- (2) Dewandre, L; FR 2774907 A 1999 CAPLUS
- (3) Merrel Dow; EP 0095123 A 1983 CAPLUS
- (4) Merrel Dow; EP 0173293 A 1986 CAPLUS
- (5) Seppic; WO 9936445 A 1999 CAPLUS
- (6) Seppic; WO 9942521 A 1999 CAPLUS
- (7) Seppic; WO 0135922 A 2001 CAPLUS
- (8) Tabacchi, G; US 2001051686 A1 2001 CAPLUS
- (9) Tabacchi, G; US 2001053801 A1 2001 CAPLUS
- (10) Tabacchi, G; US 2002032243 A1 2002 CAPLUS
- (11) Toyo Capsule Kk; JP 63246333 A 1988 CAPLUS
- (12) Toyo Kapuseru Kk; JP 63246322 A 1988 CAPLUS

L7 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, Phthalic acid, biological studies 110-15-6,  
 Succinic acid, biological studies 111-20-6, Sebacic acid,  
 biological studies 124-04-9, Adipic acid, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 111-20-6 CAPLUS  
CN Decanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>8</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2003:696654 CAPLUS  
DOCUMENT NUMBER: 139:229691  
TITLE: Nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.  
INVENTOR(S): Purpura, Martin; Jaeger, Ralf; Koenig, Harro  
PATENT ASSIGNEE(S): Degussa Bioactives G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003071884	A1	20030904	WO 2003-EP2042	20030227
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10208568	A1	20030918	DE 2002-10208568	20020227
AU 2003215607	A1	20030909	AU 2003-215607	20030227
PRIORITY APPLN. INFO.:			DE 2002-10208568	A 20020227
			WO 2003-EP2042	W 20030227
AN 2003:696654 CAPLUS				
DN 139:229691				
ED Entered STN: 05 Sep 2003				
TI Nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.				
IN Purpura, Martin; Jaeger, Ralf; Koenig, Harro				
PA Degussa Bioactives G.m.b.H., Germany				
SO PCT Int. Appl., 30 pp.				
CODEN: PIXXD2				



DT Patent  
 LA German  
 IC ICM A23L001-305  
 ICS A61K031-155; A61P003-00; C07C279-14  
 CC 17-6 (Food and Feed Chemistry)  
 Section cross-reference(s): 18, 62, 63  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003071884	A1	20030904	WO 2003-EP2042	20030227
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10208568	A1	20030918	DE 2002-10208568	20020227
	AU 2003215607	A1	20030909	AU 2003-215607	20030227
PRAI	DE 2002-10208568	A	20020227		
	WO 2003-EP2042	W	20030227		

# CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2003071884	ICM	A23L001-305
		ICS	A61K031-155; A61P003-00; C07C279-14
		IPCI	A23L0001-305 [ICM,7]; A61K0031-155 [ICS,7]; A61P0003-00 [ICS,7]; C07C0279-14 [ICS,7]; C07C0279-00 [ICS,7,C*]
		IPCR	A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; C07C0279-00 [I,C*]; C07C0279-14 [I,A]
		ECLA	A23L001/305A; A61K031/155; A61K031/155+M; A61K045/06; C07C279/14
	DE 10208568	IPCI	C07C0279-14 [ICM,7]; C07C0279-00 [ICM,7,C*]; A23L0001-29 [ICS,7]; A23L0001-30 [ICS,7]; A23K0001-16 [ICS,7]; A61K0007-00 [ICS,7]
		IPCR	A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; C07C0279-00 [I,C*]; C07C0279-14 [I,A]
		ECLA	A23L001/305A; A61K031/155; A61K031/155+M; A61K045/06; C07C279/14
	AU 2003215607	IPCI	A23L0001-305 [ICM,7]; A61K0031-155 [ICS,7]; A61P0003-00 [ICS,7]; C07C0279-14 [ICS,7]; C07C0279-00 [ICS,7,C*]
		IPCR	A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; C07C0279-00 [I,C*]; C07C0279-14 [I,A]

AB The invention relates to a compound containing creatine, an acid component and/or a complexing agent. The invention also relates to methods for producing said compound, to a formulation containing the same, and to the use

of the inventive compound

ST creatine carboxylate amino acid complexing agent nutritional supplement; nerve muscle health creatine carboxylate amino acid nutritional supplement

IT Heterocyclic compounds

RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)  
 (acids; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Strength  
 (agents for enhancement of muscle; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Sulfonic acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (alkanesulfonic; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Sulfonic acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (arenesulfonic; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Food  
 (dietetic; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Exercise  
 (endurance, agents for enhancement of; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (inorg.; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Cytoprotective agents  
 Nervous system agents  
 (neuroprotective agents; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Coloring materials  
 Cosmetics  
 Dispersing agents  
 Food additives  
 Food functional properties  
 Food preservatives  
 Food texture  
 Human  
 Nervous system stimulants  
 Nutrients  
 Odor and Odorous substances  
 Parting materials  
 Solubilizers  
 Temperature effects, biological  
 Vacuum  
 Wound healing  
 (nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Amino acids, biological studies  
 Carboxylic acids, biological studies  
 Fatty acids, biological studies  
 Lecithins  
 Neurotransmitters  
 Phosphatidylcholines, biological studies  
 Phosphatidylserines

Polymers, biological studies  
 Trace elements, biological studies  
 Vitamins  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

IT Acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (organic; nutritional supplement containing creatine, an acid component  
 and/or a complexing agent for improvement of muscle and nerve health.)

IT Alcohols, biological studies  
 Carbohydrates, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (phosphorylated; nutritional supplement containing creatine, an acid  
 component and/or a complexing agent for improvement of muscle and nerve  
 health.)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (polyunsatd., omega-3; nutritional supplement containing creatine, an acid  
 component and/or a complexing agent for improvement of muscle and nerve  
 health.)

IT Muscle, disease  
 Muscular dystrophy  
 (protective agents for; nutritional supplement containing creatine, an acid  
 component and/or a complexing agent for improvement of muscle and nerve  
 health.)

IT Exercise  
 (sports; nutritional supplement containing creatine, an acid component  
 and/or a complexing agent for improvement of muscle and nerve health.)

IT Amino acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (D-; nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

IT 50-21-5, Lactic acid, biological studies 50-71-5, Alloxan 51-35-4,  
 4-Hydroxyproline 52-90-4, Cysteine, biological studies 56-12-2,  
 γ-Aminobutyric acid, biological studies 56-40-6, Glycine,  
 biological studies 56-41-7, L-Alanine, biological studies 56-45-1,  
 L-Serine, biological studies 56-84-8, L-Aspartic acid, biological  
 studies 56-85-9, L-Glutamine, biological studies 56-86-0, L-Glutamic  
 acid, biological studies 56-87-1, L-Lysine, biological studies  
 56-89-3, Cystine, biological studies 57-00-1, Creatine 57-10-3,  
 Palmitic acid, biological studies 57-11-4, Stearic acid, biological  
 studies 57-50-1, Sucrose, biological studies 58-85-5, Biotin  
 59-67-6, Nicotinic acid, biological studies 60-18-4, L-Tyrosine,  
 biological studies 60-33-3, Linoleic acid, biological studies 61-90-5,  
 L-Leucine, biological studies 62-49-7, Choline 63-68-3, L-Methionine,  
 biological studies 63-91-2, L-Phenylalanine, biological studies  
 64-18-6, Formic acid, biological studies 64-19-7, Acetic  
 acid, biological studies 65-85-0, Benzoic acid, biological  
 studies 67-52-7, Barbituric acid 69-72-7, Salicylic acid, biological  
 studies 69-93-2, Uric acid, biological studies 70-18-8, Glutathione,  
 biological studies 70-26-8, L-Ornithine 70-47-3, L-Asparagine,  
 biological studies 71-00-1, L-Histidine, biological studies 72-18-4,  
 L-Valine, biological studies 73-22-3, L-Tryptophan, biological studies  
 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine,

biological studies 75-75-2, Methanesulfonic acid 79-10-7,  
 Acrylic acid, biological studies 79-14-1, Glycolic  
 acid, biological studies 79-31-2, Isobutyric acid 79-41-4, Methacrylic  
 acid, biological studies 79-83-4, Pantothenic acid 83-86-3, Phytic  
 acid 88-14-2, 2-Furancarboxylic acid 88-99-3, Phthalic acid,  
 biological studies 90-64-2, Mandelic acid 97-65-4, Itaconic acid,  
 biological studies 98-11-3, Benzenesulfonic acid, biological studies  
 98-79-3 99-05-8, 3-Aminobenzoic acid 99-06-9, 3-Hydroxybenzoic acid,  
 biological studies 99-96-7, 4-Hydroxybenzoic acid, biological studies  
 100-21-0, Terephthalic acid, biological studies 103-82-2, Phenylacetic  
 acid, biological studies 104-15-4, p-Toluenesulfonic acid, biological  
 studies 104-98-3, Urocanic acid 107-92-6, Butyric acid, biological  
 studies 107-95-9,  $\beta$ -Alanine 107-97-1, N-Methylglycine 108-80-5,  
 Cyanuric acid 110-15-6, Succinic acid, biological studies  
 110-44-1, Sorbic acid 110-94-1, Glutaric acid 111-14-8, Heptanoic acid  
 111-16-0, Pimelic acid 111-20-6, Sebacic acid, biological  
 studies 112-37-8, Undecanoic acid 118-92-3, 2-Aminobenzoic acid  
 123-99-9, Azelaic acid, biological studies 124-04-9, Adipic  
 acid, biological studies 124-07-2, Octanoic acid, biological studies  
 141-78-6, Ethyl acetate, biological studies 141-82-2, Malonic acid,  
 biological studies 142-62-1, Hexanoic acid, biological studies  
 143-07-7, Dodecanoic acid, biological studies 144-62-7, Oxalic acid,  
 biological studies 147-85-3, L-Proline, biological studies 150-13-0,  
 4-Aminobenzoic acid 305-84-0, Carnosine 320-77-4, Isocitric acid  
 328-42-7, Oxalacetic acid 334-48-5, Decanoic acid 463-40-1, Linolenic  
 acid 473-81-4, Glyceric acid 473-90-5, Mesoxalic acid 495-69-2,  
 Hippuric acid 498-24-8, Mesaconic acid 505-48-6, Suberic acid  
 506-32-1, Arachidonic acid 526-95-4, Gluconic acid 535-75-1, Pipecolic  
 acid 541-48-0,  $\beta$ -Aminobutyric acid 541-50-4, Acetoacetic acid,  
 biological studies 544-63-8, Tetradecanoic acid, biological studies  
 585-84-2, cis-Aconitic acid 621-82-9, Cinnamic acid, biological studies  
 1493-13-6, Trifluoromethanesulfonic acid 2033-24-1, Meldrumic acid  
 2835-81-6,  $\alpha$ -Aminobutyric acid 3724-65-0, Crotonic acid  
 4023-65-8, trans-Aconitic acid 4350-09-8, 5-Hydroxytryptophan  
 5329-14-6, Sulfamic acid 6205-14-7, Hydroxycitric acid 6556-12-3,  
 D-Glucuronic acid 7631-86-9, Silica, biological studies 7664-38-2D,  
 Phosphoric acid, esters 9000-07-1, Carrageenan 9003-01-4, Polyacrylic  
 acid 9004-32-4, Carboxymethylcellulose sodium salt 9004-34-6,  
 Cellulose, biological studies 9005-32-7, Alginate acid 10043-35-3,  
 Boric acid, biological studies 11138-66-2, Xanthan 25525-21-7,  
 Glucaric acid 51750-56-2, Propanetricarboxylic acid  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)

(nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

IT 592465-35-5

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

IT 6020-87-7, Creatine monohydrate

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

IT 592465-34-4P 592465-36-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

(1) Albion Lab; WO 0104128 A 2001

(2) Anon; SIGMA CATALOGOUS: BIOCHEMICALS, ORGANIC COMPOUNDS FOR RESEARCH AND


DIAGNOSTIC REAGENTS 1989, P473

- (3) Biosalts, S; WO 0117948 A 2001 CAPLUS
- (4) Biosalts, S; WO 02076931 A 2002 CAPLUS
- (5) Douglas, K; US 2001008641 A1 2001
- (6) Flamma Spa; WO 9604240 A 1996 CAPLUS
- (7) Kenneth, T; US 6211407 B1 2001 CAPLUS
- (8) Sen-Maw, F; US 5994581 A 1999 CAPLUS
- (9) Sueddeutsche, K; DE 19653225 A 1998 CAPLUS
- (10) Sueddeutsche, K; DE 19707694 A 1998 CAPLUS
- (11) Sueddeutsche, K; DE 19929993 A 2001 CAPLUS


L7 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 88-99-3D, Phthalic acid, esters 110-15-6, Succinic acid,  
 biological studies 117-81-7, Dioctyl Phthalate 124-04-9  
 , Adipic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release compns. containing opioids and polymers)  
 RN 88-99-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)



RN 117-81-7 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2003:242150 CAPLUS  
 DOCUMENT NUMBER: 138:276257  
 TITLE: Controlled release compositions containing opioids and polymers  
 INVENTOR(S): Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Jensen, Christine

PATENT ASSIGNEE(S): Egalet A/S, Den.  
 SOURCE: PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024430	A1	20030327	WO 2002-DK619	20020923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002339414	A1	20030401	AU 2002-339414	20020923
EP 1429744	A1	20040623	EP 2002-776906	20020923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20040253310	A1	20041216	US 2004-490169	20040723
PRIORITY APPLN. INFO.:			DK 2001-1376	A 20010921
			WO 2002-DK619	W 20020923

AN 2003:242150 CAPLUS  
 DN 138:276257  
 ED Entered STN: 28 Mar 2003  
 TI Controlled release compositions containing opioids and polymers  
 IN Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Jensen, Christine  
 PA Egalet A/S, Den.  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-28  
 ICS A61K047-00; A61K009-22; A61K031-485  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024430	A1	20030327	WO 2002-DK619	20020923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002339414	A1	20030401	AU 2002-339414	20020923
EP 1429744	A1	20040623	EP 2002-776906	20020923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20040253310	A1	20041216	US 2004-490169	20040723

PRAI DK 2001-1376	A	20010921
WO 2002-DK619	W	20020923

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003024430	ICM	A61K009-28
	ICS	A61K047-00; A61K009-22; A61K031-485
	IPCI	A61K0009-28 [ICM,7]; A61K0047-00 [ICS,7]; A61K0009-22 [ICS,7]; A61K0031-485 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [N,C*]; A61K0009-28 [N,A]
AU 2002339414	ECLA	A61K009/00Z4; A61K009/20P
	IPCI	A61K0009-28 [ICM,7]; A61K0047-00 [ICS,7]; A61K0009-22 [ICS,7]; A61K0031-485 [ICS,7]
EP 1429744	IPCI	A61K0009-28 [ICM,7]; A61K0047-00 [ICS,7]; A61K0009-22 [ICS,7]; A61K0031-485 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [N,C*]; A61K0009-28 [N,A]
US 20040253310	ECLA	A61K009/00Z4; A61K009/20P; K61K; K61K
	IPCI	A61K0009-24 [ICM,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [N,C*]; A61K0009-28 [N,A]
	NCL	424/472.000
	ECLA	A61K009/00Z4; A61K009/20P

AB A pharmaceutical composition for controlled release of an active substance. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises a matrix containing polymer or

a mixture of polymers, an active substance and, optionally, 1 or more excipients, and a coating. A zero order drug release is desirable. The matrix typically comprises PEG and the active substance is typically an opioid such as morphine or a glucuronide. The coating comprises a first cellulose derivative which is substantially insol. in the aqueous medium and at least 1 of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and, a filler. A composition was prepared from the following ingredients: PEG-200,000 83.5, and morphine sulfate 16.5% by weight. The coating and the matrix were prepared as described above. The composition

was 9 mm long and had elliptic formed surfaces. Morphine sulfate (96.65%) was released in 8 h.

ST controlled release opioid polymer; morphine controlled release polymer

IT Alcohols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C16-18; controlled release compns. containing opioids and polymers)

IT Viscosity

(adjusting agents; controlled release compns. containing opioids and polymers)

IT Solubility

(agents for decrease of; controlled release compns. containing opioids and polymers)

IT Molding of plastics and rubbers

(blow; controlled release compns. containing opioids and polymers)

IT Molding of plastics and rubbers

(compression; controlled release compns. containing opioids and polymers)

IT Acacia

- Analgesics
- Antioxidants
- Coating materials
- Drug bioavailability
- Extrusion of plastics and rubbers
- Fillers
- Gums and Mucilages
- Human
- Molasses
- Molecular weight distribution
- Particle size distribution
- Plasticizers
- Preservatives
- Solubilizers
- Solvents
- Stability
  - (controlled release compns. containing opioids and polymers)

IT Acids, biological studies

- Alkali metal salts
- Alkaline earth salts
- Amides, biological studies
- Amines, biological studies
- Amino acids, biological studies
- Bases, biological studies
- Bentonite, biological studies
- Carbohydrates, biological studies
- Carboxylic acids, biological studies
- Clays, biological studies
- Disaccharides
- Ethers, biological studies
- Fatty acids, biological studies
- Gelatins, biological studies
- Glycerides, biological studies
- Kaolin, biological studies
- Monosaccharides
- Oligosaccharides, biological studies
- Opioids
- Paraffin oils
- Polymers, biological studies
- Polyoxyalkylenes, biological studies
- Polyoxyalkylenes, biological studies
- Polysaccharides, biological studies
- Salts, biological studies
- Smectite-group minerals

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled release compns. containing opioids and polymers)

IT Drug delivery systems

- (controlled-release; controlled release compns. containing opioids and polymers)

IT Carboxylic acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dicarboxylic; controlled release compns. containing opioids and polymers)

IT Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(esters or ethers; controlled release compns. containing opioids and polymers)

IT Fatty acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(esters; controlled release compns. containing opioids and polymers)

IT Chondrus crispus

(exts.; controlled release compns. containing opioids and polymers)



IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty; controlled release compns. containing opioids and polymers)

IT Plantago psyllium  
 (husk exts. (Isabgol); controlled release compns. containing opioids and polymers)

IT Molding of plastics and rubbers  
 (injection; controlled release compns. containing opioids and polymers)

IT Bases, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inorg.; controlled release compns. containing opioids and polymers)

IT Surfactants  
 (nonionic; controlled release compns. containing opioids and polymers)

IT Alkaloids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (opium, hydrochlorides; controlled release compns. containing opioids and polymers)

IT Natural products, pharmaceutical  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (opium; controlled release compns. containing opioids and polymers)

IT Acids, biological studies  
 Bases, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (organic; controlled release compns. containing opioids and polymers)

IT Gums and Mucilages  
 (panwar; controlled release compns. containing opioids and polymers)

IT Polyoxoalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyester-, block; controlled release compns. containing opioids and polymers)

IT Polyoxoalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyester-, graft; controlled release compns. containing opioids and polymers)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyoxoalkylene-, block; controlled release compns. containing opioids and polymers)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyoxoalkylene-, graft; controlled release compns. containing opioids and polymers)

IT Dissolution  
 (rate; controlled release compns. containing opioids and polymers)

IT Urine  
 (retention, side effect; controlled release compns. containing opioids and polymers)

IT Dizziness  
 Nausea  
 Pruritus  
 Sedation  
 Sweat  
 (side effect; controlled release compns. containing opioids and polymers)

IT Carbohydrates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sugar esters; controlled release compns. containing opioids and polymers)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; controlled release compns. containing opioids and polymers)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable; controlled release compns. containing opioids and polymers)

IT Mouth, disease  
 (xerostomia, side effect; controlled release compns. containing opioids and polymers)

IT 57-27-2, Morphine, biological studies 64-31-3, Morphine sulfate  
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release compns. containing opioids and polymers)

IT 50-21-5, Lactic acid, biological studies 50-69-1, Ribose 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Glucose, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-03-4, Glycerophosphoric acid 57-11-4, Stearic acid, biological studies 57-42-1, Meperidine 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 58-86-6, Xylose, biological studies 62-53-3, Aniline, biological studies 62-54-4, Calcium acetate 62-67-9, Nalorphine 63-42-3, Lactose 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-39-1, Promedol 65-42-9, Lyxose 65-85-0, Benzoic acid, biological studies 69-65-8, Mannitol 75-15-0, Carbon disulfide, biological studies 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-58-4, Ethylmorphine 76-99-3, Methadone 77-07-6, Levorphanol 77-14-5, Proheptazine 77-15-6, Ethoheptazine 77-20-3, Alphaprodine 77-86-1, Triis(hydroxymethyl)aminomethane 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid, biological studies 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-89-8, Inositol 87-99-0, Xylitol 88-99-3D, Phthalic acid, esters 90-64-2, Mandelic acid 98-10-2, Benzenesulfonamide 98-95-3, Nitrobenzene, biological studies 100-02-7, p-Nitrophenol, biological studies 109-97-7, Pyrrole 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-44-1, Sorbic acid 110-94-1, Glutaric acid 111-16-0, Pimelic acid 111-42-2, Diethanolamine, biological studies 112-72-1, Myristyl alcohol 112-92-5, Stearyl alcohol 117-81-7, Dioctyl Phthalate 123-56-8, Succinimide 123-76-2, Levulinic acid 124-04-9, Adipic acid, biological studies 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 127-08-2, Potassium acetate 127-09-3, Sodium acetate 127-17-3, Pyruvic acid, biological studies 127-35-5, Phenazocine 140-99-8, Calcium succinate 141-82-2, Malonic acid, biological studies 143-28-2, Oleyl alcohol 143-52-2, Metopon 144-14-9, Anileridine 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Oxalic acid, biological studies 147-81-9, Arabinose 149-91-7, Gallic acid, biological studies 152-02-3, Levallorphan 288-32-4, Imidazole, biological studies 298-12-4, Glyoxylic acid 298-14-6 302-01-2, Hydrazine, biological studies 302-41-0, Piritramide 357-56-2, Dextromoramide 359-83-1, Pentazocine 427-00-9, Desomorphine 437-38-7, Fentanyl 441-61-2, Ethylmethylthiambutene 463-77-4, Carbamic acid, biological studies 466-40-0, Isomethadone 466-97-7, Normorphine 466-99-9, Hydromorphone 467-18-5, Myrophine 467-83-4, Dipipanone 467-84-5, Phenadoxone 467-85-6, Normethadone 467-86-7, Dioxaphetyl butyrate 468-07-5, Phenomorphan 468-56-4, Hydroxypethidine 469-62-5, Dextropropoxyphene 469-79-4, Ketobemidone 471-34-1, Calcium carbonate, biological studies 471-47-6, Oxamic acid 473-81-4, Glyceric acid 490-79-9, Gentisic acid 497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium carbonate 509-60-4, Dihydromorphine 509-78-4, Dimenoxadol 524-84-5, Dimethylthiambutene 526-94-3, MonoSodium tartrate 545-90-4, Dimepheptanol 546-93-0, Magnesium carbonate 557-04-0 561-27-3, Heroin 561-48-8, Norpipanone 561-76-2, Properidine 562-26-5, Phenoperidine 565-63-9, Angelic acid 584-08-7,

Potassium carbonate 593-67-9, Ethenamine 597-44-4, Citramalic acid 613-78-5,  $\beta$ -Naphthyl salicylate 621-82-9, Cinnamic acid, biological studies 639-48-5, Nicomorphine 868-14-4, MonoPotassium tartrate 911-65-9, Etonitazene 994-36-5, Sodium citrate 1310-58-3, Potassium hydroxide (K(OH)), biological studies 1310-73-2, Sodium hydroxide, biological studies 1336-21-6, Ammonium hydroxide 1344-28-1, Aluminum oxide, biological studies 1531-12-0, Norlevorphanol 1592-23-0, Calcium stearate 1724-02-3, Glutaconic acid 2466-09-3, Pyrophosphoric acid 3164-34-9, Calcium tartrate 3458-28-4, Mannose 3572-80-3, Cycloazocine 3688-85-5, Diapamide 3734-52-9, Metazocine 3861-76-5, Clonitazene 4468-02-4, Zinc gluconate 5987-68-8, Altrose 6038-51-3, Allose 6915-15-7, Malic acid 7429-90-5D, Aluminum, compds. 7447-40-7, Potassium chloride (KCl), biological studies 7558-79-4, DiSodium hydrogen phosphate 7558-80-7, Sodium dihydrogen phosphate 7601-54-9, TriSodium phosphate 7631-86-9, Silica, biological studies 7632-05-5, Sodium phosphate 7647-01-0, Hydrochloric acid, biological studies 7647-14-5, Sodium chloride, biological studies 7664-38-2, Orthophosphoric acid, biological studies 7664-38-2D, Phosphoric acid, esters 7664-93-9, Sulfuric acid, biological studies 7693-13-2, Calcium citrate 7733-02-0, Zinc sulfate 7757-82-6, Sodium sulfate, biological studies 7757-93-9, DiCalcium phosphate 7758-11-4, Potassium monohydrogen phosphate 7778-18-9, Calcium sulfate 7778-49-6, Potassium citrate 7778-77-0, Potassium dihydrogen phosphate 7778-80-5, Potassium sulfate, biological studies 7786-30-3, Magnesium chloride (MgCl<sub>2</sub>), biological studies 7803-49-8, Hydroxylamine, biological studies 9000-28-6, Ghatti gum 9000-69-5, Pectin 9002-18-0, Agar 9003-11-6 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, derivs. 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-48-2, Cellulose propionate 9004-53-9, Dextrin 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl Cellulose 9004-58-4, Ethyl hydroxyethyl Cellulose 9004-59-5, Ethyl methyl Cellulose 9004-62-0, Hydroxyethyl Cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl Cellulose 9004-70-0, Cellulose nitrate 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-35-0, Calcium Alginate 9005-38-3, Sodium Alginate 9005-82-7, Amylose 9014-63-5, Xylan 9032-42-2, Hydroxyethyl methyl Cellulose 9037-22-3, Amylopectin 10043-35-3, Boric acid, biological studies 10043-52-4, Calcium chloride, biological studies 10061-32-2, Levophenacetylmorphan 10103-46-5, Calcium phosphate 10316-66-2, 2-Hydroxy-2-cyclohexenone 10343-62-1, Metaphosphoric acid 13463-67-7, Titanium oxide, biological studies 13495-09-5, Pimindine 14047-56-4 14297-87-1, Benzylmorphine 14807-96-6, Talc, biological studies 15301-48-1, Bezitramide 15686-91-6, Propiram 16068-46-5, Potassium phosphate 20290-09-9, Morphine 3-glucuronide 20290-10-2, Morphine 6-glucuronide 20594-83-6, Nalbuphine 21645-51-2, Aluminum oxide hydrate, biological studies 22445-04-1 25322-68-3, Polyethylene glycol 25322-68-3D, Polyethylene glycol, esters or ethers 25384-17-2, Allylproline 27203-92-5, Tramadol 30435-30-4 36653-82-4, Cetyl alcohol 37353-59-6, HydroxyMethyl Cellulose 42408-82-2, Butorphanol 51931-66-9, Tilidine 52485-79-7, Buprenorphine 53648-55-8, Dezocine 54340-58-8, Meptazinol 56030-54-7, Sufentanil 61380-40-3, Lofentanil 62212-91-3, Sodium Starch 69670-80-0, Hydroxymethyl propyl cellulose 71195-58-9, Alfentanil 72522-13-5, Eptazocine 74811-65-7, Croscarmellose sodium 106392-12-5, Polyethylene glycol-polypropylene glycol block copolymer 199915-32-7, Glycolic acid-lactic acid-polyethylene glycol block copolymer 443360-37-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled release compns. containing opioids and polymers)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE


(1) Alza Corp; WO 9944591 A 1999 CAPLUS

- (2) Bukh Meditec; WO 8909066 A 1989 CAPLUS  
 (3) Bukh Meditec; WO 9104015 A 1991 CAPLUS  
 (4) Daniel, B; WO 9522962 A 1995 CAPLUS  
 (5) Daniel, B; WO 9951208 A 1999 CAPLUS


L7 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
 IT 88-99-3D, Phthalic acid, esters 110-15-6, Succinic acid,  
 biological studies 117-81-7, Dioctyl phthalate 124-04-9  
 , Adipic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release pharmaceutical compns. containing polymers)  
 RN 88-99-3 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
 CN Butanedioic acid (CA INDEX NAME)



RN 117-81-7 CAPLUS  
 CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2003:242149 CAPLUS  
 DOCUMENT NUMBER: 138:276256  
 TITLE: Controlled release pharmaceutical compositions  
 containing polymers  
 INVENTOR(S): Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian;  
 Lademann, Anne-Marie; Jensen, Christine  
 PATENT ASSIGNEE(S): Egalet A/S, Den.  
 SOURCE: PCT Int. Appl., 105 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024429	A1	20030327	WO 2002-DK620	20020923
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002342573	A1	20030401	AU 2002-342573	20020923
EP 1429739	A1	20040623	EP 2002-779224	20020923
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
EP 1929998	A2	20080611	EP 2007-24778	20020923
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR			
US 20040234602	A1	20041125	US 2004-490308	20040623
PRIORITY APPLN. INFO.:			DK 2001-1377	A 20010921
			DK 2002-1044	A 20020703
			DK 2001-1375	A 20010921
			DK 2001-1611	A 20011031
			EP 2002-776907	A3 20020923
			WO 2002-DK620	W 20020923

AN 2003:242149 CAPLUS  
DN 138:276256  
ED Entered STN: 28 Mar 2003  
TI Controlled release pharmaceutical compositions containing polymers  
IN Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Lademann, Anne-Marie; Jensen, Christine  
PA Egalet A/S, Den.  
SO PCT Int. Appl., 105 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K009-22  
ICS A61K009-28; A61K047-00; A61K031-403  
CC 63-6 (Pharmaceuticals)  
Section cross-reference(s): 1, 62

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024429	A1	20030327	WO 2002-DK620	20020923
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002342573	A1	20030401	AU 2002-342573	20020923
EP 1429739	A1	20040623	EP 2002-779224	20020923
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 EP 1929998 A2 20080611 EP 2007-24778 20020923  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,  
 LI, LU, MC, NL, PT, SE, SK, TR  
 US 20040234602 A1 20041125 US 2004-490308 20040623  
 PRAI DK 2001-1377 A 20010921  
 DK 2002-1044 A 20020703  
 DK 2001-1375 A 20010921  
 DK 2001-1611 A 20011031  
 EP 2002-776907 A3 20020923  
 WO 2002-DK620 W 20020923

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003024429	ICM	A61K009-22
	ICS	A61K009-28; A61K047-00; A61K031-403
	IPCI	A61K0009-22 [ICM,7]; A61K0009-28 [ICS,7]; A61K0047-00 [ICS,7]; A61K0031-403 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2
AU 2002342573	IPCI	A61K0009-22 [ICM,7]; A61K0009-28 [ICS,7]; A61K0047-00 [ICS,7]; A61K0031-403 [ICS,7]
EP 1429739	IPCI	A61K0009-22 [ICM,7]; A61K0009-28 [ICS,7]; A61K0047-00 [ICS,7]; A61K0031-403 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2
EP 1929998	IPCI	A61K0009-16 [I,A]; A61K0009-22 [I,A]; A61K0009-28 [I,A]; A61P0009-04 [I,A]; A61P0009-00 [I,C*]; A61K0031-403 [N,A]
US 20040234602	IPCI	A61K0009-24 [ICM,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]
	NCL	424/473.000
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2

AB A method for controlling the release of at least one therapeutically, prophylactically and/or diagnostically active substance into an aqueous medium by erosion of at least one surface of a pharmaceutical composition. The method comprises adjusting the concentration and/or the nature of the ingredients making up the matrix composition in such a manner so as to obtain an approx. zero-order release of the drug from the pharmaceutical composition when subject to an in vitro dissoln. test as described herein. The composition comprises a matrix composition containing a polymer or a mixture of polymers that may be substantially water soluble and/or crystalline, an active substance and, optionally, one or more pharmaceutically acceptable excipients, and a coating. Typical polymers are PEG. The coating comprises a first cellulose derivative which is substantially insol. in the aqueous medium, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The active ingredient may be

carvedilol. Stable solid dispersions of active substances having low water solubility are also disclosed. Thus, a composition contained PEG 64.6, carvedilol 30, and citric acid 5.4% by weight

ST controlled release solid dispersion carvedilol polymer

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C16-18; controlled release pharmaceutical compns. containing polymers)

IT Viscosity  
 (adjusting agents; controlled release pharmaceutical compns. containing polymers)

IT Heart, disease  
 (angina pectoris; controlled release pharmaceutical compns. containing polymers)

IT Molding of plastics and rubbers  
 (blow; controlled release pharmaceutical compns. containing polymers)

IT Molding of plastics and rubbers  
 (compression; controlled release pharmaceutical compns. containing polymers)

IT Antihypertensives  
 Antioxidants  
 Binders  
 Buffers  
 Cardiovascular agents  
 Coating materials  
 Deodorants (personal)  
 Dietary supplements  
 Diffusion  
 Disinfectants  
 Dissolution  
 Fillers  
 Gums and Mucilages  
 Human  
 Hypertension  
 Lubricants  
 Molasses  
 Molecular weight distribution  
 Particle size distribution  
 Plasticizers  
 Polymorphism (crystal)  
 Solubility  
 Solubilizers  
 Solvents  
 Stability  
 Stabilizing agents  
 (controlled release pharmaceutical compns. containing polymers)

IT Acids, biological studies  
 Alkali metal salts  
 Alkaline earth salts  
 Amides, biological studies  
 Amines, biological studies  
 Amino acids, biological studies  
 Bentonite, biological studies  
 Carbohydrates, biological studies  
 Carboxylic acids, biological studies  
 Clays, biological studies  
 Disaccharides  
 Ethers, biological studies  
 Fatty acids, biological studies  
 Glycerides, biological studies  
 Kaolin, biological studies  
 Monosaccharides

Oligosaccharides, biological studies  
 Paraffin oils  
 Polymers, biological studies  
 Polyoxyalkylenes, biological studies  
 Polyoxyalkylenes, biological studies  
 Polysaccharides, biological studies  
 Salts, biological studies  
 Smectite-group minerals  
 Vitamins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release pharmaceutical compns. containing polymers)

IT Drug delivery systems  
 (controlled-release; controlled release pharmaceutical compns. containing polymers)

IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; controlled release pharmaceutical compns. containing polymers)

IT Polyoxyalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters or ethers; controlled release pharmaceutical compns. containing polymers)

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters; controlled release pharmaceutical compns. containing polymers)

IT Chondrus crispus  
 (exts.; controlled release pharmaceutical compns. containing polymers)

IT Heart, disease  
 (failure; controlled release pharmaceutical compns. containing polymers)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty; controlled release pharmaceutical compns. containing polymers)

IT Plantago psyllium  
 (husk exts. (Isagbol); controlled release pharmaceutical compns. containing polymers)

IT Molding of plastics and rubbers  
 (injection; controlled release pharmaceutical compns. containing polymers)

IT Bases, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inorg.; controlled release pharmaceutical compns. containing polymers)

IT Surfactants  
 (nonionic; controlled release pharmaceutical compns. containing polymers)

IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oligo-; controlled release pharmaceutical compns. containing polymers)

IT Acids, biological studies  
 Bases, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (organic; controlled release pharmaceutical compns. containing polymers)

IT Gums and Mucilages  
 (panwar; controlled release pharmaceutical compns. containing polymers)

IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polycarboxylic; controlled release pharmaceutical compns. containing polymers)

IT Polyoxyalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyester-, block; controlled release pharmaceutical compns. containing polymers)

IT Polyoxyalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(polyester-, graft; controlled release pharmaceutical compns. containing polymers)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyoxyalkylene-, block; controlled release pharmaceutical compns. containing polymers)

IT Polyesters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyoxyalkylene-, graft; controlled release pharmaceutical compns. containing polymers)

IT Humidity  
 (relative; controlled release pharmaceutical compns. containing polymers)

IT Drug delivery systems  
 (solid dispersions; controlled release pharmaceutical compns. containing polymers)

IT Carbohydrates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sugar esters; controlled release pharmaceutical compns. containing polymers)

IT Drug delivery systems  
 (tablets, controlled-release; controlled release pharmaceutical compns. containing polymers)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; controlled release pharmaceutical compns. containing polymers)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable; controlled release pharmaceutical compns. containing polymers)

IT 72956-09-3, Carvedilol  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release pharmaceutical compns. containing polymers)

IT 50-21-5, Lactic acid, biological studies 50-69-1, Ribose 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Glucose, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-03-4, Glycerophosphoric acid 57-11-4, Stearic acid, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 62-53-3, Aniline, biological studies 62-54-4, Calcium acetate 63-42-3, Lactose 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-31-3, Morphine sulfate 65-42-9, Lyxose 65-85-0, Benzoic acid, biological studies 69-65-8, Mannitol 75-15-0, Carbon disulfide, biological studies 77-86-1, Tris(hydroxymethyl)aminomethane 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid, biological studies 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-89-8, Inositol 88-99-3D, Phthalic acid, esters 90-64-2, Mandelic acid 98-10-2, Benzenesulfonamide 98-95-3, Nitrobenzene, biological studies 100-02-7, p-Nitrophenol, biological studies 109-97-7, Pyrrole 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 111-16-0, Pimelic acid 111-42-2, Diethanolamine, biological studies 112-72-1, Myristyl alcohol 112-92-5, Stearyl alcohol 117-81-7, Dioctyl phthalate 123-56-8, Succinimide 123-76-2, Levulinic acid 124-04-9, Adipic acid, biological studies 127-08-2, Potassium acetate 127-09-3, Sodium acetate 127-17-3, Pyruvic acid, biological studies 140-99-8, Calcium succinate 141-82-2, Malonic acid, biological studies 143-28-2,

Oleyl alcohol 144-55-8, Sodium hydrogen carbonate, biological studies  
 144-62-7, Oxalic acid, biological studies 147-81-9, Arabinose  
 149-91-7, Gallic acid, biological studies 150-90-3, Sodium succinate  
 288-32-4, Imidazole, biological studies 298-12-4, Glyoxylic acid  
 298-14-6 302-01-2, Hydrazine, biological studies 463-77-4, Carbamic  
 acid, biological studies 471-34-1, Calcium carbonate, biological studies  
 471-47-6, Oxamic acid 473-81-4, Glyceric acid 490-79-9, Gentisic acid  
 497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium  
 carbonate 546-93-0, Magnesium carbonate 557-04-0 565-63-9, Angelic  
 acid 584-08-7, Potassium carbonate 593-67-9, Ethylenamine 597-44-4,  
 Citramalic acid 613-78-5,  $\beta$ -Naphthyl salicylate 621-82-9,  
 Cinnamic acid, biological studies 676-47-1 868-18-8, Sodium tartrate  
 921-53-9, Potassium tartrate 994-36-5, Sodium citrate 1310-58-3,  
 Potassium hydroxide (K(OH)), biological studies 1310-73-2, Sodium  
 hydroxide, biological studies 1336-21-6, Ammonium hydroxide 1344-28-1,  
 Aluminum oxide, biological studies 1724-02-3, Glutaconic acid  
 2152-76-3, Idose 2466-09-3, Pyrophosphoric acid 3164-34-9, Calcium  
 tartrate 3458-28-4, Mannose 4468-02-4, Zinc gluconate 5987-68-8,  
 Altrose 6038-51-3, Allose 6915-15-7, Malic acid 7429-90-5D,  
 Aluminum, compds. 7447-40-7, Potassium chloride, biological studies  
 7558-79-4, Disodium hydrogen phosphate 7558-80-7, Sodium dihydrogen  
 phosphate 7601-54-9, Trisodium phosphate 7631-86-9, Silica, biological  
 studies 7632-05-5, Sodium phosphate 7647-01-0, Hydrochloric acid,  
 biological studies 7647-14-5, Sodium chloride, biological studies  
 7664-38-2, Orthophosphoric acid, biological studies 7664-38-2D,  
 Phosphoric acid, esters 7664-93-9, Sulfuric acid, biological studies  
 7693-13-2, Calcium citrate 7733-02-0, Zinc sulfate 7757-82-6, Sodium  
 sulfate, biological studies 7757-93-9, DiCalcium phosphate 7758-11-4  
 7778-18-9, Calcium sulfate 7778-49-6, Potassium citrate 7778-53-2,  
 TriPotassium phosphate 7778-77-0, Potassium dihydrogen phosphate  
 7778-80-5, Potassium sulfate, biological studies 7786-30-3, Magnesium  
 chloride, biological studies 7803-49-8, Hydroxylamine, biological  
 studies 9000-01-5, Acacia gum 9000-28-6, Ghatti gum 9000-69-5,  
 Pectin 9004-32-4, Carboxymethyl cellulose 9004-32-4D, Carboxymethyl  
 cellulose, crosslinked 9004-34-6, Cellulose, biological studies  
 9004-34-6D, Cellulose, derivs. 9004-35-7, Cellulose acetate 9004-38-0,  
 Cellulose acetate phthalate 9004-48-2, Cellulose propionate 9004-53-9,  
 Dextrin 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl  
 cellulose 9004-58-4, Ethyl hydroxyethyl cellulose 9004-59-5, Ethyl  
 methyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2,  
 Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose  
 9004-70-0, Cellulose nitrate 9004-99-3, Polyethylene glycol monostearate  
 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid  
 9005-35-0, Calcium Alginate 9005-38-3, Sodium Alginate 9005-82-7,  
 Amylose 9014-63-5, Xylan 9032-42-2, Hydroxyethyl methyl cellulose  
 9037-22-3, Amylopectin 10043-35-3, Boric acid, biological studies  
 10043-52-4, Calcium chloride, biological studies 10103-46-5, Calcium  
 phosphate 10316-66-2, 2-Hydroxy-2-cyclohexenone 10343-62-1,  
 Metaphosphoric acid 13463-67-7, Titanium oxide, biological studies  
 14807-96-6, Talc, biological studies 16068-46-5, Potassium phosphate  
 18859-54-6 19163-87-2, Gulose 21645-51-2, Aluminum oxide trihydrate,  
 biological studies 25322-68-3, Polyethylene glycol 25322-68-3D,  
 Polyethylene glycol, esters or ethers 30077-17-9, Talose 30435-30-4  
 36653-82-4, Cetyl alcohol 37353-59-6, Hydroxymethyl cellulose  
 62212-91-3, Sodium Starch 69670-80-0, Hydroxymethyl propyl cellulose  
 74811-65-7, Croscarmellose sodium 106392-12-5, Polyethylene  
 glycol-polypropylene glycol block copolymer 199915-32-7, Glycolic  
 acid-lactic acid-polyethylene glycol block copolymer 443360-37-0  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release pharmaceutical compns. containing polymers)

RE

- (1) Andronis, V; WO 02065834 A 2002 CAPLUS
- (2) Bukh Meditec; WO 9104015 A 1991 CAPLUS
- (3) Daniel, B; WO 9522962 A 1995 CAPLUS
- (4) Daniel, B; WO 9951208 A 1999 CAPLUS
- (5) Hoffmann La Roche; WO 0174357 A 2001 CAPLUS
- (6) Oh, C; US 20020054911 A1 2002
- (7) Venkatesh, G; WO 0135958 A 2001 CAPLUS

L7 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3D, Phthalic acid, esters 110-15-6, Succinic acid,  
biological studies 117-81-7, Dioctyl phthalate 124-04-9  
, Adipic acid, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled release solid dispersions containing carvedilol)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)




RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2003:242148 CAPLUS

DOCUMENT NUMBER: 138:276255

TITLE: Controlled release solid dispersions containing carvedilol

INVENTOR(S): Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Lademann, Anne-Marie; Jensen, Christine

PATENT ASSIGNEE(S): Egalet A/S, Den.

SOURCE: PCT Int. Appl., 110 pp.

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 2 English  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024426	A1	20030327	WO 2002-DK621	20020923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002339415	A1	20030401	AU 2002-339415	20020923
EP 1429734	A1	20040623	EP 2002-776907	20020923
EP 1429734	B1	20071226		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
AT 381924	T	20080115	AT 2002-776907	20020923
ES 2298401	T3	20080516	ES 2002-776907	20020923
EP 1929998	A2	20080611	EP 2007-24778	20020923
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
US 20050019399	A1	20050127	US 2004-490170	20040921
PRIORITY APPLN. INFO.:				
			DK 2001-1375	A 20010921
			DK 2001-1611	A 20011031
			DK 2002-1044	A 20020703
			EP 2002-776907	A3 20020923
			WO 2002-DK621	W 20020923

AN 2003:242148 CAPLUS  
 DN 138:276255  
 ED Entered STN: 28 Mar 2003  
 TI Controlled release solid dispersions containing carvedilol  
 IN Fischer, Gina; Bar-Shalom, Daniel; Slot, Lillian; Lademann, Anne-Marie; Jensen, Christine  
 PA Egalet A/S, Den.  
 SO PCT Int. Appl., 110 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-16  
 ICS A61K009-22; A61K009-28; A61K031-403  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1, 62  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024426	A1	20030327	WO 2002-DK621	20020923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2002339415	A1 200304001	AU 2002-339415 20020923
EP 1429734	A1 20040623	EP 2002-776907 20020923
EP 1429734	B1 20071226	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		
AT 381924	T 20080115	AT 2002-776907 20020923
ES 2298401	T3 20080516	ES 2002-776907 20020923
EP 1929998	A2 20080611	EP 2007-24778 20020923
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR		
US 20050019399	A1 20050127	US 2004-490170 20040921
PRAI DK 2001-1375	A 20010921	
DK 2001-1611	A 20011031	
DK 2002-1044	A 20020703	
EP 2002-776907	A3 20020923	
WO 2002-DK621	W 20020923	

CLASS		
PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003024426	ICM	A61K009-16
	ICS	A61K009-22; A61K009-28; A61K031-403
	IPCI	A61K0009-16 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-28 [ICS,7]; A61K0031-403 [ICS,7]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2
AU 2002339415	IPCI	A61K0009-16 [ICM,7]; A61K0031-403 [ICS,7]; A61K0009-22 [ICS,7]; A61K0009-28 [ICS,7]
EP 1429734	IPCI	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61K0009-28 [I,C]; A61K0009-28 [I,A]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2; K61K; K61K; K61K; K61K; K61K; K61K
AT 381924	IPCI	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61K0009-28 [I,C]; A61K0009-28 [I,A]
	IPCR	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61K0009-28 [I,C]; A61K0009-28 [I,A]
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2; K61K; K61K; K61K; K61K; K61K; K61K
ES 2298401	IPCI	A61K0009-16 [I,C]; A61K0009-16 [I,A]; A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61K0009-28 [I,C]; A61K0009-28 [I,A]
	IPCR	A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]
	ECLA	A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2; A61K031/403; K61K; K61K; K61K; K61K; K61K; K61K
EP 1929998	IPCI	A61K0009-16 [I,A]; A61K0009-22 [I,A]; A61K0009-28 [I,A]; A61P0009-04 [I,A]; A61P0009-00 [I,C*]; A61K0031-403 [N,A]

US 20050019399 IPCI A61K0009-22 [ICM,7]; A61K0031-403 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-28 [I,C\*]; A61K0009-28 [I,A]  
 NCL 424/468.000; 514/411.000  
 ECLA A61K009/00Z4; A61K009/00L4; A61K009/20H6D; A61K009/20P; A61K009/28H6F2

AB A controlled release pharmaceutical composition for oral use comprises a solid dispersion of at least one therapeutical agent and/or diagnostic substance, which at least partially is in an amorphous form, a polymer that has plasticizing properties, and optionally, a stabilizing agent, the at least one active substance having a limited water solubility, and the composition

being designed to release the active substance with a substantially zero order release. The polymer is typically a polyethylene glycol and/or polyethylene oxide having a mol. weight of at least about 20,000 in crystalline and/or amorphous form or a mixture of such polymers, and the active substance is typically carvedilol. The composition may comprise a coated matrix, the coating comprising a first cellulose derivative which is substantially insol. in the aqueous medium, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and

a filler. Thus, a composition contained PEG 64.6, carvedilol 30, and citric acid 5.4% by weight. The dissoln. profile corresponded to a zero-order release of carvedilol from the composition

ST controlled release solid dispersion carvedilol polymer

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C16-18; controlled release solid dispersions containing carvedilol)

IT Viscosity  
 (adjusting agents; controlled release solid dispersions containing carvedilol)

IT Heart, disease  
 (angina pectoris; controlled release solid dispersions containing carvedilol)

IT Molding of plastics and rubbers  
 (blow; controlled release solid dispersions containing carvedilol)

IT Molding of plastics and rubbers  
 (compression; controlled release solid dispersions containing carvedilol)

IT Antihypertensives  
 Antioxidants  
 Binders  
 Buffers  
 Cardiovascular agents  
 Coating materials  
 Deodorants (personal)  
 Dietary supplements  
 Diffusion  
 Disinfectants  
 Dissolution  
 Fillers  
 Gums and Mucilages  
 Human  
 Hypertension  
 Lubricants  
 Molasses  
 Molecular weight distribution  
 Particle size distribution  
 Plasticizers  
 Polymorphism (crystal)

Solubility  
 Solubilizers  
 Solvents  
 Stability  
 Stabilizing agents  
 (controlled release solid dispersions containing carvedilol)

IT Acids, biological studies  
 Alkali metal salts  
 Alkaline earth salts  
 Amides, biological studies  
 Amines, biological studies  
 Amino acids, biological studies  
 Bentonite, biological studies  
 Carbohydrates, biological studies  
 Carboxylic acids, biological studies  
 Clays, biological studies  
 Disaccharides  
 Ethers, biological studies  
 Fatty acids, biological studies  
 Glycerides, biological studies  
 Kaolin, biological studies  
 Monosaccharides  
 Oligosaccharides, biological studies  
 Paraffin oils  
 Polymers, biological studies  
 Polyoxyalkylenes, biological studies  
 Polyoxyalkylenes, biological studies  
 Polysaccharides, biological studies  
 Salts, biological studies  
 Smectite-group minerals  
 Vitamins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release solid dispersions containing carvedilol)

IT Drug delivery systems  
 (controlled-release, solid dispersions; controlled release solid  
 dispersions containing carvedilol)

IT Carboxylic acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; controlled release solid dispersions containing carvedilol)

IT Polyoxyalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters or ethers; controlled release solid dispersions containing  
 carvedilol)

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters; controlled release solid dispersions containing carvedilol)

IT Chondrus crispus  
 (exts.; controlled release solid dispersions containing carvedilol)

IT Heart, disease  
 (failure; controlled release solid dispersions containing carvedilol)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty; controlled release solid dispersions containing carvedilol)

IT Plantago psyllium  
 (husk exts. (Isagbol); controlled release solid dispersions containing  
 carvedilol)

IT Molding of plastics and rubbers  
 (injection; controlled release solid dispersions containing carvedilol)

IT Bases, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inorg.; controlled release solid dispersions containing carvedilol)

IT Surfactants  
(nonionic; controlled release solid dispersions containing carvedilol)

IT Carboxylic acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oligo-; controlled release solid dispersions containing carvedilol)

IT Acids, biological studies  
Bases, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(organic; controlled release solid dispersions containing carvedilol)

IT Gums and Mucilages  
(panwar; controlled release solid dispersions containing carvedilol)

IT Carboxylic acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polycarboxylic; controlled release solid dispersions containing carvedilol)

IT Polyoxalkylenes, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyester-, block; controlled release solid dispersions containing carvedilol)

IT Polyoxalkylenes, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyester-, graft; controlled release solid dispersions containing carvedilol)

IT Polyesters, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyoxalkylene-, block; controlled release solid dispersions containing carvedilol)

IT Polyesters, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyoxalkylene-, graft; controlled release solid dispersions containing carvedilol)

IT Humidity  
(relative; controlled release solid dispersions containing carvedilol)

IT Drug delivery systems  
(solid dispersions; controlled release solid dispersions containing carvedilol)

IT Carbohydrates, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sugar esters; controlled release solid dispersions containing carvedilol)

IT Drug delivery systems  
(tablets, controlled-release; controlled release solid dispersions containing carvedilol)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated; controlled release solid dispersions containing carvedilol)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable; controlled release solid dispersions containing carvedilol)

IT 72956-09-3, Carvedilol  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled release solid dispersions containing carvedilol)

IT 50-21-5, Lactic acid, biological studies 50-69-1, Ribose 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Glucose, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-03-4, Glycerophosphoric acid 57-11-4, Stearic acid, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 62-53-3, Aniline, biological studies



62-54-4, Calcium acetate 63-42-3, Lactose 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-42-9, Lyxose 65-85-0, Benzoic acid, biological studies 69-65-8, Mannitol 75-15-0, Carbon disulfide, biological studies 77-86-1, Tris(hydroxymethyl)aminomethane 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid, biological studies 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-89-8, Inositol 88-99-3D, Phthalic acid, esters 90-64-2, Mandelic acid 98-10-2, Benzenesulfonamide 98-95-3, Nitrobenzene, biological studies 100-02-7, p-Nitrophenol, biological studies 109-97-7, Pyrrole 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 111-16-0, Pimelic acid 111-42-2, Diethanolamine, biological studies 112-72-1, Myristyl alcohol 112-92-5, Stearyl alcohol 117-81-7, Dioctyl phthalate 123-56-8, Succinimide 123-76-2, Levulinic acid 124-04-9, Adipic acid, biological studies 127-08-2, Potassium acetate 127-09-3, Sodium acetate 127-17-3, Pyruvic acid, biological studies 140-99-8, Calcium succinate 141-82-2, Malonic acid, biological studies 143-28-2, Oleyl alcohol 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Oxalic acid, biological studies 147-81-9, Arabinose 149-91-7, Gallic acid, biological studies 150-90-3, Sodium succinate 288-32-4, Imidazole, biological studies 298-12-4, Glyoxylic acid 298-14-6 302-01-2, Hydrazine, biological studies 463-77-4, Carbamic acid, biological studies 471-34-1, Calcium carbonate, biological studies 471-47-6, Oxamic acid 473-81-4, Glyceric acid 490-79-9, Gentisic acid 497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium carbonate 546-93-0, Magnesium carbonate 557-04-0 565-63-9, Angelic acid 584-08-7, Potassium carbonate 593-67-9, Ethylenamine 597-44-4, Citramalic acid 613-78-5,  $\beta$ -Naphthyl salicylate 621-82-9, Cinnamic acid, biological studies 676-47-1 868-18-8, Sodium tartrate 921-53-9, Potassium tartrate 994-36-5, Sodium citrate 1310-58-3, Potassium hydroxide (K(OH)), biological studies 1310-73-2, Sodium hydroxide, biological studies 1336-21-6, Ammonium hydroxide 1344-28-1, Aluminum oxide, biological studies 1724-02-3, Glutaconic acid 2152-76-3, Idose 2466-09-3, Pyrophosphoric acid 3164-34-9, Calcium tartrate 3458-28-4, Mannose 4468-02-4, Zinc gluconate 5987-68-8, Altrose 6038-51-3, Allose 6915-15-7, Malic acid 7429-90-5D, Aluminum, compds. 7447-40-7, Potassium chloride (KCl), biological studies 7558-79-4, Disodium hydrogen phosphate 7558-80-7, Sodium dihydrogen phosphate 7601-54-9, Trisodium phosphate 7631-86-9, Silica, biological studies 7632-05-5, Sodium phosphate 7647-01-0, Hydrochloric acid, biological studies 7647-14-5, Sodium chloride, biological studies 7664-38-2, Orthophosphoric acid, biological studies 7664-38-2D, Phosphoric acid, esters 7664-93-9, Sulfuric acid, biological studies 7693-13-2, Calcium citrate 7733-02-0, Zinc sulfate 7757-82-6, Sodium sulfate, biological studies 7757-93-9, Dicalcium phosphate 7758-11-4 7778-18-9, Calcium sulfate 7778-49-6, Potassium citrate 7778-53-2, TriPotassium phosphate 7778-77-0, Potassium dihydrogen phosphate 7778-80-5, Potassium sulfate, biological studies 7786-30-3, Magnesium chloride, biological studies 7803-49-8, Hydroxylamine, biological studies 9000-01-5, Acacia gum 9000-28-6, Ghatti gum 9000-69-5, Pectin 9003-11-6 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, derivs. 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-48-2, Cellulose propionate 9004-53-9, Dextrin 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-58-4, Ethyl hydroxyethyl cellulose 9004-59-5, Ethyl methyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose 9004-70-0, Cellulose nitrate 9004-99-3, Polyethylene glycol monostearate

9005-25-8, Starch, biological studies 9005-32-7, Alginic acid  
 9005-35-0, Calcium Alginate 9005-38-3, Sodium Alginate 9005-82-7,  
 Amylose 9014-63-5, Xylan 9032-42-2, Hydroxyethyl methyl cellulose  
 9037-22-3, Amylopectin 10043-35-3, Boric acid, biological studies  
 10043-52-4, Calcium chloride, biological studies 10103-46-5, Calcium  
 phosphate 10316-66-2, 2-Hydroxy-2-cyclohexenone 10343-62-1,  
 Metaphosphoric acid 13463-67-7, Titanium oxide, biological studies  
 14807-96-6, Talc, biological studies 16068-46-5, Potassium phosphate  
 18859-54-6 19163-87-2, Gulose 21645-51-2, Aluminum oxide trihydrate,  
 biological studies 25322-68-3, Polyethylene glycol 25322-68-3D,  
 Polyethylene glycol, esters or ethers 30077-17-9, Talose 30435-30-4  
 36653-82-4, Cetyl alcohol 37353-59-6, Hydroxymethyl cellulose  
 62212-91-3, Sodium Starch 69670-80-0, Hydroxymethyl propyl cellulose  
 72956-44-6, DesmethylCarvedilol 74811-65-7, Croscarmellose sodium  
 95093-99-5 95094-00-1 106392-12-5, Polyethylene glycol-polypropylene  
 glycol block copolymer 199915-32-7, Glycolic acid-lactic  
 acid-polyethylene glycol block copolymer 443360-37-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled release solid dispersions containing carvedilol)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Andronis, V; WO 02065834 A 2002 CAPLUS
- (2) Bukh Meditec; WO 9104015 A 1991 CAPLUS
- (3) Daniel, B; WO 9522962 A 1995 CAPLUS
- (4) Daniel, B; WO 9951208 A 1999 CAPLUS
- (5) Hoffmann La Roche; WO 0174357 A 2001 CAPLUS
- (6) Oh, C; US 20020054911 A1 2002
- (7) Venkatesh, G; WO 0135958 A 2001 CAPLUS

L7 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, uses

RL: TEM (Technical or engineered material use); USES (Uses)  
 (etchant; harmless compns. for etching of sandblasted glass articles  
 and treatment of etching wastewater)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2003:15464 CAPLUS

DOCUMENT NUMBER: 138:77217

TITLE: Glass-etching compositions, surface treatment of  
 sandblasted glass articles, and treatment of etching  
 wastewater

INVENTOR(S): Miwa, Hiroshi

PATENT ASSIGNEE(S): Japan

SOURCE: Jpn. Kokai Tokyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
JP 2003002685	A	20030108	JP 2001-191115	20010625
PRIORITY APPLN. INFO.:			JP 2001-191115	20010625
AN 2003:15464 CAPLUS				
DN 138:77217				

ED Entered STN: 08 Jan 2003  
 TI Glass-etching compositions, surface treatment of sandblasted glass  
 articles, and treatment of etching wastewater  
 IN Miwa, Hiroshi  
 PA Japan  
 SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM C03C015-00

ICS B44C001-22; B44F001-02; C03C019-00

CC 57-1 (Ceramics)

Section cross-reference(s): 60

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003002685	A	20030108	JP 2001-191115	20010625
PRAI	JP 2001-191115		20010625		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2003002685	ICM	C03C015-00
	ICS	B44C001-22; B44F001-02; C03C019-00
	IPCI	C03C0015-00 [ICM,7]; B44C0001-22 [ICS,7]; B44F0001-02 [ICS,7]; B44F0001-00 [ICS,7,C*]; C03C0019-00 [ICS,7]
	IPCR	B44C0001-22 [I,C*]; B44C0001-22 [I,A]; B44F0001-00 [I,C*]; B44F0001-02 [I,A]; C03C0015-00 [I,C*]; C03C0015-00 [I,A]; C03C0019-00 [I,C*]; C03C0019-00 [I,A]

AB The compns. comprise fluoride, acid, water, and water-compatible organic solvent. The compns. may contain a gelation agent, a surfactant, sucrose (as stabilizer), and/or dye (as indicator for wastewater treatment). The sandblasted surfaces of the glass articles, which may have flat, curved, tubular, or any shape, are treated by the harmless etching compns. to make translucent and glossy surfaces. On treatment of the etching wastewater with an aqueous solution containing NaOH, Na2CO3, CaCl2, or

Ca(OH)2; a pH indicator or an alkaline solution-containing container with a mark indicating the maximum neutralizable amount of the wastewater is used.

ST sandblasted glass etching compn harmless; fluoride acid water solvent glass etchant; glass etching wastewater treatment neutralization indicator container

IT Gelation agents

Surfactants

(etching compns. containing; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Acids, uses

Fluorides, uses

RL: TEM (Technical or engineered material use); USES (Uses)

(etching compns. containing; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Glycols, uses

RL: TEM (Technical or engineered material use); USES (Uses)

(ethers, solvent; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Glues

Gums and Mucilages

(gelling agent; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Bentonite, uses

Gelatins, uses  
Glass powders  
Silica gel, uses  
Smectite-group minerals  
RL: MOA (Modifier or additive use); USES (Uses)  
(gelling agent; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Ethers, uses  
RL: TEM (Technical or engineered material use); USES (Uses)  
(glycol, solvent; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Etching  
(harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Glass, processes  
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PROC (Process)  
(harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Clay minerals  
RL: MOA (Modifier or additive use); USES (Uses)  
(hydrophilic, gelling agent; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Wastewater treatment  
(neutralization; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Dyes  
(pH indicator, etching compns. containing; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Alcohols, uses  
Glycols, uses  
Polyoxyalkylenes, uses  
RL: TEM (Technical or engineered material use); USES (Uses)  
(solvent; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT Solvents  
(water-compatible, organic, etching compns. containing; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT 64-19-7, Acetic acid, uses 77-92-9, Citric acid, uses 110-15-6, Succinic acid, uses 1333-83-1, Sodium hydrogenfluoride 1341-49-7, Ammonium hydrogenfluoride 7647-01-0, Hydrochloric acid, uses 7664-38-2, Phosphoric acid, uses 7664-39-3, Hydrofluoric acid, uses 7664-93-9, Sulfuric acid, uses 7681-49-4, Sodium fluoride, uses 7697-37-2, Nitric acid, uses 7789-23-3, Potassium fluoride 7789-29-9, Potassium hydrogenfluoride 12125-01-8, Ammonium fluoride  
RL: TEM (Technical or engineered material use); USES (Uses)  
(etchant; harmless compns. for etching of sandblasted glass articles and treatment of etching wastewater)

IT 1344-28-1, Aluminum oxide, uses 9000-01-5, Gum arabic 9000-30-0, Guar gum 9000-36-6, Gum karaya 9000-40-2, Locust bean gum 9000-65-1, Tragacanth gum 9002-18-0, Agar agar 9002-89-5, Poly(vinyl alcohol) 9003-05-8, Polyacrylamide 9003-20-7, Polyvinyl acetate 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Sodium carboxymethylcellulose 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropylmethylcellulose 9004-67-5, Methyl cellulose 9004-70-0, Cellulose nitrate 9005-25-8, Starch, uses 9005-38-3, Sodium alginate 9046-40-6, Pectic acid 11078-30-1, Galactomannan 11138-66-2, Xanthan gum 12173-47-6, Hectorite 25751-21-7, Acrylic acid-methacrylic acid copolymer 29132-58-9,

Acrylic acid-maleic acid copolymer 37353-59-6,  
Hydroxymethyl cellulose 71010-52-1, Gellan gum 96949-21-2, Rhamsan gum  
96949-22-3, Welan gum  
RL: MOA (Modifier or additive use); USES (Uses)  
(gelling agent; harmless compns. for etching of sandblasted glass  
articles and treatment of etching wastewater)

IT 497-19-8, Sodium carbonate, uses 1305-62-0, Slaked lime, uses  
1310-73-2, Sodium hydroxide, uses 10043-52-4, Calcium chloride, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(neutralizing agent in wastewater treatment; harmless compns. for  
etching of sandblasted glass articles and treatment of etching  
wastewater)

IT 76-59-5, Bromothymol blue  
RL: MOA (Modifier or additive use); USES (Uses)  
(pH indicator; harmless compns. for etching of sandblasted glass  
articles and treatment of etching wastewater)

IT 50-70-4, Sorbitol, uses 56-81-5, Glycerin, uses 57-55-6, Propylene  
glycol, uses 64-17-5, Ethyl alcohol, uses 67-56-1, Methyl alcohol,  
uses 67-63-0, Isopropyl alcohol, uses 71-23-8, n-Propyl alcohol, uses  
71-36-3, N-Butylalcohol, uses 78-83-1, Isobutyl alcohol, uses  
106-69-4, 1,2,6-Hexanetriol 107-21-1, Ethylene glycol, uses 109-86-4,  
Methyl glycol 110-63-4, 1,4-Butanediol, uses 110-80-5 111-46-6,  
Diethylene glycol, uses 111-77-3, Diethylene glycol monomethyl ether  
111-90-0, Diethylene glycol monoethyl ether 112-34-5, Diethylene glycol  
monobutyl ether 463-57-0, Methylene glycol 504-63-2, 1,3-Propanediol  
4407-89-0, Dimethylene glycol 5412-01-1, Diethylene glycol monoisopropyl  
ether 9015-98-9, Polymethylene glycol 25265-71-8, Dipropylene glycol  
25322-68-3, Polyethylene glycol 29911-28-2 30025-38-8, Dipropylene  
glycol monomethyl ether 34590-94-8, Dipropylene glycol monomethyl ether  
94247-68-4  
RL: TEM (Technical or engineered material use); USES (Uses)  
(solvent; harmless compns. for etching of sandblasted glass articles  
and treatment of etching wastewater)

IT 57-50-1, Sucrose, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(stabilizer; harmless compns. for etching of sandblasted glass articles  
and treatment of etching wastewater)

IT 112-00-5, Dodecyltrimethylammonium chloride 112-02-7,  
Hexadecyltrimethylammonium chloride 112-03-8, Octadecyl trimethyl  
ammonium chloride 122-19-0, Octadecyl dimethylbenzyl ammonium chloride  
139-08-2, Tetradecyl dimethylbenzyl ammonium chloride 1337-30-0,  
Sorbitan laurate 2016-54-8, Tetradecyl amine acetate 2190-04-7,  
Octadecyl amine acetate 7212-69-3, Dioleil dimethyl ammonium chloride  
8061-52-7, Calcium ligninsulfonate 9002-92-0, Poly(oxyethylene) lauryl  
ether 9004-98-2, Poly(oxyethylene) oleyl ether 9005-00-9,  
Poly(oxyethylene) stearyl ether 9005-64-5, Polyoxethylenesorbitan  
monolaurate 9005-65-6, Polyoxethylenesorbitan monooleate 9005-66-7,  
Polyoxethylenesorbitan monopalmitate 9005-67-8, Polyoxethylenesorbitan  
monostearate 9016-45-9, Polyoxethylene nonylphenyl ether 9063-89-2,  
Poly(oxyethylene) octylphenyl ether 25155-30-0, Sodium  
dodecylbenzenesulfonate 26266-57-9, Sorbitan palmitate 27613-77-0,  
Polyethylene glycol monoacetate 28299-33-4, Imidazoline 37318-79-9,  
Sorbitan oleate 56451-84-4, Sorbitan stearate  
RL: MOA (Modifier or additive use); USES (Uses)  
(surfactant; harmless compns. for etching of sandblasted glass articles  
and treatment of etching wastewater)


L7 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2008 ACS ON STN

IT 84-66-2, Diethylphthalate 84-74-2, Phthalic acid,  
dibutyl ester 100-42-5, Styrene, biological studies  
117-81-7, Bis-2-ethylhexyl phthalate 124-04-9, Adipic

acid, biological studies 131-11-3, Phthalic acid, dimethyl ester  
 RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)  
 (industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)


RN 84-66-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-diethyl ester (CA INDEX NAME)




RN 84-74-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester (CA INDEX NAME)




RN 100-42-5 CAPLUS

CN Benzene, ethenyl- (CA INDEX NAME)




RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)




RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)



RN 131-11-3 CAPLUS  
CN 1,2-Benzenedicarboxylic acid, 1,2-dimethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 2002:550896 CAPLUS  
DOCUMENT NUMBER: 137:267469  
TITLE: Populations at risk  
AUTHOR(S): Pedersen, David H.; Young, Randy O.; Rose, Vernon E.  
CORPORATE SOURCE: National Institute for Occupational Safety and Health,  
Cincinnati, OH, USA  
SOURCE: Patty's Toxicology (5th Edition) (2001), Volume 8,  
699-1080. Editor(s): Bingham, Eula; Cochrane,  
Barbara; Powell, Charles H. John Wiley & Sons, Inc.:  
New York, N. Y.  
CODEN: 69CWST; ISBN: 0-471-31943-0  
DOCUMENT TYPE: Conference  
LANGUAGE: English  
AN 2002:550896 CAPLUS  
DN 137:267469  
ED Entered STN: 25 Jul 2002  
TI Populations at risk  
AU Pedersen, David H.; Young, Randy O.; Rose, Vernon E.  
CS National Institute for Occupational Safety and Health, Cincinnati, OH, USA  
SO Patty's Toxicology (5th Edition) (2001), Volume 8, 699-1080. Editor(s):  
Bingham, Eula; Cochrane, Barbara; Powell, Charles H. Publisher: John Wiley  
& Sons, Inc., New York, N. Y.  
CODEN: 69CWST; ISBN: 0-471-31943-0  
DT Conference  
LA English  
CC 59-5 (Air Pollution and Industrial Hygiene)  
Section cross-reference(s): 4, 45, 49  
AB The recognition and anticipation of potential occupational health  
problems, followed by assessment of occupational health risks based on  
chemical, phys., or biol. properties of toxic agents and their potential  
contact or exposure under use conditions, in the practice of industrial  
hygiene and toxicol. for worker populations at risk is discussed. Topics  
covered include: background (Industrial Classification, Occupational  
Classification Codes, Chemical Master, Facilities, Exposure, and Trade Named  
Ingredients files); data source considerations; data display  
considerations; calcn. and display of ests. (industry-specific exposure  
concentration by facility employment size, industry-specific exposure concns.,  
all industries exposure concentration by facility employment size, summary  
estimate).  
An appendix displays information on the industrial distribution potential  
occupational exposures to >300 selected chemical agents or groups of agents  
in 290 tables.  
ST occupational health hazard industrial toxic chem exposure  
IT Named reagents and solutions  
RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered  
material use); BIOL (Biological study); USES (Uses)  
(Stoddard; industry-specific workplace populations at risk from

- exposure to or contact with toxic chemical agents)
- IT Coal tar pitch
  - Human
  - Industrial hygiene
  - Occupational health hazard
  - Toxicity
  - Tripoli
    - (industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)
- IT Asbestos
  - Asphalt
  - Carbon black, biological studies
  - Diatomite
  - Hydrocarbon waxes, biological studies
  - Kaolin, biological studies
  - Ligroine
  - Limestone, biological studies
  - Mica-group minerals, biological studies
  - Naphtha
  - Pyrethrins
  - Rosin
  - Turpentine
  - RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)
    - (industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)
- IT 7631-86-9, Silica, biological studies
  - RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)
    - (fumes; industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)
- IT 26140-60-3, Terphenyl
  - RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)
    - (hydrogenated; industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)
- IT 50-78-2 55-63-0, Nitroglycerin 56-23-5, Carbon tetrachloride, biological studies 56-81-5, Glycerol, biological studies 57-50-1, Sucrose, biological studies 58-89-9, Lindane 62-53-3, Aniline, biological studies 62-73-7, biological studies 63-25-2, Carbamic acid, methyl-, 1-naphthyl ester 64-17-5, Ethyl alcohol, biological studies 64-19-7, Acetic acid, biological studies 67-56-1, Methanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1, Acetone, biological studies 67-66-3, Chloroform, biological studies 67-72-1, Hexachloroethane 68-11-1, Thioglycolic acid, biological studies 68-12-2, N,N-Dimethylformamide, biological studies 71-23-8, 1-Propanol, biological studies 71-43-2, Benzene, biological studies 71-55-6, 1,1,1-Trichloroethane 74-82-8, Methane, biological studies 74-84-0, Ethane, biological studies 74-85-1, Ethylene, biological studies 74-86-2, Acetylene, biological studies 74-87-3, Chloromethane, biological studies 74-89-5, Methylamine, biological studies 74-90-8, Hydrogen cyanide, biological studies 74-96-4, Bromoethane 74-98-6, Propane, biological studies 75-00-3, Chloroethane 75-01-4, Chloroethylene, biological studies 75-05-8, Acetonitrile, biological studies 75-07-0, Acetaldehyde, biological studies 75-09-2, Dichloromethane, biological studies 75-15-0, Carbon disulfide, biological studies 75-31-0, Isopropylamine, biological studies 75-43-4, Dichlorodifluoromethane 75-45-6, Chlorodifluoromethane 75-47-8, Iodoform 75-52-5, Nitromethane, biological studies 75-56-9, Propylene oxide, biological studies 75-69-4, Trichlorodifluoromethane 75-71-8, Dichlorodifluoromethane 76-03-9, Trichloroacetic acid,



biological studies 76-13-1 76-14-2, 1,2-Dichlorotetrafluoroethane  
 76-15-3 76-22-2, Camphor 77-78-1, Dimethylsulfate 78-00-2,  
 Tetraethylplumbane 78-59-1, Isophorone 78-78-4, biological studies  
 78-83-1, Isobutyl alcohol, biological studies 78-93-3, 2-Butanone,  
 biological studies 79-01-6, Trichloroethylene, biological studies  
 79-06-1, Acrylamide, biological studies 79-09-4, Propionic acid,  
 biological studies 79-10-7, Acrylic acid, biological  
 studies 79-20-9, Acetic acid, methyl ester  
 79-41-4,  $\alpha$ -Methacrylic acid, biological studies 79-46-9,  
 2-Nitropropane 80-62-6, Methacrylic acid methyl ester 83-79-4,  
 Rotenone 84-66-2, Diethylphthalate 84-74-2, Phthalic  
 acid, dibutyl ester 85-44-9, Phthalic anhydride 87-86-5,  
 Pentachlorophenol 88-89-1, Picric acid 91-20-3, Naphthalene,  
 biological studies 92-84-2, Phenothiazine 94-36-0, Benzoyl peroxide,  
 biological studies 95-47-6, biological studies 95-48-7, biological  
 studies 95-49-8, 1-Chloro-2-methylbenzene 95-50-1, o-Dichlorobenzene  
 95-53-4, o-Toluidine, biological studies 96-33-3, Methyl acrylate  
 96-69-5 97-77-8 98-82-8, Cumene 98-86-2, Acetophenone, biological  
 studies 100-37-8, Diethylaminoethanol 100-41-4, Ethylbenzene,  
 biological studies 100-42-5, Styrene, biological studies  
 100-44-7, Benzyl chloride, biological studies 101-68-8 101-77-9,  
 4,4'-Methylenedianiline 101-84-8, Phenyl ether 102-71-6, biological  
 studies 105-60-2, biological studies 106-35-4, 3-Heptanone 106-42-3,  
 biological studies 106-44-5, biological studies 106-46-7,  
 p-Dichlorobenzene 106-50-3, p-Phenylenediamine, biological studies  
 106-51-4, p-Benzoquinone, biological studies 106-89-8, Epichlorohydrin,  
 biological studies 106-93-4, 1,2-Dibromoethane 107-06-2,  
 1,2-Dichloroethane, biological studies 107-13-1, Acrylonitrile,  
 biological studies 107-15-3, Ethylenediamine, biological studies  
 107-19-7, 2-Propyn-1-ol 107-21-1, Ethylene glycol, biological studies  
 107-41-5 107-87-9, 2-Pentanone 107-98-2 108-03-2, 1-Nitropropane  
 108-05-4, Acetic acid, ethenyl ester, biological  
 studies 108-10-1, 4-Methyl-2-pentanone 108-11-2, 4-Methyl-2-pentanol  
 108-21-4, Acetic acid, isopropyl ester 108-24-7,  
 Acetic anhydride 108-31-6, Maleic anhydride, biological studies  
 108-38-3, biological studies 108-39-4, biological studies 108-45-2,  
 m-Phenylenediamine, biological studies 108-46-3, Resorcinol, biological  
 studies 108-83-8, 2,6-Dimethyl-4-heptanone 108-87-2, Methylcyclohexane  
 108-88-3, Toluene, biological studies 108-90-7, Chlorobenzene,  
 biological studies 108-91-8, Cyclohexylamine, biological studies  
 108-93-0, Cyclohexanol, biological studies 108-94-1, Cyclohexanone,  
 biological studies 108-95-2, Phenol, biological studies 109-60-4,  
 Propyl acetate 109-66-0, Pentane, biological studies 109-86-4,  
 2-Methoxyethanol 109-87-5, Dimethoxymethane 109-89-7, Diethylamine,  
 biological studies 109-99-9, Tetrahydrofuran, biological studies  
 110-12-3, 5-Methyl-2-hexanone 110-19-0, Isobutyl acetate 110-43-0,  
 2-Heptanone 110-49-6 110-54-3, Hexane, biological studies 110-80-5,  
 2-Ethoxy ethanol 110-82-7, Cyclohexane, biological studies 110-86-1,  
 Pyridine, biological studies 110-91-8, Morpholine, biological studies  
 111-15-9 111-40-0, Diethylenetriamine 111-42-2, biological studies  
 111-65-9, Octane, biological studies 114-26-1 115-77-5,  
 Pentaerythritol, biological studies 115-86-6, Triphenyl phosphate  
 117-81-7, Bis-2-ethylhexyl phthalate 119-93-7,  
 3,3'-Dimethylbenzidine 120-80-9, Pyrocatechol, biological studies  
 121-44-8, Triethylamine, biological studies 121-45-9, Trimethyl  
 phosphite 121-69-7, N,N-Dimethylaniline, biological studies 121-75-5  
 122-39-4, Diphenylamine, biological studies 122-60-1, Phenyl glycidyl  
 ether 123-31-9, Hydroquinone, biological studies 123-42-2,  
 4-Hydroxy-4-methyl-2-pentanone 123-51-3, Isopentyl alcohol 123-91-1,  
 1,4-Dioxane, biological studies 124-04-9, Adipic acid,  
 biological studies 124-38-9, Carbon dioxide, biological studies

124-40-3, Dimethylamine, biological studies 126-73-8, Tributylphosphate, biological studies 126-99-8, 2-Chloro-1,3-butadiene 127-18-4, Tetrachloroethylene, biological studies 127-19-5, N,N-Dimethylacetamide 128-37-0, biological studies 131-11-3, Phthalic acid, dimethyl ester 137-05-3 137-26-8 140-11-4, Benzyl acetate 140-88-5, Ethyl acrylate 141-43-5, 2-Amino ethanol, biological studies 142-82-5, Heptane, biological studies 143-33-9, Sodium cyanide (Na(CN)) 144-62-7, Oxalic acid, biological studies 150-76-5, p-Methoxyphenol 151-50-8, Potassium cyanide (K(CN)) 151-67-7, Halothane 218-01-9, Chrysene 302-01-2, Hydrazine, biological studies 333-41-5 409-21-2, Silicon carbide, biological studies 546-93-0, Carbonic acid, magnesium salt 552-30-7 584-84-9 592-01-8, Calcium cyanide (Ca(CN)2) 594-42-3, Trichloromethanesulfonyl chloride 628-63-7, Acetic acid, pentyl ester 630-08-0, Carbon monoxide, biological studies 822-06-0 1305-78-8, Calcium oxide, biological studies 1309-37-1, Iron oxide (Fe2O3), biological studies 1309-48-4, Magnesium oxide (MgO), biological studies 1309-64-4, Antimony trioxide, biological studies 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1314-13-2, Zinc oxide (ZnO), biological studies 1319-77-3, Cresol 1330-20-7, biological studies 1333-74-0, Hydrogen, biological studies 1338-23-4, Methyl ethyl ketone peroxide 1344-28-1, Aluminum oxide, biological studies 1344-95-2, Silicic acid, calcium salt 2426-08-6, Propane, 1-butoxy-2,3-epoxy- 2528-36-1, Phosphoric acid, dibutyl phenyl ester 2551-62-4, Sulfur hexafluoride 2921-88-2, biological studies 3689-24-5 7085-85-0 7429-90-5, Aluminum, biological studies 7439-92-1, Lead, biological studies 7439-96-5, Manganese, biological studies 7439-97-6, Mercury, biological studies 7439-98-7, Molybdenum, biological studies 7440-02-0, Nickel, biological studies 7440-06-4, Platinum, biological studies 7440-16-6, Rhodium, biological studies 7440-21-3, Silicon, biological studies 7440-22-4, Silver, biological studies 7440-31-5, Tin, biological studies 7440-33-7, Tungsten, biological studies 7440-36-0, Antimony, biological studies 7440-37-1, Argon, biological studies 7440-38-2, Arsenic, biological studies 7440-39-3, Barium, biological studies 7440-41-7, Beryllium, biological studies 7440-43-9, Cadmium, biological studies 7440-47-3, Chromium, biological studies 7440-48-4, Cobalt, biological studies 7440-50-8, Copper, biological studies 7440-59-7, Helium, biological studies 7446-09-5, Sulfur dioxide, biological studies 7553-56-2, Iodine, biological studies  
 RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)  
 (industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)  
 IT 7631-90-5, Sodium bisulfite 7646-85-7, Zinc chloride, biological studies 7647-01-0, Hydrochloric acid, biological studies 7664-38-2, Phosphoric acid, biological studies 7664-39-3, Hydrogen fluoride, biological studies 7664-41-7, Ammonia, biological studies 7664-93-9, Sulfuric acid, biological studies 7681-57-4 7697-37-2, Nitric acid, biological studies 7722-84-1, Hydrogen peroxide, biological studies 7722-88-5, Tetrasodium pyrophosphate 7723-14-0, Phosphorus, biological studies 7727-21-1 7727-37-9, Nitrogen, biological studies 7727-43-7, Barium sulfate 7727-54-0 7758-97-6 7773-06-0, Ammonium sulfamate 7775-27-1 7778-18-9, Calcium sulfate 7782-42-5, Graphite, biological studies 7782-49-2, Selenium, biological studies 7782-50-5, Chlorine, biological studies 7783-06-4, Hydrogen sulfide, biological studies 7789-06-2 7803-62-5, Silane, biological studies 9005-25-8, Starch, biological studies 10024-97-2, Nitrous oxide, biological studies 10025-67-9, Sulfur chloride 10025-87-3, Phosphoryl chloride 10028-15-6, Ozone, biological studies 10035-10-6, Hydrogen bromide, biological studies 10102-43-9, Nitric oxide, biological studies 10102-44-0, Nitrogen dioxide, biological studies 11103-86-9, Potassium

zinc chromate hydroxide (KZn2(CrO4)2(OH)) 12125-02-9, Ammonium chloride, biological studies 13463-67-7, Titania, biological studies 13494-80-9, Tellurium, biological studies 13530-65-9 13765-19-0, Calcium chromate 13838-16-9 14464-46-1, Cristobalite 14808-60-7, Quartz, biological studies 25013-15-4, Vinyltoluene 26628-22-8, Sodium azide 26952-21-6, Isooctyl alcohol 34590-94-8 37300-23-5, C.I. Pigment Yellow 36 60676-86-0

RL: ADV (Adverse effect, including toxicity); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)

(industry-specific workplace populations at risk from exposure to or contact with toxic chemical agents)

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) American Chemical Society; Chemical Abstracts Service
- (2) Anon; A National Goal for Occupational Health 1966
- (3) Anon; American Conference of Governmental Industrial Hygienists 1999
- (4) Anon; Patty's Industrial Hygiene and Toxicology 1998
- (5) De la Hoz, R; Am J Ind Med 1997, V31, P195 MEDLINE
- (6) Frazier, T; Scand J Work Env Hlth 1983, V9 MEDLINE
- (7) Griefe, A; Appl Occ Env Hyg 1995, V10(4), P264
- (8) Hull, D; Personal Communication from D Hull 1999
- (9) Kauppinen, T; Finnish Institute for Occupational Health 1998
- (10) Kauppinen, T; Occupat Environ Med in press 1999
- (11) Lee, J; Am Ind Hyg Assoc J 1971, V32, P194 MEDLINE
- (12) National Institute for Occupational Safety and Health; Data Editing and Data Base Development 1977
- (13) National Institute for Occupational Safety and Health; Registry of Toxic Effects of Chemical Substances NIOSH
- (14) National Institute for Occupational Safety and Health; Survey Manual 1974
- (15) National Institute for Occupational Safety and Health; Survey Analysis and Supplemental Tables 1977
- (16) Pedersen, D; A Model for the Identification of High Risk Occupational Groups using NOHS/RTECS Data 1983
- (17) Pedersen, D; Am J Ind Med 1989, V15(2) MEDLINE
- (18) Pedersen, D; Analysis of Management Interview Responses 1988
- (19) Pedersen, D; J Occ Med 1990, V32(10) MEDLINE
- (20) Powell, C; Trans Am Conf Gov Ind Hyg 1968
- (21) Rose, V; J Occ Med 1970, V12(6), P193 MEDLINE
- (22) Rose, V; The Occupational Environment-Its Evaluation and Control 1998
- (23) Seligman, P; Am J Pub Hlth 1988, V78(8)
- (24) Seta, J; Survey Manual 1988
- (25) Sieber, W; Sampling Methodology 1990
- (26) US Government Printing Office; Standard Industrial Classification Manual 1972


L7 ANSWER 30 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 77-90-7, Acetyl tributyl citrate 84-74-2, Dibutyl phthalate 88-99-3D, Phthalic acid, tricresyl derivs. 117-81-7, Diocetyl phthalate

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(nail enamel composition containing urea-modified thixotropic agent)


RN 77-90-7 CAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-tributyl ester (CA INDEX NAME)



RN 84-74-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-dibutyl ester (CA INDEX NAME)




RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



ACCESSION NUMBER: 2002:449456 CAPLUS

DOCUMENT NUMBER: 137:37389

TITLE: Nail enamel composition containing a urea-modified thixotropic agent

INVENTOR(S): Carrion, Danuvio; Farer, Alan; Frankfurt, Chris

PATENT ASSIGNEE(S): L'Oreal S.A., Fr.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

WO 2002045663 A1 20020613 WO 2000-US42513 20001204  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2397587 A1 20020613 CA 2000-2397587 20001204  
 CA 2397587 C 20080527  
 AU 2001043090 A 20020618 AU 2001-43090 20001204  
 EP 1341501 A1 20030910 EP 2000-992383 20001204  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004514728 T 20040520 JP 2002-547449 20001204  
 WO 2000-US42513 W 20001204

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 137:37389

AN 2002:449456 CAPLUS

DN 137:37389

ED Entered STN: 14 Jun 2002

TI Nail enamel composition containing a urea-modified thixotropic agent

IN Carrion, Danuvio; Farer, Alan; Frankfurt, Chris

PA L'Oreal S.A., Fr.

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-043

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002045663	A1	20020613	WO 2000-US42513	20001204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397587	A1	20020613	CA 2000-2397587	20001204
CA 2397587	C	20080527		
AU 2001043090	A	20020618	AU 2001-43090	20001204
EP 1341501	A1	20030910	EP 2000-992383	20001204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514728	T	20040520	JP 2002-547449	20001204
PRAI WO 2000-US42513	W	20001204		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2002045663 ICM A61K007-043  
 IPCI A61K0007-043 [ICM,7]  
 IPCR A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-40

		[I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]
CA 2397587	ECLA	A61K008/44; A61Q003/02
	IPCI	A61K0008-44 [I,A]; A61K0008-30 [I,C*]; A61K0008-73 [N,A]; A61K0008-81 [N,A]; A61K0008-85 [N,A]; A61K0008-87 [N,A]; A61K0008-72 [N,C*]; A61Q0003-02 [I,A]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]
AU 2001043090	IPCI	A61K0007-043 [ICM,7]
EP 1341501	IPCI	A61K0007-043 [ICM,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]
JP 2004514728	ECLA	A61K008/44; A61Q003/02
	IPCI	A61K0007-043 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61Q0003-02 [I,A]; A61Q0003-02 [I,C*]
	FTERM	4C083/AA121; 4C083/AB211; 4C083/AB432; 4C083/AC011; 4C083/AC101; 4C083/AC102; 4C083/AC171; 4C083/AC211; 4C083/AC212; 4C083/AC341; 4C083/AC342; 4C083/AC351; 4C083/AC371; 4C083/AC372; 4C083/AC391; 4C083/AC441; 4C083/AC512; 4C083/AC641; 4C083/AC681; 4C083/AC682; 4C083/AC762; 4C083/AC851; 4C083/AC901; 4C083/AC902; 4C083/AD021; 4C083/AD042; 4C083/AD071; 4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD222; 4C083/AD261; 4C083/AD262; 4C083/AD611; 4C083/BB21; 4C083/BB41; 4C083/BB46; 4C083/BB60; 4C083/CC28; 4C083/DD23; 4C083/EE06; 4C083/EE07
OS	MARPAT	137:37389
AB	A nail enamel composition which contains, in a cosmetically acceptable solvent, at least one film-forming substance and at least one urea-modified thixotropic agent is described. The use of such a thixotropic agent gives nail enamel compns. with higher gloss, high clarity, improved aesthetics in the bottle, excellent thixotropic properties, and improved application properties. For example, a clear top coat formulation was prepared containing Et acetate 25.65%, Bu acetate 25%, Pr acetate 20%, nitrocellulose 10%, iso-Pr alc. 5%, sucrose acetate isobutyrate 5%, N-Et tosylamide 5%, tosylamide epoxy resin 2%, acrylate copolymer 1.5-1.5%, etocrylene 0.5%, benzophenone-1 0.1%, and modified urea-urethane (BYK 410) 0.25%. This formulation exhibited improved body and viscosity, while maintaining excellent clarity, when compared to the classic composition	
ST	urea thixotropic agent nail enamel	
IT	Alcohols, biological studies	
	RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)	
	(C1-6; nail enamel composition containing urea-modified thixotropic agent)	
IT	Sulfonamides	
	RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)	
	(arenesulfonamides, resins; nail enamel composition containing urea-modified thixotropic agent)	

IT Glycols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (ethers; nail enamel composition containing urea-modified thixotropic agent)

IT Ethers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (glycol; nail enamel composition containing urea-modified thixotropic agent)

IT Cosmetics  
 (moisturizers; nail enamel composition containing urea-modified thixotropic agent)

IT Flavoring materials  
 Odor and Odorous substances  
 Perfumes  
 Pigments, nonbiological  
 Plasticizers  
 Thixotropic agents  
 UV stabilizers  
 (nail enamel composition containing urea-modified thixotropic agent)

IT Alkanes, biological studies  
 Alkyd resins  
 Castor oil  
 Fibers  
 Ketones, biological studies  
 Mica-group minerals, biological studies  
 Minerals, biological studies  
 Polyesters, biological studies  
 Polymers, biological studies  
 Polyurethanes, biological studies  
 Vitamins  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (nail enamel composition containing urea-modified thixotropic agent)

IT Cosmetics  
 (nail lacquers; nail enamel composition containing urea-modified thixotropic agent)

IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; nail enamel composition containing urea-modified thixotropic agent)

IT Aromatic compounds  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sulfonamides, resins; nail enamel composition containing urea-modified thixotropic agent)

IT Epoxy resins, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (tosylamide-containing; nail enamel composition containing urea-modified thixotropic agent)

IT 50-21-5D, Lactic acid, alkyl esters 56-81-5D, Glycerol, di- and trialkyl esters 57-13-6, Urea, biological studies 64-17-5, Ethanol, biological studies 64-19-7D, Acetic acid, C1-6 alkyl esters 67-63-0, Isopropanol, biological studies 70-55-3, Tosyl amide 70-55-3D, Tosylamide, epoxy resins 71-36-3, Butanol, biological studies 76-22-2, Camphor 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, esters 79-10-7D, Acrylic acid, vinyl copolymers 79-41-4D, Methacrylic acid, vinyl copolymers 80-39-7, N-Ethyltosylamide 84-74-2, Dibutyl phthalate 87-92-3, Dibutyl tartrate 88-99-3D, Phthalic acid, tricesyl derivs. 108-88-3, Toluene, biological studies 109-60-4, Propyl acetate 115-86-6, Triphenyl phosphate 117-81-7, Dioctyl phthalate 117-83-9 120-51-4, Benzyl benzoate 123-42-2, Diacetone alcohol 123-86-4, Butyl acetate 123-95-5, Butyl stearate 126-13-6, Sucrose acetate isobutyrate 126-73-8, Tributyl phosphate, biological studies 131-18-0,

Diamylphthalate 131-56-6, Benzophenone-1 140-04-5, Butyl acetyl  
 ricinoleate 141-78-6, Ethyl acetate, biological studies 872-50-4,  
 N-Methyl pyrrolidone, biological studies 1330-20-7, Xylene, biological  
 studies 5232-99-5, Etocrylene 5281-04-9, D And C Red 7 calcium lake  
 6417-83-0, D And C Red 34 Calcium Lake 7397-62-8, Butyl glycolate  
 9002-86-2, Polyvinyl chloride 9003-18-3, Acrylonitrile-butadiene  
 copolymer 9003-20-7, Polyvinyl acetate 9003-55-8, Styrene-butadiene  
 copolymer 9004-34-6D, Cellulose, derivs. 9004-35-7, Cellulose acetate  
 9004-36-8, Cellulose acetate butyrate 9004-57-3, Ethyl cellulose  
 9004-70-0, Nitrocellulose 12691-60-0, Stearalkonium hectorite  
 17852-98-1, D And C Red 6 barium lake 24937-78-8, Ethylene-vinyl acetate  
 copolymer 24980-58-3, Acrylic acid-vinyl acetate  
 copolymer 24991-31-9, Polyvinyl butyrate 25038-59-9, biological  
 studies 25869-00-5, Ferric Ammonium Ferrocyanide 224174-19-0, BYK 410  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(nail enamel composition containing urea-modified thixotropic agent)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Farer, A; US 6156325 A 2000 CAPLUS

(2) Oreal; WO 0027347 A 2000 CAPLUS

L7 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 100-42-5, Styrene, biological studies 117-81-7,

Ethylhexyl phthalate

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(quant. structure-activity relationships for prediction of skin

permeation of exogenous chems.)


RN 100-42-5 CAPLUS

CN Benzene, ethenyl- (CA INDEX NAME)

H<sub>2</sub>C=CH-Ph

RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



ACCESSION NUMBER: 2002:442310 CAPLUS

DOCUMENT NUMBER: 138:34354

TITLE: Quantitative structure-activity relationships (QSARs)  
 for the prediction of skin permeation of exogenous  
 chemicals

AUTHOR(S): Patel, Hiren; ten Berge, Wil; Cronin, Mark T. D.  
 CORPORATE SOURCE: School of Pharmacy and Chemistry, Liverpool John  
 Moores University, Liverpool, L3 3AF, UK

SOURCE: Chemosphere (2002), 48(6), 603-613

CODEN: CMSHAF; ISSN: 0045-6535

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal



LANGUAGE: English

AN 2002:442310 CAPLUS

DN 138:34354

ED Entered STN: 12 Jun 2002

TI Quantitative structure-activity relationships (QSARs) for the prediction of skin permeation of exogenous chemicals

AU Patel, Hiren; ten Berge, Wil; Cronin, Mark T. D.

CS School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, L3 3AF, UK

SO Chemosphere (2002), 48(6), 603-613

CODEN: CMSHAF; ISSN: 0045-6535

PB Elsevier Science Ltd.

DT Journal

LA English

CC 4-3 (Toxicology)

AB Quant. structure-activity relationships (QSARs) for the skin permeability coeffs. of 158 compds. through excised human skin in vitro have been developed. A number of compds., including hydrocortisone derivs., were removed from the dataset as reported permeability data for these compds. was considered to be in error. QSARs developed for the dataset with the outliers removed included terms for hydrophobicity, mol. size, and hydrogen bonding. These descriptors provided an excellent fit to the data ( $r^2=0.90$ ), are easily calculated from mol. structure, and are mechanistically interpretable. Further analyses of the dataset indicated that good QSARs could be developed utilizing hydrophobicity and mol. size alone, with mol. volume and mol. weight providing good quantification of mol. size.

ST skin permeation chem structure activity relationship

IT Biological transport

(permeation; quant. structure-activity relationships for prediction of skin permeation of exogenous chems.)

IT Human

Hydrogen bond

Hydrophobicity

Molar volume

Molecular weight

Skin

(quant. structure-activity relationships for prediction of skin permeation of exogenous chems.)

IT Structure-activity relationship

(skin-penetrating; quant. structure-activity relationships for prediction of skin permeation of exogenous chems.)

IT 50-00-0, Formaldehyde, biological studies 50-06-6, Phenobarbital, biological studies 50-22-6, Corticosterone 50-23-7, Hydrocortisone 50-23-7D, Hydrocortisone, hemipimelate derivative 50-23-7D, Hydrocortisone, octanoate derivative 50-27-1, Estriol 50-28-2, Estradiol, biological studies 51-34-3, Scopolamine 51-55-8, Atropine, biological studies 52-39-1, Aldosterone 53-06-5, Cortisone 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-11-5, Nicotine 55-63-0, Nitroglycerine 57-13-6, Urea, biological studies 57-27-2, Morphine, biological studies 57-42-1, Meperidine 57-43-2, Amylobarbitol 57-44-3, Barbitol 57-50-1, Sucrose, biological studies 57-83-0, Progesterone, biological studies 60-12-8, 2-Phenylethanol 60-29-7, Ethyl ether, biological studies 60-34-4, Monomethylhydrazine 62-53-3, Aniline, biological studies 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 64-85-7, Cortexone 67-56-1, Methanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1, Acetone, biological studies 67-72-1, Hexachloroethane 68-96-2, Hydroxyprogesterone 69-72-7, Salicylic acid, biological studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol, biological studies 71-41-0, n-Pentanol, biological studies 71-43-2, Benzene, biological studies

71-55-6, 1,1,1-Trichloroethane 71-63-6, Digitoxin 75-04-7, Ethylamine, biological studies 75-05-8, Acetonitrile, biological studies 75-07-0, Acetaldehyde, biological studies 75-31-0, Isopropylamine, biological studies 75-56-9, Propylene oxide, biological studies 76-57-3, Codeine 77-28-1, Butobarbital 78-83-1, Isobutyl alcohol, biological studies 78-87-5, Propylene dichloride 78-93-3, 2-Butanone, biological studies 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-41-4, Methylacrylic acid, biological studies 87-68-3, Hexachlorobutadiene 88-06-2, 2,4,6-Trichlorophenol 89-83-8, Thymol 90-89-1, Diethylcarbamazine 95-48-7, 2-Cresol, biological studies 95-53-4, biological studies 95-54-5, 1,2-Phenylenediamine, biological studies 95-57-8, 2-Chlorophenol 95-65-8, 3,4-Xylenol 96-33-3, Methyl acrylate 98-82-8, Cumene 99-57-0, 2-Amino-4-nitrophenol 100-02-7, 4-Nitrophenol, biological studies 100-41-4, Ethylbenzene, biological studies 100-42-5, Styrene, biological studies 100-51-6, Benzyl alcohol, biological studies 100-52-7, Benzaldehyde, biological studies 100-66-3, Anisole, biological studies 106-41-2, 4-Bromophenol 106-44-5, 4-Cresol, biological studies 106-48-9, 4-Chlorophenol 106-50-3, 1,4-Phenylenediamine, biological studies 106-89-8, Epichlorohydrin, biological studies 107-02-8, Acrolein, biological studies 107-06-2, Ethylene dichloride, biological studies 107-13-1, Acrylonitrile, biological studies 107-18-6, Allyl alcohol, biological studies 107-21-1, Ethylene glycol, biological studies 107-87-9, 2-Pentanone 107-92-6, Butyric acid, biological studies 108-05-4, Vinyl acetate, biological studies 108-11-2, 4-Methyl-2-pentanol 108-38-3, 1,3-Xylene, biological studies 108-39-4, biological studies 108-46-3, Resorcinol, biological studies 108-88-3, Toluene, biological studies 108-94-1, Cyclohexanone, biological studies 108-95-2, Phenol, biological studies 109-52-4, Pentanoic acid, biological studies 109-86-4, Methylcellosolve 109-89-7, Diethylamine, biological studies 109-94-4, Ethyl formate 110-43-0, 2-Heptanone 110-80-5, 2-Ethoxyethanol 110-86-1, Pyridine, biological studies 110-91-8, Morpholine, biological studies 111-14-8, Heptanoic acid 111-27-3, n-Hexanol, biological studies 111-42-2, Diethanolamine, biological studies 111-76-2, 2-Butoxyethanol 111-87-5, n-Octanol, biological studies 112-30-1, 1-Decanol 113-92-8, Chlorpheniramine 117-81-7, Ethylhexyl phthalate 119-34-6, 4-Amino-2-nitrophenol 119-65-3, Isoquinoline 120-80-9, Catechol, biological studies 120-83-2, 2,4-Dichlorophenol 121-44-8, Triethylamine, biological studies 121-69-7, N,N-Dimethylaniline, biological studies 122-60-1, Phenyl glycidyl ether 123-07-9, 4-Ethylphenol 123-51-3, Isoamyl alcohol 123-91-1, Dioxane, biological studies 124-07-2, Octanoic acid, biological studies 127-19-5, Dimethylacetamide 135-19-3,  $\beta$ -Naphthol, biological studies 140-88-5, Ethyl acrylate 141-32-2, Butyl acrylate 141-43-5, Ethanol amine, biological studies 142-62-1, Hexanoic acid, biological studies 145-13-1, Pregnenolone 152-58-9, Cortisolone 299-42-3, Ephedrine 356-12-7, Flucocinonide 437-38-7, Fentanyl 466-99-9, Hydromorphone 509-60-4, Dihydromorphone 513-85-9, 2,3-Butanediol 542-75-6, 1,3-Dichloropropene 554-84-7, 3-Nitrophenol 591-78-6, 2-Hexanone 630-60-4, Ouabain 1116-54-7, n-Nitrosodiethanolamine 1321-10-4, Chlorocresol 1321-23-9, Chloroxylenol 2203-97-6, Hydrocortisone hemisuccinate 3593-96-2, Hydrocortisone hexanoate 5307-14-2, 2-Nitro-1,4-phenylenediamine 6677-98-1, Hydrocortisone propionate 7732-18-5, Water, biological studies 12041-98-4, Hydroxypregnenolone 14521-96-1, Etorphine 15307-86-5, Diclofenac 22204-53-1, Naproxen 28473-21-4, Nonanol 29468-36-8, Methyl hydroxybenzoate 36322-90-4, Piroxicam 53535-33-4, Heptanol 56030-54-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(quant. structure-activity relationships for prediction of skin

permeation of exogenous chems.)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Abraham, M; Journal of Pharmacy and Pharmacology 1995, V47, P8 CAPLUS
- (2) Abraham, M; Journal of Pharmacy and Pharmacology 1997, V49, P858 CAPLUS
- (3) Abraham, M; Pesticide Science 1999, V55, P78 CAPLUS
- (4) Barratt, M; Toxicology in Vitro 1995, V9, P27 CAPLUS
- (5) Barry, B; Drugs and the Pharmaceutical Sciences 1983, V18
- (6) Cronin, M; European Journal of Pharmaceutical Sciences 1999, V7, P325 CAPLUS
- (7) Cronin, M; Journal of Pharmacy and Pharmacology 1998, V50, P143 CAPLUS
- (8) Degim, I; International Journal of Pharmaceutics 1998, V170, P129 CAPLUS
- (9) El Tayar, N; Journal of Pharmaceutical Sciences 1991, V80, P744 CAPLUS
- (10) Flynn, G; Principles of Route-to-Route Extrapolation for Risk Assessment 1990, P93
- (11) Harada, K; Journal of Pharmacy and Pharmacology 1993, V45, P414 CAPLUS
- (12) Hauser, H; Biochimica et Biophysica Acta 1981, V650, P21 CAPLUS
- (13) Idson, B; Transdermal Delivery of Drugs 1987, VIII, P85
- (14) Johnson, M; Journal of Pharmaceutical Sciences 1995, V84, P1144 CAPLUS
- (15) Kier, L; Molecular Connectivity in Structure-Activity Analysis 1986
- (16) Kier, L; Molecular Structure Description. The Electrotological State 1999
- (17) Kirchner, L; ATLA 1997, V25, P359
- (18) Lien, E; Pharmaceutical Research 1995, V4, P583
- (19) Lipinski, C; Advanced Drug Delivery Reviews 1997, V23, P3 CAPLUS
- (20) Magee, P; Comparative QSAR 1998, P137
- (21) Moss, G; Toxicology in vitro, in press 2002
- (22) Patel, H; Journal of Chemical Information and Computer Sciences 2001, V41, P1228 CAPLUS
- (23) Patel, H; Theochem, in press 2001
- (24) Potts, R; Pharmaceutical Research 1992, V9, P663 CAPLUS
- (25) Potts, R; Pharmaceutical Research 1995, V12, P1628 CAPLUS
- (26) Pugh, W; International Journal of Pharmaceutics 1996, V138, P149 CAPLUS
- (27) Pugh, W; International Journal of Pharmaceutics 2000, V197, P203 CAPLUS
- (28) Raevsky, O; Quantitative Structure-Activity Relationships 2000, V19, P366 CAPLUS
- (29) Roberts, M; Journal of Pharmacy and Pharmacology 1977, V29, P677 CAPLUS
- (30) Scheuplein, R; Journal of Investigative Dermatology 1969, V52, P63 CAPLUS
- (31) Scheuplein, R; Physiological Reviews 1971, V51, P702 CAPLUS
- (32) Todeschini, R; Quantitative Structure-Activity Relationships 1997, V16, P113 CAPLUS
- (33) Weininger, D; Journal of Chemical Information and Computer Sciences 1988, V28, P31 CAPLUS
- (34) Wilschut, A; Chemosphere 1995, V30, P1275 CAPLUS

L7 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 100-42-5, Styrene, biological studies 117-81-7,  
Ethylhexyl phthalate  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(QSPRs of steroids for percutaneous absorption)


RN 100-42-5 CAPLUS

CN Benzene, ethenyl- (CA INDEX NAME)

H<sub>2</sub>C=CH-Ph

RN 117-81-7 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester (CA INDEX NAME)



ACCESSION NUMBER: 2002:335245 CAPLUS  
 DOCUMENT NUMBER: 138:175644  
 TITLE: Quantitative structure-permeability relationships for percutaneous absorption: re-analysis of steroid data  
 AUTHOR(S): Moss, Gary P.; Cronin, Mark T. D.  
 CORPORATE SOURCE: Liverpool John Moores University, School of Pharmacy and Chemistry, Liverpool, L3 3AF, UK  
 SOURCE: International Journal of Pharmaceutics (2002), 238(1-2), 105-109  
 CODEN: IJPHDE; ISSN: 0378-5173  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AN 2002:335245 CAPLUS  
 DN 138:175644  
 ED Entered STN: 06 May 2002  
 TI Quantitative structure-permeability relationships for percutaneous absorption: re-analysis of steroid data  
 AU Moss, Gary P.; Cronin, Mark T. D.  
 CS Liverpool John Moores University, School of Pharmacy and Chemistry, Liverpool, L3 3AF, UK  
 SO International Journal of Pharmaceutics (2002), 238(1-2), 105-109  
 CODEN: IJPHDE; ISSN: 0378-5173  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 CC 63-5 (Pharmaceuticals)  
 AB Certain mols., in particular steroids, have been observed to be outliers to quant. structure-permeability relationships (QSPRs) for skin permeability (kp). Recently, however, many of the historical skin permeability data for these compds. have been found not to be consistent with more modern data. In this study QSPRs were re-analyzed replacing the originally published steroid permeability data with those from more recent studies. A highly significant QSPR describing skin permeability in terms of the octanol-water partition coefficient (log P) and mol. weight (MW) was derived  
 (log  
 $kp = 0.74 \log P - 0.0091 MW - 2.39$ ). This model is similar to those published previously. Statistical anal. of the residuals from the QSPR determined that the steroids are no longer outliers to this model. Thus, they may be considered to penetrate the skin by the same means as the majority of exogenous chems. in this model.  
 ST steroid permeability skin QSPR  
 IT Partition  
 Permeability  
 QSPR (quantitative structure-property relationship)  
 Skin  
 (QSPRs of steroids for percutaneous absorption)  
 IT Steroids, biological studies  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(QSPRs of steroids for percutaneous absorption)

- II 50-00-0, Formaldehyde, biological studies 50-06-6, Phenobarbital, biological studies 50-22-6, Corticosterone 50-23-7, Hydrocortisone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-78-2, Aspirin 51-34-3, Scopolamine 51-55-8, Atropine, biological studies 52-39-1, Aldosterone 53-06-5, Cortisone 53-16-7, Estrone, biological studies 54-11-5, Nicotine 57-27-2, Morphine, biological studies 57-42-1, Meperidine 57-43-2, Amobarbital 57-50-1, Sucrose, biological studies 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 60-29-7, Ethyl ether, biological studies 60-34-4, Monomethyl hydrazine 62-53-3, Aniline, biological studies 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 67-56-1, Methanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1, Acetone, biological studies 67-72-1, Hexachloro ethane 68-96-2, 17-Hydroxyprogesterone 69-72-7, Salicylic acid, biological studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butyl alcohol, biological studies 71-41-0, n-Pentanol, biological studies 71-63-6, Digitoxin 75-04-7, Ethylamine, biological studies 75-05-8, Acetonitrile, biological studies 75-07-0, Acetaldehyde, biological studies 75-31-0, Isopropyl amine, biological studies 75-56-9, Propylene oxide, biological studies 77-28-1, Butobarbital 78-83-1, Isobutyl alcohol, biological studies 78-93-3, 2-Butanone, biological studies 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-41-4, Methyl acrylic acid, biological studies 87-68-3, Hexachloro butadiene 88-04-0, Chloroxylenol 88-06-2, 2,4,6-Trichloro phenol 89-83-8, Thymol 93-60-7, Methyl nicotinate 95-48-7, 2-Cresol, biological studies 95-53-4, biological studies 95-57-8, 2-Chlorophenol 96-33-3, Methyl acrylate 98-82-8, Cumene 100-41-4, Ethylbenzene, biological studies 100-42-5, Styrene, biological studies 100-51-6, Benzyl alcohol, biological studies 106-41-2, 4-Bromophenol 106-44-5, 4-Cresol, biological studies 106-48-9, 4-Chlorophenol 106-89-8, Epichlorohydrin, biological studies 107-02-8, Acrolein, biological studies 107-06-2, Ethylene dichloride, biological studies 107-13-1, Acrylonitrile, biological studies 107-18-6, Allyl alcohol, biological studies 107-21-1, Ethylene glycol, biological studies 107-87-9, 2-Pentanone 107-92-6, Butyric acid, biological studies 108-05-4, Vinyl acetate, biological studies 108-11-2, 4-Methyl-2-pentanol 108-38-3, biological studies 108-39-4, biological studies 108-46-3, Resorcinol, biological studies 108-88-3, Toluene, biological studies 108-94-1, Cyclohexanone, biological studies 108-95-2, Phenol, biological studies 109-52-4, Pentanoic acid, biological studies 109-86-4, Methyl cellosolve 109-89-7, Diethylamine, biological studies 109-94-4, Ethyl formate 110-43-0, 2-Heptanone 110-86-1, Pyridine, biological studies 110-91-8, Morpholine, biological studies 111-14-8, Heptanoic acid 111-27-3, n-Hexanol, biological studies 111-42-2, Diethanolamine, biological studies 111-70-6, n-Heptanol 111-76-2, 2-Butoxy ethanol 111-87-5, n-Octanol, biological studies 112-30-1, 1-Decanol 117-81-7, Ethylhexyl phthalate 119-65-3, Isoquinoline 120-80-9, Catechol, biological studies 120-83-2, 2,4-Dichloro phenol 121-44-8, Triethylamine, biological studies 121-69-7, N,N-Dimethylaniline, biological studies 122-60-1, Phenyl glycidyl ether 123-07-9, 4-Ethyl phenol 123-51-3, Isoamyl alcohol 123-91-1, Dioxane, biological studies 124-07-2, Octanoic acid, biological studies 127-19-5, Dimethylacetamide 140-88-5, Ethyl acrylate 141-32-2, Butyl acrylate 141-43-5, Ethanolamine, biological studies 142-62-1, Hexanoic acid, biological studies 152-58-9, Cortaxolone 437-38-7, Pentanyl 466-99-9, Hydromorphone 513-85-9, 2,3-Butanediol 563-54-2 591-78-6, 2-Hexanone 1116-54-7, N-Nitroso diethanolamine 14521-96-1, Etorphine 15307-86-5, Diclofenac

15687-27-1, Ibuprofen 22204-53-1, Naproxen  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)

(QSPRs of steroids for percutaneous absorption)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Buchwald, P; J Pharm Pharmacol 2001, V53, P1087 CAPLUS
- (2) Cronin, M; Eur J Pharm Sci 1999, V7, P325 CAPLUS
- (3) Degim, I; Int J Pharm 1998, V170, P129 CAPLUS
- (4) Flynn, G; Principles of Route-to-Route Extrapolation for Risk Assessment 1990, P93
- (5) Johnson, M; J Pharm Sci 1995, V84, P1144 CAPLUS
- (6) Kirchner, L; ATLA 1997, V25, P359
- (7) Potts, R; Pharm Res 1992, V9, P663 CAPLUS
- (8) Scheuplein, R; J Invest Dermatol 1969, V52, P63 CAPLUS

L7 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, 1,2-Benzenedicarboxylic acid, occurrence 110-15-6  
, Succinic acid, occurrence

RL: POL (Pollutant); PRP (Properties); OCCU (Occurrence)  
(relation between BOD and combustion heat of organic compds. in water)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2002:329722 CAPLUS

DOCUMENT NUMBER: 137:113996

TITLE: Batching relationship of biochemical oxygen demand and  
combustion heat of common organic compounds

AUTHOR(S): Shi, Yu-Hong

CORPORATE SOURCE: Liaoning Chaoyang Teacher's College, Chaoyang, 122000,  
Peop. Rep. China

SOURCE: Jinzhou Shifan Xueyuan Xuebao, Ziran Kexueban (2002),  
23(1), 29-32

CODEN: JZSXAR; ISSN: 1007-533X

PUBLISHER: Jinzhou Shifan Xueyuan Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AN 2002:329722 CAPLUS

DN 137:113996

ED Entered STN: 03 May 2002

TI Batching relationship of biochemical oxygen demand and combustion heat of  
common organic compounds

AU Shi, Yu-Hong

CS Liaoning Chaoyang Teacher's College, Chaoyang, 122000, Peop. Rep. China

SO Jinzhou Shifan Xueyuan Xuebao, Ziran Kexueban (2002), 23(1), 29-32

CODEN: JZSXAR; ISSN: 1007-533X

PB Jinzhou Shifan Xueyuan Xuebao Bianjibu

DT Journal  
 LA Chinese  
 CC 61-2 (Water)  
 Section cross-reference(s): 60

AB In this paper, the batching relationship between BOD and combustion heat of organic acids, alcs., aldehydes, saccharides and nitrogen-containing compds. in water is defined by a linear regression method based on bibliog. data.

ST BOD combustion heat org nitrogen compd water; org acid alc aldehyde ketone carbohydrate BOD combustion heat

IT Carbohydrates, occurrence  
 RL: POL (Pollutant); PRP (Properties); OCCU (Occurrence)  
 (aldoses; relation between BOD and combustion heat of organic compds. in water)

IT Organic compounds, occurrence  
 RL: POL (Pollutant); PRP (Properties); OCCU (Occurrence)  
 (nitrogen-containing; relation between BOD and combustion heat of organic compds. in water)

IT Biochemical oxygen demand  
 Combustion enthalpy  
 (relation between BOD and combustion heat of organic compds.)

IT Alcohols, occurrence  
 Aldehydes, occurrence  
 Carbohydrates, occurrence  
 Carboxylic acids, occurrence  
 Ketones, occurrence  
 RL: POL (Pollutant); PRP (Properties); OCCU (Occurrence)  
 (relation between BOD and combustion heat of organic compds. in water)

IT 50-00-0, Formaldehyde, occurrence 50-99-7, Glucose, occurrence  
 56-40-6, Aminoacetic acid, occurrence 56-41-7, Alanine, occurrence  
 56-81-5, Glycerol, occurrence 57-50-1, Sucrose, occurrence  
 60-35-5, Acetamide, occurrence 63-42-3, Lactose 64-17-5, Ethanol,  
 occurrence 64-18-6, Formic acid, occurrence 64-19-7, Acetic  
 acid, occurrence 65-85-0, Benzoic acid, occurrence 67-56-1,  
 Methanol, occurrence 67-63-0, Isopropanol, occurrence 67-64-1,  
 Propanone, occurrence 69-72-7, Salicylic acid, occurrence 71-23-8,  
 Propanol, occurrence 71-36-3, Butanol, occurrence 71-41-0, Pentanol,  
 occurrence 75-04-7, Ethyl amine, occurrence 75-07-0, Acet aldehyde,  
 occurrence 78-83-1, Isobutanol, occurrence 78-93-3, Butanone,  
 occurrence 79-09-4, Propanoic acid, occurrence 79-10-7,  
 Acrylic acid, occurrence 88-99-3,  
 1,2-Benzenedicarboxylic acid, occurrence 91-22-5, Quinoline, occurrence  
 98-86-2, Acetophenone, occurrence 100-21-0, p-Phthalic acid, occurrence  
 100-52-7, Benzaldehyde, occurrence 106-49-0, p-Methyl aniline,  
 occurrence 107-21-1, Ethylene glycol, occurrence 107-92-6, Butanoic  
 acid, occurrence 108-93-0, Cyclohexanol, occurrence 108-94-1,  
 Cyclohexanone, occurrence 109-52-4, Pentanoic acid, occurrence  
 109-73-9, Butyl amine, occurrence 110-15-6, Succinic acid,  
 occurrence 110-16-7, Maleic acid, occurrence 110-17-8, Fumaric acid,  
 occurrence 110-86-1, Pyridine, occurrence 123-72-8, Butanal  
 144-62-7, Oxalic acid, occurrence 526-83-0, Tartaric acid 584-02-1,  
 3-Pentanol 25168-10-9, Naphthyl amine  
 RL: POL (Pollutant); PRP (Properties); OCCU (Occurrence)  
 (relation between BOD and combustion heat of organic compds. in water)

L7 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 9002-88-4, Polyethylene  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hypertonic polymer-based hydrogel patch for treatment of traumatic  
 burns or blisters)

RN 9002-88-4 CAPLUS

CN Ethene, homopolymer (CA INDEX NAME)

CM 1  
CRN 74-85-1  
CMF C2 H4

H<sub>2</sub>C=CH<sub>2</sub>

ACCESSION NUMBER: 2001:936032 CAPLUS  
DOCUMENT NUMBER: 136:58887  
TITLE: Treating traumatic burns or blisters of the skin by a  
polymer-based hydrogel  
INVENTOR(S): Hymes, Alan C.; Nichols, Jane  
PATENT ASSIGNEE(S): Lectec Corp., USA  
SOURCE: U.S. Pat. Appl. Publ., 11 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010055608	A1	20011227	US 1999-314271	19990518
US 6348212	B2	20020219		
PRIORITY APPLN. INFO.:			US 1999-314271	19990518

AN 2001:936032 CAPLUS  
DN 136:58887

ED Entered STN: 28 Dec 2001

TI Treating traumatic burns or blisters of the skin by a polymer-based hydrogel

IN Hymes, Alan C.; Nichols, Jane

PA Lectec Corp., USA

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-74

ICS A61K009-00; A01N025-00; A61K009-70; A61F013-00; A61L015-16;  
A61L015-00; A61F013-02; B65D073-00

INCL 424443000

CC 63-7 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20010055608	A1	20011227	US 1999-314271	19990518
US 6348212	B2	20020219		
PRAI US 1999-314271		19990518		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20010055608	ICM	A61K031-74
	ICS	A61K009-00; A01N025-00; A61K009-70; A61F013-00; A61L015-16; A61L015-00; A61F013-02; B65D073-00
	INCL	424443000
	IPCI	A61K0031-74 [ICM,7]; A61K0009-00 [ICS,7]; A01N0025-00 [ICS,7]; A61K0009-70 [ICS,7]; A61F0013-00 [ICS,7]; A61L0015-16 [ICS,7]; A61L0015-00 [ICS,7]; A61F0013-02 [ICS,7]; B65D0073-00 [ICS,7]



IPCR A61F0013-00 [N,C\*]; A61F0013-00 [N,A]; A61F0013-02 [I,C\*]; A61F0013-02 [I,A]; A61K0009-70 [I,C\*]; A61K0009-70 [I,A]; A61L0015-16 [I,C\*]; A61L0015-58 [I,A]; A61L0015-60 [I,A]

NCL 424/443.000; 206/461.000; 206/462.000; 206/463.000; 206/464.000; 206/466.000; 424/078.020; 424/078.060; 424/405.000; 424/444.000; 424/445.000; 424/446.000; 424/447.000; 424/448.000; 424/449.000; 424/400.000

ECLA A61F013/02B; A61K009/70E; A61L015/58; A61L015/60

AB Blisters of the skin are treated by applying to the skin over the blister a flexible moisture-containing hydrophilic hydrogel patch that includes a backing support such as paper, cloth or plastic and a water-based hydrogel layer applied to the backing. The hydrogel layer comprises a hydrophilic natural or synthetic polymer to provide body dispersed in water and can be a tacky adhesive. The polymer can comprise any high mol. weight hydrophilic carbohydrate such as karaya, cornstarch, or a kelp gel and/or a synthetic hydrophilic polymer such as polyacrylamide or polyacrylic acid. A humectant such as a polyhydric alc., keeps the gel layer moist. A solute such as salt, protein, sugar or an alc. is dissolved in the water in a quantity sufficient to raise the osmotic pressure enough to maintain the hydrogel layer in a hypertonic state with respect to the blister. The hydrogel which hydrates the normally dry upper layer of skin forms a hydrophilic bridge with the patient's skin that allows fluid to be drawn by osmotic pressure from the blister through the normally dry stratum corneum into the patch. In addition, the hydrogel very quickly significantly diminishes the pain secondary to skin burns and blisters. For example, a hydrophilic adhesive composition contained (by weight) glycerin 22.0%, water 10.0%, propylene glycol 20.0%, NaCl 1.0%, and polyquaternary amine 37.0%. Patches containing this composition were applied to the patient with second degree burns and blisters on the hand and fingers. Within 5 min the patient reported that the pain was completely gone. The patches were replaced about 3 h after they were first placed. Examination of the fingers revealed there was no clin. fluid within the blisters and there was no recurrent pain to the air or gentle palpation. When the burned areas were examined 4 days later, there were only minimal findings in the wounded areas. Further, the patient had never had any recurrence of pain or limitations of motion and use of the fingers. The probable action of the hypertonic hydrophilic gel layer of the patch on first and second degree burns is twofold. First, the hypertonic gel layer removed the fluid within the blisters and some of the increased extracellular fluid in the surrounding areas as a result of the burn. The result of this action reduced the inflammation which apparently never returned. Second, the immediate effect of the hydrophilic gel almost immediately removed the pain by covering the burned surface with a moist layer of hydrogel, thereby reducing or eliminating the irritation to the pain sensors in the burned skin. As the fluid was removed and the acute inflammation subsided, the pain also clin. abated without the presence of the hydrogel patch.

ST polymer hypertonic hydrogel dressing blister burn

IT Textiles  
(backing support; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Plastics, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(backing support; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Medical goods  
(bandages, cloth; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Medical goods  
(dressings; hypertonic polymer-based hydrogel patch for treatment of

traumatic burns or blisters)

IT Acrylic polymers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (emulsions; hypertonic polymer-based hydrogel patch for treatment of  
 traumatic burns or blisters)

IT Polyelectrolytes  
 (gels; hypertonic polymer-based hydrogel patch for treatment of  
 traumatic burns or blisters)

IT Seaweed  
 (gum; hypertonic polymer-based hydrogel patch for treatment of  
 traumatic burns or blisters)

IT Antimicrobial agents  
 Blister  
 Burn  
 Gelation agents  
 Gums and Mucilages  
 Humectants  
 Osmolytes  
 Thickening agents  
 (hypertonic polymer-based hydrogel patch for treatment of traumatic  
 burns or blisters)

IT Albumins, biological studies  
 Biopolymers  
 Carbohydrates, biological studies  
 Fluoropolymers, biological studies  
 Polymers, biological studies  
 Polysiloxanes, biological studies  
 Waxes  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hypertonic polymer-based hydrogel patch for treatment of traumatic  
 burns or blisters)

IT Acids, biological studies  
 Alcohols, biological studies  
 Amino acids, biological studies  
 Bases, biological studies  
 Proteins  
 Salts, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (osmotic pressure increase by; hypertonic polymer-based hydrogel patch  
 for treatment of traumatic burns or blisters)

IT Hydrogels  
 (patches; hypertonic polymer-based hydrogel patch for treatment of  
 traumatic burns or blisters)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyhydric; hypertonic polymer-based hydrogel patch for treatment of  
 traumatic burns or blisters)

IT Quaternary ammonium compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polymeric; hypertonic polymer-based hydrogel patch for treatment of  
 traumatic burns or blisters)

IT Vinyl compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polymers, emulsions; hypertonic polymer-based hydrogel patch for  
 treatment of traumatic burns or blisters)

IT Polymers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polysulfonates; hypertonic polymer-based hydrogel patch for treatment  
 of traumatic burns or blisters)

IT Adhesives

(pressure-sensitive; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Inflammation  
Pain  
Swelling, biological  
(reduction of; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Hydration, physiological  
(skin; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Osmotic pressure  
(solutes for increase of; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT Skin  
(stratum corneum, hydrophilic bridge with; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT 9005-25-8, Starch, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(corn; hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT 7647-14-5, Sodium Chloride, biological studies 10043-52-4, Calcium chloride, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

IT 56-81-5, Glycerin, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene Glycol, biological studies 60-54-8, Tetracycline 64-19-7, Acetic acid, biological studies 67-63-0, Isopropyl alcohol, biological studies 69-72-7, Salicylic acid, biological studies 70-30-4, Hexachlorophene 79-10-7D, Acrylic acid, esters, copolymer 94-36-0, Benzoyl peroxide, biological studies 107-21-1, Ethylene Glycol, biological studies 114-07-8, Erythromycin 129-16-8, Mercurochrome 302-79-4, Retinoic acid 4759-48-2, Isotretinoin 7722-84-1, Hydrogen peroxide, biological studies 7761-88-8, Silver nitrate, biological studies 9000-36-6, Karaya gum 9000-69-5, Pectin 9002-84-0, Polytetrafluoroethylene 9002-88-4, Polyethylene 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-05-8, Polyacrylamide 9003-20-7, Vinyl acetate resin 9004-32-4, Carboxymethyl cellulose 9050-36-6, Maltodextrin 18472-51-0, Chlorhexidine gluconate 22916-47-8, Miconazole 25549-84-2, Polysodium acrylate 25655-41-8, Povidone iodine 26061-64-3, Dioctyl maleate-vinyl acetate copolymer 59277-89-3, Acyclovir 66676-63-9, Carboxypropyl cellulose  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hypertonic polymer-based hydrogel patch for treatment of traumatic burns or blisters)

L7 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, Phthalic acid, biological studies 110-15-6, Succinic acid, biological studies 110-15-6D, Succinic acid, salts 124-04-9, Adipic acid, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

RN 88-99-3 CAPLUS


CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)



ACCESSION NUMBER: 2001:300515 CAPLUS  
DOCUMENT NUMBER: 134:300833  
TITLE: Compositions containing pyroglutamic acid for prevention and treatment of cold and influenza-like symptoms and their methods of use  
INVENTOR(S): Rennie, Paul John; King, Simon Phillip; Biedermann, Kimberly Ann; Morgan, Jeffrey Michael  
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
SOURCE: PCI Int. Appl., 15 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 27  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028556	A2	20010426	WO 2000-US28856	20001019
WO 2001028556	A3	20011011		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2388802	A1	20010426	CA 2000-2388802	20001019
CA 2388802	C	20070911		
TR 200201048	T2	20020821	TR 2002-1048	20001019
EP 1242073	A2	20020925	EP 2000-973658	20001019
EP 1242073	B1	20040922		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003512325	T	20030402	JP 2001-531386	20001019
HU 2002004123	A2	20030428	HU 2002-4123	20001019
HU 2002004123	A3	20030528		
NZ 518117	A	20040326	NZ 2000-518117	20001019
RU 2228177	C2	20040510	RU 2002-113092	20001019
AT 276749	T	20041015	AT 2000-973658	20001019
AU 777549	B2	20041021	AU 2001-12147	20001019
ES 2223601	T3	20050301	ES 2000-973658	20001019
ZA 2002002475	A	20030627	ZA 2002-2475	20020327
IN 2002KN00406	A	20060203	IN 2002-KN406	20020327
NO 2002001830	A	20020418	NO 2002-1830	20020418
MX 2002PA03882	A	20021023	MX 2002-PA3882	20020418

PRIORITY APPLN. INFO.:

US 1999-421131	A	19991019
WO 2000-US28856	W	20001019

AN 2001:300515 CAPLUS

DN 134:300833

ED Entered STN: 27 Apr 2001

TI Compositions containing pyroglutamic acid for prevention and treatment of cold and influenza-like symptoms and their methods of use

IN Rennie, Paul John; King, Simon Phillip; Biedermann, Kimberly Ann; Morgan, Jeffrey Michael

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-4015

ICS A61K031-4015; A61K033-30; A61K033-24; A61K031-375; A61K031-194; A61K031-19

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 27

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001028556	A2	20010426	WO 2000-US28856	20001019
WO 2001028556	A3	20011011		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2388802	A1	20010426	CA 2000-2388802	20001019
CA 2388802	C	20070911		
TR 200201048	T2	20020821	TR 2002-1048	20001019
EP 1242073	A2	20020925	EP 2000-973658	20001019
EP 1242073	B1	20040922		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003512325	T	20030402	JP 2001-531386	20001019
HU 2002004123	A2	20030428	HU 2002-4123	20001019
HU 2002004123	A3	20030528		
NZ 518117	A	20040326	NZ 2000-518117	20001019
RU 2228177	C2	20040510	RU 2002-113092	20001019
AT 276749	T	20041015	AT 2000-973658	20001019
AU 777549	B2	20041021	AU 2001-12147	20001019
ES 2223601	T3	20050301	ES 2000-973658	20001019

ZA 2002002475	A	20030627	ZA 2002-2475	20020327
IN 2002KN00406	A	20060203	IN 2002-KN406	20020327
NO 2002001830	A	20020418	NO 2002-1830	20020418
MX 2002PA03882	A	20021023	MX 2002-PA3882	20020418
PRAI US 1999-421131	A	19991019		
WO 2000-US28856	W	20001019		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001028556	ICM	A61K031-4015
	ICS	A61K031-4015; A61K033-30; A61K033-24; A61K031-375; A61K031-194; A61K031-19
	IPCI	A61K0031-4015 [ICM,7]; A61K0031-4015 [ICS,7]; A61K0033-30 [ICS,7]; A61K0033-24 [ICS,7]; A61K0031-375 [ICS,7]; A61K0031-194 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0009-72 [I,C*]; A61K0009-72 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-375 [I,C*]; A61K0031-375 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A]; A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0011-00 [I,C*]; A61P0011-02 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
	ECLA	A61K008/02C; A61K008/49C2; A61K031/28+M; A61Q017/00; D21H021/36; N21H
CA 2388802	IPCI	A61K0031-19 [I,A]; A61K0031-194 [I,A]; A61K0031-185 [I,C*]; A61K0031-375 [I,A]; A61K0031-4015 [I,A]; A61P0031-16 [I,A]; A61P0031-00 [I,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0031-4015 [I,C]; A61K0031-4015 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0009-72 [I,C*]; A61K0009-72 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194

		[I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-375 [I,C]; A61K0031-375 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A]; A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0011-00 [I,C*]; A61P0011-02 [I,A]; A61P0031-00 [I,C]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
	ECLA	A61K008/02C; A61K008/49C2; A61K031/28+M; A61Q017/00; D21H021/36; N21H
TR 200201048	IPCI	A61K0031-4015 [ICM,7]; A61K0033-30 [ICS,7]; A61K0033-24 [ICS,7]; A61K0031-375 [ICS,7]; A61K0031-194 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0009-72 [I,C*]; A61K0009-72 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A]; A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
EP 1242073	IPCI	A61K0031-4015 [ICM,6]; A61K0031-4015 [ICI,6]; A61K0033-30 [ICI,6]; A61K0033-24 [ICI,6]; A61K0031-375 [ICI,6]; A61K0031-194 [ICI,6]; A61K0031-19 [ICI,6]; A61K0031-185 [ICI,6,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00

JP 2003512325

IPCI

[I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*];  
A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-34  
[I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A];  
A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-70  
[I,C\*]; A61K0009-70 [I,A]; A61K0009-72 [I,C\*];  
A61K0009-72 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19  
[I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A];  
A61K0031-194 [I,A]; A61K0031-28 [I,C\*]; A61K0031-28  
[I,A]; A61K0031-375 [I,C\*]; A61K0031-375 [I,A];  
A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A]; A61K0033-24  
[I,C\*]; A61K0033-24 [I,A]; A61K0033-26 [I,C\*];  
A61K0033-26 [I,A]; A61K0033-30 [I,C\*]; A61K0033-30  
[I,A]; A61K0033-34 [I,C\*]; A61K0033-34 [I,A];  
A61K0047-02 [I,C\*]; A61K0047-04 [I,A]; A61K0047-10  
[I,C\*]; A61K0047-10 [I,A]; A61K0047-12 [I,C\*];  
A61K0047-12 [I,A]; A61K0047-16 [I,C\*]; A61K0047-18  
[I,A]; A61K0047-22 [I,C\*]; A61K0047-22 [I,A];  
A61K0047-24 [I,C\*]; A61K0047-24 [I,A]; A61K0047-32  
[I,C\*]; A61K0047-32 [I,A]; A61L0002-16 [I,C\*];  
A61L0002-16 [I,A]; A61L0002-18 [I,C\*]; A61L0002-18  
[I,A]; A61M0011-00 [I,C\*]; A61M0011-00 [I,A];  
A61P0011-00 [I,C\*]; A61P0011-02 [I,A]; A61P0031-00  
[I,C\*]; A61P0031-04 [I,A]; A61P0031-12 [I,A];  
A61P0031-16 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02  
[I,A]; A61Q0017-00 [I,C\*]; A61Q0017-00 [I,A];  
A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A]; C11D0003-02  
[I,C\*]; C11D0003-02 [I,A]; C11D0003-26 [I,C\*];  
C11D0003-33 [I,A]; C11D0003-48 [I,C\*]; C11D0003-48  
[I,A]; D21H0021-14 [I,C\*]; D21H0021-36 [I,A];  
D21H0027-30 [N,C\*]; D21H0027-32 [N,A]  
A61K0031-4015 [ICM,7]; A61K0009-12 [ICS,7]; A61K0031-19  
[ICS,7]; A61K0031-191 [ICS,7]; A61K0031-192 [ICS,7];  
A61K0031-194 [ICS,7]; A61K0031-185 [ICS,7,C\*];  
A61K0047-04 [ICS,7]; A61K0047-02 [ICS,7,C\*];  
A61K0047-12 [ICS,7]; A61K0047-18 [ICS,7]; A61K0047-16  
[ICS,7,C\*]; A61K0047-22 [ICS,7]; A61K0047-24 [ICS,7];  
A61K0047-32 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-16  
[ICS,7]; A61P0031-00 [ICS,7,C\*]  
IPCR A61K0009-12 [I,C\*]; A61K0009-12 [I,A]; A61K0008-00  
[I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*];  
A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-34  
[I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A];  
A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-70  
[I,C\*]; A61K0009-70 [I,A]; A61K0009-72 [I,C\*];  
A61K0009-72 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19  
[I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A];  
A61K0031-194 [I,A]; A61K0031-28 [I,C\*]; A61K0031-28  
[I,A]; A61K0031-375 [I,C\*]; A61K0031-375 [I,A];  
A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A]; A61K0033-24  
[I,C\*]; A61K0033-24 [I,A]; A61K0033-26 [I,C\*];  
A61K0033-26 [I,A]; A61K0033-30 [I,C\*]; A61K0033-30  
[I,A]; A61K0033-34 [I,C\*]; A61K0033-34 [I,A];  
A61K0047-02 [I,C\*]; A61K0047-04 [I,A]; A61K0047-10  
[I,C\*]; A61K0047-10 [I,A]; A61K0047-12 [I,C\*];  
A61K0047-12 [I,A]; A61K0047-16 [I,C\*]; A61K0047-18  
[I,A]; A61K0047-22 [I,C\*]; A61K0047-22 [I,A];  
A61K0047-24 [I,C\*]; A61K0047-24 [I,A]; A61K0047-32  
[I,C\*]; A61K0047-32 [I,A]; A61L0002-16 [I,C\*];  
A61L0002-16 [I,A]; A61M0011-00 [I,C\*]; A61M0011-00 [I,A];  
A61P0011-00 [I,C\*]; A61P0011-02 [I,A]; A61P0031-00



HU 2002004123

IPCI  
IPCR

[I,C\*]; A61P0031-04 [I,A]; A61P0031-12 [I,A];  
A61P0031-16 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02  
[I,A]; A61Q0017-00 [I,C\*]; A61Q0017-00 [I,A];  
A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A]; C11D0003-02  
[I,C\*]; C11D0003-02 [I,A]; C11D0003-26 [I,C\*];  
C11D0003-33 [I,A]; C11D0003-48 [I,C\*]; C11D0003-48  
[I,A]; D21H0021-14 [I,C\*]; D21H0021-36 [I,A];  
D21H0027-30 [N,C\*]; D21H0027-32 [N,A]  
A61P0011-00 [I,C\*]; A61P0011-02 [I,A]  
A61K0009-12 [I,C\*]; A61K0009-12 [I,A]; A61K0008-00  
[I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*];  
A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-34  
[I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A];  
A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-70  
[I,C\*]; A61K0009-70 [I,A]; A61K0009-72 [I,C\*];  
A61K0009-72 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19  
[I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A];  
A61K0031-194 [I,A]; A61K0031-28 [I,C\*]; A61K0031-28  
[I,A]; A61K0031-375 [I,C\*]; A61K0031-375 [I,A];  
A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A]; A61K0033-24  
[I,C\*]; A61K0033-24 [I,A]; A61K0033-26 [I,C\*];  
A61K0033-26 [I,A]; A61K0033-30 [I,C\*]; A61K0033-30  
[I,A]; A61K0033-34 [I,C\*]; A61K0033-34 [I,A];  
A61K0047-02 [I,C\*]; A61K0047-04 [I,A]; A61K0047-10  
[I,C\*]; A61K0047-10 [I,A]; A61K0047-12 [I,C\*];  
A61K0047-12 [I,A]; A61K0047-16 [I,C\*]; A61K0047-18  
[I,A]; A61K0047-22 [I,C\*]; A61K0047-22 [I,A];  
A61K0047-24 [I,C\*]; A61K0047-24 [I,A]; A61K0047-32  
[I,C\*]; A61K0047-32 [I,A]; A61L0002-16 [I,C\*];  
A61L0002-16 [I,A]; A61L0002-18 [I,C\*]; A61L0002-18  
[I,A]; A61M0011-00 [I,C\*]; A61M0011-00 [I,A];  
A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-12  
[I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C\*];  
A61Q0005-02 [I,A]; A61Q0017-00 [I,C\*]; A61Q0017-00  
[I,A]; A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A];  
C11D0003-02 [I,C\*]; C11D0003-02 [I,A]; C11D0003-26  
[I,C\*]; C11D0003-33 [I,A]; C11D0003-48 [I,C\*];  
C11D0003-48 [I,A]; D21H0021-14 [I,C\*]; D21H0021-36  
[I,A]; D21H0027-30 [N,C\*]; D21H0027-32 [N,A]  
ECLA A61K008/02C; A61K008/49C2; A61K031/28+M; A61Q017/00;  
D21H021/36; N21H  
NZ 518117 IPCI A61K0031-4015 [ICM,7]; A01N0043-36 [ICS,7]; A01N0043-34  
[ICS,7,C\*]; D21H0021-36 [ICS,7]; D21H0021-14 [ICS,7,C\*]  
IPCR A61K0009-12 [I,C\*]; A61K0009-12 [I,A]; A61K0008-00  
[I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*];  
A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-34  
[I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A];  
A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-70  
[I,C\*]; A61K0009-70 [I,A]; A61K0009-72 [I,C\*];  
A61K0009-72 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19  
[I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A];  
A61K0031-194 [I,A]; A61K0031-28 [I,C\*]; A61K0031-28  
[I,A]; A61K0031-375 [I,C\*]; A61K0031-375 [I,A];  
A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A]; A61K0033-24  
[I,C\*]; A61K0033-24 [I,A]; A61K0033-26 [I,C\*];  
A61K0033-26 [I,A]; A61K0033-30 [I,C\*]; A61K0033-30  
[I,A]; A61K0033-34 [I,C\*]; A61K0033-34 [I,A];  
A61K0047-02 [I,C\*]; A61K0047-04 [I,A]; A61K0047-10  
[I,C\*]; A61K0047-10 [I,A]; A61K0047-12 [I,C\*];  
A61K0047-12 [I,A]; A61K0047-16 [I,C\*]; A61K0047-18  
[I,A]; A61K0047-22 [I,C\*]; A61K0047-22 [I,A];

		A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0011-00 [I,C*]; A61P0011-02 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A];
RU 2228177	IPCI	A61K0031-4015 [ICM,7]; A61P0011-02 [ICS,7]; A61P0011-00 [ICS,7,C*]; A61P0031-16 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0009-72 [I,C*]; A61K0009-72 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-375 [I,C*]; A61K0031-375 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A]; A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0011-00 [I,C*]; A61P0011-02 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A];
	ECLA	A61K008/02C; A61K008/49C2; A61K031/28+M; A61Q017/00; D21H021/36
AT 276749	IPCI	A61K0031-4015 [ICM,7]; A61K0033-30 [ICS,7]; A61K0033-24 [ICS,7]; A61K0031-375 [ICS,7]; A61K0031-194 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0009-72 [I,C*]; A61K0009-72 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-375 [I,C*]; A61K0031-375 [I,A];

		A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A]; A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0011-00 [I,C*]; A61P0011-02 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
AU 777549	IPCI	A61K0031-4015 [ICM,7]; A61K0031-19 [ICS,7]; A61K0031-194 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-375 [ICS,7]; A61K0033-24 [ICS,7]; A61K0033-30 [ICS,7]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0009-72 [I,C*]; A61K0009-72 [I,A]; A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-375 [I,C*]; A61K0031-375 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0033-26 [I,C*]; A61K0033-26 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A]; A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-24 [I,C*]; A61K0047-24 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61L0002-16 [I,C*]; A61L0002-16 [I,A]; A61L0002-18 [I,C*]; A61L0002-18 [I,A]; A61M0011-00 [I,C*]; A61M0011-00 [I,A]; A61P0011-00 [I,C*]; A61P0011-02 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C*]; C11D0003-02 [I,A]; C11D0003-26 [I,C*]; C11D0003-33 [I,A]; C11D0003-48 [I,C*]; C11D0003-48 [I,A]; D21H0021-14 [I,C*]; D21H0021-36 [I,A]; D21H0027-30 [N,C*]; D21H0027-32 [N,A]
ES 2223601	IPCI	A61K0031-4015 [ICM,7]; A61K0033-30 [ICS,7]; A61K0033-24 [ICS,7]; A61K0031-375 [ICS,7]; A61K0031-194 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*];

A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-34 [I,A]; A61K0008-44 [I,A]; A61K0008-49 [I,A]; A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-70 [I,C\*]; A61K0009-70 [I,A]; A61K0009-72 [I,C\*]; A61K0009-72 [I,A]; A61K0031-185 [I,C\*]; A61K0031-19 [I,A]; A61K0031-191 [I,A]; A61K0031-192 [I,A]; A61K0031-194 [I,A]; A61K0031-28 [I,C\*]; A61K0031-28 [I,A]; A61K0031-3/5 [I,C\*]; A61K0031-3/5 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A]; A61K0033-24 [I,C\*]; A61K0033-24 [I,A]; A61K0033-26 [I,C\*]; A61K0033-26 [I,A]; A61K0033-30 [I,C\*]; A61K0033-30 [I,A]; A61K0033-34 [I,C\*]; A61K0033-34 [I,A]; A61K0047-02 [I,C\*]; A61K0047-04 [I,A]; A61K0047-10 [I,C\*]; A61K0047-10 [I,A]; A61K0047-12 [I,C\*]; A61K0047-12 [I,A]; A61K0047-16 [I,C\*]; A61K0047-18 [I,A]; A61K0047-22 [I,C\*]; A61K0047-22 [I,A]; A61K0047-24 [I,C\*]; A61K0047-24 [I,A]; A61K0047-32 [I,C\*]; A61K0047-32 [I,A]; A61L0002-16 [I,C\*]; A61L0002-16 [I,A]; A61L0002-18 [I,C\*]; A61L0002-18 [I,A]; A61M0011-00 [I,C\*]; A61M0011-00 [I,A]; A61P0011-00 [I,C\*]; A61P0011-02 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02 [I,A]; A61Q0017-00 [I,C\*]; A61Q0017-00 [I,A]; A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C\*]; C11D0003-02 [I,A]; C11D0003-26 [I,C\*]; C11D0003-33 [I,A]; C11D0003-48 [I,C\*]; C11D0003-48 [I,A]; D21H0021-14 [I,C\*]; D21H0021-36 [I,A]; D21H0027-30 [N,C\*]; D21H0027-32 [N,A]; A01N [ICM,7]; A61K [ICS,7]; D21H [ICS,7]; B32B [ICS,7] A61K0031-4015 [ICM,7]; A61K0033-30 [ICS,7]; A61K0033-24 [ICS,7]; A61K0031-375 [ICS,7]; A61K0031-194 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C\*]

ZA 2002002475 IPCI  
 IN 2002KN00406 IPCI

NO 2002001830 IPCI  
 IPCR

A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A]; C11D0003-02 [I,C\*]; C11D0003-02 [I,A]; C11D0003-26 [I,C\*]; C11D0003-33 [I,A]; C11D0003-48 [I,C\*]; C11D0003-48 [I,A]; D21H0021-14 [I,C\*]; D21H0021-36 [I,A]; D21H0027-30 [N,C\*]; D21H0027-32 [N,A]; D21H0031-4015 [ICM,5]; A61K0033-24 [ICS,5]; A61K0033-30 [ICS,5]

MX 2002PA03882 IPCI

AB Nasal compns. for prevention and treatment of cold and influenza-like symptoms due to respiratory tract viral infections based on pyroglutamic acid (0.01-20%) and an organic acid having a dissociation constant (pKa) of 3.0-5.0 are described. These compds. and their method of application are effective in both preventing the onset of the symptoms of colds and influenza or significantly mitigating them if already afflicted with such symptoms. A nasal spray composition was prepared containing (by weight) pyroglutamic acid 1.00%, ascorbic acid 1.00%, phytic acid as a chelating agent 1.00%, a mucoadhesive polymer (Carbopol 980) 1.00%, eucalyptol 0.01%, Ph Et alc. 0.50%, and water up to 100%, resp. The pH was adjusted to 3.5 with addition of NaOH. A recommended dosage was 100  $\mu$ L of the solution into each nostril three times a day.

ST pyroglutamate carboxylate nasal pharmaceutical cold influenza

IT Vinyl compounds, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (carboxy-containing, polymers; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Antiviral agents  
 Buffers  
 Chelating agents  
 Common cold  
 Crosslinking agents  
 Dissociation constant  
 Influenza  
 Influenza virus  
 pH  
 (compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Carboxylic acids, biological studies  
 Chlorides, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Carboxylic acids, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Respiratory tract  
 (infection, viral; compns. containing pyroglutamic and other organic acids for prevention and treatment of respiratory tract viral infections)

IT Drug delivery systems  
 (inhalants, nasal; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Drug delivery systems  
(nasal sprays; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Drug delivery systems  
(nasal; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Drug delivery systems  
(powders, nasal; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Carboxylic acids, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(salts; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Polyphosphoric acids  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sodium salts; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT Carboxylic acids, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tricarboxylic acids; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts 50-81-7, Ascorbic acid, biological studies 50-81-7D, Ascorbic acid, salts 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 64-19-7, Acetic acid, biological studies 64-19-7D, Acetic acid, salts, biological studies 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, salts, biological studies 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, salts 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, salts 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid, biological studies 88-99-3, Phthalic acid, biological studies 98-79-3, Pyroglutamic acid 110-15-6, Succinic acid, biological studies 110-15-6D, Succinic acid, salts 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 110-94-1D, Glutaric acid, salts 124-04-9, Adipic acid, biological studies 141-82-2, Malonic acid, biological studies 141-82-2D, Malonic acid, salts 526-95-4, Gluconic acid 526-95-4D, Gluconic acid, salts 557-34-6, Zinc acetate 994-36-5, Sodium citrate 6915-15-7, Malic acid 6915-15-7D, Malic acid, salts  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT 60-12-8, Phenyl ethyl alcohol 62-33-9, Calcium EDTA 63-42-3, Lactose 64-02-8, Tetrasodium EDTA 64-17-5, Ethanol, biological studies 83-86-3, Phytic acid 139-33-3, Disodium EDTA 148-24-3, 8-Hydroxyquinoline, biological studies 150-25-4, Di(hydroxyethyl)glycine 470-82-6, Eucalyptol 9003-01-4, Carboxypolymethylene 26266-58-0, Sorbitan trioleate 138757-67-2, Carbopol 980  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT 79-10-7D, Acrylic acid, esters, polymers  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (crosslinked; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

IT 57-50-1D, Sucrose, allyl ethers 115-77-5D, Pentaerythritol, allyl ethers 1069-23-4, Divinyl glycol  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (crosslinking agent; compns. containing pyroglutamic and other organic acids for prevention and treatment of cold and influenza)

L7 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 110-15-6, Succinic acid, biological studies 124-04-9, Adipic acid, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$

RN 124-04-9 CAPLUS  
 CN Hexanedioic acid (CA INDEX NAME)

$\text{HO}_2\text{C}-(\text{CH}_2)_4-\text{CO}_2\text{H}$

ACCESSION NUMBER: 2001:136991 CAPLUS  
 DOCUMENT NUMBER: 134:198075  
 TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents  
 INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing  
 PATENT ASSIGNEE(S): Lipocine, Inc., USA  
 SOURCE: PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817
CA 2380642	A1	20010222	CA 2000-2380642	20000710
EP 1210063	A1	20020605	EP 2000-947184	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T	20030218	JP 2001-516502	20000710

NZ 517659	A	20041224	NZ 2000-517659	20000710
AU 780877	B2	20050421	AU 2000-60838	20000710
US 20010024658	A1	20010927	US 2000-751968	20001229
US 6458383	B2	20021001		

PRIORITY APPLN. INFO.:

US 1999-375636	A	19990817
WO 2000-US18807	W	20000710

AN 2001:136991 CAPLUS

DN 134:198075

ED Entered STN: 25 Feb 2001

TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

IN Patel, Mahesh V.; Chen, Feng-Jing

PA Lipocine, Inc., USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-00

ICS A61K009-14; A61K009-16; A61K009-20; A61K009-22; A61K009-28;

A61K009-48

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012155	A1	20010222	WO 2000-US18807	20000710
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6309663	B1	20011030	US 1999-375636	19990817
	CA 2380642	A1	20010222	CA 2000-2380642	20000710
	EP 1210063	A1	20020605	EP 2000-947184	20000710
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506476	T	20030218	JP 2001-516502	20000710
	NZ 517659	A	20041224	NZ 2000-517659	20000710
	AU 780877	B2	20050421	AU 2000-60838	20000710
	US 20010024658	A1	20010927	US 2000-751968	20001229
	US 6458383	B2	20021001		
PRAI	US 1999-375636	A	19990817		
	WO 2000-US18807	W	20000710		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001012155	ICM	A61K009-00
	ICS	A61K009-14; A61K009-16; A61K009-20; A61K009-22; A61K009-28; A61K009-48
	IPCI	A61K0009-00 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7]; A61K0009-28 [ICS,7]; A61K0009-48 [ICS,7]
	IPCR	A61K0009-02 [I,C*]; A61K0009-02 [I,A]; A61K0009-06 [I,C*]; A61K0009-06 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-10 [I,C*]; A61K0009-10 [I,A]; A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0009-20



US 6309663

ECLA  
IPC1  
IPCR

[I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48  
[I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A];  
A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352  
[I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*];  
A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425  
[I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A];  
A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A];  
A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A];  
A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A];  
A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727  
[I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A];  
A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22  
[I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*];  
A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27  
[I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A];  
A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08  
[I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A];  
A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44  
[I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*];  
A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02  
[I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];  
A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38  
[I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A];  
A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04  
[I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A];  
A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06  
[I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*];  
A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06  
[I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A];  
A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04  
[I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A];  
A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22  
[I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*];  
A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04  
[I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A];  
A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06  
[I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*];  
A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02  
[I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]  
A61K009/107D; A61K009/48H4; A61K009/48Z  
A61K0009-127 [ICM,7]  
A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06  
[I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*];  
A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10  
[I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A];  
A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20  
[I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48  
[I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A];  
A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352  
[I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*];  
A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425  
[I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A];  
A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A];  
A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A];  
A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A];  
A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727  
[I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A];

A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*]; A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A]; A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A]; A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*]; A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A]; A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A]; A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]

NCL 424/450.000; 424/435.000; 424/451.000; 424/455.000; 424/456.000; 424/463.000; 424/464.000; 424/489.000; 424/499.000; 424/502.000; 514/937.000; 514/938.000; 514/939.000; 514/940.000; 514/941.000; 514/942.000; 514/943.000; 514/975.000

ECLA A61K009/107D

CA 2380642 IPCI A61K0009-00 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7]; A61K0009-28 [ICS,7]; A61K0009-48 [ICS,7]

IPCR A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06 [I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10 [I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A]; A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A]; A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352 [I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A]; A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662 [I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A]; A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A]; A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727 [I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A]; A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*]; A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A]; A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A];

EP 1210063

IPCI

IPCR

A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*]; A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A]; A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A]; A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]; A61K0009-00 [ICM,6]; A61K0009-14 [ICS,6]; A61K0009-16 [ICS,6]; A61K0009-20 [ICS,6]; A61K0009-22 [ICS,6]; A61K0009-28 [ICS,6]; A61K0009-48 [ICS,6]; A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06 [I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10 [I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A]; A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A]; A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352 [I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A]; A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662 [I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A]; A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A]; A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727 [I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A]; A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*]; A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A]; A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A]; A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*]; A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A];

JP 2003506476

ECLA  
IPCI

IPCR

A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A]; A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]; A61K0009/107D; A61K0009/48H4; A61K0009/48Z  
A61K0045-08 [ICM,7]; A61K0045-00 [ICM,7,C\*]; A61K0009-02 [ICS,7]; A61K0009-06 [ICS,7]; A61K0009-08 [ICS,7]; A61K0009-10 [ICS,7]; A61K0009-14 [ICS,7]; A61K0009-20 [ICS,7]; A61K0009-48 [ICS,7]; A61K0031-155 [ICS,7]; A61K0031-352 [ICS,7]; A61K0031-427 [ICS,7]; A61K0031-4425 [ICS,7]; A61K0031-522 [ICS,7]; A61K0031-519 [ICS,7,C\*]; A61K0031-546 [ICS,7]; A61K0031-662 [ICS,7]; A61K0031-663 [ICS,7]; A61K0031-7036 [ICS,7]; A61K0031-7028 [ICS,7,C\*]; A61K0031-7048 [ICS,7]; A61K0031-7052 [ICS,7]; A61K0031-7042 [ICS,7,C\*]; A61K0031-727 [ICS,7]; A61K0031-726 [ICS,7,C\*]  
A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06 [I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10 [I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A]; A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A]; A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352 [I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A]; A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662 [I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A]; A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A]; A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727 [I,A]; A61K0031-727 [I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A]; A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*]; A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A]; A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A]; A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*]; A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A]; A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A];

NZ 517659

IPCI

IPCR

A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]; A61K0009-00 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7]; A61K0009-28 [ICS,7]; A61K0009-48 [ICS,7]; A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06 [I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*]; A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10 [I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A]; A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*]; A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A]; A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352 [I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A]; A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662 [I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A]; A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A]; A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A]; A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727 [I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A]; A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*]; A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A]; A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A]; A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*]; A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A]; A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A]; A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*]; A61P0037-02 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]; A61K0009-00 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]; A61K0009-20 [ICS,7]; A61K0009-22 [ICS,7]; A61K0009-28 [ICS,7]; A61K0009-48 [ICS,7]; A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06

AU 780877

IPCI

IPCR

[I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*];  
 A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10  
 [I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A];  
 A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20  
 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48  
 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A];  
 A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352  
 [I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*];  
 A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425  
 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A];  
 A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662  
 [I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A];  
 A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A];  
 A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A];  
 A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727  
 [I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A];  
 A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22  
 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*];  
 A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27  
 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A];  
 A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08  
 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A];  
 A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44  
 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*];  
 A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02  
 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];  
 A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38  
 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A];  
 A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04  
 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A];  
 A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06  
 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*];  
 A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06  
 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A];  
 A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04  
 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A];  
 A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22  
 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*];  
 A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04  
 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A];  
 A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06  
 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*];  
 A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02  
 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]  
 A61K0031-727 [ICM,7]; A61K0031-726 [ICM,7,C\*];  
 A61K0009-48 [ICS,7]  
 A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-06  
 [I,C\*]; A61K0009-06 [I,A]; A61K0009-08 [I,C\*];  
 A61K0009-08 [I,A]; A61K0009-10 [I,C\*]; A61K0009-10  
 [I,A]; A61K0009-107 [I,C\*]; A61K0009-107 [I,A];  
 A61K0009-14 [I,C\*]; A61K0009-14 [I,A]; A61K0009-20  
 [I,C\*]; A61K0009-20 [I,A]; A61K0009-22 [I,C\*];  
 A61K0009-22 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48  
 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A];  
 A61K0031-155 [I,C\*]; A61K0031-155 [I,A]; A61K0031-352  
 [I,C\*]; A61K0031-352 [I,A]; A61K0031-427 [I,C\*];  
 A61K0031-427 [I,A]; A61K0031-4425 [I,C\*]; A61K0031-4425  
 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A];  
 A61K0031-546 [I,C\*]; A61K0031-546 [I,A]; A61K0031-662  
 [I,C\*]; A61K0031-662 [I,A]; A61K0031-663 [I,A];

US 20010024658 IPCI

IPCR

A61K0031-7028 [I,C\*]; A61K0031-7036 [I,A];  
 A61K0031-7042 [I,C\*]; A61K0031-7048 [I,A];  
 A61K0031-7052 [I,A]; A61K0031-726 [I,C\*]; A61K0031-727  
 [I,A]; A61K0038-00 [I,C\*]; A61K0038-00 [I,A];  
 A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-22  
 [I,C\*]; A61K0038-22 [I,A]; A61K0038-23 [I,C\*];  
 A61K0038-23 [I,A]; A61K0038-27 [I,C\*]; A61K0038-27  
 [I,A]; A61K0038-28 [I,C\*]; A61K0038-28 [I,A];  
 A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61K0045-08  
 [I,A]; A61K0047-06 [I,C\*]; A61K0047-06 [I,A];  
 A61K0047-30 [I,C\*]; A61K0047-30 [I,A]; A61K0047-44  
 [I,C\*]; A61K0047-44 [I,A]; A61P0001-00 [I,C\*];  
 A61P0001-04 [I,A]; A61P0003-00 [I,C\*]; A61P0003-02  
 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];  
 A61P0005-00 [I,C\*]; A61P0005-16 [I,A]; A61P0005-38  
 [I,A]; A61P0007-00 [I,C\*]; A61P0007-02 [I,A];  
 A61P0007-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-04  
 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A];  
 A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-06  
 [I,A]; A61P0011-14 [I,A]; A61P0017-00 [I,C\*];  
 A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06  
 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A];  
 A61P0025-00 [I,C\*]; A61P0025-00 [I,A]; A61P0025-04  
 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A];  
 A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22  
 [I,A]; A61P0025-24 [I,A]; A61P0029-00 [I,C\*];  
 A61P0029-00 [I,A]; A61P0031-00 [I,C\*]; A61P0031-04  
 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A];  
 A61P0033-00 [I,C\*]; A61P0033-02 [I,A]; A61P0033-06  
 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C\*];  
 A61P0035-00 [I,A]; A61P0037-00 [I,C\*]; A61P0037-02  
 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]  
 NCL 424/452.000; 514/056.000; 514/171.000; 424/451.000;  
 424/434.000; 424/435.000; 424/450.000; 424/455.000;  
 424/456.000; 424/463.000; 424/464.000; 424/489.000;  
 424/499.000; 424/502.000; 514/937.000; 514/938.000;  
 514/939.000; 514/940.000; 514/941.000; 514/942.000;  
 514/943.000; 514/975.000  
 ECLA A61K009/107D; A61K009/48H4; A61K009/48Z

- AB The present invention relates to triglyceride-free pharmaceutical compns.,  
 pharmaceutical systems, and methods for enhanced absorption of hydrophilic  
 therapeutic agents. The compns. and systems include an absorption  
 enhancing carrier, where the carrier is formed from a combination of at  
 least two surfactants, at least one of which is hydrophilic. A  
 hydrophilic therapeutic agent can be incorporated into the composition, or can  
 be co-administered with the composition as part of a pharmaceutical system.  
 The invention also provides methods of treatment with hydrophilic  
 therapeutic agents using these compns. and systems. For example, when a  
 composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate  
 0.18,  
 and propylene glycol 0.32 g, resp., was used, the relative absorption of  
 PEG 4000 as a model macromol. drug was enhanced by 991%.  
 ST hydrophilic drug surfactant absorption enhancement  
 IT Lysophospholipids  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C18; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)  
 IT Diglycerides  
 Glycerides, biological studies  
 Monoglycerides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C8-10 monoglycerides and diglycerides; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C8-10, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C8-18 and C18-unsatd. mono- and di-, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antibodies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Fc fragment, fusion protein with TNF receptor; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lung  
 Mucous membrane  
 (administration by; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
 (aerosols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Phenols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkyl, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (almond, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antiarthritics  
 (anti-gout agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
 (beads; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Natural products, pharmaceutical  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (belladonna; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
 (buccal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
 (capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gelatins, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gonadotropins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chorionic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Analgesics  
 Anthelmintics  
 Anti-inflammatory agents  
 Antianginal agents  
 Antiarrhythmics  
 Antiasthmatics  
 Antibacterial agents  
 Anticoagulants



- Anticonvulsants
- Antidepressants
- Antidiabetic agents
- Antifoaming agents
- Antihistamines
- Antihypertensives
- Antimalarials
- Antimigraine agents
- Antiparkinsonian agents
- Antipsychotics
- Antitumor agents
- Antitussives
- Antiviral agents
- Anxiolytics
- Blood serum
- Buffers
- Chelating agents
- Compression
- Diuretics
- Drug delivery systems
- Encapsulation
- Extrusion, nonbiological
- Flavoring materials
- Fungicides
- Hypnotics and Sedatives
- Immunosuppressants
- Inotropics
- Molding
- Muscarinic antagonists
- Muscle relaxants
- Nervous system stimulants
- Nutrients
- Peptidomimetics
- Plasticizers
- Preservatives
- Protozoacides
- Solubilizers
- Spheronization
- Surfactants
- Vaccines
- (comps. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT    Acrylic polymers, biological studies

- Alcohols, biological studies
- Amides, biological studies
- Amino acids, biological studies
- Carbohydrates, biological studies
- Corticosteroids, biological studies
- Cytokines
- Diglycerides
- Elastins
- Enkephalins
- Esters, biological studies
- Fatty acids, biological studies
- Genetic element
- Glycerides, biological studies
- Glycosides
- Interleukin 2
- Interleukin 3
- Lecithins
- Lysophosphatidic acids

Lysophosphatidylcholines  
Lysophosphatidylethanolamines  
Lysophosphatidylserines  
Macromolecular compounds  
Nucleic acids  
Nucleosides, biological studies  
Nucleotides, biological studies  
Oligonucleotides  
Peptides, biological studies  
Phosphatidic acids  
Phosphatidylcholines, biological studies  
Phosphatidylethanolamines, biological studies  
Phosphatidylglycerols  
Phosphatidylserines  
Phospholipids, biological studies  
Platelet-derived growth factors  
Polyoxyalkylenes, biological studies  
Proteins, general, biological studies  
Sex hormones  
Shellac  
Sterols  
Sulfonic acids, biological studies  
Tannins  
Toxoids  
Tumor necrosis factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(controlled-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(corn, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Bath preparations  
(douches; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(drops; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(elixirs; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(emulsions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Castor oil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated, Emalex C40; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Sterols  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated; Nikkol BPS 30, compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Corn oil  
Ethers, biological studies  
Palm kernel oil  
Sterols

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated; compns. for enhanced absorption of hydrophilic drugs)

using combination of surfactants)

IT Tumor necrosis factor receptors  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fusion protein with antibody Fc fragment; compns. for enhanced  
 absorption of hydrophilic drugs using combination of surfactants)

IT Drugs  
 (gastrointestinal; compns. for enhanced absorption of hydrophilic drugs  
 using combination of surfactants)

IT Drug delivery systems  
 (gels; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Drug delivery systems  
 (granules; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Vaccines  
 (hepatitis A; compns. for enhanced absorption of hydrophilic drugs  
 using combination of surfactants)

IT Vaccines  
 (hepatitis B; compns. for enhanced absorption of hydrophilic drugs  
 using combination of surfactants)

IT Castor oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated, ethoxylated; compns. for enhanced absorption of  
 hydrophilic drugs using combination of surfactants)

IT Vaccines  
 (influenza; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Enzymes, biological studies  
 Thyroid hormones  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Skin preparations (pharmaceutical)  
 (keratolytics; compns. for enhanced absorption of hydrophilic drugs  
 using combination of surfactants)

IT Lipids, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (lipid regulating agents; compns. for enhanced absorption of  
 hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
 (lotions; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Lysophosphatides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lysophosphatidylglycerols; compns. for enhanced absorption of  
 hydrophilic drugs using combination of surfactants)

IT Vaccines  
 (measles; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Polymers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mucoadhesive; compns. for enhanced absorption of hydrophilic drugs  
 using combination of surfactants)

IT Vaccines  
 (mumps; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Drug delivery systems  
 (nasal; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT Surfactants  
 (nonionic; compns. for enhanced absorption of hydrophilic drugs using

combination of surfactants)

IT Drug delivery systems  
(ointments, creams; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(ointments; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(oral; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(particles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(pastes; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(pellets; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antioxidants  
(pharmaceutical; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection  
(plague, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyhydric; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Phosphatidylethanolamines, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(reaction products, with PEG and PVP; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(rectal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(salts, carnitine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(solns.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Sterols  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(soya, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(sprays; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Monoglycerides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(succinylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(suppositories, vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(suppositories; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems

(suspensions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(sustained-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(syrups; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycosides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thioglycosides, alkyl esters; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Haemophilus influenzae  
(type b, conjugated vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Human poliovirus  
(vaccine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Japanese encephalitis virus  
Mycobacterium BCG  
Neisseria meningitidis  
Rabies  
Rotavirus  
Streptococcus pneumoniae  
Typhoid fever  
(vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems  
(vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Human herpesvirus 3  
(varicella from, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection  
(variola, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, ethoxylated, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fever and Hyperthermia  
(yellow, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\alpha$ ; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Adrenoceptor antagonists  
( $\beta$ -; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\beta$ ; compns. for enhanced absorption of hydrophilic drugs using

combination of surfactants)

IT 9011-29-4, Nikkol GS 6  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Nikkol GS 460; compns. for enhanced absorption of hydrophilic drugs  
 using combination of surfactants)

IT 9005-25-8, Starch, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (capsules; compns. for enhanced absorption of hydrophilic drugs using  
 combination of surfactants)

IT 59277-89-3, Acyclovir  
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU  
 (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (compns. for enhanced absorption of hydrophilic drugs using combination  
 of surfactants)

IT 63585-09-1, Foscarnet sodium  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (compns. for enhanced absorption of hydrophilic drugs using combination  
 of surfactants)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, acyl  
 esters 50-56-6, Oxytocin, biological studies 50-70-4, Sorbitol,  
 biological studies 50-81-7, Ascorbic acid, biological studies 51-15-0,  
 Pralidoxime chloride 51-43-4, Epinephrine 51-55-8, Atropine,  
 biological studies 51-60-5, Neostigmine methyl sulfate 52-24-4,  
 Thiotepea 53-79-2, Puromycin 56-81-5, Glycerol, biological studies  
 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid,  
 biological studies 57-13-6, Urea, biological studies 57-22-7,  
 Vincristine 57-55-6, Propylene glycol, biological studies 57-55-6D,  
 Propylene glycol, ethers 57-64-7, Physostigmine salicylate 57-88-5,  
 Cholesterol, biological studies 57-94-3, Tubocurarine chloride  
 59-05-2, Methotrexate 60-00-4, EDTA, biological studies 60-00-4D,  
 EDTA, conjugates with antipain and chitosan 60-31-1, Acetylcholine  
 chloride 60-33-3, Linoleic acid, biological studies 62-31-7, Dopamine  
 hydrochloride 63-91-2, Phenylalanine, biological studies 64-18-6,  
 Formic acid, biological studies 64-19-7, Acetic acid  
 , biological studies 65-28-1, Phentolamine mesylate 65-85-0, Benzoic  
 acid, biological studies 66-71-7, 1,10-Phenanthroline 67-42-5, EGTA  
 68-11-1, Thioglycolic acid, biological studies 68-19-9, Vitamin B12  
 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies  
 69-79-4D, Maltose, alkyl esters 69-93-2, Uric acid, biological studies  
 70-51-9, Deferoxamine 71-27-2, Suxamethonium chloride 74-89-5,  
 Methanamine, biological studies 75-75-2, Methanesulfonic acid 77-19-0,  
 Dicyclomine 77-92-9, Citric acid, biological studies 77-92-9D, Citric  
 acid, glycerides 79-09-4, Propionic acid, biological studies 79-10-7,  
 Acrylic acid, biological studies 79-10-7D,  
 Acrylic acid, polymers 81-24-3, Taurocholic acid  
 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 87-69-4, Tartaric acid,  
 biological studies 87-69-4D, Tartaric acid, glycerides 89-57-6,  
 Mesalamine 89-65-6, Isoascorbic acid 101-26-8, Pyridostigmine bromide  
 102-71-6, Triethanolamine, biological studies 104-15-4,  
 p-Toluenesulfonic acid, biological studies 107-15-3, Ethylenediamine,  
 biological studies 107-21-1, Ethylene glycol, biological studies  
 107-92-6, Butyric acid, biological studies 110-15-6, Succinic  
 acid, biological studies 110-16-7, Maleic acid, biological studies  
 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate  
 111-62-6, Ethyl oleate 112-80-1, Oleic acid, biological studies  
 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-77-5,  
 Pentaerythritol, biological studies 121-44-8, Triethylamine, biological  
 studies 122-20-3, Triisopropanolamine 124-04-9, Adipic acid,  
 biological studies 124-07-2, Caprylic acid, biological studies  
 128-13-2, Ursodeoxycholic acid 129-06-6, Warfarin sodium 131-49-7,


Diatrizoate meglumine 138-36-3, p-Bromobenzenesulfonic acid 140-64-7,  
 Pentamidine isethionate 141-22-0, Ricinoleic acid 141-43-5,  
 Ethanolamine, biological studies 142-62-1, Caproic acid, biological  
 studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid,  
 biological studies 143-07-7D, Lauric acid, Macrogl glycerides  
 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Oxalic  
 acid, biological studies 145-42-6, Sodium taurocholate 147-94-4,  
 Cytarabine 148-24-3, 8-Quinololinol, biological studies 151-21-3, Sodium  
 lauryl sulfate, biological studies 151-41-7, Lauryl sulfate 154-21-2,  
 Lincomycin 155-97-5, Pyridostigmine 299-42-3, Ephedrine 334-48-5,  
 Capric acid 360-65-6, Glycodeoxycholic acid 434-13-9, Lithocholic acid  
 463-40-1, Linolenic acid 463-79-6, Carbonic acid, biological studies  
 471-34-1, Calcium carbonate, biological studies 474-25-9,  
 Chenodeoxycholic acid 475-31-0, Glycocholic acid 516-35-8,  
 Taurochenodeoxycholic acid 516-50-7, Taurodeoxycholic acid 526-95-4,  
 Gluconic acid 541-15-1D, Carnitine, fatty acid ester salts 544-35-4,  
 Ethyl linoleate 544-63-8, Myristic acid, biological studies 577-11-7,  
 Sodium docusate 616-91-1, N-Acetylcysteine 640-79-9,  
 Glycochenodeoxycholic acid 665-66-7, Amantadine hydrochloride  
 737-31-5, Diatrizoate sodium 863-57-0, Sodium glycocholate 865-21-4,  
 Vinblastin 1002-62-6, Sodium caprate 1115-70-4, Metformin  
 hydrochloride 1264-72-8, Colistin sulfate 1309-42-8, Magnesium  
 hydroxide 1310-58-3, Potassium hydroxide, biological studies  
 1310-73-2, Sodium hydroxide, biological studies 1319-82-0, Aminocaproic  
 acid 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene  
 glycol monooleate 1335-30-4, Aluminum silicate 1336-21-6, Ammonium  
 hydroxide 1338-39-2, Span 20 1338-41-6, Sorbitan monostearate  
 1338-43-8, Span 80 1397-89-3, Amphotericin B 1403-66-3, Gentamycin  
 1404-90-6, Vancomycin 1405-20-5, Polymixin B sulfate 1405-37-4,  
 Capreomycin sulfate 1405-87-4, Bacitracin 1492-18-8, Leucovorin  
 calcium 1501-84-4, Rimantadine hydrochloride 1684-40-8, Tacrine  
 hydrochloride 1695-77-8, Spectinomycin 1935-18-8, Palmitoyl carnitine  
 2016-88-8, Amiloride hydrochloride 2364-67-2, Palmitoyl carnitine  
 2466-77-5, Lauroyl carnitine 2646-38-0, Sodium chenodeoxycholate  
 2898-95-5, Sodium ursodeoxycholate 3056-17-5, Stavudine 3485-62-9,  
 Clidinium bromide 3778-73-2, Isofosfamide 3858-83-1,  
 P-Aminobenzamide 4291-63-8, Cladribine 5534-95-2, Pentagastrin  
 6303-21-5D, Phosphoric acid, dipeptide derivs. 6493-05-6, Pentoxifylline  
 7087-68-5, Diisopropylethylamine 7481-89-2, Zalcitabine 7585-39-9D,  
 $\beta$ -Cyclodextrin, ethers with propanediol 7647-01-0, Hydrochloric  
 acid, biological studies 7648-98-8, Ambenonium 7664-38-2, Phosphoric  
 acid, biological studies 7664-93-9, Sulfuric acid, biological studies  
 7664-93-9D, Sulfuric acid, alkyl esters, salts, biological studies  
 7697-37-2, Nitric acid, biological studies 8007-43-0, Sorbitan  
 sesquiolate 8068-28-8, Colistimethate sodium 9001-28-9, Factor IX  
 9002-01-1, Streptokinase 9002-60-2, Corticotropin, biological studies  
 9002-92-0, Brij 35 9002-96-4 9003-01-4D, Polyacrylic acid, conjugates  
 with bacitracin 9003-39-8D, Polyvinylpyrrolidone, reaction products with  
 phosphatidylethanolamine 9004-10-8, Insulin, biological studies  
 9004-17-5, Insulin protamine zinc 9004-32-4D, Carboxymethyl cellulose,  
 conjugates with pepstatin 9004-34-6, Cellulose, biological studies  
 9004-34-6D, Cellulose, ethers, biological studies 9004-38-0, Cellulose  
 acetate phthalate 9004-57-3, Ethyl cellulose 9004-81-3 9004-95-9,  
 Polyethylene glycol cetyl ether 9004-96-0, Crodet O40 9004-98-2,  
 Polyoxethylene oleyl ether 9004-99-3 9005-00-9, Polyoxethylene  
 stearyl ether 9005-02-1, Kessco PEG 300DL 9005-07-6, Kessco PEG 1540DO  
 9005-08-7 9005-32-7, Alginate acid 9005-63-4D, fatty acid esters  
 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40  
 9005-67-8, Tween 60 9007-48-1, Plurol Oleique 9007-92-5, Glucagon,  
 biological studies 9011-21-6 9012-76-4, Chitosan 9012-76-4D,  
 Chitosan, conjugates with antipain and EDTA 9015-68-3, Asparaginase

9034-40-6, Gonadotropin releasing hormone 9035-81-8, Trypsin inhibitor  
 9036-19-5 9039-53-6, Urokinase 9041-93-4, Bleomycin sulfate  
 9050-31-1, Hydroxypropylmethyl cellulose phthalate 9062-90-2 9063-46-1  
 9076-44-2, Chymostatin 9078-38-0, Soybean trypsin inhibitor 9087-70-1,  
 Pancreatic trypsin inhibitor 10034-85-2, Hydriodic acid 10035-10-6,  
 Hydrobromic acid, biological studies 10041-19-7D, derivs. 10043-35-3,  
 Boric acid, biological studies 10596-23-3 11000-17-2, Vasopressin  
 11061-68-0, Human insulin 11140-04-8, Imvitor 988 12584-58-6, Porcine  
 insulin 12629-01-5, Human growth hormone 13265-10-6, Methscopolamine  
 13284-86-1, Sodium lithocholate 13780-71-7D, Boronic acid,  
 $\alpha$ -aminoalkyl derivs. 14440-80-3, Stearoyl-2-lactylate  
 14605-22-2, Tauroursodeoxycholic acid 15500-66-0, Pancuronium bromide  
 15663-27-1, Cisplatin 15686-71-2, Cephalixin 15826-37-6, Cromolyn  
 sodium 16679-58-6, Desmopressin 16960-16-0, Cosyntropin 17438-29-8  
 18323-44-9, Clindamycin 18883-66-4, Streptozocin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comps. for enhanced absorption of hydrophilic drugs using combination  
 of surfactants)


IT 20537-88-6, Amifostine 21215-62-3, Calcitonin human 21645-51-2,  
 Aluminum hydroxide, biological studies 21679-14-1, Fludabine  
 22254-24-6, Ipratropium bromide 22882-95-7, Isopropyl linoleate  
 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 24356-60-3,  
 Cephalirin sodium 24938-16-7, Eudragit E 25126-32-3, Sincalide  
 25168-73-4, Sucrose monostearate 25212-88-8, Eudragit L100-55  
 25322-68-3, Polyethylene glycol 25339-99-5, Sucrose  
 monolaurate 25496-72-4, Monoolein 25597-07-3, Myristoylcarnitine  
 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate  
 26264-14-2D, Propanediol, ethers with  $\beta$ -cyclodextrin 26266-57-9,  
 Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26402-22-2,  
 Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,  
 Sucrose monopalmitate 26589-39-9, Eudragit S 26658-19-5,  
 Sorbitan tristearate 26839-75-8, Timolol 27164-46-1, Cefazolin sodium  
 27195-16-0, Sucrose distearate 27214-38-6, Nikkol MGM  
 27215-38-9, Imvitor 312 27638-00-2, Glyceryl dilaurate 29122-68-7,  
 Atenolol 30516-87-1, Zidovudine 31694-55-0D, C8-10-esters  
 33434-24-1, Eudragit RL 33515-09-2, Gonadorelin 33564-30-6, Cefoxitin  
 sodium 34787-01-4, Ticarcillin 36354-80-0, Glyceryl dicaprylate  
 36791-04-5, Ribavirin 37220-82-9, Peceol 37321-62-3, Lauroglycol  
 37330-34-0, Bowman-Birk inhibitor 37330-34-0D, Bowman-Birk inhibitor,  
 conjugates with polyacrylic acid 37691-11-5, Antipain 37691-11-5D,  
 Antipain, conjugates with chitosan and EDTA 38916-34-6, Somatostatin  
 39324-30-6, Pepstatin 39324-30-6D, Pepstatin, conjugates with  
 CM-cellulose 39366-43-3, Magnesium aluminum hydroxide 39438-11-4,  
 Sorbitan monocaprate 41575-94-4, Carboplatin 42057-22-7, Mezlocillin  
 sodium 42540-40-9, Cefamandole nafate 42766-91-6, Nikkol DHC  
 42907-92-6, Sodium tauro-24,25-dihydrofusidate 47931-85-1, Calcitonin  
 salmon 50700-72-6, Vecuronium bromide 51192-09-7, Tagat O2  
 51384-51-1, Metoprolol 51822-44-7, Eudragit L 51938-44-4, Sorbitan  
 sesquisteate 52504-24-2, Softigen 767 52581-71-2, Volpo 3  
 52907-01-4, Cellulose acetate trimellitate 53168-42-6, Myvacet 9-45  
 53237-50-6 53910-25-1, Pentostatin 53988-07-1, Glyceryl dicaprate  
 54063-53-5, Propafenone 54392-26-6, Sorbitan monoisostearate  
 54910-89-3, Fluoxetine 55123-66-5, Leupeptin 56180-94-0, Acarbose  
 57107-95-6 57171-56-9 57248-88-1, Pamidronate disodium 58561-47-0,  
 Softigen 701 58970-76-6, Bestatin 59227-89-3, 1-Dodecylazacycloheptan-  
 2-one 59703-84-3, Piperacillin sodium 59721-29-8, Camostat mesylate  
 60177-36-8, Sorbitan monocaprylate 61270-78-8, Cefonicid sodium  
 61489-71-2, Menotropin 61869-08-7, Paroxetine 62013-04-1,  
 Dirithromycin 62288-83-9, Desmopressin acetate 62893-19-0,  
 Cefoperazone 63527-52-6, Cefotaxime 64228-81-5, Atracurium besylate  
 64480-66-6, Glycoursodeoxycholic acid 64544-07-6, Cefuroxime axetil




66376-36-1, Alendronate 66419-50-9, Bovine growth hormone 67352-02-7  
67655-94-1, Amastatin 68099-86-5, Bepridil hydrochloride 68401-81-0,  
Ceftizoxime 68795-69-7, Propylene glycol monocaprate 68958-64-5  
69049-74-7, Nedocromil sodium 69070-98-0 69227-93-6, Lauryl  
 $\beta$ -maltopyranoside 69655-05-6, Didanosine 70458-92-3, Pefloxacin  
70458-96-7, Norfloxacin 71486-22-1, Vinorelbine 73384-59-5,  
Ceftriaxone 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium  
74381-53-6, Leuprolide acetate 76420-72-9, Enalaprilat 76470-66-1,  
Loracarbef 78110-38-0, Aztreonam 79350-37-1, Cefixime 79517-01-4,  
Octreotide acetate 79665-92-2 79665-93-3 81161-17-3, Esmolol  
hydrochloride 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin  
83869-56-1, Granulocyte-macrophage colony stimulating factor 83905-01-5,  
Azithromycin 85721-33-1, Ciprofloxacin 87679-37-6, Trandolapril  
88669-04-9, Trospetomycin 89703-10-6, FK-448 89987-06-4, Tiludronate  
93790-70-6, Chollysarcosine 93790-72-8, N-Methyltaurocholic acid  
93792-59-7, Hydroxypropylmethyl cellulose succinate 94749-08-3,  
Salmeterol xinafoate 98036-77-2, Hydrotalcite 98079-51-7, Lomefloxacin  
100986-85-4, Levofloxacin 104227-87-4, Famciclovir 105287-09-0,  
Aquatic 105462-24-6, Risedronic acid 106392-12-5,  
Polyoxyethylene-polyoxypropylene block copolymer 106819-53-8, Doxacurium  
chloride 106861-44-3, Mivacurium chloride 107648-80-6, Cefepime  
hydrochloride 110871-86-8, Sparfloxacin 113189-02-9, Antihemophilic  
factor 113852-37-2, Cidofovir 116094-23-6, Insulin aspart  
119914-60-2, Grepafloxacin 121368-58-9, Olpadronate 121548-04-7,  
Gelucire 44/14 121548-05-8, Gelucire 50/13 124832-26-4, Valaciclovir  
126467-48-9, Porcine somatotropin 127759-89-1, Lobucavir 127829-97-4,  
Solulan C 24 133107-64-9, Insulin lispro 134678-17-4, Lamivudine  
137862-53-4, Valsartan 138636-14-3, Eudragit NE 139110-80-8, Zanamivir  
139639-23-9, Tissue type plasminogen activator 142368-40-9, Imvitor 375  
143003-46-7, Alglucerase 143011-72-7, Granulocyte colony stimulating  
factor 146961-76-4, Alatrofloxacin 147059-72-1, Trovafloxacin  
148046-81-5, Gelucire 33/01 148553-50-8, Pregabalin 150372-93-3,  
Glycerol L 151126-32-8, Pramlintide 154361-50-9, Capecitabine  
156259-68-6, Capmul MCM 157810-81-6, Indinavir sulfate 160337-95-1,  
Insulin glargine 169148-63-4, Insulin detemir 173146-27-5, Denileukin  
difitox 191588-94-0, TNK-tPA 679809-58-6, Enoxaparin sodium  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compns. for enhanced absorption of hydrophilic drugs using combination  
of surfactants)  
IT 9001-92-7, Proteinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; compns. for enhanced absorption of hydrophilic drugs using  
combination of surfactants)  
IT 9003-98-9, Dornase 11096-26-7, Epoetin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\alpha$ ; compns. for enhanced absorption of hydrophilic drugs using  
combination of surfactants)  
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE  
(1) Cho; US 5858398 A 1999 CAPLUS  
L7 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN  
IT 110-15-6, Butanedioic acid, biological studies 124-04-9,  
Hexanedioic acid, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical compns. containing hydrophobic therapeutic agents and  
carriers containing ionizing agents and surfactants and triglycerides)  
RN 110-15-6 CAPLUS  
CN Butanedioic acid (CA INDEX NAME)




RN 124-04-9 CAPLUS  
CN Hexanedioic acid (CA INDEX NAME)




IT 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributylcitrate 77-94-1, Tributylcitrate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solubilizer; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)  
RN 77-89-4 CAPLUS  
CN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-triethyl ester (CA INDEX NAME)



RN 77-90-7 CAPLUS  
CN 1,2,3-Propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-tributyl ester (CA INDEX NAME)



RN 77-94-1 CAPLUS  
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-tributyl ester (CA INDEX NAME)



ACCESSION NUMBER: 2000:725436 CAPLUS  
DOCUMENT NUMBER: 133:301171  
TITLE: Compositions and methods for improved delivery of

ionizable hydrophobic therapeutic agents  
 INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.  
 PATENT ASSIGNEE(S): Lipocine, Inc., USA  
 SOURCE: PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
CA 2366702	A1	20001012	CA 2000-2366702	20000316
EP 1165048	A1	20020102	EP 2000-916547	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1999-287043	A 19990406
			WO 2000-US7342	W 20000316

AN 2000:725436 CAPLUS  
 DN 133:301171  
 ED Entered STN: 13 Oct 2000  
 TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents  
 IN Chen, Feng-jing; Patel, Manesh V.  
 PA Lipocine, Inc., USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-14  
 ICS A61K009-48; A61K009-64; A61K009-66; A01N025-00  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059475	A1	20001012	WO 2000-US7342	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
CA 2366702	A1	20001012	CA 2000-2366702	20000316
EP 1165048	A1	20020102	EP 2000-916547	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1999-287043	A	19990406		
WO 2000-US7342	W	20000316		

CLASS PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000059475	ICM ICS IPCI IPCR ECLA	A61K009-14 A61K009-48; A61K009-64; A61K009-66; A01N025-00 A61K0009-14 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-64 [ICS,7]; A61K0009-66 [ICS,7]; A61K0009-52 [ICS,7,C*]; A01N0025-00 [ICS,7] A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]; A61K0009-52 [I,C*]; A61K0009-64 [I,A]; A61K0009-66 [I,A]; A61K0047-02 [I,C*]; A61K0047-02 [I,A] A61K009/107D; A61K047/02; K61K; K61K
US 6383471	IPCI IPCR NCL ECLA	A61K0009-12 [ICM,7] A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]; A61K0009-52 [I,C*]; A61K0009-64 [I,A]; A61K0009-66 [I,A]; A61K0047-02 [I,C*]; A61K0047-02 [I,A] 424/045.000; 424/046.000; 424/401.000; 424/436.000; 424/451.000; 514/944.000 A61K009/107D; A61K047/02
CA 2366702	IPCI IPCR	A61K0009-14 [ICM,7]; A01N0025-00 [ICS,7]; A61K0009-48 [ICS,7]; A61K0009-64 [ICS,7]; A61K0009-66 [ICS,7]; A61K0009-52 [ICS,7,C*] A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]; A61K0009-52 [I,C*]; A61K0009-64 [I,A]; A61K0009-66 [I,A]; A61K0047-02 [I,C*]; A61K0047-02 [I,A]
EP 1165048	IPCI IPCR ECLA	A61K0009-14 [ICM,6]; A61K0009-48 [ICS,6]; A61K0009-64 [ICS,6]; A61K0009-66 [ICS,6]; A61K0009-52 [ICS,6,C*]; A01N0025-00 [ICS,6] A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-48 [N,C*]; A61K0009-48 [N,A]; A61K0009-52 [I,C*]; A61K0009-64 [I,A]; A61K0009-66 [I,A]; A61K0047-02 [I,C*]; A61K0047-02 [I,A] A61K009/107D; A61K047/02; K61K; K61K
AB	The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025,	
Tween-20	0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.	
ST	hydrophobic drug carrier base surfactant triglyceride	
IT	Diglycerides Glycerides, biological studies Monoglycerides RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C8-10 monoglycerides and diglycerides; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)	
IT	Fatty acids, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	

(C8-10, esters with propylene glycol; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C8-10, ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C8-10; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Hydroquinones  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Hydroquinosulfonic acid; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Monoglycerides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (acetates, with C6-20 fatty acid; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (aerosols; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Amines, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aliphatic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Sulfonates  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkanesulfonates; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Phenols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkyl, ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Glycosides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkyl, maltosides; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (almond, ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Sulfones  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Heterocyclic compounds  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aromatic, hydroxy; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Amines, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aromatic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
(capsules; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
(carriers; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(corn, ethoxylated, Crovol M 40, Crovol M 70; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(essential; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(esters, with polyglycerol; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Amino acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(esters; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Carbohydrates, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethers; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Castor oil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated, Incrocas 35 and Incrocas 40; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Sterols  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated; Nikkol BPS-30, pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Corn oil  
Fatty acids, biological studies  
Glycerides, biological studies  
Olive oil  
Palm kernel oil  
Peanut oil  
Sterols  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
(gels; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Aromatic compounds  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(heterocyclic, hydroxy; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Amines, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(heterocyclic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Castor oil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrogenated, ethoxylated, Cremophor RH 40; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Palm kernel oil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrogenated, ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Surfactants  
(hydrophilic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Surfactants  
(hydrophobic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Minerals, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydroxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inorg.; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Surfactants  
(ionic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
(lotions; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
(mucosal; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(non-essential; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Surfactants  
(nonionic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
ointments, creams; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
ointments; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
ophthalmic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems

(oral; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (organic; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (palm kernel-oil, ethoxylated, Crovol PK 70; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (parenterals; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (pastes; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Surfactants  
 (pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Alcohols, biological studies  
 Amino acids, biological studies  
 Bile salts  
 Carboxylic acids, biological studies  
 Diglycerides  
 Phenols, biological studies  
 Phospholipids, biological studies  
 Soybean oil  
 Sulfonamides  
 Sulfonates  
 Sulfonic acids, biological studies  
 Sulfonyleureas  
 Tannins  
 Thiols (organic), biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Sterols  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phytosterols; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyhydric, reaction products; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyhydric, solubilizer; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (pulmonary; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (rectal; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)



IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (salts; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (solns., oral; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Amides, biological studies  
 Esters, biological studies  
 Polyoxaalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solubilizer; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Sterols  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (soya, ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (sprays; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Carbohydrates, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sugar esters; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (suppositories; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (topical; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (transdermal; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Drug delivery systems  
 (vaginal; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, ethoxylated; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Fats and Glyceridic oils, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated, Sterotex NF; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies  
 Monoglycerides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (with C6-20 fatty acid; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 53824-77-4, Propylene glycol dicaprate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Captex 100; pharmaceutical compns. containing hydrophobic therapeutic

agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 9004-96-0, Polyethylene glycol monooleate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Crodol O 40, Kessco PEG 1000MO; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 79665-92-2, Hexaglycerol monooleate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Drewpol 6-10; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 9004-81-3  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Kessco PEG 1000ML, Mapeg 200ML; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 9005-02-1, Polyethylene glycol dilaurate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Kessco PEG 1540DL; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 9005-07-6, Polyethylene glycol dioleate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Kessco PEG 1540DO; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

IT 50-06-6, Phenobarbital, biological studies 50-21-5, biological studies 50-21-5D, Lactic acid, glycerides 50-44-2, Mercaptopurine 50-48-6, Amtriptyline 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-78-2 50-81-7, Ascorbic acid, biological studies 51-48-9, Levothyroxine, biological studies 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-64-9, Dexamphetamine 52-86-8, Haloperidol 53-86-1, Indomethacin 54-05-7, Chloroquine 54-11-5, Nicotine 54-31-9 56-54-2, Quinidine 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-22-7, Vincristine 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-43-2, Amylobarbitol 57-44-3, Barbitol 57-47-6, Physostigmine 57-66-9, Probenecid 57-88-5, Cholesterol, biological studies 58-14-0, Pyrimethamine 58-25-3, Chlordiazepoxide 58-32-2, Dipyrindamole 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-73-1, Diphenhydramine 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-66-5, Acetazolamide 59-87-0, Nitrofurazone 59-96-1, Phenoxybenzamine 61-56-3, Sulthiame 61-68-7, Mefenamic acid 61-72-3, Cloxacillin 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-77-7, Tolbutamide 65-85-0, Benzoic acid, biological studies 66-76-2, Dicumarol 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 68-04-2, Sodium citrate 68-11-1, Thioglycolic acid, biological studies 68-35-9, Sulfadiazine 69-23-8, Fluphenazine 69-72-7, biological studies 69-93-2, Uric acid, biological studies 72-44-6, Methaqualone 72-69-5, Nortriptyline 74-55-5, Ethambutol 75-75-2, Methanesulfonic acid 76-57-3, Codeine 76-74-4, Pentobarbital 76-99-3, Methadone 77-28-1, Butobarbital 77-36-1, Chlorthalidone 77-86-1, Tromethamine 77-92-9, biological studies 79-09-4, Propanoic acid, biological studies 79-10-7, Acrylic acid, biological studies 82-92-8, Cyclozine 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-89-6, Mepacrine 86-21-5, Pheniramine 86-22-6, Brompheniramine 86-35-1, Ethotoin 86-42-0, Amodiaquine 87-69-4, biological studies 89-57-6, Mesalamine 89-65-6, Isoascorbic acid 90-82-4, Pseudoephedrine 90-84-6, Diethylpropion 94-20-2, Chlorpropamide 97-23-4, Dichlorophen

99-66-1, Valproic acid 101-31-5, Hyoscyamine 102-71-6, biological studies 104-15-4, p-Toluenesulfonic acid, biological studies 107-15-3, 1,2-Ethanediamine, biological studies 107-92-6, Butyric acid, biological studies 110-15-6, Butanedioic acid, biological studies 110-16-7, 2-Butenedioic acid (2Z)-, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Ethyl oleate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 113-15-5, Ergotamine 113-45-1, Methylphenidate 113-59-7, Chlorprothixene 113-92-8 114-07-8, Erythromycin 115-38-8, Methylphenobarbital 117-89-5, Trifluoperazine 121-44-8, biological studies 122-09-8, Phentermine 122-20-3, Trisopropanolamine 124-04-9, Hexanedioic acid, biological studies 125-28-0, Dihydrocodeine 125-53-1, Oxyphencyclimine 125-84-8, Aminoglutethimide 127-09-3, Sodium acetate 127-33-3, Demeclocycline 127-69-5, Sulfafurazole 127-71-9, Sulfabenzamide 127-79-7, Sulfamerazine 128-13-2, Ursodeoxycholic acid 128-37-0, Butylated hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxypentazone 130-95-0, Quinine 132-17-2, Benztropine 138-36-3, p-Bromophenylsulfonic acid 139-33-3, Edetate disodium 141-43-5, biological studies 142-18-7, Glyceryl monolaurate 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 144-11-6, Benzhexol 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Ethanedioic acid, biological studies 144-80-9, Sulfacetamide 144-83-2, Sulfapyridine 145-42-6, Taurocholic acid, sodium salt 146-22-5, Nitrazepam 146-54-3, Fluopromazine 148-79-8, Thiabendazole 151-21-3, Sodium dodecyl sulfate, biological studies 154-42-7, Thioguanine 190-39-6, Bisanthene 288-14-2, Isoxazole 298-57-7, Cinnarizine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-79-4, Tretinoin 305-03-3, Chlorambucil 321-64-2, Tacrine 359-83-1, Pentazocine 361-37-5, Methysergide 364-62-5, Metoclopramide 389-08-2 396-01-0, Triamterene 404-86-4, Capsaicin 437-38-7, Fentanyl 439-14-5, Diazepam 442-52-4, Clemizole 443-48-1, Metronidazole 446-86-6, Azathioprine 458-24-2, Fenfluramine 463-79-6, Carbonic acid, biological studies 471-34-1, Calcium carbonate, biological studies 486-16-8, Carbinoxamine 500-92-5, Proguanil 511-12-6, Dihydroergotamine 514-65-8, Biperiden 519-23-3, Ellipticine 522-00-9, Ethopropazine 523-87-5, Dimenhydrinate 525-66-6 526-95-4, D-Gluconic acid 536-33-4, Ethionamide 537-21-3, Chlorproguanil 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 548-73-2, Droperidol 561-27-3, Diamorphine 564-25-0, Doxycycline 569-65-3, Meclizine 577-11-7, Docusate sodium 599-79-1, Sulfasalazine 603-50-9, Bisacodyl 604-75-1, Oxazepam 631-61-8, Ammonium Acetate 644-62-2, Meclofenamic acid 657-24-9, Metformin 668-94-0, 4,5-Diphenylimidazole 671-16-9, Procarbazine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 739-71-9, Trimipramine 745-65-3, Alprostadil 768-94-5, Amantadine 846-49-1, Lorazepam 846-50-4, Temazepam 848-75-9, Lormetazepam 865-21-4, Vinblastine 911-45-5, Clomiphene 915-30-0, Diphenoxylate 961-71-7, Phenbenzamine 968-81-0, Acetohexamide 1134-47-0, Baclofen 1156-19-0, Tolazamide 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene glycol oleate 1333-28-4, Undecenoic acid 1335-30-4, Aluminum silicate 1336-21-6, Ammonium hydroxide 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1400-61-9, Nystatin 1404-90-6, Vancomycin 1406-05-9, Penicillin 1508-75-4, Tropicamide 1553-60-2, Ibuprofen 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1812-30-2, Bromazepam 1951-25-3, Amiodarone 1972-08-3, Dronabinol 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2078-54-8, Propofol 2447-57-6, Sulfadoxine 2487-39-0, Vitamin K-S (II) 2515-61-9, 1,5-Diphenylpyrazoline

2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. containing hydrophobic therapeutic agents and  
 carriers containing ionizing agents and surfactants and triglycerides)  
 IT 2998-57-4, Estramustine 3056-17-5, Stavudine 3116-76-5, Dicloxacillin  
 3239-44-9, Dexfenfluramine 3737-09-5, Disopyramide 4117-33-3, Lysine  
 ethyl ester 4342-03-4, Dacarbazine 4759-48-2, Isotretinoin  
 5002-47-1, Fluphenazine decanoate 5036-02-2, Tetramisole 5051-62-7,  
 Guanabenz 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide  
 5588-33-0, Mesoridazine 5633-20-5, Oxybutynin 5786-21-0, Clozapine  
 6452-71-7, Oxprenolol 6493-05-6, Pentoxifylline 6506-37-2, Nimorazole  
 7087-68-5, Disopropylethylamine 7261-97-4, Dantrolene 7416-34-4,  
 Molindone 7647-01-0, Hydrochloric acid, biological studies 7664-38-2,  
 Phosphoric acid, biological studies 7664-38-2D, Phosphoric acid, esters,  
 biological studies 7664-93-9, Sulfuric acid, biological studies  
 7681-93-8, Natamycin 7689-03-4, Camptothecin 7697-37-2, Nitric acid,  
 biological studies 7778-53-2, Potassium phosphate 8007-43-0, Sorbitan  
 sesquiolate 8045-34-9, Pentaerythritol stearate 9002-92-0,  
 Polyoxyethylene lauryl ether 9002-93-1 9002-96-4, D- $\alpha$ -Tocopheryl  
 polyethylene glycol succinate 9004-74-4, Methoxy polyethylene glycol  
 9004-95-9, Polyethylene glycol cetyl ether 9004-98-2, Polyoxyethylene  
 oleyl ether 9004-99-3, Myrj 51 9005-00-9, Polyoxyethylene stearyl  
 ether 9005-08-7, Polyethylene glycol distearate 9005-32-7, Alginate  
 acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7,  
 Tween 40 9005-67-8, Tween 60 9007-48-1, Polyglyceryl oleate  
 9011-21-6 9011-29-4 9014-67-9, AloxiPrin 9016-45-9 9062-73-1,  
 Polyethylene glycol sorbitan laurate 9062-90-2, Polyethylene glycol  
 sorbitan oleate 10034-85-2, Hydriodic acid 10035-10-6, Hydrobromic  
 acid, biological studies 10043-35-3, Boric acid, biological studies  
 10238-21-8 10262-69-8, Maprotiline 10457-90-6, Bromperidol  
 10540-29-1, Tamoxifen 11140-04-8, Imvitor 988 12633-72-6, Amphotericin  
 12772-47-3, Pentaerythritol oleate 13292-46-1, Rifampin 13392-28-4,  
 Rimantadine 13523-86-9 13655-52-2, Alprenolol 14028-44-5, Amoxapine  
 14611-51-9, Selegiline 14808-79-8, Sulfate, biological studies  
 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15676-16-1, Sulpiride  
 15686-51-8, Clemastine 15686-71-2, Cephalixin 15686-83-6, Pyrantel  
 15687-27-1, Ibuprofen 16110-51-3, Cromoglicic acid 16773-42-5,  
 Ornidazole 17560-51-9, Metolazone 17617-23-1, Flurazepam 18016-80-3,  
 Lysuride 18507-89-6, Decoquinatone 18559-94-9, Albuterol 19216-56-9,  
 Prazosin 19387-91-8, Tinidazole 19794-93-5, Trazodone 20594-83-6,  
 Nalbufphine 21187-98-4, Glliclazide 21256-18-8, Oxaprozol 21645-51-2,  
 Aluminum hydroxide, biological studies 21738-42-1, Oxamniquine  
 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22131-79-9, Alclofenac  
 22204-53-1 22232-71-9, Mazindol 22494-42-4, Diflunisal 22882-95-7,  
 Isopropyl linoleate 22916-47-8, Miconazole 22994-85-0, Benznidazole  
 23031-25-6, Terbutaline 23110-15-8, Fumagillin 23288-49-5, Probutol  
 23593-75-1, Clotrimazole 24219-97-4, Mianserin 25339-99-5,  
 Sucrose monolaurate 25523-97-1, Dexchlorpheniramine  
 25614-03-3, Bromocriptine 25637-84-7, Glyceryl dioleate 25637-97-2,  
 Sucrose dipalmitate 25812-30-0, Gemfibrozil 25953-19-9,  
 Cefazolin 26097-80-3, Cambendazole 26171-23-3, Tolmetin 26266-57-9,  
 Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26402-22-2,  
 Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,  
 Sucrose monopalmitate 26658-19-5, Sorbitan tristearate  
 26839-75-8, Timolol 26912-41-4D, Polyethylene glycol caprate, glycerides  
 27195-16-0, Sucrose distearate 27203-92-5, Tramadol  
 27220-47-9, Econazole 27321-96-6, Polyethylene glycol cholesterol  
 27638-00-2, Glyceryl dilaurate 28395-03-1, Bumetanide 28657-80-9,  
 Cinoxacin 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9,  
 Glipizide 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29767-20-2,  
 Teniposide 30299-08-2, Clinofibrate 30909-51-4, Flupentixol decanoate

31431-39-7, Mebendazole 31692-85-0, Glycofurol 33419-42-0, Etoposide  
 33671-46-4, Clotiazepam 33940-98-6 34406-66-1, Nikkol Decaglyn IL  
 34580-13-7, Ketotifen 34911-55-2, Bupropion 36322-90-4, Piroxicam  
 36330-85-5, Fenbufen 36354-80-0, Glyceryl dicaprylate 36531-26-7,  
 Oxantel 36894-69-6, Labetalol 37148-27-9, Clenbuterol 37220-82-9,  
 Arlachel 186 37318-31-3, Crodesta F-160 37321-62-3, Lauroglycol FCC  
 37517-30-9, Acebutolol 38194-50-2, Sulindac 38304-91-5, Minoxidil  
 38821-53-3, Cephradine 39366-43-3, Magnesium aluminum hydroxide  
 41340-25-4, Etidolac 41859-67-0, Bezafibrate 42200-33-9, Nadolol  
 42399-41-7, Diltiazem 42766-91-6, Nikkol DHC 43200-80-2, Zopiclone  
 43210-67-9, Fenbendazole 50679-08-8, Terfenadine 51192-09-7, Nikkol  
 TMGO 5 51264-14-3, Amsacrine 51322-75-9, Tizanidine 51384-51-1,  
 Metoprolol 51481-61-9, Cimetidine 51803-78-2 51938-44-4, Sorbitan  
 sesquisteate 52081-33-1, Mitomycins 52468-60-7, Flunarizine  
 52504-24-2, Softigen 767 52581-71-2, Volpo 3 52942-31-1, Etoperidone  
 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine  
 53716-50-0, Oxfendazole 53988-07-1, Glyceryl dicaprate 54029-12-8,  
 Ricobendazole 54143-55-4, Flecainide 54340-58-8, Meptazinol  
 54392-26-6, Sorbitan monoisostearate 54910-89-3, Flouxetine  
 55142-85-3, Ticlopidine 55268-74-1, Praziquantel 55985-32-5,  
 Nicardipine 57107-95-6 57307-93-4, Pentaerythritol caprylate  
 57801-81-7, Brotizolam 57808-66-9, Domperidone 58581-89-8, Azelastine  
 59467-70-8, Midazolam 59729-33-8, Citalopram 60142-96-3, Gabapentin  
 60607-34-3, Oxatamide 60719-84-8, Amrinone 61318-90-9, Sulconazole  
 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin  
 62571-86-2, Captopril 63590-64-7, Terazosin 63675-72-9, Nisoldipine  
 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64840-90-0, Eperisone  
 64872-76-0, Butoconazole 65271-80-9, Mitoxantrone 65277-42-1,  
 Ketoconazole 65899-73-2, Tioconazole 66085-59-4, Nimodipine  
 66357-35-5, Ranitidine 67227-56-9, Fenoldopam 67352-02-7 67915-31-5,  
 Terconazole 68506-86-5, Vigabatrin 68844-77-9, Astemizole  
 68958-64-5, Polyethylene glycol glyceryl trioleate 68993-42-0D,  
 Polyethylene glycol caprylate, glycerides 69070-98-0 69756-53-2,  
 Halofantrine 70458-96-7, Norfloxacin 71125-38-7, Meloxicam  
 71486-22-1, Vinorelbine 72432-03-2, Miglitol 72509-76-3, Felodipine  
 72559-06-9, Rifabutin 72803-02-2, Darodipine 73590-58-6, Omeprazole  
 74011-58-8, Enoxacin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. containing hydrophobic therapeutic agents and  
 carriers containing ionizing agents and surfactants and triglycerides)  
 IT 74103-06-3, Ketorolac 74191-85-8, Doxazosin 74504-64-6, Polyglyceryl  
 laurate 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6,  
 Leflunomide 75847-73-3, Enalapril 76009-37-5 76547-98-3, Lisinopril  
 76584-70-8 76824-35-6, Famotidine 76963-41-2, Nizatidine 77671-31-9,  
 Enoximone 78273-80-0, Roxatidine 79617-96-2, Sertraline 79665-93-3,  
 Nikkol Decaglyn IO 79665-94-4 79794-75-5, Loratadine 80214-83-1,  
 Roxithromycin 81093-37-0, Pravastatin 81098-60-4, Cisapride  
 81103-11-9, Clarithromycin 82159-09-9, Epalrestat 82419-36-1,  
 Ofloxacin 82626-48-0, Zolpidem 82664-20-8, Flurithromycin  
 83366-66-9, Nefazodone 83799-24-0, Fexofenadine 83881-51-0, Cetirizine  
 83905-01-5, Azithromycin 84057-84-1, Lamotrigine 84449-90-1,  
 Raloxifene 84625-61-6, Itraconazole 85441-61-8, Quinapril  
 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5,  
 Benazepril 87718-67-0, Spiramycins 87848-99-5, Acrivastine  
 88105-42-9, Amlodipine 89778-26-7, Toremfene 91161-71-6, Terbinafine  
 91374-21-9, Ropinirel 91714-94-2, Bromfenac 93106-60-6, Enrofloxacin  
 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine 93479-97-1,  
 Glimipride 93957-54-1, Fluvastatin 94423-19-5 94555-53-0  
 95233-18-4, Atovaquone 97322-87-7, Troglitazone 97682-44-5, Irinotecan  
 98048-97-6, Fosinopril 98079-51-7 98913-68-9, Pentaerythritol  
 isostearate 99614-02-5, Ondansetron 100986-85-4, Levofloxacin

101828-21-1, Butenafine 102051-00-3, Nikkol Decaglyn 30 103177-37-3,  
 Pranlukast 103577-45-3, Lansoprazole 103628-46-2, Sumatriptan  
 104632-26-0, Pramipexole 105979-17-7, Benidipine 106133-20-4,  
 Tamsulosin 106266-06-2, Risperidone 106392-12-5, Polyoxethylene-  
 polyoxypropylene block copolymer 106650-56-0, Sibutramine 107753-78-6,  
 Zafirlukast 109889-09-0, Granisetron 110871-86-8, Sparfloxacin  
 111025-46-8, Pioglitazone 111974-69-7, Quetiapine 113665-84-2,  
 Clopidogrel 114798-26-4, Losartan 115103-54-3, Tiagabine  
 115956-12-2, Dolasetron 117976-89-3, Rabeprazole 119914-60-2,  
 Grepatifloxacin 120014-06-4, Donepezil 121548-04-7, Gelucire 44/14  
 121548-05-8, Gelucire 50/13 121679-13-8, Naratriptan 122320-73-4,  
 Rosiglitazone 123948-87-8, Topotecan 124937-51-5, Tolterodine  
 127779-20-8, Saquinavir 129497-78-5, Verteporfin 129618-40-2,  
 Nevirapine 132539-06-1, Olanzapine 132875-61-7, Remifentanyl  
 133040-01-4, Eprosartan 133248-87-0, Maisine 134308-13-7, Tolcapone  
 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 135062-02-1,  
 Repaglinide 136470-78-5, Abacavir 136817-59-9, Delavirdine  
 137862-53-4, Valsartan 138402-11-6 139264-17-8, Zolmitriptan  
 139481-59-7, Candesartan 139755-83-2, Sildenafil 144034-80-0,  
 Rizatriptan 144494-65-5, Tirofiban 144701-48-4, Telmisartan  
 145599-86-6, Cerivastatin 146961-76-4, Alatrofloxacin 147059-72-1,  
 Trovafloxacin 150372-93-3, Glycerol L 150378-17-9, Indinavir  
 151096-09-2, Moxifloxacin 154598-52-4, Efavirenz 155213-67-5,  
 Ritonavir 156259-68-6, Capmul MCM 158747-02-5, Frovatriptan  
 158966-92-8, Montelukast 159989-64-7, Nelfinavir 161814-49-9,  
 Amprenavir 169590-42-5, Celecoxib 185069-68-5, Polyglyceryl oleate  
 stearate 301206-59-7 301524-91-4, Captex 810

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. containing hydrophobic therapeutic agents and  
 carriers containing ionizing agents and surfactants and triglycerides)

IT 50-70-4, Sorbitol, biological studies 56-81-5, 1,2,3-Propanetriol,  
 biological studies 57-55-6, 1,2-Propanediol, biological studies  
 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological  
 studies 69-65-8, D-Mannitol 71-36-3, Butanol, biological studies  
 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl  
 citrate 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate  
 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin  
 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2,  
 biological studies 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol,  
 biological studies 115-77-5, biological studies 127-19-5,  
 Dimethylacetamide 502-44-3, 2-Oxepanone 542-28-9, 8-  
 Valerolactone 616-45-5, 2-Pyrrolidone 623-84-7, Propylene glycol  
 diacetate 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone,  
 biological studies 1331-12-0, Propylene glycol monoacetate 2687-91-4,  
 N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0,  
 β-Butyrolactone 3445-11-2 9002-89-5, Polyvinyl alcohol  
 9003-39-8, Polyvinylpyrrolidone 9004-34-6D, Cellulose, derivs.,  
 biological studies 9004-65-3, Hydroxypropyl methylcellulose 9050-36-6,  
 Maltodextrin 12619-70-4D, Cyclodextrin, derivs. 25265-75-2, Butanediol  
 25322-68-3 25322-69-4, Polypropylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solubilizer; pharmaceutical compns. containing hydrophobic therapeutic  
 agents and carriers containing ionizing agents and surfactants and  
 triglycerides)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Blair; US 4306981 A 1981 CAPLUS
- (2) Hauer; US 5342625 A 1994 CAPLUS
- (3) Story; US 4944949 A 1990 CAPLUS

IT 9002-88-4, Polyethylene  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (cleansing compns. containing surfactants and polymers for skin and/or hair  
 which also deposits skin care actives)  
 RN 9002-88-4 CAPLUS  
 CN Ethene, homopolymer (CA INDEX NAME)  
 CM 1  
 CRN 74-85-1  
 CMF C2 H4

H<sub>2</sub>C=CH<sub>2</sub>

ACCESSION NUMBER: 1999:708579 CAPLUS  
 DOCUMENT NUMBER: 131:327309  
 TITLE: Lathering surfactants in cleansing compositions for  
 skin and/or hair which also deposits skin care actives  
 INVENTOR(S): Albacarys, Lourdes Dessus; McAtee, David Michael;  
 Deckner, George Endel  
 PATENT ASSIGNEE(S): Procter + Gamble Co., USA  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 8  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955303	A1	19991104	WO 1999-IB635	19990412
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332948	A1	19991104	CA 1999-2332948	19990412
AU 9929524	A	19991116	AU 1999-29524	19990412
AU 756691	B2	20030123		
BR 9909629	A	20001219	BR 1999-9629	19990412
EP 1071396	A1	20010131	EP 1999-910615	19990412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002512944	T	20020508	JP 2000-545503	19990412
MX 2000PA10386	A	20010731	MX 2000-PA10386	20001023
PRIORITY APPLN. INFO.:			US 1998-83015P	P 19980424
			WO 1999-IB635	W 19990412
AN 1999:708579 CAPLUS				
DN 131:327309				
ED Entered STN: 05 Nov 1999				
TI Lathering surfactants in cleansing compositions for skin and/or hair which also deposits skin care actives				
IN Albacarys, Lourdes Dessus; McAtee, David Michael; Deckner, George Endel				
PA Procter + Gamble Co., USA				
SO PCT Int. Appl., 94 pp. CODEN: PIXXD2				

DT Patent  
 LA English  
 IC A61K007-50  
 CC 62-1 (Essential Oils and Cosmetics)  
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9955303	A1	19991104	WO 1999-IB635	19990412
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2332948	A1	19991104	CA 1999-2332948	19990412
	AU 9929524	A	19991116	AU 1999-29524	19990412
	AU 756691	B2	20030123		
	BR 9909629	A	20001219	BR 1999-9629	19990412
	EP 1071396	A1	20010131	EP 1999-910615	19990412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002512944	T	20020508	JP 2000-545503	19990412
	MX 2000PA10386	A	20010731	MX 2000-PA10386	20001023
PRAI	US 1998-83015P	P	19980424		
	WO 1999-IB635	W	19990412		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9955303	IC	A61K007-50
	IPCI	A61K0007-50 [ICM]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
CA 2332948	ECLA	A61K008/02C; A61Q005/02; A61Q019/10
	IPCI	A61K0007-50 [ICM,6]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97



		[I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
	ECLA	A61K0008/02C; A61Q0005/02; A61Q019/10
AU 9929524	IPCI	A61K0007-50 [ICM]
	ECLA	A61K0008/02C; A61Q0005/02; A61Q019/10
BR 9909629	IPCI	A61K0007-50 [ICM,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
	ECLA	A61K0008/02C; A61Q0005/02; A61Q019/10
EP 1071396	IPCI	A61K0007-50 [ICM,6]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
	ECLA	A61K0008/02C; A61Q0005/02; A61Q019/10
JP 2002512944	IPCI	A61K0007-50 [ICM,7]; A61K0007-075 [ICS,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
	ECLA	A61K0008/02C; A61Q0005/02; A61Q019/10
	IPCI	A61K0007-50 [ICM,7]; A61K0007-075 [ICS,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
	ECLA	A61K0008/02C; A61Q0005/02; A61Q019/10
MX 2000PA10386	IPCI	A61K0007-50 [ICM,5]

AB The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair and delivering skin care actives onto the skin or hair. These articles are used by the consumer by (i) wetting the dry article with water and (ii) generating lather by subjecting the wetted article to mech. forces, e.g.,

rubbing. The article comprises a water insol. substrate, a lathering surfactant, and a skin care active component. Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component. E.g., a surfactant phase was prepared by dissolving hydroxyethyl cellulose 0.25% and guar gum 0.25% in water (to 100% by weight) and then adding the following ingredients: Na lauroyl sarcosinate 3.33, cocamidopropyl betaine 3.33, decyl polyglucoside 3.33, Me paraben 0.25, phenoxyethanol 0.3, and benzyl alc. 0.3%, resp.. At the end, a 1.5-2.5 g of the mixture containing water 2.0 g, butylene glycol 2.0 g, and Pr paraben 0.15 g was added to the first mixture and dried. A skin care active phase was prepared containing SEFA cottonate 43.0, petrolatum 10.00, tribehenin 5.0, polyethylene wax 9.0, synthetic beeswax 3.0, C10-30 cholesterol/lanosterol esters 23.0, vitamin A acetate 2.0, and TiO2 5.0 parts. A 0.05-0.75 g of this phase was mixed with the surfactant phase to obtain a skin or hair cleansing composition

ST surfactant polymer hair skin cleansing compn

IT Acne

(acne-preventing agents; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Alcohols, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(aliphatic; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Glycosides

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(alkyl polyglycosides; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Glycosides

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(alkyl; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Surfactants

(amphiphilic; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Surfactants

(anionic; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Surfactants

(cationic, non-polymeric; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Polyelectrolytes

(cationic; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Fibers

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(cellulosic; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Hair preparations

(cleansers; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Antimicrobial agents

Cellulose pulp

Cosmetics

Cotton fibers

Emulsifying agents

Flax

Fungicides

Gums and Mucilages  
 Jute  
 Silk  
 Sponge (Porifera)  
 Sunscreens  
 Suntanning agents  
 Surfactants  
   (cleansing compns. containing surfactants and polymers for skin and/or hair  
   which also deposits skin care actives)

IT Acrylic polymers, biological studies  
 Amine oxides  
 Betaines  
 Fatty acids, biological studies  
 Glycerides, biological studies  
 Keratins  
 Lanolin  
 Monoglycerides  
 Paraffin oils  
 Paraffin waxes, biological studies  
 Petrolatum  
 Polyamides, biological studies  
 Polyester fibers, biological studies  
 Polyesters, biological studies  
 Polyethers, biological studies  
 Polymers, biological studies  
 Polyolefins  
 Polyoxymethylenes, biological studies  
 Polysiloxanes, biological studies  
 Polyurethanes, biological studies  
 Rayon, biological studies  
 Silicone rubber, biological studies  
 Sulfobetaines  
 Tocopherols  
 Waxes  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
   (cleansing compns. containing surfactants and polymers for skin and/or hair  
   which also deposits skin care actives)

IT Cosmetics  
   (cleansing; cleansing compns. containing surfactants and polymers for skin  
   and/or hair which also deposits skin care actives)

IT Cosmetics  
 Hair preparations  
   (conditioners; cleansing compns. containing surfactants and polymers for  
   skin and/or hair which also deposits skin care actives)

IT Fatty acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
   (cottonseed-oil, esters with sucrose; cleansing compns.  
   containing surfactants and polymers for skin and/or hair which also  
   deposits skin care actives)

IT Hydrophile-lipophile balance value  
   (emulsifiers; cleansing compns. containing surfactants and polymers for  
   skin and/or hair which also deposits skin care actives)

IT Cosmetics  
   (emulsions; cleansing compns. containing surfactants and polymers for skin  
   and/or hair which also deposits skin care actives)

IT Hydrocarbons, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
   (epidermal and sebaceous; cleansing compns. containing surfactants and

- polymers for skin and/or hair which also deposits skin care actives)
- IT Fatty acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (esters, C10-30, esters with cholesterol and lanosterol; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Amino acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (esters; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Alcohols, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (ethoxylated; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Amides, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (fatty, polyhydroxy; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Alcohols, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (fatty; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Cannabis sativa  
 (fiber; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Polyesters, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (hydroxy-terminated; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Carboxylic acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (imino, esters; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Hardness (mechanical)  
 (of skin care actives; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Antioxidants  
 (pharmaceutical; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Polyolefins  
 Polyolefins  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (polyester-; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Alcohols, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (polyhydric; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)
- IT Polyesters, biological studies  
 Polyesters, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)

(polyolefin-; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Biopolymers  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (protein-derived; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Cosmetics  
 (skin-lightening; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Sebum  
 (stimulators and inhibitors; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Beeswax  
 (synthetic; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (vegetable, hydrogenated; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (vegetable; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Cosmetics  
 (wrinkle-preventing; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT 50-21-5, biological studies 50-23-7, Hydrocortisone 56-81-5, 1,2,3-Propanetriol, biological studies 56-86-0D, L-Glutamic acid, esters, biological studies 57-13-6, Urea, biological studies 57-50-1D, Sucrose, esters 57-55-6, 1,2-Propanediol, biological studies 57-88-5, Cholesterol, biological studies 58-95-7, Tocopheryl acetate 59-67-6, Nicotinic acid, biological studies 64-19-7D, Acetic acid, esters, biological studies 68-26-8, Retinol 69-72-7, biological studies 79-10-7D, Acrylic acid, esters 79-14-1, biological studies 79-81-2, Retinyl palmitate 81-13-0, Panthenol 83-86-3, Phytic acid 94-13-3, Propyl paraben 96-26-4, Dihydroxyacetone 97-59-6, Allantoin 98-92-0, Niacinamide 99-76-3, Methyl paraben 100-51-6, Benzyl alcohol, biological studies 101-20-2, 3,4,4'-Trichlorocarbanilide 107-35-7D, Taurine, salts 107-36-8D, Isethionic acid, organic esters 107-41-5, Hexylene glycol 107-97-1D, Sarcosine, esters 108-46-3, Resorcinol, biological studies 112-85-6D, Behenic acid, esters 122-99-6, Phenoxyethanol 123-99-9, Nonanedioic acid, biological studies 127-47-9, Vitamin A acetate 131-57-7, Oxybenzone 137-16-6, Sodium lauroyl sarcosinate 302-79-4, trans-Retinoic acid 497-76-7, Arbutin 501-30-4, Kojic acid 555-43-1, Glyceryl tristearate 616-91-1, N-Acetyl-L-cysteine 617-57-2D, 2-Lactylic acid, esters 770-35-4, Phenoxyisopropanol 1200-22-2, Lipoic acid 2382-43-6 3380-34-5 4472-12-2D, Iminoacetic acid, alkyl esters 5300-03-8, 9-cis-Retinoic acid 5466-77-3, 2-Ethylhexyl p-methoxycinnamate 7664-38-2D, Phosphoric acid, organic esters, biological studies 7664-93-9D, Sulfuric acid, organic esters, biological studies 9000-30-0, Guar gum 9002-88-4, Polyethylene 9002-89-5, Polyvinyl alcohol 9003-07-0, Polypropylene 9003-20-7, Polyvinyl acetate 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-62-0, Hydroxyethyl cellulose 13463-67-7, Titanium dioxide, biological studies 13822-09-8, Benzyl peroxide 15687-27-1, Ibuprofen 18641-57-1, Tribehenin 19223-69-9D, N-cocoacyl derivs. 22204-53-1, Naproxen 25231-21-4 25265-75-2, Butylene glycol 25322-68-3

25322-69-4 26855-43-6, Triglyceryl monostearate 27503-81-7,  
2-Phenylbenzimidazole-5-sulfonic acid 29656-68-6, Ethyl hexanediol  
41593-38-8, Phenoxypropanol 53240-01-0 81859-24-7, Polyquaternium 10  
100895-09-8, Decaglyceryl dipalmitate 115515-88-3, Decaglyceryl stearate  
156028-14-7, Sodium lauroamphoacetate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)

(cleansing compns. containing surfactants and polymers for skin and/or hair  
which also deposits skin care actives)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Advanced Polymer Systems; WO 9325077 A 1993 CAPLUS
- (2) Kimberly-Clark; EP 0619074 A 1994 CAPLUS
- (3) Richardson-Vicks; EP 0327326 A 1989 CAPLUS
- (4) Unilever; WO 8702379 A 1987 CAPLUS

L7 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, Phthalic acid 110-15-6, Succinic acid  
124-04-9, Adipic acid  
(partition between iso-BuOH and water)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)



RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 1951:21032 CAPLUS

DOCUMENT NUMBER: 45:21032

ORIGINAL REFERENCE NO.: 45:3690d-e

TITLE: The distribution of organic compounds between  
isobutanol and water

AUTHOR(S): Collander, Runar

SOURCE: Acta Chemica Scandinavica (1950), 4, 1085-98

CODEN: ACHSE7; ISSN: 0904-213X

DOCUMENT TYPE: Journal

LANGUAGE: English

AN 1951:21032 CAPLUS

DN 45:21032

OREF 45:3690d-e

ED Entered STN: 22 Apr 2001

TI The distribution of organic compounds between isobutanol and water

AU Collander, Runar

SO Acta Chemica Scandinavica (1950), 4, 1085-98

- DT Journal  
 LA English  
 CC 2 (General and Physical Chemistry)
- AB Coeffs. for the distribution of about 150 organic compds. between isobutanol and water are given, extending a study begun with the system ether-water (cf. C.A. 44, 2828d). The effect of chemical constitution on solute distribution is estimated. Coeffs. in the butanol-water system differ much less from each other than do those in the ether-water system.
- IT Partition  
 (of organic compds. between alcs. and water, between iso-BuOH and water)
- IT Chemical constitution  
 (partition and, of organic compds. between iso-BuOH and water)
- IT 78-83-1, Isobutyl alcohol  
 (organic-compound partition between water and)
- IT 64-19-7, Acetic acid  
 (partition between Bu3PO4 and H2O, between iso-BuOH and water)
- IT 107-92-6, Butyric acid  
 (partition between amyl or iso-Bu alcs. and water, between iso-BuOH and water)
- IT 57-50-1, Sucrose  
 (partition between blood plasma and interstitial fluid, between iso-BuOH and water)
- IT 64-17-5, Ethyl alcohol  
 (partition between edestin and mother liquor, between iso-BuOH and water)
- IT 57-13-6, Urea  
 (partition between extra- and intracellular water, between iso-BuOH and water)
- IT 87-69-4, Tartaric acid 140-80-7, 1,4-Pentanediamine, N1,N1-diethyl-  
 473-81-4, Glyceric acid 598-72-1, Propionic acid, 2-bromo-  
 (partition between iso-BuOH and H2O)
- IT 50-21-5, Lactic acid 50-36-2, Cocaine 50-99-7, D-Glucose 51-55-8,  
 Atropine 56-41-7, Alanine 56-81-5, Glycerol 56-84-8, Aspartic acid  
 57-27-2, Morphine 57-48-7, Fructose 57-57-8, Hydracrylic acid,  
 $\beta$ -lactone 59-46-1, Procaine 60-35-5, Acetamide 60-80-0,  
 Antipyrine 61-90-5, Leucine 62-59-9, Cevadine 64-18-6, Formic acid  
 64-69-7, Acetic acid, iodo- 65-85-0, Benzoic acid  
 69-65-8, Mannitol 69-72-7, Salicylic acid 69-79-4, Maltose 74-88-4,  
 Methane, iodo- 74-89-5, Methylamine 75-03-6, Ethane, iodo- 75-04-7,  
 Ethylamine 75-07-0, Acetaldehyde 75-12-7, Formamide 75-50-3,  
 Trimethylamine 75-98-9, Pivalic acid 76-03-9, Acetic  
 acid, trichloro- 76-57-3, Codeine 77-92-9, Citric acid  
 77-98-5, Ammonium, tetraethyl-, hydroxide 78-90-0, 1,2-Propanediamine  
 78-96-6, 2-Propanol, 1-amino- 79-05-0, Propionamide 79-08-3,  
 Acetic acid, bromo- 79-10-7, Acrylic  
 acid 79-11-8, Acetic acid, chloro-  
 79-14-1, Glycolic acid 79-20-9, Acetic acid, methyl  
 ester 80-58-0, Butyric acid, 2-bromo- 85-47-2, 1-Naphthalenesulfonic  
 acid 88-75-5, Phenol, o-nitro- 88-99-3, Phthalic acid  
 90-39-1, Sparteine 90-64-2, Mandelic acid 90-80-2, Gluconic acid,  
 lactone 97-30-3, Glucoside,  $\alpha$ -methyl- 97-65-4, Itaconic acid  
 98-11-3, Benzenesulfonic acid 99-05-8, Benzoic acid, m-amino- 99-06-9,  
 Benzoic acid, m-hydroxy- 99-14-9, Tricarballic acid 99-17-2,  
 Salicin, 6'-benzoate 99-96-7, Benzoic acid, p-hydroxy- 100-02-7,  
 Phenol, p-nitro- 100-37-8, Ethanol, 2-diethylamino- 100-46-9,  
 Benzylamine 100-97-0, Hexamethylenetetramine 102-71-6, Ethanol,  
 2,2',2''-nitrilotri- 103-82-2, Acetic acid, phenyl-  
 107-10-8, Propylamine 107-15-3, Ethylenediamine 108-13-4, Malonamide  
 108-18-9, Diisopropylamine 109-73-9, Butylamine 109-76-2,  
 1,3-Propanediamine 109-89-7, Diethylamine 110-15-6, Succinic

acid 110-16-7, Maleic acid 110-17-8, Fumaric acid 110-60-1, Putrescine 110-85-0, Piperazine 110-89-4, Piperidine 110-94-1, Glutaric acid 110-96-3, Diisobutylamine 110-99-6, Diglycolic acid 111-16-0, Pimelic acid 111-26-2, Hexylamine 111-42-2, Ethanol, 2,2'-iminodi- 111-55-7, Ethylene glycol, acetate (di-) 111-86-4, Octylamine 112-24-3, Triethylenetetramine 112-27-6, Triethylene glycol 112-60-7, Tetraethylene glycol 115-37-7, Thebaine 115-77-5, Pentaerythritol 118-92-3, Anthranilic acid 120-29-6, Tropine 121-44-8, Triethylamine 123-38-6, Propionaldehyde 123-72-8, Butyraldehyde 123-76-2, Levulinic acid 123-99-9, Azelaic acid 124-04-9, Adipic acid 124-40-3, Dimethylamine 141-43-5, Ethanol, 2-amino- 141-78-6, Ethyl acetate 141-82-2, Malonic acid 142-62-1, Hexanoic acid 142-84-7, Dipropylamine 144-62-7, Oxalic acid 147-81-9, Arabinose 149-32-6, Erythritol 150-13-0, Benzoic acid, p-amino- 299-42-3, Ephedrine 357-57-3, Brucine 458-88-8, Coniine 461-58-5, Guanidine, cyano- 462-94-2, Cadaverine 497-76-7, Arbutin 499-12-7, Aconitic acid 503-74-2, Isovaleric acid 504-29-0, Pyridine, 2-amino- 510-20-3, Malonic acid, diethyl- 526-95-4, Gluconic acid 541-35-5, Butyramide 553-24-2, Neutral red 554-84-7, Phenol, m-nitro- 554-95-0, Trimesic acid 594-61-6, Lactic acid, 2-methyl- 595-46-0, Malonic acid, dimethyl- 597-71-7, Pentaerythritol, tetraacetate 598-50-5, Urea, methyl- 598-78-7, Propionic acid, 2-chloro- 616-29-5, 2-Propanol, 1,3-diamino- 616-75-1, Malonic acid, benzyl- 625-45-6, Acetic acid, methoxy- 923-06-8, Succinic acid, bromo- 2086-83-1, Berberine 2835-81-6, Butyric acid, 2-amino- 3615-41-6, Rhamnose 6915-15-7, Malic acid 36413-60-2, Quinic acid (partition between iso-BuOH and water)

IT 110-86-1, Pyridine (partition between tert-AmOH and buffer systems, between iso-BuOH and water)

IT 67-56-1, Methanol (partition of, between iso-BuOH and water)

IT 58-08-2, Caffeine (system, BuOH-H2O-)

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON 24 JUN 2008

L3 432048 S L2  
L4 13513 S L3 AND ("ACETIC ACID")  
L5 603 S L4 AND SUCROSE  
L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
L7 39 S L5 AND ("ACRYLIC ACID")  
L8 10 S L7 AND ACRYLATE  
L9 3 S L8 AND POLYETHYLENE

=> s "polyethylen wax"

L10 0 "POLYETHYLEN WAX"



```

=> s "polyethylene wax"
L11      6753 "POLYETHYLENE WAX"

=> s l11 and ("linear fatty alcohol?")
L12      2 L11 AND ("LINEAR FATTY ALCOHOL?")

=> s l11 and ("Performacol 550 alcohol")
L13      0 L11 AND ("PERFORMACOL 550 ALCOHOL")

=> s      ("Performacol 550 alcohol")
L14      0 ("PERFORMACOL 550 ALCOHOL")

=> s l11 and performacol
L15      4 L11 AND PERFORMACOL

=> s l11 and ("sucrose acetate isobutyrate")
L16      3 L11 AND ("SUCROSE ACETATE ISOBUTYRATE")

=> s l11 and perfume
L17      89 L11 AND PERFUME

=> s l17 and polycaprolactone
L18      0 L17 AND POLYCAPROLACTONE

=> s polycaprolactone and lipstick
L19      14 POLYCAPROLACTONE AND LIPSTICK

=> s l19 and ("pigment paste")
L20      0 L19 AND ("PIGMENT PASTE")

=> s l19 and pigment?
L21      8 L19 AND PIGMENT?

=>
=> s ("Kraton G1701")
L22      45 ("KRATON G1701")

=> s ("550 alcohol")
L23      1 ("550 ALCOHOL")

=> d scan l1

L1      1 ANSWERS  CAPLUS  COPYRIGHT 2008 ACS on STN
IC      ICM A61K007-48
CC      62-4 (Essential Oils and Cosmetics)
TI      Cosmetic composition containing a polymer particle dispersion and polymer
        plasticizer
ST      makeup cosmetic polymer plasticizer lipstick
IT      Polymers, biological studies
        RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
            (block; cosmetic composition containing a polymer particle dispersion and
            polymer plasticizer)
IT      Cosmetics
        Gelation agents
        Molecular weight distribution
        Plasticizers
        Skin
        Stabilizing agents
            (cosmetic composition containing a polymer particle dispersion and polymer
            plasticizer)
IT      Polymers, biological studies

```

Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic, derivs.; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (eye liners; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (graft; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (lipsticks; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (makeups; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (mascaras; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (tricarboxylic acids, derivs.; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT 77-89-4, Triethyl acetylacrylate 77-90-7, Tributylacetylacrylate  
 77-94-1, Tributyl citrate 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate 85-68-7, Butylbenzyl phthalate 88-99-3D, Phthalic acid, esters 100-42-5D, Styrene, copolymers 103-23-1, Diethyl-2-hexyl adipate 105-99-7, Dibutyl adipate 109-43-3, Dibutyl sebacate 110-15-6D, Succinic acid, esters 110-40-7, Diethyl sebacate 111-20-6D, Sebacic acid, esters 117-81-7 122-62-3 123-25-1, Diethyl succinate 124-04-9D, Adipic acid, esters 131-11-3, Dimethyl phthalate 144-15-0 2915-57-3 6938-94-9, Diisopropyl adipate 7491-02-3, Diisopropyl sebacate 9002-88-4, Polyethylene 9003-27-4D, Polyisobutene, hydrogenation products 17140-33-9, Acetylcitric acid 24817-92-3 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone 27924-99-8, Poly(12-hydroxystearic acid) 31807-55-3, Isododecane 39413-05-3, Isopropyl citrate 58128-22-6, Poly(12-hydroxystearic acid) stearate 60908-77-2, Isohexadecane 82469-79-2 90605-17-7, Isodecyl citrate 105729-79-1, Isoprene-styrene block copolymer 106107-54-4, Butadiene-styrene block copolymer 108388-87-0, Ethylene-propylene-styrene block copolymer 110900-80-6, Butadiene-ethylene-styrene block copolymer 144470-58-6  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008  
E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

L2 FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008  
41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

L3 432048 S L2  
L4 13513 S L3 AND ("ACETIC ACID")  
L5 603 S L4 AND SUCROSE  
L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
L7 39 S L5 AND ("ACRYLIC ACID")  
L8 10 S L7 AND ACRYLATE  
L9 3 S L8 AND POLYETHYLENE  
L10 0 S "POLYETHYLEN WAX"  
L11 6753 S "POLYETHYLENE WAX"  
L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")  
L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
L14 0 S ("PERFORMACOL 550 ALCOHOL")  
L15 4 S L11 AND PERFORMACOL  
L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
L17 89 S L11 AND PERFUME  
L18 0 S L17 AND POLYCAPROLACTONE  
L19 14 S POLYCAPROLACTONE AND LIPSTICK  
L20 0 S L19 AND ("PIGMENT PASTE")  
L21 8 S L19 AND PIGMENT?  
L22 45 S ("KRATON G1701")  
L23 1 S ("550 ALCOHOL")

=> dup rem 17 18 112 115 116 117 119 121 122 123

PROCESSING COMPLETED FOR L7

PROCESSING COMPLETED FOR L8

PROCESSING COMPLETED FOR L12

PROCESSING COMPLETED FOR L15

PROCESSING COMPLETED FOR L16

PROCESSING COMPLETED FOR L17

PROCESSING COMPLETED FOR L19

PROCESSING COMPLETED FOR L21

PROCESSING COMPLETED FOR L22

PROCESSING COMPLETED FOR L23

L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICATES  
REMOVED)

ANSWERS '1-189' FROM FILE CAPLUS

=> s 124 and ("carboxylic acid?")

L25 37 L24 AND ("CARBOXYLIC ACID?")

=> s 125 and cosmetic

L26 16 L25 AND COSMETIC

=> d 126 1-16 hitstr ibib all

L26 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1289961 CAPLUS

DOCUMENT NUMBER: 144:40387

TITLE: Cosmetic composition containing a semicrystalline polymer and a dimer-diol ester  
 INVENTOR(S): Lebre, Caroline; Ferrari, Veronique  
 PATENT ASSIGNEE(S): L'Oreal, Fr.  
 SOURCE: Fr. Demande, 25 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2871054	A1	20051209	FR 2004-6168	20040608
FR 2871054	B1	20060728		
EP 1604638	A2	20051214	EP 2005-291042	20050513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2005350464	A	20051222	JP 2005-167516	20050607
US 20050287101	A1	20051229	US 2005-147353	20050608
PRIORITY APPLN. INFO.:			FR 2004-6168	A 20040608
			US 2004-580365P	P 20040618

AN 2005:1289961 CAPLUS  
 DN 144:40387  
 ED Entered SIN: 09 Dec 2005  
 TI Cosmetic composition containing a semicrystalline polymer and a dimer-diol ester  
 IN Lebre, Caroline; Ferrari, Veronique  
 PA L'Oreal, Fr.  
 SO Fr. Demande, 25 pp.  
 CODEN: FRXXBL  
 DT Patent  
 LA French  
 IC ICM A61K007-027  
 ICS A61K007-02; A61K007-48; A61K007-021  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2871054	A1	20051209	FR 2004-6168	20040608
FR 2871054	B1	20060728		
EP 1604638	A2	20051214	EP 2005-291042	20050513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2005350464	A	20051222	JP 2005-167516	20050607
US 20050287101	A1	20051229	US 2005-147353	20050608
PRAI FR 2004-6168	A	20040608		
US 2004-580365P	P	20040618		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2871054	ICM	A61K007-027
	ICS	A61K007-02; A61K007-48; A61K007-021
	IPCI	A61K0007-027 [ICM,7]; A61K0007-02 [ICS,7]; A61K0007-48 [ICS,7]; A61K0007-021 [ICS,7]
	IPCR	A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-33 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-81 [I,A];

A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C\*]; A61Q0001-12 [I,A]

EP 1604638 ECLA A61K008/33; A61K008/36; A61Q001/06  
 IPCI A61K0007-027 [ICM,7]; A61K0007-02 [ICS,7]; A61K0007-48 [ICS,7]; A61K0007-021 [ICS,7]  
 IPCR A61K0008-72 [I,C\*]; A61K0008-72 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-30 [I,C\*]; A61K0008-30 [I,A]; A61K0008-33 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-81 [I,A]; A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C\*]; A61Q0001-12 [I,A]

JP 2005350464 ECLA A61K008/33; A61K008/36; A61Q001/06  
 IPCI A61K0007-00 [ICM,7]; A61K0007-02 [ICS,7]; A61K0007-025 [ICS,7]; A61K0007-032 [ICS,7]  
 FTERM 4C083/AB172; 4C083/AB432; 4C083/AC012; 4C083/AC092; 4C083/AC372; 4C083/AC391; 4C083/AC392; 4C083/AD011; 4C083/AD022; 4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD392; 4C083/CC12; 4C083/CC13; 4C083/CC14; 4C083/DD17; 4C083/DD21

US 20050287101 IPCI A61K0007-06 [ICM,7]; A61K0007-11 [ICS,7]  
 IPCR A61K0008-30 [I,C\*]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-06 [I,A]  
 NCL 424/070.160  
 ECLA A61K008/37C; A61K008/81K4; A61K008/81R; A61Q001/06

AB A cosmetic composition contains a dimer-diolester, a C4-34 mono-carboxylic or di-carboxylic acid, and a semicryst. polymer with m.p. higher or equal to 30°. A lipstick contained a polymer dispersion 30, 2-decyl tetradecanoic acid triglyceride 2.02, Lusplan DD-DA5 10, octyldodecanol 9, preservatives 0.47, polycaprolactone 9, eicosene-vinyl pyrrolidone copolymer 6, microcryst. wax 10, polyethylene wax 2, polymethylene wax 10, pigments 6.03, dimethicone-coated silica 5, and fragrance 0.48%.

ST cosmetic lipstick carboxylic acid semicryst polymer

IT dimer diol ester

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (avocado; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Sunscreens  
 (cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Acrylic polymers, biological studies  
 Carboxylic acids, biological studies  
 Castor oil  
 Cottonseed oil  
 Fatty acids, biological studies  
 Jojoba oil  
 Olive oil  
 Palm oil  
 Soybean oil  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; cosmetic composition containing semicryst. polymer and

dimer-diol ester)

IT Cosmetics  
(eye liners; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
Rosin  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(macadamia nut; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Cosmetics  
(mascaras; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(mink; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Essential oils  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(orange, sour; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wheat germ; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT 25248-42-4, Polycaprolactone sru  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(CAPA 1215; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 59-67-6, Nicotinic acid, biological studies 60-33-3, Linoleic acid, biological studies 65-85-0, Benzoic acid, biological studies 69-72-7, Salicylic acid, biological studies 75-98-9, Pivalic acid 79-31-2, Isobutanoic acid 98-79-3, Pyrrolidonecarboxylic acid 98-89-5, Cyclohexanoic acid 99-96-7, biological studies 106-14-9, 12-Hydroxyoctadecanoic acid 107-92-6, Butanoic acid, biological studies 109-52-4, Pentanoic acid, biological studies 111-14-8, Heptanoic acid 112-05-0, Nonanoic acid 112-37-8, Undecanoic acid 112-79-8, Elaidinic acid 112-80-1, Oleic acid, biological studies 112-85-6, Docosanoic acid 112-86-7, Erucic acid 124-07-2, Octanoic acid, biological studies 142-62-1, Hexanoic acid, biological studies 143-07-7, Dodecanoic acid, biological studies 149-57-5, 2-Ethylhexanoic acid 149-91-7, Gallic acid, biological studies 150-13-0, p-Aminobenzoic acid 334-48-5, Decanoic acid 373-49-9, Palmitoleic acid 503-74-2, Isopentanoic acid 506-12-7, Heptadecanoic acid 506-30-9, Eicosanoic acid 506-32-1, Arachidonic acid 506-33-2, Brassidic acid 514-10-3, Abietic acid 514-10-3D, Abietic acid, hydrogenated 544-57-0, 2-Hydroxytetradecanoic acid 544-63-8, Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid 557-59-5, Tetracosanoic acid 600-15-7, 2-Hydroxybutanoic acid 617-31-2, 2-Hydroxypentanoic acid 617-73-2, 2-Hydroxyoctanoic acid 621-82-9, Cinnamic acid, biological studies 629-22-1, 2-Hydroxyoctadecanoic acid 636-69-1, 2-Hydroxyheptanoic acid 638-53-9, Tridecanoic acid 646-07-1, Isohexanoic acid 646-30-0, Nonadecanoic acid 764-67-0, 2-Hydroxyhexadecanoic acid 830-09-1, p-Methoxycinnamic acid 1002-84-2, Pentadecanoic acid 1330-19-4, Isoheptanoic acid 1333-28-4, Undecenoic acid 2507-55-3, 2-Hydroxytetradecanoic acid 2984-55-6, 2-Hydroxydodecanoic acid 5393-81-7, 2-Hydroxydecanoic acid

6064-63-7, 2-Hydroxyhexanoic acid 6144-28-1, Dilinoleic acid  
 7089-43-2, Linderic acid 13980-14-8, 2-Hydroxydocosanoic acid  
 15896-36-3, 2-Hydroxynonanoic acid 16742-48-6, 2-Hydroxyeicosanoic acid  
 19790-86-4, 2-Hydroxyundecanoic acid 19790-87-5, 2-Hydroxy-tridecanoic  
 acid 24980-41-4, Polycaprolactone 25022-78-0,  
 2-Hydroxyheptadecanoic acid 25103-52-0, Isooctanoic acid 25167-62-8,  
 Docosaheptaenoic acid 25354-97-6, 2-Hexyldecanoic acid 25378-27-2,  
 Eicosapentaenoic acid 25448-24-2, Isotridecanoic acid 25986-77-0,  
 Intelimer IPA 13-1 26403-17-8, Isodecanoic acid 26896-18-4,  
 Isononanoic acid 27610-92-0, 2-Butyloctanoic acid 29204-02-2, Gadoleic  
 acid 29385-00-0, Isododecanoic acid 32844-67-0, Isohexadecanoic acid  
 40596-46-1, 2-Octyldodecanoic acid 50973-09-6, Isopentadecanoic acid  
 57683-20-2, Isoundecanoic acid 65437-21-0, Isotetradecanoic acid  
 73756-37-3, 2-DoDecylhexadecanoic acid 73756-39-5, 2-  
 Tetradecyloctadecanoic acid 77035-98-4, Eicosene-vinyl pyrrolidone  
 copolymer 82430-11-3, Dimethyloctanoic acid 89547-15-9,  
 2-Hexadecyloctadecanoic acid 93361-63-8, 2-Hydroxynonadecanoic acid  
 93778-52-0, 2-Decyltetradecanoic acid 98989-29-8, Isoeicosanoic acid  
 512778-00-6, Lusplan DD-AA 5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing semicryst. polymer and dimer-diol  
 ester)

IT 694523-05-2D, hydrogenated, block, diblock  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (isoprene-styrene rubber; cosmetic composition containing semicryst.  
 polymer and dimer-diol ester)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) L'Oreal; WO 9722328 A 1997 CAPLUS  
 (2) Nippon Fine Chem Co; FR 2795309 A 2000 CAPLUS  
 (3) Nippon Shikizai Inc; JP 2003113015 A 2003 CAPLUS

L26 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1289842 CAPLUS

DOCUMENT NUMBER: 144:40384

TITLE: Cosmetic composition containing an ester and  
 a film-forming agent

INVENTOR(S): Filippi, Vanina; Lebre, Caroline

PATENT ASSIGNEE(S): L'Oreal, Fr.

SOURCE: Fr. Demande, 75 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2871057	A1	20051209	FR 2004-6175	20040608
FR 2871057	B1	20060728		
EP 1604634	A1	20051214	EP 2005-291036	20050513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2005350466	A	20051222	JP 2005-167519	20050607
US 20050287103	A1	20051229	US 2005-147269	20050608
PRIORITY APPLN. INFO.:			FR 2004-6175	A 20040608
			US 2004-580103P	P 20040617

OTHER SOURCE(S): MARPAT 144:40384

AN 2005:1289842 CAPLUS

DN 144:40384

ED Entered STN: 09 Dec 2005  
 TI Cosmetic composition containing an ester and a film-forming agent  
 IN Filippi, Vanina; Lebre, Caroline  
 PA L'Oreal, Fr.  
 SO Fr. Demande, 75 pp.  
 CODEN: FRXXBL  
 DT Patent  
 LA French  
 IC ICM A61K007-027  
 ICS A61K007-02; A61K007-48; A61K007-032; A61K007-025; A61K007-031;  
 A61K007-043

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2871057	A1	20051209	FR 2004-6175	20040608
	FR 2871057	B1	20060728		
	EP 1604634	A1	20051214	EP 2005-291036	20050513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP 2005350466	A	20051222	JP 2005-167519	20050607
	US 20050287103	A1	20051229	US 2005-147269	20050608
PRAI	FR 2004-6175	A	20040608		
	US 2004-580103P	P	20040617		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2871057	ICM	A61K007-027
	ICS	A61K007-02; A61K007-48; A61K007-032; A61K007-025; A61K007-031; A61K007-043
	IPCI	A61K0007-027 [ICM,7]; A61K0007-02 [ICS,7]; A61K0007-48 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-025 [ICS,7]; A61K0007-031 [ICS,7]; A61K0007-043 [ICS,7]
	IPCR	A61K0008-30 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
EP 1604634	IPCI	A61K0007-025 [ICM,7]; A61K0007-032 [ICS,7]; A61K0007-043 [ICS,7]
	IPCR	A61K0008-30 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
JP 2005350466	IPCI	A61K0007-00 [ICM,7]; A61K0007-021 [ICS,7]; A61K0007-025 [ICS,7]; A61K0007-027 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-043 [ICS,7]
	FTERM	4C083/AB172; 4C083/AC011; 4C083/AC012; 4C083/AC021; 4C083/AC072; 4C083/AC371; 4C083/AC391; 4C083/AC392; 4C083/AC422; 4C083/AC472; 4C083/AC482; 4C083/AD021; 4C083/AD071; 4C083/AD091; 4C083/AD092; 4C083/AD131; 4C083/AD151; 4C083/AD161; 4C083/AD261; 4C083/AD271;



4C083/AD281; 4C083/AD301; 4C083/AD321; 4C083/AD331;  
4C083/AD341; 4C083/AD351; 4C083/AD411; 4C083/AD441;  
4C083/AD601; 4C083/BB11; 4C083/BB14; 4C083/BB21;  
4C083/CC01; 4C083/CC11; 4C083/CC12; 4C083/CC13;  
4C083/CC14; 4C083/CC28; 4C083/DD11; 4C083/EE01;  
4C083/EE03; 4C083/EE06; 4C083/EE07

US 20050287103 IPCI A61K0007-075 [ICM,7]  
IPCR A61K0008-30 [I,C\*]; A61K0008-37 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-81 [I,A]; A61Q0001-02 [I,C\*];  
A61Q0001-06 [I,A]  
NCL 424/070.220  
ECLA A61K008/37C; A61K008/81C2; A61K008/81K4; A61Q001/06

OS MARPAT 144:40384

AB A cosmetic composition contains a ester, a fatty acid dimer or a  
film-forming agent. A lipstick contained a polymer dispersion  
30, 2-decyl tetradecanoic acid triglyceride 2.02, Lusplan DD-DA5 10,  
octyldodecanol 9, BHT 0.07, parabens mixture 0.4, polycaprolactone  
9, eicosene-vinyl pyrrolidone copolymer 6, microcryst. wax 10,  
polyethylene wax 2, polymethylene wax 10, pigments 6.03,  
dimethicone-coated silica 5, and fragrance 0.48%.

ST cosmetic lipstick ester film forming agent

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(acrylates; cosmetic composition containing ester and film-forming  
agent)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(avocado; cosmetic composition containing ester and film-forming  
agent)

IT Polymers, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(block, diblock; cosmetic composition containing ester and  
film-forming agent)

IT Sunscreens  
(cosmetic composition containing ester and film-forming agent)

IT Acrylic polymers, biological studies  
Carboxylic acids, biological studies  
Castor oil  
Cottonseed oil  
Fatty acids, biological studies  
Fluoropolymers, biological studies  
Jojoba oil  
Olive oil  
Palm oil  
Polyesters, biological studies  
Polysiloxanes, biological studies  
Polyureas  
Polyurethanes, biological studies  
Soybean oil  
Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing ester and film-forming agent)

IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(dicarboxylic; cosmetic composition containing ester and film-forming  
agent)

IT Cosmetics  
(eye liners; cosmetic composition containing ester and film-forming  
agent)

IT Fats and Glyceridic oils, biological studies  
Rosin

- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated; cosmetic composition containing ester and film-forming agent)
- IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(macadamia nut; cosmetic composition containing ester and film-forming agent)
- IT Cosmetics  
(mascaras; cosmetic composition containing ester and film-forming agent)
- IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(mink; cosmetic composition containing ester and film-forming agent)
- IT Essential oils  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(orange, sweet; cosmetic composition containing ester and film-forming agent)
- IT Polyesters, biological studies  
Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyamide-; cosmetic composition containing ester and film-forming agent)
- IT Polyamides, biological studies  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyester-; cosmetic composition containing ester and film-forming agent)
- IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyether-; cosmetic composition containing ester and film-forming agent)
- IT Vinyl compounds, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polymers; cosmetic composition containing ester and film-forming agent)
- IT Polyamides, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polysiloxane-; cosmetic composition containing ester and film-forming agent)
- IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; cosmetic composition containing ester and film-forming agent)
- IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; cosmetic composition containing ester and film-forming agent)
- IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wheat germ; cosmetic composition containing ester and film-forming agent)
- IT 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(CAPA 1215; cosmetic composition containing ester and film-forming agent)
- IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 59-67-6, Nicotinic acid, biological studies 60-33-3, Linoleic acid, biological studies 65-85-0, Benzoic acid, biological studies 69-72-7, Salicylic acid, biological studies 75-98-9, Pivalic acid 79-31-2, Isobutanoic acid 98-79-3,

Pyrrolidonecarboxylic acid 98-89-5, Cyclohexanoic acid 99-96-7,  
 biological studies 106-14-9, 12-Hydroxyoctadecanoic acid 107-92-6,  
 Butanoic acid, biological studies 109-52-4, Pentanoic acid, biological  
 studies 111-14-8, Heptanoic acid 112-05-0, Nonanoic acid 112-37-8,  
 Undecanoic acid 112-79-8, Elaidinic acid 112-80-1, Oleic acid,  
 biological studies 112-85-6, Docosanoic acid 112-86-7, Erucic acid  
 124-07-2, Octanoic acid, biological studies 142-62-1, Hexanoic acid,  
 biological studies 143-07-7, Dodecanoic acid, biological studies  
 149-57-5, 2-Ethylhexanoic acid 149-91-7, Gallic acid, biological studies  
 150-13-0, p-Aminobenzoic acid 334-48-5, Decanoic acid 373-49-9,  
 Palmitoleic acid 503-74-2, Isopentanoic acid 506-12-7, Heptadecanoic  
 acid 506-30-9, Eicosanoic acid 506-32-1, Arachidonic acid 506-33-2,  
 Brassidic acid 514-10-3, Abietic acid 514-10-3D, Abietic acid,  
 hydrogenated 544-57-0, 2-Hydroxytetradecanoic acid 544-63-8,  
 Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid  
 557-59-5, Tetracosanoic acid 600-15-7, 2-Hydroxybutanoic acid  
 617-31-2, 2-Hydroxypentanoic acid 617-73-2, 2-Hydroxyoctanoic acid  
 621-82-9, Cinnamic acid, biological studies 629-22-1,  
 2-Hydroxyoctadecanoic acid 636-69-1, 2-Hydroxyheptanoic acid 638-53-9,  
 Tridecanoic acid 646-07-1, Isohexanoic acid 646-30-0, Nonadecanoic  
 acid 764-67-0, 2-Hydroxyhexadecanoic acid 830-09-1, p-Methoxycinnamic  
 acid 1002-84-2, Pentadecanoic acid 1330-19-4, Isoheptanoic acid  
 1333-28-4, Undecenoic acid 2507-55-3, 2-Hydroxytetradecanoic acid  
 2984-55-6, 2-Hydroxydodecanoic acid 5393-81-7, 2-Hydroxydecanoic acid  
 6064-63-7, 2-Hydroxyhexanoic acid 6144-28-1, Dilinoleic acid  
 7089-43-2, Linderic acid 9003-05-8 9003-53-6, Polystyrene  
 13980-14-8, 2-Hydroxydocosanoic acid 15896-36-3, 2-Hydroxynonanoic acid  
 16742-48-6, 2-Hydroxyeicosanoic acid 19790-86-4, 2-Hydroxyundecanoic  
 acid 19790-87-5, 2-Hydroxytridecanoic acid 25022-78-0,  
 2-Hydroxyheptadecanoic acid 25103-52-0, Isooctanoic acid 25167-62-8,  
 Docosahexaenoic acid 25354-97-6, 2-Hexyldecanoic acid 25378-27-2,  
 Eicosapentaenoic acid 25448-24-2, Isotridecanoic acid 25986-77-0,  
 Intelimer ipa 13-1 26403-17-8, Isodecanoic acid 26896-18-4,  
 Isononanoic acid 27610-92-0, 2-Butyloctanoic acid 29204-02-2, Gadoleic  
 acid 29385-00-0, Isododecanoic acid 32844-67-0, Isohexadecanoic acid  
 40596-46-1, 2-Octyldodecanoic acid 50973-09-6, Isopentadecanoic acid  
 57683-20-2, Isoundecanoic acid 65437-21-0, Isotetradecanoic acid  
 73756-37-3, 2-Dodecylhexadecanoic acid 73756-39-5, 2-  
 Tetradecyloctadecanoic acid 77035-98-4, Eicosene-vinyl pyrrolidone  
 copolymer 82430-11-3, Dimethyloctanoic acid 89547-15-9,  
 2-Hexacycloctadecanoic acid 93361-63-8, 2-Hydroxynonadecanoic acid  
 93778-52-0, 2-Decyltetradecanoic acid 98989-29-8, Isoeicosanoic acid  
 512778-00-6, Lusplan DD-DA 5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing ester and film-forming agent)

IT 694523-05-2D, hydrogenated, block, diblock  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (isoprene-styrene rubber; cosmetic composition containing ester and  
 film-forming agent)

IT 25038-57-7, Poly(methylene)  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wax; cosmetic composition containing ester and film-forming agent)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Batdorf; US 6342556 B1 2002 CAPLUS
- (2) Daikin Industries Ltd; EP 1066815 A 2001 CAPLUS
- (3) Kao Corporation; EP 1066826 A 2001 CAPLUS
- (4) Kose Kk; JP 2002128623 A 2002 CAPLUS
- (5) L'Oreal; EP 0923928 A 1999 CAPLUS
- (6) Lu, S; US 2003235553 A1 2003
- (7) Mohamed, K; US 2004042980 A1 2004

(8) Nippon Fine Chemical Company Limited; FR 2795309 A 2000 CAPLUS

L26 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN  
ACCESSION NUMBER: 2005:1149653 CAPLUS  
DOCUMENT NUMBER: 143:410642  
TITLE: Ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof  
INVENTOR(S): Lee, Young Suk; Lee, Sang Il; Kim, Jin Won; Kim, Ju No; Jang, Lee Sup  
PATENT ASSIGNEE(S): Amorepacific Corporation, S. Korea  
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005298510	A	20051027	JP 2005-114681	20050412
KR 2005100471	A	20051019	KR 2004-25710	20040414
			KR 2004-25710	A 20040414

PRIORITY APPLN. INFO.:

AN 2005:1149653 CAPLUS

DN 143:410642

ED Entered STN: 27 Oct 2005

TI Ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof

IN Lee, Young Suk; Lee, Sang Il; Kim, Jin Won; Kim, Ju No; Jang, Lee Sup

PA Amorepacific Corporation, S. Korea

SO Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K031-704

ICS A61K007-00; A61K007-48; A61K009-48; A61K047-32; A61K047-34; A61K047-38; A61K047-42; A61P017-00

CC 62-4 (Essential Oils and Cosmetics)

Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005298510	A	20051027	JP 2005-114681	20050412
KR 2005100471	A	20051019	KR 2004-25710	20040414
PRAI KR 2004-25710	A	20040414		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2005298510	ICM	A61K031-704
	ICS	A61K007-00; A61K007-48; A61K009-48; A61K047-32; A61K047-34; A61K047-38; A61K047-42; A61P017-00
	IPCI	A61K0031-704 [ICM,7]; A61K0031-7028 [ICM,7,C*]; A61K0007-00 [ICS,7]; A61K0007-48 [ICS,7]; A61K0009-48 [ICS,7]; A61K0047-32 [ICS,7]; A61K0047-34 [ICS,7]; A61K0047-38 [ICS,7]; A61K0047-42 [ICS,7]; A61P0017-00 [ICS,7]
	IPCR	A61K0009-48 [I,A]; A61K0009-48 [I,C*]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0047-32 [I,A]; A61K0047-32 [I,C*]; A61K0047-34 [I,A]; A61K0047-34 [I,C*]; A61K0047-38 [I,A]; A61K0047-38 [I,C*]; A61K0047-42 [I,A]; A61K0047-42 [I,C*]; A61P0017-00 [I,A]; A61P0017-00 [I,C*]

FTERM 4C076/AA53; 4C076/BB31; 4C076/CC18; 4C076/EE06H;  
 4C076/EE08H; 4C076/EE16H; 4C076/EE16Q; 4C076/EE27Q;  
 4C076/EE31Q; 4C076/EE38Q; 4C076/EE42Q; 4C076/FF65;  
 4C083/AC022; 4C083/AC072; 4C083/AC102; 4C083/AC112;  
 4C083/AC122; 4C083/AC182; 4C083/AC242; 4C083/AC392;  
 4C083/AC522; 4C083/AC712; 4C083/AD071; 4C083/AD072;  
 4C083/AD091; 4C083/AD092; 4C083/AD111; 4C083/AD112;  
 4C083/AD161; 4C083/AD162; 4C083/AD241; 4C083/AD242;  
 4C083/AD261; 4C083/AD262; 4C083/AD352; 4C083/AD411;  
 4C083/AD412; 4C083/AD491; 4C083/AD492; 4C083/AD662;  
 4C083/CC02; 4C083/CC04; 4C083/CC05; 4C083/DD14;  
 4C083/DD23; 4C083/DD31; 4C083/EE12; 4C086/AA01;  
 4C086/AA02; 4C086/EA10; 4C086/MA01; 4C086/MA03;  
 4C086/MA04; 4C086/MA05; 4C086/MA37; 4C086/NA10;  
 4C086/ZA89

- KR 2005100471 IPCI A61K0007-48 [ICM,7]
- AB The invention relates to polymer microcapsules containing ginsenoside, suitable for use in an anti-aging cosmetic composition, wherein the use of the microcapsules prevents discoloration the cosmetic composition and malodor due to ginsenoside during storage. A method for manufacturing the microcapsules is also disclosed. For example, polycaprolactone microcapsules containing Panax ginseng-derived ginsenoside were prepared in the presence of polyvinyl alc. dispersion stabilizer. The obtained microcapsules 5 parts was mixed with other ingredients to obtain a skin-softening lotion.
- ST ginsenoside polymer microcapsule antiaging cosmetic
- IT Cosmetics  
 (aerosols; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Ethers, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (alkyl vinyl, polymers, dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Cosmetics  
 (antiaging; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Capsules  
 (cosmetic microcapsules; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Cosmetics  
 (creams; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (di-Me, polystyrene-, block, dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Gelatins, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Cosmetics  
 (emulsions; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)
- IT Cosmetics

(foundations; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
(gels; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Ginsenosides  
RL: COS (Cosmetic use); NPO (Natural product occurrence); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)  
(ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Polyesters, biological studies  
RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
(ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
(lipsticks; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
(lotions; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
(makeups, base; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
(microcapsules; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
(packs; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
(unsatd.; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT 9000-11-7, Carboxymethyl cellulose 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinylpyrrolidone 9004-62-0, Hydroxyethyl cellulose 9005-25-8, Starch, biological studies  
RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
(dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT 39262-14-1 53963-43-2, Ginsenoside F1  
RL: COS (Cosmetic use); NPO (Natural product occurrence); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)  
(ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT 111-01-3, Squalane 9004-32-4, Sodium carboxymethyl cellulose  
RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
(ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT 9003-01-4, Polyacrylic acid 9003-19-4, Polyvinylether 24980-41-4,

Polycaprolactone 25248-42-4, Polycaprolactone  
 RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process);  
 PYP (Physical process); BIOL (Biological study); PROC (Process); USES  
 (Uses)  
 (ginsenoside-encapsulated polymer microcapsules for cosmetics  
 , and manufacture thereof)

L26 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:521763 CAPLUS  
 DOCUMENT NUMBER: 143:65128  
 TITLE: Cosmetic composition containing and a  
 polymer dispersion and a plasticizer  
 INVENTOR(S): Blin, Xavier  
 PATENT ASSIGNEE(S): L'Oreal, Fr.  
 SOURCE: Fr. Demande, 54 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2863491	A1	20050617	FR 2003-14654	20031212
WO 2005058257	A1	20050630	WO 2004-FR3191	20041210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: FR 2003-14654 A 20031212  
 US 2004-539352P P 20040128

OTHER SOURCE(S): MARPAT 143:65128

AN 2005:521763 CAPLUS  
 DN 143:65128  
 ED Entered STN: 17 Jun 2005  
 TI Cosmetic composition containing and a polymer dispersion and a  
 plasticizer  
 IN Blin, Xavier  
 PA L'Oreal, Fr.  
 SO Fr. Demande, 54 pp.  
 CODEN: FRXXBL  
 DT Patent  
 LA French  
 IC ICM A61K007-48  
 ICS A61K007-025; A61K007-02  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2863491	A1	20050617	FR 2003-14654	20031212
WO 2005058257	A1	20050630	WO 2004-FR3191	20041210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

PRAI FR 2003-14654 A 20031212  
 US 2004-539352P P 20040128

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2863491	ICM	A61K007-48
	ICS	A61K007-025; A61K007-02
	IPCI	A61K0007-48 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-02 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-60 [I,A]; A61K0008-72 [I,C*]; A61K0008-91 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
WO 2005058257	ECLA	A61K008/37; A61K008/60; A61K008/91; A61Q001/06
	IPCI	A61K0007-027 [ICM,7]; A61K0007-031 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-043 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-91 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]
OS	MARPAT	143:65128
AB	A cosmetic composition for hair and skin comprises a dispersion of an ethylene polymer particles in a liquid fatty phase, and a plasticizer having a parameter of solubility $\delta h$ from 55 to 11 (J/cm <sup>3</sup> ) <sup>2</sup> . A polymer dispersion was obtained by polymerization of Me acrylate and methacrylate-terminated ethylene-butylene copolymer in isododecane. A lipstick contained hydrogenated polyisobutene 5.2, saccharose acetate isobutyrate (Octacare DSPOL300) 5, Performacol 550 2, pigments 8.2, polyethylene wax 10, a dispersion of above polymer 68.82, and fragrances q.s. 100 g.	
ST	cosmetic polymer dispersion plasticizer lipstick acrylic polymer	
IT	Hair preparations	
	Plasticizers	
	Solubility	
	(cosmetic composition containing and polymer dispersion and plasticizer)	
IT	Polysiloxanes, biological studies	
	RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)	
	(cosmetic composition containing and polymer dispersion and plasticizer)	
IT	Acrylic polymers, biological studies	
	RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)	
	(cosmetic composition containing and polymer dispersion and plasticizer)	
IT	Carboxylic acids, biological studies	
	RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)	
	(esters; cosmetic composition containing and polymer dispersion and plasticizer)	
IT	Cosmetics	
	(lipsticks; cosmetic composition containing and polymer dispersion and plasticizer)	
IT	Carboxylic acids, biological studies	



RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polycarboxylic; cosmetic composition containing and polymer  
 dispersion and plasticizer)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyhydric; cosmetic composition containing and polymer dispersion  
 and plasticizer)

IT 50-69-1, D-Ribose 50-70-4, Sorbitol, biological studies 50-99-7,  
 D-Glucose, biological studies 50-99-7, D-Glucose, biological studies  
 57-48-7, D-Fructose, biological studies 57-50-1, Saccharose, biological  
 studies 58-86-6, D-Xylose, biological studies 59-23-4, D-Galactose,  
 biological studies 63-42-3, Lactose 64-19-7D, Acetic acid, esters  
 65-85-0D, Benzoic acid, esters 69-79-4, Maltose 77-89-4, Triethyl  
 acetyl-citrate 77-90-7, Tributyl Acetyl-citrate 77-92-9, Citric Acid,  
 biological studies 77-94-1, Tributyl citrate 79-09-4D, Propanoic acid,  
 esters 79-31-2D, Isobutanoic acid, esters 84-66-2, Diethyl phthalate  
 84-74-2, Butyl phthalate 87-99-0, Xylitol 103-23-1, Di(ethyl-2-hexyl)  
 adipate 105-99-7, Dibutyl adipate 107-92-6D, Butanoic acid, esters  
 109-43-3, Dibutyl sebacate 109-52-4D, n-Pentanoic acid, esters  
 110-40-7, Diethyl sebacate 117-81-7 122-62-3, Di(ethyl-2-hexyl)  
 sebacate 123-25-1, Diethyl succinate 126-13-6 131-11-3, Dimethyl  
 phthalate 144-15-0 149-32-6, Erythritol 523-31-9, Benzyl phthalate  
 551-84-8, D-Xylulose 2915-57-3, Di(ethyl-2-hexyl) succinate 3458-28-4,  
 D-Mannose 5328-37-0, L-Arabinose 7147-34-4, Tris(2-ethylhexyl) citrate  
 7491-02-3, Diisopropyl sebacate 17140-33-9, Acetyl-citric acid  
 24817-92-3 64831-33-0 74592-76-0, Triisopropyl citrate 82469-79-2  
 278777-48-3 854262-19-4 854262-20-7 854275-83-5 854275-84-6  
 854275-85-7 854275-86-8

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing and polymer dispersion and  
 plasticizer)

IT 854275-82-4P  
 RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (cosmetic composition containing and polymer dispersion and  
 plasticizer)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Bolich, R; US 5632998 A 1997 CAPLUS
- (2) Lion, B; WO 9735541 A 1997 CAPLUS
- (3) Oreal; EP 0749747 A 1996 CAPLUS
- (4) Oreal; EP 1038519 A 2000 CAPLUS
- (5) Oreal; WO 0228359 A 2002 CAPLUS
- (6) Oreal; EP 1411069 A 2004 CAPLUS
- (7) Oreal; EP 1428843 A 2004 CAPLUS
- (8) Oreal; EP 1428844 A 2004 CAPLUS

L26 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2005:177858 CAPLUS  
 DOCUMENT NUMBER: 142:245658  
 TITLE: Cosmetic composition comprising a particular  
 ester, and uses thereof  
 INVENTOR(S): Arnaud, Pascal  
 PATENT ASSIGNEE(S): L'oreal, Fr.  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018584	A1	20050303	WO 2003-FR2357	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003273476	A1	20050310	AU 2003-273476	20030725
EP 1653919	A1	20060510	EP 2003-755636	20030725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
JP 2007516935	T	20070628	JP 2005-508162	20030725
US 20070190003	A1	20070816	US 2006-565635	20060717
PRIORITY APPLN. INFO.:			WO 2003-FR2357	A 20030725

OTHER SOURCE(S): MARPAT 142:245658

AN 2005:177858 CAPLUS

DN 142:245658

ED Entered STN: 03 Mar 2005

TI Cosmetic composition comprising a particular ester, and uses thereof

IN Arnaud, Pascal

PA L'oreal, Fr.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA French

IC ICM A61K007-025

ICS A61K007-027

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005018584	A1	20050303	WO 2003-FR2357	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003273476	A1	20050310	AU 2003-273476	20030725
EP 1653919	A1	20060510	EP 2003-755636	20030725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
JP 2007516935	T	20070628	JP 2005-508162	20030725
US 20070190003	A1	20070816	US 2006-565635	20060717
PRAI WO 2003-FR2357	A	20030725		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005018584	ICM	A61K007-025
	ICS	A61K007-027

	IPCI	A61K0007-025 [ICM,7]; A61K0007-027 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]
AU 2003273476	ECLA	A61K008/37C; A61Q001/02; A61Q001/06
	IPCI	A61K0007-025 [ICM,7]; A61K0007-027 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]
EP 1653919	IPCI	A61K0008-37 [ICM,7]; A61K0008-30 [ICM,7,C*]; A61Q0001-02 [ICS,7]; A61Q0001-06 [ICS,7]
JP 2007516935	IPCI	A61K0008-37 [I,A]; A61K0008-30 [I,C*]; A61Q0001-00 [I,A]; A61K0008-06 [I,A]; A61K0008-04 [I,C*]; A61Q0001-06 [I,A]; A61Q0001-02 [I,C*]
	IPCR	A61K0008-30 [I,C]; A61K0008-37 [I,A]; A61K0008-04 [I,C]; A61K0008-06 [I,A]; A61Q0001-00 [I,C]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]
	ECLA	A61K008/37C; A61Q001/02; A61Q001/06
	FTERM	4C083/AA121; 4C083/AB232; 4C083/AB242; 4C083/AB442; 4C083/AC021; 4C083/AC072; 4C083/AC342; 4C083/AC352; 4C083/AC372; 4C083/AC391; 4C083/AC392; 4C083/AC422; 4C083/AD022; 4C083/AD042; 4C083/AD152; 4C083/AD351; 4C083/AD512; 4C083/AD662; 4C083/BB11; 4C083/BB12; 4C083/BB21; 4C083/BB31; 4C083/BB60; 4C083/CC11; 4C083/DD32; 4C083/DD33; 4C083/EE06; 4C083/EE07
US 20070190003	IPCI	A61K0008-37 [I,A]; A61K0008-30 [I,C*]
	NCL	424/064.000
OS	MARPAT	142:245658
AB	The invention relates to a composition in the form of a physiologically acceptable medium containing a fatty phase comprising at least one ester resulting from the reaction of a polyol with a carboxylic acid, having formula R1(R2)(R3)COOH, wherein: R1, R2 and R3 are radicals which are selected independently from optionally-functionalized alkyl, aryl, aralkyl radicals, and the combinations thereof. The invention also relates to the use of an ester having the aforementioned formula in a cosmetic composition with performance properties, for example, in terms of color and/or brightness and/or comfort and/or non-migration. A lipstick contained diisostearyl malate 4.1, oxypropylene lanolin wax 4.1, polybutene 8.2, octyl-2-dodecanol 4.1, octyl-2-dodecyl neopentanoate 0.9, GH 0.04, modified hectorite 0.8, polyethylene wax 10.8, octacosanyl stearate 3.6, hydrogenated coco-glycerides 5, titanium oxide 2.7, DC Red 7, 2.2, DC RED 27 lake 1.8, Yellow 6-lake 3, iron oxide 2, glyceryl tri-neopentanoate 17.3, $\alpha$ -tocopheryl acetate 0.3, ethylhexyl methoxycinnamate 0.7, perfume 0.2, and hydrogenated polyisobutene q.s. 100%.	
ST	cosmetic lipstick ester octyldodecyl neopentanoate	
IT	Esters, biological studies	
	RL:	COS (Cosmetic use); BIOL (Biological study); USES (Uses) (cosmetic composition comprising particular ester, and uses thereof)
IT	Carboxylic acids, reactions	
	RL:	RCT (Reactant); RACT (Reactant or reagent) (cosmetic composition comprising particular ester, and uses thereof)
IT	Polyoxyalkylenes, reactions	
	RL:	RCT (Reactant); RACT (Reactant or reagent) (cosmetic composition comprising particular ester, and uses thereof)
IT	Cosmetics	
		(foundations; cosmetic composition comprising particular ester, and uses thereof)
IT	Cosmetics	

(lipsticks; cosmetic composition comprising particular ester, and uses thereof)

IT Alcohols, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (polyhydric; cosmetic composition comprising particular ester, and uses thereof)

IT 595-37-9, Neohexanoic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Neohexanoic acid; cosmetic composition comprising particular ester, and uses thereof)

IT 42928-74-5 42928-76-7 57346-62-0 58006-18-1  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising particular ester, and uses thereof)

IT 50-70-4, Sorbitol, reactions 56-81-5, Glycerol, reactions 57-55-6, Propylene glycol, reactions 75-98-9, Neopentanoic acid 107-21-1, Ethylene glycol, reactions 110-63-4, Butylene glycol, reactions 126-30-7, Neopentyl glycol 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 26896-20-8, Neodecanoic acid 33113-10-9, Neohexanoic acid 56090-54-1, Triglycerol 59113-36-9, Diglycerol 307313-22-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cosmetic composition comprising particular ester, and uses thereof)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Bochkova; ZHURNAL PRIKLADNI KHIMII 1973, V46(8), P1929
- (2) Bodelin-Lecomte, S; US 5928652 A 1999 CAPLUS
- (3) Coopersmith, M; US 3651102 A 1972
- (4) Corcoran, C; US 5368857 A 1994 CAPLUS
- (5) Fefer; JOURNAL OF THE AMERICAN OIL CHEMIST'S SOCIETY 1968, V45, P5 CAPLUS
- (6) Hoffman, W; US 3523084 A 1970 CAPLUS
- (7) Oguchi, N; WO 03026698 A 2003 CAPLUS
- (8) Oreal; WO 0217861 A 2002 CAPLUS
- (9) Vanlerberghe, G; US 4224311 A 1980 CAPLUS

L26 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:753134 CAPLUS

DOCUMENT NUMBER: 141:282426

TITLE: Cosmetic composition containing a polyester of an hydroxylated carboxylic acid triglyceride and an oil with a molar mass of 650-1000 g/mol

INVENTOR(S): Blin, Xavier; Filippi, Vanina

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1457201	A1	20040915	EP 2004-290593	20040304
EP 1457201	B1	20070411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
FR 2852234	A1	20040917	FR 2003-3078	20030312
AT 359057	T	20070515	AT 2004-290593	20040304
ES 2285373	T3	20071116	ES 2004-290593	20040304

JP 2004277420	A	20041007	JP 2004-69539	20040311
US 20040241198	A1	20041202	US 2004-796979	20040311
PRIORITY APPLN. INFO.:			FR 2003-3078	A 20030312
			US 2003-458371P	P 20030331

AN 2004:753134 CAPLUS  
 DN 141:282426  
 ED Entered STN: 16 Sep 2004  
 TI Cosmetic composition containing a polyester of an hydroxylated carboxylic acid triglyceride and an oil with a molar mass of 650-1000 g/mol  
 IN Blin, Xavier; Filippi, Vanina  
 PA L'oreal, Fr.  
 SO Eur. Pat. Appl., 17 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA French  
 IC ICM A61K007-48  
 ICS A61K007-021; A61K007-025  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1457201	A1	20040915	EP 2004-290593	20040304
	EP 1457201	B1	20070411		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	FR 2852234	A1	20040917	FR 2003-3078	20030312
	AT 359057	T	20070515	AT 2004-290593	20040304
	ES 2285373	T3	20071116	ES 2004-290593	20040304
	JP 2004277420	A	20041007	JP 2004-69539	20040311
	US 20040241198	A1	20041202	US 2004-796979	20040311
PRAI	FR 2003-3078	A	20030312		
	US 2003-458371P	P	20030331		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 1457201	ICM	A61K007-48
	ICS	A61K007-021; A61K007-025
	IPCI	A61K0008-30 [I,C]; A61K0008-92 [I,C]; A61Q0001-00 [I,C]; A61Q0001-02 [I,C]; A61K0008-37 [I,A]; A61K0008-92 [I,A]; A61Q0001-00 [I,A]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]
	IPCR	A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-30 [I,C]; A61K0008-37 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-72 [I,C*]; A61K0008-85 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0001-00 [I,C]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0005-10 [I,C*]; A61Q0005-10 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
	ECLA	A61K008/37C; A61K008/92C; A61Q001/00; A61Q001/02; A61Q001/06
FR 2852234	IPCR	A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-85 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A];

		A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0005-10 [I,C*]; A61Q0005-10 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
AT 359057	IPCI	A61K0008-37 [ICS,7]; A61K0008-30 [ICS,7,C*]; A61K0008-92 [ICS,7]; A61Q0001-00 [ICS,7]; A61Q0001-06 [ICS,7]; A61Q0001-02 [ICS,7]
	IPCR	A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-85 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0005-10 [I,C*]; A61Q0005-10 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
	ECLA	A61K008/37C; A61K008/92C; A61Q001/00; A61Q001/02; A61Q001/06
ES 2285373	IPCI	A61K0008-30 [I,C]; A61K0008-37 [I,A]; A61K0008-92 [I,C]; A61K0008-92 [I,A]; A61Q0001-00 [I,C]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]
	IPCR	A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-30 [I,C]; A61K0008-37 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-72 [I,C*]; A61K0008-85 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0001-00 [I,C]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0005-10 [I,C*]; A61Q0005-10 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
	ECLA	A61K008/37C; A61K008/92C; A61Q001/00; A61Q001/02; A61Q001/06
JP 2004277420	IPCI	A61K0007-02 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-04 [ICS,7]; A61K0007-06 [ICS,7]; A61K0007-13 [ICS,7]; A61K0007-42 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
	FTERM	4C083/AA121; 4C083/AB442; 4C083/AC182; 4C083/AC392; 4C083/AC421; 4C083/AC422; 4C083/AC432; 4C083/AC441; 4C083/AD011; 4C083/AD021; 4C083/AD022; 4C083/AD042; 4C083/AD071; 4C083/AD151; 4C083/AD152; 4C083/BB11; 4C083/BB21; 4C083/CC01; 4C083/CC13; 4C083/CC14; 4C083/CC19; 4C083/CC28; 4C083/CC31; 4C083/CC36; 4C083/EE01; 4C083/EE06; 4C083/EE07; 4C083/EE17; 4C083/EE26

US 20040241198 IPCI C11D0003-00 [ICM,7]; A61K0007-00 [ICS,7]  
 IPCR A61K0008-30 [I,C\*]; A61K0008-37 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]  
 NCL 424/401.000  
 ECLA A61K008/37C; A61K008/92C; A61Q001/02; A61Q001/06

AB The title compns. are claimed which have remarkable cosmetic properties such as luster, and comfort. A lipstick contained Zenigloss 22, Elefacos ST9 11,2-decyltetradecanoic acid triglyceride 20,hydrogenated polyisobutene 10,di-isostearyl malate 11, polybutylene 2.5,octacosanyl stearate 5, a mixture of lauric, myristic, palmitic, stearic acid triglycerides 2, polyethylene wax 5,hectorite modified by di-stearyl di-Me ammonium chloride 3, pigments q.s., preservatives q.s., and perfume q.s. 100%.

ST cosmetic carboxylic acid polyester triglyceride oil

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (Ph; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Esters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (aromatic; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Glycerides, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (carboxylic acid; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Cosmetics  
 Sunscreens  
 Suntanning agents  
 (cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Fatty acids, biological studies  
 Oils  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Hair preparations  
 (dyes; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Cosmetics  
 (eye liners; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (lipophilic; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Cosmetics  
 (lipsticks; cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

IT Cosmetics  
(mascaras; cosmetic composition containing polyester of hydroxylated  
carboxylic acid triglyceride and oil)

IT Cosmetics  
(nail lacquers; cosmetic composition containing polyester of  
hydroxylated carboxylic acid triglyceride and oil)

IT Cosmetics  
(powders; cosmetic composition containing polyester of hydroxylated  
carboxylic acid triglyceride and oil)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(sesame; cosmetic composition containing polyester of hydroxylated  
carboxylic acid triglyceride and oil)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(vegetable; cosmetic composition containing polyester of hydroxylated  
carboxylic acid triglyceride and oil)

IT 106-14-9, 12-Hydroxy stearic acid 120-87-6, 9,10-Dihydroxy octadecanoic  
acid 141-22-0, Ricinoleic acid 498-36-2, Leucic acid 629-22-1,  
 $\alpha$ -Hydroxyoctadecanoic acid 4130-35-2, Tridecyl trimellitate  
4444-16-0 6949-98-0 9003-27-4D, Polyisobutylene, hydrogenated  
9003-29-6, Polybutylene 9003-39-8, PVP 13893-40-8,  
3-Hydroxy-4-hexenoic acid 14450-05-6, Pentaerythrityl tetrapelargonate  
25027-95-6, 9,10,12-Trihydroxy octadecanoic acid 25754-87-4,  
9,12-Dihydroxy octadecanoic acid 26942-95-0, Glyceryl triisostearate  
26952-14-7D, Hexadecene, copolymers 30306-47-9, Hydroxynervonic acid  
30399-84-9, Isostearic Acid 37309-58-3, Polydecene 37309-58-3D,  
Polydecene, hydrogenated 62125-22-8, Pentaerythrityl tetraisostearate  
93803-89-5, Pentaerythrityl tetraisononanoate 187887-27-0 301824-14-6,  
Triisooarachidyl citrate 337975-97-0, 2-Ethyl-3-hydroxycaprylic acid  
338450-65-0, Hexahydroxyoctadecanoic acid 338450-66-1,  
Octahydroxyoctadecanoic acid 375375-69-2 710306-07-3 756899-84-0,  
14-Hydroxycosenoic acid 756900-61-5  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing polyester of hydroxylated  
carboxylic acid triglyceride and oil)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Oreal; EP 1097699 A 2001 CAPLUS
- (2) Oreal; EP 1112734 A 2001 CAPLUS
- (3) Oreal; FR 2829924 A 2003 CAPLUS
- (4) O'Lenick; COSMETICS TOILETRIES 2002, V117(6), P59 CAPLUS
- (5) O'Lenick, A; US 5786389 A 1998 CAPLUS
- (6) O'Lenick, A; US 6342527 B1 2002 CAPLUS
- (7) O'Lenick, A; US 2003007950 A1 2003

L26 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:753127 CAPLUS

DOCUMENT NUMBER: 141:265584

TITLE: Cosmetic composition comprising a  
hydroxylated carboxylic acid  
triglyceride polyester and a pasty compound

INVENTOR(S): Blin, Xavier; Filippi, Vanina

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1457193	A1	20040915	EP 2004-290592	20040304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
FR 2852233	A1	20040917	FR 2003-3077	20030312
FR 2852233	B1	20060630		
FR 2852235	A1	20040917	FR 2003-3079	20030312
FR 2852235	B1	20060630		
JP 2004277419	A	20041007	JP 2004-69538	20040311
US 20040241121	A1	20041202	US 2004-797051	20040311
PRIORITY APPLN. INFO.:			FR 2003-3077	A 20030312
			FR 2003-3079	A 20030312
			US 2003-456228P	P 20030321
			US 2003-456230P	P 20030321

AN 2004:753127 CAPLUS  
DN 141:265584  
ED Entered STN: 16 Sep 2004  
TI Cosmetic composition comprising a hydroxylated carboxylic acid triglyceride polyester and a pasty compound  
IN Blin, Xavier; Filippi, Vanina  
PA L'oreal, Fr.  
SO Eur. Pat. Appl., 19 pp.  
CODEN: EPXXDW  
DT Patent  
LA French  
IC ICM A61K007-025  
CC 62-4 (Essential Oils and Cosmetics)  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1457193	A1	20040915	EP 2004-290592	20040304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
FR 2852233	A1	20040917	FR 2003-3077	20030312
FR 2852233	B1	20060630		
FR 2852235	A1	20040917	FR 2003-3079	20030312
FR 2852235	B1	20060630		
JP 2004277419	A	20041007	JP 2004-69538	20040311
US 20040241121	A1	20041202	US 2004-797051	20040311
PRAI FR 2003-3077	A	20030312		
FR 2003-3079	A	20030312		
US 2003-456228P	P	20030321		
US 2003-456230P	P	20030321		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 1457193	ICM	A61K007-025
	IPCI	A61K0007-025 [ICM,7]
	IPCR	A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-37 [I,A]; A61K0008-81 [I,A]; A61K0008-85 [I,A]; A61K0008-89 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0005-10 [I,C*]; A61Q0005-10 [I,A]; A61Q0015-00 [I,C*]; A61Q0015-00

		[I,A]
FR 2852233	ECLA	A61K008/37C; A61K008/92C; A61Q001/06
	IPCI	A61K0007-025 [ICM,7]; A61K0007-02 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-92 [I,C*]; A61Q0001-02 [I,C*]; A61K0008-37 [I,A]; A61K0008-92 [I,A]; A61Q0001-06 [I,A]
FR 2852235	ECLA	A61K008/37C; A61K008/92C; A61Q001/06
	IPCI	A61K0007-025 [ICM,7]; A61K0007-02 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-92 [I,C*]; A61Q0001-02 [I,C*]; A61K0008-37 [I,A]; A61K0008-92 [I,A]; A61Q0001-06 [I,A]
JP 2004277419	ECLA	A61K008/37C; A61K008/92C; A61Q001/06
	IPCI	A61K0007-00 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-04 [ICS,7]; A61K0007-06 [ICS,7]; A61K0007-13 [ICS,7]; A61K0007-32 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
	FTERM	4C083/AA122; 4C083/AB432; 4C083/AC012; 4C083/AC122; 4C083/AC182; 4C083/AC352; 4C083/AC421; 4C083/AC422; 4C083/AC432; 4C083/AD021; 4C083/AD022; 4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD161; 4C083/AD162; 4C083/AD491; 4C083/CC13; 4C083/CC14; 4C083/CC17; 4C083/CC28; 4C083/CC31; 4C083/CC36; 4C083/DD21; 4C083/DD22; 4C083/EE06; 4C083/EE07
US 20040241121	IPCI	A61K0007-06 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
	NCL	424/070.110
	ECLA	A61K008/37C; A61K008/92C; A61Q001/06
AB	The title compns. are claimed which have remarkable cosmetic properties such as luster, and comfort. A lipstick contained Zenigloss 22, Elefacos ST9 11, 2-decyltetradecanoic acid triglyceride 20, hydrogenated polyisobutene 10, di-isostearyl malate 11, polybutylene 2.5, octacosanyl stearate 5, a mixture of lauric, myristic, palmitic, stearic acid triglycerides 2, polyethylene wax 5, hectorite modified by di-stearyl di-Me ammonium chloride 3, pigments q.s., preservatives q.s., and perfume q.s. 100%.	
ST	cosmetic carboxylic acid polyester triglyceride paste	
IT	Polysiloxanes, biological studies RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (Ph; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)	
IT	Glycerides, biological studies RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (carboxylic acid; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)	
IT	Beeswax Cosmetics Deodorants Sunscreens Suntanning agents (cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)	
IT	Acrylic polymers, biological studies Fatty acids, biological studies Fluoropolymers, biological studies	

Oils  
 Polyolefins  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Hair preparations  
 (dyes; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (eye liners; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (lipsticks; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (mascaras; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Hydrocarbon waxes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (nail lacquers; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Sterols  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (phyto-; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (powders; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sesame; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT 106-14-9, 12-Hydroxy stearic acid 115-77-5D, Pentaerythritol, esters  
 120-87-6, 9 10-Dihydroxy octadecanoic acid 141-22-0, Ricinoleic acid  
 498-36-2 629-22-1,  $\alpha$ -Hydroxy octadecanoic acid 4444-16-0  
 6949-98-0 9003-19-4, Vinyl ether polymers 9003-27-4D, Polyisobutylene,  
 hydrogenated 9003-29-6, Polybutylene 9003-39-8, PVP 9016-00-6D,  
 Polydimethylsiloxane, Me trifluoropropyl alkyl derivs. 13893-40-8

25027-95-6, 9,10, 12 Trihydroxy octadecanoic acid 25754-87-4, 9,  
 12-Dihydroxy octadecanoic acid 26952-14-7D, Hexadecene, copolymers  
 30306-47-9 30399-84-9, Isostearic Acid 31900-57-9D,  
 Polydimethylsiloxane, Me trifluoropropyl alkyl derivs. 37309-58-3,  
 Polydecene 37309-58-3D, Polydecene, hydrogenated 65591-14-2, Arachidyl  
 propionate 337975-97-0 338450-65-0 338450-66-1 756899-84-0  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(cosmetic composition comprising hydroxylated carboxylic  
 acid triglyceride polyester and pasty compound)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bhikhu, S; JOURNAL OF APPLIED POLYMER SCIENCE 1993, V50(12), P2143
- (2) Murthy, C; JOURNAL OF APPLIED POLYMER SCIENCE 1991, V43(5), P993 CAPLUS
- (3) O'Lenick, A; US 5786389 A 1998 CAPLUS
- (4) O'Lenick, A; US 6342527 B1 2002 CAPLUS
- (5) O'Lenick, A; US 2003007950 A1 2003

L26 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:703076 CAPLUS

DOCUMENT NUMBER: 141:230308

TITLE: Cosmetic composition containing a polymer  
 particle dispersion and polymer plasticizer

INVENTOR(S): Blin, Xavier; Lebre, Caroline; Lion, Bertrand

PATENT ASSIGNEE(S): L'Oreal, Fr.

SOURCE: Fr. Demande, 40 pp.

CODEN: FRXXBL

DOCUMENT TYPE:

Patent

LANGUAGE:

French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2851468	A1	20040827	FR 2003-50035	20030225
EP 1477153	A1	20041117	EP 2004-290462	20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004256538	A	20040916	JP 2004-48673	20040224
CN 1535675	A	20041013	CN 2004-10032657	20040224
KR 2004076808	A	20040903	KR 2004-12748	20040225
US 20040234612	A1	20041125	US 2004-785093	20040225
BR 2004001143	A	20050517	BR 2004-1143	20040225
PRIORITY APPLN. INFO.:			FR 2003-50035	A 20030225
			US 2003-452064P	P 20030306

OTHER SOURCE(S): MARPAT 141:230308

AN 2004:703076 CAPLUS

DN 141:230308

ED Entered STN: 27 Aug 2004

TI Cosmetic composition containing a polymer particle dispersion  
 and polymer plasticizer

IN Blin, Xavier; Lebre, Caroline; Lion, Bertrand

PA L'Oreal, Fr.

SO Fr. Demande, 40 pp.

CODEN: FRXXBL

DT Patent

LA French

IC ICM A61K007-48

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	FR 2851468	A1	20040827	FR 2003-50035	20030225
	EP 1477153	A1	20041117	EP 2004-290462	20040220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2004256538	A	20040916	JP 2004-48673	20040224
	CN 1535675	A	20041013	CN 2004-10032657	20040224
	KR 2004076808	A	20040903	KR 2004-12748	20040225
	US 20040234612	A1	20041125	US 2004-785093	20040225
	BR 2004001143	A	20050517	BR 2004-1143	20040225
PRAI	FR 2003-50035	A	20030225		
	US 2003-452064P	P	20030306		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2851468	ICM	A61K007-48
	IPCI	A61K0007-48 [ICM,7]
	IPCR	A61K0008-30 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-81 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]
EP 1477153	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61K0007-02 [ICM,7]; A61K0007-48 [ICS,7]; A61K0007-025 [ICS,7]
	IPCR	A61K0008-30 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-81 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]
JP 2004256538	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61K0007-00 [ICM,7]; A61K0007-021 [ICS,7]; A61K0007-025 [ICS,7]; A61K0007-027 [ICS,7]; A61K0007-031 [ICS,7]; A61K0007-032 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
	FTERM	4C083/AC011; 4C083/AC071; 4C083/AC072; 4C083/AC101; 4C083/AC291; 4C083/AC311; 4C083/AC341; 4C083/AC351; 4C083/AC371; 4C083/AD011; 4C083/AD021; 4C083/AD022; 4C083/AD041; 4C083/AD071; 4C083/AD091; 4C083/AD092; 4C083/AD151; 4C083/AD152; 4C083/AD161; 4C083/AD162; 4C083/AD192; 4C083/BB13; 4C083/CC12; 4C083/CC13; 4C083/CC14; 4C083/DD11; 4C083/DD22; 4C083/DD23; 4C083/DD30; 4C083/EE01; 4C083/EE05
CN 1535675	IPCI	A61K0007-48 [ICM,7]; A61K0007-06 [ICS,7]

IPCR A61K0008-30 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*]; A61K0008-72 [I,A]; A61K0008-81 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C\*]; A61Q0001-12 [I,A]  
 KR 2004076808 ECLA A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06  
 IPCI A61K0007-48 [ICM,7]  
 ECLA A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06  
 US 20040234612 IPCI A61K0009-14 [ICM,7]  
 IPCR A61K0008-30 [I,C\*]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-06 [I,A]  
 424/489.000  
 BR 2004001143 NCL A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06  
 ECLA A61K0007-02 [ICM,7]; A61K0007-48 [ICS,7]  
 IPCI A61K0008-30 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*]; A61K0008-72 [I,A]; A61K0008-81 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C\*]; A61Q0001-12 [I,A]

OS MARPAT 141:230308

AB The present invention refers to a composition, in particular cosmetic for the care or make-up of the skin and/or of superficial body growths and/or the lips, including a physiolo. acceptable medium containing (a) at least one liquid fatty phase; (b) polymer particles dispersed in the aforementioned fatty phase; and at least (c) one compound chosen among esters of the polycarboxylic aliphatic or aromatic acids and of aliphatic or aromatic alcs. containing from 1 to 10 carbon atoms, the aforementioned compound being present in a sufficient quantity to plasticize the aforementioned polymere. The invention also refers to a cosmetic for the care or the make-up of the skin and/or superficial body growths and/or lips, including a physiolo. acceptable medium containing (a) at least one liquid fatty phase (b) polymer particles dispersed in the aforementioned fatty phase, and at least (c) one compound having a parameter of solubility  $S_h$  ranging between 5,5 and 11 (J/cm3)1/2. The aforementioned compound is present in a sufficient quantity to plasticize the aforementioned polymere. This composition makes it possible to obtain on the skin, the superficial body growths or the lips a film which does not transfer, of good behavior and which settles easily. The invention also pertains to a process of care or make-up of the skin, superficial body growths and lips using such a composition  
 ST makeup cosmetic polymer plasticizer lipstick  
 IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block; cosmetic composition containing a polymer particle dispersion

and polymer plasticizer)

IT Cosmetics  
Gelation agents  
Molecular weight distribution  
Plasticizers  
Skin  
Stabilizing agents  
(cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Polymers, biological studies  
Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(dicarboxylic, derivs.; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
(eye liners; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Alcohols, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(fatty; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Polymers, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(graft; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
(lipsticks; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
(makeups; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
(mascaras; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(tricarboxylic acids, derivs.; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT 77-89-4, Triethyl acetylcitrate 77-90-7, Tributylacetylcitrate  
77-94-1, Tributyl citrate 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate 85-68-7, Butylbenzyl phthalate 88-99-3D, Phthalic acid, esters 100-42-5D, Styrene, copolymers 103-23-1, Diethyl-2-hexyl adipate 105-99-7, Dibutyl adipate 109-43-3, Dibutyl sebacate 110-15-6D, Succinic acid, esters 110-40-7, Diethyl sebacate 111-20-6D, Sebacic acid, esters 117-81-7 122-62-3 123-25-1, Diethyl succinate 124-04-9D, Adipic acid, esters 131-11-3, Dimethyl phthalate 144-15-0 2915-57-3 6938-94-9, Diisopropyl adipate 7491-02-3, Diisopropyl sebacate 9002-88-4, Polyethylene 9003-27-4D, Polyisobutene, hydrogenation products 17140-33-9, Acetylcitric acid 24817-92-3 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone 27924-99-8, Poly(12-hydroxystearic acid) 31807-55-3, Isododecane 39413-05-3, Isopropyl citrate 58128-22-6, Poly(12-hydroxystearic acid) stearate 60908-77-2, Isohexadecane 82469-79-2 90605-17-7, Isodecyl citrate 105729-79-1, Isoprene-styrene block copolymer 106107-54-4, Butadiene-styrene block copolymer 108388-87-0, Ethylene-propylene-styrene block copolymer 110900-80-6, Butadiene-ethylene-styrene block copolymer 144470-58-6

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing a polymer particle dispersion and  
polymer plasticizer)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Oreal; EP 0987012 A 2000 CAPLUS
- (2) Oreal; EP 1044673 A 2000 CAPLUS
- (3) Oreal; FR 2794970 A 2000 CAPLUS
- (4) Oreal; EP 1163897 A 2001 CAPLUS
- (5) Oreal; EP 1249223 A 2002 CAPLUS

L26 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:700356 CAPLUS

DOCUMENT NUMBER: 141:230306

TITLE: Cosmetic composition comprising a dispersion  
of polymer particles and an acid ester and polyol

INVENTOR(S): Blin, Xavier; Lebre, Caroline

PATENT ASSIGNEE(S): L'Oreal, Fr.

SOURCE: Fr. Demande, 36 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2851467	A1	20040827	FR 2003-50034	20030225
FR 2851467	B1	20060707		
WO 2004078106	A2	20040916	WO 2004-FR342	20040213
WO 2004078106	A3	20050519		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1470811	A1	20041027	EP 2004-290463	20040220
EP 1470811	B1	20060503		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, HR			
AT 324931	T	20060615	AT 2004-290463	20040220
ES 2263116	T3	20061201	ES 2004-290463	20040220
JP 2004256539	A	20040916	JP 2004-48674	20040224
CN 1535672	A	20041013	CN 2004-10032684	20040224
KR 2004076807	A	20040903	KR 2004-12747	20040225
US 20040247552	A1	20041209	US 2004-784948	20040225
BR 2004000982	A	20050111	BR 2004-982	20040225
US 20080107697	A1	20080508	US 2007-4050	20071220
PRIORITY APPLN. INFO.:			FR 2003-50034	A 20030225
			US 2003-452066P	P 20030306
			US 2004-784948	B1 20040225

AN 2004:700356 CAPLUS

DN 141:230306

ED Entered STN: 27 Aug 2004

TI Cosmetic composition comprising a dispersion of polymer  
particles and an acid ester and polyol

IN Blin, Xavier; Lebre, Caroline

PA L'Oreal, Fr.



SO Fr. Demande, 36 pp.  
 CODEN: FRXXBL  
 DT Patent  
 LA French  
 IC ICM A61K007-48  
 ICS A61K007-02  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2851467	A1	20040827	FR 2003-50034	20030225
	FR 2851467	B1	20060707		
	WO 2004078106	A2	20040916	WO 2004-FR342	20040213
	WO 2004078106	A3	20050519		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1470811	A1	20041027	EP 2004-290463	20040220
	EP 1470811	B1	20060503		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, HR			
	AT 324931	T	20060615	AT 2004-290463	20040220
	ES 2263116	T3	20061201	ES 2004-290463	20040220
	JP 2004256539	A	20040916	JP 2004-48674	20040224
	CN 1535672	A	20041013	CN 2004-10032684	20040224
	KR 2004076807	A	20040903	KR 2004-12747	20040225
	US 20040247552	A1	20041209	US 2004-784948	20040225
	BR 2004000982	A	20050111	BR 2004-982	20040225
	US 20080107697	A1	20080508	US 2007-4050	20071220
PRAI	FR 2003-50034	A	20030225		
	US 2003-452066P	P	20030306		
	US 2004-784948	B1	20040225		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2851467	ICM	A61K007-48
	ICS	A61K007-02
	IPCI	A61K0007-48 [ICM,7]; A61K0007-02 [ICS,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-04 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
WO 2004078106	IPCI	A61K [ICM,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*];

		A61K0008-04 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
EP 1470811	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61Q0001-02 [I,C]; A61Q0001-00 [I,C]; A61Q0019-00 [I,C]; A61Q0001-04 [I,A]; A61Q0001-00 [I,A]; A61Q0019-00 [I,A]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61Q0001-02 [I,C]; A61Q0001-04 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-04 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C]; A61Q0001-00 [I,A]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0019-00 [I,C]; A61Q0019-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
AT 324931	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61Q0001-04 [ICS,7]; A61Q0001-02 [ICS,7,C*]; A61Q0001-00 [ICS,7]; A61Q0019-00 [ICS,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-02 [I,C*]; A61K0008-04 [I,C*]; A61K0008-30 [I,C*]; A61K0008-72 [I,C*]; A61K0008-92 [I,C*]; A61Q0001-00 [I,C*]; A61Q0001-02 [I,C*]; A61Q0001-12 [I,C*]; A61Q0005-00 [I,C*]; A61Q0019-00 [I,C*]; C08L0083-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,A]; A61K0008-04 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,A]; A61Q0001-00 [I,A]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,A]; A61Q0005-00 [I,A]; A61Q0019-00 [I,A]; C08L0083-04 [I,A]
ES 2263116	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61Q0001-04 [ICS,4]; A61Q0001-02 [ICS,4,C*]; A61Q0001-00 [ICS,4]; A61Q0019-00 [ICS,4]
	IPCR	A61K0008-00 [I,C*]; A61K0008-02 [I,C*]; A61K0008-04 [I,C*]; A61K0008-30 [I,C*]; A61K0008-72 [I,C*]; A61K0008-92 [I,C*]; A61Q0001-00 [I,C*]; A61Q0001-02 [I,C*]; A61Q0001-12 [I,C*]; A61Q0005-00 [I,C*]; A61Q0019-00 [I,C*]; C08L0083-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,A]; A61K0008-04 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,A]; A61Q0001-00 [I,A]; A61Q0001-02 [I,A]; A61Q0001-04

		[I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,A]; A61Q0005-00 [I,A]; A61Q0019-00 [I,A]; C08L0083-04 [I,A]
JP 2004256539	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61K0007-48 [ICM,7]; A61K0007-00 [ICS,7]; A61K0007-021 [ICS,7]; A61K0007-025 [ICS,7]; A61K0007-031 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-06 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
	FTERM	4C083/AC011; 4C083/AC012; 4C083/AC022; 4C083/AC072; 4C083/AC111; 4C083/AC241; 4C083/AC342; 4C083/AC351; 4C083/AC391; 4C083/AC421; 4C083/AD021; 4C083/AD022; 4C083/AD071; 4C083/AD091; 4C083/AD092; 4C083/AD151; 4C083/AD152; 4C083/AD161; 4C083/AD162; 4C083/AD221; 4C083/AD222; 4C083/BB13; 4C083/BB21; 4C083/CC11; 4C083/CC12; 4C083/CC13; 4C083/CC14; 4C083/CC31; 4C083/DD11; 4C083/DD22; 4C083/DD23; 4C083/DD28; 4C083/DD39; 4C083/EE06; 4C083/EE07; 4C083/EE11; 4C083/EE21
CN 1535672	IPCI	A61K0007-027 [ICM,7]; A61K0007-48 [ICS,7]; A61K0007-06 [ICS,7]; A61K0007-04 [ICS,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-04 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
KR 2004076807	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
	IPCI	A61K0007-48 [ICM,7]
	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
US 20040247552	IPCI	A61K0007-06 [ICM,7]; A61K0007-11 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]
	NCL	424/070.130; 424/401.000
	ECLA	A61K008/37C; A61K008/81K4; A61K008/90; A61Q001/06
BR 2004000982	IPCI	A61K0007-02 [ICM,7]; A61K0007-021 [ICS,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-04 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-90 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A]; A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]
US 20080107697	IPCI	A61K0008-04 [I,A]; A61K0047-32 [I,A]; A61Q0019-00 [I,A]

- AB The present invention refers to a cosmetic composition for the care or the make-up of the skin and/or of the superficial body growths and/or the lips, including a physiologically acceptable medium containing a) at least a fatty liquid phase, b) polymer particles dispersed in the aforementioned fatty phase, and at least c) an ester of at least a carboxylic acid including 1 to 7 atoms of carbons and of a polyol including at least 4 hydroxyl groups, the aforementioned ester having a mol. mass lower than 5000 g/mol. This composition makes it possible to obtain on the skin, superficial body growths or the lips a film which does not transfer, and which settles easily. The invention also pertains to a process of care or make-up of the skin, superficial body growths and lips using such a composition
- ST cosmetic polymer dispersion ester polyol
- IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block, diblock; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block, triblock; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Polyureas  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (copolymers; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Colloids  
 Cosmetics  
 Gelation agents  
 Molecular weight distribution  
 Skin  
 Stabilizing agents  
 (cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Disaccharides  
 Esters, biological studies  
 Monosaccharides  
 Polyesters, biological studies  
 Polymers, biological studies  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Carboxylic acids, biological studies  
 Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Cosmetics  
 (eye liners; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)
- IT Polysiloxanes, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fluoro; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics  
 (lipsticks; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics  
 (makeups; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics  
 (mascaras; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polyesters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyamide-; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polyamides, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyester-; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyhydric; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 57-50-1, Sucrose, biological studies 64-19-7D, Acetic acid, esters 65-85-0D, Benzoic acid, esters 75-98-9 79-09-4D, Propanoic acid, esters 79-31-2 79-31-2D, Isobutanoic acid, esters 87-99-0, Xylitol 107-92-6D, Butanoic acid, esters 109-52-4D, Pentanoic acid, esters 126-13-6 149-32-6, Erythritol 9002-88-4, Polyethylene 9003-01-4D, Polyacrylic acid, copolymers 9003-27-4D, Polyisobutene, hydrogenation products 24980-41-4D, Polycaprolactone, derivs. 25248-42-4D, Polycaprolactone, derivs. 27924-99-8, Poly(12-hydroxystearic acid) 31807-55-3, Isododecane 60908-77-2, Isohexadecane 105729-79-1D, Isoprene-styrene block copolymer, derivs. 106107-54-4D, Butadiene-styrene block copolymer, derivs. 108388-87-0, Ethylene-propylene-styrene block copolymer 110900-80-6, Butadiene-ethylene-styrene block copolymer 144470-58-6  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Oreal; EP 1044673 A 2000 CAPLUS
- (2) Oreal; FR 2794970 A 2000 CAPLUS
- (3) Oreal; EP 1249223 A 2002 CAPLUS
- (4) Oreal; EP 1262164 A 2002 CAPLUS

L26 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:515310 CAPLUS

DOCUMENT NUMBER: 141:76379

TITLE: Lanolin-free cosmetic compositions  
 containing an aromatic ester of a hydroxy fatty acid  
 Filippi, Vanina; Salem, Sophie; Auguste, Frederic  
 L'oreal, Fr.

SOURCE: Fr. Demande, 24 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2848823	A1	20040625	FR 2002-16533	20021223
FR 2848823	B1	20050506		
EP 1433458	A1	20040630	EP 2003-293094	20031210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004203885	A	20040722	JP 2003-425849	20031222
US 20040166130	A1	20040826	US 2003-743084	20031223
PRIORITY APPLN. INFO.:				
			FR 2002-16533	A 20021223
			US 2003-438772P	P 20030109

OTHER SOURCE(S): MARPAT 141:76379

AN 2004:515310 CAPLUS

DN 141:76379

ED Entered STN: 25 Jun 2004

TI Lanolin-free cosmetic compositions containing an aromatic ester of a hydroxy fatty acid

IN Filippi, Vanina; Salem, Sophie; Auguste, Frederic

PA L'oreal, Fr.

SO Fr. Demande, 24 pp.

CODEN: FRXXBL

DT Patent

LA French

IC ICM A61K007-027

ICS A61K007-02; A61K007-06; A61K007-043; A61K007-32; A61K007-42; A61K007-48

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2848823	A1	20040625	FR 2002-16533	20021223
FR 2848823	B1	20050506		
EP 1433458	A1	20040630	EP 2003-293094	20031210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004203885	A	20040722	JP 2003-425849	20031222
US 20040166130	A1	20040826	US 2003-743084	20031223
PRAI FR 2002-16533	A	20021223		
US 2003-438772P	P	20030109		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2848823	ICM	A61K007-027
	ICS	A61K007-02; A61K007-06; A61K007-043; A61K007-32; A61K007-42; A61K007-48
	IPCI	A61K0007-027 [ICM,7]; A61K0007-02 [ICS,7]; A61K0007-06 [ICS,7]; A61K0007-043 [ICS,7]; A61K0007-32 [ICS,7]; A61K0007-42 [ICS,7]; A61K0007-48 [ICS,7]
	IPCR	A61K0008-30 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-30 [I,C*]; A61K0008-33 [I,A]; A61K0008-36 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-81 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C*];

A61Q0003-02 [I,A]; A61Q0005-10 [I,C\*]; A61Q0005-10 [I,A]  
 ECLA A61K008/37; A61Q001/06  
 EP 1433458 IPCI A61K0007-02 [ICM,7]; A61K0007-48 [ICS,7]  
 IPCR A61K0008-30 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-30 [I,C\*]; A61K0008-33 [I,A]; A61K0008-36 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-72 [I,C\*]; A61K0008-72 [I,A]; A61K0008-81 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-96 [I,C\*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0003-00 [I,C\*]; A61Q0003-00 [I,A]; A61Q0003-02 [I,C\*]; A61Q0003-02 [I,A]; A61Q0005-10 [I,C\*]; A61Q0005-10 [I,A]  
 ECLA A61K008/37; A61Q001/06  
 JP 2004203885 IPCI A61K0007-00 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-04 [ICS,7]; A61K0007-13 [ICS,7]  
 FTERM 4C083/AA111; 4C083/AA121; 4C083/AB442; 4C083/AC241; 4C083/AC301; 4C083/AC302; 4C083/AC311; 4C083/AC341; 4C083/AC342; 4C083/AC371; 4C083/AC372; 4C083/AC421; 4C083/AC422; 4C083/AC471; 4C083/AC581; 4C083/AC641; 4C083/AC681; 4C083/AD021; 4C083/AD022; 4C083/AD041; 4C083/AD042; 4C083/AD071; 4C083/AD091; 4C083/AD151; 4C083/AD491; 4C083/AD531; 4C083/AD621; 4C083/AD641; 4C083/AD661; 4C083/BB21; 4C083/BB47; 4C083/BB48; 4C083/CC13; 4C083/CC14; 4C083/CC28; 4C083/CC36; 4C083/DD11; 4C083/DD22; 4C083/EE06; 4C083/EE07; 4C083/EE11; 4C083/EE21  
 US 20040166130 IPCI A61K0007-06 [ICM,7]  
 NCL 424/401.000  
 OS MARPAT 141:76379  
 AB A cosmetic makeup composition free from lanolin or its derivs. contains at least a liquid ester resulting from the esterification of an aromatic acid with a hydroxy fatty acid. This composition makes it possible to give a shining deposit on keratins. The aliphatic hydroxy compound is a hydroxy fatty acid such as ricinoleic acid or hydroxystearic acid. The composition contains a pasty compound having a hardness at 25° ranging 0.001-0.5 MPa, preferably 0.002-0.4 MPa, and whose liquid fraction at 23° lies between 9 and 97% in weight. Thus, a rouge formulation contained Finsolv BCO 22, Elfacos ST9 11, 2-decyltetradecanoic acid triglyceride 20, hydrogenated polyisobutene 10, diisostearyl malate 11, polybutylene 2.5, octacosanyl stearate 5, triglyceride mixture from lauric, myristic, palmitic, and stearic acids 2, polyethylene wax 5, and modified Hectorite 3%, pigments and preservatives and perfume qs.  
 ST cosmetic lanolin free arom ester; hydroxy fatty acid ester  
 cosmetic  
 IT Castor oil  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (benzoate esters, Finsolv BCO; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (emollients; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)  
 IT Sterols  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (esters; lanolin-free cosmetic composition containing aromatic esters of

hydroxy fatty acids)

IT Embryophyta  
Plants  
(exts.; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT Castor oil  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated, esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Fatty acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydroxy, esters, aromatic; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydroxy, esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Cosmetics  
Deodorants (personal)  
Gums and Mucilages  
Hair preparations  
Hardness (mechanical)  
Refractive index  
Viscosity  
(lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Fluoropolymers, biological studies  
Polyesters, biological studies  
Polyolefins  
Polyoxyalkylenes, biological studies  
Polysiloxanes, biological studies  
Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Aloe barbadensis  
Antioxidants  
Dispersing agents  
Dyes  
Gelation agents  
Pigments, nonbiological  
Preservatives  
(lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT Ceramides  
Cocoa butter  
Essential oils  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT Cosmetics  
(lipsticks; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Cosmetics  
(makeups; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Cosmetics  
(mascaras; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Cosmetics  
(nail lacquers; lanolin-free cosmetic composition containing aromatic



- esters of hydroxy fatty acids)
- IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polycarboxylic acid esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)
- IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyhydric, esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)
- IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)
- IT Cosmetics  
 (rouges; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)
- IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sesame; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)
- IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (vegetable; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)
- IT Cosmetics  
 (wrinkle-preventing; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)
- IT 50-21-5D, Lactic acid, esters 57-10-3D, Hexadecanoic acid, esters 57-11-4D, Octadecanoic acid, esters 65-85-0D, Benzoic acid, esters with hydroxy fatty acids 69-72-7D, Salicylic acid, esters with hydroxy fatty acids 77-92-9D, Citric acid, esters 79-10-7D, Acrylic acid, alkyl esters, polymers 79-14-1D, Glycolic acid, esters 79-41-4D, MethAcrylic acid, alkyl esters, polymers 87-69-4D, Tartaric acid, esters 88-12-0D, polymers 89-05-4D, Pyromellitic acid, esters with hydroxy fatty acids 100-21-0D, Terephthalic acid, esters with hydroxy fatty acids 103-82-2D, Phenylacetic acid, esters with hydroxy fatty acids 106-14-9D, 12-Hydroxyoctadecanoic acid, esters 111-14-8D, Heptanoic acid, esters 112-05-0D, Nonanoic acid, esters 112-37-8D, Undecanoic acid, esters 112-85-6D, Docosanoic acid, esters 120-87-6D, 9,10-DiHydroxyoctadecanoic acid, esters 124-07-2D, Octanoic acid, esters 139-44-6, Glyceryl tris(12-hydroxystearate) 141-22-0D, Ricinoleic acid, esters 142-62-1D, Hexanoic acid, esters 143-07-7D, Dodecanoic acid, esters 149-57-5D, 2-Ethylhexanoic acid, esters 151-13-3, Butyl ricinoleate 334-48-5D, Decanoic acid, esters 498-36-2D, Leucic acid, esters 501-52-0D, 3-Phenylpropanoic acid, esters with hydroxy fatty acids 506-12-7D, Heptadecanoic acid, esters 506-13-8D, Juniperic acid, esters 506-30-9D, Eicosanoic acid, esters 528-44-9D, Trimellitic acid, esters with hydroxy fatty acids 544-63-8D, Tetradecanoic acid, esters 621-82-9D, Cinnamic acid, esters with hydroxy fatty acids 629-22-1D,  $\alpha$ -Hydroxyoctadecanoic acid, esters 638-53-9D, Tridecanoic acid, esters 646-30-0D, Nonadecanoic acid, esters 1002-84-2D, Pentadecanoic acid, esters 1323-03-1, Myristyl lactate 2363-71-5D, HenEicosanoic acid, esters 2540-54-7, Glyceryl triricinoleate 4130-35-2, Tridecyl trimellitate 4444-16-0D, esters 6250-72-2D, Isoarachidic acid, esters 6915-15-7D, Malic acid, esters 6949-98-0D, Aleuritic acid, esters 9003-11-6 9003-27-4D, Polyisobutylene, hydrogenated 9003-29-6, Polybutylene 10401-55-5, Cetyl ricinoleate 13893-40-8D, esters 14450-05-6, Pentaerythritol tetrapelargonate 25754-87-4D, 9,12-DiHydroxyoctadecanoic acid, esters 26699-71-8, Glyceryl adipate 29710-25-6, 2-Ethylhexyl 12-hydroxystearate 30399-84-9D, Isostearic acid, esters 37309-58-3, Polydecene 37309-58-3D, Polydecene,

hydrogenated 42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate 59231-36-6, Isodecyl 12-hydroxystearate 61332-02-3, Glyceryl isostearate 65591-14-2, Arachidyl propionate 68796-52-1D, esters 73572-07-3D, esters 77035-99-5, Hexadecene-Vinylpyrrolidone copolymer 81230-05-9, Diisostearyl malate 92232-12-7 93803-89-5 94689-35-7 95268-26-1 112385-10-1, Octyldodecyl lactate 113431-54-2, Triisostearyl citrate 187887-27-0 199277-59-3 220716-31-4 301824-14-6 337975-97-0D, esters 338450-65-0D, esters 338450-66-1D, esters 375375-69-2 710306-06-2 710306-07-3 710320-46-0 710320-47-1 710320-48-2 710320-49-3 710320-50-6D, esters

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT 50-81-7, Vitamin C, biological studies 81-13-0, D-Panthenol 89-78-1, Menthol 97-59-6, Allantoin 98-92-0, Vitamin B3 515-69-5,  $\alpha$ -Bisabolol 1406-18-4, Vitamin E 9006-65-9, Dimethicone 11103-57-4, Vitamin A 56265-06-6, Arginine PCA 63317-82-8, Octacosanyl stearate 76845-99-3, Elfacos ST9 290364-89-5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Johnson and Johnson Consumer Products Inc; EP 0586106 A 1994 CAPLUS
- (2) L'Oreal; EP 1097699 A 2001 CAPLUS
- (3) L'Oreal; EP 1213008 A 2002 CAPLUS
- (4) L'Oreal; EP 1266647 A 2002 CAPLUS

L26 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

IT 88-99-3, Phthalic acid, biological studies 110-15-6, Succinic acid, biological studies 111-20-6, Sebacic acid, biological studies 124-04-9, Adipic acid, biological studies  
RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

RN 88-99-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid (CA INDEX NAME)




RN 110-15-6 CAPLUS

CN Butanedioic acid (CA INDEX NAME)



RN 111-20-6 CAPLUS

CN Decanedioic acid (CA INDEX NAME)



RN 124-04-9 CAPLUS

CN Hexanedioic acid (CA INDEX NAME)

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

ACCESSION NUMBER: 2003:696654 CAPLUS  
DOCUMENT NUMBER: 139:229691  
TITLE: Nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.  
INVENTOR(S): Purpura, Martin; Jaeger, Ralf; Koenig, Harro  
PATENT ASSIGNEE(S): Degussa Bioactives G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003071884	A1	20030904	WO 2003-EP2042	20030227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10208568	A1	20030918	DE 2002-10208568	20020227
AU 2003215607	A1	20030909	AU 2003-215607	20030227
PRIORITY APPLN. INFO.:			DE 2002-10208568	A 20020227
			WO 2003-EP2042	W 20030227

AN 2003:696654 CAPLUS  
DN 139:229691  
ED Entered STN: 05 Sep 2003  
TI Nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.  
IN Purpura, Martin; Jaeger, Ralf; Koenig, Harro  
PA Degussa Bioactives G.m.b.H., Germany  
SO PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
IC ICM A23L001-305  
ICS A61K031-155; A61P003-00; C07C279-14  
CC 17-6 (Food and Feed Chemistry)  
Section cross-reference(s): 18, 62, 63  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003071884	A1	20030904	WO 2003-EP2042	20030227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				

	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
DE	10208568	A1 20030918 DE 2002-10208568 20020227
AU	2003215607	A1 20030909 AU 2003-215607 20030227
PRAI	DE 2002-10208568	A 20020227
WO	2003-EP2042	W 20030227

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003071884	ICM	A23L001-305
	ICS	A61K031-155; A61P003-00; C07C279-14
	IPCI	A23L0001-305 [ICM,7]; A61K0031-155 [ICS,7]; A61P0003-00 [ICS,7]; C07C0279-14 [ICS,7]; C07C0279-00 [ICS,7,C*]
	IPCR	A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; C07C0279-00 [I,C*]; C07C0279-14 [I,A]
	ECLA	A23L001/305A; A61K031/155; A61K031/155+M; A61K045/06; C07C279/14
DE 10208568	IPCI	C07C0279-14 [ICM,7]; C07C0279-00 [ICM,7,C*]; A23L0001-29 [ICS,7]; A23L0001-30 [ICS,7]; A23K0001-16 [ICS,7]; A61K0007-00 [ICS,7]
	IPCR	A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; C07C0279-00 [I,C*]; C07C0279-14 [I,A]
	ECLA	A23L001/305A; A61K031/155; A61K031/155+M; A61K045/06; C07C279/14
AU 2003215607	IPCI	A23L0001-305 [ICM,7]; A61K0031-155 [ICS,7]; A61P0003-00 [ICS,7]; C07C0279-14 [ICS,7]; C07C0279-00 [ICS,7,C*]
	IPCR	A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-155 [I,C*]; A61K0031-155 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; C07C0279-00 [I,C*]; C07C0279-14 [I,A]
AB	The invention relates to a compound containing creatine, an acid component and/or a complexing agent. The invention also relates to methods for producing said compound, to a formulation containing the same, and to the use of the inventive compound	
ST	creatine carboxylate amino acid complexing agent nutritional supplement; nerve muscle health creatine carboxylate amino acid nutritional supplement	
IT	Heterocyclic compounds RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (acid; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)	
IT	Strength (agents for enhancement of muscle; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)	
IT	Sulfonic acids, biological studies RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkanesulfonic; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)	
IT	Sulfonic acids, biological studies RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);	

BIOL (Biological study); USES (Uses)  
 (arenesulfonic; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Food  
 (dietetic; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Exercise  
 (endurance, agents for enhancement of; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (inorg.; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Cytoprotective agents  
 Nervous system agents  
 (neuroprotective agents; nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Coloring materials  
 Cosmetics  
 Dispersing agents  
 Food additives  
 Food functional properties  
 Food preservatives  
 Food texture  
 Human  
 Nervous system stimulants  
 Nutrients  
 Odor and Odorous substances  
 Parting materials  
 Solubilizers  
 Temperature effects, biological  
 Vacuum  
 Wound healing  
 (nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Amino acids, biological studies  
 Carboxylic acids, biological studies  
 Fatty acids, biological studies  
 Lecithins  
 Neurotransmitters  
 Phosphatidylcholines, biological studies  
 Phosphatidylserines  
 Polymers, biological studies  
 Trace elements, biological studies  
 Vitamins  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT Acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (organic; nutritional supplement containing creatine, an acid component and/or  
 a complexing agent for improvement of muscle and nerve health.)

IT Alcohols, biological studies  
 Carbohydrates, biological studies

RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (phosphorylated; nutritional supplement containing creatine, an acid  
 component and/or a complexing agent for improvement of muscle and nerve  
 health.)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (polyunsatd., omega-3; nutritional supplement containing creatine, an acid  
 component and/or a complexing agent for improvement of muscle and nerve  
 health.)

IT Muscle, disease  
 Muscular dystrophy  
 (protective agents for; nutritional supplement containing creatine, an acid  
 component and/or a complexing agent for improvement of muscle and nerve  
 health.)

IT Exercise  
 (sports; nutritional supplement containing creatine, an acid component  
 and/or a complexing agent for improvement of muscle and nerve health.)

IT Amino acids, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (D; nutritional supplement containing creatine, an acid component and/or a  
 complexing agent for improvement of muscle and nerve health.)

IT 50-21-5, Lactic acid, biological studies 50-71-5, Alloxan 51-35-4,  
 4-Hydroxyproline 52-90-4, Cysteine, biological studies 56-12-2,  
 $\gamma$ -Aminobutyric acid, biological studies 56-40-6, Glycine,  
 biological studies 56-41-7, L-Alanine, biological studies 56-45-1,  
 L-Serine, biological studies 56-84-8, L-Aspartic acid, biological  
 studies 56-85-9, L-Glutamine, biological studies 56-86-0, L-Glutamic  
 acid, biological studies 56-87-1, L-Lysine, biological studies  
 56-89-3, Cystine, biological studies 57-00-1, Creatine 57-10-3,  
 Palmitic acid, biological studies 57-11-4, Stearic acid, biological  
 studies 57-50-1, Sucrose, biological studies 58-85-5, Biotin  
 59-67-6, Nicotinic acid, biological studies 60-18-4, L-Tyrosine,  
 biological studies 60-33-3, Linoleic acid, biological studies 61-90-5,  
 L-Leucine, biological studies 62-49-7, Choline 63-68-3, L-Methionine,  
 biological studies 63-91-2, L-Phenylalanine, biological studies  
 64-18-6, Formic acid, biological studies 64-19-7, Acetic  
 acid, biological studies 65-85-0, Benzoic acid, biological  
 studies 67-52-7, Barbituric acid 69-72-7, Salicylic acid, biological  
 studies 69-93-2, Uric acid, biological studies 70-18-8, Glutathione,  
 biological studies 70-26-8, L-Ornithine 70-47-3, L-Asparagine,  
 biological studies 71-00-1, L-Histidine, biological studies 72-18-4,  
 L-Valine, biological studies 73-22-3, L-Tryptophan, biological studies  
 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine,  
 biological studies 75-75-2, Methanesulfonic acid 79-10-7,  
 Acrylic acid, biological studies 79-14-1, Glycolic  
 acid, biological studies 79-31-2, Isobutyric acid 79-41-4, Methacrylic  
 acid, biological studies 79-83-4, Pantothenic acid 83-86-3, Phytic  
 acid 88-14-2, 2-Furancarboxylic acid 88-99-3, Phthalic acid,  
 biological studies 90-64-2, Mandelic acid 97-65-4, Itaconic acid,  
 biological studies 98-11-3, Benzenesulfonic acid, biological studies  
 98-79-3 99-05-8, 3-Aminobenzoic acid 99-06-9, 3-Hydroxybenzoic acid,  
 biological studies 99-96-7, 4-Hydroxybenzoic acid, biological studies  
 100-21-0, Terephthalic acid, biological studies 103-82-2, Phenylacetic  
 acid, biological studies 104-15-4, p-Toluenesulfonic acid, biological  
 studies 104-98-3, Urocanic acid 107-92-6, Butyric acid, biological  
 studies 107-95-9,  $\beta$ -Alanine 107-97-1, N-Methylglycine 108-80-5,  
 Cyanuric acid 110-15-6, Succinic acid, biological studies  
 110-44-1, Sorbic acid 110-94-1, Glutaric acid 111-14-8, Heptanoic acid

111-16-0, Pimelic acid 111-20-6, Sebacic acid, biological studies 112-37-8, Undecanoic acid 118-92-3, 2-Aminobenzoic acid 123-99-9, Azelaic acid, biological studies 124-04-9, Adipic acid, biological studies 124-07-2, Octanoic acid, biological studies 141-78-6, Ethyl acetate, biological studies 141-82-2, Malonic acid, biological studies 142-62-1, Hexanoic acid, biological studies 143-07-7, Dodecanoic acid, biological studies 144-62-7, Oxalic acid, biological studies 147-85-3, L-Proline, biological studies 150-13-0, 4-Aminobenzoic acid 305-84-0, Carnosine 320-77-4, Isocitric acid 328-42-7, Oxalacetic acid 334-48-5, Decanoic acid 463-40-1, Linolenic acid 473-81-4, Glyceric acid 473-90-5, Mesoxalic acid 495-69-2, Hippuric acid 498-24-8, Mesaconic acid 505-48-6, Suberic acid 506-32-1, Arachidonic acid 526-95-4, Gluconic acid 535-75-1, Pipecolic acid 541-48-0,  $\beta$ -Aminobutyric acid 541-50-4, Acetoacetic acid, biological studies 544-63-8, Tetradecanoic acid, biological studies 585-84-2, cis-Aconitic acid 621-82-9, Cinnamic acid, biological studies 1493-13-6, Trifluoromethanesulfonic acid 2033-24-1, Meldrumic acid 2835-81-6,  $\alpha$ -Aminobutyric acid 3724-65-0, Crotonic acid 4023-65-8, trans-Aconitic acid 4350-09-8, 5-Hydroxytryptophan 5329-14-6, Sulfamic acid 6205-14-7, Hydroxycitric acid 6556-12-3, D-Glucuronic acid 7631-86-9, Silica, biological studies 7664-38-2D, Phosphoric acid, esters 9000-07-1, Carrageenan 9003-01-4, Polyacrylic acid 9004-32-4, Carboxymethylcellulose sodium salt 9004-34-6, Cellulose, biological studies 9005-32-7, Alginate acid 10043-35-3, Boric acid, biological studies 11138-66-2, Xanthan 25525-21-7, Glucaric acid 51750-56-2, Propanetricarboxylic acid  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT 592465-35-5  
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT 6020-87-7, Creatine monohydrate  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

IT 592465-34-4P 592465-36-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (nutritional supplement containing creatine, an acid component and/or a complexing agent for improvement of muscle and nerve health.)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Albion Lab; WO 0104128 A 2001
- (2) Anon; SIGMA CATALOGUS: BIOCHEMICALS, ORGANIC COMPOUNDS FOR RESEARCH AND DIAGNOSTIC REAGENTS 1989, P473
- (3) Biosalts, S; WO 0117948 A 2001 CAPLUS
- (4) Biosalts, S; WO 02076931 A 2002 CAPLUS
- (5) Douglas, K; US 2001008641 A1 2001
- (6) Flamma Spa; WO 9604240 A 1996 CAPLUS
- (7) Kenneth, T; US 6211407 B1 2001 CAPLUS
- (8) Sen-Maw, F; US 5994581 A 1999 CAPLUS
- (9) Sueddeutsche, K; DE 19653225 A 1998 CAPLUS
- (10) Sueddeutsche, K; DE 19707694 A 1998 CAPLUS
- (11) Sueddeutsche, K; DE 19929993 A 2001 CAPLUS

L26 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:465762 CAPLUS

DOCUMENT NUMBER: 137:52019

TITLE: Cosmetic compositions structured with a

INVENTOR(S): polymer containing a heteroatom and an organogelator  
 Ferrari, Veronique  
 PATENT ASSIGNEE(S): L'oreal, Fr.  
 SOURCE: PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047628	A1	20020620	WO 2000-IB2028	20001213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001025392	A	20020624	AU 2001-25392	20001213
WO 2002055030	A2	20020718	WO 2001-IB2780	20011212
WO 2002055030	A3	20021205		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2002241186	A1	20020724	AU 2002-241186	20011212
EP 1294342	A2	20030326	EP 2001-988098	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004517856	T	20040617	JP 2002-555767	20011212
CN 1997346	A	20070711	CN 2001-804903	20011212
US 20040223987	A1	20041111	US 2002-129377	20021016
US 20080057011	A1	20080306	US 2007-826997	20070719
PRIORITY APPLN. INFO.:			WO 2000-IB2028	A 20001213
			WO 2001-IB2780	W 20011212
			US 2002-129377	A1 20021016

OTHER SOURCE(S): MARPAT 137:52019  
 AN 2002:465762 CAPLUS  
 DN 137:52019  
 ED Entered STN: 21 Jun 2002  
 TI Cosmetic compositions structured with a polymer containing a heteroatom and an organogelator  
 IN Ferrari, Veronique  
 PA L'oreal, Fr.  
 SO PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K007-027  
 ICS A61K007-031; A61K007-032; A61K007-48  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002047628	A1	20020620	WO 2000-IB2028	20001213
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001025392	A	20020624	AU 2001-25392	20001213
	WO 2002055030	A2	20020718	WO 2001-IB2780	20011212
	WO 2002055030	A3	20021205		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2002241186	A1	20020724	AU 2002-241186	20011212
	EP 1294342	A2	20030326	EP 2001-988098	20011212
PRAI	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004517856	T	20040617	JP 2002-555767	20011212
	CN 1997346	A	20070711	CN 2001-804903	20011212
	US 20040223987	A1	20041111	US 2002-129377	20021016
	US 20080057011	A1	20080306	US 2007-826997	20070719
	WO 2000-IB2028	A	20001213		
	WO 2001-IB2780	W	20011212		
	US 2002-129377	A1	20021016		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002047628	ICM	A61K007-027
	ICS	A61K007-031; A61K007-032; A61K007-48
	IPCI	A61K0007-027 [ICM,7]; A61K0007-031 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-48 [ICS,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-63 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-89 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61K0008-98 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0003-04 [I,C*]; A61Q0003-04 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]

	ECLA	A61K008/42; A61K008/88; A61Q001/02; A61Q001/06; A61Q001/08; A61Q001/10
AU 2001025392	IPCI	A61K0007-027 [ICM,7]; A61K0007-031 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-48 [ICS,7]
WO 2002055030	IPCI	A61K0007-00 [ICM,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-63 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61K0008-98 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0003-04 [I,C*]; A61Q0003-04 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
	ECLA	A61K008/42; A61K008/88; A61Q001/02; A61Q001/06; A61Q001/08; A61Q001/10
AU 2002241186	IPCI	A61K0007-027 [ICS,7]; A61K0007-48 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-72 [I,C*]; A61Q0001-02 [I,C*]; A61K0008-42 [I,A]; A61K0008-88 [I,A]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]
EP 1294342	IPCI	A61K0007-027 [ICM,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-63 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61K0008-98 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0003-04 [I,C*]; A61Q0003-04 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
JP 2004517856	IPCI	A61K0007-00 [ICM]; A61K0007-02 [ICS]; A61K0007-021 [ICS]; A61K0007-027 [ICS]; A61K0007-031 [ICS]; A61K0007-032 [ICS]; A61K0007-035 [ICS]; A61K0007-043 [ICS]; A61K0007-075 [ICS]; A61K0007-08 [ICS]; A61K0007-42 [ICS]
	IPCR	A61K0008-30 [I,C*]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-88 [I,A]; A61Q0001-02 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]
CN 1997346	IPCI	A61K0008-88 [I,A]; A61K0008-72 [I,A]; A61Q0001-06

		[I,A]; A61Q0001-02 [I,C*]; A61Q0019-00 [I,A]
	IPCR	A61K0008-72 [I,C]; A61K0008-72 [I,A]; A61K0008-88 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-63 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61K0008-98 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0003-04 [I,C*]; A61Q0003-04 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
	ECLA	A61K008/42; A61K008/88; A61Q001/02; A61Q001/06; A61Q001/08; A61Q001/10
US 20040223987	IPCI	A61K0007-00 [ICM,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-63 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61K0008-98 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]; A61Q0003-04 [I,C*]; A61Q0003-04 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
	NCL	424/401.000
	ECLA	A61K008/42; A61K008/88; A61Q001/02; A61Q001/06; A61Q001/08; A61Q001/10
US 20080057011	IPCI	A61K0008-88 [I,A]; A61K0008-72 [I,C*]; A61Q0001-04 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-12 [I,A]; A61Q0015-00 [I,A]; A61Q0017-04 [I,A]; A61Q0003-00 [I,A]; A61Q0005-02 [I,A]
	NCL	424/059.000; 424/061.000; 424/064.000; 424/070.110; 424/070.700; 424/078.030; 424/078.350
OS	MARPAT 137:52019	
AB	A physiol. acceptable composition, in particular a cosmetic composition, comprising at least one liquid fatty phase which comprises (i) at least one structuring polymer having a polymer skeleton which comprises at least one hydrocarbon-based repeating unit containing at least one hetero atom; and (ii) at least one organogelator. A polymer skeleton is chosen from polyurethane, polyurea, and polyurethane-polyurea skeletons, and at least one structuring polymer is chosen from polyamide polymers. For example, a lipstick was prepared containing: Phase A - Uniclear 100 18%, GP-1 5%, isononyl	

isononanoate 3.33%, diisostearyl malate 15.33%, and hydrogenated polybutene 2.34%; Phase B - hydrophobic silica 3%, hydrogenated polybutene 25%, and isononyl isononanoate 12%; Phase C - pigments 7% and hydrogenated polybutene 9%. The sticks of lipstick obtained had a diameter of 12.7 mm and a hardness of 204±20 g measured using a "cheese wire". The sticks of lipstick did not break during measurement of the dynamic fragility carried out on 3 sticks.

- ST polymer organogelator liq fatty phase cosmetic; gelation agent  
polymer liq fatty phase lipstick
- IT Fatty acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(C8-26; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Japan wax; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Ph; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Steroids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(amido; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Amides, biological studies  
Steroids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(amino; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Hair  
Lip  
Nail (anatomical)  
Skin  
(anhydrous cosmetic compns. for hair, skin, lips, and nails with liquid fatty phase containing structuring polymers and organogelators)
- IT Amide group  
Amino group  
Amphiphiles  
Antioxidants  
Beeswax  
Carbonyl group  
Carboxyl group  
Coloring materials  
Deodorants  
Hardness (mechanical)  
Hydrogen bond  
Hydrophile-lipophile balance value  
Hydroxyl group  
Odor and Odorous substances  
Ozocerite  
Pearlescent pigments  
Perfumes  
Pi bond  
Pigments, nonbiological  
Preservatives  
Shampoos  
Sunscreens  
Surfactants  
Thickening agents  
(anhydrous cosmetic compns. with liquid fatty phase containing

structuring polymers and organogelators)

IT Alditols  
Alkenes, biological studies  
Amides, biological studies  
Candelilla wax  
Carnauba wax  
Cyclic compounds  
Essential oils  
Esters, biological studies  
Ethers, biological studies  
Fats and Glyceridic oils, biological studies  
Glycerides, biological studies  
Hydrocarbon oils  
Montan wax  
Organometallic compounds  
Paraffin waxes, biological studies  
Polyamides, biological studies  
Polymers, biological studies  
Polyureas  
Polyurethanes, biological studies  
Resins  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(anhydrous cosmetic compns. with liquid fatty phase containing  
structuring polymers and organogelators)

IT Steroids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(azobenzene; anhydrous cosmetic compns. with liquid fatty phase  
containing structuring polymers and organogelators)

IT Functional groups  
(benzyl group; anhydrous cosmetic compns. with liquid fatty phase  
containing structuring polymers and organogelators)

IT Cosmetics  
(blushers; anhydrous cosmetic compns. with liquid fatty phase  
containing structuring polymers and organogelators)

IT Cosmetics  
(concealers; anhydrous cosmetic compns. with liquid fatty phase  
containing structuring polymers and organogelators)

IT Hair preparations  
(conditioners; anhydrous cosmetic compns. with liquid fatty phase  
containing structuring polymers and organogelators)

IT Bond  
(coordinate, with organometallic compds.; anhydrous cosmetic  
compns. with liquid fatty phase containing structuring polymers and  
organogelators)

IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cork fiber; anhydrous cosmetic compns. with liquid fatty phase  
containing structuring polymers and organogelators)

IT Dipeptides  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cyclodipeptides; anhydrous cosmetic compns. with liquid fatty  
phase containing structuring polymers and organogelators)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cyclodisiloxane-, di-Me; anhydrous cosmetic compns. with liquid  
fatty phase containing structuring polymers and organogelators)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(di-Me; anhydrous cosmetic compns. with liquid fatty phase containing  
structuring polymers and organogelators)

IT Amides, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (diamides; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Ketones, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (diketones, copper  $\beta$ -diketonates; anhydrous cosmetic  
 compns. with liquid fatty phase containing structuring polymers and  
 organogelators)

IT Cosmetics  
 (emulsions; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Amino acids, biological studies  
 Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT Cosmetics  
 (eye liners; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Cosmetics  
 (eye shadows; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty, C8-26; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Cosmetics  
 (foundations; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Cosmetics  
 (gels; anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Dyes  
 (hydrophilic and lipophilic; anhydrous cosmetic compns. with  
 liquid fatty phase containing structuring polymers and organogelators)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydroxy, and salts; anhydrous cosmetic compns. with liquid fatty  
 phase containing structuring polymers and organogelators)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydroxy, esters; anhydrous cosmetic compns. with liquid fatty  
 phase containing structuring polymers and organogelators)

IT Cosmetics  
 (lipsticks; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Cosmetics  
 (makeup removers; anhydrous cosmetic compns. with liquid fatty  
 phase containing structuring polymers and organogelators)

IT Cosmetics  
 (mascaras; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Hydrocarbon waxes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Cosmetics

- (nail lacquers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Gelation agents  
(organogelators; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(ouricury; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polycarboxylic, salts, binuclear copper tetracarboxylates; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Cosmetics  
(powders; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Aggregation  
(self-; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(silicone; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Cyclosiloxanes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(siloxane-, di-Me; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Softening (mechanical)  
(softening point, of structuring polymers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Amines, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(steroidal; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Cosmetics  
(sticks; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(sugarane; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Lanolin  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wax; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Metalloporphyrins  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(zinc; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT 50-70-4D, D-Sorbitol, benzylidene derivs. 56-41-7D, L-Alanine, esters 72-18-4D, L-Valine, esters 81-25-4, Cholic acid 83-44-3, Deoxycholic

acid 106-14-9, 12-Hydroxystearic acid 108-93-0D, Cyclohexanol, alkylaryl derivs. 120-12-7D, Anthracene, derivs. 434-13-9, Lithocholic acid 641-81-6, Apocholeic acid 7003-56-7 7664-38-2D, Phosphoric acid, alkyl derivs., alkali metal and aluminum salts 9003-28-5D, Polybutene, hydrogenated 19046-64-1, 1,3:2,4-Di-o-benzylidene-D-sorbitol 19437-01-5 34513-50-3, Octyl dodecanol 42131-25-9, Isononyl isononanoate 61796-47-2 63663-21-8, Coagulan GP 1 81212-19-3, 12-Hydroxyoleic acid 81230-05-9, Diisostearyl malate 114118-81-9 141102-25-2 151493-20-8 189299-29-4 189299-30-7 189301-40-4 212268-42-3 212268-43-4 388609-83-4, Uniclear 100 390747-74-7 390747-75-8 390747-76-9

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT 60-33-3, Linoleic acid, reactions 107-15-3, Ethylenediamine, reactions 112-80-1, Oleic acid, reactions 124-09-4, Hexylenediamine, reactions 463-40-1, Linolenic acid 25265-76-3, Phenylenediamine 44170-50-5, Ethylenetriamine

RL: RCT (Reactant); RACT (Reactant or reagent)  
(anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT 7631-86-9, Fumed silica, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(colloidal, hydrophobic-treated, rheol. agent; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT 112-52-7, Lauryl chloride 29256-90-4, Diaminocyclohexane

RL: RCT (Reactant); RACT (Reactant or reagent)  
(cyclohexanetricarboxamides from; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT 67-52-7D, Barbituric acid, dialkyl derivs.

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(mol. assocns. with 2,4,6-triaminopyrimidine alkyl derivs.; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT 1004-38-2D, 2,4,6-Triaminopyrimidine, alkyl derivs.

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(mol. assocns. with dialkyl barbituric acid; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT 9002-88-4, Polyethylene

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(waxes; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Mark, H; US 3148125 A 1964

(2) Oreal; EP 1068855 A 2001 CAPLUS

(3) Oreal; EP 1068856 A 2001 CAPLUS

(4) Unilever Plc; EP 0797976 A 1997 CAPLUS

L26 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:465759 CAPLUS

DOCUMENT NUMBER: 137:37404

TITLE: Cosmetic compositions containing at least one heteropolymer and at least one gelling agent  
INVENTOR(S): Ferrari, Veronique; Pinzon, Carlos O.; Thau, Paul  
PATENT ASSIGNEE(S): L'oreal S. A., Fr.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: P1XXD2

DOCUMENT TYPE: Patent



LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047624	A1	20020620	WO 2000-IB2006	20001212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2002056544	A	20020624	AU 2002-56544	20001212
WO 2002058643	A1	20020801	WO 2001-IB2840	20011212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002238796	A1	20020806	AU 2002-238796	20011212
BR 2001008381	A	20021029	BR 2001-8381	20011212
EP 1359886	A1	20031112	EP 2001-986956	20011212
EP 1359886	B1	20070328		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517907	T	20040617	JP 2002-558977	20011212
AT 357907	T	20070415	AT 2001-986956	20011212
ES 2283449	T3	20071101	ES 2001-986956	20011212
US 20030185780	A1	20031002	US 2002-203254	20021220
US 7314612	B2	20080101		
PRIORITY APPLN. INFO.:			WO 2000-IB2006	A 20001212
			WO 2001-IB2840	W 20011212

AN 2002:465759 CAPLUS  
 DN 137:37404  
 ED Entered STN: 21 Jun 2002  
 TI Cosmetic compositions containing at least one heteropolymer and at least one gelling agent  
 IN Ferrari, Veronique; Pinzon, Carlos O.; Thau, Paul  
 PA L'oreal S. A., Fr.  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K007-02  
 ICS A61K007-025; A61K007-027  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002047624	A1	20020620	WO 2000-IB2006	20001212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 2002056544 A 20020624 AU 2002-56544 20001212  
 WO 2002058643 A1 20020801 WO 2001-IB2840 20011212  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LB, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2002238796 A1 20020806 AU 2002-238796 20011212  
 BR 2001008381 A 20021029 BR 2001-8381 20011212  
 EP 1359886 A1 20031112 EP 2001-986956 20011212  
 EP 1359886 B1 20070328  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004517907 T 20040617 JP 2002-558977 20011212  
 AT 357907 T 20070415 AT 2001-986956 20011212  
 ES 2283449 T3 20071101 ES 2001-986956 20011212  
 US 20030185780 A1 20031002 US 2002-203254 20021220  
 US 7314612 B2 20080101  
 PRAI WO 2000-1B2006 A 20001212  
 WO 2001-IB2840 W 20011212

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002047624	ICM	A61K007-02
	ICS	A61K007-025; A61K007-027
	IPCI	A61K0007-02 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-027 [ICS,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-06 [I,A]; A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-19 [I,C*]; A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]; A61K008/88; A61Q001/02; A61Q001/06; A61Q017/04
AU 2002056544	IPCI	A61K0007-02 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-027 [ICS,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-06 [I,A]; A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-19 [I,C*];

		A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
WO 2002058643	IPCI	A61K0007-02 [ICM]; A61K0007-025 [ICS]; A61K0007-027 [ICS]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-06 [I,A]; A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-19 [I,C*]; A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
AU 2002238796	IPCI	A61K0007-02 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-027 [ICS,7]
BR 2001008381	IPCI	A61K0007-02 [ICM,7]; A61K0007-025 [ICS,7]; A61K0007-027 [ICS,7]
	IPCR	A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-04 [I,C*]; A61K0008-06 [I,A]; A61K0008-18 [I,C*]; A61K0008-18 [I,A]; A61K0008-19 [I,C*]; A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]
EP 1359886	IPCI	A61K0008-72 [I,C]; A61Q0001-02 [I,C]; A61Q0017-04 [I,C]; A61K0008-88 [I,A]; A61Q0001-02 [I,A];

A61Q0001-06 [I,A]; A61Q0017-04 [I,A]  
 IPCR A61K0008-72 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-04 [I,C\*]; A61K0008-06 [I,A]; A61K0008-18 [I,C\*]; A61K0008-18 [I,A]; A61K0008-19 [I,C\*]; A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C\*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61K0008-96 [I,C\*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C\*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C\*]; A61Q0001-14 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02 [I,A]; A61Q0005-12 [I,C\*]; A61Q0005-12 [I,A]; A61Q0017-04 [I,C\*]; A61Q0017-04 [I,A]  
 JP 2004517907 ECLA A61K008/88; A61Q001/02; A61Q001/06; A61Q017/04  
 IPCI A61K0007-00 [ICM,7]; A61K0007-02 [ICS,7]; A61K0007-027 [ICS,7]; A61K0007-031 [ICS,7]; A61K0007-032 [ICS,7]; A61K0007-035 [ICS,7]; A61K0007-075 [ICS,7]; A61K0007-08 [ICS,7]; A61K0007-42 [ICS,7]  
 IPCR A61K0008-72 [I,C\*]; A61K0008-88 [I,A]; A61Q0001-02 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-06 [I,A]; A61Q0017-04 [I,A]; A61Q0017-04 [I,C\*]  
 FTERM 4C083/AA121; 4C083/AA122; 4C083/AB171; 4C083/AB172; 4C083/AB441; 4C083/AB442; 4C083/AC011; 4C083/AC071; 4C083/AC072; 4C083/AC171; 4C083/AC212; 4C083/AC241; 4C083/AC341; 4C083/AC351; 4C083/AC352; 4C083/AC372; 4C083/AC421; 4C083/AC482; 4C083/AD011; 4C083/AD021; 4C083/AD022; 4C083/AD071; 4C083/AD072; 4C083/AD151; 4C083/AD161; 4C083/AD171; 4C083/AD211; 4C083/AD261; 4C083/AD262; 4C083/AD351; 4C083/AD511; 4C083/BB13; 4C083/BB21; 4C083/BB41; 4C083/BB44; 4C083/BB47; 4C083/BB48; 4C083/BB60; 4C083/CC01; 4C083/CC11; 4C083/CC12; 4C083/CC13; 4C083/CC14; 4C083/CC19; 4C083/CC38; 4C083/CC39; 4C083/DD11; 4C083/DD21; 4C083/DD31; 4C083/DD34; 4C083/DD41; 4C083/EE07  
 AT 357907 IPCI A61K0008-88 [ICS,7]; A61K0008-72 [ICS,7,C\*]; A61Q0001-02 [ICS,7]; A61Q0001-06 [ICS,7]; A61Q0017-04 [ICS,7]  
 IPCR A61K0008-72 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-04 [I,C\*]; A61K0008-06 [I,A]; A61K0008-18 [I,C\*]; A61K0008-18 [I,A]; A61K0008-19 [I,C\*]; A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C\*]; A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61K0008-96 [I,C\*]; A61K0008-96 [I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C\*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C\*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C\*]; A61Q0001-14 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02

ES 2283449 ECLA [I,A]; A61Q0005-12 [I,C\*]; A61Q0005-12 [I,A];  
A61Q0017-04 [I,C\*]; A61Q0017-04 [I,A]  
IPCI A61K0008/88; A61Q001/02; A61Q001/06; A61Q017/04  
A61K0008-72 [I,C]; A61K0008-88 [I,A]; A61Q0001-02  
[I,C]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A];  
A61Q0017-04 [I,C]; A61Q0017-04 [I,A]  
IPCR A61K0008-72 [I,C]; A61K0008-72 [I,A]; A61K0008-88  
[I,A]; A61K0008-00 [I,C\*]; A61K0008-00 [I,A];  
A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-04  
[I,C\*]; A61K0008-06 [I,A]; A61K0008-18 [I,C\*];  
A61K0008-18 [I,A]; A61K0008-19 [I,C\*]; A61K0008-19  
[I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C\*];  
A61K0008-30 [I,A]; A61K0008-31 [I,A]; A61K0008-34  
[I,A]; A61K0008-36 [I,A]; A61K0008-37 [I,A];  
A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-89  
[I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C\*];  
A61K0008-92 [I,A]; A61K0008-96 [I,C\*]; A61K0008-96  
[I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C\*];  
A61Q0001-00 [I,A]; A61Q0001-02 [I,C]; A61Q0001-02  
[I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A];  
A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12  
[I,C\*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C\*];  
A61Q0001-14 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02  
[I,A]; A61Q0005-12 [I,C\*]; A61Q0005-12 [I,A];  
A61Q0017-04 [I,C]; A61Q0017-04 [I,A]  
US 20030185780 ECLA A61K0008/88; A61Q001/02; A61Q001/06; A61Q017/04  
IPCI A61K0031-74 [I,A]  
IPCR A61K0008-72 [I,A]; A61K0008-00 [I,C\*]; A61K0008-00  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A];  
A61K0008-04 [I,C\*]; A61K0008-06 [I,A]; A61K0008-18  
[I,C\*]; A61K0008-18 [I,A]; A61K0008-19 [I,C\*];  
A61K0008-19 [I,A]; A61K0008-25 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-30 [I,A]; A61K0008-31 [I,A];  
A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-37  
[I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A];  
A61K0008-81 [I,A]; A61K0008-88 [I,A]; A61K0008-89  
[I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C\*];  
A61K0008-92 [I,A]; A61K0008-96 [I,C\*]; A61K0008-96  
[I,A]; A61K0008-97 [I,A]; A61Q0001-00 [I,C\*];  
A61Q0001-00 [I,A]; A61Q0001-02 [I,C\*]; A61Q0001-02  
[I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A];  
A61Q0001-08 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12  
[I,C\*]; A61Q0001-12 [I,A]; A61Q0001-14 [I,C\*];  
A61Q0001-14 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02  
[I,A]; A61Q0005-12 [I,C\*]; A61Q0005-12 [I,A];  
A61Q0017-04 [I,C\*]; A61Q0017-04 [I,A]  
NCL 424/070.110; 424/078.080; 424/078.020; 424/400.000;  
424/401.000; 424/486.000  
ECLA A61K0008/88; A61Q001/02; A61Q001/06; A61Q017/04  
AB The invention relates to a physiolog. acceptable compns., in particular a  
cosmetic composition, containing at least one liquid fatty phase comprising  
(i) at least one structuring polymer comprising a polymer skeleton having  
hydrocarbon-based repeating units containing at least one hetero atom, and  
(ii) at least one gelling agent, e.g., silica, Me 12-hydroxystearate,  
12-hydroxystearic acid, or stearylalkonium hectorite, for the fatty phase.  
This composition may be in the form of a stick of lipstick which is stable,  
does not exude and whose application produces a glossy deposit with good  
staying power over time. For example, a lipstick was prepared containing:  
Phase A - Uniclear 100 18%, isononyl isononanoate 5%, diisostearyl malate 17%,  
and hydrogenated polybutene 4%; Phase B - hydrophobic silica (Aerosil

R972) 3%, hydrogenated polybutene 25%, and isononyl isononanoate 12%; and Phase C - pigments 7% and hydrogenated polybutene 9%. The sticks of lipstick obtained had a diameter of 8.1 mm and a hardness of 46±5 g measured using a "cheese wire". The composition was found to have good stability in that there was no exudation at room temperature or at 37°, or 47° for 2 mo.

- ST heteropolymer gelation agent liq fatty phase cosmetic; lipstick  
sunscreens stick heteropolymer gelation agent
- IT Fatty acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(C8-26; cosmetic compns. containing structuring heteropolymer and  
gelling agent in liquid fatty phase)
- IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Japan wax; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)
- IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Ph; cosmetic compns. containing structuring heteropolymer and  
gelling agent in liquid fatty phase)
- IT Polymers, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(block; cosmetic compns. containing structuring heteropolymer and  
gelling agent in liquid fatty phase)
- IT Cosmetics  
(blushes; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)
- IT Hair  
Lip  
Skin  
(compns. for skin, lips, and hair containing structuring heteropolymer and  
gelling agent in liquid fatty phase)
- IT Cosmetics  
(concealers; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)
- IT Cosmetics  
Hair preparations  
(conditioners; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)
- IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cork fiber; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)
- IT Amphiphiles  
Antioxidants  
Beeswax  
Coloring materials  
Gums and Mucilages  
Hair preparations  
Hardness (mechanical)  
Odor and Odorous substances  
Ozocerite  
Pearlescent pigments  
Perfumes  
Pigments, nonbiological  
Preservatives  
Shampoos  
Sunscreens  
Thickening agents  
(cosmetic compns. containing structuring heteropolymer and  
gelling agent in liquid fatty phase)

IT Candelilla wax  
 Carnauba wax  
 Castor oil  
 Clays, biological studies  
 Essential oils  
 Esters, biological studies  
 Ethers, biological studies  
 Fats and Glyceridic oils, biological studies  
 Glycerides, biological studies  
 Hydrocarbon oils  
 Minerals, biological studies  
 Montan wax  
 Paraffin waxes, biological studies  
 Polyamides, biological studies  
 Polyureas  
 Polyurethanes, biological studies  
 Resins  
 Silicone rubber, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cyclsiloxane-, di-Me; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (di-Me; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Amines, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (diamines; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Carboxylic acids, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (dicarboxylic; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
 (emulsions; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Cosmetics  
 (eye liners; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
 (eye shadows; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty, C8-26; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
 (foundations; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
 (gels; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Polymers, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(heteropolymers; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Fats and Glyceridic oils, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Dyes  
(hydrophilic and lipophilic; cosmetic compns. containing  
structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(lipsticks; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Cosmetics  
(makeup removers; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(makeups; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Cosmetics  
(mascaras; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Hydrocarbon waxes, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(microcryst.; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Hydrophile-lipophile balance value  
(of amphiphilic compds.; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(ouricury; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Polyurethanes, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(powders; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(silicone; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Cyclosiloxanes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(siloxane-, di-Me; cosmetic compns. containing structuring  
heteropolymer and gelling agent in liquid fatty phase)

IT Softening (mechanical)  
(softening point, of structuring polymers; cosmetic compns.  
containing structuring heteropolymer and gelling agent in liquid fatty  
phase)

IT Cosmetics  
(solids; cosmetic compns. containing structuring heteropolymer  
and gelling agent in liquid fatty phase)

IT Cosmetics  
(sticks; cosmetic compns. containing structuring heteropolymer



and gelling agent in liquid fatty phase)

IT Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sugarcane; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Amines, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (triamines; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Lanolin  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wax; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT 7631-86-9, Silica, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (colloidal; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT 94-13-3, Propyl Paraben 106-14-9, 12-Hydroxystearic acid 131-57-7,  
 Uvinul M40 141-23-1, Methyl 12-hydroxystearate 5466-77-3, Parsol MCX  
 6197-30-4, Neo Heliopan 303 9003-28-5D, Polybutene, hydrogenated  
 9004-57-3, Ethyl cellulose 11078-30-1D, Galactomannan, alkylated  
 12691-60-0, Stearalkonium hectorite 15763-02-7, Dioctyl Malate  
 36653-82-4, Cetyl Alcohol 42131-25-9, Isononyl isononanoate  
 70356-09-1, Parsol 1789 81230-05-9, Diisostearyl malate 98932-83-3,  
 Macromelt 6212 110736-08-8, Ethyl guar gum 111517-88-5, Propylene  
 Glycol Ricinoleate 136959-34-7, Glucquat 100 388609-83-4, Uniclear 100  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT 60-33-3, Linoleic acid, reactions 107-15-3, Ethylenediamine, reactions  
 112-80-1, Oleic acid, reactions 124-09-4, Hexylenediamine, reactions  
 463-40-1, Linolenic acid 25265-76-3, Phenylenediamine 44170-50-5,  
 Ethylenetriamine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT 9002-88-4, Polyethylene  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (waxes; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Jean-Pierre, A; US 4871536 A 1989 CAPLUS
- (2) Oreal; EP 1068856 A 2001 CAPLUS
- (3) Roulier, V; US 6103249 A 2000 CAPLUS

L26 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:496287 CAPLUS

DOCUMENT NUMBER: 135:97221

TITLE: Oil-based cosmetics containing acrylic  
 silicone graft copolymers, waxes, and branched ester  
 oils

INVENTOR(S): Ishida, Kazuhiro

PATENT ASSIGNEE(S): Kosei Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 2001187712	A	20010710	JP 1999-375616	19991228
PRIORITY APPLN. INFO.:				JP 1999-375616	19991228

AN 2001:496287 CAPLUS  
DN 135:97221

ED Entered STN: 10 Jul 2001  
TI Oil-based cosmetics containing acrylic silicone graft

copolymers, waxes, and branched ester oils  
IN Ishida, Kazuhiro

PA Kosei Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF  
DT Patent

LA Japanese  
IC ICM A61K007-00

ICS A61K007-025  
CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1  
PATENT NO.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001187712	A	20010710	JP 1999-375616	19991228
PRAI	JP 1999-375616		19991228		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

JP 2001187712	ICM	A61K007-00
	ICS	A61K007-025
	IPCI	A61K0007-00 [ICM,7]; A61K0007-025 [ICS,7]
	IPCR	A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-81 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-04 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]; C08L0083-00 [I,C*]; C08L0083-10 [I,A]

AB Cosmetics contain (a) acrylic silicone graft copolymers manufactured from radically polymerizable end group-containing organopolysiloxanes and radically polymerizable monomers mainly containing C16-22 alkyl (meth)acrylate 1-50, (b) oils having m.p. 70-120° 0.1-20, and (c) liquid branched ester oils 5-70 weight%. The cosmetics show long-lasting gross, durability, and shape-retaining property. A lip stick was prepared from polyethylene-polypropylene copolymer 8, candelilla wax 5, KP 561 (stearyl-containing acrylate silicone) 15, hydrogenated Me abietate, cetyl isooctanoate 5, isotridecyl isononanoate 30, polyoxyethylene-Me polysiloxane copolymer 0.5, octyl p-methoxycinnamate 0.5, oxybenzone 0.1, colorants, perfume 0.5, and triisostearic acid diglyceride to 100%.

ST cosmetic oil acrylic silicone graft polymer; branched ester oil wax fat cosmetic

IT Fats and Glyceridic oils, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(Japan wax; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Polysiloxanes, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(acrylic, graft, KP 561, KP 562; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Carboxylic acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)  
 (esters, oils; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Cosmetics  
 (lipsticks; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Hydrocarbon waxes, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (microcryst.; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Candelilla wax  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Cosmetics  
 (oily; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT Acrylic polymers, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (siloxane-, graft; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT 42131-27-1, Isotridecyl isononanoate 69086-01-7 72585-97-8, Cetyl isooctanoate 72812-41-0, Isooctyl myristate  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

IT 9002-88-4, Polyethylene 9010-79-1, Ethylene-propylene copolymer  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (wax; oil-based cosmetics containing acrylic silicone graft copolymers, waxes, and branched ester oils)

L26 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

IT 9002-88-4, Polyethylene  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

RN 9002-88-4 CAPLUS

CN Ethene, homopolymer (CA INDEX NAME)

CM 1

CRN 74-85-1

CMF C2 H4

H<sub>2</sub>C=CH<sub>2</sub>

ACCESSION NUMBER: 1999:708579 CAPLUS  
 DOCUMENT NUMBER: 131:327309  
 TITLE: Lathering surfactants in cleansing compositions for skin and/or hair which also deposits skin care actives  
 INVENTOR(S): Albacarys, Lourdes Dessus; McAtee, David Michael; Deckner, George Endel

PATENT ASSIGNEE(S): Procter + Gamble Co., USA  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 8  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955303	A1	19991104	WO 1999-IB635	19990412
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332948	A1	19991104	CA 1999-2332948	19990412
AU 9929524	A	19991116	AU 1999-29524	19990412
AU 756691	B2	20030123		
BR 9909629	A	20001219	BR 1999-9629	19990412
EP 1071396	A1	20010131	EP 1999-910615	19990412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002512944	T	20020508	JP 2000-545503	19990412
MX 2000PA10386	A	20010731	MX 2000-PA10386	20001023
PRIORITY APPLN. INFO.:			US 1998-83015P	P 19980424
			WO 1999-IB635	W 19990412

AN 1999:708579 CAPLUS  
 DN 131:327309  
 ED Entered STN: 05 Nov 1999  
 TI Lathering surfactants in cleansing compositions for skin and/or hair which also deposits skin care actives  
 IN Albacarys, Lourdes Dessus; McAtee, David Michael; Deckner, George Endel  
 PA Procter + Gamble Co., USA  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC A61K007-50  
 CC 62-1 (Essential Oils and Cosmetics)  
 FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9955303	A1	19991104	WO 1999-IB635	19990412
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332948	A1	19991104	CA 1999-2332948	19990412
AU 9929524	A	19991116	AU 1999-29524	19990412
AU 756691	B2	20030123		
BR 9909629	A	20001219	BR 1999-9629	19990412
EP 1071396	A1	20010131	EP 1999-910615	19990412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002512944	T	20020508	JP 2000-545503	19990412

MX 2000PA10386	A	20010731	MX 2000-PA10386	20001023
PRAI US 1998-83015P	P	19980424		
WO 1999-IB635	W	19990412		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9955303	IC	A61K007-50
	IPCI	A61K0007-50 [ICM]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
CA 2332948	ECLA	A61K008/02C; A61Q005/02; A61Q019/10
	IPCI	A61K0007-50 [ICM,6]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
AU 9929524	ECLA	A61K008/02C; A61Q005/02; A61Q019/10
	IPCI	A61K0007-50 [ICM]
BR 9909629	ECLA	A61K008/02C; A61Q005/02; A61Q019/10
	IPCI	A61K0007-50 [ICM,7]
	IPCR	A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-19 [I,C*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0008-96 [I,C*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*]; A61Q0019-10 [I,A]
EP 1071396	ECLA	A61K008/02C; A61Q005/02; A61Q019/10
	IPCI	A61K0007-50 [ICM,6]

IPCR A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-19 [I,C\*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61K0008-96 [I,C\*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A]; A61K008/02C; A61Q005/02; A61Q019/10  
 JP 2002512944 IPCI A61K0007-50 [ICM,7]; A61K0007-075 [ICS,7]  
 IPCR A61K0008-00 [I,C\*]; A61K0008-00 [I,A]; A61K0008-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-19 [I,C\*]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-35 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-40 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-64 [I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0008-86 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61K0008-92 [I,C\*]; A61K0008-92 [I,A]; A61K0008-96 [I,C\*]; A61K0008-97 [I,A]; A61Q0005-02 [I,C\*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C\*]; A61Q0019-10 [I,A]  
 MX 2000PA10386 IPCI A61K0007-50 [ICM,5]  
 AB The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair and delivering skin care actives onto the skin or hair. These articles are used by the consumer by (i) wetting the dry article with water and (ii) generating lather by subjecting the wetted article to mech. forces, e.g., rubbing. The article comprises a water insol. substrate, a lathering surfactant, and a skin care active component. Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component. E.g., a surfactant phase was prepared by dissolving hydroxyethyl cellulose 0.25% and guar gum 0.25% in water (to 100% by weight) and then adding the following ingredients: Na lauroyl sarcosinate 3.33, cocamidopropyl betaine 3.33, decyl polyglucoside 3.33, Me paraben 0.25, phenoxyethanol 0.3, and benzyl alc. 0.3%, resp.. At the end, a 1.5-2.5 g of the mixture containing water 2.0 g, butylene glycol 2.0 g, and Pr paraben 0.15 g was added to the first mixture and dried. A skin care active phase was prepared containing SEFA cottonate 43.0, petrolatum 10.00, tribehenin 5.0, polyethylene wax 9.0, synthetic beeswax 3.0, C10-30 cholesterol/lanosterol esters 23.0, vitamin A acetate 2.0, and TiO2 5.0 parts. A 0.05-0.75 g of this phase was mixed with the surfactant phase to obtain a skin or hair cleansing composition  
 ST surfactant polymer hair skin cleansing compn  
 IT Acne (acne-preventing agents; cleansing compns. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)  
 IT Alcohols, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (aliphatic; cleansing compns. containing surfactants and polymers for skin

and/or hair which also deposits skin care actives)

IT Glycosides  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (alkyl polyglycosides; cleansing compns. containing surfactants and  
 polymers for skin and/or hair which also deposits skin care actives)

IT Glycosides  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (alkyl; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)

IT Surfactants  
 (amphiphilic; cleansing compns. containing surfactants and polymers for  
 skin and/or hair which also deposits skin care actives)

IT Surfactants  
 (anionic; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)

IT Surfactants  
 (cationic, non-polymeric; cleansing compns. containing surfactants and  
 polymers for skin and/or hair which also deposits skin care actives)

IT Polyelectrolytes  
 (cationic; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)

IT Fibers  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (cellulosic; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)

IT Hair preparations  
 (cleansers; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)

IT Antimicrobial agents  
 Cellulose pulp  
 Cosmetics  
 Cotton fibers  
 Emulsifying agents  
 Flax  
 Fungicides  
 Gums and Mucilages  
 Jute  
 Silk  
 Sponge (Porifera)  
 Sunscreens  
 Suntanning agents  
 Surfactants  
 (cleansing compns. containing surfactants and polymers for skin and/or hair  
 which also deposits skin care actives)

IT Acrylic polymers, biological studies  
 Amine oxides  
 Betaines  
 Fatty acids, biological studies  
 Glycerides, biological studies  
 Keratins  
 Lanolin  
 Monoglycerides  
 Paraffin oils  
 Paraffin waxes, biological studies  
 Petrolatum  
 Polyamides, biological studies  
 Polyester fibers, biological studies  
 Polyesters, biological studies

Polyethers, biological studies  
 Polymers, biological studies  
 Polyolefins  
 Polyoxyalkylenes, biological studies  
 Polysiloxanes, biological studies  
 Polyurethanes, biological studies  
 Rayon, biological studies  
 Silicone rubber, biological studies  
 Sulfobetaines  
 Tocopherols  
 Waxes  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (cleansing compns. containing surfactants and polymers for skin and/or hair  
 which also deposits skin care actives)  
 IT Cosmetics  
 (cleansing; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)  
 IT Cosmetics  
 Hair preparations  
 (conditioners; cleansing compns. containing surfactants and polymers for  
 skin and/or hair which also deposits skin care actives)  
 IT Fatty acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (cottonseed-oil, esters with sucrose; cleansing compns.  
 containing surfactants and polymers for skin and/or hair which also  
 deposits skin care actives)  
 IT Hydrophile-lipophile balance value  
 (emulsifiers; cleansing compns. containing surfactants and polymers for  
 skin and/or hair which also deposits skin care actives)  
 IT Cosmetics  
 (emulsions; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)  
 IT Hydrocarbons, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (epidermal and sebaceous; cleansing compns. containing surfactants and  
 polymers for skin and/or hair which also deposits skin care actives)  
 IT Fatty acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (esters, C10-30, esters with cholesterol and lanosterol; cleansing  
 compns. containing surfactants and polymers for skin and/or hair which also  
 deposits skin care actives)  
 IT Amino acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (esters; cleansing compns. containing surfactants and polymers for skin  
 and/or hair which also deposits skin care actives)  
 IT Alcohols, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (ethoxylated; cleansing compns. containing surfactants and polymers for  
 skin and/or hair which also deposits skin care actives)  
 IT Amides, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (fatty, polyhydroxy; cleansing compns. containing surfactants and polymers  
 for skin and/or hair which also deposits skin care actives)  
 IT Alcohols, biological studies



RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(fatty; cleansing compns. containing surfactants and polymers for skin  
and/or hair which also deposits skin care actives)

IT Cannabis sativa  
(fiber; cleansing compns. containing surfactants and polymers for skin  
and/or hair which also deposits skin care actives)

IT Polyesters, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(hydroxy-terminated; cleansing compns. containing surfactants and polymers  
for skin and/or hair which also deposits skin care actives)

IT Carboxylic acids, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(imino, esters; cleansing compns. containing surfactants and polymers for  
skin and/or hair which also deposits skin care actives)

IT Hardness (mechanical)  
(of skin care actives; cleansing compns. containing surfactants and  
polymers for skin and/or hair which also deposits skin care actives)

IT Antioxidants  
(pharmaceutical; cleansing compns. containing surfactants and polymers for  
skin and/or hair which also deposits skin care actives)

IT Polyolefins  
Polyolefins  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(polyester-; cleansing compns. containing surfactants and polymers for skin  
and/or hair which also deposits skin care actives)

IT Alcohols, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(polyhydric; cleansing compns. containing surfactants and polymers for skin  
and/or hair which also deposits skin care actives)

IT Polyesters, biological studies  
Polyesters, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(polyolefin-; cleansing compns. containing surfactants and polymers for  
skin and/or hair which also deposits skin care actives)

IT Biopolymers  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(protein-derived; cleansing compns. containing surfactants and polymers for  
skin and/or hair which also deposits skin care actives)

IT Cosmetics  
(skin-lightening; cleansing compns. containing surfactants and polymers for  
skin and/or hair which also deposits skin care actives)

IT Sebum  
(stimulators and inhibitors; cleansing compns. containing surfactants and  
polymers for skin and/or hair which also deposits skin care actives)

IT Beeswax  
(synthetic; cleansing compns. containing surfactants and polymers for skin  
and/or hair which also deposits skin care actives)

IT Fats and Glyceridic oils, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
(Uses)  
(vegetable, hydrogenated; cleansing compns. containing surfactants and  
polymers for skin and/or hair which also deposits skin care actives)

IT Fats and Glyceridic oils, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)

(vegetable; cleansing comps. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT Cosmetics

(wrinkle-preventing; cleansing comps. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

IT 50-23-5, biological studies 50-23-7, Hydrocortisone 56-81-5, 1,2,3-Propanetriol, biological studies 56-86-0D, L-Glutamic acid, esters, biological studies 57-13-6, Urea, biological studies 57-50-1D, Sucrose, esters 57-55-6, 1,2-Propanediol, biological studies 57-88-5, Cholesterol, biological studies 58-95-7, Tocopheryl acetate 59-67-6, Nicotinic acid, biological studies 64-19-7D, Acetic acid, esters, biological studies 68-26-8, Retinol 69-72-7, biological studies 79-10-7D, Acrylic acid, esters 79-14-1, biological studies 79-81-2, Retinyl palmitate 81-13-0, Panthenol 83-86-3, Phytic acid 94-13-3, Propyl paraben 96-26-4, Dihydroxyacetone 97-59-6, Allantoin 98-92-0, Niacinamide 99-76-3, Methyl paraben 100-51-6, Benzyl alcohol, biological studies 101-20-2, 3,4,4'-Trichlorocarbanilide 107-35-7D, Taurine, salts 107-36-8D, Isethionic acid, organic esters 107-41-5, Hexylene glycol 107-97-1D, Sarcosine, esters 108-46-3, Resorcinol, biological studies 112-85-6D, Behenic acid, esters 122-99-6, Phenoxyethanol 123-99-9, Nonanedioic acid, biological studies 127-47-9, Vitamin A acetate 131-57-7, Oxybenzone 137-16-6, Sodium lauroyl sarcosinate 302-79-4, trans-Retinoic acid 497-76-7, Arbutin 501-30-4, Kojic acid 555-43-1, Glyceryl tristearate 616-91-1, N-Acetyl-L-cysteine 617-57-2D, 2-Lactic acid, esters 770-35-4, Phenoxyisopropanol 1200-22-2, Lipic acid 2382-43-6 3380-34-5 4472-12-2D, Iminoacetic acid, alkyl esters 5300-03-8, 9-cis-Retinoic acid 5466-77-3, 2-Ethylhexyl p-methoxycinnamate 7664-38-2D, Phosphoric acid, organic esters, biological studies 7664-93-9D, Sulfuric acid, organic esters, biological studies 9000-30-0, Guar gum 9002-88-4, Polyethylene 9002-89-5, Polyvinyl alcohol 9003-07-0, Polypropylene 9003-20-7, Polyvinyl acetate 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-62-0, Hydroxyethyl cellulose 13463-67-7, Titanium dioxide, biological studies 13822-09-8, Benzyl peroxide 15687-27-1, Ibuprofen 18641-57-1, Tribehenin 19223-69-9D, N-cocoacyl derivs. 22204-53-1, Naproxen 25231-21-4 25265-75-2, Butylene glycol 25322-68-3 25322-69-4 26855-43-6, Triglycerol monostearate 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid 29656-68-6, Ethyl hexanediol 41593-38-8, Phenoxypropanol 53240-01-0 81859-24-7, Polyquaternium 10 100895-09-8, Decaglycerol dipalmitate 115515-88-3, Decaglycerol stearate 156028-14-7, Sodium lauroamphoacetate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)

(cleansing comps. containing surfactants and polymers for skin and/or hair which also deposits skin care actives)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Advanced Polymer Systems; WO 9325077 A 1993 CAPLUS
- (2) Kimberly-Clark; EP 0619074 A 1994 CAPLUS
- (3) Richardson-Vicks; EP 0327326 A 1989 CAPLUS
- (4) Unilever; WO 8702379 A 1987 CAPLUS

L26 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:118745 CAPLUS

DOCUMENT NUMBER: 108:118745

ORIGINAL REFERENCE NO.: 108:19365a,19368a

TITLE: Cosmetic makeups containing organosilicone resins, emulsifiers, humectants, and water

INVENTOR(S): Ikeda, Toshihide; Oku, Tsurahiro; Omura, Masanori

PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62238212	A	19871019	JP 1986-82495	19860410
JP 07055885	B	19950614		

PRIORITY APPLN. INFO.: JP 1986-82495 19860410

AN 1988:118745 CAPLUS

DN 108:118745

OREF 108:19365a,19368a

ED Entered SIN: 01 Apr 1988

TI Cosmetic makeups containing organosilicone resins, emulsifiers, humectants, and water

IN Ikeda, Toshihide; Oku, Tsurahiho; Omura, Masanori

PA Shiseido Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K007-021

ICS A61K007-025

CC 62-4 (Essential Oils and Cosmetics)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62238212	A	19871019	JP 1986-82495	19860410
JP 07055885	B	19950614		

PRAI JP 1986-82495 19860410

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 62238212	ICM	A61K007-021
	ICS	A61K007-025
	IPCI	A61K0007-021 [ICM,4]; A61K0007-025 [ICS,4]
	IPCR	A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-44 [I,A]; A61K0008-64 [I,A]; A61K0008-73 [I,A]; A61K0008-89 [I,A]; A61K0008-891 [I,A]; A61Q0001-00 [I,C*]; A61Q0001-00 [I,A]; A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-04 [I,A]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A]; A61Q0001-12 [I,C*]; A61Q0001-12 [I,A]

ECLA A61K007/021; A61K007/025

AB A cosmetic makeup contains an organosilicone resin, emulsifier, humectant, and H<sub>2</sub>O. The organosilicone resin is RnSiO(2-n)/2 where R = C1-6 hydrocarbyl, Ph; n = 1.0-1.8, and it is prepared by hydrolysis of organomonochlorosilane and organotetrachlorosilane (sic) and condensation of the hydrolyzates. The emulsifier is selected from polyoxyalkylene-denatured organopolysiloxane, a clay mineral, organoclay minerals, while the humectant is selected from mucopolysaccharides, reduced sugar alcs., glycols, amino acids, etc. This makeup is safe to use and it holds moisture on the skin for a long period. An eye shadow contained microcryst. wax 5, polyethylene wax 10, liquid paraffin

10, decamethylcyclopentasiloxane 20, an organosilicone resin  
 [Me1.23(C6H5)0.18SiO1.30] 20, polyether-treated di-Me polysiloxanes 0.5,  
 Veegum HV 3, H2O 1, hyaluronic acid 0.1, Ultramarine Blue 4, Red Iron  
 Oxide 1.4, titanium mica 25 parts by weight plus a perfume q.s.

ST makeup silicone emulsifier humectant

IT Clay minerals

RL: BIOL (Biological study)  
 (emulsifiers, for cosmetic makeups)

IT Amino acids, biological studies

Carboxylic acids, biological studies

Collagens, biological studies

Glycols, biological studies

Mucopolysaccharides, biological studies

Polysaccharides, biological studies

Proteins, biological studies

RL: BIOL (Biological study)  
 (humectants, for cosmetic makeups)

IT Siloxanes and Silicones, biological studies

RL: BIOL (Biological study)  
 (Me Ph, cosmetic makeups containing)

IT Carbohydrates and Sugars, biological studies

RL: BIOL (Biological study)  
 (alditols, humectants, for cosmetic makeups)

IT Cosmetics

(makeups, containing organosilicone resins and emulsifiers and humectants)

IT Siloxanes and Silicones, biological studies

RL: BIOL (Biological study)  
 (polyoxyalkylene-, emulsifiers, for cosmetic makeups)

IT Polyoxyalkylenes, biological studies

RL: BIOL (Biological study)  
 (siloxane-, emulsifiers, for cosmetic makeups)

IT 72-17-3, Sodium lactate 107-88-0, 1,3-Butyleneglycol 9004-61-9,  
 Hyaluronic acid 9007-28-7, Chondroitin sulfate

RL: BIOL (Biological study)  
 (humectant, for cosmetic makeups)

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
 24 JUN 2008

L3 432048 S L2

L4 13513 S L3 AND ("ACETIC ACID")

L5 603 S L4 AND SUCROSE

L6 0 S L5 AND ("ACRYLIC COPOLYMER")

L7 39 S L5 AND ("ACRYLIC ACID")

L8 10 S L7 AND ACRYLATE

L9 3 S L8 AND POLYETHYLENE

L10 0 S "POLYETHYLENE WAX"

L11 6753 S "POLYETHYLENE WAX"

L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")

L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
 L14 0 S ("PERFORMACOL 550 ALCOHOL")  
 L15 4 S L11 AND PERFORMACOL  
 L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
 L17 89 S L11 AND PERFUME  
 L18 0 S L17 AND POLYCAPROLACTONE  
 L19 14 S POLYCAPROLACTONE AND LIPSTICK  
 L20 0 S L19 AND ("PIGMENT PASTE")  
 L21 8 S L19 AND PIGMENT?  
 L22 45 S ("KRATON G1701")  
 L23 1 S ("550 ALCOHOL")  
 L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA  
 L25 37 S L24 AND ("CARBOXYLIC ACID?")  
 L26 16 S L25 AND COSMETIC

=> dup rem 126 123  
 PROCESSING COMPLETED FOR L26  
 PROCESSING COMPLETED FOR L23  
 L27 17 DUP REM L26 L23 (0 DUPLICATES REMOVED)  
 ANSWERS '1-17' FROM FILE CAPLUS

=> d 123 1 hitstr ibib all

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on SIN  
 ACCESSION NUMBER: 1997:456045 CAPLUS  
 DOCUMENT NUMBER: 127:137191  
 ORIGINAL REFERENCE NO.: 127:26447a,26450a  
 TITLE: Diesters of polymerized fatty acids, their  
 preparation, their use in formulating hot-melt inks,  
 and printing  
 INVENTOR(S): Pavlin, Mark S.  
 PATENT ASSIGNEE(S): Union Camp Corp., USA  
 SOURCE: U.S., 7 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5645632	A	19970708	US 1996-601208	19960214
CA 2246428	A1	19970821	CA 1997-2246428	19970127
CA 2246428	C	20031111		
WO 9730129	A1	19970821	WO 1997-US1483	19970127
W: AU, CA, JP, KR, MX, SG				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9718476	A	19970902	AU 1997-18476	19970127
AU 705370	B2	19990520		
EP 880563	A1	19981202	EP 1997-904092	19970127
EP 880563	B1	20030521		
R: BE, DE, FR, GB, IT, SE				
JP 2000505446	T	20000509	JP 1997-529360	19970127
JP 4005635	B2	20071107		
JP 2007070637	A	20070322	JP 2006-284376	20061018
PRIORITY APPLN. INFO.:				
			US 1996-601208	A 19960214
			JP 1997-529360	A3 19970127
			WO 1997-US1483	W 19970127

AN 1997:456045 CAPLUS  
 DN 127:137191  
 OREF 127:26447a,26450a

ED Entered STN: 21 Jul 1997  
 TI Diesters of polymerized fatty acids, their preparation, their use in  
 formulating hot-melt inks, and printing  
 IN Pavlin, Mark S.  
 PA Union Camp Corp., USA  
 SO U.S., 7 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM C09D011-02  
 INCL 106031290  
 CC 42-12 (Coatings, Inks, and Related Products)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5645632	A	19970708	US 1996-601208	19960214
	CA 2246428	A1	19970821	CA 1997-2246428	19970127
	CA 2246428	C	20031111		
	WO 9730129	A1	19970821	WO 1997-US1483	19970127
	W: AU, CA, JP, KR, MX, SG				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9718476	A	19970902	AU 1997-18476	19970127
	AU 705370	B2	19990520		
	EP 880563	A1	19981202	EP 1997-904092	19970127
	EP 880563	B1	20030521		
	R: BE, DE, FR, GB, IT, SE				
	JP 2000505446	T	20000509	JP 1997-529360	19970127
	JP 4005635	B2	20071107		
	JP 2007070637	A	20070322	JP 2006-284376	20061018
PRAI	US 1996-601208	A	19960214		
	JP 1997-529360	A3	19970127		
	WO 1997-US1483	W	19970127		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5645632	ICM	C09D011-02
	INCL	106031290
	IPCI	C09D0011-02 [ICM,6]
	IPCR	B41J0002-01 [I,C*]; B41J0002-01 [I,A]; C07C0069-00 [I,C*]; C07C0069-34 [I,A]; C07C0069-602 [I,A]; C09D0011-00 [I,C*]; C09D0011-00 [I,A]; C09D0011-02 [I,C*]; C09D0011-02 [I,A]; C09D0011-10 [I,C*]; C09D0011-10 [I,A]
	NCL	106/031.290; 106/031.610; 347/099.000; 347/100.000; 554/121.000
CA 2246428	ECLA	C09D011/00C4; C09D011/02
	IPCI	C07C0069-52 [ICM,6]; C07C0069-00 [ICM,6,C*]; C09D0011-02 [ICS,6]; C09D0011-06 [ICS,6]; C07C0233-38 [ICS,6]; C07C0233-00 [ICS,6,C*]
	IPCR	B41J0002-01 [I,C*]; B41J0002-01 [I,A]; C07C0069-00 [I,C*]; C07C0069-34 [I,A]; C07C0069-602 [I,A]; C09D0011-00 [I,C*]; C09D0011-00 [I,A]; C09D0011-02 [I,C*]; C09D0011-02 [I,A]; C09D0011-10 [I,C*]; C09D0011-10 [I,A]
WO 9730129	IPCI	C09D0011-02 [ICM,6]; C09D0011-06 [ICS,6]
	IPCR	B41J0002-01 [I,C*]; B41J0002-01 [I,A]; C07C0069-00 [I,C*]; C07C0069-34 [I,A]; C07C0069-602 [I,A]; C09D0011-00 [I,C*]; C09D0011-00 [I,A]; C09D0011-02 [I,C*]; C09D0011-02 [I,A]; C09D0011-10 [I,C*]; C09D0011-10 [I,A]
	ECLA	C09D011/00C4; C09D011/02

AU 9718476 IPCI C09D0011-02 [ICM,6]; C09D0011-06 [ICS,6]  
 IPCR B41J0002-01 [I,C\*]; B41J0002-01 [I,A]; C07C0069-00 [I,C\*]; C07C0069-34 [I,A]; C07C0069-602 [I,A]; C09D0011-00 [I,C\*]; C09D0011-00 [I,A]; C09D0011-02 [I,C\*]; C09D0011-02 [I,A]; C09D0011-10 [I,C\*]; C09D0011-10 [I,A]

EP 880563 IPCI C09D0011-02 [ICM,6]; C09D0011-06 [ICS,6]  
 IPCR B41J0002-01 [I,C\*]; B41J0002-01 [I,A]; C07C0069-00 [I,C\*]; C07C0069-34 [I,A]; C07C0069-602 [I,A]; C09D0011-00 [I,C\*]; C09D0011-00 [I,A]; C09D0011-02 [I,C\*]; C09D0011-02 [I,A]; C09D0011-10 [I,C\*]; C09D0011-10 [I,A]

JP 2000505446 IPCI C07C0069-34 [I,A]; B41J0002-01 [I,A]; C07C0069-602 [I,A]; C07C0069-00 [I,C\*]; C09D0011-10 [I,A]  
 IPCR B41J0002-01 [I,C\*]; B41J0002-01 [I,A]; C07C0069-00 [I,C\*]; C07C0069-34 [I,A]; C07C0069-602 [I,A]; C09D0011-00 [I,C\*]; C09D0011-00 [I,A]; C09D0011-02 [I,C\*]; C09D0011-02 [I,A]; C09D0011-10 [I,C\*]; C09D0011-10 [I,A]

JP 2007070637 IPCI C09D0011-00 [I,A]; B41J0002-01 [I,A]; B41M0005-00 [I,A]  
 IPCR C09D0011-00 [I,C]; C09D0011-00 [I,A]; B41J0002-01 [I,C]; B41J0002-01 [I,A]; B41M0005-00 [I,C]; B41M0005-00 [I,A]  
 FTERM 2C056/EA04; 2C056/FC01; 2H186/FB05; 2H186/FB29; 2H186/FB30; 4J039/AD23; 4J039/BC07; 4J039/BC19; 4J039/BC20; 4J039/BC34; 4J039/CA09; 4J039/EA46; 4J039/GA03; 4J039/GA24

AB Title solid diesters for hot-melt inks (jet, gravure or intaglio printing) are prepared by reaction of polymerized fatty acid with long chain primary monohydric alcs., optionally in the presence of diamine. The esterification of liquid polymerized fatty acid with monohydric alc. (long chain alcs. have .gtorsim.20 C atoms, and preferably  $\geq 24$  C atoms) provides a diester that is solid at room temperature and has a m.p. .ltorsim.150°. Heating 21.4 g EMPOL 1008 dimer acid and 50.7 g UNILIN 550 alc. to 220°-225° and holding for 3 h yielded a hard, brittle, off-white, tack-free, nearly opaque solid having a softening point 99° and a viscosity (130°) 21 cP.

ST fatty acid polymer long chain monol; vehicle diester hot melt ink; solid diester hot melt ink; jet printing hot melt ink; intaglio printing hot melt ink; gravure printing hot melt ink; amide diester hot melt ink

IT Esters, uses  
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
 (diesters, long chain  $\geq 20$  C alcs. diesters of polymerized fatty acids; diesters of polymerized fatty acids for hot-melt ink vehicles)

IT Fatty acids, uses  
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
 (esters, polymers, adduct with long chain  $\geq 20$  C alcs.; diesters of polymerized fatty acids for hot-melt ink vehicles)

IT Inks  
 (hot-melt; diesters of polymerized fatty acids for hot-melt ink vehicles)

IT 124-09-4DP, Hexamethylene diamine, reaction products with esters of polymerized fatty acid and long chain alcs. 661-19-8DP, 1-Docosanol, reaction products with polymerized fatty acid and diamine 113096-41-6DP, UNILIN 550, ester with polymerized fatty acid 150872-29-0DP, EMPOL 1008, ester with long chain alcs. 165169-28-8DP, UNILIN 350, ester with polymerized fatty acid  
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(diesters of polymerized fatty acids for hot-melt ink vehicles)

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

L3 432048 S L2  
L4 13513 S L3 AND ("ACETIC ACID")  
L5 603 S L4 AND SUCROSE  
L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
L7 39 S L5 AND ("ACRYLIC ACID")  
L8 10 S L7 AND ACRYLATE  
L9 3 S L8 AND POLYETHYLENE  
L10 0 S "POLYETHYLEN WAX"  
L11 6753 S "POLYETHYLENE WAX"  
L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")  
L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
L14 0 S ("PERFORMACOL 550 ALCOHOL")  
L15 4 S L11 AND PERFORMACOL  
L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
L17 89 S L11 AND PERFUME  
L18 0 S L17 AND POLYCAPROLACTONE  
L19 14 S POLYCAPROLACTONE AND LIPSTICK  
L20 0 S L19 AND ("PIGMENT PASTE")  
L21 8 S L19 AND PIGMENT?  
L22 45 S ("KRATON G1701")  
L23 1 S ("550 ALCOHOL")  
L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA  
L25 37 S L24 AND ("CARBOXYLIC ACID?")  
L26 16 S L25 AND COSMETIC  
L27 17 DUP REM L26 L23 (0 DUPLICATES REMOVED)

=> dup rem l26 l22

PROCESSING COMPLETED FOR L26

PROCESSING COMPLETED FOR L22

L28 59 DUP REM L26 L22 (2 DUPLICATES REMOVED)  
ANSWERS '1-59' FROM FILE CAPLUS

=> d scan l19

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
CC 62-4 (Essential Oils and Cosmetics)  
TI Cosmetic treatment with nitric oxide, device comprising nitric oxide  
eluting polymer and manufacturing method therefor  
ST skin cosmetic treatment nitric oxide device eluting polymer manuf  
IT Syringes  
(-type device; cosmetic treatment with nitric oxide, device comprising  
nitric oxide eluting polymer and manufacturing method therefor)  
IT Functional groups  
(O-nitrosylated group; cosmetic treatment with nitric oxide, device



comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Functional groups  
(S-nitrosylated group; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Absorbents  
(agent; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Skin, disease  
(aging, wrinkles; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Polysaccharides, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(backbone; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Infection  
(bacterial; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Proteins  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(based polymer; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Polymers, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(biodegradable; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Human  
(body; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Sarcoma  
(caposis; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Skin  
(cellulite; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Contraceptives  
(condoms; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Anti-infective agents  
Arm  
Bile  
Blood  
Cations  
Coating materials  
Cotton fibers  
Dermatitis  
Foams  
Foot  
Hand  
Head and Neck  
Hydrogels  
Latex  
Lymph  
Medical goods  
Microcapsules  
Microspheres  
Nanoparticles  
Odor and Odorous substances  
Proton transfer

Psoriasis  
 Reproductive system  
 Stomach  
 Wart  
 (cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Amino acids, biological studies  
 Carbonates, biological studies  
 Fatty acids, biological studies  
 Fibers  
 Gelatins, biological studies  
 Peptides, biological studies  
 Phenols, biological studies  
 Phosphates, biological studies  
 Polyamides, biological studies  
 Polycarbonates, biological studies  
 Polyesters, biological studies  
 Polyethers, biological studies  
 Polyolefins  
 Polyoxyalkylenes, biological studies  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Cosmetics  
 (creams; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Functional groups  
 (diazoniumdiolate group; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Head and Neck  
 (face; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Cosmetics  
 Drug delivery systems  
 (gels; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Infection  
 Skin, disease  
 (herpes; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Clothing  
 (hosiery; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Drug delivery systems  
 (hydrogels; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Polyesters, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (hydroxycarboxylic acid-based; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Polycarbonates, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (imino-, polyamide-; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Cosmetics  
 (lipsticks, -like device; cosmetic treatment with nitric

oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Cosmetics  
Drug delivery systems  
(lotions; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Skin, disease  
(mollusks; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Drug delivery systems  
(ointments, creams; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Drug delivery systems  
(ointments; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Medical goods  
(pads; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Polymers, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(polyacrylate, absorbent agent selected from; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Alcohols, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(polyhydric; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Polyamides, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(polyiminocarbonate-; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Sponges (artificial)  
(proton donor; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Skin, disease  
(scar, reduction; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Amines, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(secondary; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Casting process  
(spin; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Fibers  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(spinning, electro spinning, air spinning, gas spinning, wet spinning, dry spinning, gel spinning; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Materials  
(tapes; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Leg  
(thigh; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Infection  
(viral; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT Cosmetics  
(wrinkle-preventing; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT 9004-34-6D, Cellulose, microcryst., biological studies 25322-68-3, Polyethylene oxide  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(absorbent agent selected from; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT 64-17-5, Ethanol, biological studies 64-19-7, Acetic acid, biological studies 67-56-1, Methanol, biological studies 71-23-8, Propanol, biological studies 71-36-3, Butanol, biological studies 71-41-0, Pentanol, biological studies 79-09-4, Propanoic acid, biological studies 107-92-6, Butanoic acid, biological studies 110-15-6, Butanedioic acid, biological studies 111-27-3, Hexanol, biological studies 1321-67-1, Naphthol 9002-86-2, Poly(vinyl chloride) 9002-88-4, Polyethylene 9002-89-5, Polyvinylalcohol 9003-01-4, Poly(acrylic acid) 9003-07-0, Polypropylene 9003-20-7, Polyvinylacetate 9003-53-6, Polystyrene 9004-32-4, Carboxy methyl cellulose 9005-25-8, Starch, biological studies 9012-76-4, Chitosan 9012-76-4D, Chitosan, aminated 9016-00-6, Polydimethylsiloxane 9032-36-4, PEIcellulose 14127-61-8, Ca<sup>2+</sup>, biological studies 17341-24-1, biological studies 17341-25-2, biological studies 22537-20-8, Be<sup>2+</sup>, biological studies 22537-22-0, Mg<sup>2+</sup>, biological studies 22537-39-9, Sr<sup>2+</sup>, biological studies 22541-12-4, Ba<sup>2+</sup>, biological studies 24203-36-9, biological studies 24980-41-4, Polycaprolactone 25014-41-9, Polyacrylonitrile 25248-42-4, Polycaprolactone 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediy)] 26100-51-6, Polylacticacid 26913-06-4, Poly[imino(1,2-ethanediy)] 31900-57-9, Polydimethylsiloxane 32290-92-9, Polypropyleneimine 37293-51-9, Amino dextran 89014-29-9, Polybutyleneimine 210106-27-7, Format 223594-45-4  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT 10102-43-9, Nitric oxide, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(eluting polymer; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT 9004-34-6, Cellulose, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mino; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

IT 7440-22-4, Silver, biological studies  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polymer comprising; cosmetic treatment with nitric oxide, device comprising nitric oxide eluting polymer and manufacturing method therefor)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):14

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
IC ICM A61K007-027  
ICS A61K007-02; A61K007-48; A61K007-021  
CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing a semicrystalline polymer and a dimer-diol ester

ST cosmetic lipstick carboxylic acid semicryst polymer dimer diol ester

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (avocado; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Sunscreens  
 (cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Acrylic polymers, biological studies  
 Carboxylic acids, biological studies  
 Castor oil  
 Cottonseed oil  
 Fatty acids, biological studies  
 Jojoba oil  
 Olive oil  
 Palm oil  
 Soybean oil  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Cosmetics  
 (eye liners; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
 Rosin  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (macadamia nut; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Cosmetics  
 (mascaras; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (mink; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (orange, sour; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wheat germ; cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT 25248-42-4, Polycaprolactone sru  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (CAPA 1215; cosmetic composition containing semicryst. polymer and dimer-diol ester)

ester)

IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 59-67-6, Nicotinic acid, biological studies 60-33-3, Linoleic acid, biological studies 65-85-0, Benzoic acid, biological studies 69-72-7, Salicylic acid, biological studies 75-98-9, Pivalic acid 79-31-2, Isobutanoic acid 98-79-3, Pyrrolidonecarboxylic acid 98-89-5, Cyclohexanoic acid 99-96-7, biological studies 106-14-9, 12-Hydroxyoctadecanoic acid 107-92-6, Butanoic acid, biological studies 109-52-4, Pentanoic acid, biological studies 111-14-8, Heptanoic acid 112-05-0, Nonanoic acid 112-37-8, Undecanoic acid 112-79-8, Elaidinic acid 112-80-1, Oleic acid, biological studies 112-85-6, Docosanoic acid 112-86-7, Erucic acid 124-07-2, Octanoic acid, biological studies 142-62-1, Hexanoic acid, biological studies 143-07-7, Dodecanoic acid, biological studies 149-57-5, 2-Ethylhexanoic acid 149-91-7, Gallic acid, biological studies 150-13-0, p-Aminobenzoic acid 334-48-5, Decanoic acid 373-49-9, Palmitoleic acid 503-74-2, Isopentanoic acid 506-12-7, Heptadecanoic acid 506-30-9, Eicosanoic acid 506-32-1, Arachidonic acid 506-33-2, Brassidic acid 514-10-3, Abietic acid 514-10-3D, Abietic acid, hydrogenated 544-57-0, 2-Hydroxytetradecanoic acid 544-63-8, Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid 557-59-5, Tetracosanoic acid 600-15-7, 2-Hydroxybutanoic acid 617-31-2, 2-Hydroxypentanoic acid 617-73-2, 2-Hydroxyoctanoic acid 621-82-9, Cinnamic acid, biological studies 629-22-1, 2-Hydroxyoctadecanoic acid 636-69-1, 2-Hydroxyheptanoic acid 638-53-9, Tridecanoic acid 646-07-1, Isohexanoic acid 646-30-0, Nonadecanoic acid 764-67-0, 2-Hydroxyhexadecanoic acid 830-09-1, p-Methoxycinnamic acid 1002-84-2, Pentadecanoic acid 1330-19-4, Isoheptanoic acid 1333-28-4, Undecenoic acid 2507-55-3, 2-Hydroxytetradecanoic acid 2984-55-6, 2-Hydroxydodecanoic acid 5393-81-7, 2-Hydroxydecanoic acid 6064-63-7, 2-Hydroxyhexanoic acid 6144-28-1, Dilinoleic acid 7089-43-2, Linderic acid 13980-14-8, 2-Hydroxydocosanoic acid 15896-36-3, 2-Hydroxynonanoic acid 16742-48-6, 2-Hydroxyeicosanoic acid 19790-86-4, 2-Hydroxyundecanoic acid 19790-87-5, 2-Hydroxy-tridecanoic acid 24980-41-4, Polycaprolactone 25022-78-0, 2-Hydroxyheptadecanoic acid 25103-52-0, Isooctanoic acid 25167-62-8, Docosahexaenoic acid 25354-97-6, 2-Hexyldecanoic acid 25378-27-2, Eicosapentaenoic acid 25448-24-2, Isotridecanoic acid 25986-77-0, Intelimer IPA 13-1 26403-17-8, Isodecanoic acid 26896-18-4, Isononanoic acid 27610-92-0, 2-Butyloctanoic acid 29204-02-2, Gadoleic acid 29385-00-0, Isododecanoic acid 32844-67-0, Isohexadecanoic acid 40596-46-1, 2-Octyldodecanoic acid 50973-09-6, Isopentadecanoic acid 57683-20-2, Isundecanoic acid 65437-21-0, Isotetradecanoic acid 73756-37-3, 2-DoDecylhexadecanoic acid 73756-39-5, 2-Tetradecyloctadecanoic acid 77035-98-4, Eicosene-vinyl pyrrolidone copolymer 82430-11-3, Dimethylolanoic acid 89547-15-9, 2-Hexadecyloctadecanoic acid 93361-63-8, 2-Hydroxynonadecanoic acid 93778-52-0, 2-Decyltetradecanoic acid 98989-29-8, Isoeicosanoic acid 512778-00-6, Lupisan DD-DA 5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing semicryst. polymer and dimer-diol ester)

IT 694523-05-2D, hydrogenated, block, diblock

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(isoprene-styrene rubber; cosmetic composition containing semicryst. polymer and dimer-diol ester)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC A61K007-027

ICS A61K007-02; A61K007-48; A61K007-032; A61K007-025; A61K007-031;  
A61K007-043

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing an ester and a film-forming agent

ST cosmetic lipstick ester film forming agent

IT Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (acrylates; cosmetic composition containing ester and film-forming agent)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (avocado; cosmetic composition containing ester and film-forming agent)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block, diblock; cosmetic composition containing ester and film-forming agent)

IT Sunscreens  
 (cosmetic composition containing ester and film-forming agent)

IT Acrylic polymers, biological studies  
 Carboxylic acids, biological studies  
 Castor oil  
 Cottonseed oil  
 Fatty acids, biological studies  
 Fluoropolymers, biological studies  
 Jojoba oil  
 Olive oil  
 Palm oil  
 Polyesters, biological studies  
 Polysiloxanes, biological studies  
 Polyureas  
 Polyurethanes, biological studies  
 Soybean oil  
 Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing ester and film-forming agent)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; cosmetic composition containing ester and film-forming agent)

IT Cosmetics  
 (eye liners; cosmetic composition containing ester and film-forming agent)

IT Fats and Glyceridic oils, biological studies  
 Rosin  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; cosmetic composition containing ester and film-forming agent)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (macadamia nut; cosmetic composition containing ester and film-forming agent)

IT Cosmetics  
 (mascaras; cosmetic composition containing ester and film-forming agent)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (mink; cosmetic composition containing ester and film-forming agent)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (orange, sweet; cosmetic composition containing ester and film-forming agent)

IT Polyesters, biological studies  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyamide-; cosmetic composition containing ester and film-forming agent)

IT Polyamides, biological studies  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(polyester-; cosmetic composition containing ester and film-forming agent)

IT Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyether-; cosmetic composition containing ester and film-forming agent)

IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; cosmetic composition containing ester and film-forming agent)

IT Polyamides, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polysiloxane-; cosmetic composition containing ester and film-forming agent)

IT Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyurea-; cosmetic composition containing ester and film-forming agent)

IT Polyureas  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyurethane-; cosmetic composition containing ester and film-forming agent)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wheat germ; cosmetic composition containing ester and film-forming agent)

IT 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (CAPA 1215; cosmetic composition containing ester and film-forming agent)

IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 59-67-6, Nicotinic acid, biological studies 60-33-3, Linoleic acid, biological studies 65-85-0, Benzoic acid, biological studies 69-72-7, Salicylic acid, biological studies 75-98-9, Pivalic acid 79-31-2, Isobutanoic acid 98-79-3, Pyrrolidonecarboxylic acid 98-89-5, Cyclohexanoic acid 99-96-7, biological studies 106-14-9, 12-Hydroxyoctadecanoic acid 107-92-6, Butanoic acid, biological studies 109-52-4, Pentanoic acid, biological studies 111-14-8, Heptanoic acid 112-05-0, Nonanoic acid 112-37-8, Undecanoic acid 112-79-8, Elaidinic acid 112-80-1, Oleic acid, biological studies 112-85-6, Docosanoic acid 112-86-7, Erucic acid 124-07-2, Octanoic acid, biological studies 142-62-1, Hexanoic acid, biological studies 143-07-7, Dodecanoic acid, biological studies 149-57-5, 2-Ethylhexanoic acid 149-91-7, Gallic acid, biological studies 150-13-0, p-Aminobenzoic acid 334-48-5, Decanoic acid 373-49-9, Palmitoleic acid 503-74-2, Isopentanoic acid 506-12-7, Heptadecanoic acid 506-30-9, Eicosanoic acid 506-32-1, Arachidonic acid 506-33-2, Brassidic acid 514-10-3, Abietic acid 514-10-3D, Abietic acid, hydrogenated 544-57-0, 2-Hydroxytetradecanoic acid 544-63-8, Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid 557-59-5, Tetracosanoic acid 600-15-7, 2-Hydroxybutanoic acid 617-31-2, 2-Hydroxypentanoic acid 617-73-2, 2-Hydroxyoctanoic acid 621-82-9, Cinnamic acid, biological studies 629-22-1, 2-Hydroxyoctadecanoic acid 636-69-1, 2-Hydroxyheptanoic acid 638-53-9, Tridecanoic acid 646-07-1, Isohexanoic acid 646-30-0, Nonadecanoic acid 764-67-0, 2-Hydroxyhexadecanoic acid 830-09-1, p-Methoxycinnamic acid 1002-84-2, Pentadecanoic acid 1330-19-4, Isoheptanoic acid 1333-28-4, Undecenoic acid 2507-55-3, 2-Hydroxytetradecanoic acid 2984-55-6, 2-Hydroxydodecanoic acid 5393-81-7, 2-Hydroxydecanoic acid 6064-63-7, 2-Hydroxyhexanoic acid 6144-28-1, Dilinoleic acid 7089-43-2, Linderic acid 9003-05-8 9003-53-6, Polystyrene 13980-14-8, 2-Hydroxydocosanoic acid 15896-36-3, 2-Hydroxynonanoic acid 16742-48-6, 2-Hydroxyeicosanoic acid 19790-86-4, 2-Hydroxyundecanoic acid 19790-87-5, 2-Hydroxytridecanoic acid 25022-78-0, 2-Hydroxyheptadecanoic acid 25103-52-0, Isooctanoic acid 25167-62-8, Docosahexaenoic acid 25354-97-6, 2-Hexyldecanoic acid 25378-27-2,



Eicosapentaenoic acid 25448-24-2, Isotridecanoic acid 25986-77-0, Intelimer ipa 13-1 26403-17-8, Isodecanoic acid 26896-18-4, Isononanoic acid 27610-92-0, 2-Butyloctanoic acid 29204-02-2, Gadoleic acid 29385-00-0, Isododecanoic acid 32844-67-0, Isohexadecanoic acid 40596-46-1, 2-Octyldodecanoic acid 50973-09-6, Isopentadecanoic acid 57683-20-2, Isoundecanoic acid 65437-21-0, Isotetradecanoic acid 73756-37-3, 2-DoDecylhexadecanoic acid 73756-39-5, 2-Tetradecyloctadecanoic acid 77035-98-4, Eicosene-vinyl pyrrolidone copolymer 82430-11-3, Dimethyloctanoic acid 89547-15-9, 2-Hexadecyloctadecanoic acid 93361-63-8, 2-Hydroxynonadecanoic acid 93778-52-0, 2-Decyltetradecanoic acid 98989-29-8, Isoeicosanoic acid 512778-00-6, Lusplan DD-DA 5

IT RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing ester and film-forming agent)

IT 694523-05-2D, hydrogenated, block, diblock  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(isoprene-styrene rubber; cosmetic composition containing ester and film-forming agent)

IT 25038-57-7, Poly(methylene)  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wax; cosmetic composition containing ester and film-forming agent)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-02  
ICS A61K007-027; A61K007-48

CC 62-4 (Essential Oils and Cosmetics)

TI Bilayered cosmetic product, its uses and a make-up kit containing it

ST lipstick cosmetic kit

IT Polymers, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(block, diblock; lipstick and make-up kit)

IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(derivs.; lipstick and make-up kit)

IT Cosmetics  
(eye liners; lipstick and make-up kit)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(fluoro; lipstick and make-up kit)

IT Binary systems  
Dispersing agents  
Gelation agents  
Molecular weight distribution  
Mother-of-pearl  
Pigments, nonbiological  
Viscosity  
(lipstick and make-up kit)

IT Essential oils  
Polyesters, biological studies  
Polyethers, biological studies  
Polyolefins  
Polysiloxanes, biological studies  
Polyurethanes, biological studies  
Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lipstick and make-up kit)

IT Cosmetics  
(lipsticks; lipstick and make-up kit)

IT Cosmetics  
(makeups; lipstick and make-up kit)

IT 9003-27-4D, Polyisobutene, hydrogenation products 9003-53-6, Polystyrene  
 9006-65-9, Dimethicone 24980-41-4, Polycaprolactone  
 25248-42-4, Polycaprolactone 31692-79-2, Dimethiconol  
 31807-55-3, Isododecane 60908-77-2, Isohexadecane  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (lipstick and make-up kit)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-032  
 ICS A61K007-48; A61K007-06

CC 62-4 (Essential Oils and Cosmetics)

TI cosmetic composition containing film-forming polymers and thermal  
 transition agents

ST cosmetic polymer mascara Avalure UR425

IT Dyes  
 Hair preparations  
 Perfumes  
 Phase transition temperature  
 Plasticizers  
 Preservatives  
 Sequestering agents  
 Sunscreens  
 Thickening agents  
 (cosmetic compns. containing film-forming polymers and thermal transition  
 agents)

IT Acids, biological studies  
 Alcohols, biological studies  
 Alkali metal hydroxides  
 Ceramides  
 Hydrocarbons, biological studies  
 Paraffin oils  
 Polyesters, biological studies  
 Polymers, biological studies  
 Polyurethanes, biological studies  
 Proteins  
 Vitamins  
 Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing film-forming polymers and thermal transition  
 agents)

IT Cosmetics  
 (emollients; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)

IT Cosmetics  
 (eye liners; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)

IT Hydrocarbons, biological studies  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fluoro; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)

IT Cosmetics  
 (foundations; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (graft; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)

IT Radicals, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; cosmetic compns. containing film-forming polymers and thermal

transition agents)

IT Cosmetics  
(lipsticks; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
(makeups; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
(mascaras; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
(moisturizers; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Liquids  
(oils; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Vinyl compounds, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polymers; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(vegetable; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT 59692-51-2, Capa223  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cosmetic compns. containing film-forming polymers and thermal transition agents)

IT 9003-53-6, Polystyrene 9004-34-6, Cellulose, biological studies  
24980-41-4, Polycaprolactone 25248-42-4,  
Polycaprolactone 250144-13-9, Avalure UR425  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic compns. containing film-forming polymers and thermal transition agents)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-025  
ICS A61K007-48; A61K007-02

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing polymer particles dispersed in a fatty phase and a non-polar oil

ST cosmetic lipstick polymer particle dispersion fat phase

IT Polysiloxanes, biological studies  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(acrylates; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Sunscreens  
Tar oils  
(cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Acrylic polymers, biological studies  
Hydrocarbon oils  
Paraffin oils  
Polyesters, biological studies  
Polysiloxanes, biological studies  
Polyureas  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Cosmetics  
(eye liners; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Isoprene-styrene rubber  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated, block, diblock; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Cosmetics  
(mascaras; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Hydrocarbon waxes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(microcryst.; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyesters, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyamide-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyamides, biological studies  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyester-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyether-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT 111-01-3, Squalane 9002-88-4 9003-05-8 9003-27-4D, Polyisobutene, hydrogenated 52845-07-5, Isoeicosane 77035-98-4, Eicosene-vinyl pyrrolidone copolymer 512778-00-6, Lusplan DD-DA 5  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT 694523-05-2D, hydrogenated, block, diblock  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(isoprene-styrene rubber; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT 25038-57-7, Poly(methylene)  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wax; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-027

ICS A61K007-02; A61K007-48; A61K007-021

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing a semicrystalline polymer and a dispersion

of polymer particles in a fatty phase

ST cosmetic lipstick semicryst polymer particle dispersion fatty phase

IT Polysiloxanes, biological studies  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (acrylates; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Sunscreens  
 Tar oils  
 (cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Acrylic polymers, biological studies  
 Paraffin oils  
 Polyesters, biological studies  
 Polysiloxanes, biological studies  
 Polyureas  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Cosmetics  
 (eye liners; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Cosmetics  
 (mascaras; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Hydrocarbon waxes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Polyesters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyamide-; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Polyamides, biological studies  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyester-; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyether-; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyurea-; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT Polyureas  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyurethane-; cosmetic composition containing semicryst. polymer and

dispersion of polymer particles in fatty phase)

IT 25248-42-4, Polycaprolactone sru  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (CAPA 1215; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT 111-01-3, Squalane 9002-88-4 9003-05-8 9003-27-4D, Polyisobutene, hydrogenated 24980-41-4, Polycaprolactone 25986-77-0, Intellimer IPA 13-1 52845-07-5, Isoeicosane 77035-98-4, Eicosene-vinyl pyrrolidone copolymer 512778-00-6, Lusplan DD-DA 5  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT 694523-05-2D, hydrogenated, block, diblock  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (isoprene-styrene rubber; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

IT 25038-57-7, Poly(methylene)  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wax; cosmetic composition containing semicryst. polymer and dispersion of polymer particles in fatty phase)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K031-704

ICS A61K007-00; A61K007-48; A61K009-48; A61K047-32; A61K047-34; A61K047-38; A61K047-42; A61P017-00

CC 62-4 (Essential Oils and Cosmetics)  
 Section cross-reference(s): 63

TI Ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof

ST ginsenoside polymer microcapsule antiaging cosmetic

IT Cosmetics  
 (aerosols; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Ethers, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (alkyl vinyl, polymers, dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
 (antiaging; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Capsules  
 (cosmetic microcapsules; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Cosmetics  
 (creams; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (di-Me, polystyrene-, block, dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT Gelatins, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological

study); PROC (Process); USES (Uses)  
 (dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules  
 for cosmetics, and manufacture thereof)

IT Cosmetics  
 (emulsions; ginsenoside-encapsulated polymer microcapsules for  
 cosmetics, and manufacture thereof)

IT Cosmetics  
 (foundations; ginsenoside-encapsulated polymer microcapsules for  
 cosmetics, and manufacture thereof)

IT Cosmetics  
 (gels; ginsenoside-encapsulated polymer microcapsules for cosmetics,  
 and manufacture thereof)

IT Ginsenosides  
 RL: COS (Cosmetic use); NPO (Natural product occurrence); PAC  
 (Pharmacological activity); PEP (Physical, engineering or chemical  
 process); PYP (Physical process); BIOL (Biological study); OCCU  
 (Occurrence); PROC (Process); USES (Uses)  
 (ginsenoside-encapsulated polymer microcapsules for cosmetics, and  
 manufacture thereof)

IT Polyesters, biological studies  
 RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process);  
 PYP (Physical process); BIOL (Biological study); PROC (Process); USES  
 (Uses)  
 (ginsenoside-encapsulated polymer microcapsules for cosmetics, and  
 manufacture thereof)

IT Cosmetics  
 (lipsticks; ginsenoside-encapsulated polymer microcapsules  
 for cosmetics, and manufacture thereof)

IT Cosmetics  
 (lotions; ginsenoside-encapsulated polymer microcapsules for cosmetics,  
 and manufacture thereof)

IT Cosmetics  
 (makeups, base; ginsenoside-encapsulated polymer microcapsules for  
 cosmetics, and manufacture thereof)

IT Cosmetics  
 (microcapsules; ginsenoside-encapsulated polymer microcapsules for  
 cosmetics, and manufacture thereof)

IT Cosmetics  
 (packs; ginsenoside-encapsulated polymer microcapsules for cosmetics,  
 and manufacture thereof)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process);  
 PYP (Physical process); BIOL (Biological study); PROC (Process); USES  
 (Uses)  
 (unsatd.; ginsenoside-encapsulated polymer microcapsules for cosmetics,  
 and manufacture thereof)

IT 9000-11-7, Carboxymethyl cellulose 9002-89-5, Polyvinyl alcohol  
 9003-39-8, Polyvinylpyrrolidone 9004-62-0, Hydroxyethyl cellulose  
 9005-25-8, Starch, biological studies  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical,  
 engineering or chemical process); PYP (Physical process); BIOL (Biological  
 study); PROC (Process); USES (Uses)  
 (dispersion stabilizer; ginsenoside-encapsulated polymer microcapsules  
 for cosmetics, and manufacture thereof)

IT 39262-14-1 53963-43-2, Ginsenoside F1  
 RL: COS (Cosmetic use); NPO (Natural product occurrence); PAC  
 (Pharmacological activity); PEP (Physical, engineering or chemical  
 process); PYP (Physical process); BIOL (Biological study); OCCU  
 (Occurrence); PROC (Process); USES (Uses)  
 (ginsenoside-encapsulated polymer microcapsules for cosmetics, and  
 manufacture thereof)

IT 111-01-3, Squalane 9004-32-4, Sodium carboxymethyl cellulose  
 RL: COS (Cosmetic use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

IT 9003-01-4, Polyacrylic acid 9003-19-4, Polyvinylether 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone  
 RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)  
 (ginsenoside-encapsulated polymer microcapsules for cosmetics, and manufacture thereof)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-48  
 ICS A61K007-02

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol

ST cosmetic polymer dispersion ester polyol

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block, diblock; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block, triblock; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polyureas  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (copolymers; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Colloids  
 Cosmetics  
 Gelation agents  
 Molecular weight distribution  
 Skin  
 Stabilizing agents  
 (cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Disaccharides  
 Esters, biological studies  
 Monosaccharides  
 Polyesters, biological studies  
 Polymers, biological studies  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Carboxylic acids, biological studies  
 Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics



(eye liners; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fluoro; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics  
 (lipsticks; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics  
 (makeups; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Cosmetics  
 (mascaras; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polyesters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyamide-; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Polyamides, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyester-; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyhydric; cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 57-50-1, Sucrose, biological studies 64-19-7D, Acetic acid, esters 65-85-0D, Benzoic acid, esters 75-98-9 79-09-4D, Propanoic acid, esters 79-31-2 79-31-2D, Isobutanoic acid, esters 87-99-0, Xylitol 107-92-6D, Butanoic acid, esters 109-52-4D, Pentanoic acid, esters 126-13-6 149-32-6, Erythritol 9002-88-4, Polyethylene 9003-01-4D, Polyacrylic acid, copolymers 9003-27-4D, Polyisobutene, hydrogenation products 24980-41-4D, Polycaprolactone, derivs. 25248-42-4D, Polycaprolactone, derivs. 27924-99-8, Poly(12-hydroxystearic acid) 31807-55-3, Isododecane 60908-77-2, Isohexadecane 105729-79-1D, Isoprene-styrene block copolymer, derivs. 106107-54-4D, Butadiene-styrene block copolymer, derivs. 108388-87-0, Ethylene-propylene-styrene block copolymer 110900-80-6, Butadiene-ethylene-styrene block copolymer 144470-58-6  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising a dispersion of polymer particles and an acid ester and polyol)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-032

ICS A61K007-48; A61K007-06

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic compositions containing film-forming polymers removed only by warm water

ST cosmetic polymer mascara Avalure UR425

IT Dyes  
 Perfumes  
 Phase transition temperature  
 Plasticizers  
 Preservatives

- Sequestering agents
- Sunscreens
- Thickening agents
  - (cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Acids, biological studies
- Alcohols, biological studies
- Alkali metal hydroxides
- Ceramides
- Hydrocarbons, biological studies
- Paraffin oils
- Polyesters, biological studies
- Polymers, biological studies
- Polyurethanes, biological studies
- Proteins
- Vitamins
- Waxes
- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (emollients; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (eye liners; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Hydrocarbons, biological studies
- Polysiloxanes, biological studies
- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (fluoro; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (foundations; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Polymers, biological studies
- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (graft; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Radicals, biological studies
- RL: BSU (Biological study, unclassified); BIOL (Biological study)
  - (inhibitors; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (lipsticks; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (makeups; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (mascaras; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Cosmetics
  - (moisturizers; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Liquids
  - (oils; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)
- IT Vinyl compounds, biological studies
- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (polymers; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (vegetable; cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)

IT 59692-51-2, Capa223  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)

IT 9004-34-6, Cellulose, biological studies 24980-41-4,  
 Polycaprolactone 25248-42-4, Polycaprolactone  
 250144-13-9, Avalure UR425  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing film-forming polymers and thermal transition agents removed only by warm water)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-025  
 ICS A61K007-48; A61K007-021

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition with good behavior containing polymer particles  
 dispersed in a fat phase

ST cosmetic lipstick polymer particle dispersion fat phase

IT Polysiloxanes, biological studies  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (acrylates; cosmetic composition with good behavior containing polymer particles  
 dispersed in fat phase)

IT Sunscreens  
 Tar oils  
 (cosmetic composition with good behavior containing polymer particles  
 dispersed in fat phase)

IT Acrylic polymers, biological studies  
 Paraffin oils  
 Polyesters, biological studies  
 Polysiloxanes, biological studies  
 Polyureas  
 Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition with good behavior containing polymer particles  
 dispersed in fat phase)

IT Cosmetics  
 (eye liners; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Isoprene-styrene rubber  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated, block, diblock; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Cosmetics  
 (mascaras; cosmetic composition with good behavior containing polymer particles  
 dispersed in fat phase)

IT Hydrocarbon waxes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyesters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyamide-; cosmetic composition with good behavior containing polymer

particles dispersed in fat phase)

IT Polyamides, biological studies  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyester-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyether-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT 111-01-3, Squalane 9002-88-4 9003-05-8 9003-27-4D, Polyisobutene, hydrogenated 52845-07-5, Isoeicosane 77035-98-4, Elcosene-vinyl pyrrolidone copolymer 512778-00-6, Lusplan DD-DA 5  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT 694523-05-2D, hydrogenated, block, diblock  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(isoprene-styrene rubber; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

IT 25038-57-7, Poly(methylene)  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wax; cosmetic composition with good behavior containing polymer particles dispersed in fat phase)

L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-027  
ICS A61K007-02; A61K007-48

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing a non-polar wax and a dispersion of polymer particles in a fatty phase

ST cosmetic lipstick polymer particle dispersion nonpolar wax

IT Polysiloxanes, biological studies  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(acrylates; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Beeswax  
Ozocerite  
Sunscreens  
Tar oils  
(cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Acrylic polymers, biological studies  
Candelilla wax  
Carnauba wax  
Ceresin  
Paraffin oils  
Paraffin waxes, biological studies  
Polyesters, biological studies  
Polysiloxanes, biological studies

Polyureas  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Cosmetics  
(eye liners; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Isoprene-styrene rubber  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated, block, diblock; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Cosmetics  
(mascaras; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Hydrocarbon waxes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(microcryst.; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Polyesters, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyamide-; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Polyamides, biological studies  
Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyester-; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyether-; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT 111-01-3, Squalane 9002-88-4 9003-05-8 9003-27-4D, Polyisobutene, hydrogenated 52845-07-5, Isocicosane 77035-98-4, Eicosene-vinyl pyrrolidone copolymer 512778-00-6, Lusplan DD-DA 5  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT 694523-05-2D, hydrogenated, block, diblock  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(isoprene-styrene rubber; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

IT 25038-57-7, Poly(methylene)  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wax; cosmetic composition containing non-polar wax and dispersion of polymer particles in fatty phase)

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing a polymer particle dispersion and polymer plasticizer

ST makeup cosmetic polymer plasticizer lipstick

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 Gelation agents  
 Molecular weight distribution  
 Plasticizers  
 Skin  
 Stabilizing agents  
 (cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Polymers, biological studies  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic, derivs.; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (eye liners; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

and

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (graft; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (lipsticks; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (makeups; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Cosmetics  
 (mascaras; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (tricarboxylic acids, derivs.; cosmetic composition containing a polymer particle dispersion and polymer plasticizer)

IT 77-89-4, Triethyl acetyl citrate 77-90-7, Tributylacetyl citrate  
 77-94-1, Tributyl citrate 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate 85-68-7, Butylbenzyl phthalate 88-99-3D, Phthalic acid, esters 100-42-5D, Styrene, copolymers 103-23-1, Diethyl-2-hexyl adipate 105-99-7, Dibutyl adipate 109-43-3, Dibutyl sebacate 110-15-6D, Succinic acid, esters 110-40-7, Diethyl sebacate 111-20-6D, Sebacic acid, esters 117-81-7 122-62-3 123-25-1, Diethyl succinate 124-04-9D, Adipic acid, esters 131-11-3, Dimethyl phthalate 144-15-0 2915-57-3 6938-94-9, Diisopropyl adipate 7491-02-3, Diisopropyl sebacate 9002-88-4, Polyethylene 9003-27-4D, Polyisobutene, hydrogenation products 17140-33-9, Acetylcitric acid 24817-92-3

24980-41-4, Polycaprolactone 25248-42-4,  
 Polycaprolactone 27924-99-8, Poly(12-hydroxystearic acid)  
 31807-55-3, Isododecane 39413-05-3, Isopropyl citrate 58128-22-6,  
 Poly(12-hydroxystearic acid) stearate 60908-77-2, Isohexadecane  
 82469-79-2 90605-17-7, Isodecyl citrate 105729-79-1, Isoprene-styrene  
 block copolymer 106107-54-4, Butadiene-styrene block copolymer  
 108388-87-0, Ethylene-propylene-styrene block copolymer 110900-80-6,  
 Butadiene-ethylene-styrene block copolymer 144470-58-6  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing a polymer particle dispersion and polymer  
 plasticizer)

- L19 14 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
 IC ICM A61K007-032  
 ICS A61K007-48; A61K007-06  
 CC 62-4 (Essential Oils and Cosmetics)  
 TI Cosmetic compositions containing film-forming polymers and thermal  
 transition agents  
 ST cosmetic polymer mascara Avalure UR425  
 IT Dyes  
 Hair preparations  
 Perfumes  
 Phase transition temperature  
 Plasticizers  
 Preservatives  
 Sequestering agents  
 Sunscreens  
 Thickening agents  
 (cosmetic compns. containing film-forming polymers and thermal transition  
 agents)  
 IT Acids, biological studies  
 Alcohols, biological studies  
 Alkali metal hydroxides  
 Ceramides  
 Hydrocarbons, biological studies  
 Paraffin oils  
 Polyesters, biological studies  
 Polymers, biological studies  
 Polyurethanes, biological studies  
 Proteins  
 Vitamins  
 Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing film-forming polymers and thermal transition  
 agents)  
 IT Cosmetics  
 (emollients; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)  
 IT Cosmetics  
 (eye liners; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)  
 IT Hydrocarbons, biological studies  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fluoro; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)  
 IT Cosmetics  
 (foundations; cosmetic compns. containing film-forming polymers and thermal  
 transition agents)  
 IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(graft; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Radicals, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
 (lipsticks; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
 (makeups; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
 (mascaras; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Cosmetics  
 (moisturizers; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Liquids  
 (oils; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (vegetable; cosmetic compns. containing film-forming polymers and thermal transition agents)

IT 59692-51-2, Capa223  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cosmetic compns. containing film-forming polymers and thermal transition agents)

IT 9003-53-6, Polystyrene 9004-34-6, Cellulose, biological studies  
 24980-41-4, Polycaprolactone 25248-42-4,  
 Polycaprolactone 250144-13-9, Avalure UR425  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing film-forming polymers and thermal transition agents)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008  
 E US2004-785093/APPS

L1 1 S E3  
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON 24 JUN 2008

L3 432048 S L2

L4 13513 S L3 AND ("ACETIC ACID")

L5 603 S L4 AND SUCROSE

L6 0 S L5 AND ("ACRYLIC COPOLYMER")



```

L7      39 S L5 AND ("ACRYLIC ACID")
L8      10 S L7 AND ACRYLATE
L9      3 S L8 AND POLYETHYLENE
L10     0 S "POLYETHYLENE WAX"
L11     6753 S "POLYETHYLENE WAX"
L12     2 S L11 AND ("LINEAR FATTY ALCOHOL?")
L13     0 S L11 AND ("PERFORMACOL 550 ALCOHOL")
L14     0 S ("PERFORMACOL 550 ALCOHOL")
L15     4 S L11 AND PERFORMACOL
L16     3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")
L17     89 S L11 AND PERFUME
L18     0 S L17 AND POLYCAPROLACTONE
L19     14 S POLYCAPROLACTONE AND LIPSTICK
L20     0 S L19 AND ("PIGMENT PASTE")
L21     8 S L19 AND PIGMENT?
L22     45 S ("KRATON G1701")
L23     1 S ("550 ALCOHOL")
L24     189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA
L25     37 S L24 AND ("CARBOXYLIC ACID?")
L26     16 S L25 AND COSMETIC
L27     17 DUP REM L26 L23 (0 DUPLICATES REMOVED)
L28     59 DUP REM L26 L22 (2 DUPLICATES REMOVED)

```

=> d scan 115

```

L15     4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC      62-3 (Essential Oils and Cosmetics)
TI      Process for coating eyelashes containing waxes
ST      mascara coating eyelash wax
IT      Hydrocarbon waxes, biological studies
RL:     COS (Cosmetic use); BIOL (Biological study); USES (Uses)
        (microcryst.; process for coating eyelashes containing waxes)
IT      Waxes
RL:     COS (Cosmetic use); BIOL (Biological study); USES (Uses)
        (polar; process for coating eyelashes containing waxes)
IT      Beeswax
        Mascaras
        (process for coating eyelashes containing waxes)
IT      Essential oils
        Hydrocarbons, biological studies
        Paraffin waxes, biological studies
        Polysiloxanes, biological studies
RL:     COS (Cosmetic use); BIOL (Biological study); USES (Uses)
        (process for coating eyelashes containing waxes)
IT      9002-88-4
RL:     COS (Cosmetic use); BIOL (Biological study); USES (Uses)
        (process for coating eyelashes containing waxes)

```

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

```

L15     4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC      62-3 (Essential Oils and Cosmetics)
        Section cross-reference(s): 38
TI      Cosmetic composition containing a dispersion of particles of polymer and
        an organopolysiloxane elastomer
ST      cosmetic dispersion particle polymer organopolysiloxane elastomer lipstick
IT      Polymers, biological studies
RL:     COS (Cosmetic use); BIOL (Biological study); USES (Uses)
        (block; cosmetic composition containing dispersion of particles of polymer
and      organopolysiloxane elastomer)

```

IT Eyeliners  
Foundations (cosmetics)  
Lipsticks  
Mascaras  
Sunscreens  
(cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

IT Acrylic polymers, biological studies  
Isoalkanes  
Silicone rubber, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

IT Polymers, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(graft; cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

and

IT Isoprene-styrene rubber  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(hydrogenated, block, diblock; cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

IT Vinyl compounds, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polymers; cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

IT 9002-88-4 9016-00-6, Polydimethylsiloxane 31900-57-9,  
Polydimethylsiloxane 60908-77-2, Isohexadecane  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

IT 694523-05-2D, hydrogenated, block, diblock  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(isoprene-styrene rubber; cosmetic composition containing dispersion of particles of polymer and organopolysiloxane elastomer)

L15 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-48  
ICS A61K007-025; A61K007-02

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition containing and a polymer dispersion and a plasticizer

ST cosmetic polymer dispersion plasticizer lipstick acrylic polymer

IT Hair preparations  
Plasticizers  
Solubility  
(cosmetic composition containing and polymer dispersion and plasticizer)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing and polymer dispersion and plasticizer)

IT Acrylic polymers, biological studies  
RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(cosmetic composition containing and polymer dispersion and plasticizer)

IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(esters; cosmetic composition containing and polymer dispersion and plasticizer)

IT Cosmetics  
(lipsticks; cosmetic composition containing and polymer dispersion and plasticizer)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polycarboxylic; cosmetic composition containing and polymer dispersion and plasticizer)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyhydric; cosmetic composition containing and polymer dispersion and plasticizer)

IT 50-69-1, D-Ribose 50-70-4, Sorbitol, biological studies 50-99-7, D-Glucose, biological studies 50-99-7, D-Glucose, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Saccharose, biological studies 58-86-6, D-Xylose, biological studies 59-23-4, D-Galactose, biological studies 63-42-3, Lactose 64-19-7D, Acetic acid, esters 65-85-0D, Benzoic acid, esters 69-79-4, Maltose 77-89-4, Triethyl acetyl-citrate 77-90-7, Tributyl Acetyl-citrate 77-92-9, Citric Acid, biological studies 77-94-1, Tributyl citrate 79-09-4D, Propanoic acid, esters 79-31-2D, Isobutanoic acid, esters 84-66-2, Diethyl phthalate 84-74-2, Butyl phthalate 87-99-0, Xylitol 103-23-1, Di(ethyl-2-hexyl) adipate 105-99-7, Dibutyl adipate 107-92-6D, Butanoic acid, esters 109-43-3, Dibutyl sebacate 109-52-4D, n-Pentanoic acid, esters 110-40-7, Diethyl sebacate 117-81-7 122-62-3, Di(ethyl-2-hexyl) sebacate 123-25-1, Diethyl succinate 126-13-6 131-11-3, Dimethyl phthalate 144-15-0 149-32-6, Erythritol 523-31-9, Benzyl phthalate 551-84-8, D-Xylulose 2915-57-3, Di(ethyl-2-hexyl) succinate 3458-28-4, D-Mannose 5328-37-0, L-Arabinose 7147-34-4, Tris(2-ethylhexyl) citrate 7491-02-3, Diisopropyl sebacate 17140-33-9, Acetyl-citric acid 24817-92-3 64831-33-0 74592-76-0, Triisopropyl citrate 82469-79-2 278777-48-3 854262-19-4 854262-20-7 854275-83-5 854275-84-6 854275-85-7 854275-86-8  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing and polymer dispersion and plasticizer)

IT 854275-82-4P  
 RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (cosmetic composition containing and polymer dispersion and plasticizer)

L15 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 62-4 (Essential Oils and Cosmetics)

IT Two-coating makeup compositions containing specified silicone polymers, usage thereof, and makeup kit containing the same

ST polysiloxane double coat cosmetic makeup

IT Cosmetics  
 (eye liners; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
 (eye shadows; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
 (foundations; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
 (lipsticks; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
 (makeups; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Acrylic polymers, biological studies  
 Polysiloxanes, biological studies  
 Silicone rubber, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (two-coating makeup compns. consisting solid composition and compns. containing

specified silicone polymers)  
 IT 9016-00-6, Poly(dimethylsiloxane)  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (AK 300000, Dow Corning 200 Fluid; two-coating makeup compns.  
 consisting solid composition and compns. containing specified silicone  
 polymers)  
 IT 25302-81-2, Acrylic acid-methyl acrylate copolymer  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (particles; two-coating makeup compns. consisting solid composition and  
 compns. containing specified silicone polymers)  
 IT 294-40-6, Cyclopentasiloxane 540-97-6, Dow Corning 246 Fluid  
 42557-10-8, DC200 700876-76-2, Ethylene-propylene-styrene diblock  
 copolymer  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (two-coating makeup compns. consisting solid composition and compns.  
 containing  
 specified silicone polymers)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008  
 E US2004-785093/APPS

L1 1 S E3  
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008  
 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
 24 JUN 2008

L3 432048 S L2  
 L4 13513 S L3 AND ("ACETIC ACID")  
 L5 603 S L4 AND SUCROSE  
 L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
 L7 39 S L5 AND ("ACRYLIC ACID")  
 L8 10 S L7 AND ACRYLATE  
 L9 3 S L8 AND POLYETHYLENE  
 L10 0 S "POLYETHYLEN WAX"  
 L11 6753 S "POLYETHYLENE WAX"  
 L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")  
 L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
 L14 0 S ("PERFORMACOL 550 ALCOHOL")  
 L15 4 S L11 AND PERFORMACOL  
 L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
 L17 89 S L11 AND PERFUME  
 L18 0 S L17 AND POLYCAPROLACTONE  
 L19 14 S POLYCAPROLACTONE AND LIPSTICK  
 L20 0 S L19 AND ("PIGMENT PASTE")  
 L21 8 S L19 AND PIGMENT?  
 L22 45 S ("KRATON G1701")  
 L23 1 S ("550 ALCOHOL")  
 L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA  
 L25 37 S L24 AND ("CARBOXYLIC ACID?")  
 L26 16 S L25 AND COSMETIC  
 L27 17 DUP REM L26 L23 (0 DUPLICATES REMOVED)  
 L28 59 DUP REM L26 L22 (2 DUPLICATES REMOVED)

=> d scan 116

L16 3 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
CC 62-4 (Essential Oils and Cosmetics)  
TI Cosmetic composition comprising an ester of an alkoxyated alcohol and a film-forming polymer  
ST cosmetic ester alkoxyated alc film forming polymer  
IT Acrylic polymers, biological studies  
Hydrocarbon oils  
Paraffin oils  
Polyamides, biological studies  
Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)  
IT Cosmetics  
(lipsticks; cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)  
IT Oils  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(non-polar; cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)  
IT Cosmetics  
(powders; cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)  
IT Cosmetics  
(solids; cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)  
IT Cosmetics  
(sticks; cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)  
IT 75-98-9, Neopentanoic acid 91-20-3, Naphthalene, biological studies  
111-01-3, Squalane 112-80-1, Oleic acid, biological studies 142-62-1, Caproic acid, biological studies 149-57-5, 2-Ethylhexanoic acid 2724-58-5, Isostearic acid 9003-27-4D, Polyisobutene, hydrogenated 9003-28-5, Polybutene 9003-29-6, Polybutene 33113-10-9, Neohexanoic acid 34513-50-3, Octyl dodecanol 37309-58-3, Polydecene 52845-07-5, Isoleicosene 77035-98-4, Eicosene Vinyl pyrrolidone copolymer 194615-27-5, Mirasil C-DPDM 522632-69-5, Liquiwax poly EFA 896130-00-0  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition comprising ester of alkoxyated alc. and film-forming polymer)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L16 3 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
IC ICM A61K007-021  
CC 62-4 (Essential Oils and Cosmetics)  
TI Bilayered make-up product containing comprises a dispersion of an ethylenic polymer particles  
ST bilayer cosmetic makeup ethylenic polymer particle dispersion  
IT Acrylic polymers, biological studies  
Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(bilayered make-up product containing comprises dispersion of ethylenic polymer particles)  
IT Cosmetics  
(lipsticks; bilayered make-up product containing comprises dispersion of ethylenic polymer particles)  
IT Cosmetics

(makeups; bilayered make-up product containing comprises dispersion of ethylenic polymer particles)

IT Cosmetics  
(sticks; bilayered make-up product containing comprises dispersion of ethylenic polymer particles)

IT 107-51-7, Octamethyltrisiloxane 141-62-8, Decamethyltetrasiloxane 540-97-6, Dodecamethylcyclohexasiloxane 541-02-6, Decamethylcyclopentasiloxane 556-67-2, Octamethylcyclotetrasiloxane 1873-90-1, Heptamethylhexyltrisiloxane 9016-00-6, Polydimethylsiloxane 17955-88-3, Heptamethyloctyltrisiloxane 31807-55-3, Isododecane 31900-57-9, Polydimethylsiloxane 34464-38-5, Isodecane 60908-77-2, Isohexadecane 288087-49-0, Kraton L 1253

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(bilayered make-up product containing comprises dispersion of ethylenic polymer particles)

L16 3 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN

CC 62-4 (Essential Oils and Cosmetics)

TI Two-coating makeup compositions containing specified silicone polymers, usage thereof, and makeup kit containing the same

ST polysiloxane double coat cosmetic makeup

IT Cosmetics  
(eye liners; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
(eye shadows; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
(foundations; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
(lipsticks; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Cosmetics  
(makeups; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT Acrylic polymers, biological studies  
Polysiloxanes, biological studies  
Silicone rubber, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT 9016-00-6, Poly(dimethylsiloxane)  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(AK 300000, Dow Corning 200 Fluid; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT 25302-81-2, Acrylic acid-methyl acrylate copolymer  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(particles; two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

IT 294-40-6, Cyclopentasiloxane 540-97-6, Dow Corning 246 Fluid 42557-10-8, DC200 700876-76-2, Ethylene-propylene-styrene diblock copolymer  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(two-coating makeup compns. consisting solid composition and compns. containing specified silicone polymers)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

L3 432048 S L2  
L4 13513 S L3 AND ("ACETIC ACID")  
L5 603 S L4 AND SUCROSE  
L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
L7 39 S L5 AND ("ACRYLIC ACID")  
L8 10 S L7 AND ACRYLATE  
L9 3 S L8 AND POLYETHYLENE  
L10 0 S "POLYETHYLEN WAX"  
L11 6753 S "POLYETHYLENE WAX"  
L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")  
L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
L14 0 S ("PERFORMACOL 550 ALCOHOL")  
L15 4 S L11 AND PERFORMACOL  
L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
L17 89 S L11 AND PERFUME  
L18 0 S L17 AND POLYCAPROLACTONE  
L19 14 S POLYCAPROLACTONE AND LIPSTICK  
L20 0 S L19 AND ("PIGMENT PASTE")  
L21 8 S L19 AND PIGMENT?  
L22 45 S ("KRATON G1701")  
L23 1 S ("550 ALCOHOL")  
L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA  
L25 37 S L24 AND ("CARBOXYLIC ACID?")  
L26 16 S L25 AND COSMETIC  
L27 17 DUP REM L26 L23 (0 DUPLICATES REMOVED)  
L28 59 DUP REM L26 L22 (2 DUPLICATES REMOVED)

=> d scan 112

L12 2 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 62-4 (Essential Oils and Cosmetics)

TI Double-layered makeup product containing silicones with improved behavior,  
its uses and a kit containing this product

ST makeup lipstick silicone property

IT Polysiloxanes, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(alkyl; double-layered makeup product containing silicones with improved  
behavior, its uses and kit containing this product)

IT Polymers, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(block, diblock; double-layered makeup product containing silicones with  
improved behavior, its uses and kit containing this product)

IT Sunscreens

Viscosity

(double-layered makeup product containing silicones with improved behavior,

its uses and kit containing this product)

IT Polysiloxanes, biological studies  
Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

IT Cosmetics  
(eye liners; double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

IT Cosmetics  
(lipsticks; double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

IT Cosmetics  
(makeups; double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

IT Vinyl compounds, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polymers; double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

IT Cosmetics  
(solids; double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

IT 9002-88-4, Ethylene polymers 9016-00-6, Poly[oxy(dimethylsilylene)]  
25302-81-2, Acrylic acid-methyl acrylate copolymer  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(double-layered makeup product containing silicones with improved behavior, its uses and kit containing this product)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L12 2 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
CC 62-4 (Essential Oils and Cosmetics)  
TI Bilayered cosmetic product comprising a silicone polymer  
ST cosmetic lipstick silicone polymer particle  
IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(acrylates; bilayered cosmetic product comprising silicone polymer)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(acrylic; bilayered cosmetic product comprising silicone polymer)

IT Particles  
(bilayered cosmetic product comprising silicone polymer)

IT Hydrocarbon oils  
Polysiloxanes, biological studies  
Silsequioxanes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(bilayered cosmetic product comprising silicone polymer)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(di-Me, di-Ph; bilayered cosmetic product comprising silicone polymer)

IT Cosmetics  
(lipsticks; bilayered cosmetic product comprising silicone polymer)

IT Cosmetics  
(makeups; bilayered cosmetic product comprising silicone polymer)

IT 9016-00-6, Belsil 1000  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Belsil 1000; bilayered cosmetic product comprising silicone polymer)

IT 873584-02-2  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(actual and assumed monomers; bilayered cosmetic product comprising silicone polymer)



IT 2116-84-9, Dc 556 5333-42-6, 2-Octyldodecanol 9003-27-4D,  
Polyisobutene, hydrogenated 9005-12-3, Phenylidimethicone 9006-65-9,  
Dimethicone 27756-15-6D, Acrylic acid stearyl methacrylate copolymer,  
grafts with polydimethylsiloxane 29806-73-3, Cegesoft C24 31900-57-9,  
Polydimethyl siloxane 32243-66-6 32360-05-7D, Stearyl methacrylate,  
grafts with polydimethylsiloxane 36120-03-3D, Acrylic acid stearyl  
acrylate copolymer, grafts with polydimethylsiloxane 42131-25-9,  
Isononyl isononanoate 42131-27-1, Isotridecyl isononanoate 42557-10-8,  
Dc 200 71672-24-7 81230-05-9, Diisostearyl malate 98914-74-0  
153315-80-1, Methylsilsesquioxane 195868-36-1, Phenyltrimethicone  
577794-76-4 680605-53-2 799269-13-9, KF 6104  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(bilayered cosmetic product comprising silicone polymer)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

L3 432048 S L2  
L4 13513 S L3 AND ("ACETIC ACID")  
L5 603 S L4 AND SUCROSE  
L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
L7 39 S L5 AND ("ACRYLIC ACID")  
L8 10 S L7 AND ACRYLATE  
L9 3 S L8 AND POLYETHYLENE  
L10 0 S "POLYETHYLEN WAX"  
L11 6753 S "POLYETHYLENE WAX"  
L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")  
L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
L14 0 S ("PERFORMACOL 550 ALCOHOL")  
L15 4 S L11 AND PERFORMACOL  
L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
L17 89 S L11 AND PERFUME  
L18 0 S L17 AND POLYCAPROLACTONE  
L19 14 S POLYCAPROLACTONE AND LIPSTICK  
L20 0 S L19 AND ("PIGMENT PASTE")  
L21 8 S L19 AND PIGMENT?  
L22 45 S ("KRATON G1701")  
L23 1 S ("550 ALCOHOL")  
L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA  
L25 37 S L24 AND ("CARBOXYLIC ACID?")  
L26 16 S L25 AND COSMETIC  
L27 17 DUP REM L26 L23 (0 DUPLICATES REMOVED)  
L28 59 DUP REM L26 L22 (2 DUPLICATES REMOVED)

=> s 117 and 122

L29 0 L17 AND L22

=> s 117 and 121  
L30 0 L17 AND L21

=> s 117 and 128  
L31 8 L17 AND L28

=> d scan 131

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN  
IC ICM A61K007-025  
CC 62-4 (Essential Oils and Cosmetics)  
TI Cosmetic composition comprising a hydroxylated  
carboxylic acid triglyceride polyester and a pasty  
compound  
ST cosmetic carboxylic acid polyester  
triglyceride paste  
IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Ph; cosmetic composition comprising hydroxylated  
carboxylic acid triglyceride polyester and pasty  
compound)  
IT Glycerides, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(carboxylic acid; cosmetic composition  
comprising hydroxylated carboxylic acid  
triglyceride polyester and pasty compound)  
IT Beeswax  
Cosmetics  
Deodorants  
Sunscreens  
Suntanning agents  
(cosmetic composition comprising hydroxylated carboxylic  
acid triglyceride polyester and pasty compound)  
IT Acrylic polymers, biological studies  
Fatty acids, biological studies  
Fluoropolymers, biological studies  
Oils  
Polyolefins  
Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition comprising hydroxylated carboxylic  
acid triglyceride polyester and pasty compound)  
IT Carboxylic acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(dicarboxylic; cosmetic composition comprising hydroxylated  
carboxylic acid triglyceride polyester and pasty  
compound)  
IT Hair preparations  
(dyes; cosmetic composition comprising hydroxylated  
carboxylic acid triglyceride polyester and pasty  
compound)  
IT Cosmetics  
(eye liners; cosmetic composition comprising hydroxylated  
carboxylic acid triglyceride polyester and pasty  
compound)  
IT Cosmetics  
(lipsticks; cosmetic composition comprising hydroxylated  
carboxylic acid triglyceride polyester and pasty  
compound)  
IT Cosmetics  
(mascaras; cosmetic composition comprising hydroxylated

carboxylic acid triglyceride polyester and pasty compound)

IT Hydrocarbon waxes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (nail lacquers; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Sterols  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (phyto-; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Cosmetics  
 (powders; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sesame; cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

IT 106-14-9, 12-Hydroxy stearic acid 115-77-5D, Pentaerythritol, esters 120-87-6, 9 10-Dihydroxy octadecanoic acid 141-22-0, Ricinoleic acid 498-36-2 629-22-1,  $\alpha$ -Hydroxy octadecanoic acid 4444-16-0 6949-98-0 9003-19-4, Vinyl ether polymers 9003-27-4D, Polyisobutylene, hydrogenated 9003-29-6, Polybutylene 9003-39-8, PVP 9016-00-6D, Polydimethylsiloxane, Me trifluoropropyl alkyl derivs. 13893-40-8 25027-95-6, 9,10, 12 Trihydroxy octadecanoic acid 25754-87-4, 9, 12-Dihydroxy octadecanoic acid 26952-14-7D, Hexadecene, copolymers 30306-47-9 30399-84-9, Isostearic Acid 31900-57-9D, Polydimethylsiloxane, Me trifluoropropyl alkyl derivs. 37309-58-3, Polydecene 37309-58-3D, Polydecene, hydrogenated 65591-14-2, Arachidyl propionate 337975-97-0 338450-65-0 338450-66-1 756899-84-0  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising hydroxylated carboxylic acid triglyceride polyester and pasty compound)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
 IC ICM A61K007-02  
 ICS A61K007-025; A61K007-027  
 CC 62-4 (Essential Oils and Cosmetics)  
 TI Cosmetic compositions containing at least one heteropolymer and at least one gelling agent  
 ST heteropolymer gelation agent liq fatty phase cosmetic; lipstick sunscreen stick heteropolymer gelation agent  
 IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (C8-26; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)  
 IT Fats and Glyceridic oils, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (Japan wax; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (Ph; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (block; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Cosmetics  
 (blushes; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Hair  
 Lip  
 Skin  
 (compns. for skin, lips, and hair containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Cosmetics  
 (concealers; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
 Hair preparations  
 (conditioners; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cork fiber; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

IT Amphiphiles  
 Antioxidants  
 Beeswax  
 Coloring materials  
 Gums and Mucilages  
 Hair preparations  
 Hardness (mechanical)  
 Odor and Odorous substances  
 Ozocerite  
 Pearlescent pigments  
 Perfumes  
 Pigments, nonbiological  
 Preservatives  
 Shampoos  
 Sunscreens  
 Thickening agents  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT Candelilla wax  
 Carnauba wax  
 Castor oil  
 Clays, biological studies  
 Essential oils  
 Esters, biological studies  
 Ethers, biological studies  
 Fats and Glyceridic oils, biological studies  
 Glycerides, biological studies  
 Hydrocarbon oils  
 Minerals, biological studies  
 Montan wax  
 Paraffin waxes, biological studies

Polyamides, biological studies  
 Polyureas  
 Polyurethanes, biological studies  
 Resins  
 Silicone rubber, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)  
 IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cyclsiloxane-, di-Me; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (di-Me; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)  
 IT Amines, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (diamines; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)  
 IT Carboxylic acids, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (dicarboxylic; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Cosmetics  
 (emulsions; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)  
 IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)  
 IT Cosmetics  
 (eye liners; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Cosmetics  
 (eye shadows; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty, C8-26; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Cosmetics  
 (foundations; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Cosmetics  
 (gels; cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)  
 IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (heteropolymers; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)  
 IT Dyes  
 (hydrophilic and lipophilic; cosmetic compns. containing  
 structuring heteropolymer and gelling agent in liquid fatty phase)  
 IT Cosmetics  
 (lipsticks; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT Cosmetics  
(makeup removers; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(makeups; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(mascaras; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Hydrocarbon waxes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(microcryst.; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Hydrophile-lipophile balance value  
(of amphiphilic compds.; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(ouricury; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Polyurethanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurea-; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Polyureas  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyurethane-; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(powders; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(silicone; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cyclosiloxanes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(siloxane-, di-Me; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Softening (mechanical)  
(softening point, of structuring polymers; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(solids; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Cosmetics  
(sticks; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Waxes  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(sugarcane; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Amines, reactions  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(trialmines; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT Lanolin  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(wax; cosmetic compns. containing structuring heteropolymer and gelling agent in liquid fatty phase)

IT 7631-86-9, Silica, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (colloidal; cosmetic compns. containing structuring heteropolymer  
 and gelling agent in liquid fatty phase)

IT 94-13-3, Propyl Paraben 106-14-9, 12-Hydroxystearic acid 131-57-7,  
 Uvinul M40 141-23-1, Methyl 12-hydroxystearate 5466-77-3, Parsol MCX  
 6197-30-4, Neo Heliopan 303 9003-28-5D, Polybutene, hydrogenated  
 9004-57-3, Ethyl cellulose 11078-30-1D, Galactomannan, alkylated  
 12691-60-0, Stearalkonium hectorite 15763-02-7, Dioctyl Malate  
 36653-82-4, Cetyl Alcohol 42131-25-9, Isononyl isononanoate  
 70356-09-1, Parsol 1789 81230-05-9, Diisostearyl malate 98932-83-3,  
 Macromelt 6212 110736-08-8, Ethyl guar gum 111517-88-5, Propylene  
 Glycol Ricinoleate 136959-34-7, Glucquat 100 388609-83-4, Uniclear 100  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT 60-33-3, Linoleic acid, reactions 107-15-3, Ethylenediamine, reactions  
 112-80-1, Oleic acid, reactions 124-09-4, Hexylenediamine, reactions  
 463-40-1, Linolenic acid 25265-76-3, Phenylenediamine 44170-50-5,  
 Ethylenetriamine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cosmetic compns. containing structuring heteropolymer and  
 gelling agent in liquid fatty phase)

IT 9002-88-4, Polyethylene  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (waxes; cosmetic compns. containing structuring  
 heteropolymer and gelling agent in liquid fatty phase)

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-025  
 ICS A61K007-027

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic composition comprising a particular ester, and uses  
 thereof

ST cosmetic lipstick ester octyldodecyl neopentanoate

IT Esters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising particular ester, and uses  
 thereof)

IT Carboxylic acids, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cosmetic composition comprising particular ester, and uses  
 thereof)

IT Polyoxyalkylenes, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cosmetic composition comprising particular ester, and uses  
 thereof)

IT Cosmetics  
 (foundations; cosmetic composition comprising particular ester,  
 and uses thereof)

IT Cosmetics  
 (lipsticks; cosmetic composition comprising particular ester, and  
 uses thereof)

IT Alcohols, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (polyhydric; cosmetic composition comprising particular ester, and  
 uses thereof)

IT 595-37-9, Neohexanoic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Neohexanoic acid; cosmetic composition comprising particular  
 ester, and uses thereof)

IT 42928-74-5 42928-76-7 57346-62-0 58006-18-1  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition comprising particular ester, and uses thereof)

IT 50-70-4, Sorbitol, reactions 56-81-5, Glycerol, reactions 57-55-6, Propylene glycol, reactions 75-98-9, Neopentanoic acid 107-21-1, Ethylene glycol, reactions 110-63-4, Butylene glycol, reactions 126-30-7, Neopentyl glycol 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 26896-20-8, Neodecanoic acid 33113-10-9, Neohexanoic acid 56090-54-1, Triglycerol 59113-36-9, Diglycerol 307313-22-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cosmetic composition comprising particular ester, and uses thereof)

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-027  
 ICS A61K007-02; A61K007-06; A61K007-043; A61K007-32; A61K007-42; A61K007-48

CC 62-4 (Essential Oils and Cosmetics)

TI Lanolin-free cosmetic compositions containing an aromatic ester of a hydroxy fatty acid

ST cosmetic lanolin free arom ester; hydroxy fatty acid ester  
 cosmetic

IT Castor oil  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (benzoate esters, Finsolv BCO; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT Cosmetics  
 (emollients; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT Sterols  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Embryophyta  
 Plants  
 (exts.; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT Castor oil  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated, esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydroxy, esters, aromatic; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydroxy, esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Cosmetics  
 Deodorants (personal)  
 Gums and Mucilages  
 Hair preparations  
 Hardness (mechanical)  
 Refractive index  
 Viscosity  
 (lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT Fluoropolymers, biological studies



Polyesters, biological studies  
 Polyolefins  
 Polyoxyalkylenes, biological studies  
 Polysiloxanes, biological studies  
 Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Aloe barbadensis  
 Antioxidants  
 Dispersing agents  
 Dyes  
 Gelation agents  
 Pigments, nonbiological  
 Preservatives  
 (lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)  
 IT Ceramides  
 Cocoa butter  
 Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (lipsticks; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (makeups; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (mascaras; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (nail lacquers; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polycarboxylic acid esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyhydric, esters; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Vinyl compounds, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polymers; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (rouges; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sesame; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (vegetable; lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)  
 IT Cosmetics  
 (wrinkle-preventing; lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

IT 50-21-5D, Lactic acid, esters 57-10-3D, Hexadecanoic acid, esters 57-11-4D, Octadecanoic acid, esters 65-85-0D, Benzoic acid, esters with hydroxy fatty acids 69-72-7D, Salicylic acid, esters with hydroxy fatty acids 77-92-9D, Citric acid, esters 79-10-7D, Acrylic acid, alkyl esters, polymers 79-14-1D, Glycolic acid, esters 79-41-4D, MethAcrylic acid, alkyl esters, polymers 87-69-4D, Tartaric acid, esters 88-12-0D, polymers 89-05-4D, Pyromellitic acid, esters with hydroxy fatty acids 100-21-0D, Terephthalic acid, esters with hydroxy fatty acids 103-82-2D, Phenylacetic acid, esters with hydroxy fatty acids 106-14-9D, 12-Hydroxyoctadecanoic acid, esters 111-14-8D, Heptanoic acid, esters 112-05-0D, Nonanoic acid, esters 112-37-8D, Undecanoic acid, esters 112-85-6D, Docosanoic acid, esters 120-87-6D, 9,10-DiHydroxyoctadecanoic acid, esters 124-07-2D, Octanoic acid, esters 139-44-6, Glyceryl tris(12-hydroxystearate) 141-22-0D, Ricinoleic acid, esters 142-62-1D, Hexanoic acid, esters 143-07-7D, Dodecanoic acid, esters 149-57-5D, 2-Ethylhexanoic acid, esters 151-13-3, Butyl ricinoleate 334-48-5D, Decanoic acid, esters 498-36-2D, Leucic acid, esters 501-52-0D, 3-Phenylpropanoic acid, esters with hydroxy fatty acids 506-12-7D, Heptadecanoic acid, esters 506-13-8D, Juniperic acid, esters 506-30-9D, Eicosanoic acid, esters 528-44-9D, Trimellitic acid, esters with hydroxy fatty acids 544-63-8D, Tetradecanoic acid, esters 621-82-9D, Cinnamic acid, esters with hydroxy fatty acids 629-22-1D,  $\alpha$ -Hydroxyoctadecanoic acid, esters 638-53-9D, Tridecanoic acid, esters 646-30-0D, Nonadecanoic acid, esters 1002-84-2D, Pentadecanoic acid, esters 1323-03-1, Myristyl lactate 2363-71-5D, HenEicosanoic acid, esters 2540-54-7, Glyceryl triricinoleate 4130-35-2, Tridecyl trimellitate 4444-16-0D, esters 6250-72-2D, Isoarachidic acid, esters 6915-15-7D, Malic acid, esters 6949-98-0D, Aleuritic acid, esters 9003-11-6 9003-27-4D, Polyisobutylene, hydrogenated 9003-29-6, Polybutylene 10401-55-5, Cetyl ricinoleate 13893-40-8D, esters 14450-05-6, Pentaerythritol tetrapelargonate 25754-87-4D, 9,12-DiHydroxyoctadecanoic acid, esters 26699-71-8, Glyceryl adipate 29710-25-6, 2-Ethylhexyl 12-hydroxystearate 30399-84-9D, Isostearic acid, esters 37309-58-3, Polydecene 37309-58-3D, Polydecene, hydrogenated 42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate 59231-36-6, Isodecyl 12-hydroxystearate 61332-02-3, Glyceryl isostearate 65591-14-2, Arachidyl propionate 68796-52-1D, esters 73572-07-3D, esters 77035-99-5, Hexadecene-Vinylpyrrolidone copolymer 81230-05-9, Diisostearyl malate 92232-12-7 93803-89-5 94689-35-7 95268-26-1 112385-10-1, Octyldodecyl lactate 113431-54-2, Triisostearyl citrate 187887-27-0 199277-59-3 220716-31-4 301824-14-6 337975-97-0D, esters 338450-65-0D, esters 338450-66-1D, esters 375375-69-2 710306-06-2 710306-07-3 710320-46-0 710320-47-1 710320-48-2 710320-49-3 710320-50-6D, esters

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lanolin-free cosmetic composition containing aromatic esters of hydroxy fatty acids)

IT 50-81-7, Vitamin C, biological studies 81-13-0, D-Panthenol 89-78-1, Menthol 97-59-6, Allantoin 98-92-0, Vitamin B3 515-69-5,  $\alpha$ -Bisabolol 1406-18-4, Vitamin E 9006-65-9, Dimethicone 11103-57-4, Vitamin A 56265-06-6, Arginine PCA 63317-82-8, Octacosanyl stearate 76845-99-3, Elfacos ST9 290364-89-5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(lanolin-free cosmetic composition containing dyes aromatic esters of hydroxy fatty acids)

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-00

ICS A61K007-025

CC 62-4 (Essential Oils and Cosmetics)

TI Oil-based cosmetics containing acrylic silicone graft

copolymers, waxes, and branched ester oils  
 ST cosmetic oil acrylic silicone graft polymer; branched ester oil  
 wax fat cosmetic  
 IT Fats and Glyceridic oils, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (Japan wax; oil-based cosmetics containing acrylic silicone graft  
 copolymers, waxes, and branched ester oils)  
 IT Polysiloxanes, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (acrylic, graft, KP 561, KP 562; oil-based cosmetics containing  
 acrylic silicone graft copolymers, waxes, and branched ester oils)  
 IT Carboxylic acids, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (esters, oils; oil-based cosmetics containing acrylic silicone  
 graft copolymers, waxes, and branched ester oils)  
 IT Cosmetics  
 (lipsticks; oil-based cosmetics containing acrylic silicone graft  
 copolymers, waxes, and branched ester oils)  
 IT Hydrocarbon waxes, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (microcryst.; oil-based cosmetics containing acrylic silicone  
 graft copolymers, waxes, and branched ester oils)  
 IT Candelilla wax  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (oil-based cosmetics containing acrylic silicone graft  
 copolymers, waxes, and branched ester oils)  
 IT Cosmetics  
 (oily; oil-based cosmetics containing acrylic silicone graft  
 copolymers, waxes, and branched ester oils)  
 IT Acrylic polymers, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (siloxane-, graft; oil-based cosmetics containing acrylic  
 silicone graft copolymers, waxes, and branched ester oils)  
 IT 42131-27-1, Isotridecyl isononanoate 69086-01-7 72585-97-8, Cetyl  
 isooctanoate 72812-41-0, Isooctyl myristate  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (oil-based cosmetics containing acrylic silicone graft  
 copolymers, waxes, and branched ester oils)  
 IT 9002-88-4, Polyethylene 9010-79-1, Ethylene-propylene  
 copolymer  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (wax; oil-based cosmetics containing acrylic silicone  
 graft copolymers, waxes, and branched ester oils)

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
 IC ICM A61K007-48  
 ICS A61K007-021; A61K007-025  
 CC 62-4 (Essential Oils and Cosmetics)  
 TI Cosmetic composition containing a polyester of an hydroxylated  
 carboxylic acid triglyceride and an oil with a molar  
 mass of 650-1000 g/mol  
 ST cosmetic carboxylic acid polyester  
 triglyceride oil

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (Ph; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Esters, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (aromatic; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Glycerides, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (carboxylic acid; cosmetic composition containing  
 polyester of hydroxylated carboxylic acid  
 triglyceride and oil)

IT Cosmetics  
 Sunscreens  
 Suntanning agents  
 (cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Fatty acids, biological studies  
 Oils  
 Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (dicarboxylic; cosmetic composition containing polyester of  
 hydroxylated carboxylic acid triglyceride and oil)

IT Hair preparations  
 (dyes; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Cosmetics  
 (eye liners; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Polymers, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (lipophilic; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Cosmetics  
 (lipsticks; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Cosmetics  
 (mascaras; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Cosmetics  
 (nail lacquers; cosmetic composition containing polyester of  
 hydroxylated carboxylic acid triglyceride and oil)

IT Cosmetics  
 (powders; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sesame; cosmetic composition containing polyester of hydroxylated  
 carboxylic acid triglyceride and oil)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (vegetable; cosmetic composition containing polyester of hydroxylated

carboxylic acid triglyceride and oil)

IT 106-14-9, 12-Hydroxy stearic acid 120-87-6, 9,10-Dihydroxy octadecanoic acid 141-22-0, Ricinoleic acid 498-36-2, Leucinic acid 629-22-1,  $\alpha$ -Hydroxyoctadecanoic acid 4130-35-2, Tridecyl trimellitate 4444-16-0 6949-98-0 9003-27-4D, Polyisobutylene, hydrogenated 9003-29-6, Polybutylene 9003-39-8, PVP 13893-40-8, 3-Hydroxy-4-hexenoic acid 14450-05-6, Pentaerythrityl tetrapelargonate 25027-95-6, 9,10,12-Trihydroxy octadecanoic acid 25754-87-4, 9,12-Dihydroxy octadecanoic acid 26942-95-0, Glyceryl triisostearate 26952-14-7D, Hexadecene, copolymers 30306-47-9, Hydroxynervonic acid 30399-84-9, Isostearic Acid 37309-58-3, Polydecene 37309-58-3D, Polydecene, hydrogenated 62125-22-8, Pentaerythrityl tetraisostearate 93803-89-5, Pentaerythrityl tetraisononanoate 187887-27-0 301824-14-6, Triisooarachidyl citrate 337975-97-0, 2-Ethyl-3-hydroxycaprylic acid 338450-65-0, Hexahydroxyoctadecanoic acid 338450-66-1, Octahydroxyoctadecanoic acid 375375-69-2 710306-07-3 756899-84-0, 14-Hydroxycososenoic acid 756900-61-5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(cosmetic composition containing polyester of hydroxylated carboxylic acid triglyceride and oil)

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K007-027  
ICS A61K007-031; A61K007-032; A61K007-48

CC 62-4 (Essential Oils and Cosmetics)

TI Cosmetic compositions structured with a polymer containing a heteroatom and an organogelator

ST polymer organogelator liq fatty phase cosmetic; gelation agent  
polymer liq fatty phase lipstick

IT Fatty acids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(C8-26; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Japan wax; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Ph; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Steroids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(amido; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Amides, biological studies  
Steroids, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(amino; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Hair  
Lip  
Nail (anatomical)  
Skin  
(anhydrous cosmetic compns. for hair, skin, lips, and nails with liquid fatty phase containing structuring polymers and organogelators)

IT Amide group  
Amino group  
Amphiphiles  
Antioxidants  
Beeswax

- Carbonyl group
- Carboxyl group
- Coloring materials
- Deodorants
- Hardness (mechanical)
- Hydrogen bond
- Hydrophile-lipophile balance value
- Hydroxyl group
- Odor and Odorous substances
- Ozocerite
- Pearlescent pigments
- Perfumes
- Pi bond
- Pigments, nonbiological
- Preservatives
- Shampoos
- Sunscreens
- Surfactants
- Thickening agents
  - (anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Alditols
- Alkenes, biological studies
- Amides, biological studies
- Candelilla wax
- Carnauba wax
- Cyclic compounds
- Essential oils
- Esters, biological studies
- Ethers, biological studies
- Fats and Glyceridic oils, biological studies
- Glycerides, biological studies
- Hydrocarbon oils
- Montan wax
- Organometallic compounds
- Paraffin waxes, biological studies
- Polyamides, biological studies
- Polymers, biological studies
- Polyureas
- Polyurethanes, biological studies
- Resins
- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Steroids, biological studies
- RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (azobenzene; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Functional groups
  - (benzyl group; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Cosmetics
  - (blushers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Cosmetics
  - (concealers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Hair preparations
  - (conditioners; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)
- IT Bond

(coordinate, with organometallic compds.; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cork fiber; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Dipeptides  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cyclodipeptides; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (cyclosiloxane-, di-Me; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (di-Me; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Amides, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (diamides; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Ketones, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (diketones, copper  $\beta$ -diketonates; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (emulsions; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Amino acids, biological studies  
 Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (esters; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (eye liners; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (eye shadows; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Alcohols, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (fatty, C8-26; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (foundations; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (gels; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Dyes  
 (hydrophilic and lipophilic; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(hydroxy, and salts; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Fatty acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (hydroxy, esters; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (lipsticks; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (makeup removers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (mascaras; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Hydrocarbon waxes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (nail lacquers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Gelation agents  
 (organogelators; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (ouricury; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Carboxylic acids, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polycarboxylic, salts, binuclear copper tetracarboxylates; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Polyurethanes, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyurea-; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Polyureas  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polyurethane-; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cosmetics  
 (powders; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Aggregation  
 (self-; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (silicone; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Cyclosiloxanes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (siloxane-, di-Me; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Softening (mechanical)  
 (softening point, of structuring polymers; anhydrous cosmetic compns. with liquid fatty phase containing structuring polymers and organogelators)

IT Amines, biological studies



RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (steroidal; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Cosmetics  
 (sticks; anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT Waxes  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sugarcane; anhydrous cosmetic compns. with liquid fatty phase  
 containing structuring polymers and organogelators)

IT Lanolin  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wax; anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT Metalloporphyrins  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (zinc; anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT 50-70-4D, D-Sorbitol, benzylidene derivs. 56-41-7D, L-Alanine, esters  
 72-18-4D, L-Valine, esters 81-25-4, Cholic acid 83-44-3, Deoxycholic  
 acid 106-14-9, 12-Hydroxystearic acid 108-93-0D, Cyclohexanol,  
 alkylaryl derivs. 120-12-7D, Anthracene, derivs. 434-13-9, Lithocholic  
 acid 641-81-6, Apocholeic acid 7003-56-7 7664-38-2D, Phosphoric acid,  
 alkyl derivs., alkali metal and aluminum salts 9003-28-5D, Polybutene,  
 hydrogenated 19046-64-1, 1,3:2,4-Di-o-benzylidene-D-sorbitol  
 19437-01-5 34513-50-3, Octyl dodecanol 42131-25-9, Isononyl  
 isononanoate 61796-47-2 63663-21-8, Coagulan GP 1 81212-19-3,  
 12-Hydroxyoleic acid 81230-05-9, Diisostearyl malate 114118-81-9  
 141102-25-2 151493-20-8 189299-29-4 189299-30-7 189301-40-4  
 212268-42-3 212268-43-4 388609-83-4, Unclear 100 390747-74-7  
 390747-75-8 390747-76-9

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT 60-33-3, Linoleic acid, reactions 107-15-3, Ethylenediamine, reactions  
 112-80-1, Oleic acid, reactions 124-09-4, Hexylenediamine, reactions  
 463-40-1, Linolenic acid 25265-76-3, Phenylenediamine 44170-50-5,  
 Ethylenetriamine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (anhydrous cosmetic compns. with liquid fatty phase containing  
 structuring polymers and organogelators)

IT 7631-86-9, Fumed silica, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (colloidal, hydrophobic-treated, rheol. agent; anhydrous cosmetic  
 compns. with liquid fatty phase containing structuring polymers and  
 organogelators)

IT 112-52-7, Lauryl chloride 29256-90-4, Diaminocyclohexane  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cyclohexanetricarboxamides from; anhydrous cosmetic compns.  
 with liquid fatty phase containing structuring polymers and organogelators)

IT 67-52-7D, Barbituric acid, dialkyl derivs.  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (mol. assocns. with 2,4,6-triaminopyrimidine alkyl derivs.; anhydrous  
 cosmetic compns. with liquid fatty phase containing structuring  
 polymers and organogelators)

IT 1004-38-2D, 2,4,6-Triaminopyrimidine, alkyl derivs.  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (mol. assocns. with dialkyl barbituric acid; anhydrous cosmetic  
 compns. with liquid fatty phase containing structuring polymers and  
 organogelators)

IT 9002-88-4, Polyethylene

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(waxes; anhydrous cosmetic compns. with liquid fatty  
phase containing structuring polymers and organogelators)

L31 8 ANSWERS CAPLUS COPYRIGHT 2008 ACS ON STN  
IC ICM A61K007-021  
ICS A61K007-025  
CC 62-4 (Essential Oils and Cosmetics)  
TI Cosmetic makeups containing organosilicone resins, emulsifiers,  
humectants, and water  
ST makeup silicone emulsifier humectant  
IT Clay minerals  
RL: BIOL (Biological study)  
(emulsifiers, for cosmetic makeups)  
IT Amino acids, biological studies  
Carboxylic acids, biological studies  
Collagens, biological studies  
Glycols, biological studies  
Mucopolysaccharides, biological studies  
Polysaccharides, biological studies  
Proteins, biological studies  
RL: BIOL (Biological study)  
(humectants, for cosmetic makeups)  
IT Siloxanes and Silicones, biological studies  
RL: BIOL (Biological study)  
(Me Ph, cosmetic makeups containing)  
IT Carbohydrates and Sugars, biological studies  
RL: BIOL (Biological study)  
(alditols, humectants, for cosmetic makeups)  
IT Cosmetics  
(makeups, containing organosilicone resins and emulsifiers and humectants)  
IT Siloxanes and Silicones, biological studies  
RL: BIOL (Biological study)  
(polyoxyalkylene-, emulsifiers, for cosmetic makeups)  
IT Polyoxyalkylenes, biological studies  
RL: BIOL (Biological study)  
(siloxane-, emulsifiers, for cosmetic makeups)  
IT 72-17-3, Sodium lactate 107-88-0, 1,3-Butyleneglycol 9004-61-9,  
Hyaluronic acid 9007-28-7, Chondroitin sulfate  
RL: BIOL (Biological study)  
(humectant, for cosmetic makeups)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 21:56:33 ON 24 JUN 2008)

FILE 'CAPLUS' ENTERED AT 21:57:54 ON 24 JUN 2008

E US2004-785093/APPS

L1 1 S E3  
SEL RN L1

FILE 'REGISTRY' ENTERED AT 21:58:45 ON 24 JUN 2008

L2 41 S E1-E41

FILE 'CAPLUS, BIOSIS, SCISEARCH, EMBASE, MEDLINE' ENTERED AT 22:03:05 ON  
24 JUN 2008

L3 432048 S L2

L4 13513 S L3 AND ("ACETIC ACID")

L5 603 S L4 AND SUCROSE  
 L6 0 S L5 AND ("ACRYLIC COPOLYMER")  
 L7 39 S L5 AND ("ACRYLIC ACID")  
 L8 10 S L7 AND ACRYLATE  
 L9 3 S L8 AND POLYETHYLENE  
 L10 0 S "POLYETHYLENE WAX"  
 L11 6753 S "POLYETHYLENE WAX"  
 L12 2 S L11 AND ("LINEAR FATTY ALCOHOL?")  
 L13 0 S L11 AND ("PERFORMACOL 550 ALCOHOL")  
 L14 0 S ("PERFORMACOL 550 ALCOHOL")  
 L15 4 S L11 AND PERFORMACOL  
 L16 3 S L11 AND ("SUCROSE ACETATE ISOBUTYRATE")  
 L17 89 S L11 AND PERFUME  
 L18 0 S L17 AND POLYCAPROLACTONE  
 L19 14 S POLYCAPROLACTONE AND LIPSTICK  
 L20 0 S L19 AND ("PIGMENT PASTE")  
 L21 8 S L19 AND PIGMENT?  
 L22 45 S ("KRATON G1701")  
 L23 1 S ("550 ALCOHOL")  
 L24 189 DUP REM L7 L8 L12 L15 L16 L17 L19 L21 L22 L23 (26 DUPLICA  
 L25 37 S L24 AND ("CARBOXYLIC ACID?")  
 L26 16 S L25 AND COSMETIC  
 L27 17 DUP REM L26 L23 (0 DUPLICATES REMOVED)  
 L28 59 DUP REM L26 L22 (2 DUPLICATES REMOVED)  
 L29 0 S L17 AND L22  
 L30 0 S L17 AND L21  
 L31 8 S L17 AND L28